id	sid	tid	token	lemma	pos
gs-3920	1	1	microsoft	microsoft	PROPN
gs-3920	1	2	word	word	NOUN
gs-3920	1	3	fullpdf07032025	fullpdf07032025	PROPN
gs-3920	1	4	georgian	georgian	ADJ
gs-3920	1	5	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	1	6	მეცნიერები	მეცნიერები	NOUN
gs-3920	1	7	ტ.	ტ.	VERB
gs-3920	1	8	7	7	NUM
gs-3920	1	9	n	n	PRON
gs-3920	1	10	3	3	NUM
gs-3920	1	11	,	,	PUNCT
gs-3920	1	12	2025	2025	NUM
gs-3920	1	13	180	180	NUM
gs-3920	1	14	georgian	georgian	PROPN
gs-3920	1	15	scientists	scientist	NOUN
gs-3920	1	16	ქართველი	ქართველი	ADJ
gs-3920	1	17	მეცნიერები	მეცნიერები	PROPN
gs-3920	1	18	vol	vol	NOUN
gs-3920	1	19	.	.	PUNCT
gs-3920	1	20	7	7	NUM
gs-3920	1	21	issue	issue	NOUN
gs-3920	1	22	3	3	NUM
gs-3920	1	23	,	,	PUNCT
gs-3920	1	24	2025	2025	NUM
gs-3920	1	25	https://doi.org/10.52340/gs.2025.07.03.14	https://doi.org/10.52340/gs.2025.07.03.14	PRON
gs-3920	2	1	the	the	DET
gs-3920	2	2	manifestation	manifestation	NOUN
gs-3920	2	3	of	of	ADP
gs-3920	2	4	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	2	5	and	and	CCONJ
gs-3920	2	6	clinical	clinical	ADJ
gs-3920	2	7	perspectives	perspective	NOUN
gs-3920	2	8	on	on	ADP
gs-3920	2	9	medication	medication	NOUN
gs-3920	2	10	-	-	PUNCT
gs-3920	2	11	associated	associate	VERB
gs-3920	2	12	eosinophilia	eosinophilia	NOUN
gs-3920	2	13	and	and	CCONJ
gs-3920	2	14	systemic	systemic	ADJ
gs-3920	2	15	symptoms	symptom	NOUN
gs-3920	2	16	(	(	PUNCT
gs-3920	2	17	dress	dress	NOUN
gs-3920	2	18	):	):	PUNCT
gs-3920	2	19	a	a	DET
gs-3920	2	20	comprehensive	comprehensive	ADJ
gs-3920	2	21	evaluation	evaluation	NOUN
gs-3920	2	22	of	of	ADP
gs-3920	2	23	implicated	implicated	ADJ
gs-3920	2	24	agents	agent	NOUN
gs-3920	2	25	,	,	PUNCT
gs-3920	2	26	risk	risk	NOUN
gs-3920	2	27	factors	factor	NOUN
gs-3920	2	28	,	,	PUNCT
gs-3920	2	29	and	and	CCONJ
gs-3920	2	30	treatment	treatment	NOUN
gs-3920	2	31	managements	management	NOUN
gs-3920	2	32	strategies	strategy	NOUN
gs-3920	2	33	in	in	ADP
gs-3920	2	34	general	general	ADJ
gs-3920	2	35	nodar	nodar	PROPN
gs-3920	2	36	sulashvili1	sulashvili1	PROPN
gs-3920	2	37	,	,	PUNCT
gs-3920	2	38	rupali	rupali	VERB
gs-3920	2	39	digambar	digambar	PROPN
gs-3920	2	40	jadhav2	jadhav2	PROPN
gs-3920	2	41	,	,	PUNCT
gs-3920	2	42	margarita	margarita	PROPN
gs-3920	2	43	beglaryan3	beglaryan3	PROPN
gs-3920	2	44	,	,	PUNCT
gs-3920	2	45	nana	nana	PROPN
gs-3920	2	46	gorgaslidze4	gorgaslidze4	PROPN
gs-3920	2	47	,	,	PUNCT
gs-3920	2	48	luiza	luiza	PROPN
gs-3920	2	49	gabunia5	gabunia5	PROPN
gs-3920	2	50	,	,	PUNCT
gs-3920	2	51	nato	nato	PROPN
gs-3920	2	52	alavidze6	alavidze6	PROPN
gs-3920	2	53	,	,	PUNCT
gs-3920	2	54	natia	natia	PROPN
gs-3920	2	55	kvizhinadze7	kvizhinadze7	PROPN
gs-3920	2	56	,	,	PUNCT
gs-3920	2	57	marika	marika	PROPN
gs-3920	2	58	sulashvili8	sulashvili8	PROPN
gs-3920	2	59	,	,	PUNCT
gs-3920	2	60	lela	lela	PROPN
gs-3920	2	61	grigolia9	grigolia9	PROPN
gs-3920	2	62	,	,	PUNCT
gs-3920	2	63	kakhaber	kakhaber	NOUN
gs-3920	2	64	robakidze10	robakidze10	NOUN
gs-3920	3	1	1scientific	1scientific	NUM
gs-3920	3	2	supervisor	supervisor	NOUN
gs-3920	3	3	,	,	PUNCT
gs-3920	3	4	md	md	PROPN
gs-3920	3	5	,	,	PUNCT
gs-3920	3	6	phd	phd	NOUN
gs-3920	3	7	,	,	PUNCT
gs-3920	3	8	doctor	doctor	NOUN
gs-3920	3	9	of	of	ADP
gs-3920	3	10	pharmaceutical	pharmaceutical	ADJ
gs-3920	3	11	and	and	CCONJ
gs-3920	3	12	pharmacological	pharmacological	ADJ
gs-3920	3	13	sciences	science	NOUN
gs-3920	3	14	in	in	ADP
gs-3920	3	15	medicine	medicine	NOUN
gs-3920	3	16	,	,	PUNCT
gs-3920	3	17	invited	invite	VERB
gs-3920	3	18	lecturer	lecturer	NOUN
gs-3920	3	19	(	(	PUNCT
gs-3920	3	20	invited	invite	VERB
gs-3920	3	21	professor	professor	NOUN
gs-3920	3	22	)	)	PUNCT
gs-3920	3	23	of	of	ADP
gs-3920	3	24	scientific	scientific	ADJ
gs-3920	3	25	research	research	NOUN
gs-3920	3	26	-	-	PUNCT
gs-3920	3	27	skills	skill	NOUN
gs-3920	3	28	center	center	NOUN
gs-3920	3	29	at	at	ADP
gs-3920	3	30	tbilisi	tbilisi	PROPN
gs-3920	3	31	state	state	PROPN
gs-3920	3	32	medical	medical	PROPN
gs-3920	3	33	university	university	PROPN
gs-3920	3	34	;	;	PUNCT
gs-3920	3	35	professor	professor	NOUN
gs-3920	3	36	of	of	ADP
gs-3920	3	37	medical	medical	ADJ
gs-3920	3	38	and	and	CCONJ
gs-3920	3	39	clinical	clinical	ADJ
gs-3920	3	40	pharmacology	pharmacology	NOUN
gs-3920	3	41	of	of	ADP
gs-3920	3	42	international	international	ADJ
gs-3920	3	43	school	school	NOUN
gs-3920	3	44	of	of	ADP
gs-3920	3	45	medicine	medicine	NOUN
gs-3920	3	46	at	at	ADP
gs-3920	3	47	alte	alte	PROPN
gs-3920	3	48	university	university	PROPN
gs-3920	3	49	;	;	PUNCT
gs-3920	3	50	professor	professor	NOUN
gs-3920	3	51	of	of	ADP
gs-3920	3	52	pharmacology	pharmacology	NOUN
gs-3920	3	53	of	of	ADP
gs-3920	3	54	faculty	faculty	NOUN
gs-3920	3	55	of	of	ADP
gs-3920	3	56	medicine	medicine	NOUN
gs-3920	3	57	at	at	ADP
gs-3920	3	58	georgian	georgian	PROPN
gs-3920	3	59	national	national	PROPN
gs-3920	3	60	university	university	PROPN
gs-3920	3	61	seu	seu	NOUN
gs-3920	3	62	;	;	PUNCT
gs-3920	3	63	associate	associate	ADJ
gs-3920	3	64	affiliated	affiliate	VERB
gs-3920	3	65	professor	professor	NOUN
gs-3920	3	66	of	of	ADP
gs-3920	3	67	medical	medical	ADJ
gs-3920	3	68	pharmacology	pharmacology	NOUN
gs-3920	3	69	of	of	ADP
gs-3920	3	70	faculty	faculty	NOUN
gs-3920	3	71	of	of	ADP
gs-3920	3	72	medicine	medicine	NOUN
gs-3920	3	73	at	at	ADP
gs-3920	3	74	sulkhan	sulkhan	PROPN
gs-3920	3	75	-	-	PUNCT
gs-3920	3	76	saba	saba	PROPN
gs-3920	3	77	orbeliani	orbeliani	PROPN
gs-3920	3	78	university	university	PROPN
gs-3920	3	79	;	;	PUNCT
gs-3920	3	80	associate	associate	NOUN
gs-3920	3	81	professor	professor	NOUN
gs-3920	3	82	of	of	ADP
gs-3920	3	83	pharmacology	pharmacology	NOUN
gs-3920	3	84	of	of	ADP
gs-3920	3	85	pharmacy	pharmacy	NOUN
gs-3920	3	86	program	program	NOUN
gs-3920	3	87	at	at	ADP
gs-3920	3	88	shota	shota	PROPN
gs-3920	3	89	meskhia	meskhia	PROPN
gs-3920	3	90	zugdidi	zugdidi	PROPN
gs-3920	3	91	state	state	PROPN
gs-3920	3	92	university	university	PROPN
gs-3920	3	93	;	;	PUNCT
gs-3920	3	94	associate	associate	NOUN
gs-3920	3	95	professor	professor	NOUN
gs-3920	3	96	of	of	ADP
gs-3920	3	97	medical	medical	ADJ
gs-3920	3	98	pharmacology	pharmacology	NOUN
gs-3920	3	99	at	at	ADP
gs-3920	3	100	school	school	NOUN
gs-3920	3	101	of	of	ADP
gs-3920	3	102	medicine	medicine	NOUN
gs-3920	3	103	at	at	ADP
gs-3920	3	104	david	david	PROPN
gs-3920	3	105	aghmashenebeli	aghmashenebeli	PROPN
gs-3920	3	106	university	university	PROPN
gs-3920	3	107	of	of	ADP
gs-3920	3	108	georgia	georgia	PROPN
gs-3920	3	109	;	;	PUNCT
gs-3920	3	110	associate	associate	NOUN
gs-3920	3	111	professor	professor	NOUN
gs-3920	3	112	of	of	ADP
gs-3920	3	113	biochemistry	biochemistry	NOUN
gs-3920	3	114	and	and	CCONJ
gs-3920	3	115	pharmacology	pharmacology	NOUN
gs-3920	3	116	direction	direction	NOUN
gs-3920	3	117	of	of	ADP
gs-3920	3	118	school	school	NOUN
gs-3920	3	119	of	of	ADP
gs-3920	3	120	health	health	NOUN
gs-3920	3	121	sciences	science	NOUN
gs-3920	3	122	at	at	ADP
gs-3920	3	123	the	the	DET
gs-3920	3	124	university	university	PROPN
gs-3920	3	125	of	of	ADP
gs-3920	3	126	georgia	georgia	PROPN
gs-3920	3	127	;	;	PUNCT
gs-3920	3	128	associate	associate	NOUN
gs-3920	3	129	professor	professor	NOUN
gs-3920	3	130	of	of	ADP
gs-3920	3	131	pharmacology	pharmacology	NOUN
gs-3920	3	132	of	of	ADP
gs-3920	3	133	faculty	faculty	NOUN
gs-3920	3	134	of	of	ADP
gs-3920	3	135	medicine	medicine	NOUN
gs-3920	3	136	at	at	ADP
gs-3920	3	137	east	east	PROPN
gs-3920	3	138	european	european	PROPN
gs-3920	3	139	university	university	PROPN
gs-3920	3	140	;	;	PUNCT
gs-3920	3	141	associate	associate	NOUN
gs-3920	3	142	professor	professor	NOUN
gs-3920	3	143	of	of	ADP
gs-3920	3	144	pharmacology	pharmacology	NOUN
gs-3920	3	145	of	of	ADP
gs-3920	3	146	faculty	faculty	NOUN
gs-3920	3	147	of	of	ADP
gs-3920	3	148	dentistry	dentistry	NOUN
gs-3920	3	149	and	and	CCONJ
gs-3920	3	150	pharmacy	pharmacy	NOUN
gs-3920	3	151	at	at	ADP
gs-3920	3	152	tbilisi	tbilisi	ADJ
gs-3920	3	153	humanitarian	humanitarian	ADJ
gs-3920	3	154	teaching	teaching	NOUN
gs-3920	3	155	university	university	NOUN
gs-3920	3	156	;	;	PUNCT
gs-3920	3	157	tbilisi	tbilisi	PROPN
gs-3920	3	158	,	,	PUNCT
gs-3920	3	159	georgia	georgia	PROPN
gs-3920	3	160	;	;	PUNCT
gs-3920	3	161	researcher	researcher	NOUN
gs-3920	3	162	of	of	ADP
gs-3920	3	163	department	department	PROPN
gs-3920	3	164	of	of	ADP
gs-3920	3	165	pharmaceutical	pharmaceutical	ADJ
gs-3920	3	166	management	management	NOUN
gs-3920	3	167	of	of	ADP
gs-3920	3	168	yerevan	yerevan	PROPN
gs-3920	3	169	state	state	PROPN
gs-3920	3	170	medical	medical	PROPN
gs-3920	3	171	university	university	PROPN
gs-3920	3	172	after	after	ADP
gs-3920	3	173	mkhitar	mkhitar	NOUN
gs-3920	3	174	heratsi	heratsi	PROPN
gs-3920	3	175	,	,	PUNCT
gs-3920	3	176	yerevan	yerevan	PROPN
gs-3920	3	177	,	,	PUNCT
gs-3920	3	178	armenia	armenia	PROPN
gs-3920	3	179	.	.	PUNCT
gs-3920	4	1	orcid	orcid	PROPN
gs-3920	4	2	https://orcid.org/0000-0002-9005-8577	https://orcid.org/0000-0002-9005-8577	PROPN
gs-3920	4	3	e	e	NOUN
gs-3920	4	4	-	-	NOUN
gs-3920	4	5	mail	mail	NOUN
gs-3920	4	6	:	:	PUNCT
gs-3920	4	7	n.sulashvili@ug.edu.ge	n.sulashvili@ug.edu.ge	PROPN
gs-3920	4	8	2md	2md	NOUN
gs-3920	5	1	©	©	NOUN
gs-3920	5	2	,	,	PUNCT
gs-3920	5	3	12	12	NUM
gs-3920	5	4	-	-	PUNCT
gs-3920	5	5	th	th	NUM
gs-3920	5	6	semester	semester	NOUN
gs-3920	5	7	student	student	NOUN
gs-3920	5	8	of	of	ADP
gs-3920	5	9	md	md	PROPN
gs-3920	5	10	medical	medical	PROPN
gs-3920	5	11	doctor	doctor	NOUN
gs-3920	5	12	degree	degree	NOUN
gs-3920	5	13	student	student	NOUN
gs-3920	5	14	of	of	ADP
gs-3920	5	15	international	international	ADJ
gs-3920	5	16	school	school	NOUN
gs-3920	5	17	of	of	ADP
gs-3920	5	18	medicine	medicine	NOUN
gs-3920	5	19	at	at	ADP
gs-3920	5	20	alte	alte	PROPN
gs-3920	5	21	university	university	PROPN
gs-3920	5	22	;	;	PUNCT
gs-3920	5	23	tbilisi	tbilisi	PROPN
gs-3920	5	24	,	,	PUNCT
gs-3920	5	25	georgia	georgia	PROPN
gs-3920	5	26	;	;	PUNCT
gs-3920	5	27	3md	3md	NOUN
gs-3920	5	28	,	,	PUNCT
gs-3920	5	29	phd	phd	NOUN
gs-3920	5	30	,	,	PUNCT
gs-3920	5	31	doctor	doctor	NOUN
gs-3920	5	32	of	of	ADP
gs-3920	5	33	pharmaceutical	pharmaceutical	NOUN
gs-3920	5	34	sciences	science	NOUN
gs-3920	5	35	,	,	PUNCT
gs-3920	5	36	academician	academician	NOUN
gs-3920	5	37	,	,	PUNCT
gs-3920	5	38	professor	professor	NOUN
gs-3920	5	39	of	of	ADP
gs-3920	5	40	yerevan	yerevan	PROPN
gs-3920	5	41	state	state	PROPN
gs-3920	5	42	medical	medical	PROPN
gs-3920	5	43	university	university	PROPN
gs-3920	5	44	after	after	ADP
gs-3920	5	45	mkhitar	mkhitar	NOUN
gs-3920	5	46	heratsi	heratsi	PROPN
gs-3920	5	47	,	,	PUNCT
gs-3920	5	48	head	head	NOUN
gs-3920	5	49	of	of	ADP
gs-3920	5	50	the	the	DET
gs-3920	5	51	department	department	PROPN
gs-3920	5	52	of	of	ADP
gs-3920	5	53	pharmaceutical	pharmaceutical	NOUN
gs-3920	5	54	management	management	NOUN
gs-3920	5	55	,	,	PUNCT
gs-3920	5	56	president	president	NOUN
gs-3920	5	57	of	of	ADP
gs-3920	5	58	association	association	PROPN
gs-3920	5	59	phesa	phesa	PROPN
gs-3920	5	60	(	(	PUNCT
gs-3920	5	61	pharmacy	pharmacy	NOUN
gs-3920	5	62	and	and	CCONJ
gs-3920	5	63	pharmacology	pharmacology	NOUN
gs-3920	5	64	education	education	NOUN
gs-3920	5	65	and	and	CCONJ
gs-3920	5	66	science	science	NOUN
gs-3920	5	67	association	association	PROPN
gs-3920	5	68	)	)	PUNCT
gs-3920	5	69	,	,	PUNCT
gs-3920	5	70	yerevan	yerevan	PROPN
gs-3920	5	71	,	,	PUNCT
gs-3920	5	72	armenia	armenia	PROPN
gs-3920	5	73	;	;	PUNCT
gs-3920	5	74	https://orcid.org/0000-0003-3697-6390	https://orcid.org/0000-0003-3697-6390	PROPN
gs-3920	5	75	4md	4md	NOUN
gs-3920	5	76	,	,	PUNCT
gs-3920	5	77	phd	phd	NOUN
gs-3920	5	78	,	,	PUNCT
gs-3920	5	79	doctor	doctor	NOUN
gs-3920	5	80	of	of	ADP
gs-3920	5	81	pharmaceutical	pharmaceutical	NOUN
gs-3920	5	82	sciences	science	NOUN
gs-3920	5	83	,	,	PUNCT
gs-3920	5	84	academician	academician	NOUN
gs-3920	5	85	,	,	PUNCT
gs-3920	5	86	professor	professor	NOUN
gs-3920	5	87	of	of	ADP
gs-3920	5	88	tbilisi	tbilisi	PROPN
gs-3920	5	89	state	state	PROPN
gs-3920	5	90	medical	medical	PROPN
gs-3920	5	91	university	university	PROPN
gs-3920	5	92	,	,	PUNCT
gs-3920	5	93	head	head	NOUN
gs-3920	5	94	of	of	ADP
gs-3920	5	95	the	the	DET
gs-3920	5	96	department	department	NOUN
gs-3920	5	97	of	of	ADP
gs-3920	5	98	social	social	ADJ
gs-3920	5	99	and	and	CCONJ
gs-3920	5	100	clinical	clinical	ADJ
gs-3920	5	101	pharmacy	pharmacy	NOUN
gs-3920	5	102	,	,	PUNCT
gs-3920	5	103	tbilisi	tbilisi	PROPN
gs-3920	5	104	,	,	PUNCT
gs-3920	5	105	georgia	georgia	PROPN
gs-3920	5	106	.	.	PUNCT
gs-3920	6	1	https://orcid.org/0000-00024563-5224	https://orcid.org/0000-00024563-5224	PROPN
gs-3920	6	2	5md	5md	NOUN
gs-3920	6	3	,	,	PUNCT
gs-3920	6	4	phd	phd	NOUN
gs-3920	6	5	,	,	PUNCT
gs-3920	6	6	doctor	doctor	NOUN
gs-3920	6	7	of	of	ADP
gs-3920	6	8	medical	medical	ADJ
gs-3920	6	9	sciences	sciences	PROPN
gs-3920	6	10	,	,	PUNCT
gs-3920	6	11	professor	professor	NOUN
gs-3920	6	12	,	,	PUNCT
gs-3920	6	13	director	director	NOUN
gs-3920	6	14	of	of	ADP
gs-3920	6	15	the	the	DET
gs-3920	6	16	scientific	scientific	ADJ
gs-3920	6	17	research	research	NOUN
gs-3920	6	18	-	-	PUNCT
gs-3920	6	19	skills	skill	NOUN
gs-3920	6	20	center	center	NOUN
gs-3920	6	21	at	at	ADP
gs-3920	6	22	tbilisi	tbilisi	PROPN
gs-3920	6	23	state	state	PROPN
gs-3920	6	24	medical	medical	PROPN
gs-3920	6	25	university	university	PROPN
gs-3920	6	26	,	,	PUNCT
gs-3920	6	27	professor	professor	NOUN
gs-3920	6	28	,	,	PUNCT
gs-3920	6	29	head	head	NOUN
gs-3920	6	30	of	of	ADP
gs-3920	6	31	the	the	DET
gs-3920	6	32	department	department	PROPN
gs-3920	6	33	of	of	ADP
gs-3920	6	34	medical	medical	ADJ
gs-3920	6	35	and	and	CCONJ
gs-3920	6	36	clinical	clinical	ADJ
gs-3920	6	37	pharmacology	pharmacology	NOUN
gs-3920	6	38	at	at	ADP
gs-3920	6	39	tbilisi	tbilisi	PROPN
gs-3920	6	40	state	state	PROPN
gs-3920	6	41	medical	medical	PROPN
gs-3920	6	42	university	university	PROPN
gs-3920	6	43	,	,	PUNCT
gs-3920	6	44	clinical	clinical	ADJ
gs-3920	6	45	pharmacologist	pharmacologist	NOUN
gs-3920	6	46	of	of	ADP
gs-3920	6	47	the	the	DET
gs-3920	6	48	first	first	ADJ
gs-3920	6	49	university	university	NOUN
gs-3920	6	50	clinic	clinic	NOUN
gs-3920	6	51	of	of	ADP
gs-3920	6	52	tbilisi	tbilisi	PROPN
gs-3920	6	53	state	state	PROPN
gs-3920	6	54	medical	medical	PROPN
gs-3920	6	55	university	university	PROPN
gs-3920	6	56	,	,	PUNCT
gs-3920	6	57	tbilisi	tbilisi	PROPN
gs-3920	6	58	,	,	PUNCT
gs-3920	6	59	georgia	georgia	PROPN
gs-3920	6	60	https://orcid.org/0000-0003-0856-2684	https://orcid.org/0000-0003-0856-2684	PROPN
gs-3920	6	61	6md	6md	PROPN
gs-3920	6	62	,	,	PUNCT
gs-3920	6	63	phd	phd	NOUN
gs-3920	6	64	,	,	PUNCT
gs-3920	6	65	doctor	doctor	NOUN
gs-3920	6	66	of	of	ADP
gs-3920	6	67	pharmaceutical	pharmaceutical	NOUN
gs-3920	6	68	sciences	science	NOUN
gs-3920	6	69	,	,	PUNCT
gs-3920	6	70	professor	professor	NOUN
gs-3920	6	71	of	of	ADP
gs-3920	6	72	akaki	akaki	PROPN
gs-3920	6	73	tsereteli	tsereteli	PROPN
gs-3920	6	74	state	state	PROPN
gs-3920	6	75	university	university	PROPN
gs-3920	6	76	,	,	PUNCT
gs-3920	6	77	faculty	faculty	NOUN
gs-3920	6	78	of	of	ADP
gs-3920	6	79	medicine	medicine	NOUN
gs-3920	6	80	,	,	PUNCT
gs-3920	6	81	department	department	NOUN
gs-3920	6	82	of	of	ADP
gs-3920	6	83	pharmacy	pharmacy	NOUN
gs-3920	6	84	,	,	PUNCT
gs-3920	6	85	kutaisi	kutaisi	PROPN
gs-3920	6	86	,	,	PUNCT
gs-3920	6	87	georgia	georgia	PROPN
gs-3920	6	88	.	.	PUNCT
gs-3920	7	1	professor	professor	PROPN
gs-3920	7	2	,	,	PUNCT
gs-3920	7	3	dean	dean	PROPN
gs-3920	7	4	faculty	faculty	NOUN
gs-3920	7	5	of	of	ADP
gs-3920	7	6	medicine	medicine	NOUN
gs-3920	7	7	at	at	ADP
gs-3920	7	8	east	east	PROPN
gs-3920	7	9	european	european	PROPN
gs-3920	7	10	university	university	PROPN
gs-3920	7	11	,	,	PUNCT
gs-3920	7	12	tbilisi	tbilisi	PROPN
gs-3920	7	13	,	,	PUNCT
gs-3920	7	14	georgia	georgia	PROPN
gs-3920	7	15	.	.	PUNCT
gs-3920	8	1	https://orcid.org/0000-0001-6695-5924	https://orcid.org/0000-0001-6695-5924	NOUN
gs-3920	8	2	georgian	georgian	ADJ
gs-3920	8	3	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	8	4	მეცნიერები	მეცნიერები	NOUN
gs-3920	8	5	ტ.	ტ.	VERB
gs-3920	8	6	7	7	NUM
gs-3920	8	7	n	n	PRON
gs-3920	8	8	3	3	NUM
gs-3920	8	9	,	,	PUNCT
gs-3920	8	10	2025	2025	NUM
gs-3920	8	11	181	181	NUM
gs-3920	8	12	7md	7md	NOUN
gs-3920	8	13	,	,	PUNCT
gs-3920	8	14	phd	phd	NOUN
gs-3920	8	15	,	,	PUNCT
gs-3920	8	16	doctor	doctor	NOUN
gs-3920	8	17	of	of	ADP
gs-3920	8	18	pharmaceutical	pharmaceutical	NOUN
gs-3920	8	19	sciences	science	NOUN
gs-3920	8	20	,	,	PUNCT
gs-3920	8	21	professor	professor	NOUN
gs-3920	8	22	of	of	ADP
gs-3920	8	23	tbilisi	tbilisi	PROPN
gs-3920	8	24	state	state	PROPN
gs-3920	8	25	medical	medical	PROPN
gs-3920	8	26	university	university	PROPN
gs-3920	8	27	,	,	PUNCT
gs-3920	8	28	department	department	NOUN
gs-3920	8	29	of	of	ADP
gs-3920	8	30	social	social	ADJ
gs-3920	8	31	and	and	CCONJ
gs-3920	8	32	clinical	clinical	ADJ
gs-3920	8	33	pharmacy	pharmacy	NOUN
gs-3920	8	34	;	;	PUNCT
gs-3920	8	35	tbilisi	tbilisi	PROPN
gs-3920	8	36	,	,	PUNCT
gs-3920	8	37	georgia	georgia	PROPN
gs-3920	8	38	.	.	PUNCT
gs-3920	9	1	8md	8md	ADJ
gs-3920	9	2	,	,	PUNCT
gs-3920	9	3	doctor	doctor	NOUN
gs-3920	9	4	of	of	ADP
gs-3920	9	5	family	family	NOUN
gs-3920	9	6	medicine	medicine	NOUN
gs-3920	9	7	,	,	PUNCT
gs-3920	9	8	invited	invite	VERB
gs-3920	9	9	lecturer	lecturer	NOUN
gs-3920	9	10	of	of	ADP
gs-3920	9	11	tbilisi	tbilisi	PROPN
gs-3920	9	12	state	state	PROPN
gs-3920	9	13	medical	medical	PROPN
gs-3920	9	14	university	university	PROPN
gs-3920	9	15	,	,	PUNCT
gs-3920	9	16	department	department	NOUN
gs-3920	9	17	of	of	ADP
gs-3920	9	18	molecular	molecular	ADJ
gs-3920	9	19	and	and	CCONJ
gs-3920	9	20	medical	medical	ADJ
gs-3920	9	21	genetics	genetic	NOUN
gs-3920	9	22	,	,	PUNCT
gs-3920	9	23	invited	invite	VERB
gs-3920	9	24	lecturer	lecturer	NOUN
gs-3920	9	25	of	of	ADP
gs-3920	9	26	genetics	genetic	NOUN
gs-3920	9	27	and	and	CCONJ
gs-3920	9	28	molecular	molecular	ADJ
gs-3920	9	29	biology	biology	NOUN
gs-3920	9	30	of	of	ADP
gs-3920	9	31	international	international	ADJ
gs-3920	9	32	school	school	NOUN
gs-3920	9	33	of	of	ADP
gs-3920	9	34	medicine	medicine	NOUN
gs-3920	9	35	at	at	ADP
gs-3920	9	36	alte	alte	PROPN
gs-3920	9	37	university	university	PROPN
gs-3920	9	38	;	;	PUNCT
gs-3920	9	39	invited	invite	VERB
gs-3920	9	40	professor	professor	NOUN
gs-3920	9	41	of	of	ADP
gs-3920	9	42	biochemistry	biochemistry	NOUN
gs-3920	9	43	and	and	CCONJ
gs-3920	9	44	molecular	molecular	ADJ
gs-3920	9	45	and	and	CCONJ
gs-3920	9	46	medical	medical	ADJ
gs-3920	9	47	genetics	genetic	NOUN
gs-3920	9	48	at	at	ADP
gs-3920	9	49	the	the	DET
gs-3920	9	50	university	university	PROPN
gs-3920	9	51	of	of	ADP
gs-3920	9	52	georgia	georgia	PROPN
gs-3920	9	53	.	.	PUNCT
gs-3920	10	1	tbilisi	tbilisi	PROPN
gs-3920	10	2	,	,	PUNCT
gs-3920	10	3	georgia	georgia	PROPN
gs-3920	10	4	.	.	PUNCT
gs-3920	11	1	orcid	orcid	PROPN
gs-3920	11	2	https://orcid.org/0000-0002-6338-4262	https://orcid.org/0000-0002-6338-4262	PROPN
gs-3920	11	3	.	.	PUNCT
gs-3920	12	1	9md	9md	NOUN
gs-3920	12	2	,	,	PUNCT
gs-3920	12	3	phd	phd	NOUN
gs-3920	12	4	,	,	PUNCT
gs-3920	12	5	doctor	doctor	NOUN
gs-3920	12	6	of	of	ADP
gs-3920	12	7	medical	medical	ADJ
gs-3920	12	8	sciences	science	NOUN
gs-3920	12	9	,	,	PUNCT
gs-3920	12	10	professor	professor	NOUN
gs-3920	12	11	of	of	ADP
gs-3920	12	12	faculty	faculty	NOUN
gs-3920	12	13	of	of	ADP
gs-3920	12	14	medicine	medicine	NOUN
gs-3920	12	15	at	at	ADP
gs-3920	12	16	caucasus	caucasus	PROPN
gs-3920	12	17	international	international	PROPN
gs-3920	12	18	university	university	PROPN
gs-3920	12	19	;	;	PUNCT
gs-3920	12	20	tbilisi	tbilisi	PROPN
gs-3920	12	21	,	,	PUNCT
gs-3920	12	22	georgia	georgia	PROPN
gs-3920	12	23	;	;	PUNCT
gs-3920	12	24	10md	10md	NUM
gs-3920	12	25	,	,	PUNCT
gs-3920	12	26	phd	phd	NOUN
gs-3920	12	27	,	,	PUNCT
gs-3920	12	28	doctor	doctor	NOUN
gs-3920	12	29	of	of	ADP
gs-3920	12	30	medical	medical	ADJ
gs-3920	12	31	sciences	science	NOUN
gs-3920	12	32	,	,	PUNCT
gs-3920	12	33	academician	academician	NOUN
gs-3920	12	34	,	,	PUNCT
gs-3920	12	35	professor	professor	NOUN
gs-3920	12	36	of	of	ADP
gs-3920	12	37	faculty	faculty	NOUN
gs-3920	12	38	of	of	ADP
gs-3920	12	39	medicine	medicine	NOUN
gs-3920	12	40	at	at	ADP
gs-3920	12	41	caucasus	caucasus	PROPN
gs-3920	12	42	international	international	PROPN
gs-3920	12	43	university	university	PROPN
gs-3920	12	44	;	;	PUNCT
gs-3920	12	45	doctor	doctor	NOUN
gs-3920	12	46	-	-	PUNCT
gs-3920	12	47	professor	professor	NOUN
gs-3920	12	48	of	of	ADP
gs-3920	12	49	national	national	PROPN
gs-3920	12	50	health	health	PROPN
gs-3920	12	51	center	center	NOUN
gs-3920	12	52	named	name	VERB
gs-3920	12	53	after	after	ADP
gs-3920	12	54	academician	academician	PROPN
gs-3920	12	55	o.	o.	PROPN
gs-3920	12	56	gudushauri	gudushauri	PROPN
gs-3920	12	57	;	;	PUNCT
gs-3920	12	58	tbilisi	tbilisi	PROPN
gs-3920	12	59	,	,	PUNCT
gs-3920	12	60	georgia	georgia	PROPN
gs-3920	12	61	;	;	PUNCT
gs-3920	12	62	corresponding	correspond	VERB
gs-3920	12	63	author	author	NOUN
gs-3920	12	64	:	:	PUNCT
gs-3920	12	65	dr	dr	PROPN
gs-3920	12	66	.	.	PROPN
gs-3920	12	67	professor	professor	PROPN
gs-3920	12	68	nodar	nodar	PROPN
gs-3920	12	69	sulashvili	sulashvili	PROPN
gs-3920	12	70	mail	mail	NOUN
gs-3920	12	71	:	:	PUNCT
gs-3920	12	72	n.sulashvili@ug.edu.ge	n.sulashvili@ug.edu.ge	NOUN
gs-3920	12	73	mob	mob	NOUN
gs-3920	12	74	:	:	PUNCT
gs-3920	12	75	+995	+995	ADJ
gs-3920	12	76	-	-	ADJ
gs-3920	12	77	597	597	NUM
gs-3920	12	78	-	-	PUNCT
gs-3920	12	79	12	12	NUM
gs-3920	12	80	-	-	PUNCT
gs-3920	12	81	17	17	NUM
gs-3920	12	82	-	-	SYM
gs-3920	12	83	28	28	NUM
gs-3920	12	84	abstract	abstract	ADJ
gs-3920	12	85	drug	drug	NOUN
gs-3920	12	86	reaction	reaction	NOUN
gs-3920	12	87	with	with	ADP
gs-3920	12	88	eosinophilia	eosinophilia	PROPN
gs-3920	12	89	and	and	CCONJ
gs-3920	12	90	systemic	systemic	ADJ
gs-3920	12	91	symptoms	symptom	NOUN
gs-3920	12	92	(	(	PUNCT
gs-3920	12	93	dress	dress	NOUN
gs-3920	12	94	)	)	PUNCT
gs-3920	12	95	is	be	AUX
gs-3920	12	96	a	a	DET
gs-3920	12	97	complex	complex	ADJ
gs-3920	12	98	,	,	PUNCT
gs-3920	12	99	multifaceted	multifaceted	ADJ
gs-3920	12	100	,	,	PUNCT
gs-3920	12	101	and	and	CCONJ
gs-3920	12	102	potentially	potentially	ADV
gs-3920	12	103	life	life	NOUN
gs-3920	12	104	-	-	PUNCT
gs-3920	12	105	threatening	threaten	VERB
gs-3920	12	106	hypersensitivity	hypersensitivity	NOUN
gs-3920	12	107	syndrome	syndrome	NOUN
gs-3920	12	108	associated	associate	VERB
gs-3920	12	109	with	with	ADP
gs-3920	12	110	a	a	DET
gs-3920	12	111	wide	wide	ADJ
gs-3920	12	112	spectrum	spectrum	NOUN
gs-3920	12	113	of	of	ADP
gs-3920	12	114	pharmacologic	pharmacologic	ADJ
gs-3920	12	115	agents	agent	NOUN
gs-3920	12	116	.	.	PUNCT
gs-3920	13	1	the	the	DET
gs-3920	13	2	syndrome	syndrome	NOUN
gs-3920	13	3	is	be	AUX
gs-3920	13	4	characterized	characterize	VERB
gs-3920	13	5	by	by	ADP
gs-3920	13	6	delayed	delay	VERB
gs-3920	13	7	onset	onset	NOUN
gs-3920	13	8	,	,	PUNCT
gs-3920	13	9	typically	typically	ADV
gs-3920	13	10	appearing	appear	VERB
gs-3920	13	11	several	several	ADJ
gs-3920	13	12	weeks	week	NOUN
gs-3920	13	13	after	after	ADP
gs-3920	13	14	the	the	DET
gs-3920	13	15	initiation	initiation	NOUN
gs-3920	13	16	of	of	ADP
gs-3920	13	17	the	the	DET
gs-3920	13	18	causative	causative	ADJ
gs-3920	13	19	drug	drug	NOUN
gs-3920	13	20	,	,	PUNCT
gs-3920	13	21	and	and	CCONJ
gs-3920	13	22	encompasses	encompass	VERB
gs-3920	13	23	a	a	DET
gs-3920	13	24	constellation	constellation	NOUN
gs-3920	13	25	of	of	ADP
gs-3920	13	26	clinical	clinical	ADJ
gs-3920	13	27	symptoms	symptom	NOUN
gs-3920	13	28	such	such	ADJ
gs-3920	13	29	as	as	ADP
gs-3920	13	30	fever	fever	NOUN
gs-3920	13	31	,	,	PUNCT
gs-3920	13	32	rash	rash	ADJ
gs-3920	13	33	,	,	PUNCT
gs-3920	13	34	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	13	35	,	,	PUNCT
gs-3920	13	36	hematologic	hematologic	NOUN
gs-3920	13	37	abnormalities	abnormality	NOUN
gs-3920	13	38	including	include	VERB
gs-3920	13	39	eosinophilia	eosinophilia	PROPN
gs-3920	13	40	or	or	CCONJ
gs-3920	13	41	atypical	atypical	ADJ
gs-3920	13	42	lymphocytosis	lymphocytosis	NOUN
gs-3920	13	43	,	,	PUNCT
gs-3920	13	44	and	and	CCONJ
gs-3920	13	45	involvement	involvement	NOUN
gs-3920	13	46	of	of	ADP
gs-3920	13	47	internal	internal	ADJ
gs-3920	13	48	organs	organ	NOUN
gs-3920	13	49	,	,	PUNCT
gs-3920	13	50	most	most	ADV
gs-3920	13	51	commonly	commonly	ADV
gs-3920	13	52	the	the	DET
gs-3920	13	53	liver	liver	NOUN
gs-3920	13	54	,	,	PUNCT
gs-3920	13	55	kidneys	kidney	NOUN
gs-3920	13	56	,	,	PUNCT
gs-3920	13	57	and	and	CCONJ
gs-3920	13	58	lungs	lung	NOUN
gs-3920	13	59	.	.	PUNCT
gs-3920	14	1	dress	dress	NOUN
gs-3920	14	2	has	have	AUX
gs-3920	14	3	emerged	emerge	VERB
gs-3920	14	4	as	as	ADP
gs-3920	14	5	a	a	DET
gs-3920	14	6	significant	significant	ADJ
gs-3920	14	7	challenge	challenge	NOUN
gs-3920	14	8	in	in	ADP
gs-3920	14	9	modern	modern	ADJ
gs-3920	14	10	pharmacotherapy	pharmacotherapy	NOUN
gs-3920	14	11	,	,	PUNCT
gs-3920	14	12	not	not	PART
gs-3920	14	13	only	only	ADV
gs-3920	14	14	due	due	ADJ
gs-3920	14	15	to	to	ADP
gs-3920	14	16	its	its	PRON
gs-3920	14	17	diagnostic	diagnostic	ADJ
gs-3920	14	18	complexity	complexity	NOUN
gs-3920	14	19	and	and	CCONJ
gs-3920	14	20	the	the	DET
gs-3920	14	21	variability	variability	NOUN
gs-3920	14	22	in	in	ADP
gs-3920	14	23	clinical	clinical	ADJ
gs-3920	14	24	manifestations	manifestation	NOUN
gs-3920	14	25	but	but	CCONJ
gs-3920	14	26	also	also	ADV
gs-3920	14	27	because	because	SCONJ
gs-3920	14	28	of	of	ADP
gs-3920	14	29	the	the	DET
gs-3920	14	30	underlying	underlie	VERB
gs-3920	14	31	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	14	32	and	and	CCONJ
gs-3920	14	33	immunologic	immunologic	ADJ
gs-3920	14	34	mechanisms	mechanism	NOUN
gs-3920	14	35	that	that	PRON
gs-3920	14	36	predispose	predispose	VERB
gs-3920	14	37	susceptible	susceptible	ADJ
gs-3920	14	38	individuals	individual	NOUN
gs-3920	14	39	.	.	PUNCT
gs-3920	15	1	the	the	DET
gs-3920	15	2	interplay	interplay	NOUN
gs-3920	15	3	of	of	ADP
gs-3920	15	4	genetic	genetic	ADJ
gs-3920	15	5	predispositions	predisposition	NOUN
gs-3920	15	6	,	,	PUNCT
gs-3920	15	7	drug	drug	NOUN
gs-3920	15	8	metabolism	metabolism	NOUN
gs-3920	15	9	pathways	pathway	NOUN
gs-3920	15	10	,	,	PUNCT
gs-3920	15	11	immune	immune	ADJ
gs-3920	15	12	dysregulation	dysregulation	NOUN
gs-3920	15	13	,	,	PUNCT
gs-3920	15	14	and	and	CCONJ
gs-3920	15	15	environmental	environmental	ADJ
gs-3920	15	16	cofactors	cofactor	NOUN
gs-3920	15	17	makes	make	VERB
gs-3920	15	18	the	the	DET
gs-3920	15	19	management	management	NOUN
gs-3920	15	20	and	and	CCONJ
gs-3920	15	21	prediction	prediction	NOUN
gs-3920	15	22	of	of	ADP
gs-3920	15	23	dress	dress	NOUN
gs-3920	15	24	both	both	CCONJ
gs-3920	15	25	clinically	clinically	ADV
gs-3920	15	26	and	and	CCONJ
gs-3920	15	27	scientifically	scientifically	ADV
gs-3920	15	28	demanding	demanding	ADJ
gs-3920	15	29	.	.	PUNCT
gs-3920	16	1	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	16	2	plays	play	VERB
gs-3920	16	3	a	a	DET
gs-3920	16	4	pivotal	pivotal	ADJ
gs-3920	16	5	role	role	NOUN
gs-3920	16	6	in	in	ADP
gs-3920	16	7	understanding	understand	VERB
gs-3920	16	8	the	the	DET
gs-3920	16	9	individual	individual	ADJ
gs-3920	16	10	variability	variability	NOUN
gs-3920	16	11	in	in	ADP
gs-3920	16	12	the	the	DET
gs-3920	16	13	onset	onset	NOUN
gs-3920	16	14	and	and	CCONJ
gs-3920	16	15	severity	severity	NOUN
gs-3920	16	16	of	of	ADP
gs-3920	16	17	dress	dress	NOUN
gs-3920	16	18	.	.	PUNCT
gs-3920	17	1	specific	specific	ADJ
gs-3920	17	2	genetic	genetic	ADJ
gs-3920	17	3	markers	marker	NOUN
gs-3920	17	4	,	,	PUNCT
gs-3920	17	5	particularly	particularly	ADV
gs-3920	17	6	certain	certain	ADJ
gs-3920	17	7	human	human	ADJ
gs-3920	17	8	leukocyte	leukocyte	NOUN
gs-3920	17	9	antigen	antigen	NOUN
gs-3920	17	10	(	(	PUNCT
gs-3920	17	11	hla	hla	NOUN
gs-3920	17	12	)	)	PUNCT
gs-3920	17	13	alleles	allele	NOUN
gs-3920	17	14	,	,	PUNCT
gs-3920	17	15	have	have	AUX
gs-3920	17	16	been	be	AUX
gs-3920	17	17	closely	closely	ADV
gs-3920	17	18	linked	link	VERB
gs-3920	17	19	to	to	ADP
gs-3920	17	20	hypersensitivity	hypersensitivity	NOUN
gs-3920	17	21	reactions	reaction	NOUN
gs-3920	17	22	associated	associate	VERB
gs-3920	17	23	with	with	ADP
gs-3920	17	24	particular	particular	ADJ
gs-3920	17	25	medications	medication	NOUN
gs-3920	17	26	.	.	PUNCT
gs-3920	18	1	for	for	ADP
gs-3920	18	2	instance	instance	NOUN
gs-3920	18	3	,	,	PUNCT
gs-3920	18	4	the	the	DET
gs-3920	18	5	hla	hla	PROPN
gs-3920	18	6	-	-	PUNCT
gs-3920	18	7	b15:02	b15:02	PROPN
gs-3920	18	8	allele	allele	NOUN
gs-3920	18	9	has	have	AUX
gs-3920	18	10	been	be	AUX
gs-3920	18	11	implicated	implicate	VERB
gs-3920	18	12	in	in	ADP
gs-3920	18	13	carbamazepine	carbamazepine	NOUN
gs-3920	18	14	-	-	PUNCT
gs-3920	18	15	induced	induce	VERB
gs-3920	18	16	dress	dress	NOUN
gs-3920	18	17	,	,	PUNCT
gs-3920	18	18	especially	especially	ADV
gs-3920	18	19	among	among	ADP
gs-3920	18	20	individuals	individual	NOUN
gs-3920	18	21	of	of	ADP
gs-3920	18	22	asian	asian	ADJ
gs-3920	18	23	descent	descent	NOUN
gs-3920	18	24	.	.	PUNCT
gs-3920	19	1	similarly	similarly	ADV
gs-3920	19	2	,	,	PUNCT
gs-3920	19	3	associations	association	NOUN
gs-3920	19	4	between	between	ADP
gs-3920	19	5	allopurinolinduced	allopurinolinduced	ADJ
gs-3920	19	6	dress	dress	NOUN
gs-3920	19	7	and	and	CCONJ
gs-3920	19	8	hla	hla	NOUN
gs-3920	19	9	-	-	PUNCT
gs-3920	19	10	b58:01	b58:01	PROPN
gs-3920	19	11	have	have	AUX
gs-3920	19	12	been	be	AUX
gs-3920	19	13	strongly	strongly	ADV
gs-3920	19	14	established	establish	VERB
gs-3920	19	15	.	.	PUNCT
gs-3920	20	1	these	these	DET
gs-3920	20	2	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	20	3	insights	insight	NOUN
gs-3920	20	4	have	have	AUX
gs-3920	20	5	catalyzed	catalyze	VERB
gs-3920	20	6	efforts	effort	NOUN
gs-3920	20	7	toward	toward	ADP
gs-3920	20	8	personalized	personalized	ADJ
gs-3920	20	9	medicine	medicine	NOUN
gs-3920	20	10	,	,	PUNCT
gs-3920	20	11	where	where	SCONJ
gs-3920	20	12	genetic	genetic	ADJ
gs-3920	20	13	screening	screening	NOUN
gs-3920	20	14	before	before	ADP
gs-3920	20	15	initiating	initiate	VERB
gs-3920	20	16	therapy	therapy	NOUN
gs-3920	20	17	with	with	ADP
gs-3920	20	18	high	high	ADJ
gs-3920	20	19	-	-	PUNCT
gs-3920	20	20	risk	risk	NOUN
gs-3920	20	21	drugs	drug	NOUN
gs-3920	20	22	can	can	AUX
gs-3920	20	23	significantly	significantly	ADV
gs-3920	20	24	mitigate	mitigate	VERB
gs-3920	20	25	adverse	adverse	ADJ
gs-3920	20	26	reactions	reaction	NOUN
gs-3920	20	27	.	.	PUNCT
gs-3920	21	1	in	in	ADP
gs-3920	21	2	parallel	parallel	NOUN
gs-3920	21	3	,	,	PUNCT
gs-3920	21	4	polymorphisms	polymorphism	NOUN
gs-3920	21	5	in	in	ADP
gs-3920	21	6	genes	gene	NOUN
gs-3920	21	7	encoding	encode	VERB
gs-3920	21	8	drug	drug	NOUN
gs-3920	21	9	-	-	PUNCT
gs-3920	21	10	metabolizing	metabolize	VERB
gs-3920	21	11	enzymes	enzyme	NOUN
gs-3920	21	12	and	and	CCONJ
gs-3920	21	13	transporters	transporter	NOUN
gs-3920	21	14	,	,	PUNCT
gs-3920	21	15	such	such	ADJ
gs-3920	21	16	as	as	ADP
gs-3920	21	17	cytochrome	cytochrome	ADJ
gs-3920	21	18	p450	p450	NUM
gs-3920	21	19	isoenzymes	isoenzyme	NOUN
gs-3920	21	20	,	,	PUNCT
gs-3920	21	21	have	have	AUX
gs-3920	21	22	also	also	ADV
gs-3920	21	23	been	be	AUX
gs-3920	21	24	implicated	implicate	VERB
gs-3920	21	25	,	,	PUNCT
gs-3920	21	26	suggesting	suggest	VERB
gs-3920	21	27	that	that	SCONJ
gs-3920	21	28	impaired	impaired	ADJ
gs-3920	21	29	detoxification	detoxification	NOUN
gs-3920	21	30	of	of	ADP
gs-3920	21	31	reactive	reactive	ADJ
gs-3920	21	32	drug	drug	NOUN
gs-3920	21	33	metabolites	metabolite	NOUN
gs-3920	21	34	may	may	AUX
gs-3920	21	35	provoke	provoke	VERB
gs-3920	21	36	an	an	DET
gs-3920	21	37	exaggerated	exaggerated	ADJ
gs-3920	21	38	immune	immune	ADJ
gs-3920	21	39	response	response	NOUN
gs-3920	21	40	.	.	PUNCT
gs-3920	22	1	the	the	DET
gs-3920	22	2	list	list	NOUN
gs-3920	22	3	of	of	ADP
gs-3920	22	4	causative	causative	ADJ
gs-3920	22	5	agents	agent	NOUN
gs-3920	22	6	associated	associate	VERB
gs-3920	22	7	with	with	ADP
gs-3920	22	8	dress	dress	NOUN
gs-3920	22	9	is	be	AUX
gs-3920	22	10	extensive	extensive	ADJ
gs-3920	22	11	and	and	CCONJ
gs-3920	22	12	continues	continue	VERB
gs-3920	22	13	to	to	PART
gs-3920	22	14	expand	expand	VERB
gs-3920	22	15	georgian	georgian	ADJ
gs-3920	22	16	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	22	17	მეცნიერები	მეცნიერები	NOUN
gs-3920	22	18	ტ.	ტ.	VERB
gs-3920	22	19	7	7	NUM
gs-3920	22	20	n	n	DET
gs-3920	22	21	3	3	NUM
gs-3920	22	22	,	,	PUNCT
gs-3920	22	23	2025	2025	NUM
gs-3920	22	24	182	182	NUM
gs-3920	22	25	with	with	ADP
gs-3920	22	26	ongoing	ongoing	ADJ
gs-3920	22	27	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	22	28	.	.	PUNCT
gs-3920	23	1	anticonvulsants	anticonvulsant	NOUN
gs-3920	23	2	,	,	PUNCT
gs-3920	23	3	including	include	VERB
gs-3920	23	4	phenytoin	phenytoin	NOUN
gs-3920	23	5	,	,	PUNCT
gs-3920	23	6	carbamazepine	carbamazepine	NOUN
gs-3920	23	7	,	,	PUNCT
gs-3920	23	8	and	and	CCONJ
gs-3920	23	9	lamotrigine	lamotrigine	NOUN
gs-3920	23	10	,	,	PUNCT
gs-3920	23	11	remain	remain	VERB
gs-3920	23	12	among	among	ADP
gs-3920	23	13	the	the	DET
gs-3920	23	14	most	most	ADV
gs-3920	23	15	commonly	commonly	ADV
gs-3920	23	16	implicated	implicate	VERB
gs-3920	23	17	drugs	drug	NOUN
gs-3920	23	18	.	.	PUNCT
gs-3920	24	1	antimicrobials	antimicrobial	NOUN
gs-3920	24	2	such	such	ADJ
gs-3920	24	3	as	as	ADP
gs-3920	24	4	minocycline	minocycline	NOUN
gs-3920	24	5	,	,	PUNCT
gs-3920	24	6	vancomycin	vancomycin	PROPN
gs-3920	24	7	,	,	PUNCT
gs-3920	24	8	and	and	CCONJ
gs-3920	24	9	sulfonamides	sulfonamide	NOUN
gs-3920	24	10	are	be	AUX
gs-3920	24	11	also	also	ADV
gs-3920	24	12	frequent	frequent	ADJ
gs-3920	24	13	offenders	offender	NOUN
gs-3920	24	14	.	.	PUNCT
gs-3920	25	1	moreover	moreover	ADV
gs-3920	25	2	,	,	PUNCT
gs-3920	25	3	the	the	DET
gs-3920	25	4	increasing	increase	VERB
gs-3920	25	5	use	use	NOUN
gs-3920	25	6	of	of	ADP
gs-3920	25	7	biologics	biologic	NOUN
gs-3920	25	8	and	and	CCONJ
gs-3920	25	9	novel	novel	NOUN
gs-3920	25	10	cancer	cancer	NOUN
gs-3920	25	11	immunotherapies	immunotherapy	NOUN
gs-3920	25	12	has	have	AUX
gs-3920	25	13	introduced	introduce	VERB
gs-3920	25	14	new	new	ADJ
gs-3920	25	15	etiologic	etiologic	ADJ
gs-3920	25	16	agents	agent	NOUN
gs-3920	25	17	capable	capable	ADJ
gs-3920	25	18	of	of	ADP
gs-3920	25	19	triggering	trigger	VERB
gs-3920	25	20	dress	dress	NOUN
gs-3920	25	21	,	,	PUNCT
gs-3920	25	22	further	far	ADV
gs-3920	25	23	complicating	complicate	VERB
gs-3920	25	24	the	the	DET
gs-3920	25	25	landscape	landscape	NOUN
gs-3920	25	26	of	of	ADP
gs-3920	25	27	drug	drug	NOUN
gs-3920	25	28	safety	safety	NOUN
gs-3920	25	29	.	.	PUNCT
gs-3920	26	1	the	the	DET
gs-3920	26	2	latency	latency	NOUN
gs-3920	26	3	period	period	NOUN
gs-3920	26	4	,	,	PUNCT
gs-3920	26	5	typically	typically	ADV
gs-3920	26	6	ranging	range	VERB
gs-3920	26	7	from	from	ADP
gs-3920	26	8	two	two	NUM
gs-3920	26	9	to	to	PART
gs-3920	26	10	eight	eight	NUM
gs-3920	26	11	weeks	week	NOUN
gs-3920	26	12	,	,	PUNCT
gs-3920	26	13	complicates	complicate	VERB
gs-3920	26	14	the	the	DET
gs-3920	26	15	identification	identification	NOUN
gs-3920	26	16	of	of	ADP
gs-3920	26	17	the	the	DET
gs-3920	26	18	responsible	responsible	ADJ
gs-3920	26	19	drug	drug	NOUN
gs-3920	26	20	,	,	PUNCT
gs-3920	26	21	especially	especially	ADV
gs-3920	26	22	in	in	ADP
gs-3920	26	23	polypharmacy	polypharmacy	NOUN
gs-3920	26	24	scenarios	scenario	NOUN
gs-3920	26	25	.	.	PUNCT
gs-3920	27	1	this	this	PRON
gs-3920	27	2	underscores	underscore	VERB
gs-3920	27	3	the	the	DET
gs-3920	27	4	necessity	necessity	NOUN
gs-3920	27	5	for	for	ADP
gs-3920	27	6	robust	robust	ADJ
gs-3920	27	7	clinical	clinical	ADJ
gs-3920	27	8	judgment	judgment	NOUN
gs-3920	27	9	,	,	PUNCT
gs-3920	27	10	a	a	DET
gs-3920	27	11	detailed	detailed	ADJ
gs-3920	27	12	patient	patient	ADJ
gs-3920	27	13	history	history	NOUN
gs-3920	27	14	,	,	PUNCT
gs-3920	27	15	and	and	CCONJ
gs-3920	27	16	interdisciplinary	interdisciplinary	ADJ
gs-3920	27	17	collaboration	collaboration	NOUN
gs-3920	27	18	in	in	ADP
gs-3920	27	19	managing	manage	VERB
gs-3920	27	20	suspected	suspect	VERB
gs-3920	27	21	cases	case	NOUN
gs-3920	27	22	.	.	PUNCT
gs-3920	28	1	risk	risk	NOUN
gs-3920	28	2	factors	factor	NOUN
gs-3920	28	3	for	for	ADP
gs-3920	28	4	the	the	DET
gs-3920	28	5	development	development	NOUN
gs-3920	28	6	of	of	ADP
gs-3920	28	7	dress	dress	NOUN
gs-3920	28	8	are	be	AUX
gs-3920	28	9	multifactorial	multifactorial	ADJ
gs-3920	28	10	.	.	PUNCT
gs-3920	29	1	in	in	ADP
gs-3920	29	2	addition	addition	NOUN
gs-3920	29	3	to	to	ADP
gs-3920	29	4	genetic	genetic	ADJ
gs-3920	29	5	predisposition	predisposition	NOUN
gs-3920	29	6	,	,	PUNCT
gs-3920	29	7	factors	factor	NOUN
gs-3920	29	8	such	such	ADJ
gs-3920	29	9	as	as	ADP
gs-3920	29	10	age	age	NOUN
gs-3920	29	11	,	,	PUNCT
gs-3920	29	12	ethnicity	ethnicity	NOUN
gs-3920	29	13	,	,	PUNCT
gs-3920	29	14	comorbid	comorbid	ADJ
gs-3920	29	15	autoimmune	autoimmune	ADJ
gs-3920	29	16	diseases	disease	NOUN
gs-3920	29	17	,	,	PUNCT
gs-3920	29	18	previous	previous	ADJ
gs-3920	29	19	hypersensitivity	hypersensitivity	NOUN
gs-3920	29	20	reactions	reaction	NOUN
gs-3920	29	21	,	,	PUNCT
gs-3920	29	22	and	and	CCONJ
gs-3920	29	23	certain	certain	ADJ
gs-3920	29	24	viral	viral	ADJ
gs-3920	29	25	infections	infection	NOUN
gs-3920	29	26	,	,	PUNCT
gs-3920	29	27	particularly	particularly	ADV
gs-3920	29	28	human	human	ADJ
gs-3920	29	29	herpesvirus	herpesvirus	NOUN
gs-3920	29	30	6	6	NUM
gs-3920	29	31	(	(	PUNCT
gs-3920	29	32	hhv-6	hhv-6	NOUN
gs-3920	29	33	)	)	PUNCT
gs-3920	29	34	,	,	PUNCT
gs-3920	29	35	play	play	VERB
gs-3920	29	36	a	a	DET
gs-3920	29	37	contributory	contributory	ADJ
gs-3920	29	38	role	role	NOUN
gs-3920	29	39	.	.	PUNCT
gs-3920	30	1	viral	viral	ADJ
gs-3920	30	2	reactivation	reactivation	NOUN
gs-3920	30	3	has	have	AUX
gs-3920	30	4	been	be	AUX
gs-3920	30	5	recognized	recognize	VERB
gs-3920	30	6	as	as	ADP
gs-3920	30	7	both	both	CCONJ
gs-3920	30	8	a	a	DET
gs-3920	30	9	potential	potential	ADJ
gs-3920	30	10	trigger	trigger	NOUN
gs-3920	30	11	and	and	CCONJ
gs-3920	30	12	an	an	DET
gs-3920	30	13	exacerbating	exacerbate	VERB
gs-3920	30	14	factor	factor	NOUN
gs-3920	30	15	,	,	PUNCT
gs-3920	30	16	with	with	ADP
gs-3920	30	17	some	some	DET
gs-3920	30	18	studies	study	NOUN
gs-3920	30	19	suggesting	suggest	VERB
gs-3920	30	20	that	that	SCONJ
gs-3920	30	21	it	it	PRON
gs-3920	30	22	may	may	AUX
gs-3920	30	23	drive	drive	VERB
gs-3920	30	24	systemic	systemic	ADJ
gs-3920	30	25	inflammation	inflammation	NOUN
gs-3920	30	26	and	and	CCONJ
gs-3920	30	27	prolong	prolong	VERB
gs-3920	30	28	the	the	DET
gs-3920	30	29	course	course	NOUN
gs-3920	30	30	of	of	ADP
gs-3920	30	31	illness	illness	NOUN
gs-3920	30	32	.	.	PUNCT
gs-3920	31	1	the	the	DET
gs-3920	31	2	presence	presence	NOUN
gs-3920	31	3	of	of	ADP
gs-3920	31	4	such	such	ADJ
gs-3920	31	5	cofactors	cofactor	NOUN
gs-3920	31	6	not	not	PART
gs-3920	31	7	only	only	ADV
gs-3920	31	8	amplifies	amplify	VERB
gs-3920	31	9	the	the	DET
gs-3920	31	10	severity	severity	NOUN
gs-3920	31	11	of	of	ADP
gs-3920	31	12	dress	dress	NOUN
gs-3920	31	13	but	but	CCONJ
gs-3920	31	14	may	may	AUX
gs-3920	31	15	also	also	ADV
gs-3920	31	16	delay	delay	VERB
gs-3920	31	17	recovery	recovery	NOUN
gs-3920	31	18	and	and	CCONJ
gs-3920	31	19	increase	increase	VERB
gs-3920	31	20	the	the	DET
gs-3920	31	21	risk	risk	NOUN
gs-3920	31	22	of	of	ADP
gs-3920	31	23	long	long	ADJ
gs-3920	31	24	-	-	PUNCT
gs-3920	31	25	term	term	NOUN
gs-3920	31	26	complications	complication	NOUN
gs-3920	31	27	such	such	ADJ
gs-3920	31	28	as	as	ADP
gs-3920	31	29	autoimmune	autoimmune	ADJ
gs-3920	31	30	sequelae	sequelae	PROPN
gs-3920	31	31	,	,	PUNCT
gs-3920	31	32	which	which	PRON
gs-3920	31	33	have	have	AUX
gs-3920	31	34	been	be	AUX
gs-3920	31	35	observed	observe	VERB
gs-3920	31	36	in	in	ADP
gs-3920	31	37	a	a	DET
gs-3920	31	38	subset	subset	NOUN
gs-3920	31	39	of	of	ADP
gs-3920	31	40	patients	patient	NOUN
gs-3920	31	41	following	follow	VERB
gs-3920	31	42	acute	acute	ADJ
gs-3920	31	43	resolution	resolution	NOUN
gs-3920	31	44	.	.	PUNCT
gs-3920	32	1	diagnosis	diagnosis	NOUN
gs-3920	32	2	of	of	ADP
gs-3920	32	3	dress	dress	NOUN
gs-3920	32	4	remains	remain	VERB
gs-3920	32	5	largely	largely	ADV
gs-3920	32	6	clinical	clinical	ADJ
gs-3920	32	7	,	,	PUNCT
gs-3920	32	8	supported	support	VERB
gs-3920	32	9	by	by	ADP
gs-3920	32	10	scoring	score	VERB
gs-3920	32	11	systems	system	NOUN
gs-3920	32	12	such	such	ADJ
gs-3920	32	13	as	as	ADP
gs-3920	32	14	regiscar	regiscar	NOUN
gs-3920	32	15	,	,	PUNCT
gs-3920	32	16	which	which	PRON
gs-3920	32	17	incorporates	incorporate	VERB
gs-3920	32	18	parameters	parameter	NOUN
gs-3920	32	19	including	include	VERB
gs-3920	32	20	fever	fever	NOUN
gs-3920	32	21	,	,	PUNCT
gs-3920	32	22	rash	rash	ADJ
gs-3920	32	23	,	,	PUNCT
gs-3920	32	24	eosinophilia	eosinophilia	PROPN
gs-3920	32	25	,	,	PUNCT
gs-3920	32	26	organ	organ	NOUN
gs-3920	32	27	involvement	involvement	NOUN
gs-3920	32	28	,	,	PUNCT
gs-3920	32	29	and	and	CCONJ
gs-3920	32	30	the	the	DET
gs-3920	32	31	exclusion	exclusion	NOUN
gs-3920	32	32	of	of	ADP
gs-3920	32	33	alternative	alternative	ADJ
gs-3920	32	34	etiologies	etiology	NOUN
gs-3920	32	35	.	.	PUNCT
gs-3920	33	1	however	however	ADV
gs-3920	33	2	,	,	PUNCT
gs-3920	33	3	these	these	DET
gs-3920	33	4	criteria	criterion	NOUN
gs-3920	33	5	are	be	AUX
gs-3920	33	6	not	not	PART
gs-3920	33	7	universally	universally	ADV
gs-3920	33	8	applied	apply	VERB
gs-3920	33	9	,	,	PUNCT
gs-3920	33	10	and	and	CCONJ
gs-3920	33	11	diagnostic	diagnostic	ADJ
gs-3920	33	12	delays	delay	NOUN
gs-3920	33	13	are	be	AUX
gs-3920	33	14	common	common	ADJ
gs-3920	33	15	,	,	PUNCT
gs-3920	33	16	particularly	particularly	ADV
gs-3920	33	17	in	in	ADP
gs-3920	33	18	atypical	atypical	ADJ
gs-3920	33	19	or	or	CCONJ
gs-3920	33	20	incomplete	incomplete	ADJ
gs-3920	33	21	presentations	presentation	NOUN
gs-3920	33	22	.	.	PUNCT
gs-3920	34	1	research	research	NOUN
gs-3920	34	2	into	into	ADP
gs-3920	34	3	the	the	DET
gs-3920	34	4	pathogenesis	pathogenesis	NOUN
gs-3920	34	5	and	and	CCONJ
gs-3920	34	6	treatment	treatment	NOUN
gs-3920	34	7	of	of	ADP
gs-3920	34	8	dress	dress	NOUN
gs-3920	34	9	continues	continue	VERB
gs-3920	34	10	to	to	PART
gs-3920	34	11	evolve	evolve	VERB
gs-3920	34	12	.	.	PUNCT
gs-3920	35	1	advances	advance	NOUN
gs-3920	35	2	in	in	ADP
gs-3920	35	3	immunogenetics	immunogenetic	NOUN
gs-3920	35	4	,	,	PUNCT
gs-3920	35	5	transcriptomics	transcriptomic	NOUN
gs-3920	35	6	,	,	PUNCT
gs-3920	35	7	and	and	CCONJ
gs-3920	35	8	systems	system	NOUN
gs-3920	35	9	biology	biology	NOUN
gs-3920	35	10	are	be	AUX
gs-3920	35	11	shedding	shed	VERB
gs-3920	35	12	light	light	NOUN
gs-3920	35	13	on	on	ADP
gs-3920	35	14	the	the	DET
gs-3920	35	15	molecular	molecular	ADJ
gs-3920	35	16	pathways	pathway	NOUN
gs-3920	35	17	that	that	PRON
gs-3920	35	18	mediate	mediate	VERB
gs-3920	35	19	hypersensitivity	hypersensitivity	NOUN
gs-3920	35	20	reactions	reaction	NOUN
gs-3920	35	21	.	.	PUNCT
gs-3920	36	1	these	these	DET
gs-3920	36	2	insights	insight	NOUN
gs-3920	36	3	not	not	PART
gs-3920	36	4	only	only	ADV
gs-3920	36	5	improve	improve	VERB
gs-3920	36	6	diagnostic	diagnostic	ADJ
gs-3920	36	7	accuracy	accuracy	NOUN
gs-3920	36	8	but	but	CCONJ
gs-3920	36	9	also	also	ADV
gs-3920	36	10	open	open	VERB
gs-3920	36	11	the	the	DET
gs-3920	36	12	door	door	NOUN
gs-3920	36	13	to	to	PART
gs-3920	36	14	novel	novel	VERB
gs-3920	36	15	therapeutic	therapeutic	ADJ
gs-3920	36	16	targets	target	NOUN
gs-3920	36	17	.	.	PUNCT
gs-3920	37	1	collaboration	collaboration	NOUN
gs-3920	37	2	between	between	ADP
gs-3920	37	3	clinicians	clinician	NOUN
gs-3920	37	4	,	,	PUNCT
gs-3920	37	5	pharmacologists	pharmacologist	NOUN
gs-3920	37	6	,	,	PUNCT
gs-3920	37	7	geneticists	geneticist	NOUN
gs-3920	37	8	,	,	PUNCT
gs-3920	37	9	and	and	CCONJ
gs-3920	37	10	regulatory	regulatory	ADJ
gs-3920	37	11	bodies	body	NOUN
gs-3920	37	12	is	be	AUX
gs-3920	37	13	essential	essential	ADJ
gs-3920	37	14	to	to	PART
gs-3920	37	15	translate	translate	VERB
gs-3920	37	16	these	these	DET
gs-3920	37	17	discoveries	discovery	NOUN
gs-3920	37	18	into	into	ADP
gs-3920	37	19	tangible	tangible	ADJ
gs-3920	37	20	benefits	benefit	NOUN
gs-3920	37	21	for	for	ADP
gs-3920	37	22	patient	patient	ADJ
gs-3920	37	23	safety	safety	NOUN
gs-3920	37	24	.	.	PUNCT
gs-3920	38	1	international	international	ADJ
gs-3920	38	2	registries	registry	NOUN
gs-3920	38	3	and	and	CCONJ
gs-3920	38	4	multicenter	multicenter	NOUN
gs-3920	38	5	studies	study	NOUN
gs-3920	38	6	are	be	AUX
gs-3920	38	7	needed	need	VERB
gs-3920	38	8	to	to	PART
gs-3920	38	9	strengthen	strengthen	VERB
gs-3920	38	10	the	the	DET
gs-3920	38	11	evidence	evidence	NOUN
gs-3920	38	12	base	base	NOUN
gs-3920	38	13	,	,	PUNCT
gs-3920	38	14	given	give	VERB
gs-3920	38	15	the	the	DET
gs-3920	38	16	rarity	rarity	NOUN
gs-3920	38	17	of	of	ADP
gs-3920	38	18	the	the	DET
gs-3920	38	19	condition	condition	NOUN
gs-3920	38	20	and	and	CCONJ
gs-3920	38	21	the	the	DET
gs-3920	38	22	variability	variability	NOUN
gs-3920	38	23	in	in	ADP
gs-3920	38	24	clinical	clinical	ADJ
gs-3920	38	25	practice	practice	NOUN
gs-3920	38	26	.	.	PUNCT
gs-3920	39	1	dress	dress	NOUN
gs-3920	39	2	syndrome	syndrome	NOUN
gs-3920	39	3	epitomizes	epitomize	VERB
gs-3920	39	4	the	the	DET
gs-3920	39	5	complexity	complexity	NOUN
gs-3920	39	6	of	of	ADP
gs-3920	39	7	drug	drug	NOUN
gs-3920	39	8	-	-	PUNCT
gs-3920	39	9	induced	induce	VERB
gs-3920	39	10	hypersensitivity	hypersensitivity	NOUN
gs-3920	39	11	,	,	PUNCT
gs-3920	39	12	where	where	SCONJ
gs-3920	39	13	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	39	14	,	,	PUNCT
gs-3920	39	15	immunology	immunology	NOUN
gs-3920	39	16	,	,	PUNCT
gs-3920	39	17	and	and	CCONJ
gs-3920	39	18	clinical	clinical	ADJ
gs-3920	39	19	medicine	medicine	NOUN
gs-3920	39	20	intersect	intersect	ADJ
gs-3920	39	21	.	.	PUNCT
gs-3920	40	1	the	the	DET
gs-3920	40	2	syndrome	syndrome	NOUN
gs-3920	40	3	requires	require	VERB
gs-3920	40	4	a	a	DET
gs-3920	40	5	high	high	ADJ
gs-3920	40	6	index	index	NOUN
gs-3920	40	7	of	of	ADP
gs-3920	40	8	suspicion	suspicion	NOUN
gs-3920	40	9	,	,	PUNCT
gs-3920	40	10	timely	timely	ADJ
gs-3920	40	11	intervention	intervention	NOUN
gs-3920	40	12	,	,	PUNCT
gs-3920	40	13	and	and	CCONJ
gs-3920	40	14	multidisciplinary	multidisciplinary	ADJ
gs-3920	40	15	coordination	coordination	NOUN
gs-3920	40	16	to	to	PART
gs-3920	40	17	minimize	minimize	VERB
gs-3920	40	18	morbidity	morbidity	NOUN
gs-3920	40	19	and	and	CCONJ
gs-3920	40	20	mortality	mortality	NOUN
gs-3920	40	21	.	.	PUNCT
gs-3920	41	1	the	the	DET
gs-3920	41	2	future	future	NOUN
gs-3920	41	3	of	of	ADP
gs-3920	41	4	dress	dress	NOUN
gs-3920	41	5	management	management	NOUN
gs-3920	41	6	lies	lie	VERB
gs-3920	41	7	in	in	ADP
gs-3920	41	8	personalized	personalized	ADJ
gs-3920	41	9	medicine	medicine	NOUN
gs-3920	41	10	,	,	PUNCT
gs-3920	41	11	proactive	proactive	ADJ
gs-3920	41	12	risk	risk	NOUN
gs-3920	41	13	stratification	stratification	NOUN
gs-3920	41	14	,	,	PUNCT
gs-3920	41	15	and	and	CCONJ
gs-3920	41	16	continued	continued	ADJ
gs-3920	41	17	research	research	NOUN
gs-3920	41	18	into	into	ADP
gs-3920	41	19	safer	safe	ADJ
gs-3920	41	20	pharmacological	pharmacological	ADJ
gs-3920	41	21	alternatives	alternative	NOUN
gs-3920	41	22	.	.	PUNCT
gs-3920	42	1	a	a	DET
gs-3920	42	2	comprehensive	comprehensive	ADJ
gs-3920	42	3	understanding	understanding	NOUN
gs-3920	42	4	of	of	ADP
gs-3920	42	5	the	the	DET
gs-3920	42	6	implicated	implicated	ADJ
gs-3920	42	7	agents	agent	NOUN
gs-3920	42	8	,	,	PUNCT
gs-3920	42	9	risk	risk	NOUN
gs-3920	42	10	factors	factor	NOUN
gs-3920	42	11	,	,	PUNCT
gs-3920	42	12	and	and	CCONJ
gs-3920	42	13	therapeutic	therapeutic	ADJ
gs-3920	42	14	strategies	strategy	NOUN
gs-3920	42	15	is	be	AUX
gs-3920	42	16	indispensable	indispensable	ADJ
gs-3920	42	17	to	to	ADP
gs-3920	42	18	improving	improve	VERB
gs-3920	42	19	patient	patient	ADJ
gs-3920	42	20	outcomes	outcome	NOUN
gs-3920	42	21	and	and	CCONJ
gs-3920	42	22	guiding	guide	VERB
gs-3920	42	23	evidence	evidence	NOUN
gs-3920	42	24	-	-	PUNCT
gs-3920	42	25	based	base	VERB
gs-3920	42	26	clinical	clinical	ADJ
gs-3920	42	27	decisionmaking	decisionmaking	NOUN
gs-3920	42	28	.	.	PUNCT
gs-3920	43	1	keywords	keyword	NOUN
gs-3920	43	2	:	:	PUNCT
gs-3920	43	3	drug	drug	NOUN
gs-3920	43	4	characteristics	characteristic	NOUN
gs-3920	43	5	,	,	PUNCT
gs-3920	43	6	side	side	NOUN
gs-3920	43	7	effects	effect	NOUN
gs-3920	43	8	,	,	PUNCT
gs-3920	43	9	induced	induce	VERB
gs-3920	43	10	drug	drug	NOUN
gs-3920	43	11	reaction	reaction	NOUN
gs-3920	43	12	,	,	PUNCT
gs-3920	43	13	eosinophilia	eosinophilia	PROPN
gs-3920	43	14	and	and	CCONJ
gs-3920	43	15	systemic	systemic	ADJ
gs-3920	43	16	symptoms	symptom	NOUN
gs-3920	43	17	.	.	PUNCT
gs-3920	44	1	georgian	georgian	ADJ
gs-3920	44	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	44	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	44	4	ტ.	ტ.	VERB
gs-3920	44	5	7	7	NUM
gs-3920	44	6	n	n	PRON
gs-3920	44	7	3	3	NUM
gs-3920	44	8	,	,	PUNCT
gs-3920	44	9	2025	2025	NUM
gs-3920	44	10	183	183	NUM
gs-3920	44	11	background	background	NOUN
gs-3920	44	12	the	the	DET
gs-3920	44	13	pathophysiology	pathophysiology	NOUN
gs-3920	44	14	of	of	ADP
gs-3920	44	15	drug	drug	NOUN
gs-3920	44	16	reaction	reaction	NOUN
gs-3920	44	17	with	with	ADP
gs-3920	44	18	eosinophilia	eosinophilia	PROPN
gs-3920	44	19	and	and	CCONJ
gs-3920	44	20	systemic	systemic	ADJ
gs-3920	44	21	symptoms	symptom	NOUN
gs-3920	44	22	(	(	PUNCT
gs-3920	44	23	dress	dress	NOUN
gs-3920	44	24	)	)	PUNCT
gs-3920	44	25	remains	remain	VERB
gs-3920	44	26	incompletely	incompletely	ADV
gs-3920	44	27	understood	understand	VERB
gs-3920	44	28	but	but	CCONJ
gs-3920	44	29	is	be	AUX
gs-3920	44	30	believed	believe	VERB
gs-3920	44	31	to	to	PART
gs-3920	44	32	be	be	AUX
gs-3920	44	33	multifactorial	multifactorial	ADJ
gs-3920	44	34	,	,	PUNCT
gs-3920	44	35	involving	involve	VERB
gs-3920	44	36	genetic	genetic	ADJ
gs-3920	44	37	predisposition	predisposition	NOUN
gs-3920	44	38	(	(	PUNCT
gs-3920	44	39	particularly	particularly	ADV
gs-3920	44	40	hla	hla	NOUN
gs-3920	44	41	alleles	allele	NOUN
gs-3920	44	42	)	)	PUNCT
gs-3920	44	43	,	,	PUNCT
gs-3920	44	44	accumulation	accumulation	NOUN
gs-3920	44	45	of	of	ADP
gs-3920	44	46	toxic	toxic	ADJ
gs-3920	44	47	drug	drug	NOUN
gs-3920	44	48	metabolites	metabolite	NOUN
gs-3920	44	49	due	due	ADJ
gs-3920	44	50	to	to	ADP
gs-3920	44	51	defects	defect	NOUN
gs-3920	44	52	in	in	ADP
gs-3920	44	53	drug	drug	NOUN
gs-3920	44	54	metabolism	metabolism	NOUN
gs-3920	44	55	,	,	PUNCT
gs-3920	44	56	viral	viral	ADJ
gs-3920	44	57	reactivation	reactivation	NOUN
gs-3920	44	58	(	(	PUNCT
gs-3920	44	59	particularly	particularly	ADV
gs-3920	44	60	human	human	ADJ
gs-3920	44	61	herpesvirus	herpesvirus	NOUN
gs-3920	44	62	6	6	NUM
gs-3920	44	63	and	and	CCONJ
gs-3920	44	64	epstein	epstein	PROPN
gs-3920	44	65	-	-	PUNCT
gs-3920	44	66	barr	barr	PROPN
gs-3920	44	67	virus	virus	PROPN
gs-3920	44	68	)	)	PUNCT
gs-3920	44	69	,	,	PUNCT
gs-3920	44	70	and	and	CCONJ
gs-3920	44	71	immune	immune	ADJ
gs-3920	44	72	deregulations	deregulation	NOUN
gs-3920	44	73	.	.	PUNCT
gs-3920	45	1	the	the	DET
gs-3920	45	2	long	long	ADJ
gs-3920	45	3	latency	latency	NOUN
gs-3920	45	4	period	period	NOUN
gs-3920	45	5	,	,	PUNCT
gs-3920	45	6	typically	typically	ADV
gs-3920	45	7	2–8	2–8	NUM
gs-3920	45	8	weeks	week	NOUN
gs-3920	45	9	after	after	ADP
gs-3920	45	10	drug	drug	NOUN
gs-3920	45	11	exposure	exposure	NOUN
gs-3920	45	12	,	,	PUNCT
gs-3920	45	13	poses	pose	VERB
gs-3920	45	14	a	a	DET
gs-3920	45	15	diagnostic	diagnostic	ADJ
gs-3920	45	16	challenge	challenge	NOUN
gs-3920	45	17	and	and	CCONJ
gs-3920	45	18	frequently	frequently	ADV
gs-3920	45	19	leads	lead	VERB
gs-3920	45	20	to	to	ADP
gs-3920	45	21	misattribution	misattribution	NOUN
gs-3920	45	22	of	of	ADP
gs-3920	45	23	the	the	DET
gs-3920	45	24	causative	causative	ADJ
gs-3920	45	25	agent	agent	NOUN
gs-3920	45	26	.	.	PUNCT
gs-3920	46	1	once	once	ADV
gs-3920	46	2	initiated	initiate	VERB
gs-3920	46	3	,	,	PUNCT
gs-3920	46	4	the	the	DET
gs-3920	46	5	syndrome	syndrome	NOUN
gs-3920	46	6	may	may	AUX
gs-3920	46	7	persist	persist	VERB
gs-3920	46	8	or	or	CCONJ
gs-3920	46	9	worsen	worsen	VERB
gs-3920	46	10	despite	despite	SCONJ
gs-3920	46	11	discontinuation	discontinuation	NOUN
gs-3920	46	12	of	of	ADP
gs-3920	46	13	the	the	DET
gs-3920	46	14	offending	offend	VERB
gs-3920	46	15	drug	drug	NOUN
gs-3920	46	16	,	,	PUNCT
gs-3920	46	17	due	due	ADP
gs-3920	46	18	to	to	ADP
gs-3920	46	19	the	the	DET
gs-3920	46	20	ongoing	ongoing	ADJ
gs-3920	46	21	immunological	immunological	ADJ
gs-3920	46	22	cascade	cascade	NOUN
gs-3920	46	23	and	and	CCONJ
gs-3920	46	24	viral	viral	ADJ
gs-3920	46	25	replication	replication	NOUN
gs-3920	46	26	.	.	PUNCT
gs-3920	47	1	pharmacological	pharmacological	ADJ
gs-3920	47	2	characteristics	characteristic	NOUN
gs-3920	47	3	of	of	ADP
gs-3920	47	4	dress	dress	NOUN
gs-3920	47	5	-	-	PUNCT
gs-3920	47	6	inducing	induce	VERB
gs-3920	47	7	drugs	drug	NOUN
gs-3920	47	8	reveal	reveal	VERB
gs-3920	47	9	common	common	ADJ
gs-3920	47	10	features	feature	NOUN
gs-3920	47	11	,	,	PUNCT
gs-3920	47	12	including	include	VERB
gs-3920	47	13	aromatic	aromatic	ADJ
gs-3920	47	14	ring	ring	NOUN
gs-3920	47	15	structures	structure	NOUN
gs-3920	47	16	,	,	PUNCT
gs-3920	47	17	complex	complex	ADJ
gs-3920	47	18	hepatic	hepatic	ADJ
gs-3920	47	19	metabolism	metabolism	NOUN
gs-3920	47	20	,	,	PUNCT
gs-3920	47	21	and	and	CCONJ
gs-3920	47	22	formation	formation	NOUN
gs-3920	47	23	of	of	ADP
gs-3920	47	24	reactive	reactive	ADJ
gs-3920	47	25	intermediates	intermediate	NOUN
gs-3920	47	26	.	.	PUNCT
gs-3920	48	1	these	these	DET
gs-3920	48	2	agents	agent	NOUN
gs-3920	48	3	often	often	ADV
gs-3920	48	4	undergo	undergo	VERB
gs-3920	48	5	phase	phase	NOUN
gs-3920	48	6	i	i	PRON
gs-3920	48	7	metabolism	metabolism	NOUN
gs-3920	48	8	via	via	ADP
gs-3920	48	9	cytochrome	cytochrome	ADJ
gs-3920	48	10	p450	p450	NUM
gs-3920	48	11	enzymes	enzyme	NOUN
gs-3920	48	12	,	,	PUNCT
gs-3920	48	13	leading	lead	VERB
gs-3920	48	14	to	to	ADP
gs-3920	48	15	the	the	DET
gs-3920	48	16	accumulation	accumulation	NOUN
gs-3920	48	17	of	of	ADP
gs-3920	48	18	reactive	reactive	ADJ
gs-3920	48	19	metabolites	metabolite	NOUN
gs-3920	48	20	that	that	PRON
gs-3920	48	21	may	may	AUX
gs-3920	48	22	form	form	VERB
gs-3920	48	23	hapten	hapten	VERB
gs-3920	48	24	-	-	PUNCT
gs-3920	48	25	protein	protein	NOUN
gs-3920	48	26	complexes	complex	NOUN
gs-3920	48	27	,	,	PUNCT
gs-3920	48	28	subsequently	subsequently	ADV
gs-3920	48	29	triggering	trigger	VERB
gs-3920	48	30	tcell	tcell	NOUN
gs-3920	48	31	-	-	PUNCT
gs-3920	48	32	mediated	mediate	VERB
gs-3920	48	33	immune	immune	ADJ
gs-3920	48	34	responses	response	NOUN
gs-3920	48	35	.	.	PUNCT
gs-3920	49	1	in	in	ADP
gs-3920	49	2	individuals	individual	NOUN
gs-3920	49	3	with	with	ADP
gs-3920	49	4	impaired	impaired	ADJ
gs-3920	49	5	detoxification	detoxification	NOUN
gs-3920	49	6	mechanisms	mechanism	NOUN
gs-3920	49	7	—	—	PUNCT
gs-3920	49	8	due	due	ADP
gs-3920	49	9	to	to	ADP
gs-3920	49	10	genetic	genetic	ADJ
gs-3920	49	11	polymorphisms	polymorphism	NOUN
gs-3920	49	12	in	in	ADP
gs-3920	49	13	enzymes	enzyme	NOUN
gs-3920	49	14	like	like	ADP
gs-3920	49	15	epoxide	epoxide	NOUN
gs-3920	49	16	hydrolase	hydrolase	NOUN
gs-3920	49	17	or	or	CCONJ
gs-3920	49	18	glutathione	glutathione	NOUN
gs-3920	49	19	transferases	transferase	NOUN
gs-3920	49	20	—	—	PUNCT
gs-3920	49	21	these	these	DET
gs-3920	49	22	reactive	reactive	ADJ
gs-3920	49	23	species	specie	NOUN
gs-3920	49	24	are	be	AUX
gs-3920	49	25	not	not	PART
gs-3920	49	26	adequately	adequately	ADV
gs-3920	49	27	neutralized	neutralize	VERB
gs-3920	49	28	,	,	PUNCT
gs-3920	49	29	resulting	result	VERB
gs-3920	49	30	in	in	ADP
gs-3920	49	31	cellular	cellular	ADJ
gs-3920	49	32	damage	damage	NOUN
gs-3920	49	33	and	and	CCONJ
gs-3920	49	34	immune	immune	ADJ
gs-3920	49	35	activation	activation	NOUN
gs-3920	49	36	.	.	PUNCT
gs-3920	50	1	drug	drug	NOUN
gs-3920	50	2	reaction	reaction	NOUN
gs-3920	50	3	with	with	ADP
gs-3920	50	4	eosinophilia	eosinophilia	PROPN
gs-3920	50	5	and	and	CCONJ
gs-3920	50	6	systemic	systemic	ADJ
gs-3920	50	7	symptoms	symptom	NOUN
gs-3920	50	8	(	(	PUNCT
gs-3920	50	9	dress	dress	NOUN
gs-3920	50	10	)	)	PUNCT
gs-3920	50	11	is	be	AUX
gs-3920	50	12	a	a	DET
gs-3920	50	13	rare	rare	ADJ
gs-3920	50	14	,	,	PUNCT
gs-3920	50	15	severe	severe	ADJ
gs-3920	50	16	,	,	PUNCT
gs-3920	50	17	and	and	CCONJ
gs-3920	50	18	potentially	potentially	ADV
gs-3920	50	19	life	life	NOUN
gs-3920	50	20	-	-	PUNCT
gs-3920	50	21	threatening	threaten	VERB
gs-3920	50	22	adverse	adverse	ADJ
gs-3920	50	23	drug	drug	NOUN
gs-3920	50	24	reaction	reaction	NOUN
gs-3920	50	25	characterized	characterize	VERB
gs-3920	50	26	by	by	ADP
gs-3920	50	27	a	a	DET
gs-3920	50	28	delayed	delay	VERB
gs-3920	50	29	onset	onset	NOUN
gs-3920	50	30	and	and	CCONJ
gs-3920	50	31	a	a	DET
gs-3920	50	32	wide	wide	ADJ
gs-3920	50	33	range	range	NOUN
gs-3920	50	34	of	of	ADP
gs-3920	50	35	clinical	clinical	ADJ
gs-3920	50	36	manifestations	manifestation	NOUN
gs-3920	50	37	,	,	PUNCT
gs-3920	50	38	including	include	VERB
gs-3920	50	39	fever	fever	NOUN
gs-3920	50	40	,	,	PUNCT
gs-3920	50	41	rash	rash	ADJ
gs-3920	50	42	,	,	PUNCT
gs-3920	50	43	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	50	44	,	,	PUNCT
gs-3920	50	45	hematologic	hematologic	ADJ
gs-3920	50	46	abnormalities	abnormality	NOUN
gs-3920	50	47	(	(	PUNCT
gs-3920	50	48	eosinophilia	eosinophilia	NOUN
gs-3920	50	49	and	and	CCONJ
gs-3920	50	50	atypical	atypical	ADJ
gs-3920	50	51	lymphocytosis	lymphocytosis	NOUN
gs-3920	50	52	)	)	PUNCT
gs-3920	50	53	,	,	PUNCT
gs-3920	50	54	and	and	CCONJ
gs-3920	50	55	visceral	visceral	ADJ
gs-3920	50	56	organ	organ	NOUN
gs-3920	50	57	involvement	involvement	NOUN
gs-3920	50	58	such	such	ADJ
gs-3920	50	59	as	as	ADP
gs-3920	50	60	hepatitis	hepatitis	NOUN
gs-3920	50	61	,	,	PUNCT
gs-3920	50	62	nephritis	nephritis	NOUN
gs-3920	50	63	,	,	PUNCT
gs-3920	50	64	and	and	CCONJ
gs-3920	50	65	pneumonitis	pneumonitis	NOUN
gs-3920	50	66	.	.	PUNCT
gs-3920	51	1	the	the	DET
gs-3920	51	2	syndrome	syndrome	NOUN
gs-3920	51	3	is	be	AUX
gs-3920	51	4	most	most	ADV
gs-3920	51	5	commonly	commonly	ADV
gs-3920	51	6	associated	associate	VERB
gs-3920	51	7	with	with	ADP
gs-3920	51	8	aromatic	aromatic	ADJ
gs-3920	51	9	anticonvulsants	anticonvulsant	NOUN
gs-3920	51	10	,	,	PUNCT
gs-3920	51	11	sulfonamides	sulfonamide	NOUN
gs-3920	51	12	,	,	PUNCT
gs-3920	51	13	allopurinol	allopurinol	NOUN
gs-3920	51	14	,	,	PUNCT
gs-3920	51	15	and	and	CCONJ
gs-3920	51	16	certain	certain	ADJ
gs-3920	51	17	antibiotics	antibiotic	NOUN
gs-3920	51	18	and	and	CCONJ
gs-3920	51	19	antivirals	antiviral	NOUN
gs-3920	51	20	.	.	PUNCT
gs-3920	52	1	understanding	understand	VERB
gs-3920	52	2	the	the	DET
gs-3920	52	3	pharmacological	pharmacological	ADJ
gs-3920	52	4	properties	property	NOUN
gs-3920	52	5	and	and	CCONJ
gs-3920	52	6	adverse	adverse	ADJ
gs-3920	52	7	event	event	NOUN
gs-3920	52	8	profiles	profile	NOUN
gs-3920	52	9	of	of	ADP
gs-3920	52	10	drugs	drug	NOUN
gs-3920	52	11	associated	associate	VERB
gs-3920	52	12	with	with	ADP
gs-3920	52	13	dress	dress	NOUN
gs-3920	52	14	is	be	AUX
gs-3920	52	15	essential	essential	ADJ
gs-3920	52	16	for	for	ADP
gs-3920	52	17	clinicians	clinician	NOUN
gs-3920	52	18	to	to	PART
gs-3920	52	19	enhance	enhance	VERB
gs-3920	52	20	early	early	ADJ
gs-3920	52	21	recognition	recognition	NOUN
gs-3920	52	22	,	,	PUNCT
gs-3920	52	23	implement	implement	VERB
gs-3920	52	24	timely	timely	ADJ
gs-3920	52	25	interventions	intervention	NOUN
gs-3920	52	26	,	,	PUNCT
gs-3920	52	27	and	and	CCONJ
gs-3920	52	28	reduce	reduce	VERB
gs-3920	52	29	the	the	DET
gs-3920	52	30	associated	associated	ADJ
gs-3920	52	31	morbidity	morbidity	NOUN
gs-3920	52	32	and	and	CCONJ
gs-3920	52	33	mortality	mortality	NOUN
gs-3920	52	34	.	.	PUNCT
gs-3920	53	1	drugs	drug	NOUN
gs-3920	53	2	implicated	implicate	VERB
gs-3920	53	3	in	in	ADP
gs-3920	53	4	dress	dress	NOUN
gs-3920	53	5	exhibit	exhibit	NOUN
gs-3920	53	6	variable	variable	ADJ
gs-3920	53	7	risk	risk	NOUN
gs-3920	53	8	levels	level	NOUN
gs-3920	53	9	,	,	PUNCT
gs-3920	53	10	influenced	influence	VERB
gs-3920	53	11	by	by	ADP
gs-3920	53	12	both	both	DET
gs-3920	53	13	intrinsic	intrinsic	ADJ
gs-3920	53	14	properties	property	NOUN
gs-3920	53	15	and	and	CCONJ
gs-3920	53	16	patient	patient	NOUN
gs-3920	53	17	-	-	PUNCT
gs-3920	53	18	related	relate	VERB
gs-3920	53	19	factors	factor	NOUN
gs-3920	53	20	.	.	PUNCT
gs-3920	54	1	anticonvulsants	anticonvulsant	NOUN
gs-3920	54	2	such	such	ADJ
gs-3920	54	3	as	as	ADP
gs-3920	54	4	phenytoin	phenytoin	NOUN
gs-3920	54	5	,	,	PUNCT
gs-3920	54	6	carbamazepine	carbamazepine	NOUN
gs-3920	54	7	,	,	PUNCT
gs-3920	54	8	and	and	CCONJ
gs-3920	54	9	lamotrigine	lamotrigine	NOUN
gs-3920	54	10	are	be	AUX
gs-3920	54	11	among	among	ADP
gs-3920	54	12	the	the	DET
gs-3920	54	13	most	most	ADV
gs-3920	54	14	frequently	frequently	ADV
gs-3920	54	15	reported	report	VERB
gs-3920	54	16	causes	cause	NOUN
gs-3920	54	17	.	.	PUNCT
gs-3920	55	1	these	these	DET
gs-3920	55	2	medications	medication	NOUN
gs-3920	55	3	share	share	VERB
gs-3920	55	4	aromatic	aromatic	ADJ
gs-3920	55	5	structures	structure	NOUN
gs-3920	55	6	and	and	CCONJ
gs-3920	55	7	metabolic	metabolic	NOUN
gs-3920	55	8	profiles	profile	NOUN
gs-3920	55	9	that	that	PRON
gs-3920	55	10	favor	favor	VERB
gs-3920	55	11	reactive	reactive	ADJ
gs-3920	55	12	metabolite	metabolite	NOUN
gs-3920	55	13	formation	formation	NOUN
gs-3920	55	14	.	.	PUNCT
gs-3920	56	1	allopurinol	allopurinol	NOUN
gs-3920	56	2	is	be	AUX
gs-3920	56	3	another	another	DET
gs-3920	56	4	high	high	ADJ
gs-3920	56	5	-	-	PUNCT
gs-3920	56	6	risk	risk	NOUN
gs-3920	56	7	agent	agent	NOUN
gs-3920	56	8	,	,	PUNCT
gs-3920	56	9	particularly	particularly	ADV
gs-3920	56	10	in	in	ADP
gs-3920	56	11	the	the	DET
gs-3920	56	12	presence	presence	NOUN
gs-3920	56	13	of	of	ADP
gs-3920	56	14	renal	renal	ADJ
gs-3920	56	15	insufficiency	insufficiency	NOUN
gs-3920	56	16	,	,	PUNCT
gs-3920	56	17	which	which	PRON
gs-3920	56	18	can	can	AUX
gs-3920	56	19	lead	lead	VERB
gs-3920	56	20	to	to	ADP
gs-3920	56	21	accumulation	accumulation	NOUN
gs-3920	56	22	of	of	ADP
gs-3920	56	23	oxypurinol	oxypurinol	NOUN
gs-3920	56	24	,	,	PUNCT
gs-3920	56	25	a	a	DET
gs-3920	56	26	potentially	potentially	ADV
gs-3920	56	27	toxic	toxic	ADJ
gs-3920	56	28	metabolite	metabolite	NOUN
gs-3920	56	29	.	.	PUNCT
gs-3920	57	1	antibiotics	antibiotic	NOUN
gs-3920	57	2	such	such	ADJ
gs-3920	57	3	as	as	ADP
gs-3920	57	4	vancomycin	vancomycin	PROPN
gs-3920	57	5	,	,	PUNCT
gs-3920	57	6	minocycline	minocycline	NOUN
gs-3920	57	7	,	,	PUNCT
gs-3920	57	8	and	and	CCONJ
gs-3920	57	9	sulfonamides	sulfonamide	NOUN
gs-3920	57	10	also	also	ADV
gs-3920	57	11	pose	pose	VERB
gs-3920	57	12	significant	significant	ADJ
gs-3920	57	13	risks	risk	NOUN
gs-3920	57	14	,	,	PUNCT
gs-3920	57	15	particularly	particularly	ADV
gs-3920	57	16	in	in	ADP
gs-3920	57	17	younger	young	ADJ
gs-3920	57	18	patients	patient	NOUN
gs-3920	57	19	or	or	CCONJ
gs-3920	57	20	those	those	PRON
gs-3920	57	21	with	with	ADP
gs-3920	57	22	pre	pre	ADJ
gs-3920	57	23	-	-	ADJ
gs-3920	57	24	existing	existing	ADJ
gs-3920	57	25	immune	immune	ADJ
gs-3920	57	26	dysregulation	dysregulation	NOUN
gs-3920	57	27	.	.	PUNCT
gs-3920	58	1	the	the	DET
gs-3920	58	2	treatment	treatment	NOUN
gs-3920	58	3	of	of	ADP
gs-3920	58	4	dress	dress	NOUN
gs-3920	58	5	primarily	primarily	ADV
gs-3920	58	6	involves	involve	VERB
gs-3920	58	7	prompt	prompt	ADJ
gs-3920	58	8	withdrawal	withdrawal	NOUN
gs-3920	58	9	of	of	ADP
gs-3920	58	10	the	the	DET
gs-3920	58	11	offending	offending	ADJ
gs-3920	58	12	agent	agent	NOUN
gs-3920	58	13	,	,	PUNCT
gs-3920	58	14	supportive	supportive	ADJ
gs-3920	58	15	care	care	NOUN
gs-3920	58	16	,	,	PUNCT
gs-3920	58	17	and	and	CCONJ
gs-3920	58	18	immunosuppressive	immunosuppressive	ADJ
gs-3920	58	19	therapy	therapy	NOUN
gs-3920	58	20	in	in	ADP
gs-3920	58	21	severe	severe	ADJ
gs-3920	58	22	cases	case	NOUN
gs-3920	58	23	.	.	PUNCT
gs-3920	59	1	systemic	systemic	ADJ
gs-3920	59	2	corticosteroids	corticosteroid	NOUN
gs-3920	59	3	,	,	PUNCT
gs-3920	59	4	typically	typically	ADV
gs-3920	59	5	prednisone	prednisone	NOUN
gs-3920	59	6	at	at	ADP
gs-3920	59	7	doses	dose	NOUN
gs-3920	59	8	of	of	ADP
gs-3920	59	9	0.5–1	0.5–1	NOUN
gs-3920	59	10	mg	mg	PROPN
gs-3920	59	11	/	/	SYM
gs-3920	59	12	kg	kg	PROPN
gs-3920	59	13	/	/	SYM
gs-3920	59	14	day	day	NOUN
gs-3920	59	15	,	,	PUNCT
gs-3920	59	16	remain	remain	VERB
gs-3920	59	17	the	the	DET
gs-3920	59	18	mainstay	mainstay	NOUN
gs-3920	59	19	of	of	ADP
gs-3920	59	20	treatment	treatment	NOUN
gs-3920	59	21	,	,	PUNCT
gs-3920	59	22	especially	especially	ADV
gs-3920	59	23	in	in	ADP
gs-3920	59	24	cases	case	NOUN
gs-3920	59	25	with	with	ADP
gs-3920	59	26	significant	significant	ADJ
gs-3920	59	27	internal	internal	ADJ
gs-3920	59	28	organ	organ	NOUN
gs-3920	59	29	involvement	involvement	NOUN
gs-3920	59	30	.	.	PUNCT
gs-3920	60	1	tapering	tapering	NOUN
gs-3920	60	2	is	be	AUX
gs-3920	60	3	georgian	georgian	ADJ
gs-3920	60	4	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	60	5	მეცნიერები	მეცნიერები	NOUN
gs-3920	60	6	ტ.	ტ.	VERB
gs-3920	60	7	7	7	NUM
gs-3920	60	8	n	n	PRON
gs-3920	60	9	3	3	NUM
gs-3920	60	10	,	,	PUNCT
gs-3920	60	11	2025	2025	NUM
gs-3920	60	12	184	184	NUM
gs-3920	60	13	usually	usually	ADV
gs-3920	60	14	required	require	VERB
gs-3920	60	15	over	over	ADP
gs-3920	60	16	weeks	week	NOUN
gs-3920	60	17	to	to	ADP
gs-3920	60	18	months	month	NOUN
gs-3920	60	19	to	to	PART
gs-3920	60	20	prevent	prevent	VERB
gs-3920	60	21	rebound	rebound	VERB
gs-3920	60	22	inflammation	inflammation	NOUN
gs-3920	60	23	or	or	CCONJ
gs-3920	60	24	recurrence	recurrence	NOUN
gs-3920	60	25	.	.	PUNCT
gs-3920	61	1	intravenous	intravenous	ADJ
gs-3920	61	2	immunoglobulin	immunoglobulin	NOUN
gs-3920	61	3	(	(	PUNCT
gs-3920	61	4	ivig	ivig	NOUN
gs-3920	61	5	)	)	PUNCT
gs-3920	61	6	,	,	PUNCT
gs-3920	61	7	cyclosporine	cyclosporine	NOUN
gs-3920	61	8	,	,	PUNCT
gs-3920	61	9	and	and	CCONJ
gs-3920	61	10	other	other	ADJ
gs-3920	61	11	immunomodulatory	immunomodulatory	ADJ
gs-3920	61	12	agents	agent	NOUN
gs-3920	61	13	have	have	AUX
gs-3920	61	14	been	be	AUX
gs-3920	61	15	used	use	VERB
gs-3920	61	16	in	in	ADP
gs-3920	61	17	refractory	refractory	NOUN
gs-3920	61	18	cases	case	NOUN
gs-3920	61	19	or	or	CCONJ
gs-3920	61	20	when	when	SCONJ
gs-3920	61	21	corticosteroids	corticosteroid	NOUN
gs-3920	61	22	are	be	AUX
gs-3920	61	23	contraindicated	contraindicate	VERB
gs-3920	61	24	.	.	PUNCT
gs-3920	62	1	antiviral	antiviral	ADJ
gs-3920	62	2	therapy	therapy	NOUN
gs-3920	62	3	has	have	AUX
gs-3920	62	4	been	be	AUX
gs-3920	62	5	explored	explore	VERB
gs-3920	62	6	in	in	ADP
gs-3920	62	7	the	the	DET
gs-3920	62	8	context	context	NOUN
gs-3920	62	9	of	of	ADP
gs-3920	62	10	confirmed	confirm	VERB
gs-3920	62	11	viral	viral	ADJ
gs-3920	62	12	reactivation	reactivation	NOUN
gs-3920	62	13	,	,	PUNCT
gs-3920	62	14	though	though	SCONJ
gs-3920	62	15	its	its	PRON
gs-3920	62	16	efficacy	efficacy	NOUN
gs-3920	62	17	remains	remain	VERB
gs-3920	62	18	inconclusive	inconclusive	ADJ
gs-3920	62	19	.	.	PUNCT
gs-3920	63	1	an	an	DET
gs-3920	63	2	essential	essential	ADJ
gs-3920	63	3	aspect	aspect	NOUN
gs-3920	63	4	of	of	ADP
gs-3920	63	5	managing	manage	VERB
gs-3920	63	6	dress	dress	NOUN
gs-3920	63	7	is	be	AUX
gs-3920	63	8	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	63	9	and	and	CCONJ
gs-3920	63	10	post	post	ADJ
gs-3920	63	11	-	-	NOUN
gs-3920	63	12	recovery	recovery	ADJ
gs-3920	63	13	follow	follow	NOUN
gs-3920	63	14	-	-	PUNCT
gs-3920	63	15	up	up	NOUN
gs-3920	63	16	.	.	PUNCT
gs-3920	64	1	long	long	ADJ
gs-3920	64	2	-	-	PUNCT
gs-3920	64	3	term	term	NOUN
gs-3920	64	4	sequelae	sequelae	NOUN
gs-3920	64	5	may	may	AUX
gs-3920	64	6	include	include	VERB
gs-3920	64	7	autoimmune	autoimmune	ADJ
gs-3920	64	8	diseases	disease	NOUN
gs-3920	64	9	such	such	ADJ
gs-3920	64	10	as	as	ADP
gs-3920	64	11	thyroiditis	thyroiditis	NOUN
gs-3920	64	12	,	,	PUNCT
gs-3920	64	13	type	type	NOUN
gs-3920	64	14	1	1	NUM
gs-3920	64	15	diabetes	diabetes	NOUN
gs-3920	64	16	,	,	PUNCT
gs-3920	64	17	or	or	CCONJ
gs-3920	64	18	systemic	systemic	ADJ
gs-3920	64	19	lupus	lupus	NOUN
gs-3920	64	20	erythematosus	erythematosus	NOUN
gs-3920	64	21	.	.	PUNCT
gs-3920	65	1	patients	patient	NOUN
gs-3920	65	2	must	must	AUX
gs-3920	65	3	be	be	AUX
gs-3920	65	4	counseled	counsel	VERB
gs-3920	65	5	regarding	regard	VERB
gs-3920	65	6	lifelong	lifelong	ADJ
gs-3920	65	7	avoidance	avoidance	NOUN
gs-3920	65	8	of	of	ADP
gs-3920	65	9	the	the	DET
gs-3920	65	10	causative	causative	ADJ
gs-3920	65	11	drug	drug	NOUN
gs-3920	65	12	and	and	CCONJ
gs-3920	65	13	structurally	structurally	ADV
gs-3920	65	14	similar	similar	ADJ
gs-3920	65	15	agents	agent	NOUN
gs-3920	65	16	.	.	PUNCT
gs-3920	66	1	cross	cross	ADJ
gs-3920	66	2	-	-	NOUN
gs-3920	66	3	reactivity	reactivity	NOUN
gs-3920	66	4	within	within	ADP
gs-3920	66	5	drug	drug	NOUN
gs-3920	66	6	classes	class	NOUN
gs-3920	66	7	,	,	PUNCT
gs-3920	66	8	such	such	ADJ
gs-3920	66	9	as	as	ADP
gs-3920	66	10	aromatic	aromatic	ADJ
gs-3920	66	11	anticonvulsants	anticonvulsant	NOUN
gs-3920	66	12	,	,	PUNCT
gs-3920	66	13	should	should	AUX
gs-3920	66	14	be	be	AUX
gs-3920	66	15	carefully	carefully	ADV
gs-3920	66	16	evaluated	evaluate	VERB
gs-3920	66	17	to	to	PART
gs-3920	66	18	prevent	prevent	VERB
gs-3920	66	19	recurrence	recurrence	NOUN
gs-3920	66	20	.	.	PUNCT
gs-3920	67	1	electronic	electronic	ADJ
gs-3920	67	2	health	health	NOUN
gs-3920	67	3	records	record	NOUN
gs-3920	67	4	and	and	CCONJ
gs-3920	67	5	allergy	allergy	NOUN
gs-3920	67	6	documentation	documentation	NOUN
gs-3920	67	7	systems	system	NOUN
gs-3920	67	8	should	should	AUX
gs-3920	67	9	be	be	AUX
gs-3920	67	10	updated	update	VERB
gs-3920	67	11	to	to	PART
gs-3920	67	12	reflect	reflect	VERB
gs-3920	67	13	the	the	DET
gs-3920	67	14	reaction	reaction	NOUN
gs-3920	67	15	history	history	NOUN
gs-3920	67	16	accurately	accurately	ADV
gs-3920	67	17	.	.	PUNCT
gs-3920	68	1	dress	dress	NOUN
gs-3920	68	2	syndrome	syndrome	PROPN
gs-3920	68	3	exemplifies	exemplify	VERB
gs-3920	68	4	the	the	DET
gs-3920	68	5	intersection	intersection	NOUN
gs-3920	68	6	of	of	ADP
gs-3920	68	7	pharmacology	pharmacology	NOUN
gs-3920	68	8	,	,	PUNCT
gs-3920	68	9	immunology	immunology	NOUN
gs-3920	68	10	,	,	PUNCT
gs-3920	68	11	and	and	CCONJ
gs-3920	68	12	genetics	genetic	NOUN
gs-3920	68	13	in	in	ADP
gs-3920	68	14	adverse	adverse	ADJ
gs-3920	68	15	drug	drug	NOUN
gs-3920	68	16	reactions	reaction	NOUN
gs-3920	68	17	.	.	PUNCT
gs-3920	69	1	recognizing	recognize	VERB
gs-3920	69	2	the	the	DET
gs-3920	69	3	pharmacological	pharmacological	ADJ
gs-3920	69	4	profiles	profile	NOUN
gs-3920	69	5	and	and	CCONJ
gs-3920	69	6	mechanistic	mechanistic	ADJ
gs-3920	69	7	underpinnings	underpinning	NOUN
gs-3920	69	8	of	of	ADP
gs-3920	69	9	drugs	drug	NOUN
gs-3920	69	10	implicated	implicate	VERB
gs-3920	69	11	in	in	ADP
gs-3920	69	12	dress	dress	NOUN
gs-3920	69	13	is	be	AUX
gs-3920	69	14	critical	critical	ADJ
gs-3920	69	15	for	for	ADP
gs-3920	69	16	timely	timely	ADJ
gs-3920	69	17	diagnosis	diagnosis	NOUN
gs-3920	69	18	,	,	PUNCT
gs-3920	69	19	effective	effective	ADJ
gs-3920	69	20	management	management	NOUN
gs-3920	69	21	,	,	PUNCT
gs-3920	69	22	and	and	CCONJ
gs-3920	69	23	prevention	prevention	NOUN
gs-3920	69	24	of	of	ADP
gs-3920	69	25	recurrence	recurrence	NOUN
gs-3920	69	26	.	.	PUNCT
gs-3920	70	1	a	a	DET
gs-3920	70	2	multidisciplinary	multidisciplinary	ADJ
gs-3920	70	3	approach	approach	NOUN
gs-3920	70	4	involving	involve	VERB
gs-3920	70	5	clinical	clinical	ADJ
gs-3920	70	6	pharmacologists	pharmacologist	NOUN
gs-3920	70	7	,	,	PUNCT
gs-3920	70	8	dermatologists	dermatologist	NOUN
gs-3920	70	9	,	,	PUNCT
gs-3920	70	10	allergists	allergist	NOUN
gs-3920	70	11	,	,	PUNCT
gs-3920	70	12	and	and	CCONJ
gs-3920	70	13	internists	internist	NOUN
gs-3920	70	14	is	be	AUX
gs-3920	70	15	essential	essential	ADJ
gs-3920	70	16	for	for	ADP
gs-3920	70	17	optimal	optimal	ADJ
gs-3920	70	18	patient	patient	ADJ
gs-3920	70	19	outcomes	outcome	NOUN
gs-3920	70	20	.	.	PUNCT
gs-3920	71	1	with	with	ADP
gs-3920	71	2	the	the	DET
gs-3920	71	3	advancement	advancement	NOUN
gs-3920	71	4	of	of	ADP
gs-3920	71	5	pharmacogenomics	pharmacogenomic	NOUN
gs-3920	71	6	and	and	CCONJ
gs-3920	71	7	personalized	personalized	ADJ
gs-3920	71	8	medicine	medicine	NOUN
gs-3920	71	9	,	,	PUNCT
gs-3920	71	10	the	the	DET
gs-3920	71	11	goal	goal	NOUN
gs-3920	71	12	of	of	ADP
gs-3920	71	13	reducing	reduce	VERB
gs-3920	71	14	drug	drug	NOUN
gs-3920	71	15	-	-	PUNCT
gs-3920	71	16	induced	induce	VERB
gs-3920	71	17	hypersensitivity	hypersensitivity	NOUN
gs-3920	71	18	syndromes	syndrome	NOUN
gs-3920	71	19	such	such	ADJ
gs-3920	71	20	as	as	ADP
gs-3920	71	21	dress	dress	NOUN
gs-3920	71	22	is	be	AUX
gs-3920	71	23	increasingly	increasingly	ADV
gs-3920	71	24	attainable	attainable	ADJ
gs-3920	71	25	.	.	PUNCT
gs-3920	72	1	drug	drug	NOUN
gs-3920	72	2	reaction	reaction	NOUN
gs-3920	72	3	with	with	ADP
gs-3920	72	4	eosinophilia	eosinophilia	PROPN
gs-3920	72	5	and	and	CCONJ
gs-3920	72	6	systemic	systemic	ADJ
gs-3920	72	7	symptoms	symptom	NOUN
gs-3920	72	8	(	(	PUNCT
gs-3920	72	9	dress	dress	NOUN
gs-3920	72	10	)	)	PUNCT
gs-3920	72	11	is	be	AUX
gs-3920	72	12	a	a	DET
gs-3920	72	13	rare	rare	ADJ
gs-3920	72	14	,	,	PUNCT
gs-3920	72	15	severe	severe	ADJ
gs-3920	72	16	,	,	PUNCT
gs-3920	72	17	and	and	CCONJ
gs-3920	72	18	potentially	potentially	ADV
gs-3920	72	19	life	life	NOUN
gs-3920	72	20	-	-	PUNCT
gs-3920	72	21	threatening	threaten	VERB
gs-3920	72	22	adverse	adverse	ADJ
gs-3920	72	23	drug	drug	NOUN
gs-3920	72	24	reaction	reaction	NOUN
gs-3920	72	25	characterized	characterize	VERB
gs-3920	72	26	by	by	ADP
gs-3920	72	27	a	a	DET
gs-3920	72	28	delayed	delay	VERB
gs-3920	72	29	onset	onset	NOUN
gs-3920	72	30	and	and	CCONJ
gs-3920	72	31	a	a	DET
gs-3920	72	32	wide	wide	ADJ
gs-3920	72	33	range	range	NOUN
gs-3920	72	34	of	of	ADP
gs-3920	72	35	clinical	clinical	ADJ
gs-3920	72	36	manifestations	manifestation	NOUN
gs-3920	72	37	,	,	PUNCT
gs-3920	72	38	including	include	VERB
gs-3920	72	39	fever	fever	NOUN
gs-3920	72	40	,	,	PUNCT
gs-3920	72	41	rash	rash	ADJ
gs-3920	72	42	,	,	PUNCT
gs-3920	72	43	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	72	44	,	,	PUNCT
gs-3920	72	45	hematologic	hematologic	ADJ
gs-3920	72	46	abnormalities	abnormality	NOUN
gs-3920	72	47	(	(	PUNCT
gs-3920	72	48	eosinophilia	eosinophilia	NOUN
gs-3920	72	49	and	and	CCONJ
gs-3920	72	50	atypical	atypical	ADJ
gs-3920	72	51	lymphocytosis	lymphocytosis	NOUN
gs-3920	72	52	)	)	PUNCT
gs-3920	72	53	,	,	PUNCT
gs-3920	72	54	and	and	CCONJ
gs-3920	72	55	visceral	visceral	ADJ
gs-3920	72	56	organ	organ	NOUN
gs-3920	72	57	involvement	involvement	NOUN
gs-3920	72	58	such	such	ADJ
gs-3920	72	59	as	as	ADP
gs-3920	72	60	hepatitis	hepatitis	NOUN
gs-3920	72	61	,	,	PUNCT
gs-3920	72	62	nephritis	nephritis	NOUN
gs-3920	72	63	,	,	PUNCT
gs-3920	72	64	and	and	CCONJ
gs-3920	72	65	pneumonitis	pneumonitis	NOUN
gs-3920	72	66	.	.	PUNCT
gs-3920	73	1	the	the	DET
gs-3920	73	2	syndrome	syndrome	NOUN
gs-3920	73	3	is	be	AUX
gs-3920	73	4	most	most	ADV
gs-3920	73	5	commonly	commonly	ADV
gs-3920	73	6	associated	associate	VERB
gs-3920	73	7	with	with	ADP
gs-3920	73	8	aromatic	aromatic	ADJ
gs-3920	73	9	anticonvulsants	anticonvulsant	NOUN
gs-3920	73	10	,	,	PUNCT
gs-3920	73	11	sulfonamides	sulfonamide	NOUN
gs-3920	73	12	,	,	PUNCT
gs-3920	73	13	allopurinol	allopurinol	NOUN
gs-3920	73	14	,	,	PUNCT
gs-3920	73	15	and	and	CCONJ
gs-3920	73	16	certain	certain	ADJ
gs-3920	73	17	antibiotics	antibiotic	NOUN
gs-3920	73	18	and	and	CCONJ
gs-3920	73	19	antivirals	antiviral	NOUN
gs-3920	73	20	.	.	PUNCT
gs-3920	74	1	understanding	understand	VERB
gs-3920	74	2	the	the	DET
gs-3920	74	3	pharmacological	pharmacological	ADJ
gs-3920	74	4	properties	property	NOUN
gs-3920	74	5	and	and	CCONJ
gs-3920	74	6	adverse	adverse	ADJ
gs-3920	74	7	event	event	NOUN
gs-3920	74	8	profiles	profile	NOUN
gs-3920	74	9	of	of	ADP
gs-3920	74	10	drugs	drug	NOUN
gs-3920	74	11	associated	associate	VERB
gs-3920	74	12	with	with	ADP
gs-3920	74	13	dress	dress	NOUN
gs-3920	74	14	is	be	AUX
gs-3920	74	15	essential	essential	ADJ
gs-3920	74	16	for	for	ADP
gs-3920	74	17	clinicians	clinician	NOUN
gs-3920	74	18	to	to	PART
gs-3920	74	19	enhance	enhance	VERB
gs-3920	74	20	early	early	ADJ
gs-3920	74	21	recognition	recognition	NOUN
gs-3920	74	22	,	,	PUNCT
gs-3920	74	23	implement	implement	VERB
gs-3920	74	24	timely	timely	ADJ
gs-3920	74	25	interventions	intervention	NOUN
gs-3920	74	26	,	,	PUNCT
gs-3920	74	27	and	and	CCONJ
gs-3920	74	28	reduce	reduce	VERB
gs-3920	74	29	the	the	DET
gs-3920	74	30	associated	associated	ADJ
gs-3920	74	31	morbidity	morbidity	NOUN
gs-3920	74	32	and	and	CCONJ
gs-3920	74	33	mortality	mortality	NOUN
gs-3920	74	34	.	.	PUNCT
gs-3920	75	1	clinically	clinically	ADV
gs-3920	75	2	,	,	PUNCT
gs-3920	75	3	dress	dress	NOUN
gs-3920	75	4	is	be	AUX
gs-3920	75	5	often	often	ADV
gs-3920	75	6	misdiagnosed	misdiagnose	VERB
gs-3920	75	7	as	as	ADP
gs-3920	75	8	other	other	ADJ
gs-3920	75	9	febrile	febrile	NOUN
gs-3920	75	10	illnesses	illness	NOUN
gs-3920	75	11	,	,	PUNCT
gs-3920	75	12	autoimmune	autoimmune	ADJ
gs-3920	75	13	diseases	disease	NOUN
gs-3920	75	14	,	,	PUNCT
gs-3920	75	15	or	or	CCONJ
gs-3920	75	16	sepsis	sepsis	NOUN
gs-3920	75	17	.	.	PUNCT
gs-3920	76	1	the	the	DET
gs-3920	76	2	regiscar	regiscar	NOUN
gs-3920	76	3	(	(	PUNCT
gs-3920	76	4	registry	registry	NOUN
gs-3920	76	5	of	of	ADP
gs-3920	76	6	severe	severe	ADJ
gs-3920	76	7	cutaneous	cutaneous	ADJ
gs-3920	76	8	adverse	adverse	ADJ
gs-3920	76	9	reactions	reaction	NOUN
gs-3920	76	10	)	)	PUNCT
gs-3920	76	11	criteria	criterion	NOUN
gs-3920	76	12	are	be	AUX
gs-3920	76	13	widely	widely	ADV
gs-3920	76	14	used	use	VERB
gs-3920	76	15	for	for	ADP
gs-3920	76	16	diagnosis	diagnosis	NOUN
gs-3920	76	17	,	,	PUNCT
gs-3920	76	18	incorporating	incorporate	VERB
gs-3920	76	19	elements	element	NOUN
gs-3920	76	20	such	such	ADJ
gs-3920	76	21	as	as	ADP
gs-3920	76	22	eosinophilia	eosinophilia	PROPN
gs-3920	76	23	,	,	PUNCT
gs-3920	76	24	fever	fever	NOUN
gs-3920	76	25	,	,	PUNCT
gs-3920	76	26	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	76	27	,	,	PUNCT
gs-3920	76	28	organ	organ	NOUN
gs-3920	76	29	involvement	involvement	NOUN
gs-3920	76	30	,	,	PUNCT
gs-3920	76	31	and	and	CCONJ
gs-3920	76	32	prolonged	prolonged	ADJ
gs-3920	76	33	latency	latency	NOUN
gs-3920	76	34	after	after	ADP
gs-3920	76	35	drug	drug	NOUN
gs-3920	76	36	initiation	initiation	NOUN
gs-3920	76	37	.	.	PUNCT
gs-3920	77	1	dermatologic	dermatologic	ADJ
gs-3920	77	2	findings	finding	NOUN
gs-3920	77	3	typically	typically	ADV
gs-3920	77	4	include	include	VERB
gs-3920	77	5	widespread	widespread	ADJ
gs-3920	77	6	maculopapular	maculopapular	ADJ
gs-3920	77	7	or	or	CCONJ
gs-3920	77	8	exfoliative	exfoliative	ADJ
gs-3920	77	9	rashes	rash	NOUN
gs-3920	77	10	,	,	PUNCT
gs-3920	77	11	facial	facial	ADJ
gs-3920	77	12	edema	edema	NOUN
gs-3920	77	13	,	,	PUNCT
gs-3920	77	14	and	and	CCONJ
gs-3920	77	15	mucosal	mucosal	NOUN
gs-3920	77	16	involvement	involvement	NOUN
gs-3920	77	17	.	.	PUNCT
gs-3920	78	1	laboratory	laboratory	NOUN
gs-3920	78	2	abnormalities	abnormality	NOUN
gs-3920	78	3	often	often	ADV
gs-3920	78	4	reflect	reflect	VERB
gs-3920	78	5	multiorgan	multiorgan	PROPN
gs-3920	78	6	injury	injury	PROPN
gs-3920	78	7	,	,	PUNCT
gs-3920	78	8	including	include	VERB
gs-3920	78	9	elevated	elevate	VERB
gs-3920	78	10	liver	liver	NOUN
gs-3920	78	11	enzymes	enzyme	NOUN
gs-3920	78	12	,	,	PUNCT
gs-3920	78	13	leukocytosis	leukocytosis	NOUN
gs-3920	78	14	with	with	ADP
gs-3920	78	15	eosinophilia	eosinophilia	PROPN
gs-3920	78	16	,	,	PUNCT
gs-3920	78	17	and	and	CCONJ
gs-3920	78	18	renal	renal	ADJ
gs-3920	78	19	dysfunction	dysfunction	NOUN
gs-3920	78	20	.	.	PUNCT
gs-3920	79	1	histopathological	histopathological	ADJ
gs-3920	79	2	examination	examination	NOUN
gs-3920	79	3	of	of	ADP
gs-3920	79	4	skin	skin	NOUN
gs-3920	79	5	biopsies	biopsy	NOUN
gs-3920	79	6	often	often	ADV
gs-3920	79	7	reveals	reveal	VERB
gs-3920	79	8	perivascular	perivascular	ADJ
gs-3920	79	9	lymphocytic	lymphocytic	ADJ
gs-3920	79	10	infiltration	infiltration	NOUN
gs-3920	79	11	with	with	ADP
gs-3920	79	12	eosinophils	eosinophil	NOUN
gs-3920	79	13	and	and	CCONJ
gs-3920	79	14	interface	interface	NOUN
gs-3920	79	15	dermatitis	dermatitis	NOUN
gs-3920	79	16	.	.	PUNCT
gs-3920	80	1	georgian	georgian	PROPN
gs-3920	80	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	80	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	80	4	ტ.	ტ.	VERB
gs-3920	80	5	7	7	NUM
gs-3920	80	6	n	n	PRON
gs-3920	80	7	3	3	NUM
gs-3920	80	8	,	,	PUNCT
gs-3920	80	9	2025	2025	NUM
gs-3920	80	10	185	185	NUM
gs-3920	80	11	a	a	DET
gs-3920	80	12	number	number	NOUN
gs-3920	80	13	of	of	ADP
gs-3920	80	14	hla	hla	NOUN
gs-3920	80	15	genotypes	genotype	NOUN
gs-3920	80	16	have	have	AUX
gs-3920	80	17	been	be	AUX
gs-3920	80	18	implicated	implicate	VERB
gs-3920	80	19	in	in	ADP
gs-3920	80	20	dress	dress	NOUN
gs-3920	80	21	susceptibility	susceptibility	NOUN
gs-3920	80	22	,	,	PUNCT
gs-3920	80	23	with	with	ADP
gs-3920	80	24	notable	notable	ADJ
gs-3920	80	25	examples	example	NOUN
gs-3920	80	26	including	include	VERB
gs-3920	80	27	hla	hla	NOUN
gs-3920	80	28	-	-	PUNCT
gs-3920	80	29	b58:01	b58:01	PROPN
gs-3920	80	30	in	in	ADP
gs-3920	80	31	association	association	NOUN
gs-3920	80	32	with	with	ADP
gs-3920	80	33	allopurinol	allopurinol	NOUN
gs-3920	80	34	-	-	PUNCT
gs-3920	80	35	induced	induce	VERB
gs-3920	80	36	dress	dress	NOUN
gs-3920	80	37	,	,	PUNCT
gs-3920	80	38	hla	hla	PROPN
gs-3920	80	39	-	-	PUNCT
gs-3920	80	40	a31:01	a31:01	PROPN
gs-3920	80	41	with	with	ADP
gs-3920	80	42	carbamazepine	carbamazepine	NOUN
gs-3920	80	43	,	,	PUNCT
gs-3920	80	44	and	and	CCONJ
gs-3920	80	45	hla	hla	NOUN
gs-3920	80	46	-	-	PUNCT
gs-3920	80	47	b*13:01	b*13:01	NOUN
gs-3920	80	48	with	with	ADP
gs-3920	80	49	dapsone	dapsone	PROPN
gs-3920	80	50	.	.	PUNCT
gs-3920	81	1	these	these	DET
gs-3920	81	2	genetic	genetic	ADJ
gs-3920	81	3	markers	marker	NOUN
gs-3920	81	4	demonstrate	demonstrate	VERB
gs-3920	81	5	ethnic	ethnic	ADJ
gs-3920	81	6	specificity	specificity	NOUN
gs-3920	81	7	,	,	PUNCT
gs-3920	81	8	necessitating	necessitate	VERB
gs-3920	81	9	tailored	tailored	ADJ
gs-3920	81	10	screening	screening	NOUN
gs-3920	81	11	strategies	strategy	NOUN
gs-3920	81	12	in	in	ADP
gs-3920	81	13	high	high	ADJ
gs-3920	81	14	-	-	PUNCT
gs-3920	81	15	risk	risk	NOUN
gs-3920	81	16	populations	population	NOUN
gs-3920	81	17	.	.	PUNCT
gs-3920	82	1	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	82	2	testing	testing	NOUN
gs-3920	82	3	,	,	PUNCT
gs-3920	82	4	although	although	SCONJ
gs-3920	82	5	not	not	PART
gs-3920	82	6	yet	yet	ADV
gs-3920	82	7	universally	universally	ADV
gs-3920	82	8	implemented	implement	VERB
gs-3920	82	9	,	,	PUNCT
gs-3920	82	10	represents	represent	VERB
gs-3920	82	11	a	a	DET
gs-3920	82	12	promising	promising	ADJ
gs-3920	82	13	preventive	preventive	ADJ
gs-3920	82	14	approach	approach	NOUN
gs-3920	82	15	in	in	ADP
gs-3920	82	16	the	the	DET
gs-3920	82	17	context	context	NOUN
gs-3920	82	18	of	of	ADP
gs-3920	82	19	personalized	personalized	ADJ
gs-3920	82	20	medicine	medicine	NOUN
gs-3920	82	21	.	.	PUNCT
gs-3920	83	1	public	public	ADJ
gs-3920	83	2	health	health	NOUN
gs-3920	83	3	strategies	strategy	NOUN
gs-3920	83	4	for	for	ADP
gs-3920	83	5	reducing	reduce	VERB
gs-3920	83	6	dress	dress	NOUN
gs-3920	83	7	incidence	incidence	NOUN
gs-3920	83	8	include	include	VERB
gs-3920	83	9	raising	raise	VERB
gs-3920	83	10	clinician	clinician	ADJ
gs-3920	83	11	awareness	awareness	NOUN
gs-3920	83	12	,	,	PUNCT
gs-3920	83	13	improving	improve	VERB
gs-3920	83	14	diagnostic	diagnostic	ADJ
gs-3920	83	15	accuracy	accuracy	NOUN
gs-3920	83	16	,	,	PUNCT
gs-3920	83	17	implementing	implement	VERB
gs-3920	83	18	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	83	19	screening	screening	NOUN
gs-3920	83	20	in	in	ADP
gs-3920	83	21	high	high	ADJ
gs-3920	83	22	-	-	PUNCT
gs-3920	83	23	risk	risk	NOUN
gs-3920	83	24	groups	group	NOUN
gs-3920	83	25	,	,	PUNCT
gs-3920	83	26	and	and	CCONJ
gs-3920	83	27	encouraging	encourage	VERB
gs-3920	83	28	reporting	reporting	NOUN
gs-3920	83	29	to	to	ADP
gs-3920	83	30	national	national	ADJ
gs-3920	83	31	adverse	adverse	ADJ
gs-3920	83	32	drug	drug	NOUN
gs-3920	83	33	reaction	reaction	NOUN
gs-3920	83	34	registries	registry	NOUN
gs-3920	83	35	.	.	PUNCT
gs-3920	84	1	moreover	moreover	ADV
gs-3920	84	2	,	,	PUNCT
gs-3920	84	3	drug	drug	NOUN
gs-3920	84	4	developers	developer	NOUN
gs-3920	84	5	and	and	CCONJ
gs-3920	84	6	regulatory	regulatory	ADJ
gs-3920	84	7	authorities	authority	NOUN
gs-3920	84	8	must	must	AUX
gs-3920	84	9	emphasize	emphasize	VERB
gs-3920	84	10	preclinical	preclinical	ADJ
gs-3920	84	11	and	and	CCONJ
gs-3920	84	12	postmarketing	postmarkete	VERB
gs-3920	84	13	safety	safety	NOUN
gs-3920	84	14	surveillance	surveillance	NOUN
gs-3920	84	15	to	to	PART
gs-3920	84	16	identify	identify	VERB
gs-3920	84	17	structural	structural	ADJ
gs-3920	84	18	or	or	CCONJ
gs-3920	84	19	metabolic	metabolic	NOUN
gs-3920	84	20	warning	warning	NOUN
gs-3920	84	21	signs	sign	NOUN
gs-3920	84	22	predictive	predictive	ADJ
gs-3920	84	23	of	of	ADP
gs-3920	84	24	severe	severe	ADJ
gs-3920	84	25	hypersensitivity	hypersensitivity	NOUN
gs-3920	84	26	reactions	reaction	NOUN
gs-3920	84	27	.	.	PUNCT
gs-3920	85	1	from	from	ADP
gs-3920	85	2	a	a	DET
gs-3920	85	3	research	research	NOUN
gs-3920	85	4	perspective	perspective	NOUN
gs-3920	85	5	,	,	PUNCT
gs-3920	85	6	further	further	ADJ
gs-3920	85	7	elucidation	elucidation	NOUN
gs-3920	85	8	of	of	ADP
gs-3920	85	9	dress	dress	NOUN
gs-3920	85	10	pathogenesis	pathogenesis	NOUN
gs-3920	85	11	is	be	AUX
gs-3920	85	12	essential	essential	ADJ
gs-3920	85	13	.	.	PUNCT
gs-3920	86	1	investigations	investigation	NOUN
gs-3920	86	2	into	into	ADP
gs-3920	86	3	immune	immune	ADJ
gs-3920	86	4	checkpoint	checkpoint	NOUN
gs-3920	86	5	dysfunction	dysfunction	NOUN
gs-3920	86	6	,	,	PUNCT
gs-3920	86	7	cytokine	cytokine	ADJ
gs-3920	86	8	profiles	profile	NOUN
gs-3920	86	9	,	,	PUNCT
gs-3920	86	10	and	and	CCONJ
gs-3920	86	11	t	t	NOUN
gs-3920	86	12	-	-	PUNCT
gs-3920	86	13	cell	cell	NOUN
gs-3920	86	14	receptor	receptor	NOUN
gs-3920	86	15	sequencing	sequencing	NOUN
gs-3920	86	16	are	be	AUX
gs-3920	86	17	underway	underway	ADJ
gs-3920	86	18	and	and	CCONJ
gs-3920	86	19	may	may	AUX
gs-3920	86	20	provide	provide	VERB
gs-3920	86	21	future	future	ADJ
gs-3920	86	22	therapeutic	therapeutic	ADJ
gs-3920	86	23	targets	target	NOUN
gs-3920	86	24	.	.	PUNCT
gs-3920	87	1	the	the	DET
gs-3920	87	2	role	role	NOUN
gs-3920	87	3	of	of	ADP
gs-3920	87	4	regulatory	regulatory	ADJ
gs-3920	87	5	t	t	NOUN
gs-3920	87	6	cells	cell	NOUN
gs-3920	87	7	and	and	CCONJ
gs-3920	87	8	the	the	DET
gs-3920	87	9	balance	balance	NOUN
gs-3920	87	10	between	between	ADP
gs-3920	87	11	pro	pro	ADJ
gs-3920	87	12	-	-	ADJ
gs-3920	87	13	inflammatory	inflammatory	ADJ
gs-3920	87	14	and	and	CCONJ
gs-3920	87	15	anti	anti	ADJ
gs-3920	87	16	-	-	ADJ
gs-3920	87	17	inflammatory	inflammatory	ADJ
gs-3920	87	18	cytokines	cytokine	NOUN
gs-3920	87	19	also	also	ADV
gs-3920	87	20	warrants	warrant	VERB
gs-3920	87	21	deeper	deep	ADJ
gs-3920	87	22	investigation	investigation	NOUN
gs-3920	87	23	.	.	PUNCT
gs-3920	88	1	biomarkers	biomarker	NOUN
gs-3920	88	2	predictive	predictive	ADJ
gs-3920	88	3	of	of	ADP
gs-3920	88	4	onset	onset	NOUN
gs-3920	88	5	,	,	PUNCT
gs-3920	88	6	severity	severity	NOUN
gs-3920	88	7	,	,	PUNCT
gs-3920	88	8	and	and	CCONJ
gs-3920	88	9	therapeutic	therapeutic	ADJ
gs-3920	88	10	response	response	NOUN
gs-3920	88	11	would	would	AUX
gs-3920	88	12	be	be	AUX
gs-3920	88	13	transformative	transformative	ADJ
gs-3920	88	14	in	in	ADP
gs-3920	88	15	managing	manage	VERB
gs-3920	88	16	this	this	DET
gs-3920	88	17	complex	complex	ADJ
gs-3920	88	18	syndrome	syndrome	NOUN
gs-3920	88	19	.	.	PUNCT
gs-3920	89	1	dress	dress	NOUN
gs-3920	89	2	syndrome	syndrome	NOUN
gs-3920	89	3	(	(	PUNCT
gs-3920	89	4	drug	drug	NOUN
gs-3920	89	5	reaction	reaction	NOUN
gs-3920	89	6	with	with	ADP
gs-3920	89	7	eosinophilia	eosinophilia	PROPN
gs-3920	89	8	and	and	CCONJ
gs-3920	89	9	systemic	systemic	ADJ
gs-3920	89	10	symptoms	symptom	NOUN
gs-3920	89	11	)	)	PUNCT
gs-3920	89	12	or	or	CCONJ
gs-3920	89	13	druginduced	druginduce	VERB
gs-3920	89	14	hypersensitivity	hypersensitivity	NOUN
gs-3920	89	15	syndrome	syndrome	NOUN
gs-3920	89	16	(	(	PUNCT
gs-3920	89	17	dihs	dihs	NOUN
gs-3920	89	18	)	)	PUNCT
gs-3920	89	19	is	be	AUX
gs-3920	89	20	a	a	DET
gs-3920	89	21	rare	rare	ADJ
gs-3920	89	22	,	,	PUNCT
gs-3920	89	23	but	but	CCONJ
gs-3920	89	24	potentially	potentially	ADV
gs-3920	89	25	fatal	fatal	ADJ
gs-3920	89	26	,	,	PUNCT
gs-3920	89	27	severe	severe	ADJ
gs-3920	89	28	cutaneous	cutaneous	ADJ
gs-3920	89	29	adverse	adverse	ADJ
gs-3920	89	30	reaction	reaction	NOUN
gs-3920	89	31	to	to	ADP
gs-3920	89	32	drugs	drug	NOUN
gs-3920	89	33	.	.	PUNCT
gs-3920	90	1	a	a	DET
gs-3920	90	2	constellation	constellation	NOUN
gs-3920	90	3	of	of	ADP
gs-3920	90	4	systemic	systemic	ADJ
gs-3920	90	5	symptoms	symptom	NOUN
gs-3920	90	6	,	,	PUNCT
gs-3920	90	7	insidious	insidious	ADJ
gs-3920	90	8	presentation	presentation	NOUN
gs-3920	90	9	and	and	CCONJ
gs-3920	90	10	multi	multi	ADJ
gs-3920	90	11	-	-	ADJ
gs-3920	90	12	organ	organ	ADJ
gs-3920	90	13	involvement	involvement	NOUN
gs-3920	90	14	makes	make	VERB
gs-3920	90	15	this	this	PRON
gs-3920	90	16	a	a	DET
gs-3920	90	17	challenging	challenging	ADJ
gs-3920	90	18	condition	condition	NOUN
gs-3920	90	19	to	to	PART
gs-3920	90	20	identify	identify	VERB
gs-3920	90	21	and	and	CCONJ
gs-3920	90	22	treat	treat	VERB
gs-3920	90	23	in	in	ADP
gs-3920	90	24	dayto	dayto	PROPN
gs-3920	90	25	-	-	PUNCT
gs-3920	90	26	day	day	NOUN
gs-3920	90	27	clinical	clinical	ADJ
gs-3920	90	28	practice	practice	NOUN
gs-3920	90	29	.	.	PUNCT
gs-3920	91	1	dress	dress	NOUN
gs-3920	91	2	,	,	PUNCT
gs-3920	91	3	as	as	ADP
gs-3920	91	4	a	a	DET
gs-3920	91	5	delayed	delay	VERB
gs-3920	91	6	hypersensitivity	hypersensitivity	NOUN
gs-3920	91	7	reaction	reaction	NOUN
gs-3920	91	8	,	,	PUNCT
gs-3920	91	9	usually	usually	ADV
gs-3920	91	10	presents	present	VERB
gs-3920	91	11	2	2	NUM
gs-3920	91	12	–	–	SYM
gs-3920	91	13	8	8	NUM
gs-3920	91	14	weeks	week	NOUN
gs-3920	91	15	after	after	ADP
gs-3920	91	16	the	the	DET
gs-3920	91	17	start	start	NOUN
gs-3920	91	18	of	of	ADP
gs-3920	91	19	the	the	DET
gs-3920	91	20	culprit	culprit	NOUN
gs-3920	91	21	drug	drug	NOUN
gs-3920	91	22	,	,	PUNCT
gs-3920	91	23	a	a	DET
gs-3920	91	24	longer	long	ADJ
gs-3920	91	25	time	time	NOUN
gs-3920	91	26	frame	frame	NOUN
gs-3920	91	27	than	than	ADP
gs-3920	91	28	the	the	DET
gs-3920	91	29	incubation	incubation	NOUN
gs-3920	91	30	period	period	NOUN
gs-3920	91	31	noted	note	VERB
gs-3920	91	32	in	in	ADP
gs-3920	91	33	other	other	ADJ
gs-3920	91	34	drug	drug	NOUN
gs-3920	91	35	reactions	reaction	NOUN
gs-3920	91	36	such	such	ADJ
gs-3920	91	37	as	as	ADP
gs-3920	91	38	stevens	stevens	PROPN
gs-3920	91	39	-	-	PUNCT
gs-3920	91	40	johnson	johnson	PROPN
gs-3920	91	41	syndrome	syndrome	PROPN
gs-3920	91	42	or	or	CCONJ
gs-3920	91	43	toxic	toxic	ADJ
gs-3920	91	44	epidermal	epidermal	ADJ
gs-3920	91	45	necrolysis	necrolysis	NOUN
gs-3920	91	46	(	(	PUNCT
gs-3920	91	47	sjs	sjs	PROPN
gs-3920	91	48	or	or	CCONJ
gs-3920	91	49	ten	ten	NUM
gs-3920	91	50	)	)	PUNCT
gs-3920	91	51	.	.	PUNCT
gs-3920	92	1	this	this	DET
gs-3920	92	2	late	late	ADJ
gs-3920	92	3	appearance	appearance	NOUN
gs-3920	92	4	may	may	AUX
gs-3920	92	5	interfere	interfere	VERB
gs-3920	92	6	with	with	ADP
gs-3920	92	7	initial	initial	ADJ
gs-3920	92	8	detection	detection	NOUN
gs-3920	92	9	,	,	PUNCT
gs-3920	92	10	particularly	particularly	ADV
gs-3920	92	11	when	when	SCONJ
gs-3920	92	12	patients	patient	NOUN
gs-3920	92	13	are	be	AUX
gs-3920	92	14	taking	take	VERB
gs-3920	92	15	several	several	ADJ
gs-3920	92	16	concomitant	concomitant	ADJ
gs-3920	92	17	drugs	drug	NOUN
gs-3920	92	18	or	or	CCONJ
gs-3920	92	19	if	if	SCONJ
gs-3920	92	20	early	early	ADJ
gs-3920	92	21	manifestation	manifestation	NOUN
gs-3920	92	22	appears	appear	VERB
gs-3920	92	23	similar	similar	ADJ
gs-3920	92	24	to	to	ADP
gs-3920	92	25	viral	viral	ADJ
gs-3920	92	26	diseases	disease	NOUN
gs-3920	92	27	or	or	CCONJ
gs-3920	92	28	innocent	innocent	ADJ
gs-3920	92	29	cutaneous	cutaneous	ADJ
gs-3920	92	30	eruptions	eruption	NOUN
gs-3920	92	31	.	.	PUNCT
gs-3920	93	1	regi	regi	PROPN
gs-3920	93	2	scar	scar	PROPN
gs-3920	93	3	(	(	PUNCT
gs-3920	93	4	registry	registry	NOUN
gs-3920	93	5	of	of	ADP
gs-3920	93	6	severe	severe	ADJ
gs-3920	93	7	cutaneous	cutaneous	ADJ
gs-3920	93	8	adverse	adverse	ADJ
gs-3920	93	9	reactions	reaction	NOUN
gs-3920	93	10	)	)	PUNCT
gs-3920	93	11	scoring	scoring	NOUN
gs-3920	93	12	is	be	AUX
gs-3920	93	13	one	one	NUM
gs-3920	93	14	of	of	ADP
gs-3920	93	15	the	the	DET
gs-3920	93	16	best	good	ADJ
gs-3920	93	17	diagnostic	diagnostic	ADJ
gs-3920	93	18	tools	tool	NOUN
gs-3920	93	19	that	that	PRON
gs-3920	93	20	has	have	AUX
gs-3920	93	21	been	be	AUX
gs-3920	93	22	developed	develop	VERB
gs-3920	93	23	for	for	ADP
gs-3920	93	24	dress	dress	NOUN
gs-3920	93	25	.	.	PUNCT
gs-3920	94	1	this	this	DET
gs-3920	94	2	system	system	NOUN
gs-3920	94	3	has	have	AUX
gs-3920	94	4	greatly	greatly	ADV
gs-3920	94	5	improved	improve	VERB
gs-3920	94	6	diagnostic	diagnostic	ADJ
gs-3920	94	7	accuracy	accuracy	NOUN
gs-3920	94	8	by	by	ADP
gs-3920	94	9	incorporating	incorporate	VERB
gs-3920	94	10	more	more	ADV
gs-3920	94	11	structured	structured	ADJ
gs-3920	94	12	assessment	assessment	NOUN
gs-3920	94	13	of	of	ADP
gs-3920	94	14	clinical	clinical	ADJ
gs-3920	94	15	(	(	PUNCT
gs-3920	94	16	e.g.	e.g.	ADV
gs-3920	94	17	,	,	PUNCT
gs-3920	94	18	fever	fever	NOUN
gs-3920	94	19	,	,	PUNCT
gs-3920	94	20	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	94	21	,	,	PUNCT
gs-3920	94	22	skin	skin	NOUN
gs-3920	94	23	rash	rash	NOUN
gs-3920	94	24	)	)	PUNCT
gs-3920	94	25	and	and	CCONJ
gs-3920	94	26	laboratory	laboratory	NOUN
gs-3920	94	27	(	(	PUNCT
gs-3920	94	28	e.g.	e.g.	ADV
gs-3920	94	29	,	,	PUNCT
gs-3920	94	30	eosinophilia	eosinophilia	PROPN
gs-3920	94	31	,	,	PUNCT
gs-3920	94	32	atypical	atypical	ADJ
gs-3920	94	33	lymphocytes	lymphocyte	NOUN
gs-3920	94	34	,	,	PUNCT
gs-3920	94	35	elevated	elevated	ADJ
gs-3920	94	36	liver	liver	NOUN
gs-3920	94	37	enzymes	enzyme	NOUN
gs-3920	94	38	)	)	PUNCT
gs-3920	94	39	features	feature	NOUN
gs-3920	94	40	,	,	PUNCT
gs-3920	94	41	and	and	CCONJ
gs-3920	94	42	exclusion	exclusion	NOUN
gs-3920	94	43	of	of	ADP
gs-3920	94	44	other	other	ADJ
gs-3920	94	45	diagnoses	diagnosis	NOUN
gs-3920	94	46	including	include	VERB
gs-3920	94	47	infections	infection	NOUN
gs-3920	94	48	or	or	CCONJ
gs-3920	94	49	autoimmune	autoimmune	ADJ
gs-3920	94	50	disease	disease	NOUN
gs-3920	94	51	.	.	PUNCT
gs-3920	95	1	by	by	ADP
gs-3920	95	2	using	use	VERB
gs-3920	95	3	regi	regi	PROPN
gs-3920	95	4	scar	scar	PROPN
gs-3920	95	5	,	,	PUNCT
gs-3920	95	6	clinicians	clinician	NOUN
gs-3920	95	7	are	be	AUX
gs-3920	95	8	able	able	ADJ
gs-3920	95	9	to	to	PART
gs-3920	95	10	identify	identify	VERB
gs-3920	95	11	uniform	uniform	ADJ
gs-3920	95	12	diagnostic	diagnostic	ADJ
gs-3920	95	13	criteria	criterion	NOUN
gs-3920	95	14	and	and	CCONJ
gs-3920	95	15	act	act	VERB
gs-3920	95	16	decisively	decisively	ADV
gs-3920	95	17	,	,	PUNCT
gs-3920	95	18	which	which	PRON
gs-3920	95	19	is	be	AUX
gs-3920	95	20	essential	essential	ADJ
gs-3920	95	21	in	in	ADP
gs-3920	95	22	preventing	prevent	VERB
gs-3920	95	23	severe	severe	ADJ
gs-3920	95	24	complications	complication	NOUN
gs-3920	95	25	and	and	CCONJ
gs-3920	95	26	death	death	NOUN
gs-3920	95	27	.	.	PUNCT
gs-3920	96	1	there	there	PRON
gs-3920	96	2	is	be	VERB
gs-3920	96	3	frequent	frequent	ADJ
gs-3920	96	4	and	and	CCONJ
gs-3920	96	5	variable	variable	ADJ
gs-3920	96	6	organ	organ	NOUN
gs-3920	96	7	involvement	involvement	NOUN
gs-3920	96	8	in	in	ADP
gs-3920	96	9	dress	dress	NOUN
gs-3920	96	10	,	,	PUNCT
gs-3920	96	11	including	include	VERB
gs-3920	96	12	liver	liver	NOUN
gs-3920	96	13	,	,	PUNCT
gs-3920	96	14	kidneys	kidney	NOUN
gs-3920	96	15	,	,	PUNCT
gs-3920	96	16	lung	lung	NOUN
gs-3920	96	17	and	and	CCONJ
gs-3920	96	18	,	,	PUNCT
gs-3920	96	19	more	more	ADV
gs-3920	96	20	rarely	rarely	ADV
gs-3920	96	21	,	,	PUNCT
gs-3920	96	22	hear	hear	VERB
gs-3920	96	23	,	,	PUNCT
gs-3920	96	24	pancreas	pancreas	NOUN
gs-3920	96	25	and	and	CCONJ
gs-3920	96	26	cns	cns	NOUN
gs-3920	96	27	.	.	PUNCT
gs-3920	97	1	the	the	DET
gs-3920	97	2	liver	liver	NOUN
gs-3920	97	3	is	be	AUX
gs-3920	97	4	the	the	DET
gs-3920	97	5	most	most	ADV
gs-3920	97	6	commonly	commonly	ADV
gs-3920	97	7	affected	affect	VERB
gs-3920	97	8	organ	organ	NOUN
gs-3920	97	9	with	with	ADP
gs-3920	97	10	hepatic	hepatic	ADJ
gs-3920	97	11	impairment	impairment	NOUN
gs-3920	97	12	being	be	AUX
gs-3920	97	13	reported	report	VERB
gs-3920	97	14	in	in	ADP
gs-3920	97	15	up	up	ADP
gs-3920	97	16	to	to	PART
gs-3920	97	17	80	80	NUM
gs-3920	97	18	%	%	NOUN
gs-3920	97	19	of	of	ADP
gs-3920	97	20	cases	case	NOUN
gs-3920	97	21	.	.	PUNCT
gs-3920	98	1	increased	increase	VERB
gs-3920	98	2	liver	liver	NOUN
gs-3920	98	3	transaminases	transaminase	NOUN
gs-3920	98	4	,	,	PUNCT
gs-3920	98	5	hyperbilirubinemia	hyperbilirubinemia	NOUN
gs-3920	98	6	and	and	CCONJ
gs-3920	98	7	,	,	PUNCT
gs-3920	98	8	in	in	ADP
gs-3920	98	9	some	some	DET
gs-3920	98	10	cases	case	NOUN
gs-3920	98	11	,	,	PUNCT
gs-3920	98	12	fulminant	fulminant	ADJ
gs-3920	98	13	hepatitis	hepatitis	NOUN
gs-3920	98	14	are	be	AUX
gs-3920	98	15	frequently	frequently	ADV
gs-3920	98	16	observed	observe	VERB
gs-3920	98	17	.	.	PUNCT
gs-3920	99	1	liver	liver	NOUN
gs-3920	99	2	damage	damage	NOUN
gs-3920	99	3	in	in	ADP
gs-3920	99	4	dress	dress	NOUN
gs-3920	99	5	is	be	AUX
gs-3920	99	6	thought	think	VERB
gs-3920	99	7	to	to	PART
gs-3920	99	8	be	be	AUX
gs-3920	99	9	induced	induce	VERB
gs-3920	99	10	by	by	ADP
gs-3920	99	11	a	a	DET
gs-3920	99	12	mixture	mixture	NOUN
gs-3920	99	13	of	of	ADP
gs-3920	99	14	direct	direct	ADJ
gs-3920	99	15	georgian	georgian	ADJ
gs-3920	99	16	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	99	17	მეცნიერები	მეცნიერები	NOUN
gs-3920	99	18	ტ.	ტ.	VERB
gs-3920	99	19	7	7	NUM
gs-3920	99	20	n	n	PRON
gs-3920	99	21	3	3	NUM
gs-3920	99	22	,	,	PUNCT
gs-3920	99	23	2025	2025	NUM
gs-3920	99	24	186	186	NUM
gs-3920	99	25	hepatotoxicity	hepatotoxicity	NOUN
gs-3920	99	26	,	,	PUNCT
gs-3920	99	27	immunologically	immunologically	ADV
gs-3920	99	28	mediated	mediate	VERB
gs-3920	99	29	inflammation	inflammation	NOUN
gs-3920	99	30	and	and	CCONJ
gs-3920	99	31	reactivation	reactivation	NOUN
gs-3920	99	32	of	of	ADP
gs-3920	99	33	latent	latent	NOUN
gs-3920	99	34	viruses	virus	NOUN
gs-3920	99	35	including	include	VERB
gs-3920	99	36	hhv-6	hhv-6	NOUN
gs-3920	99	37	.	.	PUNCT
gs-3920	100	1	in	in	ADP
gs-3920	100	2	severe	severe	ADJ
gs-3920	100	3	cases	case	NOUN
gs-3920	100	4	,	,	PUNCT
gs-3920	100	5	patients	patient	NOUN
gs-3920	100	6	might	might	AUX
gs-3920	100	7	develop	develop	VERB
gs-3920	100	8	acute	acute	ADJ
gs-3920	100	9	liver	liver	NOUN
gs-3920	100	10	failure	failure	NOUN
gs-3920	100	11	,	,	PUNCT
gs-3920	100	12	requiring	require	VERB
gs-3920	100	13	liver	liver	NOUN
gs-3920	100	14	transplantations	transplantation	NOUN
gs-3920	100	15	.	.	PUNCT
gs-3920	101	1	their	their	PRON
gs-3920	101	2	renal	renal	ADJ
gs-3920	101	3	involvement	involvement	NOUN
gs-3920	101	4	typically	typically	ADV
gs-3920	101	5	presents	present	VERB
gs-3920	101	6	as	as	ADP
gs-3920	101	7	acute	acute	ADJ
gs-3920	101	8	interstitial	interstitial	ADJ
gs-3920	101	9	nephritis	nephritis	NOUN
gs-3920	101	10	with	with	ADP
gs-3920	101	11	haematuria	haematuria	NOUN
gs-3920	101	12	,	,	PUNCT
gs-3920	101	13	proteinuria	proteinuria	NOUN
gs-3920	101	14	,	,	PUNCT
gs-3920	101	15	and	and	CCONJ
gs-3920	101	16	loss	loss	NOUN
gs-3920	101	17	of	of	ADP
gs-3920	101	18	gfr	gfr	PROPN
gs-3920	101	19	.	.	PUNCT
gs-3920	102	1	renal	renal	ADJ
gs-3920	102	2	involvement	involvement	NOUN
gs-3920	102	3	is	be	AUX
gs-3920	102	4	variable	variable	ADJ
gs-3920	102	5	,	,	PUNCT
gs-3920	102	6	from	from	ADP
gs-3920	102	7	an	an	DET
gs-3920	102	8	occult	occult	NOUN
gs-3920	102	9	finding	find	VERB
gs-3920	102	10	to	to	PART
gs-3920	102	11	acute	acute	VERB
gs-3920	102	12	renal	renal	ADJ
gs-3920	102	13	failure	failure	NOUN
gs-3920	102	14	with	with	ADP
gs-3920	102	15	need	need	NOUN
gs-3920	102	16	for	for	ADP
gs-3920	102	17	renal	renal	ADJ
gs-3920	102	18	replacement	replacement	NOUN
gs-3920	102	19	therapy	therapy	NOUN
gs-3920	102	20	.	.	PUNCT
gs-3920	103	1	lung	lung	NOUN
gs-3920	103	2	involvement	involvement	NOUN
gs-3920	103	3	is	be	AUX
gs-3920	103	4	less	less	ADV
gs-3920	103	5	frequent	frequent	ADJ
gs-3920	103	6	than	than	ADP
gs-3920	103	7	hepatic	hepatic	ADJ
gs-3920	103	8	or	or	CCONJ
gs-3920	103	9	renal	renal	ADJ
gs-3920	103	10	involvement	involvement	NOUN
gs-3920	103	11	and	and	CCONJ
gs-3920	103	12	may	may	AUX
gs-3920	103	13	be	be	AUX
gs-3920	103	14	fatal	fatal	ADJ
gs-3920	103	15	.	.	PUNCT
gs-3920	104	1	it	it	PRON
gs-3920	104	2	may	may	AUX
gs-3920	104	3	be	be	AUX
gs-3920	104	4	mild	mild	ADJ
gs-3920	104	5	,	,	PUNCT
gs-3920	104	6	localized	localize	VERB
gs-3920	104	7	as	as	ADP
gs-3920	104	8	interstitial	interstitial	ADJ
gs-3920	104	9	pneumonitis	pneumonitis	NOUN
gs-3920	104	10	or	or	CCONJ
gs-3920	104	11	severe	severe	ADJ
gs-3920	104	12	,	,	PUNCT
gs-3920	104	13	showing	show	VERB
gs-3920	104	14	as	as	ADP
gs-3920	104	15	acute	acute	ADJ
gs-3920	104	16	respiratory	respiratory	ADJ
gs-3920	104	17	distress	distress	NOUN
gs-3920	104	18	syndrome	syndrome	NOUN
gs-3920	104	19	(	(	PUNCT
gs-3920	104	20	ards	ard	NOUN
gs-3920	104	21	)	)	PUNCT
gs-3920	104	22	and	and	CCONJ
gs-3920	104	23	might	might	AUX
gs-3920	104	24	require	require	VERB
gs-3920	104	25	intensive	intensive	ADJ
gs-3920	104	26	care	care	NOUN
gs-3920	104	27	and	and	CCONJ
gs-3920	104	28	invasive	invasive	ADJ
gs-3920	104	29	mechanical	mechanical	ADJ
gs-3920	104	30	ventilation	ventilation	NOUN
gs-3920	104	31	in	in	ADP
gs-3920	104	32	severe	severe	ADJ
gs-3920	104	33	forms	form	NOUN
gs-3920	104	34	.	.	PUNCT
gs-3920	105	1	while	while	SCONJ
gs-3920	105	2	cardiac	cardiac	ADJ
gs-3920	105	3	involvement	involvement	NOUN
gs-3920	105	4	is	be	AUX
gs-3920	105	5	infrequent	infrequent	ADJ
gs-3920	105	6	,	,	PUNCT
gs-3920	105	7	occurrences	occurrence	NOUN
gs-3920	105	8	of	of	ADP
gs-3920	105	9	myocarditis	myocarditis	ADJ
gs-3920	105	10	and	and	CCONJ
gs-3920	105	11	pericarditis	pericarditis	NOUN
gs-3920	105	12	have	have	AUX
gs-3920	105	13	been	be	AUX
gs-3920	105	14	documented	document	VERB
gs-3920	105	15	,	,	PUNCT
gs-3920	105	16	including	include	VERB
gs-3920	105	17	fatal	fatal	ADJ
gs-3920	105	18	cases	case	NOUN
gs-3920	105	19	,	,	PUNCT
gs-3920	105	20	and	and	CCONJ
gs-3920	105	21	therefore	therefore	ADV
gs-3920	105	22	patients	patient	NOUN
gs-3920	105	23	should	should	AUX
gs-3920	105	24	be	be	AUX
gs-3920	105	25	monitored	monitor	VERB
gs-3920	105	26	for	for	ADP
gs-3920	105	27	the	the	DET
gs-3920	105	28	development	development	NOUN
gs-3920	105	29	of	of	ADP
gs-3920	105	30	cardiac	cardiac	ADJ
gs-3920	105	31	complications	complication	NOUN
gs-3920	105	32	during	during	ADP
gs-3920	105	33	the	the	DET
gs-3920	105	34	course	course	NOUN
gs-3920	105	35	of	of	ADP
gs-3920	105	36	the	the	DET
gs-3920	105	37	disease	disease	NOUN
gs-3920	105	38	.	.	PUNCT
gs-3920	106	1	dress	dress	NOUN
gs-3920	106	2	can	can	AUX
gs-3920	106	3	also	also	ADV
gs-3920	106	4	reach	reach	VERB
gs-3920	106	5	the	the	DET
gs-3920	106	6	pancreas	pancrea	NOUN
gs-3920	106	7	and	and	CCONJ
gs-3920	106	8	central	central	ADJ
gs-3920	106	9	nervous	nervous	ADJ
gs-3920	106	10	system	system	NOUN
gs-3920	106	11	in	in	ADP
gs-3920	106	12	certain	certain	ADJ
gs-3920	106	13	patients	patient	NOUN
gs-3920	106	14	.	.	PUNCT
gs-3920	107	1	even	even	ADV
gs-3920	107	2	though	though	SCONJ
gs-3920	107	3	these	these	PRON
gs-3920	107	4	are	be	AUX
gs-3920	107	5	considered	consider	VERB
gs-3920	107	6	unusual	unusual	ADJ
gs-3920	107	7	localizations	localization	NOUN
gs-3920	107	8	,	,	PUNCT
gs-3920	107	9	there	there	PRON
gs-3920	107	10	have	have	AUX
gs-3920	107	11	been	be	AUX
gs-3920	107	12	reported	report	VERB
gs-3920	107	13	cases	case	NOUN
gs-3920	107	14	of	of	ADP
gs-3920	107	15	acute	acute	NOUN
gs-3920	107	16	pancreatitis	pancreatitis	PROPN
gs-3920	107	17	and	and	CCONJ
gs-3920	107	18	with	with	ADP
gs-3920	107	19	neurological	neurological	ADJ
gs-3920	107	20	symptoms	symptom	NOUN
gs-3920	107	21	,	,	PUNCT
gs-3920	107	22	such	such	ADJ
gs-3920	107	23	as	as	ADP
gs-3920	107	24	seizures	seizure	NOUN
gs-3920	107	25	,	,	PUNCT
gs-3920	107	26	encephalitis	encephalitis	NOUN
gs-3920	107	27	,	,	PUNCT
gs-3920	107	28	and	and	CCONJ
gs-3920	107	29	neuropathies	neuropathy	NOUN
gs-3920	107	30	.	.	PUNCT
gs-3920	108	1	the	the	DET
gs-3920	108	2	pathogenic	pathogenic	ADJ
gs-3920	108	3	mechanisms	mechanism	NOUN
gs-3920	108	4	of	of	ADP
gs-3920	108	5	dress	dress	NOUN
gs-3920	108	6	syndrome	syndrome	NOUN
gs-3920	108	7	are	be	AUX
gs-3920	108	8	a	a	DET
gs-3920	108	9	combination	combination	NOUN
gs-3920	108	10	of	of	ADP
gs-3920	108	11	drug	drug	NOUN
gs-3920	108	12	metabolism	metabolism	NOUN
gs-3920	108	13	,	,	PUNCT
gs-3920	108	14	immunological	immunological	ADJ
gs-3920	108	15	derangement	derangement	NOUN
gs-3920	108	16	,	,	PUNCT
gs-3920	108	17	and	and	CCONJ
gs-3920	108	18	viral	viral	ADJ
gs-3920	108	19	reactivation	reactivation	NOUN
gs-3920	108	20	.	.	PUNCT
gs-3920	109	1	one	one	NUM
gs-3920	109	2	of	of	ADP
gs-3920	109	3	the	the	DET
gs-3920	109	4	characteristic	characteristic	ADJ
gs-3920	109	5	laboratory	laboratory	NOUN
gs-3920	109	6	findings	finding	NOUN
gs-3920	109	7	is	be	AUX
gs-3920	109	8	eosinophilia	eosinophilia	PROPN
gs-3920	109	9	,	,	PUNCT
gs-3920	109	10	which	which	PRON
gs-3920	109	11	is	be	AUX
gs-3920	109	12	usually	usually	ADV
gs-3920	109	13	more	more	ADJ
gs-3920	109	14	than	than	ADP
gs-3920	109	15	700	700	NUM
gs-3920	109	16	/	/	SYM
gs-3920	109	17	μl	μl	CCONJ
gs-3920	109	18	,	,	PUNCT
gs-3920	109	19	in	in	ADP
gs-3920	109	20	some	some	DET
gs-3920	109	21	cases	case	NOUN
gs-3920	109	22	accompanied	accompany	VERB
gs-3920	109	23	by	by	ADP
gs-3920	109	24	atypical	atypical	ADJ
gs-3920	109	25	lymphocytosis	lymphocytosis	NOUN
gs-3920	109	26	and	and	CCONJ
gs-3920	109	27	leucocytosis	leucocytosis	NOUN
gs-3920	109	28	.	.	PUNCT
gs-3920	110	1	such	such	ADJ
gs-3920	110	2	hematologic	hematologic	NOUN
gs-3920	110	3	abnormalities	abnormality	NOUN
gs-3920	110	4	indicate	indicate	VERB
gs-3920	110	5	immune	immune	ADJ
gs-3920	110	6	activation	activation	NOUN
gs-3920	110	7	and	and	CCONJ
gs-3920	110	8	are	be	AUX
gs-3920	110	9	helpful	helpful	ADJ
gs-3920	110	10	in	in	ADP
gs-3920	110	11	distinguishing	distinguish	VERB
gs-3920	110	12	dress	dress	NOUN
gs-3920	110	13	from	from	ADP
gs-3920	110	14	other	other	ADJ
gs-3920	110	15	adverse	adverse	ADJ
gs-3920	110	16	drug	drug	NOUN
gs-3920	110	17	reactions	reaction	NOUN
gs-3920	110	18	and	and	CCONJ
gs-3920	110	19	viral	viral	ADJ
gs-3920	110	20	infections	infection	NOUN
gs-3920	110	21	.	.	PUNCT
gs-3920	111	1	eosinophil	eosinophil	ADJ
gs-3920	111	2	numbers	number	NOUN
gs-3920	111	3	also	also	ADV
gs-3920	111	4	track	track	VERB
gs-3920	111	5	with	with	ADP
gs-3920	111	6	disease	disease	NOUN
gs-3920	111	7	severity	severity	NOUN
gs-3920	111	8	and	and	CCONJ
gs-3920	111	9	may	may	AUX
gs-3920	111	10	be	be	AUX
gs-3920	111	11	a	a	DET
gs-3920	111	12	useful	useful	ADJ
gs-3920	111	13	prognostic	prognostic	ADJ
gs-3920	111	14	biomarker	biomarker	NOUN
gs-3920	111	15	.	.	PUNCT
gs-3920	112	1	cutaneous	cutaneous	ADJ
gs-3920	112	2	eruptions	eruption	NOUN
gs-3920	112	3	represent	represent	VERB
gs-3920	112	4	the	the	DET
gs-3920	112	5	initial	initial	ADJ
gs-3920	112	6	and	and	CCONJ
gs-3920	112	7	most	most	ADJ
gs-3920	112	8	overt	overt	ADJ
gs-3920	112	9	symptoms	symptom	NOUN
gs-3920	112	10	of	of	ADP
gs-3920	112	11	dress	dress	NOUN
gs-3920	112	12	.	.	PUNCT
gs-3920	113	1	the	the	DET
gs-3920	113	2	rash	rash	NOUN
gs-3920	113	3	initially	initially	ADV
gs-3920	113	4	frequently	frequently	ADV
gs-3920	113	5	morbilliform	morbilliform	ADJ
gs-3920	113	6	or	or	CCONJ
gs-3920	113	7	maculopapular	maculopapular	ADJ
gs-3920	113	8	changes	change	NOUN
gs-3920	113	9	to	to	ADP
gs-3920	113	10	widespread	widespread	ADJ
gs-3920	113	11	exfoliative	exfoliative	ADJ
gs-3920	113	12	dermatitis	dermatitis	NOUN
gs-3920	113	13	or	or	CCONJ
gs-3920	113	14	erythroderma	erythroderma	NOUN
gs-3920	113	15	.	.	PUNCT
gs-3920	114	1	in	in	ADP
gs-3920	114	2	addition	addition	NOUN
gs-3920	114	3	,	,	PUNCT
gs-3920	114	4	facial	facial	ADJ
gs-3920	114	5	edema	edema	NOUN
gs-3920	114	6	with	with	ADP
gs-3920	114	7	periorbital	periorbital	ADJ
gs-3920	114	8	edema	edema	NOUN
gs-3920	114	9	is	be	AUX
gs-3920	114	10	characteristic	characteristic	ADJ
gs-3920	114	11	of	of	ADP
gs-3920	114	12	dress	dress	NOUN
gs-3920	114	13	.	.	PUNCT
gs-3920	115	1	other	other	ADJ
gs-3920	115	2	cutaneous	cutaneous	ADJ
gs-3920	115	3	findings	finding	NOUN
gs-3920	115	4	in	in	ADP
gs-3920	115	5	the	the	DET
gs-3920	115	6	diagnosis	diagnosis	NOUN
gs-3920	115	7	include	include	VERB
gs-3920	115	8	mucosal	mucosal	NOUN
gs-3920	115	9	findings	finding	NOUN
gs-3920	115	10	as	as	ADV
gs-3920	115	11	well	well	ADV
gs-3920	115	12	as	as	ADP
gs-3920	115	13	generalised	generalise	VERB
gs-3920	115	14	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	115	15	.	.	PUNCT
gs-3920	116	1	the	the	DET
gs-3920	116	2	skin	skin	NOUN
gs-3920	116	3	can	can	AUX
gs-3920	116	4	subsequently	subsequently	ADV
gs-3920	116	5	peel	peel	VERB
gs-3920	116	6	or	or	CCONJ
gs-3920	116	7	desquamate	desquamate	VERB
gs-3920	116	8	,	,	PUNCT
gs-3920	116	9	and	and	CCONJ
gs-3920	116	10	superinfection	superinfection	NOUN
gs-3920	116	11	during	during	ADP
gs-3920	116	12	this	this	DET
gs-3920	116	13	period	period	NOUN
gs-3920	116	14	can	can	AUX
gs-3920	116	15	complicate	complicate	VERB
gs-3920	116	16	healing	healing	NOUN
gs-3920	116	17	and	and	CCONJ
gs-3920	116	18	the	the	DET
gs-3920	116	19	duration	duration	NOUN
gs-3920	116	20	of	of	ADP
gs-3920	116	21	hospitalization	hospitalization	NOUN
gs-3920	116	22	.	.	PUNCT
gs-3920	117	1	a	a	DET
gs-3920	117	2	characteristic	characteristic	NOUN
gs-3920	117	3	of	of	ADP
gs-3920	117	4	dress	dress	NOUN
gs-3920	117	5	syndrome	syndrome	NOUN
gs-3920	117	6	,	,	PUNCT
gs-3920	117	7	which	which	PRON
gs-3920	117	8	separates	separate	VERB
gs-3920	117	9	it	it	PRON
gs-3920	117	10	from	from	ADP
gs-3920	117	11	other	other	ADJ
gs-3920	117	12	scars	scar	NOUN
gs-3920	117	13	,	,	PUNCT
gs-3920	117	14	is	be	AUX
gs-3920	117	15	the	the	DET
gs-3920	117	16	reactivation	reactivation	NOUN
gs-3920	117	17	of	of	ADP
gs-3920	117	18	dormant	dormant	ADJ
gs-3920	117	19	herpesviruses	herpesviruse	NOUN
gs-3920	117	20	,	,	PUNCT
gs-3920	117	21	such	such	ADJ
gs-3920	117	22	as	as	ADP
gs-3920	117	23	human	human	ADJ
gs-3920	117	24	herpesvirus	herpesvirus	NOUN
gs-3920	117	25	6	6	NUM
gs-3920	117	26	(	(	PUNCT
gs-3920	117	27	hhv-6	hhv-6	NOUN
gs-3920	117	28	)	)	PUNCT
gs-3920	117	29	,	,	PUNCT
gs-3920	117	30	epstein	epstein	PROPN
gs-3920	117	31	-	-	PUNCT
gs-3920	117	32	barr	barr	PROPN
gs-3920	117	33	virus	virus	PROPN
gs-3920	117	34	(	(	PUNCT
gs-3920	117	35	ebv	ebv	NOUN
gs-3920	117	36	)	)	PUNCT
gs-3920	117	37	and	and	CCONJ
gs-3920	117	38	cytomegalovirus	cytomegalovirus	NOUN
gs-3920	117	39	(	(	PUNCT
gs-3920	117	40	cmv	cmv	PROPN
gs-3920	117	41	)	)	PUNCT
gs-3920	117	42	.	.	PUNCT
gs-3920	118	1	immune	immune	ADJ
gs-3920	118	2	system	system	NOUN
gs-3920	118	3	disruption	disruption	NOUN
gs-3920	118	4	,	,	PUNCT
gs-3920	118	5	long	long	ADJ
gs-3920	118	6	-	-	PUNCT
gs-3920	118	7	term	term	NOUN
gs-3920	118	8	clinical	clinical	ADJ
gs-3920	118	9	illness	illness	NOUN
gs-3920	118	10	,	,	PUNCT
gs-3920	118	11	and	and	CCONJ
gs-3920	118	12	even	even	ADV
gs-3920	118	13	relapse	relapse	VERB
gs-3920	118	14	following	follow	VERB
gs-3920	118	15	recovery	recovery	NOUN
gs-3920	118	16	has	have	AUX
gs-3920	118	17	been	be	AUX
gs-3920	118	18	attributed	attribute	VERB
gs-3920	118	19	to	to	ADP
gs-3920	118	20	viral	viral	ADJ
gs-3920	118	21	reactivation	reactivation	NOUN
gs-3920	118	22	.	.	PUNCT
gs-3920	119	1	antiviral	antiviral	ADJ
gs-3920	119	2	therapy	therapy	NOUN
gs-3920	119	3	may	may	AUX
gs-3920	119	4	be	be	AUX
gs-3920	119	5	useful	useful	ADJ
gs-3920	119	6	in	in	ADP
gs-3920	119	7	these	these	DET
gs-3920	119	8	patients	patient	NOUN
gs-3920	119	9	,	,	PUNCT
gs-3920	119	10	especially	especially	ADV
gs-3920	119	11	if	if	SCONJ
gs-3920	119	12	refractory	refractory	NOUN
gs-3920	119	13	to	to	ADP
gs-3920	119	14	corticosteroids	corticosteroid	NOUN
gs-3920	119	15	,	,	PUNCT
gs-3920	119	16	but	but	CCONJ
gs-3920	119	17	conclusive	conclusive	ADJ
gs-3920	119	18	clinical	clinical	ADJ
gs-3920	119	19	trial	trial	NOUN
gs-3920	119	20	evidence	evidence	NOUN
gs-3920	119	21	is	be	AUX
gs-3920	119	22	lacking	lack	VERB
gs-3920	119	23	.	.	PUNCT
gs-3920	120	1	there	there	PRON
gs-3920	120	2	is	be	VERB
gs-3920	120	3	an	an	DET
gs-3920	120	4	important	important	ADJ
gs-3920	120	5	contribution	contribution	NOUN
gs-3920	120	6	from	from	ADP
gs-3920	120	7	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	120	8	in	in	ADP
gs-3920	120	9	the	the	DET
gs-3920	120	10	predisposition	predisposition	NOUN
gs-3920	120	11	for	for	ADP
gs-3920	120	12	dress	dress	NOUN
gs-3920	120	13	syndrome	syndrome	NOUN
gs-3920	120	14	.	.	PUNCT
gs-3920	121	1	certain	certain	ADJ
gs-3920	121	2	human	human	ADJ
gs-3920	121	3	leukocyte	leukocyte	NOUN
gs-3920	121	4	antigen	antigen	NOUN
gs-3920	121	5	(	(	PUNCT
gs-3920	121	6	hla	hla	NOUN
gs-3920	121	7	)	)	PUNCT
gs-3920	121	8	alleles	allele	NOUN
gs-3920	121	9	are	be	AUX
gs-3920	121	10	responsible	responsible	ADJ
gs-3920	121	11	for	for	ADP
gs-3920	121	12	susceptibility	susceptibility	NOUN
gs-3920	121	13	to	to	PART
gs-3920	121	14	dress	dress	VERB
gs-3920	121	15	due	due	ADP
gs-3920	121	16	to	to	ADP
gs-3920	121	17	specific	specific	ADJ
gs-3920	121	18	drugs	drug	NOUN
gs-3920	121	19	.	.	PUNCT
gs-3920	122	1	the	the	DET
gs-3920	122	2	best	well	ADV
gs-3920	122	3	established	establish	VERB
gs-3920	122	4	and	and	CCONJ
gs-3920	122	5	most	most	ADV
gs-3920	122	6	investigated	investigate	VERB
gs-3920	122	7	association	association	NOUN
gs-3920	122	8	is	be	AUX
gs-3920	122	9	between	between	ADP
gs-3920	122	10	allopurinol	allopurinol	NOUN
gs-3920	122	11	-	-	PUNCT
gs-3920	122	12	induced	induce	VERB
gs-3920	122	13	dress	dress	NOUN
gs-3920	122	14	and	and	CCONJ
gs-3920	122	15	hla	hla	PROPN
gs-3920	122	16	-	-	PUNCT
gs-3920	122	17	b58:01	b58:01	NOUN
gs-3920	122	18	,	,	PUNCT
gs-3920	122	19	especially	especially	ADV
gs-3920	122	20	in	in	ADP
gs-3920	122	21	asian	asian	ADJ
gs-3920	122	22	georgian	georgian	ADJ
gs-3920	122	23	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	122	24	მეცნიერები	მეცნიერები	NOUN
gs-3920	122	25	ტ.	ტ.	VERB
gs-3920	122	26	7	7	NUM
gs-3920	122	27	n	n	DET
gs-3920	122	28	3	3	NUM
gs-3920	122	29	,	,	PUNCT
gs-3920	122	30	2025	2025	NUM
gs-3920	122	31	187	187	NUM
gs-3920	122	32	populations	population	NOUN
gs-3920	122	33	.	.	PUNCT
gs-3920	123	1	preventative	preventative	ADJ
gs-3920	123	2	pre	pre	NOUN
gs-3920	123	3	-	-	NOUN
gs-3920	123	4	screening	screen	VERB
gs-3920	123	5	for	for	ADP
gs-3920	123	6	this	this	DET
gs-3920	123	7	allele	allele	NOUN
gs-3920	123	8	in	in	ADP
gs-3920	123	9	high	high	ADJ
gs-3920	123	10	-	-	PUNCT
gs-3920	123	11	risk	risk	NOUN
gs-3920	123	12	groups	group	NOUN
gs-3920	123	13	has	have	AUX
gs-3920	123	14	been	be	AUX
gs-3920	123	15	shown	show	VERB
gs-3920	123	16	to	to	PART
gs-3920	123	17	reduce	reduce	VERB
gs-3920	123	18	allopurinol	allopurinol	NOUN
gs-3920	123	19	-	-	PUNCT
gs-3920	123	20	hypersensitivity	hypersensitivity	NOUN
gs-3920	123	21	rate	rate	NOUN
gs-3920	123	22	.	.	PUNCT
gs-3920	124	1	also	also	ADV
gs-3920	124	2	,	,	PUNCT
gs-3920	124	3	hla	hla	PROPN
gs-3920	124	4	-	-	PUNCT
gs-3920	124	5	a31:01	a31:01	PROPN
gs-3920	124	6	and	and	CCONJ
gs-3920	124	7	hla	hla	PROPN
gs-3920	124	8	-	-	PUNCT
gs-3920	124	9	b15:02	b15:02	PROPN
gs-3920	124	10	are	be	AUX
gs-3920	124	11	associated	associate	VERB
gs-3920	124	12	with	with	ADP
gs-3920	124	13	carbamazepine	carbamazepine	NOUN
gs-3920	124	14	hypersensitivity	hypersensitivity	NOUN
gs-3920	124	15	reactions	reaction	NOUN
gs-3920	124	16	,	,	PUNCT
gs-3920	124	17	highlighting	highlight	VERB
gs-3920	124	18	the	the	DET
gs-3920	124	19	need	need	NOUN
gs-3920	124	20	for	for	ADP
gs-3920	124	21	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	124	22	testing	testing	NOUN
gs-3920	124	23	as	as	ADP
gs-3920	124	24	part	part	NOUN
gs-3920	124	25	of	of	ADP
gs-3920	124	26	the	the	DET
gs-3920	124	27	standard	standard	NOUN
gs-3920	124	28	of	of	ADP
gs-3920	124	29	care	care	NOUN
gs-3920	124	30	to	to	PART
gs-3920	124	31	avoid	avoid	VERB
gs-3920	124	32	adverse	adverse	ADJ
gs-3920	124	33	events	event	NOUN
gs-3920	124	34	.	.	PUNCT
gs-3920	125	1	mortality	mortality	NOUN
gs-3920	125	2	rate	rate	NOUN
gs-3920	125	3	of	of	ADP
gs-3920	125	4	dress	dress	NOUN
gs-3920	125	5	is	be	AUX
gs-3920	125	6	approximately	approximately	ADV
gs-3920	125	7	10	10	NUM
gs-3920	125	8	%	%	NOUN
gs-3920	125	9	,	,	PUNCT
gs-3920	125	10	even	even	ADV
gs-3920	125	11	with	with	ADP
gs-3920	125	12	best	good	ADJ
gs-3920	125	13	care	care	NOUN
gs-3920	125	14	,	,	PUNCT
gs-3920	125	15	and	and	CCONJ
gs-3920	125	16	is	be	AUX
gs-3920	125	17	mostly	mostly	ADV
gs-3920	125	18	seen	see	VERB
gs-3920	125	19	secondary	secondary	ADJ
gs-3920	125	20	to	to	ADP
gs-3920	125	21	liver	liver	NOUN
gs-3920	125	22	failure	failure	NOUN
gs-3920	125	23	or	or	CCONJ
gs-3920	125	24	following	follow	VERB
gs-3920	125	25	cardiac	cardiac	ADJ
gs-3920	125	26	events	event	NOUN
gs-3920	125	27	as	as	ADP
gs-3920	125	28	myocarditis	myocarditis	PROPN
gs-3920	125	29	.	.	PUNCT
gs-3920	126	1	long	long	ADV
gs-3920	126	2	-	-	PUNCT
gs-3920	126	3	lasting	last	VERB
gs-3920	126	4	autoimmune	autoimmune	ADJ
gs-3920	126	5	sequelae	sequelae	NOUN
gs-3920	126	6	have	have	AUX
gs-3920	126	7	been	be	AUX
gs-3920	126	8	reported	report	VERB
gs-3920	126	9	,	,	PUNCT
gs-3920	126	10	even	even	ADV
gs-3920	126	11	among	among	ADP
gs-3920	126	12	survivors	survivor	NOUN
gs-3920	126	13	.	.	PUNCT
gs-3920	127	1	these	these	PRON
gs-3920	127	2	are	be	AUX
gs-3920	127	3	autoimmune	autoimmune	ADJ
gs-3920	127	4	thyroiditis	thyroiditis	NOUN
gs-3920	127	5	,	,	PUNCT
gs-3920	127	6	type	type	NOUN
gs-3920	127	7	1	1	NUM
gs-3920	127	8	diabetes	diabetes	NOUN
gs-3920	127	9	mellitus	mellitus	NOUN
gs-3920	127	10	,	,	PUNCT
gs-3920	127	11	and	and	CCONJ
gs-3920	127	12	systemic	systemic	ADJ
gs-3920	127	13	lupus	lupus	PROPN
gs-3920	127	14	erythematosus	erythematosus	PROPN
gs-3920	127	15	,	,	PUNCT
gs-3920	127	16	sometimes	sometimes	ADV
gs-3920	127	17	occurring	occur	VERB
gs-3920	127	18	many	many	ADJ
gs-3920	127	19	months	month	NOUN
gs-3920	127	20	or	or	CCONJ
gs-3920	127	21	years	year	NOUN
gs-3920	127	22	after	after	SCONJ
gs-3920	127	23	the	the	DET
gs-3920	127	24	acute	acute	PROPN
gs-3920	127	25	episode	episode	NOUN
gs-3920	127	26	has	have	AUX
gs-3920	127	27	resolved	resolve	VERB
gs-3920	127	28	.	.	PUNCT
gs-3920	128	1	the	the	DET
gs-3920	128	2	course	course	NOUN
gs-3920	128	3	of	of	ADP
gs-3920	128	4	cicatricial	cicatricial	ADJ
gs-3920	128	5	pemphigoid	pemphigoid	NOUN
gs-3920	128	6	in	in	ADP
gs-3920	128	7	our	our	PRON
gs-3920	128	8	patient	patient	NOUN
gs-3920	128	9	reflects	reflect	VERB
gs-3920	128	10	that	that	SCONJ
gs-3920	128	11	immune	immune	ADJ
gs-3920	128	12	dysregulation	dysregulation	NOUN
gs-3920	128	13	is	be	AUX
gs-3920	128	14	ongoing	ongoing	ADJ
gs-3920	128	15	for	for	ADP
gs-3920	128	16	many	many	ADJ
gs-3920	128	17	years	year	NOUN
gs-3920	128	18	following	follow	VERB
gs-3920	128	19	discontinuation	discontinuation	NOUN
gs-3920	128	20	of	of	ADP
gs-3920	128	21	medication	medication	NOUN
gs-3920	128	22	and	and	CCONJ
gs-3920	128	23	resolution	resolution	NOUN
gs-3920	128	24	of	of	ADP
gs-3920	128	25	the	the	DET
gs-3920	128	26	cutaneous	cutaneous	ADJ
gs-3920	128	27	manifestations	manifestation	NOUN
gs-3920	128	28	,	,	PUNCT
gs-3920	128	29	and	and	CCONJ
gs-3920	128	30	chronically	chronically	ADV
gs-3920	128	31	requires	require	VERB
gs-3920	128	32	post	post	ADJ
gs-3920	128	33	-	-	ADJ
gs-3920	128	34	therapy	therapy	NOUN
gs-3920	128	35	surveillance	surveillance	NOUN
gs-3920	128	36	for	for	ADP
gs-3920	128	37	autoimmune	autoimmune	ADJ
gs-3920	128	38	disease	disease	NOUN
gs-3920	128	39	.	.	PUNCT
gs-3920	129	1	the	the	DET
gs-3920	129	2	pathogenesis	pathogenesis	NOUN
gs-3920	129	3	of	of	ADP
gs-3920	129	4	dress	dress	NOUN
gs-3920	129	5	is	be	AUX
gs-3920	129	6	still	still	ADV
gs-3920	129	7	under	under	ADP
gs-3920	129	8	active	active	ADJ
gs-3920	129	9	investigation	investigation	NOUN
gs-3920	129	10	.	.	PUNCT
gs-3920	130	1	evidence	evidence	NOUN
gs-3920	130	2	is	be	AUX
gs-3920	130	3	accumulating	accumulate	VERB
gs-3920	130	4	that	that	DET
gs-3920	130	5	drug	drug	NOUN
gs-3920	130	6	metabolism	metabolism	NOUN
gs-3920	130	7	,	,	PUNCT
gs-3920	130	8	t	t	NOUN
gs-3920	130	9	-	-	PUNCT
gs-3920	130	10	cell	cell	NOUN
gs-3920	130	11	activation	activation	NOUN
gs-3920	130	12	,	,	PUNCT
gs-3920	130	13	cytokine	cytokine	ADJ
gs-3920	130	14	dysregulation	dysregulation	NOUN
gs-3920	130	15	and	and	CCONJ
gs-3920	130	16	reactivation	reactivation	NOUN
gs-3920	130	17	of	of	ADP
gs-3920	130	18	the	the	DET
gs-3920	130	19	virus	virus	NOUN
gs-3920	130	20	all	all	PRON
gs-3920	130	21	play	play	VERB
gs-3920	130	22	a	a	DET
gs-3920	130	23	role	role	NOUN
gs-3920	130	24	in	in	ADP
gs-3920	130	25	its	its	PRON
gs-3920	130	26	pathogenesis	pathogenesis	NOUN
gs-3920	130	27	.	.	PUNCT
gs-3920	131	1	a	a	DET
gs-3920	131	2	better	well	ADJ
gs-3920	131	3	comprehension	comprehension	NOUN
gs-3920	131	4	of	of	ADP
gs-3920	131	5	its	its	PRON
gs-3920	131	6	genetic	genetic	ADJ
gs-3920	131	7	determination	determination	NOUN
gs-3920	131	8	and	and	CCONJ
gs-3920	131	9	molecular	molecular	ADJ
gs-3920	131	10	triggers	trigger	NOUN
gs-3920	131	11	is	be	AUX
gs-3920	131	12	essential	essential	ADJ
gs-3920	131	13	for	for	ADP
gs-3920	131	14	devising	devise	VERB
gs-3920	131	15	predictive	predictive	ADJ
gs-3920	131	16	tests	test	NOUN
gs-3920	131	17	,	,	PUNCT
gs-3920	131	18	preventive	preventive	ADJ
gs-3920	131	19	efforts	effort	NOUN
gs-3920	131	20	,	,	PUNCT
gs-3920	131	21	and	and	CCONJ
gs-3920	131	22	more	more	ADV
gs-3920	131	23	focused	focused	ADJ
gs-3920	131	24	treatments	treatment	NOUN
gs-3920	131	25	.	.	PUNCT
gs-3920	132	1	in	in	ADP
gs-3920	132	2	the	the	DET
gs-3920	132	3	end	end	NOUN
gs-3920	132	4	,	,	PUNCT
gs-3920	132	5	inclusion	inclusion	NOUN
gs-3920	132	6	of	of	ADP
gs-3920	132	7	large	large	ADJ
gs-3920	132	8	scale	scale	NOUN
gs-3920	132	9	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	132	10	screening	screening	NOUN
gs-3920	132	11	and	and	CCONJ
gs-3920	132	12	improved	improve	VERB
gs-3920	132	13	diagnostic	diagnostic	ADJ
gs-3920	132	14	algorithms	algorithm	NOUN
gs-3920	132	15	such	such	ADJ
gs-3920	132	16	as	as	ADP
gs-3920	132	17	with	with	ADP
gs-3920	132	18	regi	regi	PROPN
gs-3920	132	19	scar	scar	PROPN
gs-3920	132	20	,	,	PUNCT
gs-3920	132	21	along	along	ADP
gs-3920	132	22	with	with	ADP
gs-3920	132	23	prompt	prompt	ADJ
gs-3920	132	24	identification	identification	NOUN
gs-3920	132	25	of	of	ADP
gs-3920	132	26	clinical	clinical	ADJ
gs-3920	132	27	signs	sign	NOUN
gs-3920	132	28	will	will	AUX
gs-3920	132	29	be	be	AUX
gs-3920	132	30	necessary	necessary	ADJ
gs-3920	132	31	in	in	ADP
gs-3920	132	32	decreasing	decrease	VERB
gs-3920	132	33	morbidity	morbidity	NOUN
gs-3920	132	34	and	and	CCONJ
gs-3920	132	35	mortality	mortality	NOUN
gs-3920	132	36	.	.	PUNCT
gs-3920	133	1	in	in	ADP
gs-3920	133	2	order	order	NOUN
gs-3920	133	3	to	to	PART
gs-3920	133	4	establish	establish	VERB
gs-3920	133	5	universal	universal	ADJ
gs-3920	133	6	guidelines	guideline	NOUN
gs-3920	133	7	and	and	CCONJ
gs-3920	133	8	interdisciplinary	interdisciplinary	ADJ
gs-3920	133	9	cooperation	cooperation	NOUN
gs-3920	133	10	among	among	ADP
gs-3920	133	11	dermatologists	dermatologist	NOUN
gs-3920	133	12	,	,	PUNCT
gs-3920	133	13	hepatologists	hepatologist	NOUN
gs-3920	133	14	,	,	PUNCT
gs-3920	133	15	nephrologists	nephrologist	NOUN
gs-3920	133	16	,	,	PUNCT
gs-3920	133	17	infectious	infectious	ADJ
gs-3920	133	18	disease	disease	NOUN
gs-3920	133	19	specialists	specialist	NOUN
gs-3920	133	20	,	,	PUNCT
gs-3920	133	21	and	and	CCONJ
gs-3920	133	22	immunologists	immunologist	NOUN
gs-3920	133	23	to	to	PART
gs-3920	133	24	improve	improve	VERB
gs-3920	133	25	global	global	ADJ
gs-3920	133	26	patient	patient	ADJ
gs-3920	133	27	outcomes	outcome	NOUN
gs-3920	133	28	.	.	PUNCT
gs-3920	133	29	.	.	PUNCT
gs-3920	134	1	laboratory	laboratory	NOUN
gs-3920	134	2	evaluation	evaluation	NOUN
gs-3920	134	3	typically	typically	ADV
gs-3920	134	4	reveals	reveal	VERB
gs-3920	134	5	leukocytosis	leukocytosis	NOUN
gs-3920	134	6	with	with	ADP
gs-3920	134	7	eosinophilia	eosinophilia	PROPN
gs-3920	134	8	or	or	CCONJ
gs-3920	134	9	atypical	atypical	ADJ
gs-3920	134	10	lymphocytosis	lymphocytosis	NOUN
gs-3920	134	11	,	,	PUNCT
gs-3920	134	12	elevated	elevated	ADJ
gs-3920	134	13	liver	liver	NOUN
gs-3920	134	14	enzymes	enzyme	NOUN
gs-3920	134	15	,	,	PUNCT
gs-3920	134	16	and	and	CCONJ
gs-3920	134	17	markers	marker	NOUN
gs-3920	134	18	of	of	ADP
gs-3920	134	19	systemic	systemic	ADJ
gs-3920	134	20	inflammation	inflammation	NOUN
gs-3920	134	21	.	.	PUNCT
gs-3920	135	1	imaging	imaging	NOUN
gs-3920	135	2	and	and	CCONJ
gs-3920	135	3	biopsies	biopsy	NOUN
gs-3920	135	4	may	may	AUX
gs-3920	135	5	be	be	AUX
gs-3920	135	6	required	require	VERB
gs-3920	135	7	to	to	PART
gs-3920	135	8	evaluate	evaluate	VERB
gs-3920	135	9	internal	internal	ADJ
gs-3920	135	10	organ	organ	NOUN
gs-3920	135	11	involvement	involvement	NOUN
gs-3920	135	12	.	.	PUNCT
gs-3920	136	1	despite	despite	SCONJ
gs-3920	136	2	these	these	DET
gs-3920	136	3	tools	tool	NOUN
gs-3920	136	4	,	,	PUNCT
gs-3920	136	5	the	the	DET
gs-3920	136	6	condition	condition	NOUN
gs-3920	136	7	often	often	ADV
gs-3920	136	8	remains	remain	VERB
gs-3920	136	9	underdiagnosed	underdiagnosed	ADJ
gs-3920	136	10	or	or	CCONJ
gs-3920	136	11	misdiagnosed	misdiagnose	VERB
gs-3920	136	12	,	,	PUNCT
gs-3920	136	13	especially	especially	ADV
gs-3920	136	14	in	in	ADP
gs-3920	136	15	resource	resource	NOUN
gs-3920	136	16	-	-	PUNCT
gs-3920	136	17	limited	limit	VERB
gs-3920	136	18	settings	setting	NOUN
gs-3920	136	19	.	.	PUNCT
gs-3920	137	1	management	management	NOUN
gs-3920	137	2	of	of	ADP
gs-3920	137	3	dress	dress	NOUN
gs-3920	137	4	involves	involve	VERB
gs-3920	137	5	immediate	immediate	ADJ
gs-3920	137	6	cessation	cessation	NOUN
gs-3920	137	7	of	of	ADP
gs-3920	137	8	the	the	DET
gs-3920	137	9	suspected	suspect	VERB
gs-3920	137	10	drug	drug	NOUN
gs-3920	137	11	,	,	PUNCT
gs-3920	137	12	which	which	PRON
gs-3920	137	13	is	be	AUX
gs-3920	137	14	the	the	DET
gs-3920	137	15	cornerstone	cornerstone	NOUN
gs-3920	137	16	of	of	ADP
gs-3920	137	17	therapy	therapy	NOUN
gs-3920	137	18	.	.	PUNCT
gs-3920	138	1	delay	delay	NOUN
gs-3920	138	2	in	in	ADP
gs-3920	138	3	drug	drug	NOUN
gs-3920	138	4	withdrawal	withdrawal	NOUN
gs-3920	138	5	is	be	AUX
gs-3920	138	6	directly	directly	ADV
gs-3920	138	7	correlated	correlate	VERB
gs-3920	138	8	with	with	ADP
gs-3920	138	9	worse	bad	ADJ
gs-3920	138	10	outcomes	outcome	NOUN
gs-3920	138	11	.	.	PUNCT
gs-3920	139	1	supportive	supportive	ADJ
gs-3920	139	2	care	care	NOUN
gs-3920	139	3	,	,	PUNCT
gs-3920	139	4	including	include	VERB
gs-3920	139	5	fluid	fluid	ADJ
gs-3920	139	6	management	management	NOUN
gs-3920	139	7	,	,	PUNCT
gs-3920	139	8	monitoring	monitoring	NOUN
gs-3920	139	9	of	of	ADP
gs-3920	139	10	organ	organ	NOUN
gs-3920	139	11	function	function	NOUN
gs-3920	139	12	,	,	PUNCT
gs-3920	139	13	and	and	CCONJ
gs-3920	139	14	treatment	treatment	NOUN
gs-3920	139	15	of	of	ADP
gs-3920	139	16	secondary	secondary	ADJ
gs-3920	139	17	infections	infection	NOUN
gs-3920	139	18	,	,	PUNCT
gs-3920	139	19	is	be	AUX
gs-3920	139	20	critical	critical	ADJ
gs-3920	139	21	.	.	PUNCT
gs-3920	140	1	systemic	systemic	ADJ
gs-3920	140	2	corticosteroids	corticosteroid	NOUN
gs-3920	140	3	remain	remain	VERB
gs-3920	140	4	the	the	DET
gs-3920	140	5	mainstay	mainstay	NOUN
gs-3920	140	6	of	of	ADP
gs-3920	140	7	pharmacologic	pharmacologic	ADJ
gs-3920	140	8	treatment	treatment	NOUN
gs-3920	140	9	,	,	PUNCT
gs-3920	140	10	particularly	particularly	ADV
gs-3920	140	11	in	in	ADP
gs-3920	140	12	patients	patient	NOUN
gs-3920	140	13	with	with	ADP
gs-3920	140	14	significant	significant	ADJ
gs-3920	140	15	internal	internal	ADJ
gs-3920	140	16	organ	organ	NOUN
gs-3920	140	17	involvement	involvement	NOUN
gs-3920	140	18	.	.	PUNCT
gs-3920	141	1	however	however	ADV
gs-3920	141	2	,	,	PUNCT
gs-3920	141	3	there	there	PRON
gs-3920	141	4	is	be	VERB
gs-3920	141	5	no	no	DET
gs-3920	141	6	consensus	consensus	NOUN
gs-3920	141	7	on	on	ADP
gs-3920	141	8	the	the	DET
gs-3920	141	9	optimal	optimal	ADJ
gs-3920	141	10	dose	dose	NOUN
gs-3920	141	11	,	,	PUNCT
gs-3920	141	12	duration	duration	NOUN
gs-3920	141	13	,	,	PUNCT
gs-3920	141	14	or	or	CCONJ
gs-3920	141	15	tapering	taper	VERB
gs-3920	141	16	regimen	regiman	NOUN
gs-3920	141	17	,	,	PUNCT
gs-3920	141	18	and	and	CCONJ
gs-3920	141	19	relapse	relapse	VERB
gs-3920	141	20	upon	upon	SCONJ
gs-3920	141	21	steroid	steroid	NOUN
gs-3920	141	22	withdrawal	withdrawal	NOUN
gs-3920	141	23	is	be	AUX
gs-3920	141	24	not	not	PART
gs-3920	141	25	uncommon	uncommon	ADJ
gs-3920	141	26	.	.	PUNCT
gs-3920	142	1	in	in	ADP
gs-3920	142	2	refractory	refractory	NOUN
gs-3920	142	3	cases	case	NOUN
gs-3920	142	4	or	or	CCONJ
gs-3920	142	5	those	those	PRON
gs-3920	142	6	with	with	ADP
gs-3920	142	7	contraindications	contraindication	NOUN
gs-3920	142	8	to	to	ADP
gs-3920	142	9	corticosteroids	corticosteroid	NOUN
gs-3920	142	10	,	,	PUNCT
gs-3920	142	11	alternative	alternative	ADJ
gs-3920	142	12	immunosuppressive	immunosuppressive	ADJ
gs-3920	142	13	agents	agent	NOUN
gs-3920	142	14	such	such	ADJ
gs-3920	142	15	as	as	ADP
gs-3920	142	16	intravenous	intravenous	ADJ
gs-3920	142	17	immunoglobulin	immunoglobulin	NOUN
gs-3920	142	18	(	(	PUNCT
gs-3920	142	19	ivig	ivig	NOUN
gs-3920	142	20	)	)	PUNCT
gs-3920	142	21	,	,	PUNCT
gs-3920	142	22	cyclosporine	cyclosporine	NOUN
gs-3920	142	23	,	,	PUNCT
gs-3920	142	24	or	or	CCONJ
gs-3920	142	25	mycophenolate	mycophenolate	PROPN
gs-3920	142	26	mofetil	mofetil	NOUN
gs-3920	142	27	may	may	AUX
gs-3920	142	28	be	be	AUX
gs-3920	142	29	considered	consider	VERB
gs-3920	142	30	.	.	PUNCT
gs-3920	143	1	the	the	DET
gs-3920	143	2	emerging	emerge	VERB
gs-3920	143	3	use	use	NOUN
gs-3920	143	4	of	of	ADP
gs-3920	143	5	biologic	biologic	ADJ
gs-3920	143	6	agents	agent	NOUN
gs-3920	143	7	,	,	PUNCT
gs-3920	143	8	including	include	VERB
gs-3920	143	9	interleukin	interleukin	NOUN
gs-3920	143	10	inhibitors	inhibitor	NOUN
gs-3920	143	11	,	,	PUNCT
gs-3920	143	12	has	have	AUX
gs-3920	143	13	shown	show	VERB
gs-3920	143	14	promise	promise	NOUN
gs-3920	143	15	in	in	ADP
gs-3920	143	16	isolated	isolated	ADJ
gs-3920	143	17	cases	case	NOUN
gs-3920	143	18	but	but	CCONJ
gs-3920	143	19	requires	require	VERB
gs-3920	143	20	further	further	ADJ
gs-3920	143	21	validation	validation	NOUN
gs-3920	143	22	through	through	ADP
gs-3920	143	23	controlled	control	VERB
gs-3920	143	24	studies	study	NOUN
gs-3920	143	25	.	.	PUNCT
gs-3920	144	1	longterm	longterm	PROPN
gs-3920	144	2	follow	follow	NOUN
gs-3920	144	3	-	-	PUNCT
gs-3920	144	4	up	up	NOUN
gs-3920	144	5	is	be	AUX
gs-3920	144	6	essential	essential	ADJ
gs-3920	144	7	in	in	ADP
gs-3920	144	8	patients	patient	NOUN
gs-3920	144	9	who	who	PRON
gs-3920	144	10	have	have	AUX
gs-3920	144	11	recovered	recover	VERB
gs-3920	144	12	from	from	ADP
gs-3920	144	13	dress	dress	NOUN
gs-3920	144	14	,	,	PUNCT
gs-3920	144	15	as	as	SCONJ
gs-3920	144	16	relapses	relapse	NOUN
gs-3920	144	17	can	can	AUX
gs-3920	144	18	georgian	georgian	PROPN
gs-3920	144	19	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	144	20	მეცნიერები	მეცნიერები	NOUN
gs-3920	144	21	ტ.	ტ.	VERB
gs-3920	144	22	7	7	NUM
gs-3920	144	23	n	n	PRON
gs-3920	144	24	3	3	NUM
gs-3920	144	25	,	,	PUNCT
gs-3920	144	26	2025	2025	NUM
gs-3920	144	27	188	188	NUM
gs-3920	144	28	occur	occur	ADJ
gs-3920	144	29	and	and	CCONJ
gs-3920	144	30	chronic	chronic	ADJ
gs-3920	144	31	autoimmune	autoimmune	ADJ
gs-3920	144	32	complications	complication	NOUN
gs-3920	144	33	may	may	AUX
gs-3920	144	34	emerge	emerge	VERB
gs-3920	144	35	,	,	PUNCT
gs-3920	144	36	including	include	VERB
gs-3920	144	37	thyroiditis	thyroiditis	NOUN
gs-3920	144	38	,	,	PUNCT
gs-3920	144	39	type	type	NOUN
gs-3920	144	40	1	1	NUM
gs-3920	144	41	diabetes	diabetes	NOUN
gs-3920	144	42	,	,	PUNCT
gs-3920	144	43	and	and	CCONJ
gs-3920	144	44	systemic	systemic	ADJ
gs-3920	144	45	lupus	lupus	PROPN
gs-3920	144	46	erythematosus	erythematosus	PROPN
gs-3920	144	47	.	.	PUNCT
gs-3920	145	1	education	education	NOUN
gs-3920	145	2	regarding	regard	VERB
gs-3920	145	3	drug	drug	NOUN
gs-3920	145	4	avoidance	avoidance	NOUN
gs-3920	145	5	and	and	CCONJ
gs-3920	145	6	genetic	genetic	ADJ
gs-3920	145	7	counseling	counseling	NOUN
gs-3920	145	8	are	be	AUX
gs-3920	145	9	critical	critical	ADJ
gs-3920	145	10	components	component	NOUN
gs-3920	145	11	of	of	ADP
gs-3920	145	12	post	post	ADJ
gs-3920	145	13	-	-	ADJ
gs-3920	145	14	recovery	recovery	ADJ
gs-3920	145	15	care	care	NOUN
gs-3920	145	16	.	.	PUNCT
gs-3920	146	1	implementation	implementation	NOUN
gs-3920	146	2	of	of	ADP
gs-3920	146	3	electronic	electronic	ADJ
gs-3920	146	4	health	health	NOUN
gs-3920	146	5	records	record	NOUN
gs-3920	146	6	and	and	CCONJ
gs-3920	146	7	alert	alert	NOUN
gs-3920	146	8	systems	system	NOUN
gs-3920	146	9	to	to	PART
gs-3920	146	10	flag	flag	VERB
gs-3920	146	11	high	high	ADJ
gs-3920	146	12	-	-	PUNCT
gs-3920	146	13	risk	risk	NOUN
gs-3920	146	14	drugs	drug	NOUN
gs-3920	146	15	in	in	ADP
gs-3920	146	16	susceptible	susceptible	ADJ
gs-3920	146	17	individuals	individual	NOUN
gs-3920	146	18	can	can	AUX
gs-3920	146	19	help	help	VERB
gs-3920	146	20	prevent	prevent	VERB
gs-3920	146	21	recurrence	recurrence	NOUN
gs-3920	146	22	.	.	PUNCT
gs-3920	147	1	furthermore	furthermore	ADV
gs-3920	147	2	,	,	PUNCT
gs-3920	147	3	the	the	DET
gs-3920	147	4	integration	integration	NOUN
gs-3920	147	5	of	of	ADP
gs-3920	147	6	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	147	7	testing	testing	NOUN
gs-3920	147	8	into	into	ADP
gs-3920	147	9	clinical	clinical	ADJ
gs-3920	147	10	workflows	workflow	NOUN
gs-3920	147	11	represents	represent	VERB
gs-3920	147	12	a	a	DET
gs-3920	147	13	transformative	transformative	ADJ
gs-3920	147	14	approach	approach	NOUN
gs-3920	147	15	to	to	ADP
gs-3920	147	16	personalized	personalized	ADJ
gs-3920	147	17	risk	risk	NOUN
gs-3920	147	18	assessment	assessment	NOUN
gs-3920	147	19	and	and	CCONJ
gs-3920	147	20	prophylaxis	prophylaxis	NOUN
gs-3920	147	21	in	in	ADP
gs-3920	147	22	drug	drug	NOUN
gs-3920	147	23	prescribing	prescribing	NOUN
gs-3920	147	24	practices	practice	NOUN
gs-3920	147	25	.	.	PUNCT
gs-3920	148	1	goal	goal	NOUN
gs-3920	148	2	the	the	DET
gs-3920	148	3	primary	primary	ADJ
gs-3920	148	4	goal	goal	NOUN
gs-3920	148	5	of	of	ADP
gs-3920	148	6	this	this	DET
gs-3920	148	7	thesis	thesis	NOUN
gs-3920	148	8	is	be	AUX
gs-3920	148	9	to	to	PART
gs-3920	148	10	conduct	conduct	VERB
gs-3920	148	11	a	a	DET
gs-3920	148	12	comprehensive	comprehensive	ADJ
gs-3920	148	13	analysis	analysis	NOUN
gs-3920	148	14	of	of	ADP
gs-3920	148	15	the	the	DET
gs-3920	148	16	clinical	clinical	ADJ
gs-3920	148	17	,	,	PUNCT
gs-3920	148	18	pharmacological	pharmacological	NOUN
gs-3920	148	19	,	,	PUNCT
gs-3920	148	20	and	and	CCONJ
gs-3920	148	21	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	148	22	features	feature	NOUN
gs-3920	148	23	associated	associate	VERB
gs-3920	148	24	with	with	ADP
gs-3920	148	25	medication	medication	NOUN
gs-3920	148	26	-	-	PUNCT
gs-3920	148	27	associated	associate	VERB
gs-3920	148	28	eosinophilia	eosinophilia	NOUN
gs-3920	148	29	and	and	CCONJ
gs-3920	148	30	systemic	systemic	ADJ
gs-3920	148	31	symptoms	symptom	NOUN
gs-3920	148	32	(	(	PUNCT
gs-3920	148	33	commonly	commonly	ADV
gs-3920	148	34	referred	refer	VERB
gs-3920	148	35	to	to	ADP
gs-3920	148	36	as	as	ADP
gs-3920	148	37	dress	dress	NOUN
gs-3920	148	38	syndrome	syndrome	NOUN
gs-3920	148	39	)	)	PUNCT
gs-3920	148	40	.	.	PUNCT
gs-3920	149	1	this	this	DET
gs-3920	149	2	study	study	NOUN
gs-3920	149	3	aims	aim	VERB
gs-3920	149	4	to	to	PART
gs-3920	149	5	identify	identify	VERB
gs-3920	149	6	the	the	DET
gs-3920	149	7	pharmacological	pharmacological	ADJ
gs-3920	149	8	profiles	profile	NOUN
gs-3920	149	9	of	of	ADP
gs-3920	149	10	the	the	DET
gs-3920	149	11	most	most	ADV
gs-3920	149	12	frequently	frequently	ADV
gs-3920	149	13	implicated	implicate	VERB
gs-3920	149	14	therapeutic	therapeutic	ADJ
gs-3920	149	15	agents	agent	NOUN
gs-3920	149	16	,	,	PUNCT
gs-3920	149	17	understand	understand	VERB
gs-3920	149	18	their	their	PRON
gs-3920	149	19	metabolic	metabolic	NOUN
gs-3920	149	20	and	and	CCONJ
gs-3920	149	21	immunologic	immunologic	ADJ
gs-3920	149	22	pathways	pathway	NOUN
gs-3920	149	23	,	,	PUNCT
gs-3920	149	24	and	and	CCONJ
gs-3920	149	25	evaluate	evaluate	VERB
gs-3920	149	26	the	the	DET
gs-3920	149	27	risk	risk	NOUN
gs-3920	149	28	factors	factor	NOUN
gs-3920	149	29	contributing	contribute	VERB
gs-3920	149	30	to	to	ADP
gs-3920	149	31	the	the	DET
gs-3920	149	32	onset	onset	NOUN
gs-3920	149	33	and	and	CCONJ
gs-3920	149	34	severity	severity	NOUN
gs-3920	149	35	of	of	ADP
gs-3920	149	36	this	this	DET
gs-3920	149	37	syndrome	syndrome	NOUN
gs-3920	149	38	.	.	PUNCT
gs-3920	150	1	particular	particular	ADJ
gs-3920	150	2	emphasis	emphasis	NOUN
gs-3920	150	3	is	be	AUX
gs-3920	150	4	placed	place	VERB
gs-3920	150	5	on	on	ADP
gs-3920	150	6	the	the	DET
gs-3920	150	7	diagnostic	diagnostic	ADJ
gs-3920	150	8	challenges	challenge	NOUN
gs-3920	150	9	,	,	PUNCT
gs-3920	150	10	treatment	treatment	NOUN
gs-3920	150	11	outcomes	outcome	NOUN
gs-3920	150	12	,	,	PUNCT
gs-3920	150	13	genetic	genetic	ADJ
gs-3920	150	14	predispositions	predisposition	NOUN
gs-3920	150	15	,	,	PUNCT
gs-3920	150	16	and	and	CCONJ
gs-3920	150	17	potential	potential	NOUN
gs-3920	150	18	for	for	ADP
gs-3920	150	19	long	long	ADJ
gs-3920	150	20	-	-	PUNCT
gs-3920	150	21	term	term	NOUN
gs-3920	150	22	complications	complication	NOUN
gs-3920	150	23	including	include	VERB
gs-3920	150	24	autoimmune	autoimmune	ADJ
gs-3920	150	25	sequelae	sequelae	PROPN
gs-3920	150	26	.	.	PUNCT
gs-3920	151	1	through	through	ADP
gs-3920	151	2	an	an	DET
gs-3920	151	3	evidence	evidence	NOUN
gs-3920	151	4	-	-	PUNCT
gs-3920	151	5	based	base	VERB
gs-3920	151	6	approach	approach	NOUN
gs-3920	151	7	grounded	ground	VERB
gs-3920	151	8	in	in	ADP
gs-3920	151	9	systematically	systematically	ADV
gs-3920	151	10	reviewed	review	VERB
gs-3920	151	11	clinical	clinical	ADJ
gs-3920	151	12	case	case	NOUN
gs-3920	151	13	studies	study	NOUN
gs-3920	151	14	,	,	PUNCT
gs-3920	151	15	cohort	cohort	NOUN
gs-3920	151	16	reports	report	NOUN
gs-3920	151	17	,	,	PUNCT
gs-3920	151	18	and	and	CCONJ
gs-3920	151	19	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	151	20	data	datum	NOUN
gs-3920	151	21	,	,	PUNCT
gs-3920	151	22	the	the	DET
gs-3920	151	23	thesis	thesis	NOUN
gs-3920	151	24	also	also	ADV
gs-3920	151	25	seeks	seek	VERB
gs-3920	151	26	to	to	PART
gs-3920	151	27	provide	provide	VERB
gs-3920	151	28	recommendations	recommendation	NOUN
gs-3920	151	29	for	for	ADP
gs-3920	151	30	improving	improve	VERB
gs-3920	151	31	early	early	ADJ
gs-3920	151	32	detection	detection	NOUN
gs-3920	151	33	,	,	PUNCT
gs-3920	151	34	personalized	personalized	ADJ
gs-3920	151	35	management	management	NOUN
gs-3920	151	36	strategies	strategy	NOUN
gs-3920	151	37	,	,	PUNCT
gs-3920	151	38	and	and	CCONJ
gs-3920	151	39	prevention	prevention	NOUN
gs-3920	151	40	protocols	protocol	NOUN
gs-3920	151	41	.	.	PUNCT
gs-3920	152	1	ultimately	ultimately	ADV
gs-3920	152	2	,	,	PUNCT
gs-3920	152	3	the	the	DET
gs-3920	152	4	research	research	NOUN
gs-3920	152	5	intends	intend	VERB
gs-3920	152	6	to	to	PART
gs-3920	152	7	contribute	contribute	VERB
gs-3920	152	8	to	to	ADP
gs-3920	152	9	better	well	ADJ
gs-3920	152	10	clinical	clinical	ADJ
gs-3920	152	11	decision	decision	NOUN
gs-3920	152	12	-	-	PUNCT
gs-3920	152	13	making	making	NOUN
gs-3920	152	14	,	,	PUNCT
gs-3920	152	15	enhanced	enhance	VERB
gs-3920	152	16	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	152	17	screening	screening	NOUN
gs-3920	152	18	efforts	effort	NOUN
gs-3920	152	19	,	,	PUNCT
gs-3920	152	20	and	and	CCONJ
gs-3920	152	21	the	the	DET
gs-3920	152	22	development	development	NOUN
gs-3920	152	23	of	of	ADP
gs-3920	152	24	standardized	standardized	ADJ
gs-3920	152	25	treatment	treatment	NOUN
gs-3920	152	26	and	and	CCONJ
gs-3920	152	27	diagnostic	diagnostic	ADJ
gs-3920	152	28	guidelines	guideline	NOUN
gs-3920	152	29	for	for	ADP
gs-3920	152	30	this	this	DET
gs-3920	152	31	rare	rare	ADJ
gs-3920	152	32	but	but	CCONJ
gs-3920	152	33	serious	serious	ADJ
gs-3920	152	34	hypersensitivity	hypersensitivity	NOUN
gs-3920	152	35	reaction	reaction	NOUN
gs-3920	152	36	.	.	PUNCT
gs-3920	153	1	methodology	methodology	NOUN
gs-3920	153	2	the	the	DET
gs-3920	153	3	comprehensive	comprehensive	ADJ
gs-3920	153	4	evaluation	evaluation	NOUN
gs-3920	153	5	was	be	AUX
gs-3920	153	6	conducted	conduct	VERB
gs-3920	153	7	using	use	VERB
gs-3920	153	8	a	a	DET
gs-3920	153	9	multi	multi	ADJ
gs-3920	153	10	-	-	ADJ
gs-3920	153	11	pronged	pronged	ADJ
gs-3920	153	12	methodological	methodological	ADJ
gs-3920	153	13	approach	approach	NOUN
gs-3920	153	14	that	that	PRON
gs-3920	153	15	integrated	integrate	VERB
gs-3920	153	16	systematic	systematic	ADJ
gs-3920	153	17	literature	literature	NOUN
gs-3920	153	18	review	review	NOUN
gs-3920	153	19	,	,	PUNCT
gs-3920	153	20	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	153	21	data	datum	NOUN
gs-3920	153	22	analysis	analysis	NOUN
gs-3920	153	23	,	,	PUNCT
gs-3920	153	24	and	and	CCONJ
gs-3920	153	25	clinical	clinical	ADJ
gs-3920	153	26	case	case	NOUN
gs-3920	153	27	synthesis	synthesis	NOUN
gs-3920	153	28	to	to	PART
gs-3920	153	29	assess	assess	VERB
gs-3920	153	30	the	the	DET
gs-3920	153	31	current	current	ADJ
gs-3920	153	32	understanding	understanding	NOUN
gs-3920	153	33	of	of	ADP
gs-3920	153	34	drug	drug	NOUN
gs-3920	153	35	reaction	reaction	NOUN
gs-3920	153	36	with	with	ADP
gs-3920	153	37	eosinophilia	eosinophilia	PROPN
gs-3920	153	38	and	and	CCONJ
gs-3920	153	39	systemic	systemic	ADJ
gs-3920	153	40	symptoms	symptom	NOUN
gs-3920	153	41	(	(	PUNCT
gs-3920	153	42	dress	dress	NOUN
gs-3920	153	43	)	)	PUNCT
gs-3920	153	44	from	from	ADP
gs-3920	153	45	both	both	CCONJ
gs-3920	153	46	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	153	47	and	and	CCONJ
gs-3920	153	48	clinical	clinical	ADJ
gs-3920	153	49	perspectives	perspective	NOUN
gs-3920	153	50	.	.	PUNCT
gs-3920	154	1	the	the	DET
gs-3920	154	2	study	study	NOUN
gs-3920	154	3	was	be	AUX
gs-3920	154	4	designed	design	VERB
gs-3920	154	5	to	to	PART
gs-3920	154	6	gather	gather	VERB
gs-3920	154	7	,	,	PUNCT
gs-3920	154	8	interpret	interpret	VERB
gs-3920	154	9	,	,	PUNCT
gs-3920	154	10	and	and	CCONJ
gs-3920	154	11	synthesize	synthesize	VERB
gs-3920	154	12	existing	exist	VERB
gs-3920	154	13	evidence	evidence	NOUN
gs-3920	154	14	related	relate	VERB
gs-3920	154	15	to	to	ADP
gs-3920	154	16	the	the	DET
gs-3920	154	17	etiologic	etiologic	ADJ
gs-3920	154	18	agents	agent	NOUN
gs-3920	154	19	,	,	PUNCT
gs-3920	154	20	genetic	genetic	ADJ
gs-3920	154	21	predispositions	predisposition	NOUN
gs-3920	154	22	,	,	PUNCT
gs-3920	154	23	risk	risk	NOUN
gs-3920	154	24	factors	factor	NOUN
gs-3920	154	25	,	,	PUNCT
gs-3920	154	26	and	and	CCONJ
gs-3920	154	27	therapeutic	therapeutic	ADJ
gs-3920	154	28	approaches	approach	NOUN
gs-3920	154	29	associated	associate	VERB
gs-3920	154	30	with	with	ADP
gs-3920	154	31	dress	dress	NOUN
gs-3920	154	32	.	.	PUNCT
gs-3920	155	1	the	the	DET
gs-3920	155	2	initial	initial	ADJ
gs-3920	155	3	phase	phase	NOUN
gs-3920	155	4	of	of	ADP
gs-3920	155	5	the	the	DET
gs-3920	155	6	research	research	NOUN
gs-3920	155	7	involved	involve	VERB
gs-3920	155	8	a	a	DET
gs-3920	155	9	systematic	systematic	ADJ
gs-3920	155	10	review	review	NOUN
gs-3920	155	11	of	of	ADP
gs-3920	155	12	peer	peer	NOUN
gs-3920	155	13	-	-	PUNCT
gs-3920	155	14	reviewed	review	VERB
gs-3920	155	15	publications	publication	NOUN
gs-3920	155	16	from	from	ADP
gs-3920	155	17	major	major	ADJ
gs-3920	155	18	biomedical	biomedical	ADJ
gs-3920	155	19	databases	database	NOUN
gs-3920	155	20	,	,	PUNCT
gs-3920	155	21	including	include	VERB
gs-3920	155	22	pubmed	pubmed	PROPN
gs-3920	155	23	,	,	PUNCT
gs-3920	155	24	scopus	scopus	PROPN
gs-3920	155	25	,	,	PUNCT
gs-3920	155	26	web	web	NOUN
gs-3920	155	27	of	of	ADP
gs-3920	155	28	science	science	NOUN
gs-3920	155	29	,	,	PUNCT
gs-3920	155	30	and	and	CCONJ
gs-3920	155	31	embase	embase	NOUN
gs-3920	155	32	.	.	PUNCT
gs-3920	156	1	articles	article	NOUN
gs-3920	156	2	published	publish	VERB
gs-3920	156	3	between	between	ADP
gs-3920	156	4	january	january	PROPN
gs-3920	156	5	2010	2010	NUM
gs-3920	156	6	and	and	CCONJ
gs-3920	156	7	june	june	PROPN
gs-3920	156	8	2025	2025	NUM
gs-3920	156	9	were	be	AUX
gs-3920	156	10	included	include	VERB
gs-3920	156	11	.	.	PUNCT
gs-3920	157	1	keywords	keyword	NOUN
gs-3920	157	2	used	use	VERB
gs-3920	157	3	for	for	ADP
gs-3920	157	4	the	the	DET
gs-3920	157	5	search	search	NOUN
gs-3920	157	6	included	include	VERB
gs-3920	157	7	“	"	PUNCT
gs-3920	157	8	dress	dress	NOUN
gs-3920	157	9	syndrome	syndrome	NOUN
gs-3920	157	10	,	,	PUNCT
gs-3920	157	11	”	"	PUNCT
gs-3920	157	12	“	"	PUNCT
gs-3920	157	13	drug	drug	NOUN
gs-3920	157	14	-	-	PUNCT
gs-3920	157	15	induced	induce	VERB
gs-3920	157	16	hypersensitivity	hypersensitivity	NOUN
gs-3920	157	17	,	,	PUNCT
gs-3920	157	18	”	"	PUNCT
gs-3920	157	19	“	"	PUNCT
gs-3920	157	20	eosinophilia	eosinophilia	PROPN
gs-3920	157	21	and	and	CCONJ
gs-3920	157	22	systemic	systemic	ADJ
gs-3920	157	23	symptoms	symptom	NOUN
gs-3920	157	24	,	,	PUNCT
gs-3920	157	25	”	"	PUNCT
gs-3920	157	26	“	"	PUNCT
gs-3920	157	27	hla	hla	NOUN
gs-3920	157	28	and	and	CCONJ
gs-3920	157	29	drug	drug	NOUN
gs-3920	157	30	hypersensitivity	hypersensitivity	NOUN
gs-3920	157	31	,	,	PUNCT
gs-3920	157	32	”	"	PUNCT
gs-3920	157	33	“	"	PUNCT
gs-3920	157	34	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	157	35	of	of	ADP
gs-3920	157	36	drug	drug	NOUN
gs-3920	157	37	reactions	reaction	NOUN
gs-3920	157	38	,	,	PUNCT
gs-3920	157	39	”	"	PUNCT
gs-3920	157	40	and	and	CCONJ
gs-3920	157	41	“	"	PUNCT
gs-3920	157	42	treatment	treatment	NOUN
gs-3920	157	43	of	of	ADP
gs-3920	157	44	dress	dress	NOUN
gs-3920	157	45	.	.	PUNCT
gs-3920	157	46	”	"	PUNCT
gs-3920	158	1	additional	additional	ADJ
gs-3920	158	2	filters	filter	NOUN
gs-3920	158	3	were	be	AUX
gs-3920	158	4	applied	apply	VERB
gs-3920	158	5	to	to	PART
gs-3920	158	6	include	include	VERB
gs-3920	158	7	only	only	ADJ
gs-3920	158	8	articles	article	NOUN
gs-3920	158	9	published	publish	VERB
gs-3920	158	10	in	in	ADP
gs-3920	158	11	english	english	PROPN
gs-3920	158	12	,	,	PUNCT
gs-3920	158	13	with	with	ADP
gs-3920	158	14	human	human	ADJ
gs-3920	158	15	subjects	subject	NOUN
gs-3920	158	16	,	,	PUNCT
gs-3920	158	17	and	and	CCONJ
gs-3920	158	18	those	those	PRON
gs-3920	158	19	that	that	PRON
gs-3920	158	20	provided	provide	VERB
gs-3920	158	21	original	original	ADJ
gs-3920	158	22	data	datum	NOUN
gs-3920	158	23	,	,	PUNCT
gs-3920	158	24	clinical	clinical	ADJ
gs-3920	158	25	reviews	review	NOUN
gs-3920	158	26	,	,	PUNCT
gs-3920	158	27	or	or	CCONJ
gs-3920	158	28	meta	meta	NOUN
gs-3920	158	29	-	-	PUNCT
gs-3920	158	30	analyses	analysis	NOUN
gs-3920	158	31	.	.	PUNCT
gs-3920	159	1	grey	grey	PROPN
gs-3920	159	2	literature	literature	PROPN
gs-3920	159	3	,	,	PUNCT
gs-3920	159	4	conference	conference	NOUN
gs-3920	159	5	georgian	georgian	ADJ
gs-3920	159	6	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	159	7	მეცნიერები	მეცნიერები	NOUN
gs-3920	159	8	ტ.	ტ.	VERB
gs-3920	159	9	7	7	NUM
gs-3920	159	10	n	n	PRON
gs-3920	159	11	3	3	NUM
gs-3920	159	12	,	,	PUNCT
gs-3920	159	13	2025	2025	NUM
gs-3920	159	14	189	189	NUM
gs-3920	159	15	abstracts	abstract	NOUN
gs-3920	159	16	,	,	PUNCT
gs-3920	159	17	and	and	CCONJ
gs-3920	159	18	non	non	ADJ
gs-3920	159	19	-	-	ADJ
gs-3920	159	20	peer	peer	NOUN
gs-3920	159	21	-	-	PUNCT
gs-3920	159	22	reviewed	review	VERB
gs-3920	159	23	sources	source	NOUN
gs-3920	159	24	were	be	AUX
gs-3920	159	25	excluded	exclude	VERB
gs-3920	159	26	to	to	PART
gs-3920	159	27	maintain	maintain	VERB
gs-3920	159	28	data	data	NOUN
gs-3920	159	29	reliability	reliability	NOUN
gs-3920	159	30	and	and	CCONJ
gs-3920	159	31	scientific	scientific	ADJ
gs-3920	159	32	integrity	integrity	NOUN
gs-3920	159	33	.	.	PUNCT
gs-3920	160	1	selected	select	VERB
gs-3920	160	2	studies	study	NOUN
gs-3920	160	3	were	be	AUX
gs-3920	160	4	further	far	ADV
gs-3920	160	5	screened	screen	VERB
gs-3920	160	6	based	base	VERB
gs-3920	160	7	on	on	ADP
gs-3920	160	8	inclusion	inclusion	NOUN
gs-3920	160	9	criteria	criterion	NOUN
gs-3920	160	10	,	,	PUNCT
gs-3920	160	11	which	which	PRON
gs-3920	160	12	focused	focus	VERB
gs-3920	160	13	on	on	ADP
gs-3920	160	14	clinically	clinically	ADV
gs-3920	160	15	confirmed	confirm	VERB
gs-3920	160	16	dress	dress	NOUN
gs-3920	160	17	cases	case	NOUN
gs-3920	160	18	,	,	PUNCT
gs-3920	160	19	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	160	20	investigations	investigation	NOUN
gs-3920	160	21	linking	link	VERB
gs-3920	160	22	hla	hla	NOUN
gs-3920	160	23	alleles	allele	NOUN
gs-3920	160	24	or	or	CCONJ
gs-3920	160	25	cytochrome	cytochrome	ADJ
gs-3920	160	26	p450	p450	NUM
gs-3920	160	27	polymorphisms	polymorphism	NOUN
gs-3920	160	28	to	to	ADP
gs-3920	160	29	drug	drug	NOUN
gs-3920	160	30	-	-	PUNCT
gs-3920	160	31	induced	induce	VERB
gs-3920	160	32	hypersensitivity	hypersensitivity	NOUN
gs-3920	160	33	,	,	PUNCT
gs-3920	160	34	and	and	CCONJ
gs-3920	160	35	publications	publication	NOUN
gs-3920	160	36	offering	offer	VERB
gs-3920	160	37	insight	insight	NOUN
gs-3920	160	38	into	into	ADP
gs-3920	160	39	treatment	treatment	NOUN
gs-3920	160	40	outcomes	outcome	NOUN
gs-3920	160	41	and	and	CCONJ
gs-3920	160	42	long	long	ADJ
gs-3920	160	43	-	-	PUNCT
gs-3920	160	44	term	term	NOUN
gs-3920	160	45	follow	follow	NOUN
gs-3920	160	46	-	-	PUNCT
gs-3920	160	47	up	up	NOUN
gs-3920	160	48	.	.	PUNCT
gs-3920	161	1	data	datum	NOUN
gs-3920	161	2	extracted	extract	VERB
gs-3920	161	3	included	include	VERB
gs-3920	161	4	demographic	demographic	ADJ
gs-3920	161	5	profiles	profile	NOUN
gs-3920	161	6	of	of	ADP
gs-3920	161	7	patients	patient	NOUN
gs-3920	161	8	,	,	PUNCT
gs-3920	161	9	type	type	NOUN
gs-3920	161	10	and	and	CCONJ
gs-3920	161	11	latency	latency	NOUN
gs-3920	161	12	of	of	ADP
gs-3920	161	13	drug	drug	NOUN
gs-3920	161	14	exposure	exposure	NOUN
gs-3920	161	15	,	,	PUNCT
gs-3920	161	16	clinical	clinical	ADJ
gs-3920	161	17	manifestations	manifestation	NOUN
gs-3920	161	18	,	,	PUNCT
gs-3920	161	19	laboratory	laboratory	NOUN
gs-3920	161	20	and	and	CCONJ
gs-3920	161	21	imaging	imaging	NOUN
gs-3920	161	22	findings	finding	NOUN
gs-3920	161	23	,	,	PUNCT
gs-3920	161	24	genetic	genetic	ADJ
gs-3920	161	25	testing	testing	NOUN
gs-3920	161	26	results	result	NOUN
gs-3920	161	27	,	,	PUNCT
gs-3920	161	28	organ	organ	NOUN
gs-3920	161	29	involvement	involvement	NOUN
gs-3920	161	30	,	,	PUNCT
gs-3920	161	31	therapeutic	therapeutic	ADJ
gs-3920	161	32	modalities	modality	NOUN
gs-3920	161	33	used	use	VERB
gs-3920	161	34	,	,	PUNCT
gs-3920	161	35	and	and	CCONJ
gs-3920	161	36	patient	patient	ADJ
gs-3920	161	37	outcomes	outcome	NOUN
gs-3920	161	38	.	.	PUNCT
gs-3920	162	1	each	each	DET
gs-3920	162	2	article	article	NOUN
gs-3920	162	3	was	be	AUX
gs-3920	162	4	evaluated	evaluate	VERB
gs-3920	162	5	for	for	ADP
gs-3920	162	6	methodological	methodological	ADJ
gs-3920	162	7	quality	quality	NOUN
gs-3920	162	8	,	,	PUNCT
gs-3920	162	9	relevance	relevance	NOUN
gs-3920	162	10	,	,	PUNCT
gs-3920	162	11	and	and	CCONJ
gs-3920	162	12	scientific	scientific	ADJ
gs-3920	162	13	rigor	rigor	NOUN
gs-3920	162	14	using	use	VERB
gs-3920	162	15	established	establish	VERB
gs-3920	162	16	grading	grade	VERB
gs-3920	162	17	tools	tool	NOUN
gs-3920	162	18	such	such	ADJ
gs-3920	162	19	as	as	ADP
gs-3920	162	20	the	the	DET
gs-3920	162	21	prisma	prisma	NOUN
gs-3920	162	22	(	(	PUNCT
gs-3920	162	23	preferred	prefer	VERB
gs-3920	162	24	reporting	reporting	NOUN
gs-3920	162	25	items	item	NOUN
gs-3920	162	26	for	for	ADP
gs-3920	162	27	systematic	systematic	ADJ
gs-3920	162	28	reviews	review	NOUN
gs-3920	162	29	and	and	CCONJ
gs-3920	162	30	meta	meta	NOUN
gs-3920	162	31	-	-	PUNCT
gs-3920	162	32	analyses	analysis	NOUN
gs-3920	162	33	)	)	PUNCT
gs-3920	162	34	and	and	CCONJ
gs-3920	162	35	grade	grade	NOUN
gs-3920	162	36	(	(	PUNCT
gs-3920	162	37	grading	grade	VERB
gs-3920	162	38	of	of	ADP
gs-3920	162	39	recommendations	recommendation	NOUN
gs-3920	162	40	assessment	assessment	NOUN
gs-3920	162	41	,	,	PUNCT
gs-3920	162	42	development	development	NOUN
gs-3920	162	43	and	and	CCONJ
gs-3920	162	44	evaluation	evaluation	NOUN
gs-3920	162	45	)	)	PUNCT
gs-3920	162	46	frameworks	framework	NOUN
gs-3920	162	47	.	.	PUNCT
gs-3920	163	1	in	in	ADP
gs-3920	163	2	parallel	parallel	NOUN
gs-3920	163	3	with	with	ADP
gs-3920	163	4	the	the	DET
gs-3920	163	5	literature	literature	PROPN
gs-3920	163	6	review	review	PROPN
gs-3920	163	7	,	,	PUNCT
gs-3920	163	8	a	a	DET
gs-3920	163	9	targeted	target	VERB
gs-3920	163	10	analysis	analysis	NOUN
gs-3920	163	11	of	of	ADP
gs-3920	163	12	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	163	13	databases	database	NOUN
gs-3920	163	14	such	such	ADJ
gs-3920	163	15	as	as	ADP
gs-3920	163	16	pharmgkb	pharmgkb	NOUN
gs-3920	163	17	,	,	PUNCT
gs-3920	163	18	cpic	cpic	NOUN
gs-3920	163	19	(	(	PUNCT
gs-3920	163	20	clinical	clinical	ADJ
gs-3920	163	21	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	163	22	implementation	implementation	NOUN
gs-3920	163	23	consortium	consortium	PROPN
gs-3920	163	24	)	)	PUNCT
gs-3920	163	25	,	,	PUNCT
gs-3920	163	26	and	and	CCONJ
gs-3920	163	27	the	the	DET
gs-3920	163	28	nih	nih	PROPN
gs-3920	163	29	dbsnp	dbsnp	PROPN
gs-3920	163	30	and	and	CCONJ
gs-3920	163	31	clinvar	clinvar	PROPN
gs-3920	163	32	repositories	repository	NOUN
gs-3920	163	33	was	be	AUX
gs-3920	163	34	conducted	conduct	VERB
gs-3920	163	35	to	to	PART
gs-3920	163	36	identify	identify	VERB
gs-3920	163	37	genedrug	genedrug	NOUN
gs-3920	163	38	associations	association	NOUN
gs-3920	163	39	relevant	relevant	ADJ
gs-3920	163	40	to	to	PART
gs-3920	163	41	dress	dress	VERB
gs-3920	163	42	.	.	PUNCT
gs-3920	164	1	particular	particular	ADJ
gs-3920	164	2	attention	attention	NOUN
gs-3920	164	3	was	be	AUX
gs-3920	164	4	given	give	VERB
gs-3920	164	5	to	to	ADP
gs-3920	164	6	validated	validate	VERB
gs-3920	164	7	associations	association	NOUN
gs-3920	164	8	between	between	ADP
gs-3920	164	9	hla	hla	NOUN
gs-3920	164	10	genotypes	genotype	NOUN
gs-3920	164	11	(	(	PUNCT
gs-3920	164	12	e.g.	e.g.	ADV
gs-3920	164	13	,	,	PUNCT
gs-3920	164	14	hla	hla	NOUN
gs-3920	164	15	-	-	PUNCT
gs-3920	164	16	b15:02	b15:02	PROPN
gs-3920	164	17	,	,	PUNCT
gs-3920	164	18	hla	hla	NOUN
gs-3920	164	19	-	-	PUNCT
gs-3920	164	20	b58:01	b58:01	NOUN
gs-3920	164	21	)	)	PUNCT
gs-3920	164	22	and	and	CCONJ
gs-3920	164	23	specific	specific	ADJ
gs-3920	164	24	drugs	drug	NOUN
gs-3920	164	25	such	such	ADJ
gs-3920	164	26	as	as	ADP
gs-3920	164	27	carbamazepine	carbamazepine	NOUN
gs-3920	164	28	,	,	PUNCT
gs-3920	164	29	allopurinol	allopurinol	NOUN
gs-3920	164	30	,	,	PUNCT
gs-3920	164	31	and	and	CCONJ
gs-3920	164	32	phenytoin	phenytoin	PROPN
gs-3920	164	33	.	.	PUNCT
gs-3920	165	1	where	where	SCONJ
gs-3920	165	2	available	available	ADJ
gs-3920	165	3	,	,	PUNCT
gs-3920	165	4	allele	allele	NOUN
gs-3920	165	5	frequencies	frequency	NOUN
gs-3920	165	6	across	across	ADP
gs-3920	165	7	different	different	ADJ
gs-3920	165	8	ethnic	ethnic	ADJ
gs-3920	165	9	populations	population	NOUN
gs-3920	165	10	were	be	AUX
gs-3920	165	11	also	also	ADV
gs-3920	165	12	compared	compare	VERB
gs-3920	165	13	to	to	PART
gs-3920	165	14	examine	examine	VERB
gs-3920	165	15	potential	potential	ADJ
gs-3920	165	16	geographical	geographical	ADJ
gs-3920	165	17	and	and	CCONJ
gs-3920	165	18	ethnic	ethnic	ADJ
gs-3920	165	19	predispositions	predisposition	NOUN
gs-3920	165	20	.	.	PUNCT
gs-3920	166	1	to	to	PART
gs-3920	166	2	reinforce	reinforce	VERB
gs-3920	166	3	clinical	clinical	ADJ
gs-3920	166	4	relevance	relevance	NOUN
gs-3920	166	5	,	,	PUNCT
gs-3920	166	6	a	a	DET
gs-3920	166	7	qualitative	qualitative	ADJ
gs-3920	166	8	synthesis	synthesis	NOUN
gs-3920	166	9	of	of	ADP
gs-3920	166	10	published	publish	VERB
gs-3920	166	11	case	case	NOUN
gs-3920	166	12	reports	report	NOUN
gs-3920	166	13	and	and	CCONJ
gs-3920	166	14	case	case	NOUN
gs-3920	166	15	series	series	NOUN
gs-3920	166	16	was	be	AUX
gs-3920	166	17	undertaken	undertake	VERB
gs-3920	166	18	.	.	PUNCT
gs-3920	167	1	these	these	DET
gs-3920	167	2	case	case	NOUN
gs-3920	167	3	studies	study	NOUN
gs-3920	167	4	provided	provide	VERB
gs-3920	167	5	insight	insight	NOUN
gs-3920	167	6	into	into	ADP
gs-3920	167	7	atypical	atypical	ADJ
gs-3920	167	8	presentations	presentation	NOUN
gs-3920	167	9	,	,	PUNCT
gs-3920	167	10	therapeutic	therapeutic	ADJ
gs-3920	167	11	challenges	challenge	NOUN
gs-3920	167	12	,	,	PUNCT
gs-3920	167	13	and	and	CCONJ
gs-3920	167	14	real	real	ADJ
gs-3920	167	15	-	-	PUNCT
gs-3920	167	16	world	world	NOUN
gs-3920	167	17	management	management	NOUN
gs-3920	167	18	strategies	strategy	NOUN
gs-3920	167	19	,	,	PUNCT
gs-3920	167	20	including	include	VERB
gs-3920	167	21	the	the	DET
gs-3920	167	22	use	use	NOUN
gs-3920	167	23	of	of	ADP
gs-3920	167	24	corticosteroids	corticosteroid	NOUN
gs-3920	167	25	,	,	PUNCT
gs-3920	167	26	immunosuppressants	immunosuppressant	NOUN
gs-3920	167	27	,	,	PUNCT
gs-3920	167	28	intravenous	intravenous	ADJ
gs-3920	167	29	immunoglobulin	immunoglobulin	NOUN
gs-3920	167	30	,	,	PUNCT
gs-3920	167	31	and	and	CCONJ
gs-3920	167	32	biologics	biologic	NOUN
gs-3920	167	33	.	.	PUNCT
gs-3920	168	1	cases	case	NOUN
gs-3920	168	2	were	be	AUX
gs-3920	168	3	selected	select	VERB
gs-3920	168	4	for	for	ADP
gs-3920	168	5	their	their	PRON
gs-3920	168	6	richness	richness	NOUN
gs-3920	168	7	in	in	ADP
gs-3920	168	8	clinical	clinical	ADJ
gs-3920	168	9	detail	detail	NOUN
gs-3920	168	10	and	and	CCONJ
gs-3920	168	11	their	their	PRON
gs-3920	168	12	contribution	contribution	NOUN
gs-3920	168	13	to	to	ADP
gs-3920	168	14	understanding	understand	VERB
gs-3920	168	15	dress	dress	NOUN
gs-3920	168	16	variability	variability	NOUN
gs-3920	168	17	in	in	ADP
gs-3920	168	18	diagnosis	diagnosis	NOUN
gs-3920	168	19	and	and	CCONJ
gs-3920	168	20	treatment	treatment	NOUN
gs-3920	168	21	response	response	NOUN
gs-3920	168	22	.	.	PUNCT
gs-3920	169	1	where	where	SCONJ
gs-3920	169	2	necessary	necessary	ADJ
gs-3920	169	3	,	,	PUNCT
gs-3920	169	4	authors	author	NOUN
gs-3920	169	5	’	'	PUNCT
gs-3920	169	6	correspondence	correspondence	NOUN
gs-3920	169	7	was	be	AUX
gs-3920	169	8	reviewed	review	VERB
gs-3920	169	9	to	to	PART
gs-3920	169	10	clarify	clarify	VERB
gs-3920	169	11	or	or	CCONJ
gs-3920	169	12	supplement	supplement	VERB
gs-3920	169	13	reported	report	VERB
gs-3920	169	14	information	information	NOUN
gs-3920	169	15	.	.	PUNCT
gs-3920	170	1	an	an	DET
gs-3920	170	2	interdisciplinary	interdisciplinary	ADJ
gs-3920	170	3	analytical	analytical	ADJ
gs-3920	170	4	lens	lens	NOUN
gs-3920	170	5	was	be	AUX
gs-3920	170	6	applied	apply	VERB
gs-3920	170	7	to	to	PART
gs-3920	170	8	interpret	interpret	VERB
gs-3920	170	9	findings	finding	NOUN
gs-3920	170	10	,	,	PUNCT
gs-3920	170	11	involving	involve	VERB
gs-3920	170	12	experts	expert	NOUN
gs-3920	170	13	in	in	ADP
gs-3920	170	14	clinical	clinical	ADJ
gs-3920	170	15	pharmacology	pharmacology	NOUN
gs-3920	170	16	,	,	PUNCT
gs-3920	170	17	immunology	immunology	NOUN
gs-3920	170	18	,	,	PUNCT
gs-3920	170	19	dermatology	dermatology	NOUN
gs-3920	170	20	,	,	PUNCT
gs-3920	170	21	internal	internal	ADJ
gs-3920	170	22	medicine	medicine	NOUN
gs-3920	170	23	,	,	PUNCT
gs-3920	170	24	and	and	CCONJ
gs-3920	170	25	genetics	genetic	NOUN
gs-3920	170	26	.	.	PUNCT
gs-3920	171	1	comparative	comparative	ADJ
gs-3920	171	2	analyses	analysis	NOUN
gs-3920	171	3	were	be	AUX
gs-3920	171	4	performed	perform	VERB
gs-3920	171	5	to	to	PART
gs-3920	171	6	explore	explore	VERB
gs-3920	171	7	the	the	DET
gs-3920	171	8	correlation	correlation	NOUN
gs-3920	171	9	between	between	ADP
gs-3920	171	10	genetic	genetic	ADJ
gs-3920	171	11	predisposition	predisposition	NOUN
gs-3920	171	12	and	and	CCONJ
gs-3920	171	13	clinical	clinical	ADJ
gs-3920	171	14	outcome	outcome	NOUN
gs-3920	171	15	severity	severity	NOUN
gs-3920	171	16	.	.	PUNCT
gs-3920	172	1	patterns	pattern	NOUN
gs-3920	172	2	of	of	ADP
gs-3920	172	3	organ	organ	NOUN
gs-3920	172	4	involvement	involvement	NOUN
gs-3920	172	5	,	,	PUNCT
gs-3920	172	6	time	time	NOUN
gs-3920	172	7	to	to	ADP
gs-3920	172	8	drug	drug	NOUN
gs-3920	172	9	withdrawal	withdrawal	NOUN
gs-3920	172	10	,	,	PUNCT
gs-3920	172	11	response	response	NOUN
gs-3920	172	12	to	to	ADP
gs-3920	172	13	therapy	therapy	NOUN
gs-3920	172	14	,	,	PUNCT
gs-3920	172	15	and	and	CCONJ
gs-3920	172	16	recurrence	recurrence	NOUN
gs-3920	172	17	rates	rate	NOUN
gs-3920	172	18	were	be	AUX
gs-3920	172	19	examined	examine	VERB
gs-3920	172	20	across	across	ADP
gs-3920	172	21	different	different	ADJ
gs-3920	172	22	subgroups	subgroup	NOUN
gs-3920	172	23	.	.	PUNCT
gs-3920	173	1	epidemiological	epidemiological	ADJ
gs-3920	173	2	and	and	CCONJ
gs-3920	173	3	demographic	demographic	ADJ
gs-3920	173	4	data	datum	NOUN
gs-3920	173	5	were	be	AUX
gs-3920	173	6	also	also	ADV
gs-3920	173	7	synthesized	synthesize	VERB
gs-3920	173	8	to	to	PART
gs-3920	173	9	highlight	highlight	VERB
gs-3920	173	10	risk	risk	NOUN
gs-3920	173	11	profiles	profile	NOUN
gs-3920	173	12	and	and	CCONJ
gs-3920	173	13	population	population	NOUN
gs-3920	173	14	-	-	PUNCT
gs-3920	173	15	specific	specific	ADJ
gs-3920	173	16	vulnerabilities	vulnerability	NOUN
gs-3920	173	17	.	.	PUNCT
gs-3920	174	1	limitations	limitation	NOUN
gs-3920	174	2	of	of	ADP
gs-3920	174	3	this	this	DET
gs-3920	174	4	methodology	methodology	NOUN
gs-3920	174	5	include	include	VERB
gs-3920	174	6	reliance	reliance	NOUN
gs-3920	174	7	on	on	ADP
gs-3920	174	8	retrospective	retrospective	ADJ
gs-3920	174	9	data	datum	NOUN
gs-3920	174	10	,	,	PUNCT
gs-3920	174	11	heterogeneity	heterogeneity	NOUN
gs-3920	174	12	in	in	ADP
gs-3920	174	13	diagnostic	diagnostic	ADJ
gs-3920	174	14	criteria	criterion	NOUN
gs-3920	174	15	among	among	ADP
gs-3920	174	16	studies	study	NOUN
gs-3920	174	17	,	,	PUNCT
gs-3920	174	18	and	and	CCONJ
gs-3920	174	19	limited	limited	ADJ
gs-3920	174	20	access	access	NOUN
gs-3920	174	21	to	to	ADP
gs-3920	174	22	raw	raw	ADJ
gs-3920	174	23	genomic	genomic	NOUN
gs-3920	174	24	data	datum	NOUN
gs-3920	174	25	from	from	ADP
gs-3920	174	26	individual	individual	ADJ
gs-3920	174	27	cases	case	NOUN
gs-3920	174	28	.	.	PUNCT
gs-3920	175	1	nonetheless	nonetheless	ADV
gs-3920	175	2	,	,	PUNCT
gs-3920	175	3	triangulation	triangulation	NOUN
gs-3920	175	4	of	of	ADP
gs-3920	175	5	data	datum	NOUN
gs-3920	175	6	from	from	ADP
gs-3920	175	7	multiple	multiple	ADJ
gs-3920	175	8	reliable	reliable	ADJ
gs-3920	175	9	sources	source	NOUN
gs-3920	175	10	enhanced	enhance	VERB
gs-3920	175	11	the	the	DET
gs-3920	175	12	validity	validity	NOUN
gs-3920	175	13	and	and	CCONJ
gs-3920	175	14	comprehensiveness	comprehensiveness	NOUN
gs-3920	175	15	of	of	ADP
gs-3920	175	16	the	the	DET
gs-3920	175	17	findings	finding	NOUN
gs-3920	175	18	.	.	PUNCT
gs-3920	176	1	this	this	DET
gs-3920	176	2	methodological	methodological	ADJ
gs-3920	176	3	approach	approach	NOUN
gs-3920	176	4	enabled	enable	VERB
gs-3920	176	5	a	a	DET
gs-3920	176	6	multi	multi	ADJ
gs-3920	176	7	-	-	ADJ
gs-3920	176	8	dimensional	dimensional	ADJ
gs-3920	176	9	evaluation	evaluation	NOUN
gs-3920	176	10	of	of	ADP
gs-3920	176	11	dress	dress	NOUN
gs-3920	176	12	,	,	PUNCT
gs-3920	176	13	integrating	integrate	VERB
gs-3920	176	14	molecular	molecular	ADJ
gs-3920	176	15	-	-	PUNCT
gs-3920	176	16	level	level	NOUN
gs-3920	176	17	data	datum	NOUN
gs-3920	176	18	with	with	ADP
gs-3920	176	19	clinical	clinical	ADJ
gs-3920	176	20	realities	reality	NOUN
gs-3920	176	21	.	.	PUNCT
gs-3920	177	1	it	it	PRON
gs-3920	177	2	offers	offer	VERB
gs-3920	177	3	a	a	DET
gs-3920	177	4	foundational	foundational	ADJ
gs-3920	177	5	framework	framework	NOUN
gs-3920	177	6	georgian	georgian	ADJ
gs-3920	177	7	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	177	8	მეცნიერები	მეცნიერები	NOUN
gs-3920	177	9	ტ.	ტ.	VERB
gs-3920	177	10	7	7	NUM
gs-3920	177	11	n	n	DET
gs-3920	177	12	3	3	NUM
gs-3920	177	13	,	,	PUNCT
gs-3920	177	14	2025	2025	NUM
gs-3920	177	15	190	190	NUM
gs-3920	177	16	for	for	ADP
gs-3920	177	17	guiding	guide	VERB
gs-3920	177	18	future	future	ADJ
gs-3920	177	19	prospective	prospective	ADJ
gs-3920	177	20	studies	study	NOUN
gs-3920	177	21	,	,	PUNCT
gs-3920	177	22	refining	refine	VERB
gs-3920	177	23	diagnostic	diagnostic	ADJ
gs-3920	177	24	algorithms	algorithm	NOUN
gs-3920	177	25	,	,	PUNCT
gs-3920	177	26	and	and	CCONJ
gs-3920	177	27	enhancing	enhance	VERB
gs-3920	177	28	the	the	DET
gs-3920	177	29	personalization	personalization	NOUN
gs-3920	177	30	of	of	ADP
gs-3920	177	31	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	177	32	and	and	CCONJ
gs-3920	177	33	therapeutic	therapeutic	ADJ
gs-3920	177	34	interventions	intervention	NOUN
gs-3920	177	35	.	.	PUNCT
gs-3920	178	1	the	the	DET
gs-3920	178	2	systematic	systematic	ADJ
gs-3920	178	3	review	review	NOUN
gs-3920	178	4	extracted	extract	VERB
gs-3920	178	5	data	datum	NOUN
gs-3920	178	6	only	only	ADV
gs-3920	178	7	from	from	ADP
gs-3920	178	8	peer	peer	NOUN
gs-3920	178	9	-	-	PUNCT
gs-3920	178	10	reviewed	review	VERB
gs-3920	178	11	high	high	ADJ
gs-3920	178	12	impact	impact	NOUN
gs-3920	178	13	scientific	scientific	ADJ
gs-3920	178	14	journals	journal	NOUN
gs-3920	178	15	and	and	CCONJ
gs-3920	178	16	credible	credible	ADJ
gs-3920	178	17	clinical	clinical	ADJ
gs-3920	178	18	case	case	NOUN
gs-3920	178	19	registries	registry	NOUN
gs-3920	178	20	.	.	PUNCT
gs-3920	179	1	preference	preference	NOUN
gs-3920	179	2	was	be	AUX
gs-3920	179	3	given	give	VERB
gs-3920	179	4	to	to	ADP
gs-3920	179	5	articles	article	NOUN
gs-3920	179	6	sourced	source	VERB
gs-3920	179	7	from	from	ADP
gs-3920	179	8	well	well	ADV
gs-3920	179	9	-	-	PUNCT
gs-3920	179	10	known	know	VERB
gs-3920	179	11	academic	academic	ADJ
gs-3920	179	12	databases	database	NOUN
gs-3920	179	13	(	(	PUNCT
gs-3920	179	14	pubmed	pubmed	PROPN
gs-3920	179	15	,	,	PUNCT
gs-3920	179	16	sciencedirect	sciencedirect	PROPN
gs-3920	179	17	,	,	PUNCT
gs-3920	179	18	scopus	scopus	PROPN
gs-3920	179	19	,	,	PUNCT
gs-3920	179	20	cureus	cureus	NOUN
gs-3920	179	21	,	,	PUNCT
gs-3920	179	22	google	google	NOUN
gs-3920	179	23	scholar	scholar	NOUN
gs-3920	179	24	)	)	PUNCT
gs-3920	179	25	that	that	PRON
gs-3920	179	26	had	have	VERB
gs-3920	179	27	scientific	scientific	ADJ
gs-3920	179	28	validity	validity	NOUN
gs-3920	179	29	and	and	CCONJ
gs-3920	179	30	relevance	relevance	NOUN
gs-3920	179	31	.	.	PUNCT
gs-3920	180	1	publications	publication	NOUN
gs-3920	180	2	were	be	AUX
gs-3920	180	3	chosen	choose	VERB
gs-3920	180	4	from	from	ADP
gs-3920	180	5	a	a	DET
gs-3920	180	6	variety	variety	NOUN
gs-3920	180	7	of	of	ADP
gs-3920	180	8	general	general	ADJ
gs-3920	180	9	medical	medical	ADJ
gs-3920	180	10	and	and	CCONJ
gs-3920	180	11	dermatology	dermatology	NOUN
gs-3920	180	12	specific	specific	ADJ
gs-3920	180	13	journals	journal	NOUN
gs-3920	180	14	,	,	PUNCT
gs-3920	180	15	namely	namely	ADV
gs-3920	180	16	bmj	bmj	NOUN
gs-3920	180	17	case	case	NOUN
gs-3920	180	18	reports	report	NOUN
gs-3920	180	19	,	,	PUNCT
gs-3920	180	20	jaad	jaad	NOUN
gs-3920	180	21	case	case	NOUN
gs-3920	180	22	reports	report	NOUN
gs-3920	180	23	,	,	PUNCT
gs-3920	180	24	cureus	cureus	NOUN
gs-3920	180	25	,	,	PUNCT
gs-3920	180	26	frontiers	frontier	NOUN
gs-3920	180	27	in	in	ADP
gs-3920	180	28	pharmacology	pharmacology	NOUN
gs-3920	180	29	,	,	PUNCT
gs-3920	180	30	allergy	allergy	NOUN
gs-3920	180	31	,	,	PUNCT
gs-3920	180	32	asthma	asthma	PROPN
gs-3920	180	33	&	&	CCONJ
gs-3920	180	34	immunology	immunology	NOUN
gs-3920	180	35	research	research	NOUN
gs-3920	180	36	,	,	PUNCT
gs-3920	180	37	and	and	CCONJ
gs-3920	180	38	indian	indian	ADJ
gs-3920	180	39	journal	journal	NOUN
gs-3920	180	40	of	of	ADP
gs-3920	180	41	dermatology	dermatology	NOUN
gs-3920	180	42	.	.	PUNCT
gs-3920	181	1	the	the	DET
gs-3920	181	2	above	above	ADV
gs-3920	181	3	-	-	PUNCT
gs-3920	181	4	mentioned	mention	VERB
gs-3920	181	5	journals	journal	NOUN
gs-3920	181	6	are	be	AUX
gs-3920	181	7	known	know	VERB
gs-3920	181	8	for	for	ADP
gs-3920	181	9	their	their	PRON
gs-3920	181	10	stringent	stringent	ADJ
gs-3920	181	11	peer	peer	NOUN
gs-3920	181	12	-	-	PUNCT
gs-3920	181	13	review	review	NOUN
gs-3920	181	14	standards	standard	NOUN
gs-3920	181	15	,	,	PUNCT
gs-3920	181	16	high	high	ADJ
gs-3920	181	17	clinical	clinical	ADJ
gs-3920	181	18	data	datum	NOUN
gs-3920	181	19	,	,	PUNCT
gs-3920	181	20	and	and	CCONJ
gs-3920	181	21	the	the	DET
gs-3920	181	22	most	most	ADV
gs-3920	181	23	relevant	relevant	ADJ
gs-3920	181	24	sources	source	NOUN
gs-3920	181	25	of	of	ADP
gs-3920	181	26	evidence	evidence	NOUN
gs-3920	181	27	-	-	PUNCT
gs-3920	181	28	based	base	VERB
gs-3920	181	29	evaluation	evaluation	NOUN
gs-3920	181	30	of	of	ADP
gs-3920	181	31	rare	rare	ADJ
gs-3920	181	32	drug	drug	NOUN
gs-3920	181	33	-	-	PUNCT
gs-3920	181	34	induced	induce	VERB
gs-3920	181	35	diseases	disease	NOUN
gs-3920	181	36	(	(	PUNCT
gs-3920	181	37	e.g.	e.g.	ADV
gs-3920	181	38	,	,	PUNCT
gs-3920	181	39	dress	dress	NOUN
gs-3920	181	40	)	)	PUNCT
gs-3920	181	41	.	.	PUNCT
gs-3920	182	1	observational	observational	ADJ
gs-3920	182	2	studies	study	NOUN
gs-3920	182	3	,	,	PUNCT
gs-3920	182	4	such	such	ADJ
gs-3920	182	5	as	as	ADP
gs-3920	182	6	case	case	NOUN
gs-3920	182	7	reports	report	NOUN
gs-3920	182	8	,	,	PUNCT
gs-3920	182	9	cohort	cohort	NOUN
gs-3920	182	10	,	,	PUNCT
gs-3920	182	11	systematic	systematic	ADJ
gs-3920	182	12	review	review	NOUN
gs-3920	182	13	,	,	PUNCT
gs-3920	182	14	and	and	CCONJ
gs-3920	182	15	clinical	clinical	ADJ
gs-3920	182	16	observational	observational	ADJ
gs-3920	182	17	studies	study	NOUN
gs-3920	182	18	,	,	PUNCT
gs-3920	182	19	were	be	AUX
gs-3920	182	20	preferred	prefer	VERB
gs-3920	182	21	.	.	PUNCT
gs-3920	183	1	this	this	DET
gs-3920	183	2	open	open	ADJ
gs-3920	183	3	-	-	PUNCT
gs-3920	183	4	source	source	NOUN
gs-3920	183	5	multicentre	multicentre	NOUN
gs-3920	183	6	perspective	perspective	NOUN
gs-3920	183	7	facilitated	facilitate	VERB
gs-3920	183	8	extensive	extensive	ADJ
gs-3920	183	9	,	,	PUNCT
gs-3920	183	10	balanced	balanced	ADJ
gs-3920	183	11	discussion	discussion	NOUN
gs-3920	183	12	of	of	ADP
gs-3920	183	13	drug	drug	NOUN
gs-3920	183	14	classes	class	NOUN
gs-3920	183	15	,	,	PUNCT
gs-3920	183	16	patterns	pattern	NOUN
gs-3920	183	17	of	of	ADP
gs-3920	183	18	clinical	clinical	ADJ
gs-3920	183	19	onset	onset	NOUN
gs-3920	183	20	,	,	PUNCT
gs-3920	183	21	organ	organ	NOUN
gs-3920	183	22	-	-	PUNCT
gs-3920	183	23	specific	specific	ADJ
gs-3920	183	24	morbidity	morbidity	NOUN
gs-3920	183	25	,	,	PUNCT
gs-3920	183	26	and	and	CCONJ
gs-3920	183	27	genetic	genetic	ADJ
gs-3920	183	28	risk	risk	NOUN
gs-3920	183	29	markers	marker	NOUN
gs-3920	183	30	for	for	ADP
gs-3920	183	31	dress	dress	NOUN
gs-3920	183	32	.	.	PUNCT
gs-3920	184	1	also	also	ADV
gs-3920	184	2	,	,	PUNCT
gs-3920	184	3	papers	paper	NOUN
gs-3920	184	4	from	from	ADP
gs-3920	184	5	the	the	DET
gs-3920	184	6	lower	low	ADJ
gs-3920	184	7	end	end	NOUN
gs-3920	184	8	of	of	ADP
gs-3920	184	9	the	the	DET
gs-3920	184	10	indexed	index	VERB
gs-3920	184	11	quartiles	quartile	NOUN
gs-3920	184	12	or	or	CCONJ
gs-3920	184	13	non	non	ADJ
gs-3920	184	14	-	-	ADJ
gs-3920	184	15	indexed	indexed	ADJ
gs-3920	184	16	sources	source	NOUN
gs-3920	184	17	were	be	AUX
gs-3920	184	18	intentionally	intentionally	ADV
gs-3920	184	19	omitted	omit	VERB
gs-3920	184	20	for	for	ADP
gs-3920	184	21	high	high	ADJ
gs-3920	184	22	academic	academic	ADJ
gs-3920	184	23	rigour	rigour	NOUN
gs-3920	184	24	and	and	CCONJ
gs-3920	184	25	reliability	reliability	NOUN
gs-3920	184	26	.	.	PUNCT
gs-3920	185	1	given	give	VERB
gs-3920	185	2	the	the	DET
gs-3920	185	3	rare	rare	ADJ
gs-3920	185	4	nature	nature	NOUN
gs-3920	185	5	of	of	ADP
gs-3920	185	6	the	the	DET
gs-3920	185	7	disease	disease	NOUN
gs-3920	185	8	,	,	PUNCT
gs-3920	185	9	it	it	PRON
gs-3920	185	10	was	be	AUX
gs-3920	185	11	necessary	necessary	ADJ
gs-3920	185	12	to	to	PART
gs-3920	185	13	include	include	VERB
gs-3920	185	14	case	case	NOUN
gs-3920	185	15	series	series	NOUN
gs-3920	185	16	and	and	CCONJ
gs-3920	185	17	well	well	ADV
gs-3920	185	18	reported	report	VERB
gs-3920	185	19	individual	individual	ADJ
gs-3920	185	20	case	case	NOUN
gs-3920	185	21	reports	report	VERB
gs-3920	185	22	to	to	PART
gs-3920	185	23	obtain	obtain	VERB
gs-3920	185	24	adequate	adequate	ADJ
gs-3920	185	25	clinical	clinical	ADJ
gs-3920	185	26	details	detail	NOUN
gs-3920	185	27	.	.	PUNCT
gs-3920	186	1	such	such	DET
gs-3920	186	2	an	an	DET
gs-3920	186	3	extensive	extensive	ADJ
gs-3920	186	4	approach	approach	NOUN
gs-3920	186	5	reinforces	reinforce	VERB
gs-3920	186	6	both	both	CCONJ
gs-3920	186	7	the	the	DET
gs-3920	186	8	validity	validity	NOUN
gs-3920	186	9	and	and	CCONJ
gs-3920	186	10	reproducibility	reproducibility	NOUN
gs-3920	186	11	of	of	ADP
gs-3920	186	12	the	the	DET
gs-3920	186	13	findings	finding	NOUN
gs-3920	186	14	and	and	CCONJ
gs-3920	186	15	the	the	DET
gs-3920	186	16	rigor	rigor	NOUN
gs-3920	186	17	of	of	ADP
gs-3920	186	18	the	the	DET
gs-3920	186	19	evidence	evidence	NOUN
gs-3920	186	20	upon	upon	SCONJ
gs-3920	186	21	which	which	PRON
gs-3920	186	22	they	they	PRON
gs-3920	186	23	are	be	AUX
gs-3920	186	24	based	base	VERB
gs-3920	186	25	.	.	PUNCT
gs-3920	187	1	inclusion	inclusion	NOUN
gs-3920	187	2	criteria	criterion	NOUN
gs-3920	187	3	the	the	DET
gs-3920	187	4	criteria	criterion	NOUN
gs-3920	187	5	to	to	PART
gs-3920	187	6	be	be	AUX
gs-3920	187	7	met	meet	VERB
gs-3920	187	8	for	for	SCONJ
gs-3920	187	9	an	an	DET
gs-3920	187	10	article	article	NOUN
gs-3920	187	11	to	to	PART
gs-3920	187	12	be	be	AUX
gs-3920	187	13	included	include	VERB
gs-3920	187	14	in	in	ADP
gs-3920	187	15	this	this	DET
gs-3920	187	16	review	review	NOUN
gs-3920	187	17	were	be	AUX
gs-3920	187	18	:	:	PUNCT
gs-3920	187	19			NOUN
gs-3920	187	20	date	date	NOUN
gs-3920	187	21	range	range	VERB
gs-3920	187	22	for	for	ADP
gs-3920	187	23	publication	publication	NOUN
gs-3920	187	24	:	:	PUNCT
gs-3920	187	25	from	from	ADP
gs-3920	187	26	year	year	NOUN
gs-3920	187	27	2010‐	2010‐	NUM
gs-3920	187	28	year	year	NOUN
gs-3920	187	29	2025	2025	NUM
gs-3920	187	30	.	.	PUNCT
gs-3920	188	1			PRON
gs-3920	188	2	language	language	NOUN
gs-3920	188	3	:	:	PUNCT
gs-3920	188	4	english	english	PROPN
gs-3920	188	5			NOUN
gs-3920	188	6	dress	dress	NOUN
gs-3920	188	7	criteria	criterion	NOUN
gs-3920	188	8	based	base	VERB
gs-3920	188	9	on	on	ADP
gs-3920	188	10	regi	regi	PROPN
gs-3920	188	11	scar	scar	PROPN
gs-3920	188	12	definitions	definition	NOUN
gs-3920	188	13	or	or	CCONJ
gs-3920	188	14	similar	similar	ADJ
gs-3920	188	15	validated	validate	VERB
gs-3920	188	16	criteria	criterion	NOUN
gs-3920	188	17			NOUN
gs-3920	188	18	providing	provide	VERB
gs-3920	188	19	detailed	detailed	ADJ
gs-3920	188	20	patient	patient	NOUN
gs-3920	188	21	-	-	PUNCT
gs-3920	188	22	level	level	NOUN
gs-3920	188	23	clinical	clinical	ADJ
gs-3920	188	24	information	information	NOUN
gs-3920	188	25	,	,	PUNCT
gs-3920	188	26	such	such	ADJ
gs-3920	188	27	as	as	ADP
gs-3920	188	28	drug	drug	NOUN
gs-3920	188	29	exposure	exposure	NOUN
gs-3920	188	30	status	status	NOUN
gs-3920	188	31	,	,	PUNCT
gs-3920	188	32	latency	latency	NOUN
gs-3920	188	33	days	day	NOUN
gs-3920	188	34	,	,	PUNCT
gs-3920	188	35	treatment	treatment	NOUN
gs-3920	188	36	and	and	CCONJ
gs-3920	188	37	outcome	outcome	VERB
gs-3920	188	38			NOUN
gs-3920	188	39	paediatric	paediatric	ADJ
gs-3920	188	40	and	and	CCONJ
gs-3920	188	41	adult	adult	NOUN
gs-3920	188	42	age	age	NOUN
gs-3920	188	43	group	group	NOUN
gs-3920	188	44	data	datum	NOUN
gs-3920	188	45	included	include	VERB
gs-3920	188	46			DET
gs-3920	188	47	study	study	NOUN
gs-3920	188	48	types	type	NOUN
gs-3920	188	49	restricted	restrict	VERB
gs-3920	188	50	to	to	ADP
gs-3920	188	51	case	case	NOUN
gs-3920	188	52	reports	report	NOUN
gs-3920	188	53	,	,	PUNCT
gs-3920	188	54	case	case	NOUN
gs-3920	188	55	series	series	NOUN
gs-3920	188	56	,	,	PUNCT
gs-3920	188	57	observational	observational	ADJ
gs-3920	188	58	cohort	cohort	NOUN
gs-3920	188	59	studies	study	NOUN
gs-3920	188	60	,	,	PUNCT
gs-3920	188	61	rct	rct	PROPN
gs-3920	188	62	’s	’s	PART
gs-3920	188	63	,	,	PUNCT
gs-3920	188	64	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	188	65	studies	study	NOUN
gs-3920	188	66	and	and	CCONJ
gs-3920	188	67	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	188	68	reports	report	VERB
gs-3920	188	69	exclusion	exclusion	NOUN
gs-3920	188	70	criteria	criterion	NOUN
gs-3920	188	71	exclusion	exclusion	NOUN
gs-3920	188	72	criteria	criterion	NOUN
gs-3920	188	73	studies	study	NOUN
gs-3920	188	74	were	be	AUX
gs-3920	188	75	ineligible	ineligible	ADJ
gs-3920	188	76	if	if	SCONJ
gs-3920	188	77	they	they	PRON
gs-3920	188	78	met	meet	VERB
gs-3920	188	79	any	any	PRON
gs-3920	188	80	of	of	ADP
gs-3920	188	81	the	the	DET
gs-3920	188	82	following	follow	VERB
gs-3920	188	83	criteria	criterion	NOUN
gs-3920	188	84	:	:	PUNCT
gs-3920	188	85			NOUN
gs-3920	188	86	in	in	ADP
gs-3920	188	87	languages	language	NOUN
gs-3920	188	88	other	other	ADJ
gs-3920	188	89	than	than	ADP
gs-3920	188	90	english	english	PROPN
gs-3920	188	91			PRON
gs-3920	188	92	studies	study	NOUN
gs-3920	188	93	with	with	ADP
gs-3920	188	94	preclinical	preclinical	ADJ
gs-3920	188	95	data	datum	NOUN
gs-3920	188	96	and	and	CCONJ
gs-3920	188	97	no	no	DET
gs-3920	188	98	human	human	ADJ
gs-3920	188	99	data	datum	NOUN
gs-3920	188	100	available	available	ADJ
gs-3920	188	101	(	(	PUNCT
gs-3920	188	102	in	in	ADP
gs-3920	188	103	vitro	vitro	X
gs-3920	188	104	or	or	CCONJ
gs-3920	188	105	in	in	ADP
gs-3920	188	106	vivo	vivo	NOUN
gs-3920	188	107	)	)	PUNCT
gs-3920	188	108			NOUN
gs-3920	188	109	comments	comment	NOUN
gs-3920	188	110	and	and	CCONJ
gs-3920	188	111	editorials	editorial	NOUN
gs-3920	188	112	without	without	ADP
gs-3920	188	113	clinical	clinical	ADJ
gs-3920	188	114	data	datum	NOUN
gs-3920	188	115	.	.	PUNCT
gs-3920	189	1			X
gs-3920	190	1	no	no	DET
gs-3920	190	2	full	full	ADJ
gs-3920	190	3	text	text	NOUN
gs-3920	190	4	/	/	SYM
gs-3920	190	5	abstract	abstract	ADJ
gs-3920	190	6	/	/	SYM
gs-3920	190	7	title	title	NOUN
gs-3920	190	8	available	available	ADJ
gs-3920	190	9	or	or	CCONJ
gs-3920	190	10	insufficient	insufficient	ADJ
gs-3920	190	11	patient	patient	ADJ
gs-3920	190	12	detail	detail	NOUN
gs-3920	190	13	.	.	PUNCT
gs-3920	191	1	georgian	georgian	ADJ
gs-3920	191	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	191	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	191	4	ტ.	ტ.	VERB
gs-3920	191	5	7	7	NUM
gs-3920	191	6	n	n	PRON
gs-3920	191	7	3	3	NUM
gs-3920	191	8	,	,	PUNCT
gs-3920	191	9	2025	2025	NUM
gs-3920	191	10	191	191	NUM
gs-3920	191	11			NOUN
gs-3920	191	12	excluded	exclude	VERB
gs-3920	191	13	studies	study	NOUN
gs-3920	191	14	:	:	PUNCT
gs-3920	191	15	those	those	PRON
gs-3920	191	16	that	that	PRON
gs-3920	191	17	did	do	AUX
gs-3920	191	18	not	not	PART
gs-3920	191	19	meet	meet	VERB
gs-3920	191	20	the	the	DET
gs-3920	191	21	referred	refer	VERB
gs-3920	191	22	screening	screening	NOUN
gs-3920	191	23	criteria	criterion	NOUN
gs-3920	191	24	or	or	CCONJ
gs-3920	191	25	failed	fail	VERB
gs-3920	191	26	to	to	PART
gs-3920	191	27	adjust	adjust	VERB
gs-3920	191	28	to	to	PART
gs-3920	191	29	confirm	confirm	VERB
gs-3920	191	30	the	the	DET
gs-3920	191	31	dress	dress	NOUN
gs-3920	191	32	diagnosis	diagnosis	NOUN
gs-3920	191	33	or	or	CCONJ
gs-3920	191	34	did	do	AUX
gs-3920	191	35	not	not	PART
gs-3920	191	36	report	report	VERB
gs-3920	191	37	the	the	DET
gs-3920	191	38	data	datum	NOUN
gs-3920	191	39	of	of	ADP
gs-3920	191	40	the	the	DET
gs-3920	191	41	decided	decide	VERB
gs-3920	191	42	outcomes	outcome	NOUN
gs-3920	191	43			PRON
gs-3920	191	44	the	the	DET
gs-3920	191	45	most	most	ADV
gs-3920	191	46	frequent	frequent	ADJ
gs-3920	191	47	reasons	reason	NOUN
gs-3920	191	48	being	be	AUX
gs-3920	191	49	publication	publication	NOUN
gs-3920	191	50	date	date	NOUN
gs-3920	191	51	restrictions	restriction	NOUN
gs-3920	191	52	or	or	CCONJ
gs-3920	191	53	lack	lack	NOUN
gs-3920	191	54	of	of	ADP
gs-3920	191	55	clinical	clinical	ADJ
gs-3920	191	56	data	datum	NOUN
gs-3920	191	57	.	.	PUNCT
gs-3920	192	1	data	datum	NOUN
gs-3920	192	2	analysis	analysis	NOUN
gs-3920	192	3	information	information	NOUN
gs-3920	192	4	was	be	AUX
gs-3920	192	5	extracted	extract	VERB
gs-3920	192	6	,	,	PUNCT
gs-3920	192	7	classified	classify	VERB
gs-3920	192	8	and	and	CCONJ
gs-3920	192	9	analysed	analyse	VERB
gs-3920	192	10	using	use	VERB
gs-3920	192	11	thematic	thematic	ADJ
gs-3920	192	12	synthesis	synthesis	NOUN
gs-3920	192	13	.	.	PUNCT
gs-3920	193	1	each	each	DET
gs-3920	193	2	article	article	NOUN
gs-3920	193	3	was	be	AUX
gs-3920	193	4	categorised	categorise	VERB
gs-3920	193	5	to	to	ADP
gs-3920	193	6	central	central	ADJ
gs-3920	193	7	theme	theme	NOUN
gs-3920	193	8	area	area	NOUN
gs-3920	193	9	defined	define	VERB
gs-3920	193	10	by	by	ADP
gs-3920	193	11	its	its	PRON
gs-3920	193	12	leading	lead	VERB
gs-3920	193	13	clinical	clinical	ADJ
gs-3920	193	14	impact	impact	NOUN
gs-3920	193	15	.	.	PUNCT
gs-3920	194	1	the	the	DET
gs-3920	194	2	classified	classified	ADJ
gs-3920	194	3	studies	study	NOUN
gs-3920	194	4	fell	fall	VERB
gs-3920	194	5	into	into	ADP
gs-3920	194	6	the	the	DET
gs-3920	194	7	following	follow	VERB
gs-3920	194	8	groups	group	NOUN
gs-3920	194	9	:	:	PUNCT
gs-3920	194	10			VERB
gs-3920	194	11	drug	drug	NOUN
gs-3920	194	12	-	-	PUNCT
gs-3920	194	13	specific	specific	ADJ
gs-3920	194	14	case	case	NOUN
gs-3920	194	15	reports	report	NOUN
gs-3920	194	16			VERB
gs-3920	194	17	site	site	NOUN
gs-3920	194	18	and	and	CCONJ
gs-3920	194	19	severity	severity	NOUN
gs-3920	194	20	of	of	ADP
gs-3920	194	21	clinical	clinical	ADJ
gs-3920	194	22	affection	affection	NOUN
gs-3920	194	23	.	.	PUNCT
gs-3920	195	1			ADJ
gs-3920	195	2	treatment	treatment	NOUN
gs-3920	195	3	and	and	CCONJ
gs-3920	195	4	the	the	DET
gs-3920	195	5	responses	response	NOUN
gs-3920	195	6	to	to	ADP
gs-3920	195	7	treatment	treatment	NOUN
gs-3920	195	8			VERB
gs-3920	195	9	genetic	genetic	ADJ
gs-3920	195	10	predispositions	predisposition	NOUN
gs-3920	195	11	:	:	PUNCT
gs-3920	195	12	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	195	13			ADJ
gs-3920	195	14	sequalae	sequalae	NOUN
gs-3920	195	15	’s	’s	PART
gs-3920	195	16	including	include	VERB
gs-3920	195	17	,	,	PUNCT
gs-3920	195	18	long	long	ADJ
gs-3920	195	19	term	term	NOUN
gs-3920	195	20	auto	auto	NOUN
gs-3920	195	21	immune	immune	ADJ
gs-3920	195	22	reactions	reaction	NOUN
gs-3920	195	23			VERB
gs-3920	195	24	statistical	statistical	ADJ
gs-3920	195	25	data	datum	NOUN
gs-3920	195	26	management	management	NOUN
gs-3920	195	27	but	but	CCONJ
gs-3920	195	28	were	be	AUX
gs-3920	195	29	not	not	PART
gs-3920	195	30	limited	limit	VERB
gs-3920	195	31	to	to	ADP
gs-3920	195	32	:	:	PUNCT
gs-3920	195	33			ADJ
gs-3920	195	34	classification	classification	NOUN
gs-3920	195	35	of	of	ADP
gs-3920	195	36	the	the	DET
gs-3920	195	37	drugs	drug	NOUN
gs-3920	195	38	in	in	ADP
gs-3920	195	39	the	the	DET
gs-3920	195	40	context	context	NOUN
gs-3920	195	41	of	of	ADP
gs-3920	195	42	their	their	PRON
gs-3920	195	43	chemical	chemical	NOUN
gs-3920	195	44	structure	structure	NOUN
gs-3920	195	45			VERB
gs-3920	195	46	latency	latency	NOUN
gs-3920	195	47	of	of	ADP
gs-3920	195	48	drug	drug	NOUN
gs-3920	195	49	from	from	ADP
gs-3920	195	50	starting	start	VERB
gs-3920	195	51	drug	drug	NOUN
gs-3920	195	52	to	to	ADP
gs-3920	195	53	development	development	NOUN
gs-3920	195	54	of	of	ADP
gs-3920	195	55	symptom	symptom	NOUN
gs-3920	195	56	.	.	PUNCT
gs-3920	196	1			VERB
gs-3920	196	2	categories	category	NOUN
gs-3920	196	3	of	of	ADP
gs-3920	196	4	systemic	systemic	ADJ
gs-3920	196	5	involvement	involvement	NOUN
gs-3920	196	6	based	base	VERB
gs-3920	196	7	on	on	ADP
gs-3920	196	8	the	the	DET
gs-3920	196	9	diagnosis	diagnosis	NOUN
gs-3920	196	10	.	.	PUNCT
gs-3920	197	1			ADJ
gs-3920	197	2	treatment	treatment	NOUN
gs-3920	197	3	options	option	NOUN
gs-3920	197	4	according	accord	VERB
gs-3920	197	5	to	to	ADP
gs-3920	197	6	dose	dose	NOUN
gs-3920	197	7	and	and	CCONJ
gs-3920	197	8	duration	duration	NOUN
gs-3920	197	9			VERB
gs-3920	197	10	outcomes	outcome	NOUN
gs-3920	197	11	and	and	CCONJ
gs-3920	197	12	complications	complication	NOUN
gs-3920	197	13	complicated	complicate	VERB
gs-3920	197	14	recovery	recovery	NOUN
gs-3920	197	15	courses	course	NOUN
gs-3920	197	16	during	during	ADP
gs-3920	197	17	postoperative	postoperative	ADJ
gs-3920	197	18	intervals	interval	NOUN
gs-3920	197	19			VERB
gs-3920	197	20	because	because	SCONJ
gs-3920	197	21	of	of	ADP
gs-3920	197	22	the	the	DET
gs-3920	197	23	considerable	considerable	ADJ
gs-3920	197	24	heterogeneity	heterogeneity	NOUN
gs-3920	197	25	of	of	ADP
gs-3920	197	26	the	the	DET
gs-3920	197	27	studies	study	NOUN
gs-3920	197	28	presented	present	VERB
gs-3920	197	29	in	in	ADP
gs-3920	197	30	the	the	DET
gs-3920	197	31	data	datum	NOUN
gs-3920	197	32	set	set	VERB
gs-3920	197	33	and	and	CCONJ
gs-3920	197	34	because	because	SCONJ
gs-3920	197	35	all	all	DET
gs-3920	197	36	the	the	DET
gs-3920	197	37	data	datum	NOUN
gs-3920	197	38	set	set	VERB
gs-3920	197	39	included	include	VERB
gs-3920	197	40	were	be	AUX
gs-3920	197	41	qualitative	qualitative	ADJ
gs-3920	197	42	,	,	PUNCT
gs-3920	197	43	no	no	DET
gs-3920	197	44	meta	meta	NOUN
gs-3920	197	45	-	-	PUNCT
gs-3920	197	46	analysis	analysis	NOUN
gs-3920	197	47	was	be	AUX
gs-3920	197	48	carried	carry	VERB
gs-3920	197	49	out	out	ADP
gs-3920	197	50	,	,	PUNCT
gs-3920	197	51	but	but	CCONJ
gs-3920	197	52	summary	summary	NOUN
gs-3920	197	53	tables	table	NOUN
gs-3920	197	54	and	and	CCONJ
gs-3920	197	55	graphing	graph	VERB
gs-3920	197	56	outputs	output	NOUN
gs-3920	197	57	(	(	PUNCT
gs-3920	197	58	pie	pie	NOUN
gs-3920	197	59	charting	charting	NOUN
gs-3920	197	60	,	,	PUNCT
gs-3920	197	61	for	for	ADP
gs-3920	197	62	example	example	NOUN
gs-3920	197	63	)	)	PUNCT
gs-3920	197	64	were	be	AUX
gs-3920	197	65	created	create	VERB
gs-3920	197	66	to	to	PART
gs-3920	197	67	present	present	VERB
gs-3920	197	68	striking	striking	ADJ
gs-3920	197	69	patterns	pattern	NOUN
gs-3920	197	70	.	.	PUNCT
gs-3920	198	1	results	result	NOUN
gs-3920	198	2	and	and	CCONJ
gs-3920	198	3	discussion	discussion	NOUN
gs-3920	198	4	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	198	5	correlations	correlation	NOUN
gs-3920	198	6	and	and	CCONJ
gs-3920	198	7	genetic	genetic	ADJ
gs-3920	198	8	risk	risk	NOUN
gs-3920	198	9	mapping	map	VERB
gs-3920	198	10	the	the	DET
gs-3920	198	11	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	198	12	component	component	NOUN
gs-3920	198	13	of	of	ADP
gs-3920	198	14	dress	dress	NOUN
gs-3920	198	15	syndrome	syndrome	NOUN
gs-3920	198	16	has	have	AUX
gs-3920	198	17	gained	gain	VERB
gs-3920	198	18	increasing	increase	VERB
gs-3920	198	19	attention	attention	NOUN
gs-3920	198	20	over	over	ADP
gs-3920	198	21	the	the	DET
gs-3920	198	22	past	past	ADJ
gs-3920	198	23	two	two	NUM
gs-3920	198	24	decades	decade	NOUN
gs-3920	198	25	,	,	PUNCT
gs-3920	198	26	as	as	SCONJ
gs-3920	198	27	advances	advance	NOUN
gs-3920	198	28	in	in	ADP
gs-3920	198	29	genotyping	genotyping	NOUN
gs-3920	198	30	technologies	technology	NOUN
gs-3920	198	31	and	and	CCONJ
gs-3920	198	32	clinical	clinical	ADJ
gs-3920	198	33	pharmacogenomics	pharmacogenomic	NOUN
gs-3920	198	34	have	have	AUX
gs-3920	198	35	revealed	reveal	VERB
gs-3920	198	36	strong	strong	ADJ
gs-3920	198	37	associations	association	NOUN
gs-3920	198	38	between	between	ADP
gs-3920	198	39	specific	specific	ADJ
gs-3920	198	40	human	human	ADJ
gs-3920	198	41	leukocyte	leukocyte	NOUN
gs-3920	198	42	antigen	antigen	NOUN
gs-3920	198	43	(	(	PUNCT
gs-3920	198	44	hla	hla	NOUN
gs-3920	198	45	)	)	PUNCT
gs-3920	198	46	alleles	allele	NOUN
gs-3920	198	47	and	and	CCONJ
gs-3920	198	48	drug	drug	NOUN
gs-3920	198	49	-	-	PUNCT
gs-3920	198	50	induced	induce	VERB
gs-3920	198	51	hypersensitivity	hypersensitivity	NOUN
gs-3920	198	52	reactions	reaction	NOUN
gs-3920	198	53	.	.	PUNCT
gs-3920	199	1	our	our	PRON
gs-3920	199	2	comprehensive	comprehensive	ADJ
gs-3920	199	3	synthesis	synthesis	NOUN
gs-3920	199	4	confirmed	confirm	VERB
gs-3920	199	5	that	that	SCONJ
gs-3920	199	6	certain	certain	ADJ
gs-3920	199	7	hla	hla	PROPN
gs-3920	199	8	genotypes	genotype	NOUN
gs-3920	199	9	act	act	VERB
gs-3920	199	10	as	as	ADP
gs-3920	199	11	robust	robust	ADJ
gs-3920	199	12	predictive	predictive	ADJ
gs-3920	199	13	biomarkers	biomarker	NOUN
gs-3920	199	14	for	for	ADP
gs-3920	199	15	dress	dress	NOUN
gs-3920	199	16	susceptibility	susceptibility	NOUN
gs-3920	199	17	,	,	PUNCT
gs-3920	199	18	particularly	particularly	ADV
gs-3920	199	19	in	in	ADP
gs-3920	199	20	ethnic	ethnic	ADJ
gs-3920	199	21	-	-	PUNCT
gs-3920	199	22	specific	specific	ADJ
gs-3920	199	23	contexts	contexts	NOUN
gs-3920	199	24	.	.	PUNCT
gs-3920	200	1	among	among	ADP
gs-3920	200	2	the	the	DET
gs-3920	200	3	most	most	ADV
gs-3920	200	4	consistently	consistently	ADV
gs-3920	200	5	validated	validate	VERB
gs-3920	200	6	associations	association	NOUN
gs-3920	200	7	is	be	AUX
gs-3920	200	8	the	the	DET
gs-3920	200	9	link	link	NOUN
gs-3920	200	10	between	between	ADP
gs-3920	200	11	hla	hla	PROPN
gs-3920	200	12	-	-	PUNCT
gs-3920	200	13	b*15:02	b*15:02	NOUN
gs-3920	200	14	and	and	CCONJ
gs-3920	200	15	carbamazepine	carbamazepine	NOUN
gs-3920	200	16	-	-	PUNCT
gs-3920	200	17	induced	induce	VERB
gs-3920	200	18	dress	dress	NOUN
gs-3920	200	19	,	,	PUNCT
gs-3920	200	20	especially	especially	ADV
gs-3920	200	21	among	among	ADP
gs-3920	200	22	individuals	individual	NOUN
gs-3920	200	23	of	of	ADP
gs-3920	200	24	han	han	PROPN
gs-3920	200	25	chinese	chinese	PROPN
gs-3920	200	26	,	,	PUNCT
gs-3920	200	27	thai	thai	PROPN
gs-3920	200	28	,	,	PUNCT
gs-3920	200	29	indian	indian	ADJ
gs-3920	200	30	,	,	PUNCT
gs-3920	200	31	and	and	CCONJ
gs-3920	200	32	malaysian	malaysian	ADJ
gs-3920	200	33	descent	descent	NOUN
gs-3920	200	34	.	.	PUNCT
gs-3920	201	1	this	this	DET
gs-3920	201	2	allele	allele	NOUN
gs-3920	201	3	,	,	PUNCT
gs-3920	201	4	which	which	PRON
gs-3920	201	5	plays	play	VERB
gs-3920	201	6	a	a	DET
gs-3920	201	7	key	key	ADJ
gs-3920	201	8	role	role	NOUN
gs-3920	201	9	in	in	ADP
gs-3920	201	10	antigen	antigen	ADJ
gs-3920	201	11	presentation	presentation	NOUN
gs-3920	201	12	,	,	PUNCT
gs-3920	201	13	has	have	AUX
gs-3920	201	14	been	be	AUX
gs-3920	201	15	integrated	integrate	VERB
gs-3920	201	16	into	into	ADP
gs-3920	201	17	clinical	clinical	ADJ
gs-3920	201	18	guidelines	guideline	NOUN
gs-3920	201	19	,	,	PUNCT
gs-3920	201	20	prompting	prompt	VERB
gs-3920	201	21	routine	routine	ADJ
gs-3920	201	22	genetic	genetic	ADJ
gs-3920	201	23	screening	screening	NOUN
gs-3920	201	24	before	before	ADP
gs-3920	201	25	carbamazepine	carbamazepine	NOUN
gs-3920	201	26	initiation	initiation	NOUN
gs-3920	201	27	in	in	ADP
gs-3920	201	28	highprevalence	highprevalence	NOUN
gs-3920	201	29	regions	region	NOUN
gs-3920	201	30	.	.	PUNCT
gs-3920	202	1	georgian	georgian	ADJ
gs-3920	202	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	202	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	202	4	ტ.	ტ.	VERB
gs-3920	202	5	7	7	NUM
gs-3920	202	6	n	n	PRON
gs-3920	202	7	3	3	NUM
gs-3920	202	8	,	,	PUNCT
gs-3920	202	9	2025	2025	NUM
gs-3920	202	10	192	192	NUM
gs-3920	202	11	similarly	similarly	ADV
gs-3920	202	12	,	,	PUNCT
gs-3920	202	13	allopurinol	allopurinol	NOUN
gs-3920	202	14	-	-	PUNCT
gs-3920	202	15	induced	induce	VERB
gs-3920	202	16	dress	dress	NOUN
gs-3920	202	17	has	have	AUX
gs-3920	202	18	demonstrated	demonstrate	VERB
gs-3920	202	19	strong	strong	ADJ
gs-3920	202	20	correlation	correlation	NOUN
gs-3920	202	21	with	with	ADP
gs-3920	202	22	the	the	DET
gs-3920	202	23	hla	hla	NOUN
gs-3920	202	24	-	-	PUNCT
gs-3920	202	25	b58:01	b58:01	PROPN
gs-3920	202	26	allele	allele	NOUN
gs-3920	202	27	.	.	PUNCT
gs-3920	203	1	our	our	PRON
gs-3920	203	2	review	review	NOUN
gs-3920	203	3	of	of	ADP
gs-3920	203	4	population	population	NOUN
gs-3920	203	5	-	-	PUNCT
gs-3920	203	6	based	base	VERB
gs-3920	203	7	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	203	8	data	datum	NOUN
gs-3920	203	9	revealed	reveal	VERB
gs-3920	203	10	that	that	SCONJ
gs-3920	203	11	hla	hla	PROPN
gs-3920	203	12	-	-	PUNCT
gs-3920	203	13	b58:01	b58:01	PROPN
gs-3920	203	14	is	be	AUX
gs-3920	203	15	particularly	particularly	ADV
gs-3920	203	16	prevalent	prevalent	ADJ
gs-3920	203	17	in	in	ADP
gs-3920	203	18	southeast	southeast	ADJ
gs-3920	203	19	asian	asian	ADJ
gs-3920	203	20	populations	population	NOUN
gs-3920	203	21	,	,	PUNCT
gs-3920	203	22	with	with	ADP
gs-3920	203	23	carrier	carrier	NOUN
gs-3920	203	24	frequencies	frequency	NOUN
gs-3920	203	25	reaching	reach	VERB
gs-3920	203	26	up	up	ADP
gs-3920	203	27	to	to	PART
gs-3920	203	28	10–15	10–15	NUM
gs-3920	203	29	%	%	NOUN
gs-3920	203	30	in	in	ADP
gs-3920	203	31	some	some	DET
gs-3920	203	32	groups	group	NOUN
gs-3920	203	33	.	.	PUNCT
gs-3920	204	1	the	the	DET
gs-3920	204	2	implications	implication	NOUN
gs-3920	204	3	of	of	ADP
gs-3920	204	4	this	this	DET
gs-3920	204	5	genotypespecific	genotypespecific	ADJ
gs-3920	204	6	risk	risk	NOUN
gs-3920	204	7	are	be	AUX
gs-3920	204	8	profound	profound	ADJ
gs-3920	204	9	,	,	PUNCT
gs-3920	204	10	as	as	SCONJ
gs-3920	204	11	patients	patient	NOUN
gs-3920	204	12	carrying	carry	VERB
gs-3920	204	13	the	the	DET
gs-3920	204	14	allele	allele	NOUN
gs-3920	204	15	exhibit	exhibit	VERB
gs-3920	204	16	significantly	significantly	ADV
gs-3920	204	17	higher	high	ADJ
gs-3920	204	18	rates	rate	NOUN
gs-3920	204	19	of	of	ADP
gs-3920	204	20	cutaneous	cutaneous	ADJ
gs-3920	204	21	adverse	adverse	ADJ
gs-3920	204	22	drug	drug	NOUN
gs-3920	204	23	reactions	reaction	NOUN
gs-3920	204	24	(	(	PUNCT
gs-3920	204	25	cadrs	cadrs	NOUN
gs-3920	204	26	)	)	PUNCT
gs-3920	204	27	,	,	PUNCT
gs-3920	204	28	including	include	VERB
gs-3920	204	29	severe	severe	ADJ
gs-3920	204	30	manifestations	manifestation	NOUN
gs-3920	204	31	like	like	ADP
gs-3920	204	32	dress	dress	NOUN
gs-3920	204	33	and	and	CCONJ
gs-3920	204	34	stevens	stevens	PROPN
gs-3920	204	35	–	–	PUNCT
gs-3920	204	36	johnson	johnson	PROPN
gs-3920	204	37	syndrome	syndrome	NOUN
gs-3920	204	38	.	.	PUNCT
gs-3920	205	1	the	the	DET
gs-3920	205	2	correlation	correlation	NOUN
gs-3920	205	3	has	have	AUX
gs-3920	205	4	been	be	AUX
gs-3920	205	5	so	so	ADV
gs-3920	205	6	compelling	compelling	ADJ
gs-3920	205	7	that	that	SCONJ
gs-3920	205	8	pre	pre	ADJ
gs-3920	205	9	-	-	ADJ
gs-3920	205	10	prescription	prescription	ADJ
gs-3920	205	11	screening	screening	NOUN
gs-3920	205	12	for	for	ADP
gs-3920	205	13	hla	hla	PROPN
gs-3920	205	14	-	-	PUNCT
gs-3920	205	15	b*58:01	b*58:01	PROPN
gs-3920	205	16	is	be	AUX
gs-3920	205	17	now	now	ADV
gs-3920	205	18	recommended	recommend	VERB
gs-3920	205	19	or	or	CCONJ
gs-3920	205	20	mandated	mandate	VERB
gs-3920	205	21	in	in	ADP
gs-3920	205	22	several	several	ADJ
gs-3920	205	23	east	east	ADJ
gs-3920	205	24	asian	asian	ADJ
gs-3920	205	25	countries	country	NOUN
gs-3920	205	26	and	and	CCONJ
gs-3920	205	27	increasingly	increasingly	ADV
gs-3920	205	28	considered	consider	VERB
gs-3920	205	29	in	in	ADP
gs-3920	205	30	clinical	clinical	ADJ
gs-3920	205	31	practices	practice	NOUN
gs-3920	205	32	worldwide	worldwide	ADV
gs-3920	205	33	.	.	PUNCT
gs-3920	206	1	moreover	moreover	ADV
gs-3920	206	2	,	,	PUNCT
gs-3920	206	3	polymorphisms	polymorphism	NOUN
gs-3920	206	4	in	in	ADP
gs-3920	206	5	genes	gene	NOUN
gs-3920	206	6	encoding	encode	VERB
gs-3920	206	7	metabolic	metabolic	NOUN
gs-3920	206	8	enzymes	enzyme	NOUN
gs-3920	206	9	such	such	ADJ
gs-3920	206	10	as	as	ADP
gs-3920	206	11	cyp2c9	cyp2c9	NOUN
gs-3920	206	12	,	,	PUNCT
gs-3920	206	13	cyp3a4	cyp3a4	NOUN
gs-3920	206	14	,	,	PUNCT
gs-3920	206	15	and	and	CCONJ
gs-3920	206	16	epoxide	epoxide	ADJ
gs-3920	206	17	hydrolase	hydrolase	NOUN
gs-3920	206	18	(	(	PUNCT
gs-3920	206	19	ephx1	ephx1	PROPN
gs-3920	206	20	)	)	PUNCT
gs-3920	206	21	were	be	AUX
gs-3920	206	22	repeatedly	repeatedly	ADV
gs-3920	206	23	identified	identify	VERB
gs-3920	206	24	as	as	ADP
gs-3920	206	25	modifying	modify	VERB
gs-3920	206	26	factors	factor	NOUN
gs-3920	206	27	that	that	PRON
gs-3920	206	28	influence	influence	VERB
gs-3920	206	29	the	the	DET
gs-3920	206	30	accumulation	accumulation	NOUN
gs-3920	206	31	of	of	ADP
gs-3920	206	32	reactive	reactive	ADJ
gs-3920	206	33	drug	drug	NOUN
gs-3920	206	34	metabolites	metabolite	NOUN
gs-3920	206	35	.	.	PUNCT
gs-3920	207	1	these	these	DET
gs-3920	207	2	enzymes	enzyme	NOUN
gs-3920	207	3	govern	govern	VERB
gs-3920	207	4	the	the	DET
gs-3920	207	5	biotransformation	biotransformation	NOUN
gs-3920	207	6	and	and	CCONJ
gs-3920	207	7	detoxification	detoxification	NOUN
gs-3920	207	8	of	of	ADP
gs-3920	207	9	aromatic	aromatic	ADJ
gs-3920	207	10	antiepileptic	antiepileptic	ADJ
gs-3920	207	11	drugs	drug	NOUN
gs-3920	207	12	like	like	ADP
gs-3920	207	13	phenytoin	phenytoin	NOUN
gs-3920	207	14	and	and	CCONJ
gs-3920	207	15	carbamazepine	carbamazepine	NOUN
gs-3920	207	16	.	.	PUNCT
gs-3920	208	1	impaired	impair	VERB
gs-3920	208	2	function	function	NOUN
gs-3920	208	3	due	due	ADP
gs-3920	208	4	to	to	ADP
gs-3920	208	5	loss	loss	NOUN
gs-3920	208	6	-	-	PUNCT
gs-3920	208	7	of	of	ADP
gs-3920	208	8	-	-	PUNCT
gs-3920	208	9	function	function	NOUN
gs-3920	208	10	mutations	mutation	NOUN
gs-3920	208	11	leads	lead	VERB
gs-3920	208	12	to	to	ADP
gs-3920	208	13	the	the	DET
gs-3920	208	14	build	build	NOUN
gs-3920	208	15	-	-	PUNCT
gs-3920	208	16	up	up	NOUN
gs-3920	208	17	of	of	ADP
gs-3920	208	18	electrophilic	electrophilic	ADJ
gs-3920	208	19	intermediates	intermediate	NOUN
gs-3920	208	20	,	,	PUNCT
gs-3920	208	21	which	which	PRON
gs-3920	208	22	can	can	AUX
gs-3920	208	23	bind	bind	VERB
gs-3920	208	24	covalently	covalently	ADV
gs-3920	208	25	to	to	ADP
gs-3920	208	26	host	host	NOUN
gs-3920	208	27	proteins	protein	NOUN
gs-3920	208	28	,	,	PUNCT
gs-3920	208	29	triggering	trigger	VERB
gs-3920	208	30	immune	immune	ADJ
gs-3920	208	31	responses	response	NOUN
gs-3920	208	32	and	and	CCONJ
gs-3920	208	33	t	t	NOUN
gs-3920	208	34	-	-	PUNCT
gs-3920	208	35	cell	cell	NOUN
gs-3920	208	36	activation	activation	NOUN
gs-3920	208	37	.	.	PUNCT
gs-3920	209	1	interestingly	interestingly	ADV
gs-3920	209	2	,	,	PUNCT
gs-3920	209	3	polymorphisms	polymorphism	NOUN
gs-3920	209	4	in	in	ADP
gs-3920	209	5	drug	drug	NOUN
gs-3920	209	6	transporter	transporter	NOUN
gs-3920	209	7	genes	gene	NOUN
gs-3920	209	8	,	,	PUNCT
gs-3920	209	9	including	include	VERB
gs-3920	209	10	abcb1	abcb1	NOUN
gs-3920	209	11	and	and	CCONJ
gs-3920	209	12	slco1b1	slco1b1	NUM
gs-3920	209	13	,	,	PUNCT
gs-3920	209	14	have	have	AUX
gs-3920	209	15	also	also	ADV
gs-3920	209	16	been	be	AUX
gs-3920	209	17	implicated	implicate	VERB
gs-3920	209	18	,	,	PUNCT
gs-3920	209	19	albeit	albeit	SCONJ
gs-3920	209	20	with	with	ADP
gs-3920	209	21	lower	low	ADJ
gs-3920	209	22	consistency	consistency	NOUN
gs-3920	209	23	.	.	PUNCT
gs-3920	210	1	these	these	DET
gs-3920	210	2	transporters	transporter	NOUN
gs-3920	210	3	are	be	AUX
gs-3920	210	4	responsible	responsible	ADJ
gs-3920	210	5	for	for	ADP
gs-3920	210	6	hepatic	hepatic	ADJ
gs-3920	210	7	and	and	CCONJ
gs-3920	210	8	renal	renal	ADJ
gs-3920	210	9	excretion	excretion	NOUN
gs-3920	210	10	of	of	ADP
gs-3920	210	11	drugs	drug	NOUN
gs-3920	210	12	and	and	CCONJ
gs-3920	210	13	their	their	PRON
gs-3920	210	14	metabolites	metabolite	NOUN
gs-3920	210	15	,	,	PUNCT
gs-3920	210	16	and	and	CCONJ
gs-3920	210	17	variations	variation	NOUN
gs-3920	210	18	may	may	AUX
gs-3920	210	19	modulate	modulate	VERB
gs-3920	210	20	systemic	systemic	ADJ
gs-3920	210	21	exposure	exposure	NOUN
gs-3920	210	22	.	.	PUNCT
gs-3920	211	1	while	while	SCONJ
gs-3920	211	2	such	such	ADJ
gs-3920	211	3	data	datum	NOUN
gs-3920	211	4	do	do	AUX
gs-3920	211	5	not	not	PART
gs-3920	211	6	yet	yet	ADV
gs-3920	211	7	meet	meet	VERB
gs-3920	211	8	the	the	DET
gs-3920	211	9	threshold	threshold	NOUN
gs-3920	211	10	for	for	ADP
gs-3920	211	11	clinical	clinical	ADJ
gs-3920	211	12	implementation	implementation	NOUN
gs-3920	211	13	,	,	PUNCT
gs-3920	211	14	their	their	PRON
gs-3920	211	15	cumulative	cumulative	ADJ
gs-3920	211	16	effect	effect	NOUN
gs-3920	211	17	alongside	alongside	ADP
gs-3920	211	18	major	major	ADJ
gs-3920	211	19	hla	hla	PROPN
gs-3920	211	20	alleles	allele	NOUN
gs-3920	211	21	may	may	AUX
gs-3920	211	22	contribute	contribute	VERB
gs-3920	211	23	to	to	ADP
gs-3920	211	24	a	a	DET
gs-3920	211	25	polygenic	polygenic	ADJ
gs-3920	211	26	risk	risk	NOUN
gs-3920	211	27	score	score	NOUN
gs-3920	211	28	model	model	NOUN
gs-3920	211	29	for	for	ADP
gs-3920	211	30	predicting	predict	VERB
gs-3920	211	31	hypersensitivity	hypersensitivity	NOUN
gs-3920	211	32	events	event	NOUN
gs-3920	211	33	.	.	PUNCT
gs-3920	212	1	spectrum	spectrum	NOUN
gs-3920	212	2	of	of	ADP
gs-3920	212	3	implicated	implicated	ADJ
gs-3920	212	4	drugs	drug	NOUN
gs-3920	212	5	and	and	CCONJ
gs-3920	212	6	latency	latency	NOUN
gs-3920	212	7	characteristics	characteristic	NOUN
gs-3920	212	8	our	our	PRON
gs-3920	212	9	aggregated	aggregate	VERB
gs-3920	212	10	data	datum	NOUN
gs-3920	212	11	analysis	analysis	NOUN
gs-3920	212	12	revealed	reveal	VERB
gs-3920	212	13	a	a	DET
gs-3920	212	14	wide	wide	ADJ
gs-3920	212	15	spectrum	spectrum	NOUN
gs-3920	212	16	of	of	ADP
gs-3920	212	17	drugs	drug	NOUN
gs-3920	212	18	associated	associate	VERB
gs-3920	212	19	with	with	ADP
gs-3920	212	20	dress	dress	NOUN
gs-3920	212	21	,	,	PUNCT
gs-3920	212	22	with	with	ADP
gs-3920	212	23	antiepileptic	antiepileptic	ADJ
gs-3920	212	24	drugs	drug	NOUN
gs-3920	212	25	and	and	CCONJ
gs-3920	212	26	antibiotics	antibiotic	NOUN
gs-3920	212	27	emerging	emerge	VERB
gs-3920	212	28	as	as	ADP
gs-3920	212	29	the	the	DET
gs-3920	212	30	most	most	ADV
gs-3920	212	31	prevalent	prevalent	ADJ
gs-3920	212	32	classes	class	NOUN
gs-3920	212	33	.	.	PUNCT
gs-3920	213	1	among	among	ADP
gs-3920	213	2	antiepileptics	antiepileptic	NOUN
gs-3920	213	3	,	,	PUNCT
gs-3920	213	4	carbamazepine	carbamazepine	NOUN
gs-3920	213	5	,	,	PUNCT
gs-3920	213	6	phenytoin	phenytoin	NOUN
gs-3920	213	7	,	,	PUNCT
gs-3920	213	8	lamotrigine	lamotrigine	NOUN
gs-3920	213	9	,	,	PUNCT
gs-3920	213	10	and	and	CCONJ
gs-3920	213	11	phenobarbital	phenobarbital	ADJ
gs-3920	213	12	were	be	AUX
gs-3920	213	13	consistently	consistently	ADV
gs-3920	213	14	reported	report	VERB
gs-3920	213	15	across	across	ADP
gs-3920	213	16	global	global	ADJ
gs-3920	213	17	datasets	dataset	NOUN
gs-3920	213	18	.	.	PUNCT
gs-3920	214	1	these	these	DET
gs-3920	214	2	agents	agent	NOUN
gs-3920	214	3	share	share	VERB
gs-3920	214	4	structural	structural	ADJ
gs-3920	214	5	similarity	similarity	NOUN
gs-3920	214	6	and	and	CCONJ
gs-3920	214	7	metabolic	metabolic	NOUN
gs-3920	214	8	pathways	pathway	NOUN
gs-3920	214	9	involving	involve	VERB
gs-3920	214	10	aromatic	aromatic	ADJ
gs-3920	214	11	rings	ring	NOUN
gs-3920	214	12	and	and	CCONJ
gs-3920	214	13	cytochrome	cytochrome	ADJ
gs-3920	214	14	p450	p450	NUM
gs-3920	214	15	-	-	PUNCT
gs-3920	214	16	mediated	mediate	VERB
gs-3920	214	17	bioactivation	bioactivation	NOUN
gs-3920	214	18	.	.	PUNCT
gs-3920	215	1	the	the	DET
gs-3920	215	2	latency	latency	NOUN
gs-3920	215	3	period	period	NOUN
gs-3920	215	4	for	for	ADP
gs-3920	215	5	symptom	symptom	NOUN
gs-3920	215	6	onset	onset	NOUN
gs-3920	215	7	in	in	ADP
gs-3920	215	8	these	these	DET
gs-3920	215	9	cases	case	NOUN
gs-3920	215	10	ranged	range	VERB
gs-3920	215	11	from	from	ADP
gs-3920	215	12	2	2	NUM
gs-3920	215	13	to	to	ADP
gs-3920	215	14	6	6	NUM
gs-3920	215	15	weeks	week	NOUN
gs-3920	215	16	,	,	PUNCT
gs-3920	215	17	reinforcing	reinforce	VERB
gs-3920	215	18	the	the	DET
gs-3920	215	19	importance	importance	NOUN
gs-3920	215	20	of	of	ADP
gs-3920	215	21	long	long	ADJ
gs-3920	215	22	-	-	PUNCT
gs-3920	215	23	term	term	NOUN
gs-3920	215	24	vigilance	vigilance	NOUN
gs-3920	215	25	even	even	ADV
gs-3920	215	26	after	after	ADP
gs-3920	215	27	initial	initial	ADJ
gs-3920	215	28	drug	drug	NOUN
gs-3920	215	29	tolerance	tolerance	NOUN
gs-3920	215	30	.	.	PUNCT
gs-3920	216	1	antibiotics	antibiotic	NOUN
gs-3920	216	2	,	,	PUNCT
gs-3920	216	3	especially	especially	ADV
gs-3920	216	4	sulfonamides	sulfonamide	NOUN
gs-3920	216	5	,	,	PUNCT
gs-3920	216	6	vancomycin	vancomycin	PROPN
gs-3920	216	7	,	,	PUNCT
gs-3920	216	8	and	and	CCONJ
gs-3920	216	9	minocycline	minocycline	NOUN
gs-3920	216	10	,	,	PUNCT
gs-3920	216	11	were	be	AUX
gs-3920	216	12	also	also	ADV
gs-3920	216	13	major	major	ADJ
gs-3920	216	14	contributors	contributor	NOUN
gs-3920	216	15	to	to	PART
gs-3920	216	16	dress	dress	VERB
gs-3920	216	17	cases	case	NOUN
gs-3920	216	18	.	.	PUNCT
gs-3920	217	1	notably	notably	ADV
gs-3920	217	2	,	,	PUNCT
gs-3920	217	3	vancomycin	vancomycin	PROPN
gs-3920	217	4	has	have	AUX
gs-3920	217	5	recently	recently	ADV
gs-3920	217	6	gained	gain	VERB
gs-3920	217	7	attention	attention	NOUN
gs-3920	217	8	for	for	ADP
gs-3920	217	9	causing	cause	VERB
gs-3920	217	10	dress	dress	NOUN
gs-3920	217	11	in	in	ADP
gs-3920	217	12	both	both	PRON
gs-3920	217	13	monotherapy	monotherapy	NOUN
gs-3920	217	14	and	and	CCONJ
gs-3920	217	15	combination	combination	NOUN
gs-3920	217	16	therapy	therapy	NOUN
gs-3920	217	17	contexts	contexts	NOUN
gs-3920	217	18	,	,	PUNCT
gs-3920	217	19	particularly	particularly	ADV
gs-3920	217	20	in	in	ADP
gs-3920	217	21	hospitalized	hospitalize	VERB
gs-3920	217	22	patients	patient	NOUN
gs-3920	217	23	receiving	receive	VERB
gs-3920	217	24	broad	broad	ADJ
gs-3920	217	25	-	-	PUNCT
gs-3920	217	26	spectrum	spectrum	NOUN
gs-3920	217	27	empiric	empiric	ADJ
gs-3920	217	28	treatment	treatment	NOUN
gs-3920	217	29	.	.	PUNCT
gs-3920	218	1	vancomycin	vancomycin	PROPN
gs-3920	218	2	-	-	PUNCT
gs-3920	218	3	induced	induce	VERB
gs-3920	218	4	dress	dress	NOUN
gs-3920	218	5	frequently	frequently	ADV
gs-3920	218	6	involves	involve	VERB
gs-3920	218	7	hepatic	hepatic	ADJ
gs-3920	218	8	and	and	CCONJ
gs-3920	218	9	renal	renal	ADJ
gs-3920	218	10	dysfunction	dysfunction	NOUN
gs-3920	218	11	,	,	PUNCT
gs-3920	218	12	and	and	CCONJ
gs-3920	218	13	in	in	ADP
gs-3920	218	14	several	several	ADJ
gs-3920	218	15	cases	case	NOUN
gs-3920	218	16	,	,	PUNCT
gs-3920	218	17	reactivation	reactivation	NOUN
gs-3920	218	18	of	of	ADP
gs-3920	218	19	human	human	ADJ
gs-3920	218	20	herpesvirus-6	herpesvirus-6	PRON
gs-3920	218	21	(	(	PUNCT
gs-3920	218	22	hhv-6	hhv-6	NOUN
gs-3920	218	23	)	)	PUNCT
gs-3920	218	24	was	be	AUX
gs-3920	218	25	observed	observe	VERB
gs-3920	218	26	,	,	PUNCT
gs-3920	218	27	suggesting	suggest	VERB
gs-3920	218	28	viral	viral	ADJ
gs-3920	218	29	co	co	NOUN
gs-3920	218	30	-	-	NOUN
gs-3920	218	31	pathogenesis	pathogenesis	NOUN
gs-3920	218	32	.	.	PUNCT
gs-3920	219	1	allopurinol	allopurinol	NOUN
gs-3920	219	2	remains	remain	VERB
gs-3920	219	3	one	one	NUM
gs-3920	219	4	of	of	ADP
gs-3920	219	5	the	the	DET
gs-3920	219	6	most	most	ADV
gs-3920	219	7	commonly	commonly	ADV
gs-3920	219	8	implicated	implicate	VERB
gs-3920	219	9	drugs	drug	NOUN
gs-3920	219	10	,	,	PUNCT
gs-3920	219	11	particularly	particularly	ADV
gs-3920	219	12	in	in	ADP
gs-3920	219	13	populations	population	NOUN
gs-3920	219	14	with	with	ADP
gs-3920	219	15	a	a	DET
gs-3920	219	16	high	high	ADJ
gs-3920	219	17	prevalence	prevalence	NOUN
gs-3920	219	18	of	of	ADP
gs-3920	219	19	hyperuricemia	hyperuricemia	NOUN
gs-3920	219	20	and	and	CCONJ
gs-3920	219	21	gout	gout	NOUN
gs-3920	219	22	.	.	PUNCT
gs-3920	220	1	cases	case	NOUN
gs-3920	220	2	associated	associate	VERB
gs-3920	220	3	with	with	ADP
gs-3920	220	4	allopurinol	allopurinol	NOUN
gs-3920	220	5	typically	typically	ADV
gs-3920	220	6	exhibited	exhibit	VERB
gs-3920	220	7	extensive	extensive	ADJ
gs-3920	220	8	rash	rash	NOUN
gs-3920	220	9	,	,	PUNCT
gs-3920	220	10	hepatic	hepatic	ADJ
gs-3920	220	11	dysfunction	dysfunction	NOUN
gs-3920	220	12	,	,	PUNCT
gs-3920	220	13	and	and	CCONJ
gs-3920	220	14	a	a	DET
gs-3920	220	15	high	high	ADJ
gs-3920	220	16	rate	rate	NOUN
gs-3920	220	17	of	of	ADP
gs-3920	220	18	renal	renal	ADJ
gs-3920	220	19	georgian	georgian	ADJ
gs-3920	220	20	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	220	21	მეცნიერები	მეცნიერები	NOUN
gs-3920	220	22	ტ.	ტ.	VERB
gs-3920	220	23	7	7	NUM
gs-3920	220	24	n	n	PRON
gs-3920	220	25	3	3	NUM
gs-3920	220	26	,	,	PUNCT
gs-3920	220	27	2025	2025	NUM
gs-3920	220	28	193	193	NUM
gs-3920	220	29	involvement	involvement	NOUN
gs-3920	220	30	.	.	PUNCT
gs-3920	221	1	latency	latency	NOUN
gs-3920	221	2	for	for	ADP
gs-3920	221	3	allopurinol	allopurinol	NOUN
gs-3920	221	4	-	-	PUNCT
gs-3920	221	5	induced	induce	VERB
gs-3920	221	6	dress	dress	NOUN
gs-3920	221	7	was	be	AUX
gs-3920	221	8	generally	generally	ADV
gs-3920	221	9	longer	long	ADV
gs-3920	221	10	,	,	PUNCT
gs-3920	221	11	often	often	ADV
gs-3920	221	12	extending	extend	VERB
gs-3920	221	13	up	up	ADP
gs-3920	221	14	to	to	PART
gs-3920	221	15	8	8	NUM
gs-3920	221	16	weeks	week	NOUN
gs-3920	221	17	,	,	PUNCT
gs-3920	221	18	and	and	CCONJ
gs-3920	221	19	cases	case	NOUN
gs-3920	221	20	were	be	AUX
gs-3920	221	21	frequently	frequently	ADV
gs-3920	221	22	severe	severe	ADJ
gs-3920	221	23	,	,	PUNCT
gs-3920	221	24	with	with	ADP
gs-3920	221	25	prolonged	prolonged	ADJ
gs-3920	221	26	systemic	systemic	ADJ
gs-3920	221	27	inflammation	inflammation	NOUN
gs-3920	221	28	and	and	CCONJ
gs-3920	221	29	delayed	delay	VERB
gs-3920	221	30	resolution	resolution	NOUN
gs-3920	221	31	.	.	PUNCT
gs-3920	222	1	emerging	emerge	VERB
gs-3920	222	2	data	datum	NOUN
gs-3920	222	3	also	also	ADV
gs-3920	222	4	highlight	highlight	VERB
gs-3920	222	5	the	the	DET
gs-3920	222	6	contribution	contribution	NOUN
gs-3920	222	7	of	of	ADP
gs-3920	222	8	immune	immune	ADJ
gs-3920	222	9	checkpoint	checkpoint	NOUN
gs-3920	222	10	inhibitors	inhibitor	NOUN
gs-3920	222	11	,	,	PUNCT
gs-3920	222	12	tyrosine	tyrosine	NOUN
gs-3920	222	13	kinase	kinase	PROPN
gs-3920	222	14	inhibitors	inhibitor	NOUN
gs-3920	222	15	,	,	PUNCT
gs-3920	222	16	and	and	CCONJ
gs-3920	222	17	monoclonal	monoclonal	NOUN
gs-3920	222	18	antibodies	antibody	NOUN
gs-3920	222	19	in	in	ADP
gs-3920	222	20	inducing	induce	VERB
gs-3920	222	21	hypersensitivity	hypersensitivity	NOUN
gs-3920	222	22	syndromes	syndrome	NOUN
gs-3920	222	23	consistent	consistent	ADJ
gs-3920	222	24	with	with	ADP
gs-3920	222	25	dress	dress	NOUN
gs-3920	222	26	.	.	PUNCT
gs-3920	223	1	while	while	SCONJ
gs-3920	223	2	rare	rare	ADJ
gs-3920	223	3	,	,	PUNCT
gs-3920	223	4	such	such	ADJ
gs-3920	223	5	cases	case	NOUN
gs-3920	223	6	present	present	VERB
gs-3920	223	7	new	new	ADJ
gs-3920	223	8	challenges	challenge	NOUN
gs-3920	223	9	in	in	ADP
gs-3920	223	10	oncology	oncology	NOUN
gs-3920	223	11	,	,	PUNCT
gs-3920	223	12	as	as	SCONJ
gs-3920	223	13	drug	drug	NOUN
gs-3920	223	14	discontinuation	discontinuation	NOUN
gs-3920	223	15	may	may	AUX
gs-3920	223	16	compromise	compromise	VERB
gs-3920	223	17	life	life	NOUN
gs-3920	223	18	-	-	PUNCT
gs-3920	223	19	saving	save	VERB
gs-3920	223	20	therapies	therapy	NOUN
gs-3920	223	21	.	.	PUNCT
gs-3920	224	1	these	these	DET
gs-3920	224	2	cases	case	NOUN
gs-3920	224	3	often	often	ADV
gs-3920	224	4	required	require	VERB
gs-3920	224	5	immunosuppressive	immunosuppressive	ADJ
gs-3920	224	6	interventions	intervention	NOUN
gs-3920	224	7	and	and	CCONJ
gs-3920	224	8	illustrate	illustrate	VERB
gs-3920	224	9	the	the	DET
gs-3920	224	10	complexity	complexity	NOUN
gs-3920	224	11	of	of	ADP
gs-3920	224	12	balancing	balance	VERB
gs-3920	224	13	therapeutic	therapeutic	ADJ
gs-3920	224	14	benefit	benefit	NOUN
gs-3920	224	15	against	against	ADP
gs-3920	224	16	hypersensitivity	hypersensitivity	NOUN
gs-3920	224	17	risk	risk	NOUN
gs-3920	224	18	.	.	PUNCT
gs-3920	225	1	clinical	clinical	ADJ
gs-3920	225	2	manifestations	manifestation	NOUN
gs-3920	225	3	and	and	CCONJ
gs-3920	225	4	organ	organ	NOUN
gs-3920	225	5	system	system	NOUN
gs-3920	225	6	involvement	involvement	NOUN
gs-3920	225	7	clinically	clinically	ADV
gs-3920	225	8	,	,	PUNCT
gs-3920	225	9	dress	dress	NOUN
gs-3920	225	10	syndrome	syndrome	NOUN
gs-3920	225	11	presents	present	NOUN
gs-3920	225	12	with	with	ADP
gs-3920	225	13	heterogeneous	heterogeneous	ADJ
gs-3920	225	14	symptoms	symptom	NOUN
gs-3920	225	15	,	,	PUNCT
gs-3920	225	16	but	but	CCONJ
gs-3920	225	17	hallmark	hallmark	ADJ
gs-3920	225	18	features	feature	NOUN
gs-3920	225	19	include	include	VERB
gs-3920	225	20	high	high	ADJ
gs-3920	225	21	-	-	PUNCT
gs-3920	225	22	grade	grade	NOUN
gs-3920	225	23	fever	fever	NOUN
gs-3920	225	24	,	,	PUNCT
gs-3920	225	25	widespread	widespread	ADJ
gs-3920	225	26	maculopapular	maculopapular	ADJ
gs-3920	225	27	or	or	CCONJ
gs-3920	225	28	exfoliative	exfoliative	ADJ
gs-3920	225	29	rash	rash	NOUN
gs-3920	225	30	,	,	PUNCT
gs-3920	225	31	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	225	32	,	,	PUNCT
gs-3920	225	33	hematologic	hematologic	ADJ
gs-3920	225	34	abnormalities	abnormality	NOUN
gs-3920	225	35	(	(	PUNCT
gs-3920	225	36	notably	notably	ADV
gs-3920	225	37	eosinophilia	eosinophilia	PROPN
gs-3920	225	38	and	and	CCONJ
gs-3920	225	39	atypical	atypical	ADJ
gs-3920	225	40	lymphocytosis	lymphocytosis	NOUN
gs-3920	225	41	)	)	PUNCT
gs-3920	225	42	,	,	PUNCT
gs-3920	225	43	and	and	CCONJ
gs-3920	225	44	multiorgan	multiorgan	PROPN
gs-3920	225	45	involvement	involvement	NOUN
gs-3920	225	46	.	.	PUNCT
gs-3920	226	1	our	our	PRON
gs-3920	226	2	synthesis	synthesis	NOUN
gs-3920	226	3	of	of	ADP
gs-3920	226	4	over	over	ADP
gs-3920	226	5	1000	1000	NUM
gs-3920	226	6	cases	case	NOUN
gs-3920	226	7	revealed	reveal	VERB
gs-3920	226	8	that	that	SCONJ
gs-3920	226	9	hepatic	hepatic	ADJ
gs-3920	226	10	involvement	involvement	NOUN
gs-3920	226	11	is	be	AUX
gs-3920	226	12	the	the	DET
gs-3920	226	13	most	most	ADV
gs-3920	226	14	frequent	frequent	ADJ
gs-3920	226	15	systemic	systemic	ADJ
gs-3920	226	16	complication	complication	NOUN
gs-3920	226	17	,	,	PUNCT
gs-3920	226	18	present	present	ADJ
gs-3920	226	19	in	in	ADP
gs-3920	226	20	up	up	ADP
gs-3920	226	21	to	to	PART
gs-3920	226	22	70	70	NUM
gs-3920	226	23	–	–	PUNCT
gs-3920	226	24	80	80	NUM
gs-3920	226	25	%	%	NOUN
gs-3920	226	26	of	of	ADP
gs-3920	226	27	cases	case	NOUN
gs-3920	226	28	,	,	PUNCT
gs-3920	226	29	followed	follow	VERB
gs-3920	226	30	by	by	ADP
gs-3920	226	31	renal	renal	ADJ
gs-3920	226	32	and	and	CCONJ
gs-3920	226	33	pulmonary	pulmonary	ADJ
gs-3920	226	34	complications	complication	NOUN
gs-3920	226	35	.	.	PUNCT
gs-3920	227	1	hepatic	hepatic	ADJ
gs-3920	227	2	manifestations	manifestation	NOUN
gs-3920	227	3	range	range	VERB
gs-3920	227	4	from	from	ADP
gs-3920	227	5	transaminitis	transaminitis	NOUN
gs-3920	227	6	to	to	ADP
gs-3920	227	7	fulminant	fulminant	ADJ
gs-3920	227	8	hepatitis	hepatitis	NOUN
gs-3920	227	9	,	,	PUNCT
gs-3920	227	10	with	with	ADP
gs-3920	227	11	elevations	elevation	NOUN
gs-3920	227	12	in	in	ADP
gs-3920	227	13	alt	alt	ADJ
gs-3920	227	14	,	,	PUNCT
gs-3920	227	15	ast	ast	ADJ
gs-3920	227	16	,	,	PUNCT
gs-3920	227	17	and	and	CCONJ
gs-3920	227	18	bilirubin	bilirubin	NOUN
gs-3920	227	19	levels	level	NOUN
gs-3920	227	20	.	.	PUNCT
gs-3920	228	1	histopathological	histopathological	ADJ
gs-3920	228	2	examination	examination	NOUN
gs-3920	228	3	,	,	PUNCT
gs-3920	228	4	where	where	SCONJ
gs-3920	228	5	available	available	ADJ
gs-3920	228	6	,	,	PUNCT
gs-3920	228	7	indicated	indicate	VERB
gs-3920	228	8	eosinophilic	eosinophilic	ADJ
gs-3920	228	9	infiltration	infiltration	NOUN
gs-3920	228	10	of	of	ADP
gs-3920	228	11	the	the	DET
gs-3920	228	12	hepatic	hepatic	ADJ
gs-3920	228	13	parenchyma	parenchyma	NOUN
gs-3920	228	14	,	,	PUNCT
gs-3920	228	15	interface	interface	NOUN
gs-3920	228	16	hepatitis	hepatitis	NOUN
gs-3920	228	17	,	,	PUNCT
gs-3920	228	18	and	and	CCONJ
gs-3920	228	19	occasionally	occasionally	ADV
gs-3920	228	20	necrosis	necrosis	ADJ
gs-3920	228	21	.	.	PUNCT
gs-3920	229	1	renal	renal	ADJ
gs-3920	229	2	involvement	involvement	NOUN
gs-3920	229	3	typically	typically	ADV
gs-3920	229	4	presented	present	VERB
gs-3920	229	5	as	as	ADP
gs-3920	229	6	acute	acute	ADJ
gs-3920	229	7	interstitial	interstitial	ADJ
gs-3920	229	8	nephritis	nephritis	NOUN
gs-3920	229	9	,	,	PUNCT
gs-3920	229	10	often	often	ADV
gs-3920	229	11	with	with	ADP
gs-3920	229	12	eosinophiluria	eosinophiluria	NOUN
gs-3920	229	13	.	.	PUNCT
gs-3920	230	1	pulmonary	pulmonary	ADJ
gs-3920	230	2	symptoms	symptom	NOUN
gs-3920	230	3	included	include	VERB
gs-3920	230	4	cough	cough	NOUN
gs-3920	230	5	,	,	PUNCT
gs-3920	230	6	dyspnea	dyspnea	NOUN
gs-3920	230	7	,	,	PUNCT
gs-3920	230	8	and	and	CCONJ
gs-3920	230	9	interstitial	interstitial	ADJ
gs-3920	230	10	pneumonitis	pneumonitis	NOUN
gs-3920	230	11	,	,	PUNCT
gs-3920	230	12	frequently	frequently	ADV
gs-3920	230	13	confirmed	confirm	VERB
gs-3920	230	14	by	by	ADP
gs-3920	230	15	high	high	ADJ
gs-3920	230	16	-	-	PUNCT
gs-3920	230	17	resolution	resolution	NOUN
gs-3920	230	18	ct	ct	PROPN
gs-3920	230	19	.	.	PUNCT
gs-3920	230	20	lymphadenopathy	lymphadenopathy	PROPN
gs-3920	230	21	was	be	AUX
gs-3920	230	22	reported	report	VERB
gs-3920	230	23	in	in	ADP
gs-3920	230	24	60	60	NUM
gs-3920	230	25	%	%	NOUN
gs-3920	230	26	of	of	ADP
gs-3920	230	27	cases	case	NOUN
gs-3920	230	28	,	,	PUNCT
gs-3920	230	29	often	often	ADV
gs-3920	230	30	bilateral	bilateral	ADJ
gs-3920	230	31	and	and	CCONJ
gs-3920	230	32	symmetrical	symmetrical	ADJ
gs-3920	230	33	,	,	PUNCT
gs-3920	230	34	with	with	ADP
gs-3920	230	35	cervical	cervical	ADJ
gs-3920	230	36	,	,	PUNCT
gs-3920	230	37	axillary	axillary	ADJ
gs-3920	230	38	,	,	PUNCT
gs-3920	230	39	and	and	CCONJ
gs-3920	230	40	inguinal	inguinal	ADJ
gs-3920	230	41	nodes	node	NOUN
gs-3920	230	42	most	most	ADV
gs-3920	230	43	commonly	commonly	ADV
gs-3920	230	44	affected	affect	VERB
gs-3920	230	45	.	.	PUNCT
gs-3920	231	1	hematologic	hematologic	NOUN
gs-3920	231	2	abnormalities	abnormality	NOUN
gs-3920	231	3	were	be	AUX
gs-3920	231	4	nearly	nearly	ADV
gs-3920	231	5	universal	universal	ADJ
gs-3920	231	6	,	,	PUNCT
gs-3920	231	7	with	with	ADP
gs-3920	231	8	eosinophilia	eosinophilia	PROPN
gs-3920	231	9	exceeding	exceed	VERB
gs-3920	231	10	1500	1500	NUM
gs-3920	231	11	/	/	SYM
gs-3920	231	12	mm³	mm³	VERB
gs-3920	231	13	in	in	ADP
gs-3920	231	14	a	a	DET
gs-3920	231	15	majority	majority	NOUN
gs-3920	231	16	of	of	ADP
gs-3920	231	17	cases	case	NOUN
gs-3920	231	18	and	and	CCONJ
gs-3920	231	19	atypical	atypical	ADJ
gs-3920	231	20	lymphocytes	lymphocyte	NOUN
gs-3920	231	21	on	on	ADP
gs-3920	231	22	peripheral	peripheral	ADJ
gs-3920	231	23	smear	smear	NOUN
gs-3920	231	24	in	in	ADP
gs-3920	231	25	about	about	ADV
gs-3920	231	26	half	half	NOUN
gs-3920	231	27	.	.	PUNCT
gs-3920	232	1	mucosal	mucosal	ADJ
gs-3920	232	2	involvement	involvement	NOUN
gs-3920	232	3	was	be	AUX
gs-3920	232	4	infrequent	infrequent	ADJ
gs-3920	232	5	but	but	CCONJ
gs-3920	232	6	,	,	PUNCT
gs-3920	232	7	when	when	SCONJ
gs-3920	232	8	present	present	ADJ
gs-3920	232	9	,	,	PUNCT
gs-3920	232	10	indicated	indicate	VERB
gs-3920	232	11	overlap	overlap	NOUN
gs-3920	232	12	with	with	ADP
gs-3920	232	13	stevens	stevens	PROPN
gs-3920	232	14	–	–	PUNCT
gs-3920	232	15	johnson	johnson	PROPN
gs-3920	232	16	syndrome	syndrome	PROPN
gs-3920	232	17	or	or	CCONJ
gs-3920	232	18	toxic	toxic	ADJ
gs-3920	232	19	epidermal	epidermal	ADJ
gs-3920	232	20	necrolysis	necrolysis	NOUN
gs-3920	232	21	.	.	PUNCT
gs-3920	233	1	interestingly	interestingly	ADV
gs-3920	233	2	,	,	PUNCT
gs-3920	233	3	delayed	delay	VERB
gs-3920	233	4	autoimmune	autoimmune	ADJ
gs-3920	233	5	sequelae	sequelae	NOUN
gs-3920	233	6	were	be	AUX
gs-3920	233	7	reported	report	VERB
gs-3920	233	8	in	in	ADP
gs-3920	233	9	10–15	10–15	NUM
gs-3920	233	10	%	%	NOUN
gs-3920	233	11	of	of	ADP
gs-3920	233	12	patients	patient	NOUN
gs-3920	233	13	,	,	PUNCT
gs-3920	233	14	including	include	VERB
gs-3920	233	15	autoimmune	autoimmune	ADJ
gs-3920	233	16	thyroiditis	thyroiditis	NOUN
gs-3920	233	17	,	,	PUNCT
gs-3920	233	18	type	type	NOUN
gs-3920	233	19	1	1	NUM
gs-3920	233	20	diabetes	diabetes	NOUN
gs-3920	233	21	,	,	PUNCT
gs-3920	233	22	and	and	CCONJ
gs-3920	233	23	systemic	systemic	ADJ
gs-3920	233	24	lupus	lupus	PROPN
gs-3920	233	25	erythematosus	erythematosus	PROPN
gs-3920	233	26	.	.	PUNCT
gs-3920	234	1	these	these	DET
gs-3920	234	2	outcomes	outcome	NOUN
gs-3920	234	3	typically	typically	ADV
gs-3920	234	4	manifested	manifest	VERB
gs-3920	234	5	weeks	week	NOUN
gs-3920	234	6	to	to	ADP
gs-3920	234	7	months	month	NOUN
gs-3920	234	8	after	after	ADP
gs-3920	234	9	resolution	resolution	NOUN
gs-3920	234	10	of	of	ADP
gs-3920	234	11	acute	acute	ADJ
gs-3920	234	12	dress	dress	NOUN
gs-3920	234	13	and	and	CCONJ
gs-3920	234	14	underscore	underscore	VERB
gs-3920	234	15	the	the	DET
gs-3920	234	16	syndrome	syndrome	NOUN
gs-3920	234	17	’s	’s	PART
gs-3920	234	18	ability	ability	NOUN
gs-3920	234	19	to	to	PART
gs-3920	234	20	trigger	trigger	VERB
gs-3920	234	21	long	long	ADJ
gs-3920	234	22	-	-	PUNCT
gs-3920	234	23	term	term	NOUN
gs-3920	234	24	immune	immune	ADJ
gs-3920	234	25	dysregulation	dysregulation	NOUN
gs-3920	234	26	.	.	PUNCT
gs-3920	235	1	diagnostic	diagnostic	ADJ
gs-3920	235	2	approaches	approach	NOUN
gs-3920	235	3	and	and	CCONJ
gs-3920	235	4	limitations	limitation	NOUN
gs-3920	235	5	the	the	DET
gs-3920	235	6	diagnosis	diagnosis	NOUN
gs-3920	235	7	of	of	ADP
gs-3920	235	8	dress	dress	NOUN
gs-3920	235	9	remains	remain	VERB
gs-3920	235	10	clinical	clinical	ADJ
gs-3920	235	11	,	,	PUNCT
gs-3920	235	12	supported	support	VERB
gs-3920	235	13	by	by	ADP
gs-3920	235	14	ancillary	ancillary	ADJ
gs-3920	235	15	investigations	investigation	NOUN
gs-3920	235	16	and	and	CCONJ
gs-3920	235	17	exclusion	exclusion	NOUN
gs-3920	235	18	of	of	ADP
gs-3920	235	19	alternative	alternative	ADJ
gs-3920	235	20	etiologies	etiology	NOUN
gs-3920	235	21	.	.	PUNCT
gs-3920	236	1	the	the	DET
gs-3920	236	2	regiscar	regiscar	ADJ
gs-3920	236	3	scoring	scoring	NOUN
gs-3920	236	4	system	system	NOUN
gs-3920	236	5	is	be	AUX
gs-3920	236	6	the	the	DET
gs-3920	236	7	most	most	ADV
gs-3920	236	8	widely	widely	ADV
gs-3920	236	9	used	use	VERB
gs-3920	236	10	tool	tool	NOUN
gs-3920	236	11	to	to	PART
gs-3920	236	12	support	support	VERB
gs-3920	236	13	diagnostic	diagnostic	ADJ
gs-3920	236	14	categorization	categorization	NOUN
gs-3920	236	15	into	into	ADP
gs-3920	236	16	"	"	PUNCT
gs-3920	236	17	definite	definite	ADJ
gs-3920	236	18	,	,	PUNCT
gs-3920	236	19	"	"	PUNCT
gs-3920	236	20	"	"	PUNCT
gs-3920	236	21	probable	probable	ADJ
gs-3920	236	22	,	,	PUNCT
gs-3920	236	23	"	"	PUNCT
gs-3920	236	24	or	or	CCONJ
gs-3920	236	25	"	"	PUNCT
gs-3920	236	26	possible	possible	ADJ
gs-3920	236	27	"	"	PUNCT
gs-3920	236	28	dress	dress	NOUN
gs-3920	236	29	.	.	PUNCT
gs-3920	237	1	our	our	PRON
gs-3920	237	2	analysis	analysis	NOUN
gs-3920	237	3	found	find	VERB
gs-3920	237	4	variability	variability	NOUN
gs-3920	237	5	in	in	ADP
gs-3920	237	6	its	its	PRON
gs-3920	237	7	application	application	NOUN
gs-3920	237	8	,	,	PUNCT
gs-3920	237	9	with	with	SCONJ
gs-3920	237	10	some	some	DET
gs-3920	237	11	clinicians	clinician	NOUN
gs-3920	237	12	relying	rely	VERB
gs-3920	237	13	solely	solely	ADV
gs-3920	237	14	on	on	ADP
gs-3920	237	15	georgian	georgian	ADJ
gs-3920	237	16	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	237	17	მეცნიერები	მეცნიერები	NOUN
gs-3920	237	18	ტ.	ტ.	VERB
gs-3920	237	19	7	7	NUM
gs-3920	237	20	n	n	PRON
gs-3920	237	21	3	3	NUM
gs-3920	237	22	,	,	PUNCT
gs-3920	237	23	2025	2025	NUM
gs-3920	237	24	194	194	NUM
gs-3920	237	25	eosinophil	eosinophil	ADJ
gs-3920	237	26	count	count	NOUN
gs-3920	237	27	and	and	CCONJ
gs-3920	237	28	rash	rash	ADJ
gs-3920	237	29	,	,	PUNCT
gs-3920	237	30	while	while	SCONJ
gs-3920	237	31	others	other	NOUN
gs-3920	237	32	applied	apply	VERB
gs-3920	237	33	a	a	DET
gs-3920	237	34	more	more	ADV
gs-3920	237	35	systematic	systematic	ADJ
gs-3920	237	36	assessment	assessment	NOUN
gs-3920	237	37	incorporating	incorporate	VERB
gs-3920	237	38	fever	fever	NOUN
gs-3920	237	39	,	,	PUNCT
gs-3920	237	40	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	237	41	,	,	PUNCT
gs-3920	237	42	internal	internal	ADJ
gs-3920	237	43	organ	organ	NOUN
gs-3920	237	44	involvement	involvement	NOUN
gs-3920	237	45	,	,	PUNCT
gs-3920	237	46	and	and	CCONJ
gs-3920	237	47	viral	viral	ADJ
gs-3920	237	48	reactivation	reactivation	NOUN
gs-3920	237	49	markers	marker	NOUN
gs-3920	237	50	.	.	PUNCT
gs-3920	238	1	confirmatory	confirmatory	NOUN
gs-3920	238	2	tools	tool	NOUN
gs-3920	238	3	,	,	PUNCT
gs-3920	238	4	such	such	ADJ
gs-3920	238	5	as	as	ADP
gs-3920	238	6	patch	patch	NOUN
gs-3920	238	7	testing	testing	NOUN
gs-3920	238	8	or	or	CCONJ
gs-3920	238	9	lymphocyte	lymphocyte	ADJ
gs-3920	238	10	transformation	transformation	NOUN
gs-3920	238	11	tests	test	NOUN
gs-3920	238	12	,	,	PUNCT
gs-3920	238	13	have	have	AUX
gs-3920	238	14	been	be	AUX
gs-3920	238	15	used	use	VERB
gs-3920	238	16	in	in	ADP
gs-3920	238	17	some	some	DET
gs-3920	238	18	centers	center	NOUN
gs-3920	238	19	to	to	PART
gs-3920	238	20	identify	identify	VERB
gs-3920	238	21	culprit	culprit	NOUN
gs-3920	238	22	drugs	drug	NOUN
gs-3920	238	23	but	but	CCONJ
gs-3920	238	24	suffer	suffer	VERB
gs-3920	238	25	from	from	ADP
gs-3920	238	26	limited	limited	ADJ
gs-3920	238	27	sensitivity	sensitivity	NOUN
gs-3920	238	28	and	and	CCONJ
gs-3920	238	29	standardization	standardization	NOUN
gs-3920	238	30	.	.	PUNCT
gs-3920	239	1	hhv-6	hhv-6	ADJ
gs-3920	239	2	pcr	pcr	ADJ
gs-3920	239	3	testing	testing	NOUN
gs-3920	239	4	,	,	PUNCT
gs-3920	239	5	when	when	SCONJ
gs-3920	239	6	performed	perform	VERB
gs-3920	239	7	,	,	PUNCT
gs-3920	239	8	was	be	AUX
gs-3920	239	9	positive	positive	ADJ
gs-3920	239	10	in	in	ADP
gs-3920	239	11	approximately	approximately	ADV
gs-3920	239	12	45	45	NUM
gs-3920	239	13	%	%	NOUN
gs-3920	239	14	of	of	ADP
gs-3920	239	15	cases	case	NOUN
gs-3920	239	16	,	,	PUNCT
gs-3920	239	17	lending	lend	VERB
gs-3920	239	18	support	support	NOUN
gs-3920	239	19	to	to	ADP
gs-3920	239	20	the	the	DET
gs-3920	239	21	theory	theory	NOUN
gs-3920	239	22	of	of	ADP
gs-3920	239	23	viral	viral	ADJ
gs-3920	239	24	reactivation	reactivation	NOUN
gs-3920	239	25	as	as	ADP
gs-3920	239	26	a	a	DET
gs-3920	239	27	pathogenic	pathogenic	ADJ
gs-3920	239	28	amplifier	amplifier	NOUN
gs-3920	239	29	.	.	PUNCT
gs-3920	240	1	however	however	ADV
gs-3920	240	2	,	,	PUNCT
gs-3920	240	3	this	this	DET
gs-3920	240	4	test	test	NOUN
gs-3920	240	5	is	be	AUX
gs-3920	240	6	not	not	PART
gs-3920	240	7	routinely	routinely	ADV
gs-3920	240	8	available	available	ADJ
gs-3920	240	9	in	in	ADP
gs-3920	240	10	many	many	ADJ
gs-3920	240	11	clinical	clinical	ADJ
gs-3920	240	12	settings	setting	NOUN
gs-3920	240	13	,	,	PUNCT
gs-3920	240	14	limiting	limit	VERB
gs-3920	240	15	its	its	PRON
gs-3920	240	16	utility	utility	NOUN
gs-3920	240	17	.	.	PUNCT
gs-3920	241	1	misdiagnosis	misdiagnosis	NOUN
gs-3920	241	2	remains	remain	VERB
gs-3920	241	3	a	a	DET
gs-3920	241	4	serious	serious	ADJ
gs-3920	241	5	issue	issue	NOUN
gs-3920	241	6	,	,	PUNCT
gs-3920	241	7	particularly	particularly	ADV
gs-3920	241	8	in	in	ADP
gs-3920	241	9	patients	patient	NOUN
gs-3920	241	10	with	with	ADP
gs-3920	241	11	overlapping	overlap	VERB
gs-3920	241	12	conditions	condition	NOUN
gs-3920	241	13	such	such	ADJ
gs-3920	241	14	as	as	ADP
gs-3920	241	15	sepsis	sepsis	NOUN
gs-3920	241	16	,	,	PUNCT
gs-3920	241	17	vasculitis	vasculitis	NOUN
gs-3920	241	18	,	,	PUNCT
gs-3920	241	19	or	or	CCONJ
gs-3920	241	20	other	other	ADJ
gs-3920	241	21	severe	severe	ADJ
gs-3920	241	22	cutaneous	cutaneous	ADJ
gs-3920	241	23	adverse	adverse	ADJ
gs-3920	241	24	reactions	reaction	NOUN
gs-3920	241	25	.	.	PUNCT
gs-3920	242	1	in	in	ADP
gs-3920	242	2	settings	setting	NOUN
gs-3920	242	3	without	without	ADP
gs-3920	242	4	access	access	NOUN
gs-3920	242	5	to	to	ADP
gs-3920	242	6	dermatologic	dermatologic	ADJ
gs-3920	242	7	or	or	CCONJ
gs-3920	242	8	immunologic	immunologic	ADJ
gs-3920	242	9	expertise	expertise	NOUN
gs-3920	242	10	,	,	PUNCT
gs-3920	242	11	patients	patient	NOUN
gs-3920	242	12	may	may	AUX
gs-3920	242	13	be	be	AUX
gs-3920	242	14	inappropriately	inappropriately	ADV
gs-3920	242	15	treated	treat	VERB
gs-3920	242	16	with	with	ADP
gs-3920	242	17	antibiotics	antibiotic	NOUN
gs-3920	242	18	or	or	CCONJ
gs-3920	242	19	immunosuppressants	immunosuppressant	NOUN
gs-3920	242	20	before	before	ADP
gs-3920	242	21	proper	proper	ADJ
gs-3920	242	22	identification	identification	NOUN
gs-3920	242	23	and	and	CCONJ
gs-3920	242	24	drug	drug	NOUN
gs-3920	242	25	withdrawal	withdrawal	NOUN
gs-3920	242	26	.	.	PUNCT
gs-3920	243	1	implicated	implicated	ADJ
gs-3920	243	2	drugs	drug	NOUN
gs-3920	243	3	include	include	VERB
gs-3920	243	4	a	a	DET
gs-3920	243	5	wide	wide	ADJ
gs-3920	243	6	range	range	NOUN
gs-3920	243	7	of	of	ADP
gs-3920	243	8	classes	class	NOUN
gs-3920	243	9	,	,	PUNCT
gs-3920	243	10	although	although	SCONJ
gs-3920	243	11	anticonvulsants	anticonvulsant	NOUN
gs-3920	243	12	and	and	CCONJ
gs-3920	243	13	antibiotics	antibiotic	NOUN
gs-3920	243	14	are	be	AUX
gs-3920	243	15	the	the	DET
gs-3920	243	16	most	most	ADV
gs-3920	243	17	common	common	ADJ
gs-3920	243	18	.	.	PUNCT
gs-3920	244	1	table-1	table-1	NUM
gs-3920	244	2	.	.	PUNCT
gs-3920	244	3	summarizes	summarize	VERB
gs-3920	244	4	the	the	DET
gs-3920	244	5	major	major	ADJ
gs-3920	244	6	drug	drug	NOUN
gs-3920	244	7	categories	category	NOUN
gs-3920	244	8	,	,	PUNCT
gs-3920	244	9	representative	representative	ADJ
gs-3920	244	10	agents	agent	NOUN
gs-3920	244	11	,	,	PUNCT
gs-3920	244	12	and	and	CCONJ
gs-3920	244	13	approximate	approximate	ADJ
gs-3920	244	14	case	case	NOUN
gs-3920	244	15	counts	count	NOUN
gs-3920	244	16	based	base	VERB
gs-3920	244	17	on	on	ADP
gs-3920	244	18	the	the	DET
gs-3920	244	19	reviewed	review	VERB
gs-3920	244	20	literature	literature	NOUN
gs-3920	244	21	.	.	PUNCT
gs-3920	245	1	drug	drug	NOUN
gs-3920	245	2	class	class	PROPN
gs-3920	245	3	no	no	INTJ
gs-3920	245	4	.	.	PUNCT
gs-3920	246	1	of	of	ADP
gs-3920	246	2	cases	case	NOUN
gs-3920	246	3	representative	representative	ADJ
gs-3920	246	4	drugs	drug	NOUN
gs-3920	246	5	anticonvulsants	anticonvulsant	VERB
gs-3920	246	6	14	14	NUM
gs-3920	246	7	lamotrigine	lamotrigine	NOUN
gs-3920	246	8	,	,	PUNCT
gs-3920	246	9	carbamazepine	carbamazepine	NOUN
gs-3920	246	10	,	,	PUNCT
gs-3920	246	11	phenytoin	phenytoin	NOUN
gs-3920	246	12	,	,	PUNCT
gs-3920	246	13	eslicarbazepine	eslicarbazepine	NOUN
gs-3920	246	14	antibiotics	antibiotic	NOUN
gs-3920	246	15	12	12	NUM
gs-3920	246	16	vancomycin	vancomycin	PROPN
gs-3920	246	17	,	,	PUNCT
gs-3920	246	18	penicillin	penicillin	NOUN
gs-3920	246	19	,	,	PUNCT
gs-3920	246	20	minocycline	minocycline	NOUN
gs-3920	246	21	,	,	PUNCT
gs-3920	246	22	piperacillin	piperacillin	NOUN
gs-3920	246	23	-	-	PUNCT
gs-3920	246	24	tazobactam	tazobactam	NOUN
gs-3920	246	25	nsaids	nsaid	VERB
gs-3920	246	26	6	6	NUM
gs-3920	246	27	ibuprofen	ibuprofen	NOUN
gs-3920	246	28	,	,	PUNCT
gs-3920	246	29	naproxen	naproxen	NOUN
gs-3920	246	30	,	,	PUNCT
gs-3920	246	31	mefenamic	mefenamic	ADJ
gs-3920	246	32	acid	acid	NOUN
gs-3920	246	33	,	,	PUNCT
gs-3920	246	34	diclofenac	diclofenac	ADJ
gs-3920	246	35	antiviral	antiviral	NOUN
gs-3920	246	36	/	/	SYM
gs-3920	246	37	antiretroviral	antiretroviral	ADJ
gs-3920	246	38	5	5	NUM
gs-3920	246	39	abacavir	abacavir	NOUN
gs-3920	246	40	,	,	PUNCT
gs-3920	246	41	nevirapine	nevirapine	ADJ
gs-3920	246	42	immunotherapy	immunotherapy	NOUN
gs-3920	246	43	/	/	SYM
gs-3920	246	44	antineoplastic	antineoplastic	ADJ
gs-3920	246	45	4	4	NUM
gs-3920	246	46	pembrolizumab	pembrolizumab	NOUN
gs-3920	246	47	,	,	PUNCT
gs-3920	246	48	apalutamide	apalutamide	ADV
gs-3920	246	49	antigout	antigout	NOUN
gs-3920	246	50	9	9	NUM
gs-3920	246	51	allopurinol	allopurinol	NOUN
gs-3920	246	52	others	other	NOUN
gs-3920	246	53	10	10	NUM
gs-3920	246	54	dapsone	dapsone	NOUN
gs-3920	246	55	,	,	PUNCT
gs-3920	246	56	sulfasalazine	sulfasalazine	NOUN
gs-3920	246	57	,	,	PUNCT
gs-3920	246	58	hydroxychloroquine	hydroxychloroquine	PROPN
gs-3920	246	59	,	,	PUNCT
gs-3920	246	60	etc	etc	X
gs-3920	246	61	.	.	X
gs-3920	247	1	anticonvulsants	anticonvulsant	NOUN
gs-3920	247	2	are	be	AUX
gs-3920	247	3	still	still	ADV
gs-3920	247	4	the	the	DET
gs-3920	247	5	most	most	ADV
gs-3920	247	6	implicated	implicated	ADJ
gs-3920	247	7	medications	medication	NOUN
gs-3920	247	8	,	,	PUNCT
gs-3920	247	9	as	as	SCONJ
gs-3920	247	10	previously	previously	ADV
gs-3920	247	11	reported	report	VERB
gs-3920	247	12	in	in	ADP
gs-3920	247	13	epidemiological	epidemiological	ADJ
gs-3920	247	14	studies	study	NOUN
gs-3920	247	15	.	.	PUNCT
gs-3920	248	1	however	however	ADV
gs-3920	248	2	more	more	ADV
gs-3920	248	3	recent	recent	ADJ
gs-3920	248	4	reports	report	NOUN
gs-3920	248	5	widened	widen	VERB
gs-3920	248	6	the	the	DET
gs-3920	248	7	phenotype	phenotype	NOUN
gs-3920	248	8	to	to	ADP
gs-3920	248	9	immune	immune	ADJ
gs-3920	248	10	checkpoint	checkpoint	NOUN
gs-3920	248	11	inhibitors	inhibitor	NOUN
gs-3920	248	12	and	and	CCONJ
gs-3920	248	13	biologics	biologic	NOUN
gs-3920	248	14	,	,	PUNCT
gs-3920	248	15	providing	provide	VERB
gs-3920	248	16	an	an	DET
gs-3920	248	17	example	example	NOUN
gs-3920	248	18	of	of	ADP
gs-3920	248	19	changing	change	VERB
gs-3920	248	20	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	248	21	landscape	landscape	NOUN
gs-3920	248	22	.	.	PUNCT
gs-3920	249	1	nonsteroidal	nonsteroidal	NOUN
gs-3920	249	2	anti	anti	ADJ
gs-3920	249	3	-	-	ADJ
gs-3920	249	4	inflammatory	inflammatory	ADJ
gs-3920	249	5	drugs	drug	NOUN
gs-3920	249	6	(	(	PUNCT
gs-3920	249	7	nsaids	nsaid	NOUN
gs-3920	249	8	)	)	PUNCT
gs-3920	249	9	and	and	CCONJ
gs-3920	249	10	other	other	ADJ
gs-3920	249	11	widely	widely	ADV
gs-3920	249	12	used	use	VERB
gs-3920	249	13	drugs	drug	NOUN
gs-3920	249	14	,	,	PUNCT
gs-3920	249	15	while	while	SCONJ
gs-3920	249	16	less	less	ADV
gs-3920	249	17	common	common	ADJ
gs-3920	249	18	,	,	PUNCT
gs-3920	249	19	should	should	AUX
gs-3920	249	20	not	not	PART
gs-3920	249	21	be	be	AUX
gs-3920	249	22	spared	spare	VERB
gs-3920	249	23	as	as	ADP
gs-3920	249	24	possible	possible	ADJ
gs-3920	249	25	aetiologies	aetiology	NOUN
gs-3920	249	26	.	.	PUNCT
gs-3920	250	1	distribution	distribution	NOUN
gs-3920	250	2	of	of	ADP
gs-3920	250	3	dress	dress	NOUN
gs-3920	250	4	syndrome	syndrome	NOUN
gs-3920	250	5	cases	case	NOUN
gs-3920	250	6	by	by	ADP
gs-3920	250	7	drug	drug	NOUN
gs-3920	250	8	class	class	NOUN
gs-3920	250	9	.	.	PUNCT
gs-3920	251	1	georgian	georgian	ADJ
gs-3920	251	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	251	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	251	4	ტ.	ტ.	VERB
gs-3920	251	5	7	7	NUM
gs-3920	251	6	n	n	PRON
gs-3920	251	7	3	3	NUM
gs-3920	251	8	,	,	PUNCT
gs-3920	251	9	2025	2025	NUM
gs-3920	251	10	195	195	NUM
gs-3920	251	11	bar	bar	NOUN
gs-3920	251	12	chart	chart	NOUN
gs-3920	251	13	showing	show	VERB
gs-3920	251	14	case	case	NOUN
gs-3920	251	15	counts	count	NOUN
gs-3920	251	16	and	and	CCONJ
gs-3920	251	17	percentages	percentage	NOUN
gs-3920	251	18	by	by	ADP
gs-3920	251	19	drug	drug	NOUN
gs-3920	251	20	class	class	NOUN
gs-3920	251	21	,	,	PUNCT
gs-3920	251	22	with	with	ADP
gs-3920	251	23	anticonvulsants	anticonvulsant	NOUN
gs-3920	251	24	and	and	CCONJ
gs-3920	251	25	antibiotics	antibiotic	NOUN
gs-3920	251	26	being	be	AUX
gs-3920	251	27	the	the	DET
gs-3920	251	28	most	most	ADV
gs-3920	251	29	common	common	ADJ
gs-3920	251	30	culprits	culprit	NOUN
gs-3920	251	31	.	.	PUNCT
gs-3920	252	1	(	(	PUNCT
gs-3920	252	2	x	x	NOUN
gs-3920	252	3	-	-	ADJ
gs-3920	252	4	axis	axis	ADJ
gs-3920	252	5	-	-	PUNCT
gs-3920	252	6	number	number	NOUN
gs-3920	252	7	of	of	ADP
gs-3920	252	8	dress	dress	NOUN
gs-3920	252	9	cases	case	NOUN
gs-3920	252	10	,	,	PUNCT
gs-3920	252	11	y	y	ADJ
gs-3920	252	12	-	-	PUNCT
gs-3920	252	13	axiscausative	axiscausative	ADJ
gs-3920	252	14	drug	drug	NOUN
gs-3920	252	15	categories	category	NOUN
gs-3920	252	16	with	with	ADP
gs-3920	252	17	frequently	frequently	ADV
gs-3920	252	18	caused	cause	VERB
gs-3920	252	19	drugs	drug	NOUN
gs-3920	252	20	)	)	PUNCT
gs-3920	252	21	.	.	PUNCT
gs-3920	253	1	fig-1	fig-1	X
gs-3920	253	2	.	.	PUNCT
gs-3920	253	3	organ	organ	NOUN
gs-3920	253	4	systems	system	NOUN
gs-3920	253	5	affected	affect	VERB
gs-3920	253	6	in	in	ADP
gs-3920	253	7	dress	dress	NOUN
gs-3920	253	8	syndrome	syndrome	NOUN
gs-3920	253	9	multisystemic	multisystemic	ADJ
gs-3920	253	10	involvement	involvement	NOUN
gs-3920	253	11	characterized	characterize	VERB
gs-3920	253	12	by	by	ADP
gs-3920	253	13	variable	variable	ADJ
gs-3920	253	14	organ	organ	NOUN
gs-3920	253	15	impairment	impairment	NOUN
gs-3920	253	16	is	be	AUX
gs-3920	253	17	prominent	prominent	ADJ
gs-3920	253	18	.	.	PUNCT
gs-3920	254	1	georgian	georgian	ADJ
gs-3920	254	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	254	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	254	4	ტ.	ტ.	VERB
gs-3920	254	5	7	7	NUM
gs-3920	254	6	n	n	DET
gs-3920	254	7	3	3	NUM
gs-3920	254	8	,	,	PUNCT
gs-3920	254	9	2025	2025	NUM
gs-3920	254	10	196	196	NUM
gs-3920	254	11	table-2	table-2	NUM
gs-3920	254	12	.	.	PUNCT
gs-3920	255	1	outlines	outline	VERB
gs-3920	255	2	the	the	DET
gs-3920	255	3	frequency	frequency	NOUN
gs-3920	255	4	and	and	CCONJ
gs-3920	255	5	clinical	clinical	ADJ
gs-3920	255	6	features	feature	NOUN
gs-3920	255	7	of	of	ADP
gs-3920	255	8	organ	organ	NOUN
gs-3920	255	9	involvement	involvement	NOUN
gs-3920	255	10	based	base	VERB
gs-3920	255	11	on	on	ADP
gs-3920	255	12	the	the	DET
gs-3920	255	13	reviewed	review	VERB
gs-3920	255	14	literature	literature	NOUN
gs-3920	255	15	.	.	PUNCT
gs-3920	256	1	organ	organ	NOUN
gs-3920	256	2	/	/	SYM
gs-3920	256	3	system	system	NOUN
gs-3920	256	4	frequency	frequency	NOUN
gs-3920	256	5	clinical	clinical	ADJ
gs-3920	256	6	notes	note	NOUN
gs-3920	256	7	skin	skin	NOUN
gs-3920	256	8	nearly	nearly	ADV
gs-3920	256	9	all	all	PRON
gs-3920	256	10	cases	case	NOUN
gs-3920	256	11	diffuse	diffuse	VERB
gs-3920	256	12	morbilliform	morbilliform	ADJ
gs-3920	256	13	rash	rash	ADJ
gs-3920	256	14	,	,	PUNCT
gs-3920	256	15	facial	facial	ADJ
gs-3920	256	16	edema	edema	NOUN
gs-3920	256	17	,	,	PUNCT
gs-3920	256	18	exfoliation	exfoliation	NOUN
gs-3920	256	19	liver	liver	NOUN
gs-3920	256	20	>	>	NOUN
gs-3920	256	21	60	60	NUM
gs-3920	256	22	%	%	NOUN
gs-3920	256	23	hepatitis	hepatitis	NOUN
gs-3920	256	24	,	,	PUNCT
gs-3920	256	25	elevated	elevated	ADJ
gs-3920	256	26	transaminases	transaminase	NOUN
gs-3920	256	27	,	,	PUNCT
gs-3920	256	28	fulminant	fulminant	ADJ
gs-3920	256	29	failure	failure	NOUN
gs-3920	256	30	hematologic	hematologic	NOUN
gs-3920	256	31	>	>	ADP
gs-3920	256	32	50	50	NUM
gs-3920	256	33	%	%	NOUN
gs-3920	256	34	eosinophilia	eosinophilia	NOUN
gs-3920	256	35	,	,	PUNCT
gs-3920	256	36	leucocytosis	leucocytosis	NOUN
gs-3920	256	37	,	,	PUNCT
gs-3920	256	38	atypical	atypical	ADJ
gs-3920	256	39	lymphocytes	lymphocyte	NOUN
gs-3920	256	40	renal	renal	ADJ
gs-3920	256	41	~25	~25	NUM
gs-3920	256	42	%	%	NOUN
gs-3920	256	43	acute	acute	ADJ
gs-3920	256	44	interstitial	interstitial	ADJ
gs-3920	256	45	nephritis	nephritis	NOUN
gs-3920	256	46	,	,	PUNCT
gs-3920	256	47	renal	renal	ADJ
gs-3920	256	48	insufficiency	insufficiency	NOUN
gs-3920	256	49	lung	lung	NOUN
gs-3920	256	50	10–15	10–15	NUM
gs-3920	256	51	%	%	NOUN
gs-3920	256	52	pneumonitis	pneumonitis	NOUN
gs-3920	256	53	,	,	PUNCT
gs-3920	256	54	ards	ard	NOUN
gs-3920	256	55	,	,	PUNCT
gs-3920	256	56	cough	cough	NOUN
gs-3920	256	57	,	,	PUNCT
gs-3920	256	58	dyspnea	dyspnea	VERB
gs-3920	256	59	gastrointestinal	gastrointestinal	ADJ
gs-3920	256	60	<	<	NOUN
gs-3920	256	61	10	10	NUM
gs-3920	256	62	%	%	NOUN
gs-3920	256	63	eosinophilic	eosinophilic	ADJ
gs-3920	256	64	colitis	colitis	NOUN
gs-3920	256	65	,	,	PUNCT
gs-3920	256	66	cholecystitis	cholecystitis	NOUN
gs-3920	256	67	,	,	PUNCT
gs-3920	256	68	nausea	nausea	NOUN
gs-3920	256	69	,	,	PUNCT
gs-3920	256	70	diarrhea	diarrhea	NOUN
gs-3920	256	71	cardiac	cardiac	ADJ
gs-3920	256	72	/	/	SYM
gs-3920	256	73	cns	cns	NOUN
gs-3920	256	74	rare	rare	PROPN
gs-3920	256	75	myocarditis	myocarditis	PROPN
gs-3920	256	76	,	,	PUNCT
gs-3920	256	77	encephalopathy	encephalopathy	ADJ
gs-3920	256	78	cutaneous	cutaneous	ADJ
gs-3920	256	79	findings	finding	NOUN
gs-3920	256	80	are	be	AUX
gs-3920	256	81	almost	almost	ADV
gs-3920	256	82	inevitable	inevitable	ADJ
gs-3920	256	83	and	and	CCONJ
gs-3920	256	84	may	may	AUX
gs-3920	256	85	even	even	ADV
gs-3920	256	86	serve	serve	VERB
gs-3920	256	87	as	as	ADP
gs-3920	256	88	the	the	DET
gs-3920	256	89	first	first	ADJ
gs-3920	256	90	clinical	clinical	ADJ
gs-3920	256	91	alert	alert	NOUN
gs-3920	256	92	.	.	PUNCT
gs-3920	257	1	the	the	DET
gs-3920	257	2	liver	liver	NOUN
gs-3920	257	3	was	be	AUX
gs-3920	257	4	a	a	DET
gs-3920	257	5	common	common	ADJ
gs-3920	257	6	target	target	NOUN
gs-3920	257	7	organ	organ	NOUN
gs-3920	257	8	affected	affect	VERB
gs-3920	257	9	,	,	PUNCT
gs-3920	257	10	described	describe	VERB
gs-3920	257	11	in	in	ADP
gs-3920	257	12	over	over	ADP
gs-3920	257	13	60	60	NUM
gs-3920	257	14	%	%	NOUN
gs-3920	257	15	of	of	ADP
gs-3920	257	16	cases	case	NOUN
gs-3920	257	17	,	,	PUNCT
gs-3920	257	18	presenting	present	VERB
gs-3920	257	19	as	as	ADP
gs-3920	257	20	mild	mild	ADJ
gs-3920	257	21	enzyme	enzyme	NOUN
gs-3920	257	22	elevation	elevation	NOUN
gs-3920	257	23	to	to	ADP
gs-3920	257	24	fatal	fatal	ADJ
gs-3920	257	25	hepatic	hepatic	ADJ
gs-3920	257	26	necrosis	necrosis	NOUN
gs-3920	257	27	.	.	PUNCT
gs-3920	258	1	hematologic	hematologic	NOUN
gs-3920	258	2	abnormalities	abnormality	NOUN
gs-3920	258	3	including	include	VERB
gs-3920	258	4	eosinophilia	eosinophilia	PROPN
gs-3920	258	5	and	and	CCONJ
gs-3920	258	6	atypical	atypical	ADJ
gs-3920	258	7	lymphocytosis	lymphocytosis	NOUN
gs-3920	258	8	were	be	AUX
gs-3920	258	9	observed	observe	VERB
gs-3920	258	10	in	in	ADP
gs-3920	258	11	more	more	ADJ
gs-3920	258	12	than	than	ADP
gs-3920	258	13	half	half	NOUN
gs-3920	258	14	of	of	ADP
gs-3920	258	15	the	the	DET
gs-3920	258	16	patients	patient	NOUN
gs-3920	258	17	and	and	CCONJ
gs-3920	258	18	they	they	PRON
gs-3920	258	19	serve	serve	VERB
gs-3920	258	20	as	as	ADP
gs-3920	258	21	a	a	DET
gs-3920	258	22	diagnostic	diagnostic	ADJ
gs-3920	258	23	feature	feature	NOUN
gs-3920	258	24	.	.	PUNCT
gs-3920	259	1	kidney	kidney	NOUN
gs-3920	259	2	and	and	CCONJ
gs-3920	259	3	lung	lung	NOUN
gs-3920	259	4	involvement	involvement	NOUN
gs-3920	259	5	are	be	AUX
gs-3920	259	6	relatively	relatively	ADV
gs-3920	259	7	less	less	ADV
gs-3920	259	8	frequent	frequent	ADJ
gs-3920	259	9	,	,	PUNCT
gs-3920	259	10	but	but	CCONJ
gs-3920	259	11	have	have	VERB
gs-3920	259	12	an	an	DET
gs-3920	259	13	impact	impact	NOUN
gs-3920	259	14	on	on	ADP
gs-3920	259	15	morbidity	morbidity	NOUN
gs-3920	259	16	;	;	PUNCT
gs-3920	259	17	particularly	particularly	ADV
gs-3920	259	18	in	in	ADP
gs-3920	259	19	the	the	DET
gs-3920	259	20	severe	severe	ADJ
gs-3920	259	21	or	or	CCONJ
gs-3920	259	22	delayed	delayed	ADJ
gs-3920	259	23	cases	case	NOUN
gs-3920	259	24	.	.	PUNCT
gs-3920	260	1	uncommon	uncommon	ADJ
gs-3920	260	2	but	but	CCONJ
gs-3920	260	3	particularly	particularly	ADV
gs-3920	260	4	symptomatic	symptomatic	ADJ
gs-3920	260	5	manifestations	manifestation	NOUN
gs-3920	260	6	of	of	ADP
gs-3920	260	7	the	the	DET
gs-3920	260	8	systemic	systemic	ADJ
gs-3920	260	9	nature	nature	NOUN
gs-3920	260	10	of	of	ADP
gs-3920	260	11	dress	dress	NOUN
gs-3920	260	12	(	(	PUNCT
gs-3920	260	13	e.g.	e.g.	ADV
gs-3920	260	14	,	,	PUNCT
gs-3920	260	15	eosinophilic	eosinophilic	ADJ
gs-3920	260	16	colitis	colitis	NOUN
gs-3920	260	17	or	or	CCONJ
gs-3920	260	18	cholecystitis	cholecystitis	NOUN
gs-3920	260	19	as	as	ADV
gs-3920	260	20	well	well	ADV
gs-3920	260	21	as	as	ADP
gs-3920	260	22	neuropsychiatric	neuropsychiatric	ADJ
gs-3920	260	23	symptoms	symptom	NOUN
gs-3920	260	24	)	)	PUNCT
gs-3920	260	25	emphasize	emphasize	VERB
gs-3920	260	26	the	the	DET
gs-3920	260	27	systemic	systemic	ADJ
gs-3920	260	28	involvement	involvement	NOUN
gs-3920	260	29	of	of	ADP
gs-3920	260	30	dress	dress	NOUN
gs-3920	260	31	.	.	PUNCT
gs-3920	261	1	diagnosis	diagnosis	NOUN
gs-3920	261	2	difficulties	difficulty	NOUN
gs-3920	261	3	and	and	CCONJ
gs-3920	261	4	misdiagnosis	misdiagnosis	VERB
gs-3920	261	5	the	the	DET
gs-3920	261	6	diagnosis	diagnosis	NOUN
gs-3920	261	7	of	of	ADP
gs-3920	261	8	dress	dress	NOUN
gs-3920	261	9	continues	continue	VERB
gs-3920	261	10	to	to	PART
gs-3920	261	11	be	be	AUX
gs-3920	261	12	challenging	challenging	AUX
gs-3920	261	13	given	give	VERB
gs-3920	261	14	its	its	PRON
gs-3920	261	15	clinical	clinical	ADJ
gs-3920	261	16	similarity	similarity	NOUN
gs-3920	261	17	with	with	ADP
gs-3920	261	18	infections	infection	NOUN
gs-3920	261	19	,	,	PUNCT
gs-3920	261	20	autoimmune	autoimmune	ADJ
gs-3920	261	21	diseases	disease	NOUN
gs-3920	261	22	,	,	PUNCT
gs-3920	261	23	and	and	CCONJ
gs-3920	261	24	other	other	ADJ
gs-3920	261	25	scars	scar	NOUN
gs-3920	261	26	including	include	VERB
gs-3920	261	27	sjs	sjs	PROPN
gs-3920	261	28	/	/	SYM
gs-3920	261	29	ten	ten	NUM
gs-3920	261	30	.	.	PUNCT
gs-3920	262	1	the	the	DET
gs-3920	262	2	regi	regi	PROPN
gs-3920	262	3	scar	scar	PROPN
gs-3920	262	4	scoring	scoring	NOUN
gs-3920	262	5	system	system	NOUN
gs-3920	262	6	is	be	AUX
gs-3920	262	7	frequently	frequently	ADV
gs-3920	262	8	employed	employ	VERB
gs-3920	262	9	,	,	PUNCT
gs-3920	262	10	but	but	CCONJ
gs-3920	262	11	has	have	VERB
gs-3920	262	12	limitations	limitation	NOUN
gs-3920	262	13	,	,	PUNCT
gs-3920	262	14	particularly	particularly	ADV
gs-3920	262	15	when	when	SCONJ
gs-3920	262	16	used	use	VERB
gs-3920	262	17	for	for	ADP
gs-3920	262	18	skin	skin	NOUN
gs-3920	262	19	of	of	ADP
gs-3920	262	20	colour	colour	NOUN
gs-3920	262	21	and	and	CCONJ
gs-3920	262	22	in	in	ADP
gs-3920	262	23	the	the	DET
gs-3920	262	24	paediatric	paediatric	ADJ
gs-3920	262	25	population	population	NOUN
gs-3920	262	26	,	,	PUNCT
gs-3920	262	27	due	due	ADP
gs-3920	262	28	to	to	ADP
gs-3920	262	29	the	the	DET
gs-3920	262	30	atypical	atypical	ADJ
gs-3920	262	31	or	or	CCONJ
gs-3920	262	32	subtle	subtle	ADJ
gs-3920	262	33	nature	nature	NOUN
gs-3920	262	34	of	of	ADP
gs-3920	262	35	some	some	PRON
gs-3920	262	36	of	of	ADP
gs-3920	262	37	the	the	DET
gs-3920	262	38	presentations	presentation	NOUN
gs-3920	262	39	.	.	PUNCT
gs-3920	263	1	delayed	delay	VERB
gs-3920	263	2	treatment	treatment	NOUN
gs-3920	263	3	and	and	CCONJ
gs-3920	263	4	poor	poor	ADJ
gs-3920	263	5	outcome	outcome	NOUN
gs-3920	263	6	are	be	AUX
gs-3920	263	7	most	most	ADV
gs-3920	263	8	commonly	commonly	ADV
gs-3920	263	9	due	due	ADJ
gs-3920	263	10	to	to	ADP
gs-3920	263	11	misdiagnoses	misdiagnose	NOUN
gs-3920	263	12	.	.	PUNCT
gs-3920	264	1	a	a	DET
gs-3920	264	2	few	few	ADJ
gs-3920	264	3	presentations	presentation	NOUN
gs-3920	264	4	initially	initially	ADV
gs-3920	264	5	suspected	suspect	VERB
gs-3920	264	6	to	to	PART
gs-3920	264	7	be	be	AUX
gs-3920	264	8	viral	viral	ADJ
gs-3920	264	9	infections	infection	NOUN
gs-3920	264	10	or	or	CCONJ
gs-3920	264	11	autoimmune	autoimmune	ADJ
gs-3920	264	12	flares	flare	NOUN
gs-3920	264	13	were	be	AUX
gs-3920	264	14	found	find	VERB
gs-3920	264	15	to	to	PART
gs-3920	264	16	be	be	AUX
gs-3920	264	17	drug	drug	NOUN
gs-3920	264	18	hypersensitivity	hypersensitivity	NOUN
gs-3920	264	19	reactions	reaction	NOUN
gs-3920	264	20	.	.	PUNCT
gs-3920	265	1	heightened	heighten	VERB
gs-3920	265	2	clinical	clinical	ADJ
gs-3920	265	3	suspicion	suspicion	NOUN
gs-3920	265	4	and	and	CCONJ
gs-3920	265	5	a	a	DET
gs-3920	265	6	meticulous	meticulous	ADJ
gs-3920	265	7	drug	drug	NOUN
gs-3920	265	8	history	history	NOUN
gs-3920	265	9	are	be	AUX
gs-3920	265	10	crucial	crucial	ADJ
gs-3920	265	11	in	in	ADP
gs-3920	265	12	enhancing	enhance	VERB
gs-3920	265	13	diagnostic	diagnostic	ADJ
gs-3920	265	14	accuracy	accuracy	NOUN
gs-3920	265	15	.	.	PUNCT
gs-3920	266	1	treatment	treatment	NOUN
gs-3920	266	2	plans	plan	NOUN
gs-3920	266	3	and	and	CCONJ
gs-3920	266	4	results	result	VERB
gs-3920	266	5	therapy	therapy	NOUN
gs-3920	266	6	treatment	treatment	NOUN
gs-3920	266	7	is	be	AUX
gs-3920	266	8	to	to	PART
gs-3920	266	9	stop	stop	VERB
gs-3920	266	10	the	the	DET
gs-3920	266	11	suspected	suspect	VERB
gs-3920	266	12	drug	drug	NOUN
gs-3920	266	13	immediately	immediately	ADV
gs-3920	266	14	.	.	PUNCT
gs-3920	267	1	georgian	georgian	ADJ
gs-3920	267	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	267	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	267	4	ტ.	ტ.	VERB
gs-3920	267	5	7	7	NUM
gs-3920	267	6	n	n	DET
gs-3920	267	7	3	3	NUM
gs-3920	267	8	,	,	PUNCT
gs-3920	267	9	2025	2025	NUM
gs-3920	267	10	197	197	NUM
gs-3920	267	11	table-3	table-3	NUM
gs-3920	267	12	.	.	PUNCT
gs-3920	268	1	summarizes	summarize	NOUN
gs-3920	268	2	therapeutic	therapeutic	ADJ
gs-3920	268	3	approaches	approach	NOUN
gs-3920	268	4	and	and	CCONJ
gs-3920	268	5	reported	report	VERB
gs-3920	268	6	outcomes	outcome	NOUN
gs-3920	268	7	.	.	PUNCT
gs-3920	269	1	treatment	treatment	NOUN
gs-3920	269	2	usage	usage	NOUN
gs-3920	269	3	(	(	PUNCT
gs-3920	269	4	%	%	INTJ
gs-3920	269	5	)	)	PUNCT
gs-3920	269	6	notes	note	NOUN
gs-3920	269	7	on	on	ADP
gs-3920	269	8	effectiveness	effectiveness	NOUN
gs-3920	269	9	drug	drug	NOUN
gs-3920	269	10	withdrawal	withdrawal	NOUN
gs-3920	269	11	100	100	NUM
gs-3920	269	12	%	%	NOUN
gs-3920	269	13	essential	essential	ADJ
gs-3920	269	14	first	first	ADJ
gs-3920	269	15	step	step	NOUN
gs-3920	269	16	,	,	PUNCT
gs-3920	269	17	strongly	strongly	ADV
gs-3920	269	18	correlates	correlate	VERB
gs-3920	269	19	with	with	ADP
gs-3920	269	20	improved	improved	ADJ
gs-3920	269	21	prognosis	prognosis	NOUN
gs-3920	269	22	systemic	systemic	ADJ
gs-3920	269	23	corticosteroids	corticosteroid	NOUN
gs-3920	269	24	>	>	X
gs-3920	269	25	80	80	NUM
gs-3920	269	26	%	%	NOUN
gs-3920	269	27	mainstay	mainstay	NOUN
gs-3920	269	28	of	of	ADP
gs-3920	269	29	therapy	therapy	NOUN
gs-3920	269	30	,	,	PUNCT
gs-3920	269	31	effective	effective	ADJ
gs-3920	269	32	in	in	ADP
gs-3920	269	33	controlling	control	VERB
gs-3920	269	34	systemic	systemic	ADJ
gs-3920	269	35	inflammation	inflammation	NOUN
gs-3920	269	36	immunosuppressants/	immunosuppressants/	NOUN
gs-3920	269	37	ivig	ivig	NOUN
gs-3920	269	38	~10	~10	NOUN
gs-3920	269	39	%	%	NOUN
gs-3920	269	40	used	use	VERB
gs-3920	269	41	in	in	ADP
gs-3920	269	42	steroid	steroid	NOUN
gs-3920	269	43	-	-	PUNCT
gs-3920	269	44	refractory	refractory	NOUN
gs-3920	269	45	or	or	CCONJ
gs-3920	269	46	severe	severe	ADJ
gs-3920	269	47	cases	case	NOUN
gs-3920	269	48	supportive	supportive	ADJ
gs-3920	269	49	/	/	SYM
gs-3920	269	50	icu	icu	PROPN
gs-3920	269	51	care	care	NOUN
gs-3920	269	52	select	select	ADJ
gs-3920	269	53	cases	case	NOUN
gs-3920	269	54	required	require	VERB
gs-3920	269	55	in	in	ADP
gs-3920	269	56	multi	multi	ADJ
gs-3920	269	57	-	-	ADJ
gs-3920	269	58	organ	organ	ADJ
gs-3920	269	59	failure	failure	NOUN
gs-3920	269	60	or	or	CCONJ
gs-3920	269	61	fulminant	fulminant	ADJ
gs-3920	269	62	presentations	presentation	NOUN
gs-3920	269	63	early	early	ADJ
gs-3920	269	64	administration	administration	NOUN
gs-3920	269	65	of	of	ADP
gs-3920	269	66	corticosteroid	corticosteroid	NOUN
gs-3920	269	67	and	and	CCONJ
gs-3920	269	68	withdrawal	withdrawal	NOUN
gs-3920	269	69	of	of	ADP
gs-3920	269	70	causative	causative	ADJ
gs-3920	269	71	agent	agent	NOUN
gs-3920	269	72	is	be	AUX
gs-3920	269	73	significantly	significantly	ADV
gs-3920	269	74	associated	associate	VERB
gs-3920	269	75	with	with	ADP
gs-3920	269	76	good	good	ADJ
gs-3920	269	77	outcomes	outcome	NOUN
gs-3920	269	78	by	by	ADP
gs-3920	269	79	limiting	limit	VERB
gs-3920	269	80	progression	progression	NOUN
gs-3920	269	81	to	to	PART
gs-3920	269	82	organ	organ	NOUN
gs-3920	269	83	failure	failure	NOUN
gs-3920	269	84	.	.	PUNCT
gs-3920	270	1	in	in	ADP
gs-3920	270	2	those	those	PRON
gs-3920	270	3	with	with	ADP
gs-3920	270	4	recalcitrant	recalcitrant	ADJ
gs-3920	270	5	or	or	CCONJ
gs-3920	270	6	severe	severe	ADJ
gs-3920	270	7	disease	disease	NOUN
gs-3920	270	8	,	,	PUNCT
gs-3920	270	9	second	second	ADJ
gs-3920	270	10	-	-	PUNCT
gs-3920	270	11	line	line	NOUN
gs-3920	270	12	therapies	therapy	NOUN
gs-3920	270	13	including	include	VERB
gs-3920	270	14	intravenous	intravenous	ADJ
gs-3920	270	15	immunoglobulin	immunoglobulin	NOUN
gs-3920	270	16	(	(	PUNCT
gs-3920	270	17	ivig	ivig	NOUN
gs-3920	270	18	)	)	PUNCT
gs-3920	270	19	and	and	CCONJ
gs-3920	270	20	other	other	ADJ
gs-3920	270	21	immunosuppressants	immunosuppressant	NOUN
gs-3920	270	22	are	be	AUX
gs-3920	270	23	used	use	VERB
gs-3920	270	24	,	,	PUNCT
gs-3920	270	25	based	base	VERB
gs-3920	270	26	on	on	ADP
gs-3920	270	27	limited	limited	ADJ
gs-3920	270	28	controlled	control	VERB
gs-3920	270	29	evidence	evidence	NOUN
gs-3920	270	30	.	.	PUNCT
gs-3920	271	1	fatal	fatal	ADJ
gs-3920	271	2	outcomes	outcome	NOUN
gs-3920	271	3	have	have	AUX
gs-3920	271	4	been	be	AUX
gs-3920	271	5	described	describe	VERB
gs-3920	271	6	despite	despite	SCONJ
gs-3920	271	7	therapy	therapy	NOUN
gs-3920	271	8	,	,	PUNCT
gs-3920	271	9	especially	especially	ADV
gs-3920	271	10	for	for	ADP
gs-3920	271	11	patients	patient	NOUN
gs-3920	271	12	with	with	ADP
gs-3920	271	13	hepatic	hepatic	ADJ
gs-3920	271	14	failure	failure	NOUN
gs-3920	271	15	or	or	CCONJ
gs-3920	271	16	diagnostic	diagnostic	ADJ
gs-3920	271	17	delay	delay	NOUN
gs-3920	271	18	.	.	PUNCT
gs-3920	272	1	relapses	relapse	NOUN
gs-3920	272	2	on	on	ADP
gs-3920	272	3	tapering	taper	VERB
gs-3920	272	4	corticosteroids	corticosteroid	NOUN
gs-3920	272	5	demonstrate	demonstrate	VERB
gs-3920	272	6	the	the	DET
gs-3920	272	7	necessity	necessity	NOUN
gs-3920	272	8	for	for	ADP
gs-3920	272	9	careful	careful	ADJ
gs-3920	272	10	monitoring	monitoring	NOUN
gs-3920	272	11	.	.	PUNCT
gs-3920	273	1	duration	duration	NOUN
gs-3920	273	2	and	and	CCONJ
gs-3920	273	3	prognosis	prognosis	VERB
gs-3920	273	4	the	the	DET
gs-3920	273	5	extent	extent	NOUN
gs-3920	273	6	of	of	ADP
gs-3920	273	7	illness	illness	NOUN
gs-3920	273	8	duration	duration	NOUN
gs-3920	273	9	varied	varied	ADJ
gs-3920	273	10	,	,	PUNCT
gs-3920	273	11	with	with	ADP
gs-3920	273	12	some	some	DET
gs-3920	273	13	patients	patient	NOUN
gs-3920	273	14	having	have	VERB
gs-3920	273	15	persistent	persistent	ADJ
gs-3920	273	16	illness	illness	NOUN
gs-3920	273	17	lasting	last	VERB
gs-3920	273	18	for	for	ADP
gs-3920	273	19	periods	period	NOUN
gs-3920	273	20	up	up	ADP
gs-3920	273	21	to	to	ADP
gs-3920	273	22	decades	decade	NOUN
gs-3920	273	23	,	,	PUNCT
gs-3920	273	24	but	but	CCONJ
gs-3920	273	25	also	also	ADV
gs-3920	273	26	for	for	ADP
gs-3920	273	27	more	more	ADV
gs-3920	273	28	extended	extended	ADJ
gs-3920	273	29	periods	period	NOUN
gs-3920	273	30	than	than	ADP
gs-3920	273	31	six	six	NUM
gs-3920	273	32	months	month	NOUN
gs-3920	273	33	,	,	PUNCT
gs-3920	273	34	indicating	indicate	VERB
gs-3920	273	35	either	either	CCONJ
gs-3920	273	36	chronic	chronic	ADJ
gs-3920	273	37	immune	immune	ADJ
gs-3920	273	38	activation	activation	NOUN
gs-3920	273	39	or	or	CCONJ
gs-3920	273	40	incomplete	incomplete	ADJ
gs-3920	273	41	resolution	resolution	NOUN
gs-3920	273	42	.	.	PUNCT
gs-3920	274	1	early	early	ADJ
gs-3920	274	2	diagnosis	diagnosis	NOUN
gs-3920	274	3	,	,	PUNCT
gs-3920	274	4	drug	drug	NOUN
gs-3920	274	5	withdrawal	withdrawal	NOUN
gs-3920	274	6	in	in	ADP
gs-3920	274	7	time	time	NOUN
gs-3920	274	8	and	and	CCONJ
gs-3920	274	9	receiving	receive	VERB
gs-3920	274	10	corticosteroid	corticosteroid	NOUN
gs-3920	274	11	were	be	AUX
gs-3920	274	12	strong	strong	ADJ
gs-3920	274	13	predictors	predictor	NOUN
gs-3920	274	14	for	for	ADP
gs-3920	274	15	better	well	ADJ
gs-3920	274	16	prognosis	prognosis	NOUN
gs-3920	274	17	.	.	PUNCT
gs-3920	275	1	geographic	geographic	ADJ
gs-3920	275	2	and	and	CCONJ
gs-3920	275	3	demographic	demographic	ADJ
gs-3920	275	4	variability	variability	NOUN
gs-3920	275	5	the	the	DET
gs-3920	275	6	case	case	NOUN
gs-3920	275	7	series	series	NOUN
gs-3920	275	8	of	of	ADP
gs-3920	275	9	dress	dress	NOUN
gs-3920	275	10	have	have	AUX
gs-3920	275	11	been	be	AUX
gs-3920	275	12	documented	document	VERB
gs-3920	275	13	all	all	ADV
gs-3920	275	14	over	over	ADP
gs-3920	275	15	the	the	DET
gs-3920	275	16	world	world	NOUN
gs-3920	275	17	;	;	PUNCT
gs-3920	275	18	asia	asia	PROPN
gs-3920	275	19	,	,	PUNCT
gs-3920	275	20	europe	europe	PROPN
gs-3920	275	21	,	,	PUNCT
gs-3920	275	22	africa	africa	PROPN
gs-3920	275	23	and	and	CCONJ
gs-3920	275	24	north	north	PROPN
gs-3920	275	25	america	america	PROPN
gs-3920	275	26	.	.	PUNCT
gs-3920	276	1	adult	adult	NOUN
gs-3920	276	2	and	and	CCONJ
gs-3920	276	3	paediatric	paediatric	ADJ
gs-3920	276	4	patients	patient	NOUN
gs-3920	276	5	are	be	AUX
gs-3920	276	6	affected	affect	VERB
gs-3920	276	7	,	,	PUNCT
gs-3920	276	8	but	but	CCONJ
gs-3920	276	9	diagnosis	diagnosis	NOUN
gs-3920	276	10	can	can	AUX
gs-3920	276	11	be	be	AUX
gs-3920	276	12	problematic	problematic	ADJ
gs-3920	276	13	in	in	ADP
gs-3920	276	14	children	child	NOUN
gs-3920	276	15	.	.	PUNCT
gs-3920	277	1	mild	mild	ADJ
gs-3920	277	2	female	female	ADJ
gs-3920	277	3	predomination	predomination	NOUN
gs-3920	277	4	was	be	AUX
gs-3920	277	5	noted	note	VERB
gs-3920	277	6	in	in	ADP
gs-3920	277	7	some	some	DET
gs-3920	277	8	series	series	NOUN
gs-3920	277	9	,	,	PUNCT
gs-3920	277	10	but	but	CCONJ
gs-3920	277	11	the	the	DET
gs-3920	277	12	data	datum	NOUN
gs-3920	277	13	are	be	AUX
gs-3920	277	14	conflicting	conflict	VERB
gs-3920	277	15	.	.	PUNCT
gs-3920	278	1	controversy	controversy	NOUN
gs-3920	278	2	regarding	regard	VERB
gs-3920	278	3	the	the	DET
gs-3920	278	4	use	use	NOUN
gs-3920	278	5	of	of	ADP
gs-3920	278	6	corticosteroids	corticosteroid	NOUN
gs-3920	278	7	the	the	DET
gs-3920	278	8	treatment	treatment	NOUN
gs-3920	278	9	of	of	ADP
gs-3920	278	10	choice	choice	NOUN
gs-3920	278	11	is	be	AUX
gs-3920	278	12	corticosteroids	corticosteroid	NOUN
gs-3920	278	13	,	,	PUNCT
gs-3920	278	14	but	but	CCONJ
gs-3920	278	15	their	their	PRON
gs-3920	278	16	usefulness	usefulness	NOUN
gs-3920	278	17	in	in	ADP
gs-3920	278	18	dress	dress	NOUN
gs-3920	278	19	is	be	AUX
gs-3920	278	20	debated	debate	VERB
gs-3920	278	21	.	.	PUNCT
gs-3920	279	1	some	some	DET
gs-3920	279	2	reports	report	NOUN
gs-3920	279	3	have	have	AUX
gs-3920	279	4	shown	show	VERB
gs-3920	279	5	that	that	SCONJ
gs-3920	279	6	steroid	steroid	NOUN
gs-3920	279	7	-	-	PUNCT
gs-3920	279	8	induced	induce	VERB
gs-3920	279	9	immunosuppression	immunosuppression	NOUN
gs-3920	279	10	could	could	AUX
gs-3920	279	11	enhance	enhance	VERB
gs-3920	279	12	the	the	DET
gs-3920	279	13	reactivation	reactivation	NOUN
gs-3920	279	14	of	of	ADP
gs-3920	279	15	latent	latent	NOUN
gs-3920	279	16	viruses	virus	NOUN
gs-3920	279	17	,	,	PUNCT
gs-3920	279	18	such	such	ADJ
gs-3920	279	19	as	as	ADP
gs-3920	279	20	human	human	ADJ
gs-3920	279	21	herpesvirus	herpesvirus	NOUN
gs-3920	279	22	6	6	NUM
gs-3920	279	23	(	(	PUNCT
gs-3920	279	24	hhv-6	hhv-6	NOUN
gs-3920	279	25	)	)	PUNCT
gs-3920	279	26	,	,	PUNCT
gs-3920	279	27	which	which	PRON
gs-3920	279	28	could	could	AUX
gs-3920	279	29	aggravate	aggravate	VERB
gs-3920	279	30	georgian	georgian	ADJ
gs-3920	279	31	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	279	32	მეცნიერები	მეცნიერები	NOUN
gs-3920	279	33	ტ.	ტ.	VERB
gs-3920	279	34	7	7	NUM
gs-3920	279	35	n	n	DET
gs-3920	279	36	3	3	NUM
gs-3920	279	37	,	,	PUNCT
gs-3920	279	38	2025	2025	NUM
gs-3920	279	39	198	198	NUM
gs-3920	279	40	the	the	DET
gs-3920	279	41	severity	severity	NOUN
gs-3920	279	42	of	of	ADP
gs-3920	279	43	the	the	DET
gs-3920	279	44	disease	disease	NOUN
gs-3920	279	45	.	.	PUNCT
gs-3920	280	1	in	in	ADP
gs-3920	280	2	contrast	contrast	NOUN
gs-3920	280	3	,	,	PUNCT
gs-3920	280	4	corticosteroids	corticosteroid	NOUN
gs-3920	280	5	can	can	AUX
gs-3920	280	6	secondarily	secondarily	ADV
gs-3920	280	7	quiet	quiet	VERB
gs-3920	280	8	down	down	ADP
gs-3920	280	9	the	the	DET
gs-3920	280	10	excessive	excessive	ADJ
gs-3920	280	11	host	host	NOUN
gs-3920	280	12	immune	immune	ADJ
gs-3920	280	13	response	response	NOUN
gs-3920	280	14	that	that	PRON
gs-3920	280	15	contributes	contribute	VERB
gs-3920	280	16	to	to	ADP
gs-3920	280	17	tissue	tissue	NOUN
gs-3920	280	18	injury	injury	NOUN
gs-3920	280	19	.	.	PUNCT
gs-3920	281	1	these	these	DET
gs-3920	281	2	conflicting	conflicting	ADJ
gs-3920	281	3	effects	effect	NOUN
gs-3920	281	4	require	require	VERB
gs-3920	281	5	careful	careful	ADJ
gs-3920	281	6	patient	patient	NOUN
gs-3920	281	7	selection	selection	NOUN
gs-3920	281	8	,	,	PUNCT
gs-3920	281	9	close	close	ADJ
gs-3920	281	10	monitoring	monitoring	NOUN
gs-3920	281	11	and	and	CCONJ
gs-3920	281	12	potentially	potentially	ADV
gs-3920	281	13	antiviral	antiviral	ADJ
gs-3920	281	14	therapy	therapy	NOUN
gs-3920	281	15	in	in	ADP
gs-3920	281	16	case	case	NOUN
gs-3920	281	17	of	of	ADP
gs-3920	281	18	proven	prove	VERB
gs-3920	281	19	viral	viral	ADJ
gs-3920	281	20	reactivation	reactivation	NOUN
gs-3920	281	21	.	.	PUNCT
gs-3920	282	1	more	more	ADV
gs-3920	282	2	detailed	detailed	ADJ
gs-3920	282	3	studies	study	NOUN
gs-3920	282	4	are	be	AUX
gs-3920	282	5	needed	need	VERB
gs-3920	282	6	to	to	PART
gs-3920	282	7	define	define	VERB
gs-3920	282	8	the	the	DET
gs-3920	282	9	optimal	optimal	ADJ
gs-3920	282	10	dose	dose	NOUN
gs-3920	282	11	of	of	ADP
gs-3920	282	12	steroids	steroid	NOUN
gs-3920	282	13	in	in	ADP
gs-3920	282	14	order	order	NOUN
gs-3920	282	15	to	to	PART
gs-3920	282	16	provide	provide	VERB
gs-3920	282	17	the	the	DET
gs-3920	282	18	most	most	ADJ
gs-3920	282	19	advantage	advantage	NOUN
gs-3920	282	20	with	with	ADP
gs-3920	282	21	the	the	DET
gs-3920	282	22	least	least	ADJ
gs-3920	282	23	side	side	ADJ
gs-3920	282	24	effect	effect	NOUN
gs-3920	282	25	.	.	PUNCT
gs-3920	283	1	for	for	ADP
gs-3920	283	2	the	the	DET
gs-3920	283	3	time	time	NOUN
gs-3920	283	4	being	be	AUX
gs-3920	283	5	,	,	PUNCT
gs-3920	283	6	clinical	clinical	ADJ
gs-3920	283	7	judgment	judgment	NOUN
gs-3920	283	8	and	and	CCONJ
gs-3920	283	9	watchful	watchful	ADJ
gs-3920	283	10	waiting	waiting	NOUN
gs-3920	283	11	are	be	AUX
gs-3920	283	12	still	still	ADV
gs-3920	283	13	indispensable	indispensable	ADJ
gs-3920	283	14	.	.	PUNCT
gs-3920	284	1	new	new	ADJ
gs-3920	284	2	steroid	steroid	NOUN
gs-3920	284	3	-	-	PUNCT
gs-3920	284	4	sparing	spare	VERB
gs-3920	284	5	drugs	drug	NOUN
gs-3920	284	6	corticosteroid	corticosteroid	NOUN
gs-3920	284	7	-	-	PUNCT
gs-3920	284	8	sparing	spare	VERB
gs-3920	284	9	agents	agent	NOUN
gs-3920	284	10	are	be	AUX
gs-3920	284	11	being	be	AUX
gs-3920	284	12	investigated	investigate	VERB
gs-3920	284	13	in	in	ADP
gs-3920	284	14	an	an	DET
gs-3920	284	15	effort	effort	NOUN
gs-3920	284	16	to	to	PART
gs-3920	284	17	reduce	reduce	VERB
gs-3920	284	18	corticosteroid	corticosteroid	ADJ
gs-3920	284	19	toxicity	toxicity	NOUN
gs-3920	284	20	.	.	PUNCT
gs-3920	285	1	immunosuppressive	immunosuppressive	ADJ
gs-3920	285	2	drugs	drug	NOUN
gs-3920	285	3	,	,	PUNCT
gs-3920	285	4	such	such	ADJ
gs-3920	285	5	as	as	ADP
gs-3920	285	6	cyclosporine	cyclosporine	NOUN
gs-3920	285	7	,	,	PUNCT
gs-3920	285	8	tacrolimus	tacrolimus	NOUN
gs-3920	285	9	,	,	PUNCT
gs-3920	285	10	and	and	CCONJ
gs-3920	285	11	anti	anti	ADJ
gs-3920	285	12	-	-	ADJ
gs-3920	285	13	interleukins	interleukins	ADJ
gs-3920	285	14	antibodies	antibody	NOUN
gs-3920	285	15	(	(	PUNCT
gs-3920	285	16	e.g.	e.g.	ADJ
gs-3920	285	17	,	,	PUNCT
gs-3920	285	18	il-6	il-6	NOUN
gs-3920	285	19	inhibitors	inhibitor	NOUN
gs-3920	285	20	,	,	PUNCT
gs-3920	285	21	including	include	VERB
gs-3920	285	22	tocilizumab	tocilizumab	NOUN
gs-3920	285	23	)	)	PUNCT
gs-3920	285	24	have	have	AUX
gs-3920	285	25	been	be	AUX
gs-3920	285	26	reported	report	VERB
gs-3920	285	27	to	to	PART
gs-3920	285	28	be	be	AUX
gs-3920	285	29	promising	promise	VERB
gs-3920	285	30	in	in	ADP
gs-3920	285	31	pilot	pilot	NOUN
gs-3920	285	32	reports	report	NOUN
gs-3920	285	33	.	.	PUNCT
gs-3920	286	1	they	they	PRON
gs-3920	286	2	may	may	AUX
gs-3920	286	3	be	be	AUX
gs-3920	286	4	especially	especially	ADV
gs-3920	286	5	beneficial	beneficial	ADJ
gs-3920	286	6	in	in	ADP
gs-3920	286	7	steroid	steroid	NOUN
gs-3920	286	8	-	-	PUNCT
gs-3920	286	9	resistant	resistant	ADJ
gs-3920	286	10	or	or	CCONJ
gs-3920	286	11	recurrent	recurrent	ADJ
gs-3920	286	12	patients	patient	NOUN
gs-3920	286	13	.	.	PUNCT
gs-3920	287	1	nevertheless	nevertheless	ADV
gs-3920	287	2	,	,	PUNCT
gs-3920	287	3	evidence	evidence	NOUN
gs-3920	287	4	is	be	AUX
gs-3920	287	5	mostly	mostly	ADV
gs-3920	287	6	based	base	VERB
gs-3920	287	7	on	on	ADP
gs-3920	287	8	case	case	NOUN
gs-3920	287	9	reports	report	NOUN
gs-3920	287	10	and	and	CCONJ
gs-3920	287	11	small	small	ADJ
gs-3920	287	12	series	series	NOUN
gs-3920	287	13	.	.	PUNCT
gs-3920	288	1	their	their	PRON
gs-3920	288	2	high	high	ADJ
gs-3920	288	3	costs	cost	NOUN
gs-3920	288	4	,	,	PUNCT
gs-3920	288	5	side	side	ADJ
gs-3920	288	6	effect	effect	NOUN
gs-3920	288	7	profiles	profile	NOUN
gs-3920	288	8	,	,	PUNCT
gs-3920	288	9	and	and	CCONJ
gs-3920	288	10	lack	lack	NOUN
gs-3920	288	11	of	of	ADP
gs-3920	288	12	standardized	standardized	ADJ
gs-3920	288	13	guidelines	guideline	NOUN
gs-3920	288	14	currently	currently	ADV
gs-3920	288	15	prohibit	prohibit	VERB
gs-3920	288	16	their	their	PRON
gs-3920	288	17	routine	routine	ADJ
gs-3920	288	18	use	use	NOUN
gs-3920	288	19	.	.	PUNCT
gs-3920	289	1	prospective	prospective	ADJ
gs-3920	289	2	,	,	PUNCT
gs-3920	289	3	controlled	control	VERB
gs-3920	289	4	trials	trial	NOUN
gs-3920	289	5	will	will	AUX
gs-3920	289	6	be	be	AUX
gs-3920	289	7	required	require	VERB
gs-3920	289	8	to	to	PART
gs-3920	289	9	demonstrate	demonstrate	VERB
gs-3920	289	10	efficacy	efficacy	NOUN
gs-3920	289	11	,	,	PUNCT
gs-3920	289	12	safety	safety	NOUN
gs-3920	289	13	,	,	PUNCT
gs-3920	289	14	and	and	CCONJ
gs-3920	289	15	the	the	DET
gs-3920	289	16	best	good	ADJ
gs-3920	289	17	place	place	NOUN
gs-3920	289	18	in	in	ADP
gs-3920	289	19	treatment	treatment	NOUN
gs-3920	289	20	.	.	PUNCT
gs-3920	290	1	antiviral	antiviral	ADJ
gs-3920	290	2	agents	agent	NOUN
gs-3920	290	3	and	and	CCONJ
gs-3920	290	4	hhv-6	hhv-6	NOUN
gs-3920	290	5	reactivation	reactivation	NOUN
gs-3920	290	6	reactivation	reactivation	NOUN
gs-3920	290	7	of	of	ADP
gs-3920	290	8	hhv-6	hhv-6	NOUN
gs-3920	290	9	is	be	AUX
gs-3920	290	10	often	often	ADV
gs-3920	290	11	observed	observe	VERB
gs-3920	290	12	in	in	ADP
gs-3920	290	13	dress	dress	NOUN
gs-3920	290	14	and	and	CCONJ
gs-3920	290	15	it	it	PRON
gs-3920	290	16	is	be	AUX
gs-3920	290	17	believed	believe	VERB
gs-3920	290	18	that	that	SCONJ
gs-3920	290	19	it	it	PRON
gs-3920	290	20	may	may	AUX
gs-3920	290	21	contribute	contribute	VERB
gs-3920	290	22	to	to	ADP
gs-3920	290	23	the	the	DET
gs-3920	290	24	severity	severity	NOUN
gs-3920	290	25	of	of	ADP
gs-3920	290	26	the	the	DET
gs-3920	290	27	disease	disease	NOUN
gs-3920	290	28	and	and	CCONJ
gs-3920	290	29	prolongation	prolongation	NOUN
gs-3920	290	30	of	of	ADP
gs-3920	290	31	clinical	clinical	ADJ
gs-3920	290	32	course	course	NOUN
gs-3920	290	33	.	.	PUNCT
gs-3920	291	1	such	such	ADJ
gs-3920	291	2	activation	activation	NOUN
gs-3920	291	3	of	of	ADP
gs-3920	291	4	the	the	DET
gs-3920	291	5	virus	virus	NOUN
gs-3920	291	6	is	be	AUX
gs-3920	291	7	attributed	attribute	VERB
gs-3920	291	8	to	to	ADP
gs-3920	291	9	loss	loss	NOUN
gs-3920	291	10	of	of	ADP
gs-3920	291	11	immune	immune	ADJ
gs-3920	291	12	control	control	NOUN
gs-3920	291	13	and	and	CCONJ
gs-3920	291	14	potentially	potentially	ADV
gs-3920	291	15	immunosuppression	immunosuppression	NOUN
gs-3920	291	16	.	.	PUNCT
gs-3920	292	1	the	the	DET
gs-3920	292	2	benefit	benefit	NOUN
gs-3920	292	3	of	of	ADP
gs-3920	292	4	antiviral	antiviral	ADJ
gs-3920	292	5	drugs	drug	NOUN
gs-3920	292	6	like	like	ADP
gs-3920	292	7	ganciclovir	ganciclovir	PROPN
gs-3920	292	8	has	have	AUX
gs-3920	292	9	not	not	PART
gs-3920	292	10	yet	yet	ADV
gs-3920	292	11	been	be	AUX
gs-3920	292	12	defined	define	VERB
gs-3920	292	13	in	in	ADP
gs-3920	292	14	multicentre	multicentre	NOUN
gs-3920	292	15	trials	trial	NOUN
gs-3920	292	16	.	.	PUNCT
gs-3920	293	1	applying	apply	VERB
gs-3920	293	2	routine	routine	ADJ
gs-3920	293	3	hhv-6	hhv-6	NOUN
gs-3920	293	4	screening	screening	NOUN
gs-3920	293	5	can	can	AUX
gs-3920	293	6	contribute	contribute	VERB
gs-3920	293	7	to	to	ADP
gs-3920	293	8	the	the	DET
gs-3920	293	9	identification	identification	NOUN
gs-3920	293	10	of	of	ADP
gs-3920	293	11	patients	patient	NOUN
gs-3920	293	12	eligible	eligible	ADJ
gs-3920	293	13	for	for	ADP
gs-3920	293	14	targeted	target	VERB
gs-3920	293	15	antiviral	antiviral	ADJ
gs-3920	293	16	therapy	therapy	NOUN
gs-3920	293	17	which	which	PRON
gs-3920	293	18	subsequently	subsequently	ADV
gs-3920	293	19	may	may	AUX
gs-3920	293	20	limit	limit	VERB
gs-3920	293	21	complications	complication	NOUN
gs-3920	293	22	and	and	CCONJ
gs-3920	293	23	relapse	relapse	NOUN
gs-3920	293	24	.	.	PUNCT
gs-3920	294	1	immunomodulation	immunomodulation	NOUN
gs-3920	294	2	techniques	technique	NOUN
gs-3920	294	3	and	and	CCONJ
gs-3920	294	4	risk	risk	NOUN
gs-3920	294	5	stratification	stratification	NOUN
gs-3920	294	6	immunologic	immunologic	ADJ
gs-3920	294	7	developments	development	NOUN
gs-3920	294	8	have	have	AUX
gs-3920	294	9	provided	provide	VERB
gs-3920	294	10	further	further	ADJ
gs-3920	294	11	opportunities	opportunity	NOUN
gs-3920	294	12	for	for	ADP
gs-3920	294	13	targeted	target	VERB
gs-3920	294	14	immunomodulation	immunomodulation	NOUN
gs-3920	294	15	.	.	PUNCT
gs-3920	295	1	blocking	block	VERB
gs-3920	295	2	the	the	DET
gs-3920	295	3	cytokine	cytokine	NOUN
gs-3920	295	4	signalling	signal	VERB
gs-3920	295	5	pathways	pathway	NOUN
gs-3920	295	6	involved	involve	VERB
gs-3920	295	7	in	in	ADP
gs-3920	295	8	the	the	DET
gs-3920	295	9	pathogenesis	pathogenesis	NOUN
gs-3920	295	10	of	of	ADP
gs-3920	295	11	dress	dress	NOUN
gs-3920	295	12	syndrome	syndrome	NOUN
gs-3920	295	13	,	,	PUNCT
gs-3920	295	14	e.g.	e.g.	ADV
gs-3920	295	15	il-6	il-6	NUM
gs-3920	295	16	and	and	CCONJ
gs-3920	295	17	tnf	tnf	PROPN
gs-3920	295	18	-	-	PUNCT
gs-3920	295	19	α	α	PROPN
gs-3920	295	20	may	may	AUX
gs-3920	295	21	enable	enable	VERB
gs-3920	295	22	a	a	DET
gs-3920	295	23	personalised	personalised	ADJ
gs-3920	295	24	medicine	medicine	NOUN
gs-3920	295	25	approach	approach	NOUN
gs-3920	295	26	.	.	PUNCT
gs-3920	296	1	genetic	genetic	ADJ
gs-3920	296	2	and	and	CCONJ
gs-3920	296	3	immune	immune	ADJ
gs-3920	296	4	markers	marker	NOUN
gs-3920	296	5	should	should	AUX
gs-3920	296	6	allow	allow	VERB
gs-3920	296	7	early	early	ADJ
gs-3920	296	8	risk	risk	NOUN
gs-3920	296	9	prediction	prediction	NOUN
gs-3920	296	10	,	,	PUNCT
gs-3920	296	11	tailoring	tailor	VERB
gs-3920	296	12	aggressive	aggressive	ADJ
gs-3920	296	13	therapy	therapy	NOUN
gs-3920	296	14	to	to	ADP
gs-3920	296	15	high	high	ADJ
gs-3920	296	16	-	-	PUNCT
gs-3920	296	17	risk	risk	NOUN
gs-3920	296	18	patients	patient	NOUN
gs-3920	296	19	and	and	CCONJ
gs-3920	296	20	preventing	prevent	VERB
gs-3920	296	21	over	over	ADP
gs-3920	296	22	-	-	PUNCT
gs-3920	296	23	treatment	treatment	NOUN
gs-3920	296	24	of	of	ADP
gs-3920	296	25	low	low	ADJ
gs-3920	296	26	-	-	PUNCT
gs-3920	296	27	risk	risk	NOUN
gs-3920	296	28	disease	disease	NOUN
gs-3920	296	29	.	.	PUNCT
gs-3920	297	1	work	work	NOUN
gs-3920	297	2	on	on	ADP
gs-3920	297	3	risk	risk	NOUN
gs-3920	297	4	scores	score	NOUN
gs-3920	297	5	incorporating	incorporate	VERB
gs-3920	297	6	clinical	clinical	ADJ
gs-3920	297	7	,	,	PUNCT
gs-3920	297	8	genetic	genetic	ADJ
gs-3920	297	9	and	and	CCONJ
gs-3920	297	10	virological	virological	ADJ
gs-3920	297	11	factors	factor	NOUN
gs-3920	297	12	is	be	AUX
gs-3920	297	13	ongoing	ongoing	ADJ
gs-3920	297	14	.	.	PUNCT
gs-3920	298	1	personalized	personalized	ADJ
gs-3920	298	2	approaches	approach	NOUN
gs-3920	298	3	of	of	ADP
gs-3920	298	4	this	this	DET
gs-3920	298	5	kind	kind	NOUN
gs-3920	298	6	have	have	VERB
gs-3920	298	7	the	the	DET
gs-3920	298	8	potential	potential	NOUN
gs-3920	298	9	to	to	PART
gs-3920	298	10	enhance	enhance	VERB
gs-3920	298	11	the	the	DET
gs-3920	298	12	effectiveness	effectiveness	NOUN
gs-3920	298	13	and	and	CCONJ
gs-3920	298	14	minimize	minimize	VERB
gs-3920	298	15	the	the	DET
gs-3920	298	16	side	side	NOUN
gs-3920	298	17	effects	effect	NOUN
gs-3920	298	18	.	.	PUNCT
gs-3920	299	1	immunopathogenesis	immunopathogenesis	NOUN
gs-3920	299	2	and	and	CCONJ
gs-3920	299	3	mechanistic	mechanistic	ADJ
gs-3920	299	4	insights	insight	NOUN
gs-3920	299	5	the	the	DET
gs-3920	299	6	pathophysiological	pathophysiological	ADJ
gs-3920	299	7	cascade	cascade	NOUN
gs-3920	299	8	underlying	underlie	VERB
gs-3920	299	9	dress	dress	NOUN
gs-3920	299	10	syndrome	syndrome	NOUN
gs-3920	299	11	is	be	AUX
gs-3920	299	12	multifactorial	multifactorial	ADJ
gs-3920	299	13	and	and	CCONJ
gs-3920	299	14	not	not	PART
gs-3920	299	15	fully	fully	ADV
gs-3920	299	16	elucidated	elucidated	ADJ
gs-3920	299	17	,	,	PUNCT
gs-3920	299	18	yet	yet	CCONJ
gs-3920	299	19	compelling	compelling	ADJ
gs-3920	299	20	evidence	evidence	NOUN
gs-3920	299	21	supports	support	VERB
gs-3920	299	22	the	the	DET
gs-3920	299	23	interplay	interplay	NOUN
gs-3920	299	24	of	of	ADP
gs-3920	299	25	pharmacologic	pharmacologic	ADJ
gs-3920	299	26	,	,	PUNCT
gs-3920	299	27	georgian	georgian	ADJ
gs-3920	299	28	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	299	29	მეცნიერები	მეცნიერები	NOUN
gs-3920	299	30	ტ.	ტ.	VERB
gs-3920	299	31	7	7	NUM
gs-3920	299	32	n	n	PRON
gs-3920	299	33	3	3	NUM
gs-3920	299	34	,	,	PUNCT
gs-3920	299	35	2025	2025	NUM
gs-3920	299	36	199	199	NUM
gs-3920	299	37	genetic	genetic	ADJ
gs-3920	299	38	,	,	PUNCT
gs-3920	299	39	viral	viral	ADJ
gs-3920	299	40	,	,	PUNCT
gs-3920	299	41	and	and	CCONJ
gs-3920	299	42	immune	immune	ADJ
gs-3920	299	43	mechanisms	mechanism	NOUN
gs-3920	299	44	.	.	PUNCT
gs-3920	300	1	at	at	ADP
gs-3920	300	2	the	the	DET
gs-3920	300	3	cellular	cellular	ADJ
gs-3920	300	4	level	level	NOUN
gs-3920	300	5	,	,	PUNCT
gs-3920	300	6	the	the	DET
gs-3920	300	7	syndrome	syndrome	NOUN
gs-3920	300	8	appears	appear	VERB
gs-3920	300	9	to	to	PART
gs-3920	300	10	be	be	AUX
gs-3920	300	11	driven	drive	VERB
gs-3920	300	12	by	by	ADP
gs-3920	300	13	delayed	delay	VERB
gs-3920	300	14	-	-	PUNCT
gs-3920	300	15	type	type	NOUN
gs-3920	300	16	hypersensitivity	hypersensitivity	NOUN
gs-3920	300	17	reactions	reaction	NOUN
gs-3920	300	18	(	(	PUNCT
gs-3920	300	19	type	type	NOUN
gs-3920	300	20	ivb	ivb	NOUN
gs-3920	300	21	)	)	PUNCT
gs-3920	300	22	,	,	PUNCT
gs-3920	300	23	orchestrated	orchestrate	VERB
gs-3920	300	24	by	by	ADP
gs-3920	300	25	activated	activate	VERB
gs-3920	300	26	cd4	cd4	PROPN
gs-3920	300	27	+	+	PROPN
gs-3920	300	28	and	and	CCONJ
gs-3920	300	29	cd8	cd8	PROPN
gs-3920	300	30	+	+	PROPN
gs-3920	300	31	t	t	PROPN
gs-3920	300	32	lymphocytes	lymphocyte	VERB
gs-3920	300	33	that	that	DET
gs-3920	300	34	secrete	secrete	NOUN
gs-3920	300	35	interleukin-5	interleukin-5	PROPN
gs-3920	300	36	and	and	CCONJ
gs-3920	300	37	other	other	ADJ
gs-3920	300	38	eosinophil	eosinophil	ADJ
gs-3920	300	39	-	-	PUNCT
gs-3920	300	40	attracting	attract	VERB
gs-3920	300	41	cytokines	cytokine	NOUN
gs-3920	300	42	.	.	PUNCT
gs-3920	301	1	this	this	DET
gs-3920	301	2	inflammatory	inflammatory	ADJ
gs-3920	301	3	milieu	milieu	NOUN
gs-3920	301	4	not	not	PART
gs-3920	301	5	only	only	ADV
gs-3920	301	6	sustains	sustain	VERB
gs-3920	301	7	eosinophilia	eosinophilia	PROPN
gs-3920	301	8	but	but	CCONJ
gs-3920	301	9	also	also	ADV
gs-3920	301	10	perpetuates	perpetuate	VERB
gs-3920	301	11	tissue	tissue	NOUN
gs-3920	301	12	infiltration	infiltration	NOUN
gs-3920	301	13	and	and	CCONJ
gs-3920	301	14	damage	damage	NOUN
gs-3920	301	15	in	in	ADP
gs-3920	301	16	multiple	multiple	ADJ
gs-3920	301	17	organs	organ	NOUN
gs-3920	301	18	.	.	PUNCT
gs-3920	302	1	in	in	ADP
gs-3920	302	2	genetically	genetically	ADV
gs-3920	302	3	predisposed	predispose	VERB
gs-3920	302	4	individuals	individual	NOUN
gs-3920	302	5	,	,	PUNCT
gs-3920	302	6	reactive	reactive	ADJ
gs-3920	302	7	metabolites	metabolite	NOUN
gs-3920	302	8	generated	generate	VERB
gs-3920	302	9	during	during	ADP
gs-3920	302	10	drug	drug	NOUN
gs-3920	302	11	bioactivation	bioactivation	NOUN
gs-3920	302	12	form	form	NOUN
gs-3920	302	13	hapten	hapten	VERB
gs-3920	302	14	-	-	PUNCT
gs-3920	302	15	carrier	carrier	NOUN
gs-3920	302	16	complexes	complex	NOUN
gs-3920	302	17	or	or	CCONJ
gs-3920	302	18	bind	bind	VERB
gs-3920	302	19	directly	directly	ADV
gs-3920	302	20	to	to	ADP
gs-3920	302	21	hla	hla	NOUN
gs-3920	302	22	molecules	molecule	NOUN
gs-3920	302	23	on	on	ADP
gs-3920	302	24	antigenpresenting	antigenpresente	VERB
gs-3920	302	25	cells	cell	NOUN
gs-3920	302	26	,	,	PUNCT
gs-3920	302	27	leading	lead	VERB
gs-3920	302	28	to	to	ADP
gs-3920	302	29	aberrant	aberrant	ADJ
gs-3920	302	30	t	t	PROPN
gs-3920	302	31	-	-	PUNCT
gs-3920	302	32	cell	cell	NOUN
gs-3920	302	33	activation	activation	NOUN
gs-3920	302	34	.	.	PUNCT
gs-3920	303	1	this	this	DET
gs-3920	303	2	phenomenon	phenomenon	NOUN
gs-3920	303	3	is	be	AUX
gs-3920	303	4	central	central	ADJ
gs-3920	303	5	to	to	ADP
gs-3920	303	6	the	the	DET
gs-3920	303	7	"	"	PUNCT
gs-3920	303	8	p	p	PROPN
gs-3920	303	9	-	-	PUNCT
gs-3920	303	10	i	i	PRON
gs-3920	303	11	concept	concept	NOUN
gs-3920	303	12	"	"	PUNCT
gs-3920	303	13	(	(	PUNCT
gs-3920	303	14	pharmacological	pharmacological	ADJ
gs-3920	303	15	interaction	interaction	NOUN
gs-3920	303	16	with	with	ADP
gs-3920	303	17	immune	immune	ADJ
gs-3920	303	18	receptors	receptor	NOUN
gs-3920	303	19	)	)	PUNCT
gs-3920	303	20	,	,	PUNCT
gs-3920	303	21	where	where	SCONJ
gs-3920	303	22	the	the	DET
gs-3920	303	23	drug	drug	NOUN
gs-3920	303	24	interacts	interact	VERB
gs-3920	303	25	non	non	ADJ
gs-3920	303	26	-	-	ADJ
gs-3920	303	27	covalently	covalently	ADV
gs-3920	303	28	with	with	ADP
gs-3920	303	29	t	t	NOUN
gs-3920	303	30	-	-	PUNCT
gs-3920	303	31	cell	cell	NOUN
gs-3920	303	32	receptors	receptor	NOUN
gs-3920	303	33	or	or	CCONJ
gs-3920	303	34	hla	hla	NOUN
gs-3920	303	35	molecules	molecule	NOUN
gs-3920	303	36	,	,	PUNCT
gs-3920	303	37	bypassing	bypass	VERB
gs-3920	303	38	conventional	conventional	ADJ
gs-3920	303	39	antigen	antigen	ADJ
gs-3920	303	40	processing	processing	NOUN
gs-3920	303	41	.	.	PUNCT
gs-3920	304	1	the	the	DET
gs-3920	304	2	strong	strong	ADJ
gs-3920	304	3	association	association	NOUN
gs-3920	304	4	between	between	ADP
gs-3920	304	5	specific	specific	ADJ
gs-3920	304	6	hla	hla	NOUN
gs-3920	304	7	alleles	allele	NOUN
gs-3920	304	8	and	and	CCONJ
gs-3920	304	9	drug	drug	NOUN
gs-3920	304	10	-	-	PUNCT
gs-3920	304	11	induced	induce	VERB
gs-3920	304	12	dress	dress	NOUN
gs-3920	304	13	syndromes	syndrome	NOUN
gs-3920	304	14	further	far	ADV
gs-3920	304	15	supports	support	VERB
gs-3920	304	16	this	this	DET
gs-3920	304	17	immunogenetic	immunogenetic	ADJ
gs-3920	304	18	model	model	NOUN
gs-3920	304	19	.	.	PUNCT
gs-3920	305	1	viral	viral	ADJ
gs-3920	305	2	reactivation	reactivation	NOUN
gs-3920	305	3	,	,	PUNCT
gs-3920	305	4	particularly	particularly	ADV
gs-3920	305	5	of	of	ADP
gs-3920	305	6	herpesviruses	herpesviruse	NOUN
gs-3920	305	7	such	such	ADJ
gs-3920	305	8	as	as	ADP
gs-3920	305	9	hhv-6	hhv-6	NOUN
gs-3920	305	10	,	,	PUNCT
gs-3920	305	11	hhv-7	hhv-7	ADP
gs-3920	305	12	,	,	PUNCT
gs-3920	305	13	ebv	ebv	NOUN
gs-3920	305	14	,	,	PUNCT
gs-3920	305	15	and	and	CCONJ
gs-3920	305	16	cmv	cmv	NOUN
gs-3920	305	17	,	,	PUNCT
gs-3920	305	18	has	have	AUX
gs-3920	305	19	been	be	AUX
gs-3920	305	20	documented	document	VERB
gs-3920	305	21	in	in	ADP
gs-3920	305	22	over	over	ADP
gs-3920	305	23	40	40	NUM
gs-3920	305	24	%	%	NOUN
gs-3920	305	25	of	of	ADP
gs-3920	305	26	dress	dress	NOUN
gs-3920	305	27	patients	patient	NOUN
gs-3920	305	28	.	.	PUNCT
gs-3920	306	1	these	these	DET
gs-3920	306	2	viruses	virus	NOUN
gs-3920	306	3	may	may	AUX
gs-3920	306	4	contribute	contribute	VERB
gs-3920	306	5	to	to	ADP
gs-3920	306	6	disease	disease	NOUN
gs-3920	306	7	severity	severity	NOUN
gs-3920	306	8	by	by	ADP
gs-3920	306	9	triggering	trigger	VERB
gs-3920	306	10	further	further	ADJ
gs-3920	306	11	immune	immune	ADJ
gs-3920	306	12	stimulation	stimulation	NOUN
gs-3920	306	13	,	,	PUNCT
gs-3920	306	14	increasing	increase	VERB
gs-3920	306	15	cytokine	cytokine	ADJ
gs-3920	306	16	production	production	NOUN
gs-3920	306	17	,	,	PUNCT
gs-3920	306	18	or	or	CCONJ
gs-3920	306	19	causing	cause	VERB
gs-3920	306	20	direct	direct	ADJ
gs-3920	306	21	organ	organ	NOUN
gs-3920	306	22	injury	injury	NOUN
gs-3920	306	23	.	.	PUNCT
gs-3920	307	1	some	some	DET
gs-3920	307	2	authors	author	NOUN
gs-3920	307	3	hypothesize	hypothesize	VERB
gs-3920	307	4	a	a	DET
gs-3920	307	5	two	two	NUM
gs-3920	307	6	-	-	PUNCT
gs-3920	307	7	hit	hit	VERB
gs-3920	307	8	model	model	NOUN
gs-3920	307	9	,	,	PUNCT
gs-3920	307	10	in	in	ADP
gs-3920	307	11	which	which	PRON
gs-3920	307	12	initial	initial	ADJ
gs-3920	307	13	drug	drug	NOUN
gs-3920	307	14	-	-	PUNCT
gs-3920	307	15	induced	induce	VERB
gs-3920	307	16	immune	immune	ADJ
gs-3920	307	17	activation	activation	NOUN
gs-3920	307	18	primes	prime	VERB
gs-3920	307	19	latent	latent	ADJ
gs-3920	307	20	viral	viral	ADJ
gs-3920	307	21	reservoirs	reservoir	NOUN
gs-3920	307	22	,	,	PUNCT
gs-3920	307	23	followed	follow	VERB
gs-3920	307	24	by	by	ADP
gs-3920	307	25	viral	viral	ADJ
gs-3920	307	26	reactivation	reactivation	NOUN
gs-3920	307	27	that	that	PRON
gs-3920	307	28	intensifies	intensify	VERB
gs-3920	307	29	immunopathology	immunopathology	NOUN
gs-3920	307	30	.	.	PUNCT
gs-3920	308	1	this	this	DET
gs-3920	308	2	interplay	interplay	NOUN
gs-3920	308	3	between	between	ADP
gs-3920	308	4	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	308	5	and	and	CCONJ
gs-3920	308	6	virology	virology	NOUN
gs-3920	308	7	has	have	AUX
gs-3920	308	8	prompted	prompt	VERB
gs-3920	308	9	investigations	investigation	NOUN
gs-3920	308	10	into	into	ADP
gs-3920	308	11	antiviral	antiviral	ADJ
gs-3920	308	12	prophylaxis	prophylaxis	ADJ
gs-3920	308	13	and	and	CCONJ
gs-3920	308	14	immune	immune	ADJ
gs-3920	308	15	modulation	modulation	NOUN
gs-3920	308	16	as	as	ADP
gs-3920	308	17	adjunctive	adjunctive	ADJ
gs-3920	308	18	strategies	strategy	NOUN
gs-3920	308	19	in	in	ADP
gs-3920	308	20	high	high	ADJ
gs-3920	308	21	-	-	PUNCT
gs-3920	308	22	risk	risk	NOUN
gs-3920	308	23	patients	patient	NOUN
gs-3920	308	24	.	.	PUNCT
gs-3920	309	1	regulatory	regulatory	ADJ
gs-3920	309	2	t	t	PROPN
gs-3920	309	3	-	-	PUNCT
gs-3920	309	4	cell	cell	NOUN
gs-3920	309	5	dysfunction	dysfunction	NOUN
gs-3920	309	6	also	also	ADV
gs-3920	309	7	appears	appear	VERB
gs-3920	309	8	to	to	PART
gs-3920	309	9	contribute	contribute	VERB
gs-3920	309	10	to	to	ADP
gs-3920	309	11	the	the	DET
gs-3920	309	12	prolonged	prolonged	ADJ
gs-3920	309	13	inflammatory	inflammatory	ADJ
gs-3920	309	14	course	course	NOUN
gs-3920	309	15	of	of	ADP
gs-3920	309	16	dress	dress	NOUN
gs-3920	309	17	.	.	PUNCT
gs-3920	310	1	several	several	ADJ
gs-3920	310	2	studies	study	NOUN
gs-3920	310	3	have	have	AUX
gs-3920	310	4	demonstrated	demonstrate	VERB
gs-3920	310	5	decreased	decrease	VERB
gs-3920	310	6	treg	treg	PROPN
gs-3920	310	7	function	function	PROPN
gs-3920	310	8	and	and	CCONJ
gs-3920	310	9	persistence	persistence	NOUN
gs-3920	310	10	of	of	ADP
gs-3920	310	11	activated	activate	VERB
gs-3920	310	12	effector	effector	NOUN
gs-3920	310	13	t	t	PROPN
gs-3920	310	14	-	-	PUNCT
gs-3920	310	15	cells	cell	NOUN
gs-3920	310	16	even	even	ADV
gs-3920	310	17	after	after	ADP
gs-3920	310	18	drug	drug	NOUN
gs-3920	310	19	discontinuation	discontinuation	NOUN
gs-3920	310	20	,	,	PUNCT
gs-3920	310	21	which	which	PRON
gs-3920	310	22	may	may	AUX
gs-3920	310	23	explain	explain	VERB
gs-3920	310	24	the	the	DET
gs-3920	310	25	delayed	delay	VERB
gs-3920	310	26	onset	onset	NOUN
gs-3920	310	27	of	of	ADP
gs-3920	310	28	autoimmune	autoimmune	ADJ
gs-3920	310	29	sequelae	sequelae	NOUN
gs-3920	310	30	in	in	ADP
gs-3920	310	31	a	a	DET
gs-3920	310	32	subset	subset	NOUN
gs-3920	310	33	of	of	ADP
gs-3920	310	34	patients	patient	NOUN
gs-3920	310	35	.	.	PUNCT
gs-3920	311	1	epigenetic	epigenetic	ADJ
gs-3920	311	2	modifications	modification	NOUN
gs-3920	311	3	,	,	PUNCT
gs-3920	311	4	including	include	VERB
gs-3920	311	5	dna	dna	PROPN
gs-3920	311	6	methylation	methylation	NOUN
gs-3920	311	7	and	and	CCONJ
gs-3920	311	8	histone	histone	NOUN
gs-3920	311	9	acetylation	acetylation	NOUN
gs-3920	311	10	,	,	PUNCT
gs-3920	311	11	may	may	AUX
gs-3920	311	12	sustain	sustain	VERB
gs-3920	311	13	abnormal	abnormal	ADJ
gs-3920	311	14	t	t	NOUN
gs-3920	311	15	-	-	PUNCT
gs-3920	311	16	cell	cell	NOUN
gs-3920	311	17	phenotypes	phenotype	NOUN
gs-3920	311	18	and	and	CCONJ
gs-3920	311	19	cytokine	cytokine	ADJ
gs-3920	311	20	production	production	NOUN
gs-3920	311	21	long	long	ADV
gs-3920	311	22	after	after	ADP
gs-3920	311	23	drug	drug	NOUN
gs-3920	311	24	exposure	exposure	NOUN
gs-3920	311	25	.	.	PUNCT
gs-3920	312	1	hospitalization	hospitalization	NOUN
gs-3920	312	2	metrics	metric	NOUN
gs-3920	312	3	,	,	PUNCT
gs-3920	312	4	costs	cost	NOUN
gs-3920	312	5	,	,	PUNCT
gs-3920	312	6	and	and	CCONJ
gs-3920	312	7	morbidity	morbidity	NOUN
gs-3920	312	8	patterns	pattern	NOUN
gs-3920	312	9	dress	dress	NOUN
gs-3920	312	10	syndrome	syndrome	NOUN
gs-3920	312	11	is	be	AUX
gs-3920	312	12	associated	associate	VERB
gs-3920	312	13	with	with	ADP
gs-3920	312	14	significant	significant	ADJ
gs-3920	312	15	healthcare	healthcare	NOUN
gs-3920	312	16	utilization	utilization	NOUN
gs-3920	312	17	,	,	PUNCT
gs-3920	312	18	reflecting	reflect	VERB
gs-3920	312	19	its	its	PRON
gs-3920	312	20	complex	complex	ADJ
gs-3920	312	21	presentation	presentation	NOUN
gs-3920	312	22	and	and	CCONJ
gs-3920	312	23	potential	potential	NOUN
gs-3920	312	24	for	for	ADP
gs-3920	312	25	life	life	NOUN
gs-3920	312	26	-	-	PUNCT
gs-3920	312	27	threatening	threaten	VERB
gs-3920	312	28	complications	complication	NOUN
gs-3920	312	29	.	.	PUNCT
gs-3920	313	1	our	our	PRON
gs-3920	313	2	review	review	NOUN
gs-3920	313	3	of	of	ADP
gs-3920	313	4	hospitalization	hospitalization	NOUN
gs-3920	313	5	data	datum	NOUN
gs-3920	313	6	from	from	ADP
gs-3920	313	7	tertiary	tertiary	ADJ
gs-3920	313	8	centers	center	NOUN
gs-3920	313	9	across	across	ADP
gs-3920	313	10	north	north	PROPN
gs-3920	313	11	america	america	PROPN
gs-3920	313	12	,	,	PUNCT
gs-3920	313	13	europe	europe	PROPN
gs-3920	313	14	,	,	PUNCT
gs-3920	313	15	and	and	CCONJ
gs-3920	313	16	asia	asia	PROPN
gs-3920	313	17	found	find	VERB
gs-3920	313	18	a	a	DET
gs-3920	313	19	median	median	ADJ
gs-3920	313	20	length	length	NOUN
gs-3920	313	21	of	of	ADP
gs-3920	313	22	stay	stay	NOUN
gs-3920	313	23	between	between	ADP
gs-3920	313	24	12	12	NUM
gs-3920	313	25	and	and	CCONJ
gs-3920	313	26	21	21	NUM
gs-3920	313	27	days	day	NOUN
gs-3920	313	28	,	,	PUNCT
gs-3920	313	29	with	with	ADP
gs-3920	313	30	intensive	intensive	ADJ
gs-3920	313	31	care	care	NOUN
gs-3920	313	32	unit	unit	NOUN
gs-3920	313	33	(	(	PUNCT
gs-3920	313	34	icu	icu	PROPN
gs-3920	313	35	)	)	PUNCT
gs-3920	313	36	admissions	admission	NOUN
gs-3920	313	37	required	require	VERB
gs-3920	313	38	in	in	ADP
gs-3920	313	39	15–25	15–25	NUM
gs-3920	313	40	%	%	NOUN
gs-3920	313	41	of	of	ADP
gs-3920	313	42	patients	patient	NOUN
gs-3920	313	43	.	.	PUNCT
gs-3920	314	1	the	the	DET
gs-3920	314	2	most	most	ADV
gs-3920	314	3	common	common	ADJ
gs-3920	314	4	indications	indication	NOUN
gs-3920	314	5	for	for	ADP
gs-3920	314	6	icu	icu	PROPN
gs-3920	314	7	care	care	NOUN
gs-3920	314	8	included	include	VERB
gs-3920	314	9	fulminant	fulminant	ADJ
gs-3920	314	10	hepatic	hepatic	ADJ
gs-3920	314	11	failure	failure	NOUN
gs-3920	314	12	,	,	PUNCT
gs-3920	314	13	acute	acute	ADJ
gs-3920	314	14	kidney	kidney	NOUN
gs-3920	314	15	injury	injury	NOUN
gs-3920	314	16	requiring	require	VERB
gs-3920	314	17	dialysis	dialysis	NOUN
gs-3920	314	18	,	,	PUNCT
gs-3920	314	19	severe	severe	ADJ
gs-3920	314	20	pulmonary	pulmonary	ADJ
gs-3920	314	21	distress	distress	NOUN
gs-3920	314	22	,	,	PUNCT
gs-3920	314	23	and	and	CCONJ
gs-3920	314	24	secondary	secondary	ADJ
gs-3920	314	25	infections	infection	NOUN
gs-3920	314	26	.	.	PUNCT
gs-3920	315	1	in	in	ADP
gs-3920	315	2	-	-	PUNCT
gs-3920	315	3	hospital	hospital	NOUN
gs-3920	315	4	mortality	mortality	NOUN
gs-3920	315	5	ranged	range	VERB
gs-3920	315	6	from	from	ADP
gs-3920	315	7	2	2	NUM
gs-3920	315	8	%	%	NOUN
gs-3920	315	9	to	to	PART
gs-3920	315	10	10	10	NUM
gs-3920	315	11	%	%	NOUN
gs-3920	315	12	,	,	PUNCT
gs-3920	315	13	heavily	heavily	ADV
gs-3920	315	14	influenced	influence	VERB
gs-3920	315	15	by	by	ADP
gs-3920	315	16	age	age	NOUN
gs-3920	315	17	,	,	PUNCT
gs-3920	315	18	extent	extent	NOUN
gs-3920	315	19	of	of	ADP
gs-3920	315	20	organ	organ	NOUN
gs-3920	315	21	involvement	involvement	NOUN
gs-3920	315	22	,	,	PUNCT
gs-3920	315	23	and	and	CCONJ
gs-3920	315	24	delay	delay	VERB
gs-3920	315	25	in	in	ADP
gs-3920	315	26	drug	drug	NOUN
gs-3920	315	27	withdrawal	withdrawal	NOUN
gs-3920	315	28	.	.	PUNCT
gs-3920	316	1	patients	patient	NOUN
gs-3920	316	2	with	with	ADP
gs-3920	316	3	concurrent	concurrent	ADJ
gs-3920	316	4	viral	viral	ADJ
gs-3920	316	5	reactivation	reactivation	NOUN
gs-3920	316	6	,	,	PUNCT
gs-3920	316	7	especially	especially	ADV
gs-3920	316	8	hhv-6	hhv-6	NUM
gs-3920	316	9	and	and	CCONJ
gs-3920	316	10	ebv	ebv	NOUN
gs-3920	316	11	,	,	PUNCT
gs-3920	316	12	had	have	VERB
gs-3920	316	13	significantly	significantly	ADV
gs-3920	316	14	higher	high	ADJ
gs-3920	316	15	inflammatory	inflammatory	ADJ
gs-3920	316	16	markers	marker	NOUN
gs-3920	316	17	and	and	CCONJ
gs-3920	316	18	were	be	AUX
gs-3920	316	19	more	more	ADV
gs-3920	316	20	likely	likely	ADJ
gs-3920	316	21	to	to	PART
gs-3920	316	22	experience	experience	VERB
gs-3920	316	23	systemic	systemic	ADJ
gs-3920	316	24	complications	complication	NOUN
gs-3920	316	25	.	.	PUNCT
gs-3920	317	1	overall	overall	ADV
gs-3920	317	2	,	,	PUNCT
gs-3920	317	3	dress	dress	NOUN
gs-3920	317	4	incurs	incur	VERB
gs-3920	317	5	considerable	considerable	ADJ
gs-3920	317	6	direct	direct	ADJ
gs-3920	317	7	costs	cost	NOUN
gs-3920	317	8	,	,	PUNCT
gs-3920	317	9	with	with	SCONJ
gs-3920	317	10	average	average	ADJ
gs-3920	317	11	inpatient	inpatient	NOUN
gs-3920	317	12	expenditures	expenditure	NOUN
gs-3920	317	13	exceeding	exceed	VERB
gs-3920	317	14	$	$	SYM
gs-3920	317	15	20,000	20,000	NUM
gs-3920	317	16	per	per	ADP
gs-3920	317	17	georgian	georgian	ADJ
gs-3920	317	18	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	317	19	მეცნიერები	მეცნიერები	NOUN
gs-3920	317	20	ტ.	ტ.	VERB
gs-3920	317	21	7	7	NUM
gs-3920	317	22	n	n	DET
gs-3920	317	23	3	3	NUM
gs-3920	317	24	,	,	PUNCT
gs-3920	317	25	2025	2025	NUM
gs-3920	317	26	200	200	NUM
gs-3920	317	27	patient	patient	NOUN
gs-3920	317	28	in	in	ADP
gs-3920	317	29	the	the	DET
gs-3920	317	30	united	united	PROPN
gs-3920	317	31	states	states	PROPN
gs-3920	317	32	.	.	PUNCT
gs-3920	318	1	these	these	DET
gs-3920	318	2	costs	cost	NOUN
gs-3920	318	3	are	be	AUX
gs-3920	318	4	further	far	ADV
gs-3920	318	5	compounded	compound	VERB
gs-3920	318	6	by	by	ADP
gs-3920	318	7	post	post	ADJ
gs-3920	318	8	-	-	ADJ
gs-3920	318	9	discharge	discharge	ADJ
gs-3920	318	10	care	care	NOUN
gs-3920	318	11	,	,	PUNCT
gs-3920	318	12	including	include	VERB
gs-3920	318	13	outpatient	outpatient	NOUN
gs-3920	318	14	immunosuppressive	immunosuppressive	ADJ
gs-3920	318	15	therapy	therapy	NOUN
gs-3920	318	16	,	,	PUNCT
gs-3920	318	17	endocrinology	endocrinology	NOUN
gs-3920	318	18	follow	follow	NOUN
gs-3920	318	19	-	-	PUNCT
gs-3920	318	20	up	up	NOUN
gs-3920	318	21	for	for	ADP
gs-3920	318	22	autoimmune	autoimmune	ADJ
gs-3920	318	23	sequelae	sequelae	PROPN
gs-3920	318	24	,	,	PUNCT
gs-3920	318	25	and	and	CCONJ
gs-3920	318	26	dermatologic	dermatologic	ADJ
gs-3920	318	27	monitoring	monitoring	NOUN
gs-3920	318	28	.	.	PUNCT
gs-3920	319	1	readmission	readmission	NOUN
gs-3920	319	2	rates	rate	NOUN
gs-3920	319	3	within	within	ADP
gs-3920	319	4	90	90	NUM
gs-3920	319	5	days	day	NOUN
gs-3920	319	6	were	be	AUX
gs-3920	319	7	reported	report	VERB
gs-3920	319	8	as	as	ADV
gs-3920	319	9	high	high	ADJ
gs-3920	319	10	as	as	ADP
gs-3920	319	11	18	18	NUM
gs-3920	319	12	%	%	NOUN
gs-3920	319	13	,	,	PUNCT
gs-3920	319	14	largely	largely	ADV
gs-3920	319	15	due	due	ADJ
gs-3920	319	16	to	to	ADP
gs-3920	319	17	relapses	relapse	NOUN
gs-3920	319	18	,	,	PUNCT
gs-3920	319	19	infections	infection	NOUN
gs-3920	319	20	,	,	PUNCT
gs-3920	319	21	or	or	CCONJ
gs-3920	319	22	treatment	treatment	NOUN
gs-3920	319	23	-	-	PUNCT
gs-3920	319	24	related	relate	VERB
gs-3920	319	25	complications	complication	NOUN
gs-3920	319	26	.	.	PUNCT
gs-3920	320	1	patients	patient	NOUN
gs-3920	320	2	treated	treat	VERB
gs-3920	320	3	with	with	ADP
gs-3920	320	4	high	high	ADJ
gs-3920	320	5	-	-	PUNCT
gs-3920	320	6	dose	dose	NOUN
gs-3920	320	7	corticosteroids	corticosteroid	NOUN
gs-3920	320	8	experienced	experience	VERB
gs-3920	320	9	higher	high	ADJ
gs-3920	320	10	rates	rate	NOUN
gs-3920	320	11	of	of	ADP
gs-3920	320	12	opportunistic	opportunistic	ADJ
gs-3920	320	13	infections	infection	NOUN
gs-3920	320	14	,	,	PUNCT
gs-3920	320	15	osteoporosis	osteoporosis	NOUN
gs-3920	320	16	,	,	PUNCT
gs-3920	320	17	and	and	CCONJ
gs-3920	320	18	iatrogenic	iatrogenic	ADJ
gs-3920	320	19	diabetes	diabetes	NOUN
gs-3920	320	20	,	,	PUNCT
gs-3920	320	21	highlighting	highlight	VERB
gs-3920	320	22	the	the	DET
gs-3920	320	23	delicate	delicate	ADJ
gs-3920	320	24	balance	balance	NOUN
gs-3920	320	25	between	between	ADP
gs-3920	320	26	therapeutic	therapeutic	ADJ
gs-3920	320	27	efficacy	efficacy	NOUN
gs-3920	320	28	and	and	CCONJ
gs-3920	320	29	adverse	adverse	ADJ
gs-3920	320	30	effects	effect	NOUN
gs-3920	320	31	.	.	PUNCT
gs-3920	321	1	pediatric	pediatric	ADJ
gs-3920	321	2	considerations	consideration	NOUN
gs-3920	321	3	in	in	ADP
gs-3920	321	4	dress	dress	NOUN
gs-3920	321	5	syndrome	syndrome	NOUN
gs-3920	321	6	although	although	SCONJ
gs-3920	321	7	less	less	ADV
gs-3920	321	8	frequently	frequently	ADV
gs-3920	321	9	reported	report	VERB
gs-3920	321	10	,	,	PUNCT
gs-3920	321	11	pediatric	pediatric	ADJ
gs-3920	321	12	cases	case	NOUN
gs-3920	321	13	of	of	ADP
gs-3920	321	14	dress	dress	NOUN
gs-3920	321	15	pose	pose	VERB
gs-3920	321	16	unique	unique	ADJ
gs-3920	321	17	diagnostic	diagnostic	ADJ
gs-3920	321	18	and	and	CCONJ
gs-3920	321	19	therapeutic	therapeutic	ADJ
gs-3920	321	20	challenges	challenge	NOUN
gs-3920	321	21	.	.	PUNCT
gs-3920	322	1	children	child	NOUN
gs-3920	322	2	often	often	ADV
gs-3920	322	3	present	present	VERB
gs-3920	322	4	with	with	ADP
gs-3920	322	5	non	non	ADJ
gs-3920	322	6	-	-	ADJ
gs-3920	322	7	specific	specific	ADJ
gs-3920	322	8	symptoms	symptom	NOUN
gs-3920	322	9	such	such	ADJ
gs-3920	322	10	as	as	ADP
gs-3920	322	11	fever	fever	NOUN
gs-3920	322	12	and	and	CCONJ
gs-3920	322	13	rash	rash	NOUN
gs-3920	322	14	,	,	PUNCT
gs-3920	322	15	which	which	PRON
gs-3920	322	16	may	may	AUX
gs-3920	322	17	mimic	mimic	VERB
gs-3920	322	18	common	common	ADJ
gs-3920	322	19	viral	viral	ADJ
gs-3920	322	20	exanthems	exanthem	NOUN
gs-3920	322	21	,	,	PUNCT
gs-3920	322	22	delaying	delay	VERB
gs-3920	322	23	diagnosis	diagnosis	NOUN
gs-3920	322	24	.	.	PUNCT
gs-3920	323	1	pediatric	pediatric	ADJ
gs-3920	323	2	dress	dress	NOUN
gs-3920	323	3	has	have	AUX
gs-3920	323	4	been	be	AUX
gs-3920	323	5	associated	associate	VERB
gs-3920	323	6	with	with	ADP
gs-3920	323	7	a	a	DET
gs-3920	323	8	broader	broad	ADJ
gs-3920	323	9	range	range	NOUN
gs-3920	323	10	of	of	ADP
gs-3920	323	11	causative	causative	ADJ
gs-3920	323	12	agents	agent	NOUN
gs-3920	323	13	,	,	PUNCT
gs-3920	323	14	including	include	VERB
gs-3920	323	15	beta	beta	NOUN
gs-3920	323	16	-	-	PUNCT
gs-3920	323	17	lactam	lactam	NOUN
gs-3920	323	18	antibiotics	antibiotic	NOUN
gs-3920	323	19	,	,	PUNCT
gs-3920	323	20	antiepileptics	antiepileptic	NOUN
gs-3920	323	21	,	,	PUNCT
gs-3920	323	22	and	and	CCONJ
gs-3920	323	23	even	even	ADV
gs-3920	323	24	over	over	ADP
gs-3920	323	25	-	-	PUNCT
gs-3920	323	26	the	the	DET
gs-3920	323	27	-	-	PUNCT
gs-3920	323	28	counter	counter	NOUN
gs-3920	323	29	cold	cold	ADJ
gs-3920	323	30	remedies	remedy	NOUN
gs-3920	323	31	containing	contain	VERB
gs-3920	323	32	acetaminophen	acetaminophen	NOUN
gs-3920	323	33	and	and	CCONJ
gs-3920	323	34	pseudoephedrine	pseudoephedrine	NOUN
gs-3920	323	35	.	.	PUNCT
gs-3920	324	1	compared	compare	VERB
gs-3920	324	2	to	to	ADP
gs-3920	324	3	adults	adult	NOUN
gs-3920	324	4	,	,	PUNCT
gs-3920	324	5	pediatric	pediatric	ADJ
gs-3920	324	6	patients	patient	NOUN
gs-3920	324	7	exhibit	exhibit	VERB
gs-3920	324	8	a	a	DET
gs-3920	324	9	higher	high	ADJ
gs-3920	324	10	frequency	frequency	NOUN
gs-3920	324	11	of	of	ADP
gs-3920	324	12	lymphadenopathy	lymphadenopathy	ADJ
gs-3920	324	13	and	and	CCONJ
gs-3920	324	14	hematologic	hematologic	ADJ
gs-3920	324	15	abnormalities	abnormality	NOUN
gs-3920	324	16	but	but	CCONJ
gs-3920	324	17	slightly	slightly	ADV
gs-3920	324	18	lower	low	ADJ
gs-3920	324	19	rates	rate	NOUN
gs-3920	324	20	of	of	ADP
gs-3920	324	21	hepatic	hepatic	ADJ
gs-3920	324	22	dysfunction	dysfunction	NOUN
gs-3920	324	23	.	.	PUNCT
gs-3920	325	1	treatment	treatment	NOUN
gs-3920	325	2	protocols	protocol	NOUN
gs-3920	325	3	largely	largely	ADV
gs-3920	325	4	mirror	mirror	NOUN
gs-3920	325	5	adult	adult	NOUN
gs-3920	325	6	practices	practice	NOUN
gs-3920	325	7	,	,	PUNCT
gs-3920	325	8	with	with	ADP
gs-3920	325	9	corticosteroids	corticosteroid	NOUN
gs-3920	325	10	as	as	ADP
gs-3920	325	11	first	first	ADJ
gs-3920	325	12	-	-	PUNCT
gs-3920	325	13	line	line	NOUN
gs-3920	325	14	agents	agent	NOUN
gs-3920	325	15	and	and	CCONJ
gs-3920	325	16	ivig	ivig	NOUN
gs-3920	325	17	reserved	reserve	VERB
gs-3920	325	18	for	for	ADP
gs-3920	325	19	severe	severe	ADJ
gs-3920	325	20	or	or	CCONJ
gs-3920	325	21	steroid	steroid	NOUN
gs-3920	325	22	-	-	PUNCT
gs-3920	325	23	resistant	resistant	ADJ
gs-3920	325	24	cases	case	NOUN
gs-3920	325	25	.	.	PUNCT
gs-3920	326	1	however	however	ADV
gs-3920	326	2	,	,	PUNCT
gs-3920	326	3	long	long	ADJ
gs-3920	326	4	-	-	PUNCT
gs-3920	326	5	term	term	NOUN
gs-3920	326	6	follow	follow	NOUN
gs-3920	326	7	-	-	PUNCT
gs-3920	326	8	up	up	ADP
gs-3920	326	9	studies	study	NOUN
gs-3920	326	10	remain	remain	VERB
gs-3920	326	11	limited	limited	ADJ
gs-3920	326	12	,	,	PUNCT
gs-3920	326	13	and	and	CCONJ
gs-3920	326	14	the	the	DET
gs-3920	326	15	incidence	incidence	NOUN
gs-3920	326	16	of	of	ADP
gs-3920	326	17	post	post	ADJ
gs-3920	326	18	-	-	ADJ
gs-3920	326	19	dress	dress	ADJ
gs-3920	326	20	autoimmune	autoimmune	ADJ
gs-3920	326	21	conditions	condition	NOUN
gs-3920	326	22	in	in	ADP
gs-3920	326	23	children	child	NOUN
gs-3920	326	24	is	be	AUX
gs-3920	326	25	poorly	poorly	ADV
gs-3920	326	26	characterized	characterize	VERB
gs-3920	326	27	.	.	PUNCT
gs-3920	327	1	efforts	effort	NOUN
gs-3920	327	2	to	to	PART
gs-3920	327	3	establish	establish	VERB
gs-3920	327	4	pediatric	pediatric	ADJ
gs-3920	327	5	-	-	PUNCT
gs-3920	327	6	specific	specific	ADJ
gs-3920	327	7	diagnostic	diagnostic	ADJ
gs-3920	327	8	criteria	criterion	NOUN
gs-3920	327	9	and	and	CCONJ
gs-3920	327	10	treatment	treatment	NOUN
gs-3920	327	11	algorithms	algorithm	NOUN
gs-3920	327	12	are	be	AUX
gs-3920	327	13	ongoing	ongoing	ADJ
gs-3920	327	14	.	.	PUNCT
gs-3920	328	1	a	a	DET
gs-3920	328	2	multinational	multinational	ADJ
gs-3920	328	3	registry	registry	NOUN
gs-3920	328	4	capturing	capture	VERB
gs-3920	328	5	pediatric	pediatric	ADJ
gs-3920	328	6	drug	drug	NOUN
gs-3920	328	7	hypersensitivity	hypersensitivity	NOUN
gs-3920	328	8	reactions	reaction	NOUN
gs-3920	328	9	is	be	AUX
gs-3920	328	10	expected	expect	VERB
gs-3920	328	11	to	to	PART
gs-3920	328	12	enhance	enhance	VERB
gs-3920	328	13	our	our	PRON
gs-3920	328	14	understanding	understanding	NOUN
gs-3920	328	15	of	of	ADP
gs-3920	328	16	age	age	NOUN
gs-3920	328	17	-	-	PUNCT
gs-3920	328	18	specific	specific	ADJ
gs-3920	328	19	risk	risk	NOUN
gs-3920	328	20	factors	factor	NOUN
gs-3920	328	21	and	and	CCONJ
gs-3920	328	22	outcomes	outcome	NOUN
gs-3920	328	23	in	in	ADP
gs-3920	328	24	the	the	DET
gs-3920	328	25	near	near	ADJ
gs-3920	328	26	future	future	NOUN
gs-3920	328	27	.	.	PUNCT
gs-3920	329	1	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	329	2	,	,	PUNCT
gs-3920	329	3	reporting	reporting	NOUN
gs-3920	329	4	systems	system	NOUN
gs-3920	329	5	,	,	PUNCT
gs-3920	329	6	and	and	CCONJ
gs-3920	329	7	underdiagnosis	underdiagnosis	NOUN
gs-3920	329	8	despite	despite	SCONJ
gs-3920	329	9	its	its	PRON
gs-3920	329	10	severity	severity	NOUN
gs-3920	329	11	,	,	PUNCT
gs-3920	329	12	dress	dress	NOUN
gs-3920	329	13	syndrome	syndrome	NOUN
gs-3920	329	14	remains	remain	VERB
gs-3920	329	15	underdiagnosed	underdiagnosed	ADJ
gs-3920	329	16	and	and	CCONJ
gs-3920	329	17	underreported	underreported	ADJ
gs-3920	329	18	.	.	PUNCT
gs-3920	330	1	analysis	analysis	NOUN
gs-3920	330	2	of	of	ADP
gs-3920	330	3	adverse	adverse	ADJ
gs-3920	330	4	drug	drug	NOUN
gs-3920	330	5	reaction	reaction	NOUN
gs-3920	330	6	databases	database	NOUN
gs-3920	330	7	from	from	ADP
gs-3920	330	8	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	330	9	centers	center	NOUN
gs-3920	330	10	in	in	ADP
gs-3920	330	11	the	the	DET
gs-3920	330	12	u.s	u.s	PROPN
gs-3920	330	13	.	.	PROPN
gs-3920	330	14	(	(	PUNCT
gs-3920	330	15	faers	faer	NOUN
gs-3920	330	16	)	)	PUNCT
gs-3920	330	17	,	,	PUNCT
gs-3920	330	18	europe	europe	PROPN
gs-3920	330	19	(	(	PUNCT
gs-3920	330	20	eudravigilance	eudravigilance	NOUN
gs-3920	330	21	)	)	PUNCT
gs-3920	330	22	,	,	PUNCT
gs-3920	330	23	and	and	CCONJ
gs-3920	330	24	japan	japan	PROPN
gs-3920	330	25	revealed	reveal	VERB
gs-3920	330	26	substantial	substantial	ADJ
gs-3920	330	27	discrepancies	discrepancy	NOUN
gs-3920	330	28	between	between	ADP
gs-3920	330	29	reported	report	VERB
gs-3920	330	30	and	and	CCONJ
gs-3920	330	31	estimated	estimate	VERB
gs-3920	330	32	incidence	incidence	NOUN
gs-3920	330	33	rates	rate	NOUN
gs-3920	330	34	.	.	PUNCT
gs-3920	331	1	contributing	contribute	VERB
gs-3920	331	2	factors	factor	NOUN
gs-3920	331	3	include	include	VERB
gs-3920	331	4	lack	lack	NOUN
gs-3920	331	5	of	of	ADP
gs-3920	331	6	awareness	awareness	NOUN
gs-3920	331	7	,	,	PUNCT
gs-3920	331	8	variable	variable	ADJ
gs-3920	331	9	diagnostic	diagnostic	ADJ
gs-3920	331	10	criteria	criterion	NOUN
gs-3920	331	11	,	,	PUNCT
gs-3920	331	12	overlapping	overlap	VERB
gs-3920	331	13	clinical	clinical	ADJ
gs-3920	331	14	features	feature	NOUN
gs-3920	331	15	with	with	ADP
gs-3920	331	16	other	other	ADJ
gs-3920	331	17	syndromes	syndrome	NOUN
gs-3920	331	18	,	,	PUNCT
gs-3920	331	19	and	and	CCONJ
gs-3920	331	20	insufficient	insufficient	ADJ
gs-3920	331	21	documentation	documentation	NOUN
gs-3920	331	22	.	.	PUNCT
gs-3920	332	1	establishing	establish	VERB
gs-3920	332	2	mandatory	mandatory	ADJ
gs-3920	332	3	reporting	reporting	NOUN
gs-3920	332	4	of	of	ADP
gs-3920	332	5	severe	severe	ADJ
gs-3920	332	6	cutaneous	cutaneous	ADJ
gs-3920	332	7	adverse	adverse	ADJ
gs-3920	332	8	reactions	reaction	NOUN
gs-3920	332	9	(	(	PUNCT
gs-3920	332	10	scars	scar	NOUN
gs-3920	332	11	)	)	PUNCT
gs-3920	332	12	,	,	PUNCT
gs-3920	332	13	integrating	integrate	VERB
gs-3920	332	14	electronic	electronic	ADJ
gs-3920	332	15	medical	medical	ADJ
gs-3920	332	16	record	record	NOUN
gs-3920	332	17	alerts	alert	NOUN
gs-3920	332	18	for	for	ADP
gs-3920	332	19	high	high	ADJ
gs-3920	332	20	-	-	PUNCT
gs-3920	332	21	risk	risk	NOUN
gs-3920	332	22	drug	drug	NOUN
gs-3920	332	23	-	-	PUNCT
gs-3920	332	24	hla	hla	NOUN
gs-3920	332	25	combinations	combination	NOUN
gs-3920	332	26	,	,	PUNCT
gs-3920	332	27	and	and	CCONJ
gs-3920	332	28	increasing	increase	VERB
gs-3920	332	29	clinician	clinician	ADJ
gs-3920	332	30	education	education	NOUN
gs-3920	332	31	are	be	AUX
gs-3920	332	32	essential	essential	ADJ
gs-3920	332	33	steps	step	NOUN
gs-3920	332	34	toward	toward	ADP
gs-3920	332	35	enhancing	enhance	VERB
gs-3920	332	36	surveillance	surveillance	NOUN
gs-3920	332	37	.	.	PUNCT
gs-3920	333	1	additionally	additionally	ADV
gs-3920	333	2	,	,	PUNCT
gs-3920	333	3	harmonizing	harmonize	VERB
gs-3920	333	4	diagnostic	diagnostic	ADJ
gs-3920	333	5	algorithms	algorithm	NOUN
gs-3920	333	6	across	across	ADP
gs-3920	333	7	institutions	institution	NOUN
gs-3920	333	8	can	can	AUX
gs-3920	333	9	reduce	reduce	VERB
gs-3920	333	10	missed	miss	VERB
gs-3920	333	11	or	or	CCONJ
gs-3920	333	12	misclassified	misclassified	ADJ
gs-3920	333	13	cases	case	NOUN
gs-3920	333	14	.	.	PUNCT
gs-3920	334	1	cross	cross	ADJ
gs-3920	334	2	-	-	ADJ
gs-3920	334	3	border	border	ADJ
gs-3920	334	4	initiatives	initiative	NOUN
gs-3920	334	5	such	such	ADJ
gs-3920	334	6	as	as	ADP
gs-3920	334	7	the	the	DET
gs-3920	334	8	international	international	ADJ
gs-3920	334	9	severe	severe	ADJ
gs-3920	334	10	cutaneous	cutaneous	ADJ
gs-3920	334	11	adverse	adverse	ADJ
gs-3920	334	12	reaction	reaction	NOUN
gs-3920	334	13	(	(	PUNCT
gs-3920	334	14	iscar	iscar	NOUN
gs-3920	334	15	)	)	PUNCT
gs-3920	334	16	consortium	consortium	NOUN
gs-3920	334	17	offer	offer	VERB
gs-3920	334	18	a	a	DET
gs-3920	334	19	platform	platform	NOUN
gs-3920	334	20	for	for	ADP
gs-3920	334	21	standardization	standardization	NOUN
gs-3920	334	22	and	and	CCONJ
gs-3920	334	23	global	global	ADJ
gs-3920	334	24	data	datum	NOUN
gs-3920	334	25	sharing	sharing	NOUN
gs-3920	334	26	.	.	PUNCT
gs-3920	335	1	georgian	georgian	ADJ
gs-3920	335	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	335	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	335	4	ტ.	ტ.	VERB
gs-3920	335	5	7	7	NUM
gs-3920	335	6	n	n	PRON
gs-3920	335	7	3	3	NUM
gs-3920	335	8	,	,	PUNCT
gs-3920	335	9	2025	2025	NUM
gs-3920	335	10	201	201	NUM
gs-3920	335	11	biomarker	biomarker	NOUN
gs-3920	335	12	discovery	discovery	NOUN
gs-3920	335	13	and	and	CCONJ
gs-3920	335	14	translational	translational	ADJ
gs-3920	335	15	research	research	NOUN
gs-3920	335	16	recent	recent	ADJ
gs-3920	335	17	years	year	NOUN
gs-3920	335	18	have	have	AUX
gs-3920	335	19	witnessed	witness	VERB
gs-3920	335	20	an	an	DET
gs-3920	335	21	explosion	explosion	NOUN
gs-3920	335	22	in	in	ADP
gs-3920	335	23	research	research	NOUN
gs-3920	335	24	aimed	aim	VERB
gs-3920	335	25	at	at	ADP
gs-3920	335	26	identifying	identify	VERB
gs-3920	335	27	diagnostic	diagnostic	ADJ
gs-3920	335	28	and	and	CCONJ
gs-3920	335	29	prognostic	prognostic	ADJ
gs-3920	335	30	biomarkers	biomarker	NOUN
gs-3920	335	31	for	for	ADP
gs-3920	335	32	dress	dress	NOUN
gs-3920	335	33	.	.	PUNCT
gs-3920	336	1	proteomic	proteomic	ADJ
gs-3920	336	2	studies	study	NOUN
gs-3920	336	3	have	have	AUX
gs-3920	336	4	highlighted	highlight	VERB
gs-3920	336	5	elevated	elevated	ADJ
gs-3920	336	6	levels	level	NOUN
gs-3920	336	7	of	of	ADP
gs-3920	336	8	thymus	thymus	NOUN
gs-3920	336	9	and	and	CCONJ
gs-3920	336	10	activation	activation	NOUN
gs-3920	336	11	-	-	PUNCT
gs-3920	336	12	regulated	regulate	VERB
gs-3920	336	13	chemokine	chemokine	ADJ
gs-3920	336	14	(	(	PUNCT
gs-3920	336	15	tarc	tarc	PROPN
gs-3920	336	16	)	)	PUNCT
gs-3920	336	17	,	,	PUNCT
gs-3920	336	18	granulysin	granulysin	NOUN
gs-3920	336	19	,	,	PUNCT
gs-3920	336	20	and	and	CCONJ
gs-3920	336	21	soluble	soluble	ADJ
gs-3920	336	22	interleukin-2	interleukin-2	NOUN
gs-3920	336	23	receptor	receptor	NOUN
gs-3920	336	24	alpha	alpha	NOUN
gs-3920	336	25	(	(	PUNCT
gs-3920	336	26	sil-2rα	sil-2rα	PROPN
gs-3920	336	27	)	)	PUNCT
gs-3920	336	28	in	in	ADP
gs-3920	336	29	the	the	DET
gs-3920	336	30	acute	acute	ADJ
gs-3920	336	31	phase	phase	NOUN
gs-3920	336	32	of	of	ADP
gs-3920	336	33	disease	disease	NOUN
gs-3920	336	34	.	.	PUNCT
gs-3920	337	1	these	these	DET
gs-3920	337	2	markers	marker	NOUN
gs-3920	337	3	correlate	correlate	VERB
gs-3920	337	4	with	with	ADP
gs-3920	337	5	disease	disease	NOUN
gs-3920	337	6	activity	activity	NOUN
gs-3920	337	7	and	and	CCONJ
gs-3920	337	8	eosinophil	eosinophil	ADJ
gs-3920	337	9	count	count	NOUN
gs-3920	337	10	,	,	PUNCT
gs-3920	337	11	and	and	CCONJ
gs-3920	337	12	may	may	AUX
gs-3920	337	13	guide	guide	VERB
gs-3920	337	14	treatment	treatment	NOUN
gs-3920	337	15	response	response	NOUN
gs-3920	337	16	in	in	ADP
gs-3920	337	17	real	real	ADJ
gs-3920	337	18	time	time	NOUN
gs-3920	337	19	.	.	PUNCT
gs-3920	338	1	genomic	genomic	ADJ
gs-3920	338	2	approaches	approach	NOUN
gs-3920	338	3	,	,	PUNCT
gs-3920	338	4	including	include	VERB
gs-3920	338	5	whole	whole	ADJ
gs-3920	338	6	exome	exome	NOUN
gs-3920	338	7	sequencing	sequence	VERB
gs-3920	338	8	and	and	CCONJ
gs-3920	338	9	transcriptomic	transcriptomic	ADJ
gs-3920	338	10	profiling	profiling	NOUN
gs-3920	338	11	,	,	PUNCT
gs-3920	338	12	are	be	AUX
gs-3920	338	13	being	be	AUX
gs-3920	338	14	employed	employ	VERB
gs-3920	338	15	to	to	PART
gs-3920	338	16	identify	identify	VERB
gs-3920	338	17	new	new	ADJ
gs-3920	338	18	susceptibility	susceptibility	NOUN
gs-3920	338	19	genes	gene	NOUN
gs-3920	338	20	beyond	beyond	ADP
gs-3920	338	21	hla	hla	NOUN
gs-3920	338	22	alleles	allele	NOUN
gs-3920	338	23	.	.	PUNCT
gs-3920	339	1	meanwhile	meanwhile	ADV
gs-3920	339	2	,	,	PUNCT
gs-3920	339	3	single	single	ADJ
gs-3920	339	4	-	-	PUNCT
gs-3920	339	5	cell	cell	NOUN
gs-3920	339	6	rna	rna	NOUN
gs-3920	339	7	sequencing	sequencing	NOUN
gs-3920	339	8	has	have	AUX
gs-3920	339	9	revealed	reveal	VERB
gs-3920	339	10	distinct	distinct	ADJ
gs-3920	339	11	immune	immune	ADJ
gs-3920	339	12	cell	cell	NOUN
gs-3920	339	13	subpopulations	subpopulation	NOUN
gs-3920	339	14	driving	drive	VERB
gs-3920	339	15	different	different	ADJ
gs-3920	339	16	disease	disease	NOUN
gs-3920	339	17	phases	phase	NOUN
gs-3920	339	18	,	,	PUNCT
gs-3920	339	19	suggesting	suggest	VERB
gs-3920	339	20	new	new	ADJ
gs-3920	339	21	therapeutic	therapeutic	ADJ
gs-3920	339	22	targets	target	NOUN
gs-3920	339	23	such	such	ADJ
gs-3920	339	24	as	as	ADP
gs-3920	339	25	janus	janus	PROPN
gs-3920	339	26	kinase	kinase	PROPN
gs-3920	339	27	(	(	PUNCT
gs-3920	339	28	jak	jak	PROPN
gs-3920	339	29	)	)	PUNCT
gs-3920	339	30	pathways	pathway	NOUN
gs-3920	339	31	or	or	CCONJ
gs-3920	339	32	costimulatory	costimulatory	NOUN
gs-3920	339	33	molecules	molecule	NOUN
gs-3920	339	34	like	like	ADP
gs-3920	339	35	cd28	cd28	PROPN
gs-3920	339	36	and	and	CCONJ
gs-3920	339	37	icos	icos	PROPN
gs-3920	339	38	.	.	PUNCT
gs-3920	340	1	machine	machine	NOUN
gs-3920	340	2	learning	learning	NOUN
gs-3920	340	3	models	model	NOUN
gs-3920	340	4	integrating	integrate	VERB
gs-3920	340	5	clinical	clinical	ADJ
gs-3920	340	6	,	,	PUNCT
gs-3920	340	7	laboratory	laboratory	NOUN
gs-3920	340	8	,	,	PUNCT
gs-3920	340	9	and	and	CCONJ
gs-3920	340	10	genetic	genetic	ADJ
gs-3920	340	11	data	datum	NOUN
gs-3920	340	12	are	be	AUX
gs-3920	340	13	being	be	AUX
gs-3920	340	14	developed	develop	VERB
gs-3920	340	15	to	to	PART
gs-3920	340	16	predict	predict	VERB
gs-3920	340	17	disease	disease	NOUN
gs-3920	340	18	course	course	NOUN
gs-3920	340	19	and	and	CCONJ
gs-3920	340	20	identify	identify	VERB
gs-3920	340	21	patients	patient	NOUN
gs-3920	340	22	at	at	ADP
gs-3920	340	23	risk	risk	NOUN
gs-3920	340	24	of	of	ADP
gs-3920	340	25	relapse	relapse	NOUN
gs-3920	340	26	or	or	CCONJ
gs-3920	340	27	autoimmune	autoimmune	ADJ
gs-3920	340	28	transition	transition	NOUN
gs-3920	340	29	.	.	PUNCT
gs-3920	341	1	these	these	DET
gs-3920	341	2	precision	precision	NOUN
gs-3920	341	3	medicine	medicine	NOUN
gs-3920	341	4	approaches	approach	NOUN
gs-3920	341	5	,	,	PUNCT
gs-3920	341	6	while	while	SCONJ
gs-3920	341	7	in	in	ADP
gs-3920	341	8	their	their	PRON
gs-3920	341	9	infancy	infancy	NOUN
gs-3920	341	10	,	,	PUNCT
gs-3920	341	11	hold	hold	VERB
gs-3920	341	12	great	great	ADJ
gs-3920	341	13	promise	promise	NOUN
gs-3920	341	14	in	in	ADP
gs-3920	341	15	refining	refine	VERB
gs-3920	341	16	dress	dress	NOUN
gs-3920	341	17	management	management	NOUN
gs-3920	341	18	and	and	CCONJ
gs-3920	341	19	reducing	reduce	VERB
gs-3920	341	20	reliance	reliance	NOUN
gs-3920	341	21	on	on	ADP
gs-3920	341	22	broad	broad	ADJ
gs-3920	341	23	immunosuppression	immunosuppression	NOUN
gs-3920	341	24	.	.	PUNCT
gs-3920	342	1	ethical	ethical	ADJ
gs-3920	342	2	considerations	consideration	NOUN
gs-3920	342	3	in	in	ADP
gs-3920	342	4	genomic	genomic	ADJ
gs-3920	342	5	risk	risk	NOUN
gs-3920	342	6	stratification	stratification	NOUN
gs-3920	342	7	as	as	ADP
gs-3920	342	8	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	342	9	screening	screening	NOUN
gs-3920	342	10	becomes	become	VERB
gs-3920	342	11	more	more	ADV
gs-3920	342	12	integrated	integrate	VERB
gs-3920	342	13	into	into	ADP
gs-3920	342	14	clinical	clinical	ADJ
gs-3920	342	15	workflows	workflow	NOUN
gs-3920	342	16	,	,	PUNCT
gs-3920	342	17	ethical	ethical	ADJ
gs-3920	342	18	considerations	consideration	NOUN
gs-3920	342	19	must	must	AUX
gs-3920	342	20	be	be	AUX
gs-3920	342	21	addressed	address	VERB
gs-3920	342	22	.	.	PUNCT
gs-3920	343	1	pre	pre	ADJ
gs-3920	343	2	-	-	ADJ
gs-3920	343	3	emptive	emptive	ADJ
gs-3920	343	4	testing	testing	NOUN
gs-3920	343	5	for	for	ADP
gs-3920	343	6	hla	hla	PROPN
gs-3920	343	7	alleles	allele	NOUN
gs-3920	343	8	raises	raise	VERB
gs-3920	343	9	questions	question	NOUN
gs-3920	343	10	about	about	ADP
gs-3920	343	11	patient	patient	ADJ
gs-3920	343	12	consent	consent	NOUN
gs-3920	343	13	,	,	PUNCT
gs-3920	343	14	privacy	privacy	NOUN
gs-3920	343	15	,	,	PUNCT
gs-3920	343	16	data	datum	NOUN
gs-3920	343	17	ownership	ownership	NOUN
gs-3920	343	18	,	,	PUNCT
gs-3920	343	19	and	and	CCONJ
gs-3920	343	20	potential	potential	ADJ
gs-3920	343	21	genetic	genetic	ADJ
gs-3920	343	22	discrimination	discrimination	NOUN
gs-3920	343	23	.	.	PUNCT
gs-3920	344	1	equitable	equitable	ADJ
gs-3920	344	2	access	access	NOUN
gs-3920	344	3	to	to	ADP
gs-3920	344	4	testing	testing	NOUN
gs-3920	344	5	,	,	PUNCT
gs-3920	344	6	particularly	particularly	ADV
gs-3920	344	7	in	in	ADP
gs-3920	344	8	lowand	lowand	ADJ
gs-3920	344	9	middle	middle	ADJ
gs-3920	344	10	-	-	PUNCT
gs-3920	344	11	income	income	NOUN
gs-3920	344	12	countries	country	NOUN
gs-3920	344	13	,	,	PUNCT
gs-3920	344	14	is	be	AUX
gs-3920	344	15	another	another	DET
gs-3920	344	16	pressing	press	VERB
gs-3920	344	17	concern	concern	NOUN
gs-3920	344	18	.	.	PUNCT
gs-3920	345	1	strategies	strategy	NOUN
gs-3920	345	2	to	to	PART
gs-3920	345	3	mitigate	mitigate	VERB
gs-3920	345	4	these	these	DET
gs-3920	345	5	issues	issue	NOUN
gs-3920	345	6	include	include	VERB
gs-3920	345	7	robust	robust	ADJ
gs-3920	345	8	genetic	genetic	ADJ
gs-3920	345	9	counseling	counseling	NOUN
gs-3920	345	10	,	,	PUNCT
gs-3920	345	11	clear	clear	ADJ
gs-3920	345	12	data	datum	NOUN
gs-3920	345	13	governance	governance	NOUN
gs-3920	345	14	frameworks	framework	NOUN
gs-3920	345	15	,	,	PUNCT
gs-3920	345	16	and	and	CCONJ
gs-3920	345	17	public	public	ADJ
gs-3920	345	18	health	health	NOUN
gs-3920	345	19	policies	policy	NOUN
gs-3920	345	20	that	that	PRON
gs-3920	345	21	promote	promote	VERB
gs-3920	345	22	access	access	NOUN
gs-3920	345	23	without	without	ADP
gs-3920	345	24	imposing	impose	VERB
gs-3920	345	25	undue	undue	ADJ
gs-3920	345	26	financial	financial	ADJ
gs-3920	345	27	burden	burden	NOUN
gs-3920	345	28	.	.	PUNCT
gs-3920	346	1	importantly	importantly	ADV
gs-3920	346	2	,	,	PUNCT
gs-3920	346	3	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	346	4	data	datum	NOUN
gs-3920	346	5	should	should	AUX
gs-3920	346	6	be	be	AUX
gs-3920	346	7	interpreted	interpret	VERB
gs-3920	346	8	in	in	ADP
gs-3920	346	9	the	the	DET
gs-3920	346	10	context	context	NOUN
gs-3920	346	11	of	of	ADP
gs-3920	346	12	clinical	clinical	ADJ
gs-3920	346	13	presentation	presentation	NOUN
gs-3920	346	14	,	,	PUNCT
gs-3920	346	15	avoiding	avoid	VERB
gs-3920	346	16	deterministic	deterministic	ADJ
gs-3920	346	17	conclusions	conclusion	NOUN
gs-3920	346	18	that	that	PRON
gs-3920	346	19	may	may	AUX
gs-3920	346	20	restrict	restrict	VERB
gs-3920	346	21	therapeutic	therapeutic	ADJ
gs-3920	346	22	options	option	NOUN
gs-3920	346	23	unnecessarily	unnecessarily	ADV
gs-3920	346	24	.	.	PUNCT
gs-3920	347	1	comparative	comparative	ADJ
gs-3920	347	2	evaluation	evaluation	NOUN
gs-3920	347	3	with	with	ADP
gs-3920	347	4	other	other	ADJ
gs-3920	347	5	severe	severe	ADJ
gs-3920	347	6	cutaneous	cutaneous	ADJ
gs-3920	347	7	adverse	adverse	ADJ
gs-3920	347	8	reactions	reaction	NOUN
gs-3920	347	9	(	(	PUNCT
gs-3920	347	10	scars	scar	NOUN
gs-3920	347	11	)	)	PUNCT
gs-3920	347	12	one	one	NUM
gs-3920	347	13	of	of	ADP
gs-3920	347	14	the	the	DET
gs-3920	347	15	major	major	ADJ
gs-3920	347	16	diagnostic	diagnostic	ADJ
gs-3920	347	17	and	and	CCONJ
gs-3920	347	18	clinical	clinical	ADJ
gs-3920	347	19	challenges	challenge	NOUN
gs-3920	347	20	in	in	ADP
gs-3920	347	21	managing	manage	VERB
gs-3920	347	22	dress	dress	NOUN
gs-3920	347	23	syndrome	syndrome	NOUN
gs-3920	347	24	lies	lie	VERB
gs-3920	347	25	in	in	ADP
gs-3920	347	26	differentiating	differentiate	VERB
gs-3920	347	27	it	it	PRON
gs-3920	347	28	from	from	ADP
gs-3920	347	29	other	other	ADJ
gs-3920	347	30	severe	severe	ADJ
gs-3920	347	31	cutaneous	cutaneous	ADJ
gs-3920	347	32	adverse	adverse	ADJ
gs-3920	347	33	reactions	reaction	NOUN
gs-3920	347	34	(	(	PUNCT
gs-3920	347	35	scars	scar	NOUN
gs-3920	347	36	)	)	PUNCT
gs-3920	347	37	,	,	PUNCT
gs-3920	347	38	such	such	ADJ
gs-3920	347	39	as	as	ADP
gs-3920	347	40	stevens	stevens	PROPN
gs-3920	347	41	–	–	PUNCT
gs-3920	347	42	johnson	johnson	PROPN
gs-3920	347	43	syndrome	syndrome	PROPN
gs-3920	347	44	(	(	PUNCT
gs-3920	347	45	sjs	sjs	PROPN
gs-3920	347	46	)	)	PUNCT
gs-3920	347	47	,	,	PUNCT
gs-3920	347	48	toxic	toxic	ADJ
gs-3920	347	49	epidermal	epidermal	ADJ
gs-3920	347	50	necrolysis	necrolysis	NOUN
gs-3920	347	51	(	(	PUNCT
gs-3920	347	52	ten	ten	NUM
gs-3920	347	53	)	)	PUNCT
gs-3920	347	54	,	,	PUNCT
gs-3920	347	55	and	and	CCONJ
gs-3920	347	56	acute	acute	ADJ
gs-3920	347	57	generalized	generalize	VERB
gs-3920	347	58	exanthematous	exanthematous	ADJ
gs-3920	347	59	pustulosis	pustulosis	NOUN
gs-3920	347	60	(	(	PUNCT
gs-3920	347	61	agep	agep	NOUN
gs-3920	347	62	)	)	PUNCT
gs-3920	347	63	.	.	PUNCT
gs-3920	348	1	despite	despite	SCONJ
gs-3920	348	2	shared	share	VERB
gs-3920	348	3	features	feature	NOUN
gs-3920	348	4	like	like	ADP
gs-3920	348	5	fever	fever	NOUN
gs-3920	348	6	,	,	PUNCT
gs-3920	348	7	rash	rash	ADJ
gs-3920	348	8	,	,	PUNCT
gs-3920	348	9	and	and	CCONJ
gs-3920	348	10	drug	drug	NOUN
gs-3920	348	11	exposure	exposure	NOUN
gs-3920	348	12	,	,	PUNCT
gs-3920	348	13	the	the	DET
gs-3920	348	14	underlying	underlie	VERB
gs-3920	348	15	immunopathology	immunopathology	NOUN
gs-3920	348	16	,	,	PUNCT
gs-3920	348	17	timing	timing	NOUN
gs-3920	348	18	of	of	ADP
gs-3920	348	19	onset	onset	NOUN
gs-3920	348	20	,	,	PUNCT
gs-3920	348	21	and	and	CCONJ
gs-3920	348	22	systemic	systemic	ADJ
gs-3920	348	23	complications	complication	NOUN
gs-3920	348	24	differ	differ	VERB
gs-3920	348	25	significantly	significantly	ADV
gs-3920	348	26	.	.	PUNCT
gs-3920	349	1	in	in	ADP
gs-3920	349	2	contrast	contrast	NOUN
gs-3920	349	3	to	to	ADP
gs-3920	349	4	sjs	sjs	PROPN
gs-3920	349	5	/	/	SYM
gs-3920	349	6	ten	ten	PROPN
gs-3920	349	7	,	,	PUNCT
gs-3920	349	8	which	which	PRON
gs-3920	349	9	are	be	AUX
gs-3920	349	10	typically	typically	ADV
gs-3920	349	11	characterized	characterize	VERB
gs-3920	349	12	by	by	ADP
gs-3920	349	13	extensive	extensive	ADJ
gs-3920	349	14	epidermal	epidermal	ADJ
gs-3920	349	15	detachment	detachment	NOUN
gs-3920	349	16	and	and	CCONJ
gs-3920	349	17	mucosal	mucosal	NOUN
gs-3920	349	18	involvement	involvement	NOUN
gs-3920	349	19	within	within	ADP
gs-3920	349	20	days	day	NOUN
gs-3920	349	21	of	of	ADP
gs-3920	349	22	drug	drug	NOUN
gs-3920	349	23	initiation	initiation	NOUN
gs-3920	349	24	,	,	PUNCT
gs-3920	349	25	dress	dress	NOUN
gs-3920	349	26	exhibits	exhibit	VERB
gs-3920	349	27	a	a	DET
gs-3920	349	28	longer	long	ADJ
gs-3920	349	29	latency	latency	NOUN
gs-3920	349	30	period	period	NOUN
gs-3920	349	31	(	(	PUNCT
gs-3920	349	32	2–8	2–8	NUM
gs-3920	349	33	weeks	week	NOUN
gs-3920	349	34	)	)	PUNCT
gs-3920	349	35	and	and	CCONJ
gs-3920	349	36	is	be	AUX
gs-3920	349	37	more	more	ADV
gs-3920	349	38	often	often	ADV
gs-3920	349	39	associated	associate	VERB
gs-3920	349	40	with	with	ADP
gs-3920	349	41	hematologic	hematologic	NOUN
gs-3920	349	42	abnormalities	abnormality	NOUN
gs-3920	349	43	and	and	CCONJ
gs-3920	349	44	multiorgan	multiorgan	NOUN
gs-3920	349	45	involvement	involvement	NOUN
gs-3920	349	46	,	,	PUNCT
gs-3920	349	47	including	include	VERB
gs-3920	349	48	liver	liver	NOUN
gs-3920	349	49	and	and	CCONJ
gs-3920	349	50	kidneys	kidney	NOUN
gs-3920	349	51	.	.	PUNCT
gs-3920	350	1	dress	dress	NOUN
gs-3920	350	2	patients	patient	NOUN
gs-3920	350	3	georgian	georgian	PROPN
gs-3920	350	4	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	350	5	მეცნიერები	მეცნიერები	NOUN
gs-3920	350	6	ტ.	ტ.	VERB
gs-3920	350	7	7	7	NUM
gs-3920	350	8	n	n	PRON
gs-3920	350	9	3	3	NUM
gs-3920	350	10	,	,	PUNCT
gs-3920	350	11	2025	2025	NUM
gs-3920	350	12	202	202	NUM
gs-3920	350	13	are	be	AUX
gs-3920	350	14	less	less	ADV
gs-3920	350	15	likely	likely	ADJ
gs-3920	350	16	to	to	PART
gs-3920	350	17	have	have	VERB
gs-3920	350	18	severe	severe	ADJ
gs-3920	350	19	mucosal	mucosal	ADJ
gs-3920	350	20	erosions	erosion	NOUN
gs-3920	350	21	or	or	CCONJ
gs-3920	350	22	nikolsky	nikolsky	ADJ
gs-3920	350	23	-	-	PUNCT
gs-3920	350	24	positive	positive	ADJ
gs-3920	350	25	skin	skin	NOUN
gs-3920	350	26	,	,	PUNCT
gs-3920	350	27	but	but	CCONJ
gs-3920	350	28	more	more	ADV
gs-3920	350	29	likely	likely	ADJ
gs-3920	350	30	to	to	PART
gs-3920	350	31	show	show	VERB
gs-3920	350	32	profound	profound	ADJ
gs-3920	350	33	eosinophilia	eosinophilia	PROPN
gs-3920	350	34	,	,	PUNCT
gs-3920	350	35	atypical	atypical	ADJ
gs-3920	350	36	lymphocytes	lymphocyte	NOUN
gs-3920	350	37	,	,	PUNCT
gs-3920	350	38	and	and	CCONJ
gs-3920	350	39	elevated	elevated	ADJ
gs-3920	350	40	inflammatory	inflammatory	ADJ
gs-3920	350	41	markers	marker	NOUN
gs-3920	350	42	.	.	PUNCT
gs-3920	351	1	importantly	importantly	ADV
gs-3920	351	2	,	,	PUNCT
gs-3920	351	3	dress	dress	NOUN
gs-3920	351	4	is	be	AUX
gs-3920	351	5	also	also	ADV
gs-3920	351	6	uniquely	uniquely	ADV
gs-3920	351	7	associated	associate	VERB
gs-3920	351	8	with	with	ADP
gs-3920	351	9	delayed	delay	VERB
gs-3920	351	10	-	-	PUNCT
gs-3920	351	11	onset	onset	NOUN
gs-3920	351	12	autoimmune	autoimmune	ADJ
gs-3920	351	13	diseases	disease	NOUN
gs-3920	351	14	,	,	PUNCT
gs-3920	351	15	a	a	DET
gs-3920	351	16	feature	feature	NOUN
gs-3920	351	17	not	not	PART
gs-3920	351	18	observed	observe	VERB
gs-3920	351	19	in	in	ADP
gs-3920	351	20	sjs	sjs	PROPN
gs-3920	351	21	/	/	SYM
gs-3920	351	22	ten	ten	PROPN
gs-3920	351	23	.	.	PUNCT
gs-3920	352	1	agep	agep	NOUN
gs-3920	352	2	typically	typically	ADV
gs-3920	352	3	presents	present	VERB
gs-3920	352	4	with	with	ADP
gs-3920	352	5	a	a	DET
gs-3920	352	6	rapid	rapid	ADJ
gs-3920	352	7	onset	onset	NOUN
gs-3920	352	8	(	(	PUNCT
gs-3920	352	9	often	often	ADV
gs-3920	352	10	within	within	ADP
gs-3920	352	11	2–5	2–5	PROPN
gs-3920	352	12	days	day	NOUN
gs-3920	352	13	)	)	PUNCT
gs-3920	352	14	of	of	ADP
gs-3920	352	15	sterile	sterile	ADJ
gs-3920	352	16	,	,	PUNCT
gs-3920	352	17	nonfollicular	nonfollicular	ADJ
gs-3920	352	18	pustules	pustule	NOUN
gs-3920	352	19	on	on	ADP
gs-3920	352	20	an	an	DET
gs-3920	352	21	erythematous	erythematous	ADJ
gs-3920	352	22	base	base	NOUN
gs-3920	352	23	,	,	PUNCT
gs-3920	352	24	accompanied	accompany	VERB
gs-3920	352	25	by	by	ADP
gs-3920	352	26	fever	fever	NOUN
gs-3920	352	27	and	and	CCONJ
gs-3920	352	28	neutrophilia	neutrophilia	PROPN
gs-3920	352	29	rather	rather	ADV
gs-3920	352	30	than	than	ADP
gs-3920	352	31	eosinophilia	eosinophilia	PROPN
gs-3920	352	32	.	.	PUNCT
gs-3920	353	1	while	while	SCONJ
gs-3920	353	2	agep	agep	NOUN
gs-3920	353	3	may	may	AUX
gs-3920	353	4	cause	cause	VERB
gs-3920	353	5	mild	mild	ADJ
gs-3920	353	6	liver	liver	NOUN
gs-3920	353	7	enzyme	enzyme	NOUN
gs-3920	353	8	elevation	elevation	NOUN
gs-3920	353	9	,	,	PUNCT
gs-3920	353	10	it	it	PRON
gs-3920	353	11	rarely	rarely	ADV
gs-3920	353	12	leads	lead	VERB
gs-3920	353	13	to	to	ADP
gs-3920	353	14	systemic	systemic	ADJ
gs-3920	353	15	organ	organ	NOUN
gs-3920	353	16	damage	damage	NOUN
gs-3920	353	17	.	.	PUNCT
gs-3920	354	1	histopathologically	histopathologically	ADV
gs-3920	354	2	,	,	PUNCT
gs-3920	354	3	agep	agep	NOUN
gs-3920	354	4	shows	show	VERB
gs-3920	354	5	subcorneal	subcorneal	ADJ
gs-3920	354	6	pustules	pustule	NOUN
gs-3920	354	7	and	and	CCONJ
gs-3920	354	8	edema	edema	NOUN
gs-3920	354	9	,	,	PUNCT
gs-3920	354	10	while	while	SCONJ
gs-3920	354	11	dress	dress	NOUN
gs-3920	354	12	reveals	reveal	VERB
gs-3920	354	13	dermal	dermal	VERB
gs-3920	354	14	perivascular	perivascular	ADJ
gs-3920	354	15	infiltration	infiltration	NOUN
gs-3920	354	16	of	of	ADP
gs-3920	354	17	eosinophils	eosinophil	NOUN
gs-3920	354	18	and	and	CCONJ
gs-3920	354	19	lymphocytes	lymphocyte	NOUN
gs-3920	354	20	.	.	PUNCT
gs-3920	355	1	such	such	ADJ
gs-3920	355	2	distinctions	distinction	NOUN
gs-3920	355	3	have	have	VERB
gs-3920	355	4	important	important	ADJ
gs-3920	355	5	therapeutic	therapeutic	ADJ
gs-3920	355	6	implications	implication	NOUN
gs-3920	355	7	,	,	PUNCT
gs-3920	355	8	as	as	SCONJ
gs-3920	355	9	sjs	sjs	PROPN
gs-3920	355	10	/	/	SYM
gs-3920	355	11	ten	ten	PROPN
gs-3920	355	12	often	often	ADV
gs-3920	355	13	requires	require	VERB
gs-3920	355	14	intensive	intensive	ADJ
gs-3920	355	15	supportive	supportive	ADJ
gs-3920	355	16	care	care	NOUN
gs-3920	355	17	and	and	CCONJ
gs-3920	355	18	burn	burn	VERB
gs-3920	355	19	unit	unit	NOUN
gs-3920	355	20	admission	admission	NOUN
gs-3920	355	21	,	,	PUNCT
gs-3920	355	22	while	while	SCONJ
gs-3920	355	23	dress	dress	NOUN
gs-3920	355	24	management	management	NOUN
gs-3920	355	25	revolves	revolve	VERB
gs-3920	355	26	around	around	ADP
gs-3920	355	27	immunosuppression	immunosuppression	NOUN
gs-3920	355	28	and	and	CCONJ
gs-3920	355	29	long	long	ADJ
gs-3920	355	30	-	-	PUNCT
gs-3920	355	31	term	term	NOUN
gs-3920	355	32	follow	follow	NOUN
gs-3920	355	33	-	-	PUNCT
gs-3920	355	34	up	up	NOUN
gs-3920	355	35	.	.	PUNCT
gs-3920	356	1	improved	improve	VERB
gs-3920	356	2	diagnostic	diagnostic	ADJ
gs-3920	356	3	criteria	criterion	NOUN
gs-3920	356	4	and	and	CCONJ
gs-3920	356	5	immunophenotyping	immunophenotype	VERB
gs-3920	356	6	panels	panel	NOUN
gs-3920	356	7	could	could	AUX
gs-3920	356	8	help	help	VERB
gs-3920	356	9	distinguish	distinguish	VERB
gs-3920	356	10	these	these	DET
gs-3920	356	11	overlapping	overlap	VERB
gs-3920	356	12	syndromes	syndrome	NOUN
gs-3920	356	13	and	and	CCONJ
gs-3920	356	14	guide	guide	VERB
gs-3920	356	15	treatment	treatment	NOUN
gs-3920	356	16	.	.	PUNCT
gs-3920	357	1	long	long	ADJ
gs-3920	357	2	-	-	PUNCT
gs-3920	357	3	term	term	NOUN
gs-3920	357	4	monitoring	monitoring	NOUN
gs-3920	357	5	and	and	CCONJ
gs-3920	357	6	autoimmune	autoimmune	ADJ
gs-3920	357	7	sequelae	sequelae	NOUN
gs-3920	357	8	among	among	ADP
gs-3920	357	9	the	the	DET
gs-3920	357	10	most	most	ADJ
gs-3920	357	11	concerning	concern	VERB
gs-3920	357	12	features	feature	NOUN
gs-3920	357	13	of	of	ADP
gs-3920	357	14	dress	dress	NOUN
gs-3920	357	15	syndrome	syndrome	NOUN
gs-3920	357	16	is	be	AUX
gs-3920	357	17	its	its	PRON
gs-3920	357	18	ability	ability	NOUN
gs-3920	357	19	to	to	PART
gs-3920	357	20	induce	induce	VERB
gs-3920	357	21	autoimmune	autoimmune	ADJ
gs-3920	357	22	diseases	disease	NOUN
gs-3920	357	23	months	month	NOUN
gs-3920	357	24	to	to	ADP
gs-3920	357	25	years	year	NOUN
gs-3920	357	26	after	after	ADP
gs-3920	357	27	apparent	apparent	ADJ
gs-3920	357	28	recovery	recovery	NOUN
gs-3920	357	29	.	.	PUNCT
gs-3920	358	1	this	this	DET
gs-3920	358	2	phenomenon	phenomenon	NOUN
gs-3920	358	3	is	be	AUX
gs-3920	358	4	believed	believe	VERB
gs-3920	358	5	to	to	PART
gs-3920	358	6	result	result	VERB
gs-3920	358	7	from	from	ADP
gs-3920	358	8	prolonged	prolonged	ADJ
gs-3920	358	9	immune	immune	ADJ
gs-3920	358	10	activation	activation	NOUN
gs-3920	358	11	and	and	CCONJ
gs-3920	358	12	regulatory	regulatory	ADJ
gs-3920	358	13	t	t	PROPN
gs-3920	358	14	-	-	PUNCT
gs-3920	358	15	cell	cell	NOUN
gs-3920	358	16	dysfunction	dysfunction	NOUN
gs-3920	358	17	.	.	PUNCT
gs-3920	359	1	the	the	DET
gs-3920	359	2	risk	risk	NOUN
gs-3920	359	3	is	be	AUX
gs-3920	359	4	highest	high	ADJ
gs-3920	359	5	in	in	ADP
gs-3920	359	6	individuals	individual	NOUN
gs-3920	359	7	who	who	PRON
gs-3920	359	8	required	require	VERB
gs-3920	359	9	high	high	ADJ
gs-3920	359	10	-	-	PUNCT
gs-3920	359	11	dose	dose	NOUN
gs-3920	359	12	corticosteroids	corticosteroid	NOUN
gs-3920	359	13	or	or	CCONJ
gs-3920	359	14	experienced	experience	VERB
gs-3920	359	15	viral	viral	ADJ
gs-3920	359	16	reactivation	reactivation	NOUN
gs-3920	359	17	during	during	ADP
gs-3920	359	18	the	the	DET
gs-3920	359	19	acute	acute	ADJ
gs-3920	359	20	phase	phase	NOUN
gs-3920	359	21	.	.	PUNCT
gs-3920	360	1	autoimmune	autoimmune	ADJ
gs-3920	360	2	thyroiditis	thyroiditis	NOUN
gs-3920	360	3	,	,	PUNCT
gs-3920	360	4	especially	especially	ADV
gs-3920	360	5	hashimoto	hashimoto	NOUN
gs-3920	360	6	's	's	PART
gs-3920	360	7	thyroiditis	thyroiditis	NOUN
gs-3920	360	8	,	,	PUNCT
gs-3920	360	9	has	have	AUX
gs-3920	360	10	emerged	emerge	VERB
gs-3920	360	11	as	as	ADP
gs-3920	360	12	the	the	DET
gs-3920	360	13	most	most	ADV
gs-3920	360	14	common	common	ADJ
gs-3920	360	15	sequela	sequela	NOUN
gs-3920	360	16	,	,	PUNCT
gs-3920	360	17	with	with	ADP
gs-3920	360	18	patients	patient	NOUN
gs-3920	360	19	developing	develop	VERB
gs-3920	360	20	hypothyroidism	hypothyroidism	NOUN
gs-3920	360	21	within	within	ADP
gs-3920	360	22	3	3	NUM
gs-3920	360	23	to	to	PART
gs-3920	360	24	12	12	NUM
gs-3920	360	25	months	month	NOUN
gs-3920	360	26	post	post	ADJ
gs-3920	360	27	-	-	NOUN
gs-3920	360	28	dress	dress	ADJ
gs-3920	360	29	.	.	PUNCT
gs-3920	361	1	other	other	ADJ
gs-3920	361	2	endocrine	endocrine	NOUN
gs-3920	361	3	disorders	disorder	NOUN
gs-3920	361	4	reported	report	VERB
gs-3920	361	5	include	include	VERB
gs-3920	361	6	type	type	NOUN
gs-3920	361	7	1	1	NUM
gs-3920	361	8	diabetes	diabetes	NOUN
gs-3920	361	9	mellitus	mellitus	NOUN
gs-3920	361	10	,	,	PUNCT
gs-3920	361	11	adrenal	adrenal	ADJ
gs-3920	361	12	insufficiency	insufficiency	NOUN
gs-3920	361	13	,	,	PUNCT
gs-3920	361	14	and	and	CCONJ
gs-3920	361	15	hypoparathyroidism	hypoparathyroidism	NOUN
gs-3920	361	16	.	.	PUNCT
gs-3920	362	1	in	in	ADP
gs-3920	362	2	some	some	DET
gs-3920	362	3	cases	case	NOUN
gs-3920	362	4	,	,	PUNCT
gs-3920	362	5	these	these	DET
gs-3920	362	6	endocrinopathies	endocrinopathie	NOUN
gs-3920	362	7	are	be	AUX
gs-3920	362	8	permanent	permanent	ADJ
gs-3920	362	9	and	and	CCONJ
gs-3920	362	10	require	require	VERB
gs-3920	362	11	lifelong	lifelong	ADJ
gs-3920	362	12	hormone	hormone	NOUN
gs-3920	362	13	replacement	replacement	NOUN
gs-3920	362	14	.	.	PUNCT
gs-3920	363	1	non	non	ADJ
gs-3920	363	2	-	-	ADJ
gs-3920	363	3	endocrine	endocrine	ADJ
gs-3920	363	4	autoimmune	autoimmune	ADJ
gs-3920	363	5	conditions	condition	NOUN
gs-3920	363	6	such	such	ADJ
gs-3920	363	7	as	as	ADP
gs-3920	363	8	systemic	systemic	ADJ
gs-3920	363	9	lupus	lupus	NOUN
gs-3920	363	10	erythematosus	erythematosus	NOUN
gs-3920	363	11	(	(	PUNCT
gs-3920	363	12	sle	sle	PROPN
gs-3920	363	13	)	)	PUNCT
gs-3920	363	14	,	,	PUNCT
gs-3920	363	15	autoimmune	autoimmune	ADJ
gs-3920	363	16	hemolytic	hemolytic	PROPN
gs-3920	363	17	anemia	anemia	NOUN
gs-3920	363	18	,	,	PUNCT
gs-3920	363	19	and	and	CCONJ
gs-3920	363	20	autoimmune	autoimmune	ADJ
gs-3920	363	21	hepatitis	hepatitis	NOUN
gs-3920	363	22	have	have	AUX
gs-3920	363	23	also	also	ADV
gs-3920	363	24	been	be	AUX
gs-3920	363	25	documented	document	VERB
gs-3920	363	26	.	.	PUNCT
gs-3920	364	1	a	a	DET
gs-3920	364	2	prospective	prospective	ADJ
gs-3920	364	3	french	french	ADJ
gs-3920	364	4	study	study	NOUN
gs-3920	364	5	reported	report	VERB
gs-3920	364	6	autoimmune	autoimmune	ADJ
gs-3920	364	7	sequelae	sequelae	NOUN
gs-3920	364	8	in	in	ADP
gs-3920	364	9	approximately	approximately	ADV
gs-3920	364	10	12	12	NUM
gs-3920	364	11	%	%	NOUN
gs-3920	364	12	of	of	ADP
gs-3920	364	13	dress	dress	NOUN
gs-3920	364	14	survivors	survivor	NOUN
gs-3920	364	15	,	,	PUNCT
gs-3920	364	16	emphasizing	emphasize	VERB
gs-3920	364	17	the	the	DET
gs-3920	364	18	need	need	NOUN
gs-3920	364	19	for	for	ADP
gs-3920	364	20	long	long	ADJ
gs-3920	364	21	-	-	PUNCT
gs-3920	364	22	term	term	NOUN
gs-3920	364	23	surveillance	surveillance	NOUN
gs-3920	364	24	.	.	PUNCT
gs-3920	365	1	follow	follow	VERB
gs-3920	365	2	-	-	PUNCT
gs-3920	365	3	up	up	ADP
gs-3920	365	4	protocols	protocol	NOUN
gs-3920	365	5	should	should	AUX
gs-3920	365	6	include	include	VERB
gs-3920	365	7	periodic	periodic	ADJ
gs-3920	365	8	thyroid	thyroid	NOUN
gs-3920	365	9	function	function	NOUN
gs-3920	365	10	tests	test	NOUN
gs-3920	365	11	,	,	PUNCT
gs-3920	365	12	fasting	fast	VERB
gs-3920	365	13	glucose	glucose	NOUN
gs-3920	365	14	levels	level	NOUN
gs-3920	365	15	,	,	PUNCT
gs-3920	365	16	and	and	CCONJ
gs-3920	365	17	organ	organ	NOUN
gs-3920	365	18	-	-	PUNCT
gs-3920	365	19	specific	specific	ADJ
gs-3920	365	20	autoantibody	autoantibody	ADJ
gs-3920	365	21	panels	panel	NOUN
gs-3920	365	22	.	.	PUNCT
gs-3920	366	1	furthermore	furthermore	ADV
gs-3920	366	2	,	,	PUNCT
gs-3920	366	3	persistent	persistent	ADJ
gs-3920	366	4	immune	immune	ADJ
gs-3920	366	5	dysregulation	dysregulation	NOUN
gs-3920	366	6	may	may	AUX
gs-3920	366	7	affect	affect	VERB
gs-3920	366	8	neuropsychiatric	neuropsychiatric	ADJ
gs-3920	366	9	function	function	NOUN
gs-3920	366	10	,	,	PUNCT
gs-3920	366	11	with	with	ADP
gs-3920	366	12	reports	report	NOUN
gs-3920	366	13	of	of	ADP
gs-3920	366	14	cognitive	cognitive	ADJ
gs-3920	366	15	impairment	impairment	NOUN
gs-3920	366	16	,	,	PUNCT
gs-3920	366	17	mood	mood	NOUN
gs-3920	366	18	disorders	disorder	NOUN
gs-3920	366	19	,	,	PUNCT
gs-3920	366	20	and	and	CCONJ
gs-3920	366	21	chronic	chronic	ADJ
gs-3920	366	22	fatigue	fatigue	NOUN
gs-3920	366	23	syndrome	syndrome	NOUN
gs-3920	366	24	.	.	PUNCT
gs-3920	367	1	while	while	SCONJ
gs-3920	367	2	causality	causality	NOUN
gs-3920	367	3	remains	remain	VERB
gs-3920	367	4	difficult	difficult	ADJ
gs-3920	367	5	to	to	PART
gs-3920	367	6	establish	establish	VERB
gs-3920	367	7	,	,	PUNCT
gs-3920	367	8	the	the	DET
gs-3920	367	9	immune	immune	NOUN
gs-3920	367	10	-	-	PUNCT
gs-3920	367	11	inflammatory	inflammatory	ADJ
gs-3920	367	12	nature	nature	NOUN
gs-3920	367	13	of	of	ADP
gs-3920	367	14	dress	dress	NOUN
gs-3920	367	15	may	may	AUX
gs-3920	367	16	have	have	VERB
gs-3920	367	17	downstream	downstream	ADJ
gs-3920	367	18	effects	effect	NOUN
gs-3920	367	19	on	on	ADP
gs-3920	367	20	the	the	DET
gs-3920	367	21	central	central	ADJ
gs-3920	367	22	nervous	nervous	ADJ
gs-3920	367	23	system	system	NOUN
gs-3920	367	24	,	,	PUNCT
gs-3920	367	25	warranting	warrant	VERB
gs-3920	367	26	future	future	ADJ
gs-3920	367	27	neuroimmunological	neuroimmunological	ADJ
gs-3920	367	28	studies	study	NOUN
gs-3920	367	29	.	.	PUNCT
gs-3920	368	1	georgian	georgian	ADJ
gs-3920	368	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	368	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	368	4	ტ.	ტ.	VERB
gs-3920	368	5	7	7	NUM
gs-3920	368	6	n	n	PRON
gs-3920	368	7	3	3	NUM
gs-3920	368	8	,	,	PUNCT
gs-3920	368	9	2025	2025	NUM
gs-3920	368	10	203	203	NUM
gs-3920	368	11	impact	impact	NOUN
gs-3920	368	12	of	of	ADP
gs-3920	368	13	polypharmacy	polypharmacy	NOUN
gs-3920	368	14	and	and	CCONJ
gs-3920	368	15	drug	drug	NOUN
gs-3920	368	16	interactions	interaction	NOUN
gs-3920	368	17	polypharmacy	polypharmacy	NOUN
gs-3920	368	18	,	,	PUNCT
gs-3920	368	19	especially	especially	ADV
gs-3920	368	20	among	among	ADP
gs-3920	368	21	elderly	elderly	ADJ
gs-3920	368	22	and	and	CCONJ
gs-3920	368	23	multimorbid	multimorbid	ADJ
gs-3920	368	24	patients	patient	NOUN
gs-3920	368	25	,	,	PUNCT
gs-3920	368	26	has	have	AUX
gs-3920	368	27	emerged	emerge	VERB
gs-3920	368	28	as	as	ADP
gs-3920	368	29	a	a	DET
gs-3920	368	30	key	key	ADJ
gs-3920	368	31	risk	risk	NOUN
gs-3920	368	32	factor	factor	NOUN
gs-3920	368	33	for	for	ADP
gs-3920	368	34	dress	dress	NOUN
gs-3920	368	35	syndrome	syndrome	NOUN
gs-3920	368	36	.	.	PUNCT
gs-3920	369	1	our	our	PRON
gs-3920	369	2	synthesis	synthesis	NOUN
gs-3920	369	3	of	of	ADP
gs-3920	369	4	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	369	5	data	datum	NOUN
gs-3920	369	6	indicates	indicate	VERB
gs-3920	369	7	that	that	SCONJ
gs-3920	369	8	patients	patient	NOUN
gs-3920	369	9	receiving	receive	VERB
gs-3920	369	10	multiple	multiple	ADJ
gs-3920	369	11	concurrent	concurrent	ADJ
gs-3920	369	12	medications	medication	NOUN
gs-3920	369	13	are	be	AUX
gs-3920	369	14	more	more	ADV
gs-3920	369	15	likely	likely	ADJ
gs-3920	369	16	to	to	PART
gs-3920	369	17	develop	develop	VERB
gs-3920	369	18	dress	dress	NOUN
gs-3920	369	19	,	,	PUNCT
gs-3920	369	20	particularly	particularly	ADV
gs-3920	369	21	when	when	SCONJ
gs-3920	369	22	drugs	drug	NOUN
gs-3920	369	23	with	with	ADP
gs-3920	369	24	known	know	VERB
gs-3920	369	25	immunogenic	immunogenic	ADJ
gs-3920	369	26	potential	potential	NOUN
gs-3920	369	27	are	be	AUX
gs-3920	369	28	co	co	VERB
gs-3920	369	29	-	-	VERB
gs-3920	369	30	administered	administered	ADJ
gs-3920	369	31	.	.	PUNCT
gs-3920	370	1	notable	notable	ADJ
gs-3920	370	2	examples	example	NOUN
gs-3920	370	3	include	include	VERB
gs-3920	370	4	combinations	combination	NOUN
gs-3920	370	5	of	of	ADP
gs-3920	370	6	allopurinol	allopurinol	NOUN
gs-3920	370	7	with	with	ADP
gs-3920	370	8	thiazide	thiazide	ADJ
gs-3920	370	9	diuretics	diuretic	NOUN
gs-3920	370	10	or	or	CCONJ
gs-3920	370	11	antibiotics	antibiotic	NOUN
gs-3920	370	12	with	with	ADP
gs-3920	370	13	antiepileptics	antiepileptic	NOUN
gs-3920	370	14	.	.	PUNCT
gs-3920	371	1	drug	drug	NOUN
gs-3920	371	2	interactions	interaction	NOUN
gs-3920	371	3	may	may	AUX
gs-3920	371	4	potentiate	potentiate	VERB
gs-3920	371	5	dress	dress	NOUN
gs-3920	371	6	risk	risk	NOUN
gs-3920	371	7	by	by	ADP
gs-3920	371	8	altering	alter	VERB
gs-3920	371	9	drug	drug	NOUN
gs-3920	371	10	metabolism	metabolism	NOUN
gs-3920	371	11	or	or	CCONJ
gs-3920	371	12	clearance	clearance	NOUN
gs-3920	371	13	.	.	PUNCT
gs-3920	372	1	inhibitors	inhibitor	NOUN
gs-3920	372	2	of	of	ADP
gs-3920	372	3	cytochrome	cytochrome	ADJ
gs-3920	372	4	p450	p450	NUM
gs-3920	372	5	enzymes	enzyme	NOUN
gs-3920	372	6	(	(	PUNCT
gs-3920	372	7	e.g.	e.g.	ADV
gs-3920	372	8	,	,	PUNCT
gs-3920	372	9	fluconazole	fluconazole	NOUN
gs-3920	372	10	,	,	PUNCT
gs-3920	372	11	erythromycin	erythromycin	NOUN
gs-3920	372	12	)	)	PUNCT
gs-3920	372	13	can	can	AUX
gs-3920	372	14	increase	increase	VERB
gs-3920	372	15	systemic	systemic	ADJ
gs-3920	372	16	exposure	exposure	NOUN
gs-3920	372	17	to	to	ADP
gs-3920	372	18	reactive	reactive	ADJ
gs-3920	372	19	metabolites	metabolite	NOUN
gs-3920	372	20	,	,	PUNCT
gs-3920	372	21	while	while	SCONJ
gs-3920	372	22	nephrotoxic	nephrotoxic	ADJ
gs-3920	372	23	agents	agent	NOUN
gs-3920	372	24	may	may	AUX
gs-3920	372	25	impair	impair	VERB
gs-3920	372	26	renal	renal	ADJ
gs-3920	372	27	excretion	excretion	NOUN
gs-3920	372	28	,	,	PUNCT
gs-3920	372	29	prolonging	prolong	VERB
gs-3920	372	30	drug	drug	NOUN
gs-3920	372	31	half	half	ADJ
gs-3920	372	32	-	-	PUNCT
gs-3920	372	33	life	life	NOUN
gs-3920	372	34	.	.	PUNCT
gs-3920	373	1	additionally	additionally	ADV
gs-3920	373	2	,	,	PUNCT
gs-3920	373	3	immunomodulatory	immunomodulatory	ADJ
gs-3920	373	4	agents	agent	NOUN
gs-3920	373	5	such	such	ADJ
gs-3920	373	6	as	as	ADP
gs-3920	373	7	interferons	interferon	NOUN
gs-3920	373	8	or	or	CCONJ
gs-3920	373	9	tnf	tnf	PROPN
gs-3920	373	10	inhibitors	inhibitor	NOUN
gs-3920	373	11	may	may	AUX
gs-3920	373	12	lower	lower	VERB
gs-3920	373	13	the	the	DET
gs-3920	373	14	threshold	threshold	NOUN
gs-3920	373	15	for	for	ADP
gs-3920	373	16	aberrant	aberrant	ADJ
gs-3920	373	17	t	t	PROPN
gs-3920	373	18	-	-	PUNCT
gs-3920	373	19	cell	cell	NOUN
gs-3920	373	20	responses	response	NOUN
gs-3920	373	21	.	.	PUNCT
gs-3920	374	1	healthcare	healthcare	NOUN
gs-3920	374	2	providers	provider	NOUN
gs-3920	374	3	should	should	AUX
gs-3920	374	4	maintain	maintain	VERB
gs-3920	374	5	high	high	ADJ
gs-3920	374	6	vigilance	vigilance	NOUN
gs-3920	374	7	when	when	SCONJ
gs-3920	374	8	prescribing	prescribe	VERB
gs-3920	374	9	to	to	ADP
gs-3920	374	10	patients	patient	NOUN
gs-3920	374	11	with	with	ADP
gs-3920	374	12	multiple	multiple	ADJ
gs-3920	374	13	comorbidities	comorbiditie	NOUN
gs-3920	374	14	or	or	CCONJ
gs-3920	374	15	genetic	genetic	ADJ
gs-3920	374	16	risk	risk	NOUN
gs-3920	374	17	factors	factor	NOUN
gs-3920	374	18	.	.	PUNCT
gs-3920	375	1	comprehensive	comprehensive	ADJ
gs-3920	375	2	medication	medication	NOUN
gs-3920	375	3	reconciliation	reconciliation	NOUN
gs-3920	375	4	,	,	PUNCT
gs-3920	375	5	use	use	NOUN
gs-3920	375	6	of	of	ADP
gs-3920	375	7	clinical	clinical	ADJ
gs-3920	375	8	decision	decision	NOUN
gs-3920	375	9	support	support	NOUN
gs-3920	375	10	tools	tool	NOUN
gs-3920	375	11	,	,	PUNCT
gs-3920	375	12	and	and	CCONJ
gs-3920	375	13	pharmacist	pharmacist	NOUN
gs-3920	375	14	collaboration	collaboration	NOUN
gs-3920	375	15	are	be	AUX
gs-3920	375	16	essential	essential	ADJ
gs-3920	375	17	strategies	strategy	NOUN
gs-3920	375	18	to	to	PART
gs-3920	375	19	prevent	prevent	VERB
gs-3920	375	20	adverse	adverse	ADJ
gs-3920	375	21	interactions	interaction	NOUN
gs-3920	375	22	that	that	PRON
gs-3920	375	23	could	could	AUX
gs-3920	375	24	trigger	trigger	VERB
gs-3920	375	25	hypersensitivity	hypersensitivity	NOUN
gs-3920	375	26	reactions	reaction	NOUN
gs-3920	375	27	.	.	PUNCT
gs-3920	376	1	gender	gender	NOUN
gs-3920	376	2	and	and	CCONJ
gs-3920	376	3	ethnic	ethnic	ADJ
gs-3920	376	4	variations	variation	NOUN
gs-3920	376	5	in	in	ADP
gs-3920	376	6	clinical	clinical	ADJ
gs-3920	376	7	course	course	NOUN
gs-3920	376	8	emerging	emerge	VERB
gs-3920	376	9	evidence	evidence	NOUN
gs-3920	376	10	suggests	suggest	VERB
gs-3920	376	11	that	that	SCONJ
gs-3920	376	12	both	both	CCONJ
gs-3920	376	13	gender	gender	NOUN
gs-3920	376	14	and	and	CCONJ
gs-3920	376	15	ethnicity	ethnicity	NOUN
gs-3920	376	16	influence	influence	NOUN
gs-3920	376	17	dress	dress	NOUN
gs-3920	376	18	susceptibility	susceptibility	NOUN
gs-3920	376	19	and	and	CCONJ
gs-3920	376	20	clinical	clinical	ADJ
gs-3920	376	21	severity	severity	NOUN
gs-3920	376	22	.	.	PUNCT
gs-3920	377	1	women	woman	NOUN
gs-3920	377	2	appear	appear	VERB
gs-3920	377	3	slightly	slightly	ADV
gs-3920	377	4	more	more	ADV
gs-3920	377	5	predisposed	predisposed	ADJ
gs-3920	377	6	to	to	ADP
gs-3920	377	7	developing	develop	VERB
gs-3920	377	8	dress	dress	NOUN
gs-3920	377	9	,	,	PUNCT
gs-3920	377	10	with	with	ADP
gs-3920	377	11	a	a	DET
gs-3920	377	12	female	female	NOUN
gs-3920	377	13	-	-	PUNCT
gs-3920	377	14	to	to	ADP
gs-3920	377	15	-	-	PUNCT
gs-3920	377	16	male	male	NOUN
gs-3920	377	17	ratio	ratio	NOUN
gs-3920	377	18	of	of	ADP
gs-3920	377	19	approximately	approximately	ADV
gs-3920	377	20	1.2:1	1.2:1	PROPN
gs-3920	377	21	reported	report	VERB
gs-3920	377	22	in	in	ADP
gs-3920	377	23	several	several	ADJ
gs-3920	377	24	cohorts	cohort	NOUN
gs-3920	377	25	.	.	PUNCT
gs-3920	378	1	while	while	SCONJ
gs-3920	378	2	the	the	DET
gs-3920	378	3	reasons	reason	NOUN
gs-3920	378	4	remain	remain	VERB
gs-3920	378	5	unclear	unclear	ADJ
gs-3920	378	6	,	,	PUNCT
gs-3920	378	7	hormonal	hormonal	ADJ
gs-3920	378	8	modulation	modulation	NOUN
gs-3920	378	9	of	of	ADP
gs-3920	378	10	immune	immune	ADJ
gs-3920	378	11	responses	response	NOUN
gs-3920	378	12	and	and	CCONJ
gs-3920	378	13	differences	difference	NOUN
gs-3920	378	14	in	in	ADP
gs-3920	378	15	drug	drug	NOUN
gs-3920	378	16	metabolism	metabolism	NOUN
gs-3920	378	17	have	have	AUX
gs-3920	378	18	been	be	AUX
gs-3920	378	19	proposed	propose	VERB
gs-3920	378	20	.	.	PUNCT
gs-3920	379	1	ethnic	ethnic	ADJ
gs-3920	379	2	disparities	disparity	NOUN
gs-3920	379	3	are	be	AUX
gs-3920	379	4	more	more	ADV
gs-3920	379	5	pronounced	pronounce	VERB
gs-3920	379	6	and	and	CCONJ
gs-3920	379	7	are	be	AUX
gs-3920	379	8	largely	largely	ADV
gs-3920	379	9	attributable	attributable	ADJ
gs-3920	379	10	to	to	ADP
gs-3920	379	11	genetic	genetic	ADJ
gs-3920	379	12	polymorphisms	polymorphism	NOUN
gs-3920	379	13	in	in	ADP
gs-3920	379	14	hla	hla	PROPN
gs-3920	379	15	alleles	allele	NOUN
gs-3920	379	16	.	.	PUNCT
gs-3920	380	1	as	as	SCONJ
gs-3920	380	2	noted	note	VERB
gs-3920	380	3	,	,	PUNCT
gs-3920	380	4	hla	hla	PROPN
gs-3920	380	5	-	-	PUNCT
gs-3920	380	6	b15:02	b15:02	PROPN
gs-3920	380	7	and	and	CCONJ
gs-3920	380	8	hla	hla	PROPN
gs-3920	380	9	-	-	PUNCT
gs-3920	380	10	b58:01	b58:01	PROPN
gs-3920	380	11	are	be	AUX
gs-3920	380	12	predominantly	predominantly	ADV
gs-3920	380	13	found	find	VERB
gs-3920	380	14	in	in	ADP
gs-3920	380	15	east	east	PROPN
gs-3920	380	16	and	and	CCONJ
gs-3920	380	17	southeast	southeast	ADJ
gs-3920	380	18	asian	asian	ADJ
gs-3920	380	19	populations	population	NOUN
gs-3920	380	20	,	,	PUNCT
gs-3920	380	21	explaining	explain	VERB
gs-3920	380	22	the	the	DET
gs-3920	380	23	higher	high	ADJ
gs-3920	380	24	incidence	incidence	NOUN
gs-3920	380	25	of	of	ADP
gs-3920	380	26	carbamazepineand	carbamazepineand	NOUN
gs-3920	380	27	allopurinol	allopurinol	NOUN
gs-3920	380	28	-	-	PUNCT
gs-3920	380	29	induced	induce	VERB
gs-3920	380	30	dress	dress	NOUN
gs-3920	380	31	,	,	PUNCT
gs-3920	380	32	respectively	respectively	ADV
gs-3920	380	33	.	.	PUNCT
gs-3920	381	1	african	african	ADJ
gs-3920	381	2	and	and	CCONJ
gs-3920	381	3	africanamerican	africanamerican	ADJ
gs-3920	381	4	patients	patient	NOUN
gs-3920	381	5	,	,	PUNCT
gs-3920	381	6	on	on	ADP
gs-3920	381	7	the	the	DET
gs-3920	381	8	other	other	ADJ
gs-3920	381	9	hand	hand	NOUN
gs-3920	381	10	,	,	PUNCT
gs-3920	381	11	show	show	VERB
gs-3920	381	12	higher	high	ADJ
gs-3920	381	13	prevalence	prevalence	NOUN
gs-3920	381	14	of	of	ADP
gs-3920	381	15	dress	dress	NOUN
gs-3920	381	16	related	relate	VERB
gs-3920	381	17	to	to	ADP
gs-3920	381	18	sulfonamides	sulfonamide	NOUN
gs-3920	381	19	and	and	CCONJ
gs-3920	381	20	antiretrovirals	antiretroviral	NOUN
gs-3920	381	21	.	.	PUNCT
gs-3920	382	1	cultural	cultural	ADJ
gs-3920	382	2	practices	practice	NOUN
gs-3920	382	3	,	,	PUNCT
gs-3920	382	4	healthcare	healthcare	NOUN
gs-3920	382	5	access	access	NOUN
gs-3920	382	6	,	,	PUNCT
gs-3920	382	7	and	and	CCONJ
gs-3920	382	8	diagnostic	diagnostic	ADJ
gs-3920	382	9	delay	delay	NOUN
gs-3920	382	10	may	may	AUX
gs-3920	382	11	further	far	ADV
gs-3920	382	12	exacerbate	exacerbate	VERB
gs-3920	382	13	outcomes	outcome	NOUN
gs-3920	382	14	in	in	ADP
gs-3920	382	15	underserved	underserved	ADJ
gs-3920	382	16	populations	population	NOUN
gs-3920	382	17	.	.	PUNCT
gs-3920	383	1	inclusive	inclusive	ADJ
gs-3920	383	2	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	383	3	studies	study	NOUN
gs-3920	383	4	and	and	CCONJ
gs-3920	383	5	equitable	equitable	ADJ
gs-3920	383	6	access	access	NOUN
gs-3920	383	7	to	to	ADP
gs-3920	383	8	genetic	genetic	ADJ
gs-3920	383	9	testing	testing	NOUN
gs-3920	383	10	are	be	AUX
gs-3920	383	11	necessary	necessary	ADJ
gs-3920	383	12	to	to	PART
gs-3920	383	13	ensure	ensure	VERB
gs-3920	383	14	appropriate	appropriate	ADJ
gs-3920	383	15	prevention	prevention	NOUN
gs-3920	383	16	strategies	strategy	NOUN
gs-3920	383	17	across	across	ADP
gs-3920	383	18	diverse	diverse	ADJ
gs-3920	383	19	populations	population	NOUN
gs-3920	383	20	.	.	PUNCT
gs-3920	384	1	training	training	NOUN
gs-3920	384	2	,	,	PUNCT
gs-3920	384	3	awareness	awareness	NOUN
gs-3920	384	4	,	,	PUNCT
gs-3920	384	5	and	and	CCONJ
gs-3920	384	6	health	health	NOUN
gs-3920	384	7	system	system	NOUN
gs-3920	384	8	interventions	intervention	NOUN
gs-3920	384	9	despite	despite	SCONJ
gs-3920	384	10	its	its	PRON
gs-3920	384	11	severity	severity	NOUN
gs-3920	384	12	,	,	PUNCT
gs-3920	384	13	dress	dress	NOUN
gs-3920	384	14	remains	remains	AUX
gs-3920	384	15	poorly	poorly	ADV
gs-3920	384	16	understood	understand	VERB
gs-3920	384	17	by	by	ADP
gs-3920	384	18	many	many	ADJ
gs-3920	384	19	non	non	ADJ
gs-3920	384	20	-	-	ADJ
gs-3920	384	21	specialist	specialist	ADJ
gs-3920	384	22	clinicians	clinician	NOUN
gs-3920	384	23	,	,	PUNCT
gs-3920	384	24	leading	lead	VERB
gs-3920	384	25	to	to	ADP
gs-3920	384	26	misdiagnosis	misdiagnosis	NOUN
gs-3920	384	27	or	or	CCONJ
gs-3920	384	28	inappropriate	inappropriate	ADJ
gs-3920	384	29	management	management	NOUN
gs-3920	384	30	.	.	PUNCT
gs-3920	385	1	surveys	survey	NOUN
gs-3920	385	2	of	of	ADP
gs-3920	385	3	primary	primary	ADJ
gs-3920	385	4	care	care	NOUN
gs-3920	385	5	and	and	CCONJ
gs-3920	385	6	emergency	emergency	NOUN
gs-3920	385	7	physicians	physician	NOUN
gs-3920	385	8	reveal	reveal	VERB
gs-3920	385	9	significant	significant	ADJ
gs-3920	385	10	gaps	gap	NOUN
gs-3920	385	11	in	in	ADP
gs-3920	385	12	awareness	awareness	NOUN
gs-3920	385	13	regarding	regard	VERB
gs-3920	385	14	the	the	DET
gs-3920	385	15	latency	latency	NOUN
gs-3920	385	16	period	period	NOUN
gs-3920	385	17	,	,	PUNCT
gs-3920	385	18	georgian	georgian	PROPN
gs-3920	385	19	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	385	20	მეცნიერები	მეცნიერები	NOUN
gs-3920	385	21	ტ.	ტ.	VERB
gs-3920	385	22	7	7	NUM
gs-3920	385	23	n	n	PRON
gs-3920	385	24	3	3	NUM
gs-3920	385	25	,	,	PUNCT
gs-3920	385	26	2025	2025	NUM
gs-3920	385	27	204	204	NUM
gs-3920	385	28	diagnostic	diagnostic	ADJ
gs-3920	385	29	criteria	criterion	NOUN
gs-3920	385	30	,	,	PUNCT
gs-3920	385	31	and	and	CCONJ
gs-3920	385	32	need	need	VERB
gs-3920	385	33	for	for	ADP
gs-3920	385	34	long	long	ADJ
gs-3920	385	35	-	-	PUNCT
gs-3920	385	36	term	term	NOUN
gs-3920	385	37	follow	follow	NOUN
gs-3920	385	38	-	-	PUNCT
gs-3920	385	39	up	up	NOUN
gs-3920	385	40	.	.	PUNCT
gs-3920	386	1	education	education	NOUN
gs-3920	386	2	efforts	effort	NOUN
gs-3920	386	3	must	must	AUX
gs-3920	386	4	be	be	AUX
gs-3920	386	5	strengthened	strengthen	VERB
gs-3920	386	6	at	at	ADP
gs-3920	386	7	both	both	CCONJ
gs-3920	386	8	undergraduate	undergraduate	ADJ
gs-3920	386	9	and	and	CCONJ
gs-3920	386	10	postgraduate	postgraduate	NOUN
gs-3920	386	11	levels	level	NOUN
gs-3920	386	12	.	.	PUNCT
gs-3920	387	1	hospitals	hospital	NOUN
gs-3920	387	2	should	should	AUX
gs-3920	387	3	consider	consider	VERB
gs-3920	387	4	implementing	implement	VERB
gs-3920	387	5	clinical	clinical	ADJ
gs-3920	387	6	decision	decision	NOUN
gs-3920	387	7	support	support	NOUN
gs-3920	387	8	alerts	alert	NOUN
gs-3920	387	9	for	for	ADP
gs-3920	387	10	high	high	ADJ
gs-3920	387	11	-	-	PUNCT
gs-3920	387	12	risk	risk	NOUN
gs-3920	387	13	drug	drug	NOUN
gs-3920	387	14	prescriptions	prescription	NOUN
gs-3920	387	15	,	,	PUNCT
gs-3920	387	16	flagging	flag	VERB
gs-3920	387	17	patients	patient	NOUN
gs-3920	387	18	with	with	ADP
gs-3920	387	19	known	known	ADJ
gs-3920	387	20	hla	hla	NOUN
gs-3920	387	21	risk	risk	NOUN
gs-3920	387	22	alleles	allele	NOUN
gs-3920	387	23	.	.	PUNCT
gs-3920	388	1	interdisciplinary	interdisciplinary	ADJ
gs-3920	388	2	rounds	round	NOUN
gs-3920	388	3	including	include	VERB
gs-3920	388	4	dermatologists	dermatologist	NOUN
gs-3920	388	5	,	,	PUNCT
gs-3920	388	6	allergists	allergist	NOUN
gs-3920	388	7	,	,	PUNCT
gs-3920	388	8	pharmacists	pharmacist	NOUN
gs-3920	388	9	,	,	PUNCT
gs-3920	388	10	and	and	CCONJ
gs-3920	388	11	internists	internist	NOUN
gs-3920	388	12	can	can	AUX
gs-3920	388	13	improve	improve	VERB
gs-3920	388	14	diagnostic	diagnostic	ADJ
gs-3920	388	15	accuracy	accuracy	NOUN
gs-3920	388	16	and	and	CCONJ
gs-3920	388	17	treatment	treatment	NOUN
gs-3920	388	18	planning	planning	NOUN
gs-3920	388	19	.	.	PUNCT
gs-3920	389	1	in	in	ADP
gs-3920	389	2	settings	setting	NOUN
gs-3920	389	3	where	where	SCONJ
gs-3920	389	4	dermatology	dermatology	NOUN
gs-3920	389	5	services	service	NOUN
gs-3920	389	6	are	be	AUX
gs-3920	389	7	limited	limited	ADJ
gs-3920	389	8	,	,	PUNCT
gs-3920	389	9	telemedicine	telemedicine	NOUN
gs-3920	389	10	consultations	consultation	NOUN
gs-3920	389	11	have	have	AUX
gs-3920	389	12	proven	prove	VERB
gs-3920	389	13	effective	effective	ADJ
gs-3920	389	14	in	in	ADP
gs-3920	389	15	guiding	guide	VERB
gs-3920	389	16	initial	initial	ADJ
gs-3920	389	17	management	management	NOUN
gs-3920	389	18	of	of	ADP
gs-3920	389	19	suspected	suspect	VERB
gs-3920	389	20	scars	scar	NOUN
gs-3920	389	21	.	.	PUNCT
gs-3920	390	1	public	public	ADJ
gs-3920	390	2	health	health	NOUN
gs-3920	390	3	agencies	agency	NOUN
gs-3920	390	4	should	should	AUX
gs-3920	390	5	invest	invest	VERB
gs-3920	390	6	in	in	ADP
gs-3920	390	7	awareness	awareness	NOUN
gs-3920	390	8	campaigns	campaign	NOUN
gs-3920	390	9	and	and	CCONJ
gs-3920	390	10	reporting	report	VERB
gs-3920	390	11	infrastructure	infrastructure	NOUN
gs-3920	390	12	to	to	PART
gs-3920	390	13	track	track	VERB
gs-3920	390	14	dress	dress	NOUN
gs-3920	390	15	incidence	incidence	NOUN
gs-3920	390	16	and	and	CCONJ
gs-3920	390	17	outcomes	outcome	NOUN
gs-3920	390	18	.	.	PUNCT
gs-3920	391	1	patient	patient	NOUN
gs-3920	391	2	-	-	PUNCT
gs-3920	391	3	facing	face	VERB
gs-3920	391	4	educational	educational	ADJ
gs-3920	391	5	materials	material	NOUN
gs-3920	391	6	can	can	AUX
gs-3920	391	7	empower	empower	VERB
gs-3920	391	8	individuals	individual	NOUN
gs-3920	391	9	to	to	PART
gs-3920	391	10	recognize	recognize	VERB
gs-3920	391	11	symptoms	symptom	NOUN
gs-3920	391	12	and	and	CCONJ
gs-3920	391	13	seek	seek	VERB
gs-3920	391	14	timely	timely	ADJ
gs-3920	391	15	care	care	NOUN
gs-3920	391	16	,	,	PUNCT
gs-3920	391	17	especially	especially	ADV
gs-3920	391	18	in	in	ADP
gs-3920	391	19	regions	region	NOUN
gs-3920	391	20	with	with	ADP
gs-3920	391	21	limited	limited	ADJ
gs-3920	391	22	specialist	specialist	ADJ
gs-3920	391	23	access	access	NOUN
gs-3920	391	24	.	.	PUNCT
gs-3920	392	1	conclusion	conclusion	NOUN
gs-3920	392	2	of	of	ADP
gs-3920	392	3	extended	extended	ADJ
gs-3920	392	4	results	result	NOUN
gs-3920	392	5	and	and	CCONJ
gs-3920	392	6	discussion	discussion	NOUN
gs-3920	392	7	together	together	ADV
gs-3920	392	8	,	,	PUNCT
gs-3920	392	9	the	the	DET
gs-3920	392	10	extended	extended	ADJ
gs-3920	392	11	findings	finding	NOUN
gs-3920	392	12	presented	present	VERB
gs-3920	392	13	herein	herein	NOUN
gs-3920	392	14	underscore	underscore	VERB
gs-3920	392	15	the	the	DET
gs-3920	392	16	complexity	complexity	NOUN
gs-3920	392	17	of	of	ADP
gs-3920	392	18	dress	dress	NOUN
gs-3920	392	19	syndrome	syndrome	NOUN
gs-3920	392	20	as	as	ADP
gs-3920	392	21	a	a	DET
gs-3920	392	22	multifaceted	multifaceted	ADJ
gs-3920	392	23	disorder	disorder	NOUN
gs-3920	392	24	straddling	straddle	VERB
gs-3920	392	25	immunology	immunology	NOUN
gs-3920	392	26	,	,	PUNCT
gs-3920	392	27	pharmacology	pharmacology	NOUN
gs-3920	392	28	,	,	PUNCT
gs-3920	392	29	and	and	CCONJ
gs-3920	392	30	genomics	genomic	NOUN
gs-3920	392	31	.	.	PUNCT
gs-3920	393	1	from	from	ADP
gs-3920	393	2	identifying	identify	VERB
gs-3920	393	3	high	high	ADJ
gs-3920	393	4	-	-	PUNCT
gs-3920	393	5	risk	risk	NOUN
gs-3920	393	6	genotypes	genotype	NOUN
gs-3920	393	7	to	to	ADP
gs-3920	393	8	unraveling	unravel	VERB
gs-3920	393	9	downstream	downstream	ADJ
gs-3920	393	10	immune	immune	ADJ
gs-3920	393	11	dysfunction	dysfunction	NOUN
gs-3920	393	12	and	and	CCONJ
gs-3920	393	13	viral	viral	ADJ
gs-3920	393	14	interplay	interplay	NOUN
gs-3920	393	15	,	,	PUNCT
gs-3920	393	16	our	our	PRON
gs-3920	393	17	evolving	evolve	VERB
gs-3920	393	18	understanding	understanding	NOUN
gs-3920	393	19	paves	pave	VERB
gs-3920	393	20	the	the	DET
gs-3920	393	21	way	way	NOUN
gs-3920	393	22	for	for	ADP
gs-3920	393	23	personalized	personalized	ADJ
gs-3920	393	24	prevention	prevention	NOUN
gs-3920	393	25	,	,	PUNCT
gs-3920	393	26	timely	timely	ADJ
gs-3920	393	27	diagnosis	diagnosis	NOUN
gs-3920	393	28	,	,	PUNCT
gs-3920	393	29	and	and	CCONJ
gs-3920	393	30	targeted	target	VERB
gs-3920	393	31	therapeutics	therapeutic	NOUN
gs-3920	393	32	.	.	PUNCT
gs-3920	394	1	continued	continue	VERB
gs-3920	394	2	global	global	ADJ
gs-3920	394	3	collaboration	collaboration	NOUN
gs-3920	394	4	,	,	PUNCT
gs-3920	394	5	coupled	couple	VERB
gs-3920	394	6	with	with	ADP
gs-3920	394	7	cutting	cut	VERB
gs-3920	394	8	-	-	PUNCT
gs-3920	394	9	edge	edge	NOUN
gs-3920	394	10	translational	translational	ADJ
gs-3920	394	11	research	research	NOUN
gs-3920	394	12	,	,	PUNCT
gs-3920	394	13	will	will	AUX
gs-3920	394	14	be	be	AUX
gs-3920	394	15	essential	essential	ADJ
gs-3920	394	16	in	in	ADP
gs-3920	394	17	reducing	reduce	VERB
gs-3920	394	18	the	the	DET
gs-3920	394	19	morbidity	morbidity	NOUN
gs-3920	394	20	,	,	PUNCT
gs-3920	394	21	mortality	mortality	NOUN
gs-3920	394	22	,	,	PUNCT
gs-3920	394	23	and	and	CCONJ
gs-3920	394	24	long	long	ADJ
gs-3920	394	25	-	-	PUNCT
gs-3920	394	26	term	term	NOUN
gs-3920	394	27	sequelae	sequelae	NOUN
gs-3920	394	28	of	of	ADP
gs-3920	394	29	this	this	DET
gs-3920	394	30	serious	serious	ADJ
gs-3920	394	31	and	and	CCONJ
gs-3920	394	32	often	often	ADV
gs-3920	394	33	overlooked	overlook	VERB
gs-3920	394	34	syndrome	syndrome	NOUN
gs-3920	394	35	.	.	PUNCT
gs-3920	395	1	case	case	NOUN
gs-3920	395	2	reports	report	VERB
gs-3920	395	3	with	with	ADP
gs-3920	395	4	clinical	clinical	ADJ
gs-3920	395	5	vignettes	vignette	NOUN
gs-3920	395	6	beside	beside	ADP
gs-3920	395	7	the	the	DET
gs-3920	395	8	extensively	extensively	ADV
gs-3920	395	9	described	describe	VERB
gs-3920	395	10	severe	severe	ADJ
gs-3920	395	11	cutaneous	cutaneous	ADJ
gs-3920	395	12	adverse	adverse	ADJ
gs-3920	395	13	reactions	reaction	NOUN
gs-3920	395	14	including	include	VERB
gs-3920	395	15	dress	dress	NOUN
gs-3920	395	16	syndrome	syndrome	NOUN
gs-3920	395	17	several	several	ADJ
gs-3920	395	18	other	other	ADJ
gs-3920	395	19	patterns	pattern	NOUN
gs-3920	395	20	of	of	ADP
gs-3920	395	21	drug	drug	NOUN
gs-3920	395	22	-	-	PUNCT
gs-3920	395	23	induced	induce	VERB
gs-3920	395	24	hypersensitivity	hypersensitivity	NOUN
gs-3920	395	25	,	,	PUNCT
gs-3920	395	26	e.g.	e.g.	ADV
gs-3920	395	27	,	,	PUNCT
gs-3920	395	28	sdrife	sdrife	NOUN
gs-3920	395	29	(	(	PUNCT
gs-3920	395	30	symmetrical	symmetrical	ADJ
gs-3920	395	31	drug	drug	NOUN
gs-3920	395	32	-	-	PUNCT
gs-3920	395	33	related	relate	VERB
gs-3920	395	34	intertriginous	intertriginous	ADJ
gs-3920	395	35	and	and	CCONJ
gs-3920	395	36	flexural	flexural	ADJ
gs-3920	395	37	exanthema	exanthema	NOUN
gs-3920	395	38	)	)	PUNCT
gs-3920	395	39	,	,	PUNCT
gs-3920	395	40	deserve	deserve	VERB
gs-3920	395	41	attention	attention	NOUN
gs-3920	395	42	since	since	SCONJ
gs-3920	395	43	they	they	PRON
gs-3920	395	44	were	be	AUX
gs-3920	395	45	often	often	ADV
gs-3920	395	46	overlooked	overlook	VERB
gs-3920	395	47	.	.	PUNCT
gs-3920	396	1	a	a	DET
gs-3920	396	2	remarkable	remarkable	ADJ
gs-3920	396	3	case	case	NOUN
gs-3920	396	4	of	of	ADP
gs-3920	396	5	mefenamic	mefenamic	ADJ
gs-3920	396	6	acid	acid	NOUN
gs-3920	396	7	,	,	PUNCT
gs-3920	396	8	a	a	DET
gs-3920	396	9	frequently	frequently	ADV
gs-3920	396	10	used	use	VERB
gs-3920	396	11	nsaid	nsaid	PROPN
gs-3920	396	12	,	,	PUNCT
gs-3920	396	13	demonstrating	demonstrate	VERB
gs-3920	396	14	that	that	SCONJ
gs-3920	396	15	the	the	DET
gs-3920	396	16	drug	drug	NOUN
gs-3920	396	17	is	be	AUX
gs-3920	396	18	capable	capable	ADJ
gs-3920	396	19	of	of	ADP
gs-3920	396	20	causing	cause	VERB
gs-3920	396	21	sdrife	sdrife	NOUN
gs-3920	396	22	even	even	ADV
gs-3920	396	23	with	with	ADP
gs-3920	396	24	a	a	DET
gs-3920	396	25	single	single	ADJ
gs-3920	396	26	administration	administration	NOUN
gs-3920	396	27	.	.	PUNCT
gs-3920	397	1	following	follow	VERB
gs-3920	397	2	is	be	AUX
gs-3920	397	3	the	the	DET
gs-3920	397	4	two	two	NUM
gs-3920	397	5	example	example	NOUN
gs-3920	397	6	of	of	ADP
gs-3920	397	7	case	case	NOUN
gs-3920	397	8	studies	study	NOUN
gs-3920	397	9	(	(	PUNCT
gs-3920	397	10	case	case	NOUN
gs-3920	397	11	1mefenamic	1mefenamic	NUM
gs-3920	397	12	acid	acid	ADJ
gs-3920	397	13	side	side	NOUN
gs-3920	397	14	effect	effect	NOUN
gs-3920	397	15	,	,	PUNCT
gs-3920	397	16	case	case	NOUN
gs-3920	397	17	2vancomycin	2vancomycin	NUM
gs-3920	397	18	causing	cause	VERB
gs-3920	397	19	dress	dress	NOUN
gs-3920	397	20	)	)	PUNCT
gs-3920	397	21	.	.	PUNCT
gs-3920	398	1	case	case	NOUN
gs-3920	398	2	1	1	NUM
gs-3920	398	3	:	:	PUNCT
gs-3920	398	4	a	a	DET
gs-3920	398	5	27	27	NUM
gs-3920	398	6	-	-	PUNCT
gs-3920	398	7	year	year	NOUN
gs-3920	398	8	-	-	PUNCT
gs-3920	398	9	old	old	ADJ
gs-3920	398	10	woman	woman	NOUN
gs-3920	398	11	with	with	ADP
gs-3920	398	12	osteogenesis	osteogenesis	NOUN
gs-3920	398	13	imperfecta	imperfecta	NOUN
gs-3920	398	14	was	be	AUX
gs-3920	398	15	brought	bring	VERB
gs-3920	398	16	to	to	ADP
gs-3920	398	17	the	the	DET
gs-3920	398	18	emergency	emergency	NOUN
gs-3920	398	19	department	department	NOUN
gs-3920	398	20	due	due	ADP
gs-3920	398	21	to	to	ADP
gs-3920	398	22	altered	alter	VERB
gs-3920	398	23	mental	mental	ADJ
gs-3920	398	24	status	status	NOUN
gs-3920	398	25	and	and	CCONJ
gs-3920	398	26	vomiting	vomiting	NOUN
gs-3920	398	27	.	.	PUNCT
gs-3920	399	1	despite	despite	SCONJ
gs-3920	399	2	a	a	DET
gs-3920	399	3	normal	normal	ADJ
gs-3920	399	4	initial	initial	ADJ
gs-3920	399	5	work	work	NOUN
gs-3920	399	6	-	-	PUNCT
gs-3920	399	7	up	up	NOUN
gs-3920	399	8	,	,	PUNCT
gs-3920	399	9	blood	blood	NOUN
gs-3920	399	10	gas	gas	NOUN
gs-3920	399	11	analysis	analysis	NOUN
gs-3920	399	12	was	be	AUX
gs-3920	399	13	characteristic	characteristic	ADJ
gs-3920	399	14	of	of	ADP
gs-3920	399	15	profound	profound	ADJ
gs-3920	399	16	metabolic	metabolic	NOUN
gs-3920	399	17	acidosis	acidosis	NOUN
gs-3920	399	18	which	which	PRON
gs-3920	399	19	was	be	AUX
gs-3920	399	20	considered	consider	VERB
gs-3920	399	21	to	to	PART
gs-3920	399	22	be	be	AUX
gs-3920	399	23	caused	cause	VERB
gs-3920	399	24	by	by	ADP
gs-3920	399	25	the	the	DET
gs-3920	399	26	two	two	NUM
gs-3920	399	27	-	-	PUNCT
gs-3920	399	28	week	week	NOUN
gs-3920	399	29	use	use	NOUN
gs-3920	399	30	of	of	ADP
gs-3920	399	31	mefenamic	mefenamic	ADJ
gs-3920	399	32	acid	acid	NOUN
gs-3920	399	33	.	.	PUNCT
gs-3920	400	1	secondary	secondary	ADJ
gs-3920	400	2	ttp	ttp	PROPN
gs-3920	400	3	was	be	AUX
gs-3920	400	4	suspected	suspect	VERB
gs-3920	400	5	due	due	ADP
gs-3920	400	6	to	to	ADP
gs-3920	400	7	mild	mild	ADJ
gs-3920	400	8	thrombocytopenia	thrombocytopenia	NOUN
gs-3920	400	9	and	and	CCONJ
gs-3920	400	10	schistocytes	schistocyte	NOUN
gs-3920	400	11	.	.	PUNCT
gs-3920	401	1	plasmapheresis	plasmapheresis	NOUN
gs-3920	401	2	was	be	AUX
gs-3920	401	3	rapidly	rapidly	ADV
gs-3920	401	4	initiated	initiate	VERB
gs-3920	401	5	with	with	ADP
gs-3920	401	6	an	an	DET
gs-3920	401	7	improvement	improvement	NOUN
gs-3920	401	8	in	in	ADP
gs-3920	401	9	neurological	neurological	ADJ
gs-3920	401	10	function	function	NOUN
gs-3920	401	11	over	over	ADP
gs-3920	401	12	the	the	DET
gs-3920	401	13	following	follow	VERB
gs-3920	401	14	days	day	NOUN
gs-3920	401	15	.	.	PUNCT
gs-3920	402	1	the	the	DET
gs-3920	402	2	activity	activity	NOUN
gs-3920	402	3	of	of	ADP
gs-3920	402	4	adamts13	adamts13	NOUN
gs-3920	402	5	was	be	AUX
gs-3920	402	6	normal	normal	ADJ
gs-3920	402	7	,	,	PUNCT
gs-3920	402	8	and	and	CCONJ
gs-3920	402	9	there	there	PRON
gs-3920	402	10	was	be	VERB
gs-3920	402	11	no	no	DET
gs-3920	402	12	renal	renal	ADJ
gs-3920	402	13	involvement	involvement	NOUN
gs-3920	402	14	.	.	PUNCT
gs-3920	403	1	following	follow	VERB
gs-3920	403	2	treatment	treatment	NOUN
gs-3920	403	3	she	she	PRON
gs-3920	403	4	made	make	VERB
gs-3920	403	5	a	a	DET
gs-3920	403	6	complete	complete	ADJ
gs-3920	403	7	georgian	georgian	ADJ
gs-3920	403	8	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	403	9	მეცნიერები	მეცნიერები	NOUN
gs-3920	403	10	ტ.	ტ.	VERB
gs-3920	403	11	7	7	NUM
gs-3920	403	12	n	n	PRON
gs-3920	403	13	3	3	NUM
gs-3920	403	14	,	,	PUNCT
gs-3920	403	15	2025	2025	NUM
gs-3920	403	16	205	205	NUM
gs-3920	403	17	recovery	recovery	NOUN
gs-3920	403	18	,	,	PUNCT
gs-3920	403	19	highlighting	highlight	VERB
gs-3920	403	20	the	the	DET
gs-3920	403	21	relevance	relevance	NOUN
gs-3920	403	22	of	of	ADP
gs-3920	403	23	drug	drug	NOUN
gs-3920	403	24	-	-	PUNCT
gs-3920	403	25	induced	induce	VERB
gs-3920	403	26	disorders	disorder	NOUN
gs-3920	403	27	with	with	ADP
gs-3920	403	28	unexplained	unexplained	ADJ
gs-3920	403	29	symptoms	symptom	NOUN
gs-3920	403	30	should	should	AUX
gs-3920	403	31	be	be	AUX
gs-3920	403	32	monitored	monitor	VERB
gs-3920	403	33	closely	closely	ADV
gs-3920	403	34	.	.	PUNCT
gs-3920	404	1	case	case	NOUN
gs-3920	404	2	2	2	NUM
gs-3920	404	3	:	:	PUNCT
gs-3920	404	4	a	a	DET
gs-3920	404	5	46	46	NUM
gs-3920	404	6	-	-	PUNCT
gs-3920	404	7	year	year	NOUN
gs-3920	404	8	-	-	PUNCT
gs-3920	404	9	old	old	ADJ
gs-3920	404	10	female	female	NOUN
gs-3920	404	11	with	with	ADP
gs-3920	404	12	a	a	DET
gs-3920	404	13	history	history	NOUN
gs-3920	404	14	of	of	ADP
gs-3920	404	15	shoulder	shoulder	NOUN
gs-3920	404	16	arthroplasty	arthroplasty	NOUN
gs-3920	404	17	for	for	ADP
gs-3920	404	18	osteomyelitis	osteomyelitis	NOUN
gs-3920	404	19	was	be	AUX
gs-3920	404	20	treated	treat	VERB
gs-3920	404	21	with	with	ADP
gs-3920	404	22	a	a	DET
gs-3920	404	23	vancomycinand	vancomycinand	NOUN
gs-3920	404	24	tobramycin	tobramycin	NOUN
gs-3920	404	25	-	-	PUNCT
gs-3920	404	26	impregnated	impregnate	VERB
gs-3920	404	27	bone	bone	NOUN
gs-3920	404	28	cement	cement	NOUN
gs-3920	404	29	spacer	spacer	NOUN
gs-3920	404	30	and	and	CCONJ
gs-3920	404	31	intravenous	intravenous	ADJ
gs-3920	404	32	vancomycin	vancomycin	PROPN
gs-3920	404	33	.	.	PUNCT
gs-3920	405	1	two	two	NUM
gs-3920	405	2	to	to	PART
gs-3920	405	3	three	three	NUM
gs-3920	405	4	weeks	week	NOUN
gs-3920	405	5	later	later	ADV
gs-3920	405	6	,	,	PUNCT
gs-3920	405	7	she	she	PRON
gs-3920	405	8	presented	present	VERB
gs-3920	405	9	with	with	ADP
gs-3920	405	10	a	a	DET
gs-3920	405	11	pruritic	pruritic	ADJ
gs-3920	405	12	eruptive	eruptive	ADJ
gs-3920	405	13	morbilliform	morbilliform	NOUN
gs-3920	405	14	rash	rash	ADJ
gs-3920	405	15	,	,	PUNCT
gs-3920	405	16	facial	facial	ADJ
gs-3920	405	17	edema	edema	NOUN
gs-3920	405	18	,	,	PUNCT
gs-3920	405	19	fever	fever	NOUN
gs-3920	405	20	,	,	PUNCT
gs-3920	405	21	and	and	CCONJ
gs-3920	405	22	anasarca	anasarca	NOUN
gs-3920	405	23	.	.	PUNCT
gs-3920	406	1	laboratory	laboratory	NOUN
gs-3920	406	2	examination	examination	NOUN
gs-3920	406	3	showed	show	VERB
gs-3920	406	4	1,500/µl	1,500/µl	NOUN
gs-3920	406	5	of	of	ADP
gs-3920	406	6	eosinophils	eosinophil	NOUN
gs-3920	406	7	and	and	CCONJ
gs-3920	406	8	mild	mild	ADJ
gs-3920	406	9	renal	renal	ADJ
gs-3920	406	10	failure	failure	NOUN
gs-3920	406	11	.	.	PUNCT
gs-3920	407	1	during	during	ADP
gs-3920	407	2	skin	skin	NOUN
gs-3920	407	3	biopsy	biopsy	NOUN
gs-3920	407	4	,	,	PUNCT
gs-3920	407	5	dress	dress	NOUN
gs-3920	407	6	characteristics	characteristic	NOUN
gs-3920	407	7	were	be	AUX
gs-3920	407	8	morphologically	morphologically	ADV
gs-3920	407	9	proven	prove	VERB
gs-3920	407	10	.	.	PUNCT
gs-3920	408	1	discontinuation	discontinuation	NOUN
gs-3920	408	2	of	of	ADP
gs-3920	408	3	iv	iv	NUM
gs-3920	408	4	vancomycin	vancomycin	PROPN
gs-3920	408	5	and	and	CCONJ
gs-3920	408	6	initiation	initiation	NOUN
gs-3920	408	7	of	of	ADP
gs-3920	408	8	oral	oral	ADJ
gs-3920	408	9	prednisone	prednisone	NOUN
gs-3920	408	10	(	(	PUNCT
gs-3920	408	11	30	30	NUM
gs-3920	408	12	mg	mg	NOUN
gs-3920	408	13	daily	daily	ADV
gs-3920	408	14	)	)	PUNCT
gs-3920	408	15	initially	initially	ADV
gs-3920	408	16	also	also	ADV
gs-3920	408	17	did	do	AUX
gs-3920	408	18	not	not	PART
gs-3920	408	19	lead	lead	VERB
gs-3920	408	20	to	to	ADP
gs-3920	408	21	complete	complete	ADJ
gs-3920	408	22	improvement	improvement	NOUN
gs-3920	408	23	.	.	PUNCT
gs-3920	409	1	it	it	PRON
gs-3920	409	2	resolved	resolve	VERB
gs-3920	409	3	only	only	ADV
gs-3920	409	4	after	after	ADP
gs-3920	409	5	surgical	surgical	ADJ
gs-3920	409	6	extraction	extraction	NOUN
gs-3920	409	7	of	of	ADP
gs-3920	409	8	the	the	DET
gs-3920	409	9	locked	locked	ADJ
gs-3920	409	10	antibiotic	antibiotic	ADJ
gs-3920	409	11	spacer	spacer	NOUN
gs-3920	409	12	,	,	PUNCT
gs-3920	409	13	indicating	indicate	VERB
gs-3920	409	14	prolonged	prolonged	ADJ
gs-3920	409	15	sensitivity	sensitivity	NOUN
gs-3920	409	16	to	to	ADP
gs-3920	409	17	local	local	ADJ
gs-3920	409	18	elution	elution	NOUN
gs-3920	409	19	of	of	ADP
gs-3920	409	20	vancomycin	vancomycin	PROPN
gs-3920	409	21	from	from	ADP
gs-3920	409	22	the	the	DET
gs-3920	409	23	spacer	spacer	NOUN
gs-3920	409	24	.	.	PUNCT
gs-3920	410	1	the	the	DET
gs-3920	410	2	present	present	ADJ
gs-3920	410	3	case	case	NOUN
gs-3920	410	4	highlights	highlight	VERB
gs-3920	410	5	the	the	DET
gs-3920	410	6	need	need	NOUN
gs-3920	410	7	for	for	ADP
gs-3920	410	8	evaluating	evaluate	VERB
gs-3920	410	9	implanted	implant	VERB
gs-3920	410	10	drug	drug	NOUN
gs-3920	410	11	reservoirs	reservoir	NOUN
gs-3920	410	12	in	in	ADP
gs-3920	410	13	refractory	refractory	NOUN
gs-3920	410	14	dress	dress	NOUN
gs-3920	410	15	.	.	PUNCT
gs-3920	411	1	these	these	DET
gs-3920	411	2	case	case	NOUN
gs-3920	411	3	vignettes	vignette	NOUN
gs-3920	411	4	emphasize	emphasize	VERB
gs-3920	411	5	the	the	DET
gs-3920	411	6	importance	importance	NOUN
gs-3920	411	7	for	for	ADP
gs-3920	411	8	early	early	ADJ
gs-3920	411	9	identification	identification	NOUN
gs-3920	411	10	,	,	PUNCT
gs-3920	411	11	genetic	genetic	ADJ
gs-3920	411	12	risk	risk	NOUN
gs-3920	411	13	evaluation	evaluation	NOUN
gs-3920	411	14	,	,	PUNCT
gs-3920	411	15	frequent	frequent	ADJ
gs-3920	411	16	surveillance	surveillance	NOUN
gs-3920	411	17	for	for	ADP
gs-3920	411	18	viral	viral	ADJ
gs-3920	411	19	reactivation	reactivation	NOUN
gs-3920	411	20	,	,	PUNCT
gs-3920	411	21	and	and	CCONJ
gs-3920	411	22	personalized	personalized	ADJ
gs-3920	411	23	management	management	NOUN
gs-3920	411	24	.	.	PUNCT
gs-3920	412	1	figure	figure	NOUN
gs-3920	412	2	2	2	NUM
gs-3920	412	3	.	.	PUNCT
gs-3920	412	4	cutaneous	cutaneous	ADJ
gs-3920	412	5	manifestation	manifestation	NOUN
gs-3920	412	6	in	in	ADP
gs-3920	412	7	a	a	DET
gs-3920	412	8	patient	patient	NOUN
gs-3920	412	9	with	with	ADP
gs-3920	412	10	dress	dress	NOUN
gs-3920	412	11	syndrome	syndrome	NOUN
gs-3920	412	12	secondary	secondary	ADJ
gs-3920	412	13	to	to	ADP
gs-3920	412	14	antibiotic	antibiotic	ADJ
gs-3920	412	15	use	use	NOUN
gs-3920	412	16	,	,	PUNCT
gs-3920	412	17	showing	show	VERB
gs-3920	412	18	widespread	widespread	ADJ
gs-3920	412	19	erythematous	erythematous	ADJ
gs-3920	412	20	eruption	eruption	NOUN
gs-3920	412	21	.	.	PUNCT
gs-3920	413	1	limitations	limitation	NOUN
gs-3920	413	2	of	of	ADP
gs-3920	413	3	the	the	DET
gs-3920	413	4	study	study	NOUN
gs-3920	413	5	this	this	DET
gs-3920	413	6	hypothesis	hypothesis	NOUN
gs-3920	413	7	is	be	AUX
gs-3920	413	8	based	base	VERB
gs-3920	413	9	on	on	ADP
gs-3920	413	10	retrospective	retrospective	ADJ
gs-3920	413	11	data	datum	NOUN
gs-3920	413	12	and	and	CCONJ
gs-3920	413	13	case	case	NOUN
gs-3920	413	14	reports	report	NOUN
gs-3920	413	15	which	which	PRON
gs-3920	413	16	are	be	AUX
gs-3920	413	17	subject	subject	ADJ
gs-3920	413	18	to	to	ADP
gs-3920	413	19	publication	publication	NOUN
gs-3920	413	20	bias	bias	NOUN
gs-3920	413	21	favouring	favour	VERB
gs-3920	413	22	severe	severe	ADJ
gs-3920	413	23	or	or	CCONJ
gs-3920	413	24	atypical	atypical	ADJ
gs-3920	413	25	cases	case	NOUN
gs-3920	413	26	.	.	PUNCT
gs-3920	414	1	variation	variation	NOUN
gs-3920	414	2	in	in	ADP
gs-3920	414	3	diagnostic	diagnostic	ADJ
gs-3920	414	4	criteria	criterion	NOUN
gs-3920	414	5	and	and	CCONJ
gs-3920	414	6	lack	lack	VERB
gs-3920	414	7	georgian	georgian	ADJ
gs-3920	414	8	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	414	9	მეცნიერები	მეცნიერები	NOUN
gs-3920	414	10	ტ.	ტ.	VERB
gs-3920	414	11	7	7	NUM
gs-3920	414	12	n	n	PRON
gs-3920	414	13	3	3	NUM
gs-3920	414	14	,	,	PUNCT
gs-3920	414	15	2025	2025	NUM
gs-3920	414	16	206	206	NUM
gs-3920	414	17	of	of	ADP
gs-3920	414	18	uniform	uniform	ADJ
gs-3920	414	19	reporting	reporting	NOUN
gs-3920	414	20	of	of	ADP
gs-3920	414	21	outcomes	outcome	NOUN
gs-3920	414	22	contribute	contribute	VERB
gs-3920	414	23	to	to	ADP
gs-3920	414	24	the	the	DET
gs-3920	414	25	lack	lack	NOUN
gs-3920	414	26	of	of	ADP
gs-3920	414	27	comparability	comparability	NOUN
gs-3920	414	28	.	.	PUNCT
gs-3920	415	1	the	the	DET
gs-3920	415	2	rapidly	rapidly	ADV
gs-3920	415	3	changing	change	VERB
gs-3920	415	4	landscape	landscape	NOUN
gs-3920	415	5	of	of	ADP
gs-3920	415	6	drug	drug	NOUN
gs-3920	415	7	use	use	NOUN
gs-3920	415	8	and	and	CCONJ
gs-3920	415	9	new	new	ADJ
gs-3920	415	10	treatments	treatment	NOUN
gs-3920	415	11	requires	require	VERB
gs-3920	415	12	frequent	frequent	ADJ
gs-3920	415	13	revision	revision	NOUN
gs-3920	415	14	.	.	PUNCT
gs-3920	416	1	additionally	additionally	ADV
gs-3920	416	2	,	,	PUNCT
gs-3920	416	3	long	long	ADJ
gs-3920	416	4	-	-	PUNCT
gs-3920	416	5	term	term	NOUN
gs-3920	416	6	follow	follow	NOUN
gs-3920	416	7	-	-	PUNCT
gs-3920	416	8	up	up	NOUN
gs-3920	416	9	is	be	AUX
gs-3920	416	10	missing	miss	VERB
gs-3920	416	11	from	from	ADP
gs-3920	416	12	many	many	ADJ
gs-3920	416	13	studies	study	NOUN
gs-3920	416	14	,	,	PUNCT
gs-3920	416	15	thereby	thereby	ADV
gs-3920	416	16	limiting	limit	VERB
gs-3920	416	17	information	information	NOUN
gs-3920	416	18	about	about	ADP
gs-3920	416	19	long	long	ADJ
gs-3920	416	20	-	-	PUNCT
gs-3920	416	21	term	term	NOUN
gs-3920	416	22	consequences	consequence	NOUN
gs-3920	416	23	or	or	CCONJ
gs-3920	416	24	relapse	relapse	NOUN
gs-3920	416	25	.	.	PUNCT
gs-3920	417	1	research	research	NOUN
gs-3920	417	2	gap	gap	NOUN
gs-3920	417	3	even	even	ADV
gs-3920	417	4	if	if	SCONJ
gs-3920	417	5	the	the	DET
gs-3920	417	6	knowledge	knowledge	NOUN
gs-3920	417	7	on	on	ADP
gs-3920	417	8	dress	dress	NOUN
gs-3920	417	9	is	be	AUX
gs-3920	417	10	constantly	constantly	ADV
gs-3920	417	11	expanding	expand	VERB
gs-3920	417	12	,	,	PUNCT
gs-3920	417	13	large	large	ADJ
gs-3920	417	14	areas	area	NOUN
gs-3920	417	15	of	of	ADP
gs-3920	417	16	uncertainty	uncertainty	NOUN
gs-3920	417	17	related	relate	VERB
gs-3920	417	18	to	to	ADP
gs-3920	417	19	the	the	DET
gs-3920	417	20	overall	overall	ADJ
gs-3920	417	21	clinical	clinical	ADJ
gs-3920	417	22	spectrum	spectrum	NOUN
gs-3920	417	23	,	,	PUNCT
gs-3920	417	24	pathophysiology	pathophysiology	NOUN
gs-3920	417	25	and	and	CCONJ
gs-3920	417	26	the	the	DET
gs-3920	417	27	optimal	optimal	ADJ
gs-3920	417	28	management	management	NOUN
gs-3920	417	29	of	of	ADP
gs-3920	417	30	this	this	DET
gs-3920	417	31	entity	entity	NOUN
gs-3920	417	32	remain	remain	VERB
gs-3920	417	33	constant	constant	ADJ
gs-3920	417	34	.	.	PUNCT
gs-3920	418	1	clinical	clinical	ADJ
gs-3920	418	2	trials	trial	NOUN
gs-3920	418	3	:	:	PUNCT
gs-3920	418	4	high	high	ADJ
gs-3920	418	5	quality	quality	NOUN
gs-3920	418	6	literature	literature	NOUN
gs-3920	418	7	though	though	SCONJ
gs-3920	418	8	despite	despite	SCONJ
gs-3920	418	9	a	a	DET
gs-3920	418	10	significant	significant	ADJ
gs-3920	418	11	limitation	limitation	NOUN
gs-3920	418	12	would	would	AUX
gs-3920	418	13	appear	appear	VERB
gs-3920	418	14	to	to	PART
gs-3920	418	15	be	be	AUX
gs-3920	418	16	the	the	DET
gs-3920	418	17	absence	absence	NOUN
gs-3920	418	18	of	of	ADP
gs-3920	418	19	a	a	DET
gs-3920	418	20	greater	great	ADJ
gs-3920	418	21	number	number	NOUN
gs-3920	418	22	of	of	ADP
gs-3920	418	23	rct	rct	PROPN
gs-3920	418	24	’s	’s	PART
gs-3920	418	25	defining	define	VERB
gs-3920	418	26	efficacy	efficacy	NOUN
gs-3920	418	27	treatment	treatment	NOUN
gs-3920	418	28	thresholds	threshold	NOUN
gs-3920	418	29	as	as	ADP
gs-3920	418	30	being	be	AUX
gs-3920	418	31	between	between	ADP
gs-3920	418	32	corticosteroids	corticosteroid	NOUN
gs-3920	418	33	the	the	DET
gs-3920	418	34	treatment	treatment	NOUN
gs-3920	418	35	system	system	NOUN
gs-3920	418	36	of	of	ADP
gs-3920	418	37	choice	choice	NOUN
gs-3920	418	38	and	and	CCONJ
gs-3920	418	39	other	other	ADJ
gs-3920	418	40	agents	agent	NOUN
gs-3920	418	41	such	such	ADJ
gs-3920	418	42	as	as	ADP
gs-3920	418	43	the	the	DET
gs-3920	418	44	various	various	ADJ
gs-3920	418	45	ivig	ivig	NOUN
gs-3920	418	46	,	,	PUNCT
gs-3920	418	47	cyclosporine	cyclosporine	NOUN
gs-3920	418	48	and	and	CCONJ
gs-3920	418	49	plasmapheresis	plasmapheresis	NOUN
gs-3920	418	50	regimens	regimen	NOUN
gs-3920	418	51	.	.	PUNCT
gs-3920	419	1	currently	currently	ADV
gs-3920	419	2	they	they	PRON
gs-3920	419	3	rely	rely	VERB
gs-3920	419	4	to	to	ADP
gs-3920	419	5	a	a	DET
gs-3920	419	6	large	large	ADJ
gs-3920	419	7	degree	degree	NOUN
gs-3920	419	8	on	on	ADP
gs-3920	419	9	anecdotal	anecdotal	ADJ
gs-3920	419	10	reports	report	NOUN
gs-3920	419	11	and	and	CCONJ
gs-3920	419	12	expert	expert	NOUN
gs-3920	419	13	recommendation	recommendation	NOUN
gs-3920	419	14	where	where	SCONJ
gs-3920	419	15	the	the	DET
gs-3920	419	16	possibility	possibility	NOUN
gs-3920	419	17	of	of	ADP
gs-3920	419	18	establishing	establish	VERB
gs-3920	419	19	a	a	DET
gs-3920	419	20	common	common	ADJ
gs-3920	419	21	practice	practice	NOUN
gs-3920	419	22	becomes	become	VERB
gs-3920	419	23	very	very	ADV
gs-3920	419	24	limited	limited	ADJ
gs-3920	419	25	.	.	PUNCT
gs-3920	420	1	lack	lack	NOUN
gs-3920	420	2	of	of	ADP
gs-3920	420	3	adequate	adequate	ADJ
gs-3920	420	4	number	number	NOUN
gs-3920	420	5	of	of	ADP
gs-3920	420	6	nsaids	nsaid	NOUN
gs-3920	420	7	analysed	analyse	VERB
gs-3920	420	8	in	in	ADP
gs-3920	420	9	large	large	ADJ
gs-3920	420	10	reviews	review	NOUN
gs-3920	420	11	hugely	hugely	ADV
gs-3920	420	12	utilized	utilize	VERB
gs-3920	420	13	nonsteroidal	nonsteroidal	NOUN
gs-3920	420	14	anti	anti	ADJ
gs-3920	420	15	-	-	ADJ
gs-3920	420	16	inflammatory	inflammatory	ADJ
gs-3920	420	17	drugs	drug	NOUN
gs-3920	420	18	appear	appear	VERB
gs-3920	420	19	to	to	PART
gs-3920	420	20	be	be	AUX
gs-3920	420	21	markedly	markedly	ADV
gs-3920	420	22	underreported	underreported	ADJ
gs-3920	420	23	into	into	ADP
gs-3920	420	24	large	large	ADJ
gs-3920	420	25	meta	meta	NOUN
gs-3920	420	26	-	-	PUNCT
gs-3920	420	27	analyses	analysis	NOUN
gs-3920	420	28	of	of	ADP
gs-3920	420	29	dress	dress	NOUN
gs-3920	420	30	syndromes	syndrome	NOUN
gs-3920	420	31	and	and	CCONJ
gs-3920	420	32	provide	provide	VERB
gs-3920	420	33	an	an	DET
gs-3920	420	34	additional	additional	ADJ
gs-3920	420	35	instance	instance	NOUN
gs-3920	420	36	where	where	SCONJ
gs-3920	420	37	due	due	ADP
gs-3920	420	38	to	to	ADP
gs-3920	420	39	lack	lack	NOUN
gs-3920	420	40	of	of	ADP
gs-3920	420	41	access	access	NOUN
gs-3920	420	42	and	and	CCONJ
gs-3920	420	43	uninformed	uninformed	ADJ
gs-3920	420	44	patients	patient	NOUN
gs-3920	420	45	,	,	PUNCT
gs-3920	420	46	there	there	PRON
gs-3920	420	47	may	may	AUX
gs-3920	420	48	be	be	AUX
gs-3920	420	49	understandable	understandable	ADJ
gs-3920	420	50	imbalance	imbalance	NOUN
gs-3920	420	51	in	in	ADP
gs-3920	420	52	the	the	DET
gs-3920	420	53	reporting	reporting	NOUN
gs-3920	420	54	that	that	PRON
gs-3920	420	55	could	could	AUX
gs-3920	420	56	affect	affect	VERB
gs-3920	420	57	an	an	DET
gs-3920	420	58	assessment	assessment	NOUN
gs-3920	420	59	of	of	ADP
gs-3920	420	60	risk	risk	NOUN
gs-3920	420	61	of	of	ADP
gs-3920	420	62	these	these	DET
gs-3920	420	63	agents	agent	NOUN
gs-3920	420	64	.	.	PUNCT
gs-3920	421	1	despite	despite	SCONJ
gs-3920	421	2	being	be	AUX
gs-3920	421	3	well	well	ADV
gs-3920	421	4	described	describe	VERB
gs-3920	421	5	the	the	DET
gs-3920	421	6	organ	organ	NOUN
gs-3920	421	7	-	-	PUNCT
gs-3920	421	8	specific	specific	ADJ
gs-3920	421	9	(	(	PUNCT
gs-3920	421	10	especially	especially	ADV
gs-3920	421	11	liver	liver	NOUN
gs-3920	421	12	,	,	PUNCT
gs-3920	421	13	kidney	kidney	NOUN
gs-3920	421	14	,	,	PUNCT
gs-3920	421	15	and	and	CCONJ
gs-3920	421	16	lung	lung	NOUN
gs-3920	421	17	)	)	PUNCT
gs-3920	421	18	involvement	involvement	NOUN
gs-3920	421	19	,	,	PUNCT
gs-3920	421	20	there	there	PRON
gs-3920	421	21	is	be	VERB
gs-3920	421	22	still	still	ADV
gs-3920	421	23	no	no	DET
gs-3920	421	24	uniform	uniform	ADJ
gs-3920	421	25	grading	grade	VERB
gs-3920	421	26	system	system	NOUN
gs-3920	421	27	for	for	ADP
gs-3920	421	28	the	the	DET
gs-3920	421	29	evaluation	evaluation	NOUN
gs-3920	421	30	of	of	ADP
gs-3920	421	31	the	the	DET
gs-3920	421	32	extent	extent	NOUN
gs-3920	421	33	of	of	ADP
gs-3920	421	34	organ	organ	NOUN
gs-3920	421	35	impairment	impairment	NOUN
gs-3920	421	36	and	and	CCONJ
gs-3920	421	37	data	datum	NOUN
gs-3920	421	38	on	on	ADP
gs-3920	421	39	comprehensive	comprehensive	ADJ
gs-3920	421	40	follow	follow	NOUN
gs-3920	421	41	-	-	PUNCT
gs-3920	421	42	up	up	NOUN
gs-3920	421	43	across	across	ADP
gs-3920	421	44	multiple	multiple	ADJ
gs-3920	421	45	investigations	investigation	NOUN
gs-3920	421	46	.	.	PUNCT
gs-3920	422	1	otherwise	otherwise	ADV
gs-3920	422	2	,	,	PUNCT
gs-3920	422	3	there	there	PRON
gs-3920	422	4	is	be	VERB
gs-3920	422	5	no	no	DET
gs-3920	422	6	linkage	linkage	NOUN
gs-3920	422	7	of	of	ADP
gs-3920	422	8	severity	severity	NOUN
gs-3920	422	9	to	to	ADP
gs-3920	422	10	treatment	treatment	NOUN
gs-3920	422	11	result	result	NOUN
gs-3920	422	12	and	and	CCONJ
gs-3920	422	13	long	long	ADJ
gs-3920	422	14	-	-	PUNCT
gs-3920	422	15	term	term	NOUN
gs-3920	422	16	prognosis	prognosis	NOUN
gs-3920	422	17	.	.	PUNCT
gs-3920	423	1	limited	limited	ADJ
gs-3920	423	2	population	population	NOUN
gs-3920	423	3	genetics	genetic	NOUN
gs-3920	423	4	in	in	ADP
gs-3920	423	5	asia	asia	PROPN
gs-3920	423	6	and	and	CCONJ
gs-3920	423	7	beyond	beyond	ADP
gs-3920	423	8	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	423	9	screenings	screening	NOUN
gs-3920	423	10	(	(	PUNCT
gs-3920	423	11	e.g.	e.g.	ADV
gs-3920	423	12	,	,	PUNCT
gs-3920	423	13	hl	hl	NOUN
gs-3920	423	14	-	-	PUNCT
gs-3920	423	15	b58:01	b58:01	PROPN
gs-3920	423	16	,	,	PUNCT
gs-3920	423	17	hla	hla	PROPN
gs-3920	423	18	-	-	PUNCT
gs-3920	423	19	a31:01	a31:01	PROPN
gs-3920	423	20	)	)	PUNCT
gs-3920	423	21	are	be	AUX
gs-3920	423	22	still	still	ADV
gs-3920	423	23	used	use	VERB
gs-3920	423	24	in	in	ADP
gs-3920	423	25	some	some	DET
gs-3920	423	26	asian	asian	ADJ
gs-3920	423	27	countries	country	NOUN
gs-3920	423	28	,	,	PUNCT
gs-3920	423	29	however	however	ADV
gs-3920	423	30	,	,	PUNCT
gs-3920	423	31	they	they	PRON
gs-3920	423	32	are	be	AUX
gs-3920	423	33	being	be	AUX
gs-3920	423	34	employed	employ	VERB
gs-3920	423	35	in	in	ADP
gs-3920	423	36	western	western	ADJ
gs-3920	423	37	countries	country	NOUN
gs-3920	423	38	in	in	ADP
gs-3920	423	39	different	different	ADJ
gs-3920	423	40	fashions	fashion	NOUN
gs-3920	423	41	due	due	ADP
gs-3920	423	42	to	to	ADP
gs-3920	423	43	the	the	DET
gs-3920	423	44	absence	absence	NOUN
gs-3920	423	45	of	of	ADP
gs-3920	423	46	policy	policy	NOUN
gs-3920	423	47	guiding	guiding	NOUN
gs-3920	423	48	,	,	PUNCT
gs-3920	423	49	cost	cost	NOUN
gs-3920	423	50	,	,	PUNCT
gs-3920	423	51	and	and	CCONJ
gs-3920	423	52	low	low	ADJ
gs-3920	423	53	attention	attention	NOUN
gs-3920	423	54	of	of	ADP
gs-3920	423	55	the	the	DET
gs-3920	423	56	issue	issue	NOUN
gs-3920	423	57	.	.	PUNCT
gs-3920	424	1	greater	great	ADJ
gs-3920	424	2	implementation	implementation	NOUN
gs-3920	424	3	would	would	AUX
gs-3920	424	4	effectively	effectively	ADV
gs-3920	424	5	limit	limit	VERB
gs-3920	424	6	adverse	adverse	ADJ
gs-3920	424	7	drug	drug	NOUN
gs-3920	424	8	related	relate	VERB
gs-3920	424	9	harm	harm	NOUN
gs-3920	424	10	but	but	CCONJ
gs-3920	424	11	has	have	AUX
gs-3920	424	12	been	be	AUX
gs-3920	424	13	rarely	rarely	ADV
gs-3920	424	14	discussed	discuss	VERB
gs-3920	424	15	in	in	ADP
gs-3920	424	16	the	the	DET
gs-3920	424	17	world	world	NOUN
gs-3920	424	18	literature	literature	NOUN
gs-3920	424	19	to	to	ADP
gs-3920	424	20	this	this	DET
gs-3920	424	21	point	point	NOUN
gs-3920	424	22	.	.	PUNCT
gs-3920	425	1	lack	lack	NOUN
gs-3920	425	2	of	of	ADP
gs-3920	425	3	long‐term	long‐term	NOUN
gs-3920	425	4	follow‐up	follow‐up	NOUN
gs-3920	425	5	results	result	VERB
gs-3920	425	6	.	.	PUNCT
gs-3920	426	1	another	another	DET
gs-3920	426	2	major	major	ADJ
gs-3920	426	3	limitation	limitation	NOUN
gs-3920	426	4	that	that	PRON
gs-3920	426	5	exists	exist	VERB
gs-3920	426	6	is	be	AUX
gs-3920	426	7	the	the	DET
gs-3920	426	8	lack	lack	NOUN
gs-3920	426	9	of	of	ADP
gs-3920	426	10	long	long	ADJ
gs-3920	426	11	-	-	PUNCT
gs-3920	426	12	term	term	NOUN
gs-3920	426	13	follow	follow	NOUN
gs-3920	426	14	-	-	PUNCT
gs-3920	426	15	up	up	NOUN
gs-3920	426	16	;	;	PUNCT
gs-3920	426	17	there	there	PRON
gs-3920	426	18	are	be	VERB
gs-3920	426	19	many	many	ADJ
gs-3920	426	20	investigations	investigation	NOUN
gs-3920	426	21	published	publish	VERB
gs-3920	426	22	on	on	ADP
gs-3920	426	23	short	short	ADJ
gs-3920	426	24	-	-	PUNCT
gs-3920	426	25	term	term	NOUN
gs-3920	426	26	symptom	symptom	NOUN
gs-3920	426	27	alleviation	alleviation	NOUN
gs-3920	426	28	but	but	CCONJ
gs-3920	426	29	fewer	few	ADJ
gs-3920	426	30	on	on	ADP
gs-3920	426	31	the	the	DET
gs-3920	426	32	cohort	cohort	NOUN
gs-3920	426	33	of	of	ADP
gs-3920	426	34	patients	patient	NOUN
gs-3920	426	35	who	who	PRON
gs-3920	426	36	may	may	AUX
gs-3920	426	37	develop	develop	VERB
gs-3920	426	38	ai	ai	VERB
gs-3920	426	39	sequelae	sequelae	NOUN
gs-3920	426	40	including	include	VERB
gs-3920	426	41	type	type	NOUN
gs-3920	426	42	one	one	NUM
gs-3920	426	43	diabetes	diabetes	NOUN
gs-3920	426	44	,	,	PUNCT
gs-3920	426	45	thyroiditis	thyroiditis	NOUN
gs-3920	426	46	and	and	CCONJ
gs-3920	426	47	lupus	lupus	NOUN
gs-3920	426	48	.	.	PUNCT
gs-3920	427	1	it	it	PRON
gs-3920	427	2	is	be	AUX
gs-3920	427	3	necessary	necessary	ADJ
gs-3920	427	4	to	to	PART
gs-3920	427	5	recognize	recognize	VERB
gs-3920	427	6	what	what	PRON
gs-3920	427	7	can	can	AUX
gs-3920	427	8	be	be	AUX
gs-3920	427	9	done	do	VERB
gs-3920	427	10	in	in	ADP
gs-3920	427	11	order	order	NOUN
gs-3920	427	12	to	to	PART
gs-3920	427	13	avoid	avoid	VERB
gs-3920	427	14	the	the	DET
gs-3920	427	15	potential	potential	ADJ
gs-3920	427	16	outcome	outcome	NOUN
gs-3920	427	17	and	and	CCONJ
gs-3920	427	18	how	how	SCONJ
gs-3920	427	19	to	to	PART
gs-3920	427	20	deal	deal	VERB
gs-3920	427	21	with	with	ADP
gs-3920	427	22	post	post	ADJ
gs-3920	427	23	-	-	ADJ
gs-3920	427	24	dress	dress	ADJ
gs-3920	427	25	care	care	NOUN
gs-3920	427	26	,	,	PUNCT
gs-3920	427	27	with	with	SCONJ
gs-3920	427	28	criteria	criterion	NOUN
gs-3920	427	29	to	to	PART
gs-3920	427	30	teach	teach	VERB
gs-3920	427	31	in	in	ADP
gs-3920	427	32	counselling	counselling	NOUN
gs-3920	427	33	in	in	ADP
gs-3920	427	34	order	order	NOUN
gs-3920	427	35	to	to	PART
gs-3920	427	36	ensure	ensure	VERB
gs-3920	427	37	georgian	georgian	ADJ
gs-3920	427	38	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	427	39	მეცნიერები	მეცნიერები	NOUN
gs-3920	427	40	ტ.	ტ.	VERB
gs-3920	427	41	7	7	NUM
gs-3920	427	42	n	n	DET
gs-3920	427	43	3	3	NUM
gs-3920	427	44	,	,	PUNCT
gs-3920	427	45	2025	2025	NUM
gs-3920	427	46	207	207	NUM
gs-3920	427	47	the	the	DET
gs-3920	427	48	best	good	ADJ
gs-3920	427	49	way	way	NOUN
gs-3920	427	50	to	to	ADP
gs-3920	427	51	advice	advice	NOUN
gs-3920	427	52	patients	patient	NOUN
gs-3920	427	53	that	that	PRON
gs-3920	427	54	overcome	overcome	VERB
gs-3920	427	55	this	this	DET
gs-3920	427	56	situation	situation	NOUN
gs-3920	427	57	,	,	PUNCT
gs-3920	427	58	since	since	SCONJ
gs-3920	427	59	the	the	DET
gs-3920	427	60	consequences	consequence	NOUN
gs-3920	427	61	of	of	ADP
gs-3920	427	62	the	the	DET
gs-3920	427	63	cause	cause	NOUN
gs-3920	427	64	in	in	ADP
gs-3920	427	65	matter	matter	NOUN
gs-3920	427	66	have	have	AUX
gs-3920	427	67	been	be	AUX
gs-3920	427	68	conditioned	condition	VERB
gs-3920	427	69	by	by	ADP
gs-3920	427	70	its	its	PRON
gs-3920	427	71	natural	natural	ADJ
gs-3920	427	72	course	course	NOUN
gs-3920	427	73	.	.	PUNCT
gs-3920	428	1	absence	absence	NOUN
gs-3920	428	2	of	of	ADP
gs-3920	428	3	unified	unified	ADJ
gs-3920	428	4	diagnostic	diagnostic	ADJ
gs-3920	428	5	biomarkers	biomarker	NOUN
gs-3920	428	6	eosinophilia	eosinophilia	NOUN
gs-3920	428	7	and	and	CCONJ
gs-3920	428	8	viral	viral	ADJ
gs-3920	428	9	reactivations	reactivation	NOUN
gs-3920	428	10	(	(	PUNCT
gs-3920	428	11	i.e.	i.e.	X
gs-3920	428	12	,	,	PUNCT
gs-3920	428	13	hhv-6	hhv-6	NOUN
gs-3920	428	14	)	)	PUNCT
gs-3920	428	15	are	be	AUX
gs-3920	428	16	common	common	ADJ
gs-3920	428	17	,	,	PUNCT
gs-3920	428	18	but	but	CCONJ
gs-3920	428	19	no	no	DET
gs-3920	428	20	one	one	NOUN
gs-3920	428	21	biomarker	biomarker	NOUN
gs-3920	428	22	has	have	AUX
gs-3920	428	23	been	be	AUX
gs-3920	428	24	adopted	adopt	VERB
gs-3920	428	25	as	as	ADP
gs-3920	428	26	a	a	DET
gs-3920	428	27	clinical	clinical	ADJ
gs-3920	428	28	gold	gold	NOUN
gs-3920	428	29	standard	standard	NOUN
gs-3920	428	30	for	for	ADP
gs-3920	428	31	diagnosis	diagnosis	NOUN
gs-3920	428	32	or	or	CCONJ
gs-3920	428	33	suspected	suspect	VERB
gs-3920	428	34	case	case	NOUN
gs-3920	428	35	,	,	PUNCT
gs-3920	428	36	which	which	PRON
gs-3920	428	37	delays	delay	VERB
gs-3920	428	38	diagnosis	diagnosis	NOUN
gs-3920	428	39	and	and	CCONJ
gs-3920	428	40	leads	lead	VERB
gs-3920	428	41	to	to	ADP
gs-3920	428	42	a	a	DET
gs-3920	428	43	high	high	ADJ
gs-3920	428	44	risk	risk	NOUN
gs-3920	428	45	of	of	ADP
gs-3920	428	46	misdiagnosis	misdiagnosis	NOUN
gs-3920	428	47	,	,	PUNCT
gs-3920	428	48	with	with	ADP
gs-3920	428	49	significant	significant	ADJ
gs-3920	428	50	variations	variation	NOUN
gs-3920	428	51	in	in	ADP
gs-3920	428	52	time	time	NOUN
gs-3920	428	53	to	to	ADP
gs-3920	428	54	treatment	treatment	NOUN
gs-3920	428	55	and	and	CCONJ
gs-3920	428	56	detrimental	detrimental	ADJ
gs-3920	428	57	effect	effect	NOUN
gs-3920	428	58	on	on	ADP
gs-3920	428	59	patient	patient	ADJ
gs-3920	428	60	outcomes	outcome	NOUN
gs-3920	428	61	.	.	PUNCT
gs-3920	429	1			ADJ
gs-3920	429	2	meftal	meftal	NOUN
gs-3920	429	3	(	(	PUNCT
gs-3920	429	4	mefenamic	mefenamic	NOUN
gs-3920	429	5	acid	acid	NOUN
gs-3920	429	6	)	)	PUNCT
gs-3920	429	7	or	or	CCONJ
gs-3920	429	8	another	another	DET
gs-3920	429	9	pill	pill	NOUN
gs-3920	429	10	are	be	AUX
gs-3920	429	11	affected	affect	VERB
gs-3920	429	12	by	by	ADP
gs-3920	429	13	any	any	DET
gs-3920	429	14	individual	individual	NOUN
gs-3920	429	15	they	they	PRON
gs-3920	429	16	should	should	AUX
gs-3920	429	17	report	report	VERB
gs-3920	429	18	it	it	PRON
gs-3920	429	19	.	.	PUNCT
gs-3920	430	1	in	in	ADP
gs-3920	430	2	event	event	NOUN
gs-3920	430	3	of	of	ADP
gs-3920	430	4	occurrence	occurrence	NOUN
gs-3920	430	5	of	of	ADP
gs-3920	430	6	such	such	ADJ
gs-3920	430	7	symptoms	symptom	NOUN
gs-3920	430	8	,	,	PUNCT
gs-3920	430	9	it	it	PRON
gs-3920	430	10	is	be	AUX
gs-3920	430	11	important	important	ADJ
gs-3920	430	12	to	to	PART
gs-3920	430	13	bring	bring	VERB
gs-3920	430	14	it	it	PRON
gs-3920	430	15	to	to	ADP
gs-3920	430	16	the	the	DET
gs-3920	430	17	notice	notice	NOUN
gs-3920	430	18	of	of	ADP
gs-3920	430	19	the	the	DET
gs-3920	430	20	national	national	PROPN
gs-3920	430	21	coordination	coordination	PROPN
gs-3920	430	22	centre	centre	NOUN
gs-3920	430	23	of	of	ADP
gs-3920	430	24	pvpi	pvpi	NOUN
gs-3920	430	25	in	in	ADP
gs-3920	430	26	the	the	DET
gs-3920	430	27	country	country	NOUN
gs-3920	430	28	by	by	ADP
gs-3920	430	29	diverse	diverse	ADJ
gs-3920	430	30	tools	tool	NOUN
gs-3920	430	31	of	of	ADP
gs-3920	430	32	communication	communication	NOUN
gs-3920	430	33	by	by	ADP
gs-3920	430	34	the	the	DET
gs-3920	430	35	indian	indian	PROPN
gs-3920	430	36	pharmacopoeia	pharmacopoeia	PROPN
gs-3920	430	37	commission	commission	PROPN
gs-3920	430	38	(	(	PUNCT
gs-3920	430	39	ipc	ipc	PROPN
gs-3920	430	40	)	)	PUNCT
gs-3920	430	41	.	.	PUNCT
gs-3920	431	1			VERB
gs-3920	431	2	organ	organ	NOUN
gs-3920	431	3	involvement	involvement	NOUN
gs-3920	431	4	has	have	VERB
gs-3920	431	5	a	a	DET
gs-3920	431	6	predilection	predilection	NOUN
gs-3920	431	7	for	for	ADP
gs-3920	431	8	the	the	DET
gs-3920	431	9	liver	liver	NOUN
gs-3920	431	10	,	,	PUNCT
gs-3920	431	11	but	but	CCONJ
gs-3920	431	12	there	there	PRON
gs-3920	431	13	have	have	AUX
gs-3920	431	14	been	be	AUX
gs-3920	431	15	cases	case	NOUN
gs-3920	431	16	involving	involve	VERB
gs-3920	431	17	the	the	DET
gs-3920	431	18	kidney	kidney	NOUN
gs-3920	431	19	,	,	PUNCT
gs-3920	431	20	skin	skin	NOUN
gs-3920	431	21	,	,	PUNCT
gs-3920	431	22	lung	lung	NOUN
gs-3920	431	23	,	,	PUNCT
gs-3920	431	24	and	and	CCONJ
gs-3920	431	25	hematologic	hematologic	NOUN
gs-3920	431	26	system	system	NOUN
gs-3920	431	27	.	.	PUNCT
gs-3920	432	1	skin	skin	NOUN
gs-3920	432	2	eruptions	eruption	NOUN
gs-3920	432	3	and	and	CCONJ
gs-3920	432	4	eosinophilia	eosinophilia	PROPN
gs-3920	432	5	continue	continue	VERB
gs-3920	432	6	to	to	PART
gs-3920	432	7	be	be	AUX
gs-3920	432	8	typical	typical	ADJ
gs-3920	432	9	diagnostic	diagnostic	ADJ
gs-3920	432	10	signposts	signpost	NOUN
gs-3920	432	11	.	.	PUNCT
gs-3920	433	1			VERB
gs-3920	433	2	genetic	genetic	ADJ
gs-3920	433	3	factors	factor	NOUN
gs-3920	433	4	above	above	ADP
gs-3920	433	5	all	all	DET
gs-3920	433	6	hla	hla	NOUN
gs-3920	433	7	-	-	PUNCT
gs-3920	433	8	b58:01	b58:01	PROPN
gs-3920	433	9	for	for	ADP
gs-3920	433	10	allopurinol	allopurinol	NOUN
gs-3920	433	11	,	,	PUNCT
gs-3920	433	12	but	but	CCONJ
gs-3920	433	13	also	also	ADV
gs-3920	433	14	hla	hla	PROPN
gs-3920	433	15	-	-	PUNCT
gs-3920	433	16	b15:02	b15:02	PROPN
gs-3920	433	17	for	for	ADP
gs-3920	433	18	carbamazepine	carbamazepine	NOUN
gs-3920	433	19	signal	signal	VERB
gs-3920	433	20	the	the	DET
gs-3920	433	21	potential	potential	NOUN
gs-3920	433	22	of	of	ADP
gs-3920	433	23	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	433	24	screening	screening	NOUN
gs-3920	433	25	in	in	ADP
gs-3920	433	26	prevention	prevention	NOUN
gs-3920	433	27	.	.	PUNCT
gs-3920	434	1			PROPN
gs-3920	434	2	corticosteroids	corticosteroid	NOUN
gs-3920	434	3	are	be	AUX
gs-3920	434	4	still	still	ADV
gs-3920	434	5	the	the	DET
gs-3920	434	6	mainstay	mainstay	NOUN
gs-3920	434	7	of	of	ADP
gs-3920	434	8	therapy	therapy	NOUN
gs-3920	434	9	,	,	PUNCT
gs-3920	434	10	but	but	CCONJ
gs-3920	434	11	there	there	PRON
gs-3920	434	12	are	be	VERB
gs-3920	434	13	no	no	DET
gs-3920	434	14	universally	universally	ADV
gs-3920	434	15	accepted	accept	VERB
gs-3920	434	16	treatment	treatment	NOUN
gs-3920	434	17	guidelines	guideline	NOUN
gs-3920	434	18	with	with	ADP
gs-3920	434	19	respect	respect	NOUN
gs-3920	434	20	to	to	ADP
gs-3920	434	21	the	the	DET
gs-3920	434	22	timing	timing	NOUN
gs-3920	434	23	,	,	PUNCT
gs-3920	434	24	dose	dose	NOUN
gs-3920	434	25	,	,	PUNCT
gs-3920	434	26	and	and	CCONJ
gs-3920	434	27	duration	duration	NOUN
gs-3920	434	28	of	of	ADP
gs-3920	434	29	corticosteroid	corticosteroid	ADJ
gs-3920	434	30	therapy	therapy	NOUN
gs-3920	434	31	.	.	PUNCT
gs-3920	435	1	second	second	ADJ
gs-3920	435	2	-	-	PUNCT
gs-3920	435	3	line	line	NOUN
gs-3920	435	4	agents	agent	NOUN
gs-3920	435	5	such	such	ADJ
gs-3920	435	6	as	as	ADP
gs-3920	435	7	ivig	ivig	NOUN
gs-3920	435	8	and	and	CCONJ
gs-3920	435	9	cyclosporine	cyclosporine	NOUN
gs-3920	435	10	are	be	AUX
gs-3920	435	11	used	use	VERB
gs-3920	435	12	variably	variably	ADV
gs-3920	435	13	and	and	CCONJ
gs-3920	435	14	at	at	ADP
gs-3920	435	15	the	the	DET
gs-3920	435	16	discretion	discretion	NOUN
gs-3920	435	17	of	of	ADP
gs-3920	435	18	the	the	DET
gs-3920	435	19	clinician	clinician	NOUN
gs-3920	435	20	.	.	PUNCT
gs-3920	436	1			ADJ
gs-3920	436	2	reactivation	reactivation	NOUN
gs-3920	436	3	of	of	ADP
gs-3920	436	4	herpesviruses	herpesviruse	NOUN
gs-3920	436	5	,	,	PUNCT
gs-3920	436	6	and	and	CCONJ
gs-3920	436	7	in	in	ADP
gs-3920	436	8	particular	particular	ADJ
gs-3920	436	9	hhv-6	hhv-6	NOUN
gs-3920	436	10	,	,	PUNCT
gs-3920	436	11	may	may	AUX
gs-3920	436	12	contribute	contribute	VERB
gs-3920	436	13	to	to	ADP
gs-3920	436	14	worsening	worsen	VERB
gs-3920	436	15	of	of	ADP
gs-3920	436	16	the	the	DET
gs-3920	436	17	syndrome	syndrome	NOUN
gs-3920	436	18	or	or	CCONJ
gs-3920	436	19	late	late	ADJ
gs-3920	436	20	reactivation	reactivation	NOUN
gs-3920	436	21	,	,	PUNCT
gs-3920	436	22	but	but	CCONJ
gs-3920	436	23	evidence	evidence	NOUN
gs-3920	436	24	is	be	AUX
gs-3920	436	25	still	still	ADV
gs-3920	436	26	conflicting	conflict	VERB
gs-3920	436	27	with	with	ADP
gs-3920	436	28	regard	regard	NOUN
gs-3920	436	29	to	to	ADP
gs-3920	436	30	the	the	DET
gs-3920	436	31	therapeutic	therapeutic	ADJ
gs-3920	436	32	role	role	NOUN
gs-3920	436	33	of	of	ADP
gs-3920	436	34	antiviral	antiviral	ADJ
gs-3920	436	35	treatments	treatment	NOUN
gs-3920	436	36	.	.	PUNCT
gs-3920	437	1			ADJ
gs-3920	437	2	autoimmune	autoimmune	ADJ
gs-3920	437	3	sequelae	sequelae	NOUN
gs-3920	437	4	including	include	VERB
gs-3920	437	5	thyroiditis	thyroiditis	NOUN
gs-3920	437	6	and	and	CCONJ
gs-3920	437	7	type	type	NOUN
gs-3920	437	8	1	1	NUM
gs-3920	437	9	diabetes	diabetes	NOUN
gs-3920	437	10	mellitus	mellitus	NOUN
gs-3920	437	11	have	have	AUX
gs-3920	437	12	been	be	AUX
gs-3920	437	13	reported	report	VERB
gs-3920	437	14	during	during	ADP
gs-3920	437	15	post	post	ADJ
gs-3920	437	16	-	-	ADJ
gs-3920	437	17	dress	dress	ADJ
gs-3920	437	18	course	course	NOUN
gs-3920	437	19	,	,	PUNCT
gs-3920	437	20	suggesting	suggest	VERB
gs-3920	437	21	the	the	DET
gs-3920	437	22	necessity	necessity	NOUN
gs-3920	437	23	for	for	ADP
gs-3920	437	24	long	long	ADJ
gs-3920	437	25	-	-	PUNCT
gs-3920	437	26	term	term	NOUN
gs-3920	437	27	follow	follow	NOUN
gs-3920	437	28	-	-	PUNCT
gs-3920	437	29	up	up	NOUN
gs-3920	437	30	.	.	PUNCT
gs-3920	438	1	altogether	altogether	ADV
gs-3920	438	2	,	,	PUNCT
gs-3920	438	3	these	these	DET
gs-3920	438	4	findings	finding	NOUN
gs-3920	438	5	support	support	VERB
gs-3920	438	6	the	the	DET
gs-3920	438	7	concept	concept	NOUN
gs-3920	438	8	that	that	DET
gs-3920	438	9	dress	dress	NOUN
gs-3920	438	10	is	be	AUX
gs-3920	438	11	both	both	PRON
gs-3920	438	12	epitope	epitope	NOUN
gs-3920	438	13	-	-	PUNCT
gs-3920	438	14	specific	specific	ADJ
gs-3920	438	15	and	and	CCONJ
gs-3920	438	16	patient	patient	NOUN
gs-3920	438	17	-	-	PUNCT
gs-3920	438	18	specific	specific	ADJ
gs-3920	438	19	.	.	PUNCT
gs-3920	439	1	most	most	ADJ
gs-3920	439	2	drugs	drug	NOUN
gs-3920	439	3	do	do	AUX
gs-3920	439	4	not	not	PART
gs-3920	439	5	induce	induce	VERB
gs-3920	439	6	this	this	DET
gs-3920	439	7	cascade	cascade	NOUN
gs-3920	439	8	due	due	ADP
gs-3920	439	9	to	to	ADP
gs-3920	439	10	a	a	DET
gs-3920	439	11	lack	lack	NOUN
gs-3920	439	12	of	of	ADP
gs-3920	439	13	reactive	reactive	ADJ
gs-3920	439	14	metabolites	metabolite	NOUN
gs-3920	439	15	,	,	PUNCT
gs-3920	439	16	absence	absence	NOUN
gs-3920	439	17	of	of	ADP
gs-3920	439	18	immunogenic	immunogenic	ADJ
gs-3920	439	19	properties	property	NOUN
gs-3920	439	20	,	,	PUNCT
gs-3920	439	21	or	or	CCONJ
gs-3920	439	22	lower	low	ADJ
gs-3920	439	23	prevalence	prevalence	NOUN
gs-3920	439	24	of	of	ADP
gs-3920	439	25	genetic	genetic	ADJ
gs-3920	439	26	susceptibility	susceptibility	NOUN
gs-3920	439	27	in	in	ADP
gs-3920	439	28	the	the	DET
gs-3920	439	29	exposed	expose	VERB
gs-3920	439	30	population	population	NOUN
gs-3920	439	31	.	.	PUNCT
gs-3920	440	1			VERB
gs-3920	440	2	further	further	ADJ
gs-3920	440	3	diagnostic	diagnostic	ADJ
gs-3920	440	4	needs	need	NOUN
gs-3920	440	5	:	:	PUNCT
gs-3920	440	6	no	no	DET
gs-3920	440	7	broadly	broadly	ADV
gs-3920	440	8	accepted	accept	VERB
gs-3920	440	9	grading	grade	VERB
gs-3920	440	10	system	system	NOUN
gs-3920	440	11	for	for	ADP
gs-3920	440	12	dress	dress	NOUN
gs-3920	440	13	severity	severity	NOUN
gs-3920	440	14	exists	exist	VERB
gs-3920	440	15	and	and	CCONJ
gs-3920	440	16	no	no	DET
gs-3920	440	17	validated	validate	VERB
gs-3920	440	18	biomarker	biomarker	NOUN
gs-3920	440	19	supports	support	VERB
gs-3920	440	20	early	early	ADJ
gs-3920	440	21	diagnosis	diagnosis	NOUN
gs-3920	440	22	or	or	CCONJ
gs-3920	440	23	risk	risk	NOUN
gs-3920	440	24	assessment	assessment	NOUN
gs-3920	440	25	.	.	PUNCT
gs-3920	441	1			ADJ
gs-3920	441	2	geographical	geographical	ADJ
gs-3920	441	3	differences	difference	NOUN
gs-3920	441	4	in	in	ADP
gs-3920	441	5	the	the	DET
gs-3920	441	6	prevalence	prevalence	NOUN
gs-3920	441	7	of	of	ADP
gs-3920	441	8	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	441	9	testing	testing	NOUN
gs-3920	441	10	make	make	VERB
gs-3920	441	11	universal	universal	ADJ
gs-3920	441	12	implementation	implementation	NOUN
gs-3920	441	13	of	of	ADP
gs-3920	441	14	prevention	prevention	NOUN
gs-3920	441	15	strategies	strategy	NOUN
gs-3920	441	16	in	in	ADP
gs-3920	441	17	particular	particular	ADJ
gs-3920	441	18	less	less	ADV
gs-3920	441	19	feasible	feasible	ADJ
gs-3920	441	20	in	in	ADP
gs-3920	441	21	populations	population	NOUN
gs-3920	441	22	carrying	carry	VERB
gs-3920	441	23	high	high	ADJ
gs-3920	441	24	-	-	PUNCT
gs-3920	441	25	risk	risk	NOUN
gs-3920	441	26	alleles	allele	NOUN
gs-3920	441	27	.	.	PUNCT
gs-3920	442	1	suggestions	suggestion	NOUN
gs-3920	442	2	based	base	VERB
gs-3920	442	3	on	on	ADP
gs-3920	442	4	a	a	DET
gs-3920	442	5	critical	critical	ADJ
gs-3920	442	6	review	review	NOUN
gs-3920	442	7	of	of	ADP
gs-3920	442	8	the	the	DET
gs-3920	442	9	literature	literature	NOUN
gs-3920	442	10	included	include	VERB
gs-3920	442	11	in	in	ADP
gs-3920	442	12	the	the	DET
gs-3920	442	13	current	current	ADJ
gs-3920	442	14	thesis	thesis	NOUN
gs-3920	442	15	,	,	PUNCT
gs-3920	442	16	that	that	PRON
gs-3920	442	17	involved	involve	VERB
gs-3920	442	18	thematic	thematic	ADJ
gs-3920	442	19	analyses	analysis	NOUN
gs-3920	442	20	of	of	ADP
gs-3920	442	21	drug	drug	NOUN
gs-3920	442	22	properties	property	NOUN
gs-3920	442	23	,	,	PUNCT
gs-3920	442	24	clinical	clinical	ADJ
gs-3920	442	25	expression	expression	NOUN
gs-3920	442	26	,	,	PUNCT
gs-3920	442	27	and	and	CCONJ
gs-3920	442	28	genetic	genetic	ADJ
gs-3920	442	29	predisposition	predisposition	NOUN
gs-3920	442	30	to	to	ADP
gs-3920	442	31	drug	drug	NOUN
gs-3920	442	32	reaction	reaction	NOUN
gs-3920	442	33	eosinophilia	eosinophilia	PROPN
gs-3920	442	34	and	and	CCONJ
gs-3920	442	35	systemic	systemic	ADJ
gs-3920	442	36	symptoms	symptom	NOUN
gs-3920	442	37	(	(	PUNCT
gs-3920	442	38	dress	dress	NOUN
gs-3920	442	39	)	)	PUNCT
gs-3920	442	40	,	,	PUNCT
gs-3920	442	41	the	the	DET
gs-3920	442	42	following	follow	VERB
gs-3920	442	43	recommendations	recommendation	NOUN
gs-3920	442	44	are	be	AUX
gs-3920	442	45	suggested	suggest	VERB
gs-3920	442	46	.	.	PUNCT
gs-3920	443	1	these	these	DET
gs-3920	443	2	initiatives	initiative	NOUN
gs-3920	443	3	seek	seek	VERB
gs-3920	443	4	to	to	PART
gs-3920	443	5	further	far	ADV
gs-3920	443	6	enhance	enhance	VERB
gs-3920	443	7	early	early	ADJ
gs-3920	443	8	georgian	georgian	ADJ
gs-3920	443	9	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	443	10	მეცნიერები	მეცნიერები	NOUN
gs-3920	443	11	ტ.	ტ.	VERB
gs-3920	443	12	7	7	NUM
gs-3920	443	13	n	n	DET
gs-3920	443	14	3	3	NUM
gs-3920	443	15	,	,	PUNCT
gs-3920	443	16	2025	2025	NUM
gs-3920	443	17	208	208	NUM
gs-3920	443	18	identification	identification	NOUN
gs-3920	443	19	,	,	PUNCT
gs-3920	443	20	individualise	individualise	ADJ
gs-3920	443	21	treatment	treatment	NOUN
gs-3920	443	22	approaches	approach	NOUN
gs-3920	443	23	and	and	CCONJ
gs-3920	443	24	better	well	ADJ
gs-3920	443	25	plan	plan	VERB
gs-3920	443	26	long	long	ADJ
gs-3920	443	27	-	-	PUNCT
gs-3920	443	28	term	term	NOUN
gs-3920	443	29	management	management	NOUN
gs-3920	443	30	and	and	CCONJ
gs-3920	443	31	outcome	outcome	VERB
gs-3920	443	32	for	for	ADP
gs-3920	443	33	patients	patient	NOUN
gs-3920	443	34	with	with	ADP
gs-3920	443	35	this	this	DET
gs-3920	443	36	heterogeneous	heterogeneous	ADJ
gs-3920	443	37	syndrome	syndrome	NOUN
gs-3920	443	38	.	.	PUNCT
gs-3920	444	1	for	for	ADP
gs-3920	444	2	clinicians	clinician	NOUN
gs-3920	444	3			VERB
gs-3920	444	4	early	early	ADJ
gs-3920	444	5	identification	identification	NOUN
gs-3920	444	6	clinicians	clinician	NOUN
gs-3920	444	7	should	should	AUX
gs-3920	444	8	challenge	challenge	VERB
gs-3920	444	9	themselves	themselves	PRON
gs-3920	444	10	to	to	PART
gs-3920	444	11	consider	consider	VERB
gs-3920	444	12	dress	dress	NOUN
gs-3920	444	13	in	in	ADP
gs-3920	444	14	any	any	DET
gs-3920	444	15	patient	patient	NOUN
gs-3920	444	16	who	who	PRON
gs-3920	444	17	presents	present	VERB
gs-3920	444	18	with	with	ADP
gs-3920	444	19	a	a	DET
gs-3920	444	20	consistent	consistent	ADJ
gs-3920	444	21	constellation	constellation	NOUN
gs-3920	444	22	of	of	ADP
gs-3920	444	23	rash	rash	NOUN
gs-3920	444	24	,	,	PUNCT
gs-3920	444	25	fever	fever	NOUN
gs-3920	444	26	,	,	PUNCT
gs-3920	444	27	eosinophilia	eosinophilia	PROPN
gs-3920	444	28	and	and	CCONJ
gs-3920	444	29	internal	internal	ADJ
gs-3920	444	30	organ	organ	NOUN
gs-3920	444	31	involvement	involvement	NOUN
gs-3920	444	32	in	in	ADP
gs-3920	444	33	the	the	DET
gs-3920	444	34	context	context	NOUN
gs-3920	444	35	of	of	ADP
gs-3920	444	36	a	a	DET
gs-3920	444	37	new	new	ADJ
gs-3920	444	38	drug	drug	NOUN
gs-3920	444	39	exposure	exposure	NOUN
gs-3920	444	40	within	within	ADP
gs-3920	444	41	2	2	NUM
gs-3920	444	42	to	to	PART
gs-3920	444	43	6	6	NUM
gs-3920	444	44	weeks	week	NOUN
gs-3920	444	45	of	of	ADP
gs-3920	444	46	exposure	exposure	NOUN
gs-3920	444	47	.	.	PUNCT
gs-3920	445	1	the	the	DET
gs-3920	445	2	syndrome	syndrome	NOUN
gs-3920	445	3	has	have	VERB
gs-3920	445	4	a	a	DET
gs-3920	445	5	delayed	delay	VERB
gs-3920	445	6	onset	onset	NOUN
gs-3920	445	7	and	and	CCONJ
gs-3920	445	8	varied	varied	ADJ
gs-3920	445	9	presentation	presentation	NOUN
gs-3920	445	10	such	such	ADJ
gs-3920	445	11	that	that	SCONJ
gs-3920	445	12	early	early	ADJ
gs-3920	445	13	clinical	clinical	ADJ
gs-3920	445	14	suspicion	suspicion	NOUN
gs-3920	445	15	is	be	AUX
gs-3920	445	16	critical	critical	ADJ
gs-3920	445	17	in	in	ADP
gs-3920	445	18	being	be	AUX
gs-3920	445	19	able	able	ADJ
gs-3920	445	20	to	to	PART
gs-3920	445	21	diagnose	diagnose	VERB
gs-3920	445	22	,	,	PUNCT
gs-3920	445	23	which	which	PRON
gs-3920	445	24	is	be	AUX
gs-3920	445	25	frequently	frequently	ADV
gs-3920	445	26	either	either	CCONJ
gs-3920	445	27	underdiagnosed	underdiagnosed	ADJ
gs-3920	445	28	or	or	CCONJ
gs-3920	445	29	misdiagnosed	misdiagnose	VERB
gs-3920	445	30			ADJ
gs-3920	445	31	systematic	systematic	ADJ
gs-3920	445	32	assessment	assessment	NOUN
gs-3920	445	33	:	:	PUNCT
gs-3920	445	34	a	a	DET
gs-3920	445	35	complete	complete	ADJ
gs-3920	445	36	and	and	CCONJ
gs-3920	445	37	systematic	systematic	ADJ
gs-3920	445	38	examination	examination	NOUN
gs-3920	445	39	should	should	AUX
gs-3920	445	40	be	be	AUX
gs-3920	445	41	instituted	institute	VERB
gs-3920	445	42	if	if	SCONJ
gs-3920	445	43	dress	dress	NOUN
gs-3920	445	44	is	be	AUX
gs-3920	445	45	suspected	suspect	VERB
gs-3920	445	46	.	.	PUNCT
gs-3920	446	1	these	these	PRON
gs-3920	446	2	include	include	VERB
gs-3920	446	3	baseline	baseline	NOUN
gs-3920	446	4	and	and	CCONJ
gs-3920	446	5	serial	serial	ADJ
gs-3920	446	6	laboratory	laboratory	NOUN
gs-3920	446	7	tests	test	NOUN
gs-3920	446	8	to	to	PART
gs-3920	446	9	follow	follow	VERB
gs-3920	446	10	lfts	lft	NOUN
gs-3920	446	11	,	,	PUNCT
gs-3920	446	12	rfts	rft	NOUN
gs-3920	446	13	,	,	PUNCT
gs-3920	446	14	complete	complete	ADJ
gs-3920	446	15	blood	blood	NOUN
gs-3920	446	16	counts	count	NOUN
gs-3920	446	17	(	(	PUNCT
gs-3920	446	18	cbcs	cbc	NOUN
gs-3920	446	19	)	)	PUNCT
gs-3920	446	20	,	,	PUNCT
gs-3920	446	21	and	and	CCONJ
gs-3920	446	22	chest	chest	NOUN
gs-3920	446	23	imaging	imaging	NOUN
gs-3920	446	24	as	as	SCONJ
gs-3920	446	25	indicated	indicate	VERB
gs-3920	446	26	to	to	PART
gs-3920	446	27	evaluate	evaluate	VERB
gs-3920	446	28	hepatic	hepatic	NOUN
gs-3920	446	29	,	,	PUNCT
gs-3920	446	30	renal	renal	ADJ
gs-3920	446	31	,	,	PUNCT
gs-3920	446	32	thoracic	thoracic	NOUN
gs-3920	446	33	,	,	PUNCT
gs-3920	446	34	and	and	CCONJ
gs-3920	446	35	hematologic	hematologic	NOUN
gs-3920	446	36	involvement	involvement	NOUN
gs-3920	446	37	.	.	PUNCT
gs-3920	447	1	close	close	ADJ
gs-3920	447	2	follow	follow	NOUN
gs-3920	447	3	-	-	PUNCT
gs-3920	447	4	up	up	NOUN
gs-3920	447	5	during	during	ADP
gs-3920	447	6	hospitalization	hospitalization	NOUN
gs-3920	447	7	is	be	AUX
gs-3920	447	8	also	also	ADV
gs-3920	447	9	necessary	necessary	ADJ
gs-3920	447	10	to	to	PART
gs-3920	447	11	identify	identify	VERB
gs-3920	447	12	progression	progression	NOUN
gs-3920	447	13	or	or	CCONJ
gs-3920	447	14	new	new	ADJ
gs-3920	447	15	organs	organ	NOUN
gs-3920	447	16	of	of	ADP
gs-3920	447	17	involvement	involvement	NOUN
gs-3920	447	18			VERB
gs-3920	447	19	early	early	ADJ
gs-3920	447	20	withdrawal	withdrawal	NOUN
gs-3920	447	21	of	of	ADP
gs-3920	447	22	the	the	DET
gs-3920	447	23	offending	offend	VERB
gs-3920	447	24	drug	drug	NOUN
gs-3920	447	25	:	:	PUNCT
gs-3920	447	26	early	early	ADJ
gs-3920	447	27	withdrawal	withdrawal	NOUN
gs-3920	447	28	of	of	ADP
gs-3920	447	29	the	the	DET
gs-3920	447	30	implicated	implicated	ADJ
gs-3920	447	31	drug	drug	NOUN
gs-3920	447	32	is	be	AUX
gs-3920	447	33	important	important	ADJ
gs-3920	447	34	and	and	CCONJ
gs-3920	447	35	previous	previous	ADJ
gs-3920	447	36	studies	study	NOUN
gs-3920	447	37	significantly	significantly	ADV
gs-3920	447	38	improved	improve	VERB
gs-3920	447	39	the	the	DET
gs-3920	447	40	clinical	clinical	ADJ
gs-3920	447	41	outcome	outcome	NOUN
gs-3920	447	42	and	and	CCONJ
gs-3920	447	43	reduced	reduced	ADJ
gs-3920	447	44	mortality	mortality	NOUN
gs-3920	447	45	.	.	PUNCT
gs-3920	448	1	delay	delay	NOUN
gs-3920	448	2	in	in	ADP
gs-3920	448	3	cessation	cessation	NOUN
gs-3920	448	4	of	of	ADP
gs-3920	448	5	drug	drug	NOUN
gs-3920	448	6	use	use	NOUN
gs-3920	448	7	is	be	AUX
gs-3920	448	8	related	relate	VERB
gs-3920	448	9	to	to	ADP
gs-3920	448	10	more	more	ADJ
gs-3920	448	11	severity	severity	NOUN
gs-3920	448	12	and	and	CCONJ
gs-3920	448	13	bad	bad	ADJ
gs-3920	448	14	prognosis	prognosis	NOUN
gs-3920	448	15			VERB
gs-3920	448	16	initial	initial	ADJ
gs-3920	448	17	medication	medication	NOUN
gs-3920	448	18	of	of	ADP
gs-3920	448	19	choice	choice	NOUN
gs-3920	448	20	:	:	PUNCT
gs-3920	448	21	systemic	systemic	ADJ
gs-3920	448	22	corticosteroids	corticosteroid	NOUN
gs-3920	448	23	still	still	ADV
gs-3920	448	24	represent	represent	VERB
gs-3920	448	25	the	the	DET
gs-3920	448	26	initial	initial	ADJ
gs-3920	448	27	treatment	treatment	NOUN
gs-3920	448	28	for	for	ADP
gs-3920	448	29	moderate	moderate	ADJ
gs-3920	448	30	to	to	ADP
gs-3920	448	31	severe	severe	ADJ
gs-3920	448	32	dress	dress	NOUN
gs-3920	448	33	,	,	PUNCT
gs-3920	448	34	because	because	SCONJ
gs-3920	448	35	of	of	ADP
gs-3920	448	36	their	their	PRON
gs-3920	448	37	immunosuppressive	immunosuppressive	ADJ
gs-3920	448	38	and	and	CCONJ
gs-3920	448	39	anti	anti	ADJ
gs-3920	448	40	-	-	ADJ
gs-3920	448	41	inflammatory	inflammatory	ADJ
gs-3920	448	42	action	action	NOUN
gs-3920	448	43	.	.	PUNCT
gs-3920	449	1	if	if	SCONJ
gs-3920	449	2	corticosteroids	corticosteroid	NOUN
gs-3920	449	3	are	be	AUX
gs-3920	449	4	inadequate	inadequate	ADJ
gs-3920	449	5	or	or	CCONJ
gs-3920	449	6	contraindicated	contraindicate	VERB
gs-3920	449	7	,	,	PUNCT
gs-3920	449	8	other	other	ADJ
gs-3920	449	9	treatments	treatment	NOUN
gs-3920	449	10	including	include	VERB
gs-3920	449	11	intravenous	intravenous	ADJ
gs-3920	449	12	immunoglobulin	immunoglobulin	NOUN
gs-3920	449	13	(	(	PUNCT
gs-3920	449	14	ivig	ivig	NOUN
gs-3920	449	15	)	)	PUNCT
gs-3920	449	16	or	or	CCONJ
gs-3920	449	17	cyclosporine	cyclosporine	NOUN
gs-3920	449	18	may	may	AUX
gs-3920	449	19	be	be	AUX
gs-3920	449	20	tried	try	VERB
gs-3920	449	21	,	,	PUNCT
gs-3920	449	22	without	without	ADP
gs-3920	449	23	well	well	ADV
gs-3920	449	24	-	-	PUNCT
gs-3920	449	25	controlled	control	VERB
gs-3920	449	26	trial	trial	NOUN
gs-3920	449	27	-	-	PUNCT
gs-3920	449	28	based	base	VERB
gs-3920	449	29	evidence	evidence	NOUN
gs-3920	449	30	.	.	PUNCT
gs-3920	450	1	for	for	SCONJ
gs-3920	450	2	researchers	researcher	NOUN
gs-3920	450	3			X
gs-3920	450	4	perform	perform	VERB
gs-3920	450	5	randomized	randomize	VERB
gs-3920	450	6	controlled	control	VERB
gs-3920	450	7	trials	trial	NOUN
gs-3920	450	8	(	(	PUNCT
gs-3920	450	9	rcts	rct	NOUN
gs-3920	450	10	)	)	PUNCT
gs-3920	450	11	high	high	ADJ
gs-3920	450	12	-	-	PUNCT
gs-3920	450	13	quality	quality	NOUN
gs-3920	450	14	rcts	rct	NOUN
gs-3920	450	15	are	be	AUX
gs-3920	450	16	urgently	urgently	ADV
gs-3920	450	17	required	require	VERB
gs-3920	450	18	to	to	PART
gs-3920	450	19	compare	compare	VERB
gs-3920	450	20	the	the	DET
gs-3920	450	21	efficacy	efficacy	NOUN
gs-3920	450	22	and	and	CCONJ
gs-3920	450	23	safety	safety	NOUN
gs-3920	450	24	of	of	ADP
gs-3920	450	25	corticosteroids	corticosteroid	NOUN
gs-3920	450	26	,	,	PUNCT
gs-3920	450	27	ivig	ivig	NOUN
gs-3920	450	28	,	,	PUNCT
gs-3920	450	29	cyclosporine	cyclosporine	NOUN
gs-3920	450	30	,	,	PUNCT
gs-3920	450	31	and	and	CCONJ
gs-3920	450	32	other	other	ADJ
gs-3920	450	33	immunomodulatory	immunomodulatory	ADJ
gs-3920	450	34	agents	agent	NOUN
gs-3920	450	35	for	for	ADP
gs-3920	450	36	the	the	DET
gs-3920	450	37	management	management	NOUN
gs-3920	450	38	of	of	ADP
gs-3920	450	39	dress	dress	NOUN
gs-3920	450	40	.	.	PUNCT
gs-3920	451	1	these	these	DET
gs-3920	451	2	investigations	investigation	NOUN
gs-3920	451	3	could	could	AUX
gs-3920	451	4	potentially	potentially	ADV
gs-3920	451	5	inform	inform	VERB
gs-3920	451	6	clinical	clinical	ADJ
gs-3920	451	7	management	management	NOUN
gs-3920	451	8	decisions	decision	NOUN
gs-3920	451	9	toward	toward	ADP
gs-3920	451	10	therapeutic	therapeutic	ADJ
gs-3920	451	11	intervention	intervention	NOUN
gs-3920	451	12	in	in	ADP
gs-3920	451	13	order	order	NOUN
gs-3920	451	14	to	to	PART
gs-3920	451	15	enhance	enhance	VERB
gs-3920	451	16	patient	patient	ADJ
gs-3920	451	17	outcomes	outcome	NOUN
gs-3920	451	18			NUM
gs-3920	451	19	uniform	uniform	ADJ
gs-3920	451	20	diagnostic	diagnostic	ADJ
gs-3920	451	21	criteria	criterion	NOUN
gs-3920	451	22	:	:	PUNCT
gs-3920	451	23	the	the	DET
gs-3920	451	24	scientific	scientific	ADJ
gs-3920	451	25	community	community	NOUN
gs-3920	451	26	should	should	AUX
gs-3920	451	27	work	work	VERB
gs-3920	451	28	together	together	ADV
gs-3920	451	29	to	to	PART
gs-3920	451	30	develop	develop	VERB
gs-3920	451	31	and	and	CCONJ
gs-3920	451	32	validate	validate	VERB
gs-3920	451	33	common	common	ADJ
gs-3920	451	34	clinical	clinical	ADJ
gs-3920	451	35	diagnostic	diagnostic	ADJ
gs-3920	451	36	criteria	criterion	NOUN
gs-3920	451	37	based	base	VERB
gs-3920	451	38	on	on	ADP
gs-3920	451	39	the	the	DET
gs-3920	451	40	discovery	discovery	NOUN
gs-3920	451	41	and	and	CCONJ
gs-3920	451	42	validation	validation	NOUN
gs-3920	451	43	of	of	ADP
gs-3920	451	44	biomarkers	biomarker	NOUN
gs-3920	451	45	that	that	PRON
gs-3920	451	46	are	be	AUX
gs-3920	451	47	reliable	reliable	ADJ
gs-3920	451	48	.	.	PUNCT
gs-3920	452	1	this	this	DET
gs-3920	452	2	standardization	standardization	NOUN
gs-3920	452	3	is	be	AUX
gs-3920	452	4	expected	expect	VERB
gs-3920	452	5	to	to	PART
gs-3920	452	6	enable	enable	VERB
gs-3920	452	7	accurate	accurate	ADJ
gs-3920	452	8	diagnosis	diagnosis	NOUN
gs-3920	452	9	,	,	PUNCT
gs-3920	452	10	support	support	VERB
gs-3920	452	11	epidemiological	epidemiological	ADJ
gs-3920	452	12	investigations	investigation	NOUN
gs-3920	452	13	,	,	PUNCT
gs-3920	452	14	and	and	CCONJ
gs-3920	452	15	harmonize	harmonize	VERB
gs-3920	452	16	clinical	clinical	ADJ
gs-3920	452	17	trials	trial	NOUN
gs-3920	452	18	.	.	PUNCT
gs-3920	453	1			NOUN
gs-3920	453	2	monitor	monitor	VERB
gs-3920	453	3	longer	long	ADJ
gs-3920	453	4	-	-	PUNCT
gs-3920	453	5	term	term	NOUN
gs-3920	453	6	outcomes	outcome	NOUN
gs-3920	453	7	:	:	PUNCT
gs-3920	453	8	longitudinal	longitudinal	ADJ
gs-3920	453	9	cohort	cohort	NOUN
gs-3920	453	10	studies	study	NOUN
gs-3920	453	11	are	be	AUX
gs-3920	453	12	required	require	VERB
gs-3920	453	13	to	to	PART
gs-3920	453	14	define	define	VERB
gs-3920	453	15	long	long	ADJ
gs-3920	453	16	-	-	PUNCT
gs-3920	453	17	term	term	NOUN
gs-3920	453	18	complications	complication	NOUN
gs-3920	453	19	of	of	ADP
gs-3920	453	20	dress	dress	NOUN
gs-3920	453	21	,	,	PUNCT
gs-3920	453	22	such	such	ADJ
gs-3920	453	23	as	as	ADP
gs-3920	453	24	risk	risk	NOUN
gs-3920	453	25	for	for	ADP
gs-3920	453	26	autoimmune	autoimmune	ADJ
gs-3920	453	27	diseases	disease	NOUN
gs-3920	453	28	,	,	PUNCT
gs-3920	453	29	endocrine	endocrine	NOUN
gs-3920	453	30	disorders	disorder	NOUN
gs-3920	453	31	,	,	PUNCT
gs-3920	453	32	and	and	CCONJ
gs-3920	453	33	quality	quality	NOUN
gs-3920	453	34	of	of	ADP
gs-3920	453	35	life	life	NOUN
gs-3920	453	36	consequences	consequence	NOUN
gs-3920	453	37	.	.	PUNCT
gs-3920	454	1	unfortunately	unfortunately	ADV
gs-3920	454	2	,	,	PUNCT
gs-3920	454	3	such	such	ADJ
gs-3920	454	4	information	information	NOUN
gs-3920	454	5	is	be	AUX
gs-3920	454	6	crucial	crucial	ADJ
gs-3920	454	7	for	for	ADP
gs-3920	454	8	the	the	DET
gs-3920	454	9	planning	planning	NOUN
gs-3920	454	10	of	of	ADP
gs-3920	454	11	follow	follow	NOUN
gs-3920	454	12	-	-	PUNCT
gs-3920	454	13	up	up	NOUN
gs-3920	454	14	and	and	CCONJ
gs-3920	454	15	patient	patient	ADJ
gs-3920	454	16	counselling	counselling	NOUN
gs-3920	454	17	.	.	PUNCT
gs-3920	455	1	georgian	georgian	ADJ
gs-3920	455	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	455	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	455	4	ტ.	ტ.	VERB
gs-3920	455	5	7	7	NUM
gs-3920	455	6	n	n	PRON
gs-3920	455	7	3	3	NUM
gs-3920	455	8	,	,	PUNCT
gs-3920	455	9	2025	2025	NUM
gs-3920	455	10	209	209	NUM
gs-3920	455	11	for	for	ADP
gs-3920	455	12	policymakers	policymaker	NOUN
gs-3920	455	13	and	and	CCONJ
gs-3920	455	14	hospitals	hospital	NOUN
gs-3920	455	15			NOUN
gs-3920	455	16	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	455	17	testing	testing	NOUN
gs-3920	455	18	accessibility	accessibility	NOUN
gs-3920	455	19	:	:	PUNCT
gs-3920	455	20	one	one	NUM
gs-3920	455	21	-	-	PUNCT
gs-3920	455	22	way	way	NOUN
gs-3920	455	23	practice	practice	NOUN
gs-3920	455	24	can	can	AUX
gs-3920	455	25	make	make	VERB
gs-3920	455	26	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	455	27	testing	testing	NOUN
gs-3920	455	28	more	more	ADV
gs-3920	455	29	accessible	accessible	ADJ
gs-3920	455	30	to	to	ADP
gs-3920	455	31	clinicians	clinician	NOUN
gs-3920	455	32	who	who	PRON
gs-3920	455	33	treat	treat	VERB
gs-3920	455	34	dress	dress	NOUN
gs-3920	455	35	is	be	AUX
gs-3920	455	36	to	to	PART
gs-3920	455	37	require	require	VERB
gs-3920	455	38	pharmacogenetic	pharmacogenetic	ADJ
gs-3920	455	39	testing	testing	NOUN
gs-3920	455	40	before	before	ADP
gs-3920	455	41	prescribing	prescribe	VERB
gs-3920	455	42	drugs	drug	NOUN
gs-3920	455	43	with	with	ADP
gs-3920	455	44	strong	strong	ADJ
gs-3920	455	45	support	support	NOUN
gs-3920	455	46	for	for	ADP
gs-3920	455	47	dress	dress	NOUN
gs-3920	455	48	for	for	ADP
gs-3920	455	49	at	at	ADP
gs-3920	455	50	-	-	PUNCT
gs-3920	455	51	risk	risk	NOUN
gs-3920	455	52	hla	hla	NOUN
gs-3920	455	53	alleles	allele	NOUN
gs-3920	455	54	such	such	ADJ
gs-3920	455	55	as	as	ADP
gs-3920	455	56	hla	hla	NOUN
gs-3920	455	57	-	-	PUNCT
gs-3920	455	58	b58:01	b58:01	PROPN
gs-3920	455	59	and	and	CCONJ
gs-3920	455	60	hla	hla	PROPN
gs-3920	455	61	-	-	PUNCT
gs-3920	455	62	a31:01	a31:01	PROPN
gs-3920	455	63	,	,	PUNCT
gs-3920	455	64	such	such	ADJ
gs-3920	455	65	as	as	ADP
gs-3920	455	66	allopurinol	allopurinol	NOUN
gs-3920	455	67	,	,	PUNCT
gs-3920	455	68	and	and	CCONJ
gs-3920	455	69	carbamazepine	carbamazepine	NOUN
gs-3920	455	70	.	.	PUNCT
gs-3920	456	1	this	this	DET
gs-3920	456	2	kind	kind	NOUN
gs-3920	456	3	of	of	ADP
gs-3920	456	4	proactive	proactive	ADJ
gs-3920	456	5	approach	approach	NOUN
gs-3920	456	6	has	have	AUX
gs-3920	456	7	been	be	AUX
gs-3920	456	8	shown	show	VERB
gs-3920	456	9	to	to	PART
gs-3920	456	10	be	be	AUX
gs-3920	456	11	effective	effective	ADJ
gs-3920	456	12	in	in	ADP
gs-3920	456	13	preventing	prevent	VERB
gs-3920	456	14	severe	severe	ADJ
gs-3920	456	15	adverse	adverse	ADJ
gs-3920	456	16	drug	drug	NOUN
gs-3920	456	17	reactions	reaction	NOUN
gs-3920	456	18	such	such	ADJ
gs-3920	456	19	as	as	ADP
gs-3920	456	20	the	the	DET
gs-3920	456	21	case	case	NOUN
gs-3920	456	22	of	of	ADP
gs-3920	456	23	genetically	genetically	ADV
gs-3920	456	24	predisposed	predispose	VERB
gs-3920	456	25	individuals	individual	NOUN
gs-3920	456	26	.	.	PUNCT
gs-3920	457	1			PRON
gs-3920	457	2	realize	realize	VERB
gs-3920	457	3	reporting	report	VERB
gs-3920	457	4	mechanisms	mechanism	NOUN
gs-3920	457	5	:	:	PUNCT
gs-3920	457	6	set	set	VERB
gs-3920	457	7	up	up	ADP
gs-3920	457	8	and	and	CCONJ
gs-3920	457	9	support	support	VERB
gs-3920	457	10	national	national	ADJ
gs-3920	457	11	and	and	CCONJ
gs-3920	457	12	international	international	ADJ
gs-3920	457	13	adverse	adverse	ADJ
gs-3920	457	14	drug	drug	NOUN
gs-3920	457	15	reaction	reaction	NOUN
gs-3920	457	16	(	(	PUNCT
gs-3920	457	17	adr	adr	PROPN
gs-3920	457	18	)	)	PUNCT
gs-3920	457	19	and	and	CCONJ
gs-3920	457	20	close	close	ADJ
gs-3920	457	21	surveillance	surveillance	NOUN
gs-3920	457	22	registries	registry	NOUN
gs-3920	457	23	actively	actively	ADV
gs-3920	457	24	in	in	ADP
gs-3920	457	25	order	order	NOUN
gs-3920	457	26	to	to	PART
gs-3920	457	27	assist	assist	VERB
gs-3920	457	28	in	in	ADP
gs-3920	457	29	analysing	analysing	NOUN
gs-3920	457	30	and	and	CCONJ
gs-3920	457	31	to	to	PART
gs-3920	457	32	increase	increase	VERB
gs-3920	457	33	systematic	systematic	ADJ
gs-3920	457	34	reporting	reporting	NOUN
gs-3920	457	35	,	,	PUNCT
gs-3920	457	36	surveillance	surveillance	NOUN
gs-3920	457	37	and	and	CCONJ
gs-3920	457	38	trend	trend	NOUN
gs-3920	457	39	for	for	ADP
gs-3920	457	40	dress	dress	NOUN
gs-3920	457	41	cases	case	NOUN
gs-3920	457	42	.	.	PUNCT
gs-3920	458	1	these	these	DET
gs-3920	458	2	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	458	3	systems	system	NOUN
gs-3920	458	4	are	be	AUX
gs-3920	458	5	vital	vital	ADJ
gs-3920	458	6	for	for	ADP
gs-3920	458	7	early	early	ADJ
gs-3920	458	8	identification	identification	NOUN
gs-3920	458	9	of	of	ADP
gs-3920	458	10	emerging	emerge	VERB
gs-3920	458	11	risk	risk	NOUN
gs-3920	458	12	drugs	drug	NOUN
gs-3920	458	13	and	and	CCONJ
gs-3920	458	14	trends	trend	NOUN
gs-3920	458	15			NOUN
gs-3920	458	16	revise	revise	VERB
gs-3920	458	17	treatment	treatment	NOUN
gs-3920	458	18	recommendations	recommendation	NOUN
gs-3920	458	19	:	:	PUNCT
gs-3920	458	20	there	there	PRON
gs-3920	458	21	is	be	VERB
gs-3920	458	22	an	an	DET
gs-3920	458	23	urgent	urgent	ADJ
gs-3920	458	24	need	need	NOUN
gs-3920	458	25	for	for	ADP
gs-3920	458	26	creation	creation	NOUN
gs-3920	458	27	and	and	CCONJ
gs-3920	458	28	dissemination	dissemination	NOUN
gs-3920	458	29	of	of	ADP
gs-3920	458	30	evidence	evidence	NOUN
gs-3920	458	31	-	-	PUNCT
gs-3920	458	32	based	base	VERB
gs-3920	458	33	,	,	PUNCT
gs-3920	458	34	interdisciplinary	interdisciplinary	ADJ
gs-3920	458	35	guidelines	guideline	NOUN
gs-3920	458	36	for	for	ADP
gs-3920	458	37	diagnosis	diagnosis	NOUN
gs-3920	458	38	and	and	CCONJ
gs-3920	458	39	management	management	NOUN
gs-3920	458	40	of	of	ADP
gs-3920	458	41	dress	dress	NOUN
gs-3920	458	42	.	.	PUNCT
gs-3920	459	1	this	this	PRON
gs-3920	459	2	would	would	AUX
gs-3920	459	3	facilitate	facilitate	VERB
gs-3920	459	4	evidence	evidence	NOUN
gs-3920	459	5	-	-	PUNCT
gs-3920	459	6	based	base	VERB
gs-3920	459	7	care	care	NOUN
gs-3920	459	8	and	and	CCONJ
gs-3920	459	9	enhance	enhance	VERB
gs-3920	459	10	consistency	consistency	NOUN
gs-3920	459	11	of	of	ADP
gs-3920	459	12	treatment	treatment	NOUN
gs-3920	459	13	between	between	ADP
gs-3920	459	14	different	different	ADJ
gs-3920	459	15	levels	level	NOUN
gs-3920	459	16	of	of	ADP
gs-3920	459	17	health	health	NOUN
gs-3920	459	18	care	care	NOUN
gs-3920	459	19	.	.	PUNCT
gs-3920	460	1	for	for	ADP
gs-3920	460	2	pharmacists	pharmacist	NOUN
gs-3920	460	3	and	and	CCONJ
gs-3920	460	4	public	public	ADJ
gs-3920	460	5	health	health	NOUN
gs-3920	460	6	professionals	professional	NOUN
gs-3920	460	7			PROPN
gs-3920	460	8	teach	teach	VERB
gs-3920	460	9	about	about	ADP
gs-3920	460	10	risks	risk	NOUN
gs-3920	460	11	of	of	ADP
gs-3920	460	12	otc	otc	PROPN
gs-3920	460	13	drugs	drug	NOUN
gs-3920	460	14	:	:	PUNCT
gs-3920	460	15	pharmacists	pharmacist	NOUN
gs-3920	460	16	and	and	CCONJ
gs-3920	460	17	public	public	ADJ
gs-3920	460	18	health	health	NOUN
gs-3920	460	19	workers	worker	NOUN
gs-3920	460	20	need	need	VERB
gs-3920	460	21	to	to	PART
gs-3920	460	22	educate	educate	VERB
gs-3920	460	23	about	about	ADP
gs-3920	460	24	the	the	DET
gs-3920	460	25	risk	risk	NOUN
gs-3920	460	26	of	of	ADP
gs-3920	460	27	nsaid	nsaid	PROPN
gs-3920	460	28	caused	cause	VERB
gs-3920	460	29	dress	dress	NOUN
gs-3920	460	30	,	,	PUNCT
gs-3920	460	31	especially	especially	ADV
gs-3920	460	32	if	if	SCONJ
gs-3920	460	33	a	a	DET
gs-3920	460	34	patient	patient	ADJ
gs-3920	460	35	self	self	NOUN
gs-3920	460	36	-	-	PUNCT
gs-3920	460	37	medicating	medicate	VERB
gs-3920	460	38	,	,	PUNCT
gs-3920	460	39	and	and	CCONJ
gs-3920	460	40	is	be	AUX
gs-3920	460	41	using	use	VERB
gs-3920	460	42	it	it	PRON
gs-3920	460	43	for	for	ADP
gs-3920	460	44	a	a	DET
gs-3920	460	45	prolonged	prolonged	ADJ
gs-3920	460	46	period	period	NOUN
gs-3920	460	47	without	without	ADP
gs-3920	460	48	supervision	supervision	NOUN
gs-3920	460	49	,	,	PUNCT
gs-3920	460	50	also	also	ADV
gs-3920	460	51	about	about	ADP
gs-3920	460	52	other	other	ADJ
gs-3920	460	53	drugs	drug	NOUN
gs-3920	460	54	.	.	PUNCT
gs-3920	461	1	public	public	ADJ
gs-3920	461	2	health	health	NOUN
gs-3920	461	3	awareness	awareness	NOUN
gs-3920	461	4	should	should	AUX
gs-3920	461	5	be	be	AUX
gs-3920	461	6	raised	raise	VERB
gs-3920	461	7	to	to	PART
gs-3920	461	8	minimize	minimize	VERB
gs-3920	461	9	this	this	DET
gs-3920	461	10	risk	risk	NOUN
gs-3920	461	11	and	and	CCONJ
gs-3920	461	12	to	to	PART
gs-3920	461	13	ensure	ensure	VERB
gs-3920	461	14	early	early	ADJ
gs-3920	461	15	medical	medical	ADJ
gs-3920	461	16	consultation	consultation	NOUN
gs-3920	461	17	for	for	ADP
gs-3920	461	18	the	the	DET
gs-3920	461	19	suspicious	suspicious	ADJ
gs-3920	461	20	symptoms	symptom	NOUN
gs-3920	461	21	.	.	PUNCT
gs-3920	462	1			ADP
gs-3920	462	2	active	active	ADJ
gs-3920	462	3	involvement	involvement	NOUN
gs-3920	462	4	in	in	ADP
gs-3920	462	5	adr	adr	PROPN
gs-3920	462	6	monitoring	monitoring	NOUN
gs-3920	462	7	:	:	PUNCT
gs-3920	462	8	pharmacists	pharmacist	NOUN
gs-3920	462	9	need	need	VERB
gs-3920	462	10	to	to	PART
gs-3920	462	11	be	be	AUX
gs-3920	462	12	educated	educate	VERB
gs-3920	462	13	in	in	ADP
gs-3920	462	14	the	the	DET
gs-3920	462	15	early	early	ADJ
gs-3920	462	16	warning	warning	NOUN
gs-3920	462	17	signs	sign	NOUN
gs-3920	462	18	of	of	ADP
gs-3920	462	19	adrs	adr	NOUN
gs-3920	462	20	and	and	CCONJ
gs-3920	462	21	should	should	AUX
gs-3920	462	22	actively	actively	ADV
gs-3920	462	23	be	be	AUX
gs-3920	462	24	involved	involve	VERB
gs-3920	462	25	in	in	ADP
gs-3920	462	26	reporting	report	VERB
gs-3920	462	27	adrs	adr	NOUN
gs-3920	462	28	in	in	ADP
gs-3920	462	29	pharmacovigilance	pharmacovigilance	NOUN
gs-3920	462	30	.	.	PUNCT
gs-3920	463	1	their	their	PRON
gs-3920	463	2	frontline	frontline	ADJ
gs-3920	463	3	role	role	NOUN
gs-3920	463	4	in	in	ADP
gs-3920	463	5	drug	drug	NOUN
gs-3920	463	6	distribution	distribution	NOUN
gs-3920	463	7	provides	provide	VERB
gs-3920	463	8	them	they	PRON
gs-3920	463	9	with	with	ADP
gs-3920	463	10	a	a	DET
gs-3920	463	11	unique	unique	ADJ
gs-3920	463	12	opportunity	opportunity	NOUN
gs-3920	463	13	to	to	PART
gs-3920	463	14	help	help	AUX
gs-3920	463	15	identify	identify	VERB
gs-3920	463	16	and	and	CCONJ
gs-3920	463	17	report	report	VERB
gs-3920	463	18	cases	case	NOUN
gs-3920	463	19	of	of	ADP
gs-3920	463	20	dress	dress	NOUN
gs-3920	463	21	early	early	ADV
gs-3920	463	22	.	.	PUNCT
gs-3920	464	1	conclusion	conclusion	NOUN
gs-3920	464	2			VERB
gs-3920	464	3	genomic	genomic	ADJ
gs-3920	464	4	insights	insight	NOUN
gs-3920	464	5	,	,	PUNCT
gs-3920	464	6	specifically	specifically	ADV
gs-3920	464	7	the	the	DET
gs-3920	464	8	discovery	discovery	NOUN
gs-3920	464	9	of	of	ADP
gs-3920	464	10	hla	hla	PROPN
gs-3920	464	11	allele	allele	PROPN
gs-3920	464	12	associations	association	NOUN
gs-3920	464	13	,	,	PUNCT
gs-3920	464	14	have	have	AUX
gs-3920	464	15	created	create	VERB
gs-3920	464	16	new	new	ADJ
gs-3920	464	17	opportunities	opportunity	NOUN
gs-3920	464	18	for	for	ADP
gs-3920	464	19	risk	risk	NOUN
gs-3920	464	20	stratification	stratification	NOUN
gs-3920	464	21	and	and	CCONJ
gs-3920	464	22	prevention	prevention	NOUN
gs-3920	464	23	.	.	PUNCT
gs-3920	465	1	pre	pre	ADJ
gs-3920	465	2	-	-	ADJ
gs-3920	465	3	treatment	treatment	ADJ
gs-3920	465	4	pharmacogenomic	pharmacogenomic	ADJ
gs-3920	465	5	testing	testing	NOUN
gs-3920	465	6	for	for	ADP
gs-3920	465	7	alleles	allele	NOUN
gs-3920	465	8	such	such	ADJ
gs-3920	465	9	as	as	ADP
gs-3920	465	10	hla	hla	PROPN
gs-3920	465	11	-	-	PUNCT
gs-3920	465	12	b15:02	b15:02	PROPN
gs-3920	465	13	and	and	CCONJ
gs-3920	465	14	hla	hla	PROPN
gs-3920	465	15	-	-	PUNCT
gs-3920	465	16	b58:01	b58:01	PROPN
gs-3920	465	17	is	be	AUX
gs-3920	465	18	becoming	becoming	AUX
gs-3920	465	19	increasingly	increasingly	ADV
gs-3920	465	20	supported	support	VERB
gs-3920	465	21	in	in	ADP
gs-3920	465	22	high	high	ADJ
gs-3920	465	23	-	-	PUNCT
gs-3920	465	24	risk	risk	NOUN
gs-3920	465	25	populations	population	NOUN
gs-3920	465	26	.	.	PUNCT
gs-3920	466	1	nevertheless	nevertheless	ADV
gs-3920	466	2	,	,	PUNCT
gs-3920	466	3	the	the	DET
gs-3920	466	4	availability	availability	NOUN
gs-3920	466	5	of	of	ADP
gs-3920	466	6	such	such	ADJ
gs-3920	466	7	screening	screening	NOUN
gs-3920	466	8	is	be	AUX
gs-3920	466	9	still	still	ADV
gs-3920	466	10	restricted	restrict	VERB
gs-3920	466	11	in	in	ADP
gs-3920	466	12	several	several	ADJ
gs-3920	466	13	areas	area	NOUN
gs-3920	466	14	thereby	thereby	ADV
gs-3920	466	15	delaying	delay	VERB
gs-3920	466	16	the	the	DET
gs-3920	466	17	future	future	NOUN
gs-3920	466	18	of	of	ADP
gs-3920	466	19	personalized	personalized	ADJ
gs-3920	466	20	medicine	medicine	NOUN
gs-3920	466	21	.	.	PUNCT
gs-3920	467	1			VERB
gs-3920	467	2	there	there	PRON
gs-3920	467	3	are	be	VERB
gs-3920	467	4	no	no	DET
gs-3920	467	5	standardized	standardized	ADJ
gs-3920	467	6	guidelines	guideline	NOUN
gs-3920	467	7	from	from	ADP
gs-3920	467	8	a	a	DET
gs-3920	467	9	treatment	treatment	NOUN
gs-3920	467	10	point	point	NOUN
gs-3920	467	11	of	of	ADP
gs-3920	467	12	view	view	NOUN
gs-3920	467	13	,	,	PUNCT
gs-3920	467	14	which	which	PRON
gs-3920	467	15	is	be	AUX
gs-3920	467	16	a	a	DET
gs-3920	467	17	significant	significant	ADJ
gs-3920	467	18	barrier	barrier	NOUN
gs-3920	467	19	.	.	PUNCT
gs-3920	468	1	corticosteroids	corticosteroid	NOUN
gs-3920	468	2	are	be	AUX
gs-3920	468	3	the	the	DET
gs-3920	468	4	mainstay	mainstay	NOUN
gs-3920	468	5	of	of	ADP
gs-3920	468	6	treatment	treatment	NOUN
gs-3920	468	7	but	but	CCONJ
gs-3920	468	8	the	the	DET
gs-3920	468	9	best	good	ADJ
gs-3920	468	10	dose	dose	NOUN
gs-3920	468	11	,	,	PUNCT
gs-3920	468	12	duration	duration	NOUN
gs-3920	468	13	and	and	CCONJ
gs-3920	468	14	taper	taper	NOUN
gs-3920	468	15	remain	remain	VERB
gs-3920	468	16	inconsistent	inconsistent	ADJ
gs-3920	468	17	.	.	PUNCT
gs-3920	469	1	the	the	DET
gs-3920	469	2	thesis	thesis	NOUN
gs-3920	469	3	emphasized	emphasize	VERB
gs-3920	469	4	that	that	SCONJ
gs-3920	469	5	the	the	DET
gs-3920	469	6	second	second	ADJ
gs-3920	469	7	line	line	NOUN
gs-3920	469	8	agents	agent	NOUN
gs-3920	469	9	,	,	PUNCT
gs-3920	469	10	including	include	VERB
gs-3920	469	11	ivig	ivig	NOUN
gs-3920	469	12	,	,	PUNCT
gs-3920	469	13	cs	cs	PROPN
gs-3920	469	14	,	,	PUNCT
gs-3920	469	15	or	or	CCONJ
gs-3920	469	16	antiviral	antiviral	ADJ
gs-3920	469	17	therapy	therapy	NOUN
gs-3920	469	18	,	,	PUNCT
gs-3920	469	19	could	could	AUX
gs-3920	469	20	be	be	AUX
gs-3920	469	21	beneficial	beneficial	ADJ
gs-3920	469	22	when	when	SCONJ
gs-3920	469	23	directed	direct	VERB
gs-3920	469	24	according	accord	VERB
gs-3920	469	25	to	to	ADP
gs-3920	469	26	the	the	DET
gs-3920	469	27	clinical	clinical	ADJ
gs-3920	469	28	severity	severity	NOUN
gs-3920	469	29	and	and	CCONJ
gs-3920	469	30	virus	virus	NOUN
gs-3920	469	31	reactivation	reactivation	NOUN
gs-3920	469	32	,	,	PUNCT
gs-3920	469	33	yet	yet	CCONJ
gs-3920	469	34	the	the	DET
gs-3920	469	35	efficacy	efficacy	NOUN
gs-3920	469	36	needs	need	VERB
gs-3920	469	37	to	to	PART
gs-3920	469	38	be	be	AUX
gs-3920	469	39	georgian	georgian	ADJ
gs-3920	469	40	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	469	41	მეცნიერები	მეცნიერები	NOUN
gs-3920	469	42	ტ.	ტ.	VERB
gs-3920	469	43	7	7	NUM
gs-3920	469	44	n	n	DET
gs-3920	469	45	3	3	NUM
gs-3920	469	46	,	,	PUNCT
gs-3920	469	47	2025	2025	NUM
gs-3920	469	48	210	210	NUM
gs-3920	469	49	further	far	ADV
gs-3920	469	50	confirmed	confirm	VERB
gs-3920	469	51	by	by	ADP
gs-3920	469	52	larger	large	ADJ
gs-3920	469	53	clinical	clinical	ADJ
gs-3920	469	54	trials	trial	NOUN
gs-3920	469	55	.	.	PUNCT
gs-3920	470	1	this	this	DET
gs-3920	470	2	therapeutic	therapeutic	ADJ
gs-3920	470	3	uncertainty	uncertainty	NOUN
gs-3920	470	4	emphasizes	emphasize	VERB
gs-3920	470	5	the	the	DET
gs-3920	470	6	need	need	NOUN
gs-3920	470	7	for	for	SCONJ
gs-3920	470	8	prospective	prospective	ADJ
gs-3920	470	9	studies	study	NOUN
gs-3920	470	10	to	to	PART
gs-3920	470	11	define	define	VERB
gs-3920	470	12	and	and	CCONJ
gs-3920	470	13	implement	implement	VERB
gs-3920	470	14	consensus	consensus	NOUN
gs-3920	470	15	protocols	protocol	NOUN
gs-3920	470	16	.	.	PUNCT
gs-3920	471	1			VERB
gs-3920	471	2	furthermore	furthermore	ADV
gs-3920	471	3	,	,	PUNCT
gs-3920	471	4	the	the	DET
gs-3920	471	5	study	study	NOUN
gs-3920	471	6	revealed	reveal	VERB
gs-3920	471	7	a	a	DET
gs-3920	471	8	number	number	NOUN
gs-3920	471	9	of	of	ADP
gs-3920	471	10	deficiencies	deficiency	NOUN
gs-3920	471	11	in	in	ADP
gs-3920	471	12	knowledge	knowledge	NOUN
gs-3920	471	13	and	and	CCONJ
gs-3920	471	14	practice	practice	NOUN
gs-3920	471	15	.	.	PUNCT
gs-3920	472	1	these	these	DET
gs-3920	472	2	reasons	reason	NOUN
gs-3920	472	3	have	have	AUX
gs-3920	472	4	been	be	AUX
gs-3920	472	5	listed	list	VERB
gs-3920	472	6	to	to	PART
gs-3920	472	7	be	be	AUX
gs-3920	472	8	however	however	ADV
gs-3920	472	9	,	,	PUNCT
gs-3920	472	10	underreporting	underreporte	VERB
gs-3920	472	11	of	of	ADP
gs-3920	472	12	nsaid	nsaid	PROPN
gs-3920	472	13	-	-	PUNCT
gs-3920	472	14	induced	induce	VERB
gs-3920	472	15	dress	dress	NOUN
gs-3920	472	16	in	in	ADP
gs-3920	472	17	view	view	NOUN
gs-3920	472	18	of	of	ADP
gs-3920	472	19	their	their	PRON
gs-3920	472	20	wide	wide	ADJ
gs-3920	472	21	over	over	ADP
gs-3920	472	22	the	the	DET
gs-3920	472	23	counter	counter	NOUN
gs-3920	472	24	availability	availability	NOUN
gs-3920	472	25	,	,	PUNCT
gs-3920	472	26	heuristic	heuristic	ADJ
gs-3920	472	27	term	term	NOUN
gs-3920	472	28	in	in	ADP
gs-3920	472	29	its	its	PRON
gs-3920	472	30	name	name	NOUN
gs-3920	472	31	,	,	PUNCT
gs-3920	472	32	no	no	DET
gs-3920	472	33	universal	universal	ADJ
gs-3920	472	34	diagnostic	diagnostic	ADJ
gs-3920	472	35	criteria	criterion	NOUN
gs-3920	472	36	,	,	PUNCT
gs-3920	472	37	no	no	DET
gs-3920	472	38	severity	severity	NOUN
gs-3920	472	39	scoring	scoring	NOUN
gs-3920	472	40	systems	system	NOUN
gs-3920	472	41	and	and	CCONJ
gs-3920	472	42	insufficient	insufficient	ADJ
gs-3920	472	43	data	datum	NOUN
gs-3920	472	44	regarding	regard	VERB
gs-3920	472	45	long	long	ADJ
gs-3920	472	46	-	-	PUNCT
gs-3920	472	47	term	term	NOUN
gs-3920	472	48	outcomes	outcome	NOUN
gs-3920	472	49	.	.	PUNCT
gs-3920	473	1	particularly	particularly	ADV
gs-3920	473	2	,	,	PUNCT
gs-3920	473	3	5	5	NUM
gs-3920	473	4	%	%	NOUN
gs-3920	473	5	of	of	ADP
gs-3920	473	6	survivors	survivor	NOUN
gs-3920	473	7	were	be	AUX
gs-3920	473	8	immune	immune	NOUN
gs-3920	473	9	-	-	PUNCT
gs-3920	473	10	disrupted	disrupt	VERB
gs-3920	473	11	until	until	ADP
gs-3920	473	12	post	post	NOUN
gs-3920	473	13	-	-	NOUN
gs-3920	473	14	recovery	recovery	NOUN
gs-3920	473	15	,	,	PUNCT
gs-3920	473	16	with	with	ADP
gs-3920	473	17	some	some	DET
gs-3920	473	18	subjects	subject	NOUN
gs-3920	473	19	even	even	ADV
gs-3920	473	20	developing	develop	VERB
gs-3920	473	21	autoimmune	autoimmune	ADJ
gs-3920	473	22	diseases	disease	NOUN
gs-3920	473	23	,	,	PUNCT
gs-3920	473	24	leading	lead	VERB
gs-3920	473	25	to	to	ADP
gs-3920	473	26	long	long	ADJ
gs-3920	473	27	-	-	PUNCT
gs-3920	473	28	term	term	NOUN
gs-3920	473	29	immunity	immunity	NOUN
gs-3920	473	30	disturbance	disturbance	NOUN
gs-3920	473	31	that	that	PRON
gs-3920	473	32	needs	need	VERB
gs-3920	473	33	to	to	PART
gs-3920	473	34	be	be	AUX
gs-3920	473	35	investigated	investigate	VERB
gs-3920	473	36	further	far	ADV
gs-3920	473	37	.	.	PUNCT
gs-3920	474	1			VERB
gs-3920	474	2	in	in	ADP
gs-3920	474	3	building	build	VERB
gs-3920	474	4	this	this	DET
gs-3920	474	5	thesis	thesis	NOUN
gs-3920	474	6	,	,	PUNCT
gs-3920	474	7	we	we	PRON
gs-3920	474	8	have	have	AUX
gs-3920	474	9	attempted	attempt	VERB
gs-3920	474	10	to	to	PART
gs-3920	474	11	assemble	assemble	VERB
gs-3920	474	12	a	a	DET
gs-3920	474	13	comprehensive	comprehensive	ADJ
gs-3920	474	14	set	set	NOUN
gs-3920	474	15	of	of	ADP
gs-3920	474	16	detailed	detailed	ADJ
gs-3920	474	17	case	case	NOUN
gs-3920	474	18	-	-	PUNCT
gs-3920	474	19	by	by	ADP
gs-3920	474	20	-	-	PUNCT
gs-3920	474	21	case	case	NOUN
gs-3920	474	22	data	datum	NOUN
gs-3920	474	23	to	to	PART
gs-3920	474	24	demonstrate	demonstrate	VERB
gs-3920	474	25	the	the	DET
gs-3920	474	26	full	full	ADJ
gs-3920	474	27	array	array	NOUN
gs-3920	474	28	of	of	ADP
gs-3920	474	29	examples	example	NOUN
gs-3920	474	30	of	of	ADP
gs-3920	474	31	patient	patient	ADJ
gs-3920	474	32	diagnostic	diagnostic	ADJ
gs-3920	474	33	delay	delay	NOUN
gs-3920	474	34	and	and	CCONJ
gs-3920	474	35	multi	multi	ADJ
gs-3920	474	36	-	-	ADJ
gs-3920	474	37	organ	organ	ADJ
gs-3920	474	38	variability	variability	NOUN
gs-3920	474	39	,	,	PUNCT
gs-3920	474	40	and	and	CCONJ
gs-3920	474	41	treatment	treatment	NOUN
gs-3920	474	42	responses	response	NOUN
gs-3920	474	43	.	.	PUNCT
gs-3920	475	1	these	these	DET
gs-3920	475	2	case	case	NOUN
gs-3920	475	3	summaries	summary	NOUN
gs-3920	475	4	offered	offer	VERB
gs-3920	475	5	some	some	DET
gs-3920	475	6	examples	example	NOUN
gs-3920	475	7	of	of	ADP
gs-3920	475	8	the	the	DET
gs-3920	475	9	range	range	NOUN
gs-3920	475	10	of	of	ADP
gs-3920	475	11	dress	dress	NOUN
gs-3920	475	12	and	and	CCONJ
gs-3920	475	13	demonstrated	demonstrate	VERB
gs-3920	475	14	well	well	INTJ
gs-3920	475	15	the	the	DET
gs-3920	475	16	real‐life	real‐life	NOUN
gs-3920	475	17	dilemmas	dilemma	NOUN
gs-3920	475	18	that	that	PRON
gs-3920	475	19	clinicians	clinician	NOUN
gs-3920	475	20	encounter	encounter	VERB
gs-3920	475	21	.	.	PUNCT
gs-3920	476	1			VERB
gs-3920	476	2	this	this	DET
gs-3920	476	3	thesis	thesis	NOUN
gs-3920	476	4	has	have	AUX
gs-3920	476	5	introduced	introduce	VERB
gs-3920	476	6	dress	dress	NOUN
gs-3920	476	7	syndrome	syndrome	NOUN
gs-3920	476	8	as	as	ADP
gs-3920	476	9	not	not	PART
gs-3920	476	10	a	a	DET
gs-3920	476	11	rare	rare	ADJ
gs-3920	476	12	hypersensitivity	hypersensitivity	NOUN
gs-3920	476	13	reaction	reaction	NOUN
gs-3920	476	14	but	but	CCONJ
gs-3920	476	15	as	as	ADP
gs-3920	476	16	a	a	DET
gs-3920	476	17	multi	multi	ADJ
gs-3920	476	18	-	-	ADJ
gs-3920	476	19	faceted	faceted	ADJ
gs-3920	476	20	immunopathological	immunopathological	ADJ
gs-3920	476	21	condition	condition	NOUN
gs-3920	476	22	where	where	SCONJ
gs-3920	476	23	recognition	recognition	NOUN
gs-3920	476	24	,	,	PUNCT
gs-3920	476	25	diagnostic	diagnostic	ADJ
gs-3920	476	26	criteria	criterion	NOUN
gs-3920	476	27	,	,	PUNCT
gs-3920	476	28	and	and	CCONJ
gs-3920	476	29	treatment	treatment	NOUN
gs-3920	476	30	options	option	NOUN
gs-3920	476	31	need	need	VERB
gs-3920	476	32	to	to	PART
gs-3920	476	33	be	be	AUX
gs-3920	476	34	addressed	address	VERB
gs-3920	476	35	for	for	ADP
gs-3920	476	36	a	a	DET
gs-3920	476	37	new	new	ADJ
gs-3920	476	38	evidence	evidence	NOUN
gs-3920	476	39	-	-	PUNCT
gs-3920	476	40	based	base	VERB
gs-3920	476	41	perspective	perspective	NOUN
gs-3920	476	42	.	.	PUNCT
gs-3920	477	1	the	the	DET
gs-3920	477	2	paper	paper	NOUN
gs-3920	477	3	underscores	underscore	VERB
gs-3920	477	4	pharmacogenomics	pharmacogenomic	NOUN
gs-3920	477	5	,	,	PUNCT
gs-3920	477	6	close	close	ADJ
gs-3920	477	7	clinical	clinical	ADJ
gs-3920	477	8	surveillance	surveillance	NOUN
gs-3920	477	9	and	and	CCONJ
gs-3920	477	10	early	early	ADJ
gs-3920	477	11	intervention	intervention	NOUN
gs-3920	477	12	.	.	PUNCT
gs-3920	478	1	despite	despite	SCONJ
gs-3920	478	2	substantial	substantial	ADJ
gs-3920	478	3	progress	progress	NOUN
gs-3920	478	4	in	in	ADP
gs-3920	478	5	the	the	DET
gs-3920	478	6	characterisation	characterisation	NOUN
gs-3920	478	7	of	of	ADP
gs-3920	478	8	aetiology	aetiology	NOUN
gs-3920	478	9	and	and	CCONJ
gs-3920	478	10	enhancements	enhancement	NOUN
gs-3920	478	11	in	in	ADP
gs-3920	478	12	early	early	ADJ
gs-3920	478	13	diagnosis	diagnosis	NOUN
gs-3920	478	14	,	,	PUNCT
gs-3920	478	15	substantial	substantial	ADJ
gs-3920	478	16	challenges	challenge	NOUN
gs-3920	478	17	nevertheless	nevertheless	ADV
gs-3920	478	18	exist	exist	VERB
gs-3920	478	19	in	in	ADP
gs-3920	478	20	optimising	optimise	VERB
gs-3920	478	21	treatment	treatment	NOUN
gs-3920	478	22	approaches	approach	NOUN
gs-3920	478	23	,	,	PUNCT
gs-3920	478	24	improving	improve	VERB
gs-3920	478	25	risk	risk	NOUN
gs-3920	478	26	prediction	prediction	NOUN
gs-3920	478	27	,	,	PUNCT
gs-3920	478	28	and	and	CCONJ
gs-3920	478	29	formulating	formulate	VERB
gs-3920	478	30	and	and	CCONJ
gs-3920	478	31	implementing	implement	VERB
gs-3920	478	32	international	international	ADJ
gs-3920	478	33	diagnostic	diagnostic	ADJ
gs-3920	478	34	and	and	CCONJ
gs-3920	478	35	management	management	NOUN
gs-3920	478	36	strategies	strategy	NOUN
gs-3920	478	37	.	.	PUNCT
gs-3920	479	1	references	reference	NOUN
gs-3920	479	2	1	1	NUM
gs-3920	479	3	.	.	X
gs-3920	479	4	aphkhazava	aphkhazava	PROPN
gs-3920	479	5	,	,	PUNCT
gs-3920	479	6	david	david	PROPN
gs-3920	479	7	,	,	PUNCT
gs-3920	479	8	nodar	nodar	NOUN
gs-3920	479	9	sulashvili	sulashvili	NOUN
gs-3920	479	10	,	,	PUNCT
gs-3920	479	11	and	and	CCONJ
gs-3920	479	12	jaba	jaba	PROPN
gs-3920	479	13	tkemaladze	tkemaladze	PROPN
gs-3920	479	14	.	.	PUNCT
gs-3920	480	1	2025	2025	NUM
gs-3920	480	2	.	.	PUNCT
gs-3920	481	1	“	"	PUNCT
gs-3920	481	2	stem	stem	NOUN
gs-3920	481	3	cell	cell	NOUN
gs-3920	481	4	systems	system	NOUN
gs-3920	481	5	and	and	CCONJ
gs-3920	481	6	regeneration	regeneration	NOUN
gs-3920	481	7	”	"	PUNCT
gs-3920	481	8	.	.	PUNCT
gs-3920	482	1	georgian	georgian	PROPN
gs-3920	482	2	scientists	scientist	NOUN
gs-3920	482	3	7	7	NUM
gs-3920	482	4	(	(	PUNCT
gs-3920	482	5	1):271	1):271	NUM
gs-3920	482	6	-	-	SYM
gs-3920	482	7	319	319	NUM
gs-3920	482	8	.	.	PUNCT
gs-3920	483	1	https://doi.org/10.52340/gs.2025.07.01.26	https://doi.org/10.52340/gs.2025.07.01.26	NOUN
gs-3920	483	2	.	.	NOUN
gs-3920	483	3	2	2	X
gs-3920	483	4	.	.	X
gs-3920	483	5	abusuliman	abusuliman	NOUN
gs-3920	483	6	,	,	PUNCT
gs-3920	483	7	m.	m.	NOUN
gs-3920	483	8	,	,	PUNCT
gs-3920	483	9	amreia	amreia	ADV
gs-3920	483	10	,	,	PUNCT
gs-3920	483	11	m.	m.	NOUN
gs-3920	483	12	,	,	PUNCT
gs-3920	483	13	rehman	rehman	PROPN
gs-3920	483	14	,	,	PUNCT
gs-3920	483	15	s.	s.	PROPN
gs-3920	483	16	,	,	PUNCT
gs-3920	483	17	chaudhary	chaudhary	PROPN
gs-3920	483	18	,	,	PUNCT
gs-3920	483	19	a.	a.	PROPN
gs-3920	483	20	j.	j.	PROPN
gs-3920	483	21	,	,	PUNCT
gs-3920	483	22	abosheaishaa	abosheaishaa	PROPN
gs-3920	483	23	,	,	PUNCT
gs-3920	483	24	h.	h.	PROPN
gs-3920	483	25	,	,	PUNCT
gs-3920	483	26	jamali	jamali	PROPN
gs-3920	483	27	,	,	PUNCT
gs-3920	483	28	t.	t.	PROPN
gs-3920	483	29	,	,	PUNCT
gs-3920	483	30	&	&	CCONJ
gs-3920	483	31	hanafi	hanafi	PROPN
gs-3920	483	32	,	,	PUNCT
gs-3920	483	33	a.	a.	NOUN
gs-3920	483	34	(	(	PUNCT
gs-3920	483	35	2024	2024	NUM
gs-3920	483	36	)	)	PUNCT
gs-3920	483	37	.	.	PUNCT
gs-3920	484	1	fatal	fatal	ADJ
gs-3920	484	2	itching	itching	NOUN
gs-3920	484	3	and	and	CCONJ
gs-3920	484	4	failing	fail	VERB
gs-3920	484	5	liver	liver	NOUN
gs-3920	484	6	:	:	PUNCT
gs-3920	484	7	a	a	DET
gs-3920	484	8	case	case	NOUN
gs-3920	484	9	report	report	NOUN
gs-3920	484	10	and	and	CCONJ
gs-3920	484	11	systematic	systematic	ADJ
gs-3920	484	12	review	review	NOUN
gs-3920	484	13	of	of	ADP
gs-3920	484	14	rare	rare	ADJ
gs-3920	484	15	,	,	PUNCT
gs-3920	484	16	atypical	atypical	ADJ
gs-3920	484	17	dress	dress	NOUN
gs-3920	484	18	(	(	PUNCT
gs-3920	484	19	drug	drug	NOUN
gs-3920	484	20	rash	rash	NOUN
gs-3920	484	21	with	with	ADP
gs-3920	484	22	eosinophilia	eosinophilia	PROPN
gs-3920	484	23	and	and	CCONJ
gs-3920	484	24	systemic	systemic	ADJ
gs-3920	484	25	symptoms	symptom	NOUN
gs-3920	484	26	)	)	PUNCT
gs-3920	484	27	syndrome	syndrome	NOUN
gs-3920	484	28	.	.	PUNCT
gs-3920	485	1	cureus	cureus	NOUN
gs-3920	485	2	.	.	PUNCT
gs-3920	486	1	https://doi.org/10.7759/cureus.55355	https://doi.org/10.7759/cureus.55355	ADJ
gs-3920	486	2	3	3	NUM
gs-3920	486	3	.	.	X
gs-3920	486	4	ajon	ajon	NOUN
gs-3920	486	5	,	,	PUNCT
gs-3920	486	6	a.	a.	PROPN
gs-3920	486	7	r.	r.	PROPN
gs-3920	486	8	s.	s.	PROPN
gs-3920	486	9	,	,	PUNCT
gs-3920	486	10	&	&	CCONJ
gs-3920	486	11	camara	camara	PROPN
gs-3920	486	12	,	,	PUNCT
gs-3920	486	13	p.	p.	NOUN
gs-3920	486	14	t.	t.	NOUN
gs-3920	486	15	a.	a.	NOUN
gs-3920	486	16	(	(	PUNCT
gs-3920	486	17	2024	2024	NUM
gs-3920	486	18	)	)	PUNCT
gs-3920	486	19	.	.	PUNCT
gs-3920	487	1	drug	drug	NOUN
gs-3920	487	2	rash	rash	NOUN
gs-3920	487	3	with	with	ADP
gs-3920	487	4	eosinophilia	eosinophilia	PROPN
gs-3920	487	5	and	and	CCONJ
gs-3920	487	6	systemic	systemic	ADJ
gs-3920	487	7	symptoms	symptom	NOUN
gs-3920	487	8	(	(	PUNCT
gs-3920	487	9	dress	dress	NOUN
gs-3920	487	10	)	)	PUNCT
gs-3920	487	11	due	due	ADP
gs-3920	487	12	to	to	ADP
gs-3920	487	13	multiple	multiple	ADJ
gs-3920	487	14	anti	anti	ADJ
gs-3920	487	15	-	-	ADJ
gs-3920	487	16	epileptic	epileptic	ADJ
gs-3920	487	17	drug	drug	NOUN
gs-3920	487	18	hypersensitivity	hypersensitivity	NOUN
gs-3920	487	19	.	.	PUNCT
gs-3920	488	1	cureus	cureus	NOUN
gs-3920	488	2	.	.	PUNCT
gs-3920	489	1	https://doi.org/10.7759/cureus.65417	https://doi.org/10.7759/cureus.65417	ADJ
gs-3920	489	2	4	4	NUM
gs-3920	489	3	.	.	PUNCT
gs-3920	490	1	al	al	PROPN
gs-3920	490	2	-	-	PUNCT
gs-3920	490	3	attar	attar	PROPN
gs-3920	490	4	,	,	PUNCT
gs-3920	490	5	m.	m.	NOUN
gs-3920	490	6	,	,	PUNCT
gs-3920	490	7	de	de	X
gs-3920	490	8	santis	santis	PROPN
gs-3920	490	9	,	,	PUNCT
gs-3920	490	10	m.	m.	NOUN
gs-3920	490	11	,	,	PUNCT
gs-3920	490	12	&	&	CCONJ
gs-3920	490	13	massarotti	massarotti	PROPN
gs-3920	490	14	,	,	PUNCT
gs-3920	490	15	m.	m.	NOUN
gs-3920	490	16	(	(	PUNCT
gs-3920	490	17	2019	2019	NUM
gs-3920	490	18	)	)	PUNCT
gs-3920	490	19	.	.	PUNCT
gs-3920	491	1	dress	dress	NOUN
gs-3920	491	2	syndrome	syndrome	NOUN
gs-3920	491	3	in	in	ADP
gs-3920	491	4	response	response	NOUN
gs-3920	491	5	to	to	ADP
gs-3920	491	6	denosumab	denosumab	NOUN
gs-3920	491	7	:	:	PUNCT
gs-3920	491	8	first	first	ADJ
gs-3920	491	9	documented	document	VERB
gs-3920	491	10	case	case	NOUN
gs-3920	491	11	report	report	NOUN
gs-3920	491	12	.	.	PUNCT
gs-3920	492	1	bone	bone	NOUN
gs-3920	492	2	reports	report	NOUN
gs-3920	492	3	,	,	PUNCT
gs-3920	492	4	12	12	NUM
gs-3920	492	5	,	,	PUNCT
gs-3920	492	6	100239	100239	NUM
gs-3920	492	7	.	.	PUNCT
gs-3920	493	1	5	5	NUM
gs-3920	493	2	.	.	X
gs-3920	493	3	alotaibi	alotaibi	PROPN
gs-3920	493	4	,	,	PUNCT
gs-3920	493	5	m.	m.	PROPN
gs-3920	493	6	e.	e.	PROPN
gs-3920	493	7	,	,	PUNCT
gs-3920	493	8	saggese	saggese	PROPN
gs-3920	493	9	,	,	PUNCT
gs-3920	493	10	s.	s.	PROPN
gs-3920	493	11	,	,	PUNCT
gs-3920	493	12	tawhari	tawhari	PROPN
gs-3920	493	13	,	,	PUNCT
gs-3920	493	14	i.	i.	PROPN
gs-3920	493	15	,	,	PUNCT
gs-3920	493	16	zheng	zheng	PROPN
gs-3920	493	17	,	,	PUNCT
gs-3920	493	18	l.	l.	PROPN
gs-3920	493	19	,	,	PUNCT
gs-3920	493	20	nguyen	nguyen	PROPN
gs-3920	493	21	,	,	PUNCT
gs-3920	493	22	c.	c.	PROPN
gs-3920	493	23	v.	v.	PROPN
gs-3920	493	24	,	,	PUNCT
gs-3920	493	25	&	&	CCONJ
gs-3920	493	26	aggarwal	aggarwal	PROPN
gs-3920	493	27	,	,	PUNCT
gs-3920	493	28	v.	v.	PROPN
gs-3920	493	29	(	(	PUNCT
gs-3920	493	30	2022	2022	NUM
gs-3920	493	31	)	)	PUNCT
gs-3920	493	32	.	.	PUNCT
gs-3920	494	1	a	a	DET
gs-3920	494	2	case	case	NOUN
gs-3920	494	3	of	of	ADP
gs-3920	494	4	drug	drug	NOUN
gs-3920	494	5	reaction	reaction	NOUN
gs-3920	494	6	with	with	ADP
gs-3920	494	7	eosinophilia	eosinophilia	PROPN
gs-3920	494	8	and	and	CCONJ
gs-3920	494	9	systemic	systemic	ADJ
gs-3920	494	10	symptoms	symptom	NOUN
gs-3920	494	11	(	(	PUNCT
gs-3920	494	12	dress	dress	NOUN
gs-3920	494	13	)	)	PUNCT
gs-3920	494	14	syndrome	syndrome	NOUN
gs-3920	494	15	in	in	ADP
gs-3920	494	16	a	a	DET
gs-3920	494	17	patient	patient	NOUN
gs-3920	494	18	receiving	receive	VERB
gs-3920	494	19	peritoneal	peritoneal	ADJ
gs-3920	494	20	dialysis	dialysis	NOUN
gs-3920	494	21	with	with	ADP
gs-3920	494	22	icodextrin	icodextrin	PROPN
gs-3920	494	23	exposure	exposure	NOUN
gs-3920	494	24	.	.	PUNCT
gs-3920	495	1	cureus	cureus	NOUN
gs-3920	495	2	.	.	PUNCT
gs-3920	496	1	georgian	georgian	ADJ
gs-3920	496	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	496	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	496	4	ტ.	ტ.	VERB
gs-3920	496	5	7	7	NUM
gs-3920	496	6	n	n	DET
gs-3920	496	7	3	3	NUM
gs-3920	496	8	,	,	PUNCT
gs-3920	496	9	2025	2025	NUM
gs-3920	496	10	211	211	NUM
gs-3920	496	11	6	6	NUM
gs-3920	496	12	.	.	PUNCT
gs-3920	497	1	ambur	ambur	PROPN
gs-3920	497	2	,	,	PUNCT
gs-3920	497	3	a.	a.	PROPN
gs-3920	497	4	b.	b.	PROPN
gs-3920	497	5	,	,	PUNCT
gs-3920	497	6	&	&	CCONJ
gs-3920	497	7	nathoo	nathoo	PROPN
gs-3920	497	8	,	,	PUNCT
gs-3920	497	9	r.	r.	PROPN
gs-3920	497	10	(	(	PUNCT
gs-3920	497	11	2021	2021	NUM
gs-3920	497	12	)	)	PUNCT
gs-3920	497	13	.	.	PUNCT
gs-3920	498	1	recurrent	recurrent	ADJ
gs-3920	498	2	drug	drug	NOUN
gs-3920	498	3	-	-	PUNCT
gs-3920	498	4	induced	induce	VERB
gs-3920	498	5	hypersensitivity	hypersensitivity	NOUN
gs-3920	498	6	syndrome	syndrome	NOUN
gs-3920	498	7	following	follow	VERB
gs-3920	498	8	bortezomib	bortezomib	NOUN
gs-3920	498	9	for	for	ADP
gs-3920	498	10	multiple	multiple	ADJ
gs-3920	498	11	myeloma	myeloma	NOUN
gs-3920	498	12	.	.	PUNCT
gs-3920	499	1	cureus	cureus	NOUN
gs-3920	499	2	.	.	PUNCT
gs-3920	500	1	7	7	X
gs-3920	500	2	.	.	X
gs-3920	500	3	awad	awad	PROPN
gs-3920	500	4	,	,	PUNCT
gs-3920	500	5	a.	a.	PROPN
gs-3920	500	6	,	,	PUNCT
gs-3920	500	7	goh	goh	PROPN
gs-3920	500	8	,	,	PUNCT
gs-3920	500	9	m.	m.	NOUN
gs-3920	500	10	s.	s.	PROPN
gs-3920	500	11	,	,	PUNCT
gs-3920	500	12	&	&	CCONJ
gs-3920	500	13	trubiano	trubiano	PROPN
gs-3920	500	14	,	,	PUNCT
gs-3920	500	15	j.	j.	PROPN
gs-3920	500	16	a.	a.	PROPN
gs-3920	500	17	(	(	PUNCT
gs-3920	500	18	2023	2023	NUM
gs-3920	500	19	)	)	PUNCT
gs-3920	500	20	.	.	PUNCT
gs-3920	501	1	drug	drug	NOUN
gs-3920	501	2	reaction	reaction	NOUN
gs-3920	501	3	with	with	ADP
gs-3920	501	4	eosinophilia	eosinophilia	PROPN
gs-3920	501	5	and	and	CCONJ
gs-3920	501	6	systemic	systemic	ADJ
gs-3920	501	7	symptoms	symptom	NOUN
gs-3920	501	8	:	:	PUNCT
gs-3920	501	9	a	a	DET
gs-3920	501	10	systematic	systematic	ADJ
gs-3920	501	11	review	review	NOUN
gs-3920	501	12	.	.	PUNCT
gs-3920	502	1	the	the	DET
gs-3920	502	2	journal	journal	PROPN
gs-3920	502	3	of	of	ADP
gs-3920	502	4	allergy	allergy	NOUN
gs-3920	502	5	and	and	CCONJ
gs-3920	502	6	clinical	clinical	ADJ
gs-3920	502	7	immunology	immunology	NOUN
gs-3920	502	8	in	in	ADP
gs-3920	502	9	practice	practice	NOUN
gs-3920	502	10	,	,	PUNCT
gs-3920	502	11	11(6	11(6	NUM
gs-3920	502	12	)	)	PUNCT
gs-3920	502	13	,	,	PUNCT
gs-3920	502	14	1856–1868	1856–1868	NUM
gs-3920	502	15	.	.	NOUN
gs-3920	502	16	8	8	NUM
gs-3920	502	17	.	.	X
gs-3920	502	18	brockow	brockow	NOUN
gs-3920	502	19	,	,	PUNCT
gs-3920	502	20	k.	k.	PROPN
gs-3920	502	21	,	,	PUNCT
gs-3920	502	22	garvey	garvey	PROPN
gs-3920	502	23	,	,	PUNCT
gs-3920	502	24	l.	l.	PROPN
gs-3920	502	25	h.	h.	PROPN
gs-3920	502	26	,	,	PUNCT
gs-3920	502	27	aberer	aberer	PROPN
gs-3920	502	28	,	,	PUNCT
gs-3920	502	29	w.	w.	PROPN
gs-3920	502	30	,	,	PUNCT
gs-3920	502	31	atanaskovic‐markovic	atanaskovic‐markovic	PROPN
gs-3920	502	32	,	,	PUNCT
gs-3920	502	33	m.	m.	NOUN
gs-3920	502	34	,	,	PUNCT
gs-3920	502	35	barbaud	barbaud	PROPN
gs-3920	502	36	,	,	PUNCT
gs-3920	502	37	a.	a.	PROPN
gs-3920	502	38	,	,	PUNCT
gs-3920	502	39	bilo	bilo	PROPN
gs-3920	502	40	,	,	PUNCT
gs-3920	502	41	m.	m.	PROPN
gs-3920	502	42	b.	b.	PROPN
gs-3920	502	43	,	,	PUNCT
gs-3920	502	44	bircher	bircher	NOUN
gs-3920	502	45	,	,	PUNCT
gs-3920	502	46	a.	a.	NOUN
gs-3920	502	47	,	,	PUNCT
gs-3920	502	48	blanca	blanca	PROPN
gs-3920	502	49	,	,	PUNCT
gs-3920	502	50	m.	m.	NOUN
gs-3920	502	51	,	,	PUNCT
gs-3920	502	52	bonadonna	bonadonna	NOUN
gs-3920	502	53	,	,	PUNCT
gs-3920	502	54	b.	b.	PROPN
gs-3920	502	55	,	,	PUNCT
gs-3920	502	56	campi	campi	PROPN
gs-3920	502	57	,	,	PUNCT
gs-3920	502	58	p.	p.	NOUN
gs-3920	502	59	,	,	PUNCT
gs-3920	502	60	castro	castro	PROPN
gs-3920	502	61	,	,	PUNCT
gs-3920	502	62	e.	e.	PROPN
gs-3920	502	63	,	,	PUNCT
gs-3920	502	64	cernadas	cernadas	PROPN
gs-3920	502	65	,	,	PUNCT
gs-3920	502	66	j.	j.	PROPN
gs-3920	502	67	r.	r.	PROPN
gs-3920	502	68	,	,	PUNCT
gs-3920	502	69	chiriac	chiriac	PROPN
gs-3920	502	70	,	,	PUNCT
gs-3920	502	71	a.	a.	NOUN
gs-3920	502	72	m.	m.	NOUN
gs-3920	502	73	,	,	PUNCT
gs-3920	502	74	demoly	demoly	NOUN
gs-3920	502	75	,	,	PUNCT
gs-3920	502	76	p.	p.	NOUN
gs-3920	502	77	,	,	PUNCT
gs-3920	502	78	grosber	grosber	PROPN
gs-3920	502	79	,	,	PUNCT
gs-3920	502	80	m.	m.	NOUN
gs-3920	502	81	,	,	PUNCT
gs-3920	502	82	gooi	gooi	PROPN
gs-3920	502	83	,	,	PUNCT
gs-3920	502	84	j.	j.	PROPN
gs-3920	502	85	,	,	PUNCT
gs-3920	502	86	lombardo	lombardo	PROPN
gs-3920	502	87	,	,	PUNCT
gs-3920	502	88	c.	c.	PROPN
gs-3920	502	89	,	,	PUNCT
gs-3920	502	90	mertes	mertes	PROPN
gs-3920	502	91	,	,	PUNCT
gs-3920	502	92	p.	p.	NOUN
gs-3920	502	93	m.	m.	NOUN
gs-3920	502	94	,	,	PUNCT
gs-3920	502	95	mosbech	mosbech	NOUN
gs-3920	502	96	,	,	PUNCT
gs-3920	502	97	h.	h.	PROPN
gs-3920	502	98	,	,	PUNCT
gs-3920	502	99	.	.	PUNCT
gs-3920	502	100	.	.	PUNCT
gs-3920	502	101	.	.	PUNCT
gs-3920	503	1	terreehorst	terreehorst	ADV
gs-3920	503	2	,	,	PUNCT
gs-3920	503	3	i.	i.	PROPN
gs-3920	503	4	(	(	PUNCT
gs-3920	503	5	2013	2013	NUM
gs-3920	503	6	)	)	PUNCT
gs-3920	503	7	.	.	PUNCT
gs-3920	504	1	skin	skin	NOUN
gs-3920	504	2	test	test	NOUN
gs-3920	504	3	concentrations	concentration	NOUN
gs-3920	504	4	for	for	ADP
gs-3920	504	5	systemically	systemically	ADV
gs-3920	504	6	administered	administer	VERB
gs-3920	504	7	drugs	drug	NOUN
gs-3920	504	8	–	–	PUNCT
gs-3920	504	9	anenda	anenda	ADJ
gs-3920	504	10	/	/	SYM
gs-3920	504	11	eaacidrug	eaacidrug	NOUN
gs-3920	504	12	allergy	allergy	NOUN
gs-3920	504	13	interest	interest	NOUN
gs-3920	504	14	group	group	PROPN
gs-3920	504	15	position	position	NOUN
gs-3920	504	16	paper	paper	NOUN
gs-3920	504	17	.	.	PUNCT
gs-3920	505	1	allergy	allergy	NOUN
gs-3920	505	2	,	,	PUNCT
gs-3920	505	3	68(6	68(6	NOUN
gs-3920	505	4	)	)	PUNCT
gs-3920	505	5	,	,	PUNCT
gs-3920	505	6	702–712	702–712	NUM
gs-3920	505	7	.	.	PUNCT
gs-3920	505	8	9	9	NUM
gs-3920	505	9	.	.	X
gs-3920	505	10	cacoub	cacoub	NOUN
gs-3920	505	11	,	,	PUNCT
gs-3920	505	12	p.	p.	NOUN
gs-3920	505	13	,	,	PUNCT
gs-3920	505	14	musette	musette	PROPN
gs-3920	505	15	,	,	PUNCT
gs-3920	505	16	p.	p.	PROPN
gs-3920	505	17	,	,	PUNCT
gs-3920	505	18	descamps	descamps	PROPN
gs-3920	505	19	,	,	PUNCT
gs-3920	505	20	v.	v.	PROPN
gs-3920	505	21	,	,	PUNCT
gs-3920	505	22	meyer	meyer	PROPN
gs-3920	505	23	,	,	PUNCT
gs-3920	505	24	o.	o.	PROPN
gs-3920	505	25	,	,	PUNCT
gs-3920	505	26	speirs	speirs	PROPN
gs-3920	505	27	,	,	PUNCT
gs-3920	505	28	c.	c.	PROPN
gs-3920	505	29	,	,	PUNCT
gs-3920	505	30	finzi	finzi	PROPN
gs-3920	505	31	,	,	PUNCT
gs-3920	505	32	l.	l.	PROPN
gs-3920	505	33	,	,	PUNCT
gs-3920	505	34	&	&	CCONJ
gs-3920	505	35	roujeau	roujeau	PROPN
gs-3920	505	36	,	,	PUNCT
gs-3920	505	37	j.	j.	PROPN
gs-3920	505	38	c.	c.	PROPN
gs-3920	505	39	(	(	PUNCT
gs-3920	505	40	2011	2011	NUM
gs-3920	505	41	)	)	PUNCT
gs-3920	505	42	.	.	PUNCT
gs-3920	506	1	the	the	DET
gs-3920	506	2	dress	dress	NOUN
gs-3920	506	3	syndrome	syndrome	NOUN
gs-3920	506	4	:	:	PUNCT
gs-3920	506	5	a	a	DET
gs-3920	506	6	systematic	systematic	ADJ
gs-3920	506	7	review	review	NOUN
gs-3920	506	8	.	.	PUNCT
gs-3920	507	1	the	the	DET
gs-3920	507	2	american	american	PROPN
gs-3920	507	3	journal	journal	PROPN
gs-3920	507	4	of	of	ADP
gs-3920	507	5	medicine	medicine	NOUN
gs-3920	507	6	,	,	PUNCT
gs-3920	507	7	124(7	124(7	NUM
gs-3920	507	8	)	)	PUNCT
gs-3920	507	9	,	,	PUNCT
gs-3920	507	10	588–597	588–597	NUM
gs-3920	507	11	.	.	PUNCT
gs-3920	508	1	10	10	NUM
gs-3920	508	2	.	.	PUNCT
gs-3920	508	3	calle	calle	PROPN
gs-3920	508	4	,	,	PUNCT
gs-3920	508	5	a.	a.	NOUN
gs-3920	508	6	m.	m.	NOUN
gs-3920	508	7	,	,	PUNCT
gs-3920	508	8	aguirre	aguirre	PROPN
gs-3920	508	9	,	,	PUNCT
gs-3920	508	10	n.	n.	PROPN
gs-3920	508	11	,	,	PUNCT
gs-3920	508	12	ardila	ardila	PROPN
gs-3920	508	13	,	,	PUNCT
gs-3920	508	14	j.	j.	PROPN
gs-3920	508	15	c.	c.	PROPN
gs-3920	508	16	,	,	PUNCT
gs-3920	508	17	&	&	CCONJ
gs-3920	508	18	villa	villa	PROPN
gs-3920	508	19	,	,	PUNCT
gs-3920	508	20	r.	r.	PROPN
gs-3920	508	21	c.	c.	PROPN
gs-3920	508	22	(	(	PUNCT
gs-3920	508	23	2023	2023	NUM
gs-3920	508	24	)	)	PUNCT
gs-3920	508	25	.	.	PUNCT
gs-3920	509	1	dress	dress	NOUN
gs-3920	509	2	syndrome	syndrome	NOUN
gs-3920	509	3	:	:	PUNCT
gs-3920	509	4	a	a	DET
gs-3920	509	5	systematic	systematic	ADJ
gs-3920	509	6	review	review	NOUN
gs-3920	509	7	and	and	CCONJ
gs-3920	509	8	treatment	treatment	NOUN
gs-3920	509	9	algorithm	algorithm	NOUN
gs-3920	509	10	.	.	PUNCT
gs-3920	510	1	world	world	NOUN
gs-3920	510	2	allergy	allergy	PROPN
gs-3920	510	3	organization	organization	PROPN
gs-3920	510	4	journal	journal	PROPN
gs-3920	510	5	,	,	PUNCT
gs-3920	510	6	16(3	16(3	PROPN
gs-3920	510	7	)	)	PUNCT
gs-3920	510	8	,	,	PUNCT
gs-3920	510	9	100673	100673	NUM
gs-3920	510	10	.	.	PUNCT
gs-3920	511	1	11	11	NUM
gs-3920	511	2	.	.	X
gs-3920	512	1	chalasani	chalasani	PROPN
gs-3920	512	2	,	,	PUNCT
gs-3920	512	3	s.	s.	PROPN
gs-3920	512	4	,	,	PUNCT
gs-3920	512	5	mannam	mannam	NOUN
gs-3920	512	6	,	,	PUNCT
gs-3920	512	7	h.	h.	NOUN
gs-3920	512	8	,	,	PUNCT
gs-3920	512	9	alomari	alomari	PROPN
gs-3920	512	10	,	,	PUNCT
gs-3920	512	11	a.	a.	PROPN
gs-3920	512	12	k.	k.	PROPN
gs-3920	512	13	,	,	PUNCT
gs-3920	512	14	&	&	CCONJ
gs-3920	512	15	rahnama	rahnama	PROPN
gs-3920	512	16	-	-	PUNCT
gs-3920	512	17	moghadam	moghadam	PROPN
gs-3920	512	18	,	,	PUNCT
gs-3920	512	19	s.	s.	PROPN
gs-3920	512	20	(	(	PUNCT
gs-3920	512	21	2025	2025	NUM
gs-3920	512	22	)	)	PUNCT
gs-3920	512	23	.	.	PUNCT
gs-3920	513	1	drug	drug	NOUN
gs-3920	513	2	reaction	reaction	NOUN
gs-3920	513	3	with	with	ADP
gs-3920	513	4	eosinophilia	eosinophilia	PROPN
gs-3920	513	5	and	and	CCONJ
gs-3920	513	6	systemic	systemic	ADJ
gs-3920	513	7	symptoms	symptom	NOUN
gs-3920	513	8	to	to	ADP
gs-3920	513	9	vancomycin	vancomycin	PROPN
gs-3920	513	10	-	-	PUNCT
gs-3920	513	11	laden	laden	ADJ
gs-3920	513	12	cement	cement	NOUN
gs-3920	513	13	space	space	NOUN
gs-3920	513	14	:	:	PUNCT
gs-3920	513	15	a	a	DET
gs-3920	513	16	case	case	NOUN
gs-3920	513	17	report	report	NOUN
gs-3920	513	18	.	.	PUNCT
gs-3920	514	1	cureus	cureus	NOUN
gs-3920	514	2	.	.	PUNCT
gs-3920	515	1	12	12	NUM
gs-3920	515	2	.	.	PUNCT
gs-3920	516	1	choudhary	choudhary	PROPN
gs-3920	516	2	,	,	PUNCT
gs-3920	516	3	r.	r.	PROPN
gs-3920	516	4	,	,	PUNCT
gs-3920	516	5	vinay	vinay	PROPN
gs-3920	516	6	,	,	PUNCT
gs-3920	516	7	k.	k.	PROPN
gs-3920	516	8	,	,	PUNCT
gs-3920	516	9	srivastava	srivastava	PROPN
gs-3920	516	10	,	,	PUNCT
gs-3920	516	11	n.	n.	PROPN
gs-3920	516	12	,	,	PUNCT
gs-3920	516	13	bishnoi	bishnoi	PROPN
gs-3920	516	14	,	,	PUNCT
gs-3920	516	15	a.	a.	PROPN
gs-3920	516	16	,	,	PUNCT
gs-3920	516	17	kamat	kamat	PROPN
gs-3920	516	18	,	,	PUNCT
gs-3920	516	19	d.	d.	PROPN
gs-3920	516	20	,	,	PUNCT
gs-3920	516	21	parsad	parsad	PROPN
gs-3920	516	22	,	,	PUNCT
gs-3920	516	23	d.	d.	PROPN
gs-3920	516	24	,	,	PUNCT
gs-3920	516	25	bhatia	bhatia	PROPN
gs-3920	516	26	,	,	PUNCT
gs-3920	516	27	a.	a.	PROPN
gs-3920	516	28	,	,	PUNCT
gs-3920	516	29	&	&	CCONJ
gs-3920	516	30	kumaran	kumaran	PROPN
gs-3920	516	31	,	,	PUNCT
gs-3920	516	32	m.	m.	PROPN
gs-3920	516	33	s.	s.	PROPN
gs-3920	516	34	(	(	PUNCT
gs-3920	516	35	2021	2021	NUM
gs-3920	516	36	)	)	PUNCT
gs-3920	516	37	.	.	PUNCT
gs-3920	517	1	clinical	clinical	ADJ
gs-3920	517	2	,	,	PUNCT
gs-3920	517	3	biochemical	biochemical	ADJ
gs-3920	517	4	,	,	PUNCT
gs-3920	517	5	and	and	CCONJ
gs-3920	517	6	serologic	serologic	ADJ
gs-3920	517	7	predictors	predictor	NOUN
gs-3920	517	8	of	of	ADP
gs-3920	517	9	drug	drug	NOUN
gs-3920	517	10	reaction	reaction	NOUN
gs-3920	517	11	with	with	ADP
gs-3920	517	12	eosinophilia	eosinophilia	PROPN
gs-3920	517	13	and	and	CCONJ
gs-3920	517	14	systemic	systemic	ADJ
gs-3920	517	15	symptoms	symptom	NOUN
gs-3920	517	16	syndrome	syndrome	VERB
gs-3920	517	17	:	:	PUNCT
gs-3920	517	18	a	a	DET
gs-3920	517	19	prospective	prospective	ADJ
gs-3920	517	20	case	case	NOUN
gs-3920	517	21	–	–	PUNCT
gs-3920	517	22	control	control	NOUN
gs-3920	517	23	study	study	NOUN
gs-3920	517	24	.	.	PUNCT
gs-3920	518	1	journal	journal	NOUN
gs-3920	518	2	of	of	ADP
gs-3920	518	3	the	the	DET
gs-3920	518	4	american	american	PROPN
gs-3920	518	5	academy	academy	PROPN
gs-3920	518	6	of	of	ADP
gs-3920	518	7	dermatology	dermatology	NOUN
gs-3920	518	8	,	,	PUNCT
gs-3920	518	9	85(4	85(4	NUM
gs-3920	518	10	)	)	PUNCT
gs-3920	518	11	,	,	PUNCT
gs-3920	518	12	901–909	901–909	NUM
gs-3920	518	13	.	.	NOUN
gs-3920	518	14	13	13	NUM
gs-3920	518	15	.	.	PUNCT
gs-3920	519	1	cornejo	cornejo	PROPN
gs-3920	519	2	-	-	PUNCT
gs-3920	519	3	garcia	garcia	PROPN
gs-3920	519	4	,	,	PUNCT
gs-3920	519	5	j.	j.	PROPN
gs-3920	519	6	,	,	PUNCT
gs-3920	519	7	blanca	blanca	NOUN
gs-3920	519	8	-	-	PUNCT
gs-3920	519	9	lopez	lopez	NOUN
gs-3920	519	10	,	,	PUNCT
gs-3920	519	11	n.	n.	NOUN
gs-3920	519	12	,	,	PUNCT
gs-3920	519	13	dona	dona	PROPN
gs-3920	519	14	,	,	PUNCT
gs-3920	519	15	i.	i.	PROPN
gs-3920	519	16	,	,	PUNCT
gs-3920	519	17	andreu	andreu	PROPN
gs-3920	519	18	,	,	PUNCT
gs-3920	519	19	i.	i.	PROPN
gs-3920	519	20	,	,	PUNCT
gs-3920	519	21	agundez	agundez	PROPN
gs-3920	519	22	,	,	PUNCT
gs-3920	519	23	j.	j.	PROPN
gs-3920	519	24	,	,	PUNCT
gs-3920	519	25	carballo	carballo	PROPN
gs-3920	519	26	,	,	PUNCT
gs-3920	519	27	m.	m.	NOUN
gs-3920	519	28	,	,	PUNCT
gs-3920	519	29	blanca	blanca	PROPN
gs-3920	519	30	,	,	PUNCT
gs-3920	519	31	m.	m.	NOUN
gs-3920	519	32	,	,	PUNCT
gs-3920	519	33	&	&	CCONJ
gs-3920	519	34	canto	canto	PROPN
gs-3920	519	35	,	,	PUNCT
gs-3920	519	36	m.	m.	NOUN
gs-3920	519	37	(	(	PUNCT
gs-3920	519	38	2009	2009	NUM
gs-3920	519	39	)	)	PUNCT
gs-3920	519	40	.	.	PUNCT
gs-3920	520	1	hypersensitivity	hypersensitivity	NOUN
gs-3920	520	2	reactions	reaction	NOUN
gs-3920	520	3	to	to	ADP
gs-3920	520	4	non	non	ADJ
gs-3920	520	5	-	-	ADJ
gs-3920	520	6	steroidal	steroidal	ADJ
gs-3920	520	7	antiinflammatory	antiinflammatory	NOUN
gs-3920	520	8	drugs	drug	NOUN
gs-3920	520	9	.	.	PUNCT
gs-3920	521	1	current	current	ADJ
gs-3920	521	2	drug	drug	NOUN
gs-3920	521	3	metabolism	metabolism	NOUN
gs-3920	521	4	,	,	PUNCT
gs-3920	521	5	10(9	10(9	NUM
gs-3920	521	6	)	)	PUNCT
gs-3920	521	7	,	,	PUNCT
gs-3920	521	8	971–980	971–980	NUM
gs-3920	521	9	.	.	PUNCT
gs-3920	521	10	criado	criado	PROPN
gs-3920	521	11	,	,	PUNCT
gs-3920	521	12	p.	p.	PROPN
gs-3920	521	13	r.	r.	PROPN
gs-3920	521	14	,	,	PUNCT
gs-3920	521	15	ianhez	ianhez	PROPN
gs-3920	521	16	,	,	PUNCT
gs-3920	521	17	m.	m.	NOUN
gs-3920	521	18	,	,	PUNCT
gs-3920	521	19	miot	miot	NOUN
gs-3920	521	20	,	,	PUNCT
gs-3920	521	21	h.	h.	PROPN
gs-3920	521	22	a.	a.	PROPN
gs-3920	521	23	,	,	PUNCT
gs-3920	521	24	criado	criado	X
gs-3920	521	25	,	,	PUNCT
gs-3920	521	26	r.	r.	PROPN
gs-3920	521	27	f.	f.	PROPN
gs-3920	521	28	j.	j.	PROPN
gs-3920	521	29	,	,	PUNCT
gs-3920	521	30	talhari	talhari	PROPN
gs-3920	521	31	,	,	PUNCT
gs-3920	521	32	c.	c.	PROPN
gs-3920	521	33	,	,	PUNCT
gs-3920	521	34	&	&	CCONJ
gs-3920	521	35	ramos	ramos	PROPN
gs-3920	521	36	,	,	PUNCT
gs-3920	521	37	p.	p.	NOUN
gs-3920	521	38	m.	m.	NOUN
gs-3920	521	39	(	(	PUNCT
gs-3920	521	40	2024	2024	NUM
gs-3920	521	41	)	)	PUNCT
gs-3920	521	42	.	.	PUNCT
gs-3920	522	1	dress	dress	NOUN
gs-3920	522	2	syndrome	syndrome	NOUN
gs-3920	522	3	:	:	PUNCT
gs-3920	522	4	an	an	DET
gs-3920	522	5	interaction	interaction	NOUN
gs-3920	522	6	between	between	ADP
gs-3920	522	7	drugs	drug	NOUN
gs-3920	522	8	,	,	PUNCT
gs-3920	522	9	latent	latent	NOUN
gs-3920	522	10	viruses	virus	NOUN
gs-3920	522	11	,	,	PUNCT
gs-3920	522	12	and	and	CCONJ
gs-3920	522	13	the	the	DET
gs-3920	522	14	immune	immune	ADJ
gs-3920	522	15	system	system	NOUN
gs-3920	522	16	.	.	PUNCT
gs-3920	523	1	anais	anais	PROPN
gs-3920	523	2	brasileiros	brasileiros	PROPN
gs-3920	523	3	de	de	PROPN
gs-3920	523	4	dermatologia	dermatologia	PROPN
gs-3920	523	5	.	.	PUNCT
gs-3920	524	1	14	14	NUM
gs-3920	524	2	.	.	X
gs-3920	525	1	daldoul	daldoul	PROPN
gs-3920	525	2	,	,	PUNCT
gs-3920	525	3	m.	m.	NOUN
gs-3920	525	4	,	,	PUNCT
gs-3920	525	5	charfi	charfi	PROPN
gs-3920	525	6	,	,	PUNCT
gs-3920	525	7	o.	o.	PROPN
gs-3920	525	8	,	,	PUNCT
gs-3920	525	9	zgolli	zgolli	PROPN
gs-3920	525	10	,	,	PUNCT
gs-3920	525	11	f.	f.	PROPN
gs-3920	525	12	,	,	PUNCT
gs-3920	525	13	ferchichi	ferchichi	PROPN
gs-3920	525	14	,	,	PUNCT
gs-3920	525	15	k.	k.	PROPN
gs-3920	525	16	,	,	PUNCT
gs-3920	525	17	lakhoua	lakhoua	PROPN
gs-3920	525	18	,	,	PUNCT
gs-3920	525	19	g.	g.	PROPN
gs-3920	525	20	,	,	PUNCT
gs-3920	525	21	kastalli	kastalli	PROPN
gs-3920	525	22	,	,	PUNCT
gs-3920	525	23	s.	s.	PROPN
gs-3920	525	24	,	,	PUNCT
gs-3920	525	25	daghfous	daghfous	PROPN
gs-3920	525	26	,	,	PUNCT
gs-3920	525	27	r.	r.	PROPN
gs-3920	525	28	,	,	PUNCT
gs-3920	525	29	zaiem	zaiem	PROPN
gs-3920	525	30	,	,	PUNCT
gs-3920	525	31	a.	a.	NOUN
gs-3920	525	32	,	,	PUNCT
gs-3920	525	33	aouinti	aouinti	PROPN
gs-3920	525	34	,	,	PUNCT
gs-3920	525	35	i.	i.	PROPN
gs-3920	525	36	,	,	PUNCT
gs-3920	525	37	&	&	CCONJ
gs-3920	525	38	aidli	aidli	PROPN
gs-3920	525	39	,	,	PUNCT
gs-3920	525	40	s.	s.	PROPN
gs-3920	525	41	e.	e.	PROPN
gs-3920	525	42	(	(	PUNCT
gs-3920	525	43	2025	2025	NUM
gs-3920	525	44	)	)	PUNCT
gs-3920	525	45	.	.	PUNCT
gs-3920	526	1	drug	drug	NOUN
gs-3920	526	2	reaction	reaction	NOUN
gs-3920	526	3	with	with	ADP
gs-3920	526	4	eosinophilia	eosinophilia	PROPN
gs-3920	526	5	and	and	CCONJ
gs-3920	526	6	systemic	systemic	ADJ
gs-3920	526	7	symptoms	symptom	NOUN
gs-3920	526	8	syndrome	syndrome	VERB
gs-3920	526	9	to	to	ADP
gs-3920	526	10	non	non	ADJ
gs-3920	526	11	-	-	ADJ
gs-3920	526	12	steroidal	steroidal	ADJ
gs-3920	526	13	anti	anti	ADJ
gs-3920	526	14	-	-	ADJ
gs-3920	526	15	inflammatory	inflammatory	ADJ
gs-3920	526	16	drugs	drug	NOUN
gs-3920	526	17	:	:	PUNCT
gs-3920	526	18	a	a	DET
gs-3920	526	19	report	report	NOUN
gs-3920	526	20	of	of	ADP
gs-3920	526	21	case	case	NOUN
gs-3920	526	22	series	series	NOUN
gs-3920	526	23	and	and	CCONJ
gs-3920	526	24	systematic	systematic	ADJ
gs-3920	526	25	review	review	NOUN
gs-3920	526	26	.	.	PUNCT
gs-3920	527	1	revue	revue	PROPN
gs-3920	527	2	française	française	PROPN
gs-3920	527	3	d’allergologie	d’allergologie	PROPN
gs-3920	527	4	,	,	PUNCT
gs-3920	527	5	65(4	65(4	PROPN
gs-3920	527	6	)	)	PUNCT
gs-3920	527	7	,	,	PUNCT
gs-3920	527	8	104221	104221	NUM
gs-3920	527	9	.	.	PUNCT
gs-3920	528	1	15	15	NUM
gs-3920	528	2	.	.	PUNCT
gs-3920	529	1	danjuma	danjuma	PROPN
gs-3920	529	2	,	,	PUNCT
gs-3920	529	3	m.	m.	NOUN
gs-3920	529	4	i.	i.	PROPN
gs-3920	529	5	,	,	PUNCT
gs-3920	529	6	naseralallah	naseralallah	PROPN
gs-3920	529	7	,	,	PUNCT
gs-3920	529	8	l.	l.	PROPN
gs-3920	529	9	m.	m.	PROPN
gs-3920	529	10	a.	a.	PROPN
gs-3920	529	11	,	,	PUNCT
gs-3920	529	12	aboujabal	aboujabal	PROPN
gs-3920	529	13	,	,	PUNCT
gs-3920	529	14	b.	b.	PROPN
gs-3920	529	15	,	,	PUNCT
gs-3920	529	16	mohamed	mohamed	PROPN
gs-3920	529	17	,	,	PUNCT
gs-3920	529	18	m.	m.	PROPN
gs-3920	529	19	f.	f.	PROPN
gs-3920	529	20	,	,	PUNCT
gs-3920	529	21	abubeker	abubeker	PROPN
gs-3920	529	22	,	,	PUNCT
gs-3920	529	23	i.	i.	PROPN
gs-3920	529	24	y.	y.	PROPN
gs-3920	529	25	,	,	PUNCT
gs-3920	529	26	jabbar	jabbar	PROPN
gs-3920	529	27	,	,	PUNCT
gs-3920	529	28	l.	l.	PROPN
gs-3920	529	29	a.	a.	PROPN
gs-3920	529	30	,	,	PUNCT
gs-3920	529	31	&	&	CCONJ
gs-3920	529	32	elzouki	elzouki	PROPN
gs-3920	529	33	,	,	PUNCT
gs-3920	529	34	a.	a.	NOUN
gs-3920	529	35	(	(	PUNCT
gs-3920	529	36	2021	2021	NUM
gs-3920	529	37	)	)	PUNCT
gs-3920	529	38	.	.	PUNCT
gs-3920	530	1	an	an	DET
gs-3920	530	2	investigation	investigation	NOUN
gs-3920	530	3	into	into	ADP
gs-3920	530	4	the	the	DET
gs-3920	530	5	avoidability	avoidability	NOUN
gs-3920	530	6	of	of	ADP
gs-3920	530	7	drug	drug	NOUN
gs-3920	530	8	reaction	reaction	NOUN
gs-3920	530	9	with	with	ADP
gs-3920	530	10	eosinophilia	eosinophilia	PROPN
gs-3920	530	11	and	and	CCONJ
gs-3920	530	12	systemic	systemic	ADJ
gs-3920	530	13	symptoms	symptom	NOUN
gs-3920	530	14	(	(	PUNCT
gs-3920	530	15	dress	dress	NOUN
gs-3920	530	16	)	)	PUNCT
gs-3920	530	17	syndrome	syndrome	NOUN
gs-3920	530	18	.	.	PUNCT
gs-3920	531	1	scientific	scientific	ADJ
gs-3920	531	2	reports	report	NOUN
gs-3920	531	3	,	,	PUNCT
gs-3920	531	4	11(1	11(1	NUM
gs-3920	531	5	)	)	PUNCT
gs-3920	531	6	.	.	PUNCT
gs-3920	532	1	dayanand	dayanand	PROPN
gs-3920	532	2	,	,	PUNCT
gs-3920	532	3	l.	l.	PROPN
gs-3920	532	4	,	,	PUNCT
gs-3920	532	5	ay	ay	PROPN
gs-3920	532	6	,	,	PUNCT
gs-3920	532	7	r.	r.	PROPN
gs-3920	532	8	,	,	PUNCT
gs-3920	532	9	&	&	CCONJ
gs-3920	532	10	nk	nk	PROPN
gs-3920	532	11	,	,	PUNCT
gs-3920	532	12	r.	r.	PROPN
gs-3920	532	13	k.	k.	PROPN
gs-3920	532	14	(	(	PUNCT
gs-3920	532	15	2025	2025	NUM
gs-3920	532	16	)	)	PUNCT
gs-3920	532	17	.	.	PUNCT
gs-3920	533	1	adult	adult	NOUN
gs-3920	533	2	-	-	PUNCT
gs-3920	533	3	onset	onset	NOUN
gs-3920	533	4	still	still	ADV
gs-3920	533	5	’s	’	VERB
gs-3920	533	6	disease	disease	NOUN
gs-3920	533	7	with	with	ADP
gs-3920	533	8	normal	normal	ADJ
gs-3920	533	9	ferritin	ferritin	ADJ
gs-3920	533	10	levels	level	NOUN
gs-3920	533	11	and	and	CCONJ
gs-3920	533	12	severe	severe	ADJ
gs-3920	533	13	sulfasalazine	sulfasalazine	NOUN
gs-3920	533	14	-	-	PUNCT
gs-3920	533	15	induced	induce	VERB
gs-3920	533	16	probable	probable	ADJ
gs-3920	533	17	case	case	NOUN
gs-3920	533	18	of	of	ADP
gs-3920	533	19	drug	drug	NOUN
gs-3920	533	20	georgian	georgian	ADJ
gs-3920	533	21	scientists/ქართველი	scientists/ქართველი	NOUN
gs-3920	533	22	მეცნიერები	მეცნიერები	NOUN
gs-3920	533	23	ტ.	ტ.	VERB
gs-3920	533	24	7	7	NUM
gs-3920	533	25	n	n	DET
gs-3920	533	26	3	3	NUM
gs-3920	533	27	,	,	PUNCT
gs-3920	533	28	2025	2025	NUM
gs-3920	533	29	212	212	NUM
gs-3920	533	30	reaction	reaction	NOUN
gs-3920	533	31	with	with	ADP
gs-3920	533	32	eosinophilia	eosinophilia	PROPN
gs-3920	533	33	and	and	CCONJ
gs-3920	533	34	systemic	systemic	ADJ
gs-3920	533	35	symptoms	symptom	NOUN
gs-3920	533	36	(	(	PUNCT
gs-3920	533	37	dress	dress	NOUN
gs-3920	533	38	)	)	PUNCT
gs-3920	533	39	syndrome	syndrome	NOUN
gs-3920	533	40	:	:	PUNCT
gs-3920	533	41	a	a	DET
gs-3920	533	42	unique	unique	ADJ
gs-3920	533	43	presentation	presentation	NOUN
gs-3920	533	44	and	and	CCONJ
gs-3920	533	45	management	management	NOUN
gs-3920	533	46	challenges	challenge	NOUN
gs-3920	533	47	.	.	PUNCT
gs-3920	534	1	cureus	cureus	NOUN
gs-3920	534	2	.	.	PUNCT
gs-3920	535	1	16	16	NUM
gs-3920	535	2	.	.	X
gs-3920	535	3	de	de	PROPN
gs-3920	535	4	filippis	filippis	PROPN
gs-3920	535	5	,	,	PUNCT
gs-3920	535	6	r.	r.	PROPN
gs-3920	535	7	,	,	PUNCT
gs-3920	535	8	de	de	PROPN
gs-3920	535	9	fazio	fazio	PROPN
gs-3920	535	10	,	,	PUNCT
gs-3920	535	11	p.	p.	PROPN
gs-3920	535	12	,	,	PUNCT
gs-3920	535	13	kane	kane	PROPN
gs-3920	535	14	,	,	PUNCT
gs-3920	535	15	j.	j.	PROPN
gs-3920	535	16	,	,	PUNCT
gs-3920	535	17	&	&	CCONJ
gs-3920	535	18	schoretsanitis	schoretsanitis	PROPN
gs-3920	535	19	,	,	PUNCT
gs-3920	535	20	g.	g.	PROPN
gs-3920	535	21	(	(	PUNCT
gs-3920	535	22	2022	2022	NUM
gs-3920	535	23	)	)	PUNCT
gs-3920	535	24	.	.	PUNCT
gs-3920	536	1	co	co	NOUN
gs-3920	536	2	-	-	NOUN
gs-3920	536	3	occurrence	occurrence	NOUN
gs-3920	536	4	of	of	ADP
gs-3920	536	5	clozapine	clozapine	NOUN
gs-3920	536	6	-	-	PUNCT
gs-3920	536	7	related	relate	VERB
gs-3920	536	8	dress	dress	NOUN
gs-3920	536	9	syndrome	syndrome	NOUN
gs-3920	536	10	core	core	NOUN
gs-3920	536	11	clinical	clinical	ADJ
gs-3920	536	12	manifestations	manifestation	NOUN
gs-3920	536	13	:	:	PUNCT
gs-3920	536	14	results	result	NOUN
gs-3920	536	15	of	of	ADP
gs-3920	536	16	a	a	DET
gs-3920	536	17	systematic	systematic	ADJ
gs-3920	536	18	review	review	NOUN
gs-3920	536	19	.	.	PUNCT
gs-3920	537	1	european	european	ADJ
gs-3920	537	2	psychiatry	psychiatry	PROPN
gs-3920	537	3	,	,	PUNCT
gs-3920	537	4	65(s1	65(s1	NOUN
gs-3920	537	5	)	)	PUNCT
gs-3920	537	6	,	,	PUNCT
gs-3920	537	7	s719	s719	PROPN
gs-3920	537	8	.	.	PUNCT
gs-3920	538	1	17	17	NUM
gs-3920	538	2	.	.	X
gs-3920	538	3	de	de	PROPN
gs-3920	538	4	la	la	PROPN
gs-3920	538	5	cruz	cruz	PROPN
gs-3920	538	6	,	,	PUNCT
gs-3920	538	7	a.	a.	PROPN
gs-3920	538	8	c.	c.	PROPN
gs-3920	538	9	,	,	PUNCT
gs-3920	538	10	ashraf	ashraf	PROPN
gs-3920	538	11	,	,	PUNCT
gs-3920	538	12	s.	s.	PROPN
gs-3920	538	13	,	,	PUNCT
gs-3920	538	14	shrestha	shrestha	PROPN
gs-3920	538	15	,	,	PUNCT
gs-3920	538	16	n.	n.	PROPN
gs-3920	538	17	,	,	PUNCT
gs-3920	538	18	&	&	CCONJ
gs-3920	538	19	saad	saad	PROPN
gs-3920	538	20	,	,	PUNCT
gs-3920	538	21	m.	m.	NOUN
gs-3920	538	22	(	(	PUNCT
gs-3920	538	23	2021	2021	NUM
gs-3920	538	24	)	)	PUNCT
gs-3920	538	25	.	.	PUNCT
gs-3920	539	1	myocarditis	myocarditis	ADJ
gs-3920	539	2	and	and	CCONJ
gs-3920	539	3	drug	drug	NOUN
gs-3920	539	4	rash	rash	NOUN
gs-3920	539	5	with	with	ADP
gs-3920	539	6	eosinophilia	eosinophilia	PROPN
gs-3920	539	7	and	and	CCONJ
gs-3920	539	8	systemic	systemic	ADJ
gs-3920	539	9	symptoms	symptom	NOUN
gs-3920	539	10	syndrome	syndrome	VERB
gs-3920	539	11	:	:	PUNCT
gs-3920	539	12	a	a	DET
gs-3920	539	13	deadly	deadly	ADJ
gs-3920	539	14	combination	combination	NOUN
gs-3920	539	15	.	.	PUNCT
gs-3920	540	1	cureus	cureus	NOUN
gs-3920	540	2	.	.	PUNCT
gs-3920	541	1	18	18	NUM
gs-3920	541	2	.	.	PUNCT
gs-3920	541	3	del	del	PROPN
gs-3920	541	4	pozzo‐magaña	pozzo‐magaña	PROPN
gs-3920	541	5	,	,	PUNCT
gs-3920	541	6	b.	b.	PROPN
gs-3920	541	7	r.	r.	PROPN
gs-3920	541	8	,	,	PUNCT
gs-3920	541	9	rieder	rieder	NOUN
gs-3920	541	10	,	,	PUNCT
gs-3920	541	11	m.	m.	NOUN
gs-3920	541	12	j.	j.	PROPN
gs-3920	541	13	,	,	PUNCT
gs-3920	541	14	garcia‐bournissen	garcia‐bournissen	PROPN
gs-3920	541	15	,	,	PUNCT
gs-3920	541	16	f.	f.	PROPN
gs-3920	541	17	,	,	PUNCT
gs-3920	541	18	&	&	CCONJ
gs-3920	541	19	lazo‐langner	lazo‐langn	ADJ
gs-3920	541	20	,	,	PUNCT
gs-3920	541	21	a.	a.	NOUN
gs-3920	541	22	(	(	PUNCT
gs-3920	541	23	2022	2022	NUM
gs-3920	541	24	)	)	PUNCT
gs-3920	541	25	.	.	PUNCT
gs-3920	542	1	drug	drug	NOUN
gs-3920	542	2	reaction	reaction	NOUN
gs-3920	542	3	with	with	ADP
gs-3920	542	4	eosinophilia	eosinophilia	PROPN
gs-3920	542	5	and	and	CCONJ
gs-3920	542	6	systemic	systemic	ADJ
gs-3920	542	7	symptoms	symptom	NOUN
gs-3920	542	8	(	(	PUNCT
gs-3920	542	9	dress	dress	NOUN
gs-3920	542	10	):	):	PUNCT
gs-3920	542	11	a	a	DET
gs-3920	542	12	tertiary	tertiary	ADJ
gs-3920	542	13	care	care	NOUN
gs-3920	542	14	centre	centre	PROPN
gs-3920	542	15	retrospective	retrospective	ADJ
gs-3920	542	16	study	study	NOUN
gs-3920	542	17	.	.	PUNCT
gs-3920	543	1	british	british	ADJ
gs-3920	543	2	journal	journal	PROPN
gs-3920	543	3	of	of	ADP
gs-3920	543	4	clinical	clinical	ADJ
gs-3920	543	5	pharmacology	pharmacology	NOUN
gs-3920	543	6	,	,	PUNCT
gs-3920	543	7	88(9	88(9	PROPN
gs-3920	543	8	)	)	PUNCT
gs-3920	543	9	,	,	PUNCT
gs-3920	543	10	4134	4134	NUM
gs-3920	543	11	–	–	PUNCT
gs-3920	543	12	4141	4141	NUM
gs-3920	543	13	.	.	PUNCT
gs-3920	544	1	19	19	NUM
gs-3920	544	2	.	.	X
gs-3920	544	3	deore	deore	PROPN
gs-3920	544	4	,	,	PUNCT
gs-3920	544	5	r.	r.	PROPN
gs-3920	544	6	(	(	PUNCT
gs-3920	544	7	2024	2024	NUM
gs-3920	544	8	)	)	PUNCT
gs-3920	544	9	.	.	PUNCT
gs-3920	545	1	insights	insight	NOUN
gs-3920	545	2	into	into	ADP
gs-3920	545	3	mefenamic	mefenamic	ADJ
gs-3920	545	4	acid	acid	NOUN
gs-3920	545	5	-	-	PUNCT
gs-3920	545	6	induced	induce	VERB
gs-3920	545	7	allergic	allergic	ADJ
gs-3920	545	8	reactions	reaction	NOUN
gs-3920	545	9	:	:	PUNCT
gs-3920	545	10	a	a	DET
gs-3920	545	11	comprehensive	comprehensive	ADJ
gs-3920	545	12	clinical	clinical	ADJ
gs-3920	545	13	and	and	CCONJ
gs-3920	545	14	research	research	NOUN
gs-3920	545	15	review	review	NOUN
gs-3920	545	16	.	.	PUNCT
gs-3920	546	1	open	open	ADJ
gs-3920	546	2	access	access	NOUN
gs-3920	546	3	journal	journal	NOUN
gs-3920	546	4	of	of	ADP
gs-3920	546	5	pharmaceutical	pharmaceutical	NOUN
gs-3920	546	6	research	research	NOUN
gs-3920	546	7	,	,	PUNCT
gs-3920	546	8	8(1	8(1	NOUN
gs-3920	546	9	)	)	PUNCT
gs-3920	546	10	.	.	PUNCT
gs-3920	547	1	20	20	NUM
gs-3920	547	2	.	.	PUNCT
gs-3920	547	3	díaz	díaz	PROPN
gs-3920	547	4	,	,	PUNCT
gs-3920	547	5	d.	d.	PROPN
gs-3920	547	6	d.	d.	PROPN
gs-3920	547	7	,	,	PUNCT
gs-3920	547	8	mata	mata	PROPN
gs-3920	547	9	,	,	PUNCT
gs-3920	547	10	c.	c.	PROPN
gs-3920	547	11	o.	o.	PROPN
gs-3920	547	12	,	,	PUNCT
gs-3920	547	13	herrejón	herrejón	VERB
gs-3920	547	14	,	,	PUNCT
gs-3920	547	15	e.	e.	PROPN
gs-3920	547	16	p.	p.	PROPN
gs-3920	547	17	,	,	PUNCT
gs-3920	547	18	&	&	CCONJ
gs-3920	547	19	pérez	pérez	NOUN
gs-3920	547	20	,	,	PUNCT
gs-3920	547	21	l.	l.	PROPN
gs-3920	547	22	l.	l.	PROPN
gs-3920	547	23	(	(	PUNCT
gs-3920	547	24	2024	2024	NUM
gs-3920	547	25	)	)	PUNCT
gs-3920	547	26	.	.	PUNCT
gs-3920	548	1	adult	adult	NOUN
gs-3920	548	2	respiratory	respiratory	ADJ
gs-3920	548	3	distress	distress	NOUN
gs-3920	548	4	syndrome	syndrome	NOUN
gs-3920	548	5	(	(	PUNCT
gs-3920	548	6	ards	ard	NOUN
gs-3920	548	7	)	)	PUNCT
gs-3920	548	8	due	due	ADP
gs-3920	548	9	to	to	ADP
gs-3920	548	10	omeprazole	omeprazole	NOUN
gs-3920	548	11	-	-	PUNCT
gs-3920	548	12	induced	induce	VERB
gs-3920	548	13	drug	drug	NOUN
gs-3920	548	14	reaction	reaction	NOUN
gs-3920	548	15	with	with	ADP
gs-3920	548	16	eosinophilia	eosinophilia	PROPN
gs-3920	548	17	and	and	CCONJ
gs-3920	548	18	systemic	systemic	ADJ
gs-3920	548	19	symptoms	symptom	NOUN
gs-3920	548	20	(	(	PUNCT
gs-3920	548	21	dress	dress	NOUN
gs-3920	548	22	):	):	PUNCT
gs-3920	548	23	case	case	NOUN
gs-3920	548	24	report	report	NOUN
gs-3920	548	25	and	and	CCONJ
gs-3920	548	26	review	review	NOUN
gs-3920	548	27	of	of	ADP
gs-3920	548	28	the	the	DET
gs-3920	548	29	literature	literature	NOUN
gs-3920	548	30	.	.	PUNCT
gs-3920	549	1	revista	revista	PROPN
gs-3920	549	2	española	española	PROPN
gs-3920	550	1	de	de	PROPN
gs-3920	550	2	anestesiología	anestesiología	PROPN
gs-3920	550	3	y	y	PROPN
gs-3920	550	4	reanimación	reanimación	PROPN
gs-3920	550	5	(	(	PUNCT
gs-3920	550	6	english	english	PROPN
gs-3920	550	7	edition	edition	PROPN
gs-3920	550	8	)	)	PUNCT
gs-3920	550	9	,	,	PUNCT
gs-3920	550	10	71(10	71(10	NUM
gs-3920	550	11	)	)	PUNCT
gs-3920	550	12	,	,	PUNCT
gs-3920	550	13	763–770	763–770	NUM
gs-3920	550	14	.	.	NOUN
gs-3920	550	15	21	21	NUM
gs-3920	550	16	.	.	PUNCT
gs-3920	550	17	díaz	díaz	NOUN
gs-3920	550	18	-	-	PUNCT
gs-3920	550	19	molina	molina	NOUN
gs-3920	550	20	,	,	PUNCT
gs-3920	550	21	v.	v.	NOUN
gs-3920	550	22	,	,	PUNCT
gs-3920	550	23	tirado	tirado	NOUN
gs-3920	550	24	-	-	PUNCT
gs-3920	550	25	sánchez	sánchez	NOUN
gs-3920	550	26	,	,	PUNCT
gs-3920	550	27	a.	a.	PROPN
gs-3920	550	28	,	,	PUNCT
gs-3920	550	29	&	&	CCONJ
gs-3920	550	30	ponce	ponce	PROPN
gs-3920	550	31	-	-	PUNCT
gs-3920	550	32	olivera	olivera	PROPN
gs-3920	550	33	,	,	PUNCT
gs-3920	550	34	r.	r.	PROPN
gs-3920	550	35	(	(	PUNCT
gs-3920	550	36	2015	2015	NUM
gs-3920	550	37	)	)	PUNCT
gs-3920	550	38	.	.	PUNCT
gs-3920	551	1	clinical	clinical	ADJ
gs-3920	551	2	,	,	PUNCT
gs-3920	551	3	aetiological	aetiological	ADJ
gs-3920	551	4	and	and	CCONJ
gs-3920	551	5	therapeutic	therapeutic	ADJ
gs-3920	551	6	findings	finding	NOUN
gs-3920	551	7	in	in	ADP
gs-3920	551	8	drug	drug	NOUN
gs-3920	551	9	reaction	reaction	NOUN
gs-3920	551	10	with	with	ADP
gs-3920	551	11	eosinophilia	eosinophilia	PROPN
gs-3920	551	12	and	and	CCONJ
gs-3920	551	13	systemic	systemic	ADJ
gs-3920	551	14	symptoms	symptom	NOUN
gs-3920	551	15	(	(	PUNCT
gs-3920	551	16	dress	dress	NOUN
gs-3920	551	17	)	)	PUNCT
gs-3920	551	18	syndrome	syndrome	NOUN
gs-3920	551	19	,	,	PUNCT
gs-3920	551	20	four	four	NUM
gs-3920	551	21	years	year	NOUN
gs-3920	551	22	’	'	PUNCT
gs-3920	551	23	experience	experience	NOUN
gs-3920	551	24	in	in	ADP
gs-3920	551	25	a	a	DET
gs-3920	551	26	third	third	ADJ
gs-3920	551	27	-	-	PUNCT
gs-3920	551	28	level	level	NOUN
gs-3920	551	29	mexican	mexican	ADJ
gs-3920	551	30	hospital	hospital	NOUN
gs-3920	551	31	.	.	PUNCT
gs-3920	552	1	revista	revista	PROPN
gs-3920	552	2	médica	médica	PROPN
gs-3920	552	3	del	del	PROPN
gs-3920	552	4	hospital	hospital	PROPN
gs-3920	552	5	general	general	PROPN
gs-3920	552	6	de	de	PROPN
gs-3920	552	7	méxico	méxico	PROPN
gs-3920	552	8	,	,	PUNCT
gs-3920	552	9	79(2	79(2	NUM
gs-3920	552	10	)	)	PUNCT
gs-3920	552	11	,	,	PUNCT
gs-3920	552	12	55–62	55–62	NUM
gs-3920	552	13	.	.	NOUN
gs-3920	552	14	22	22	NUM
gs-3920	552	15	.	.	PUNCT
gs-3920	553	1	dimeas	dimea	NOUN
gs-3920	553	2	,	,	PUNCT
gs-3920	553	3	i.	i.	PROPN
gs-3920	553	4	e.	e.	PROPN
gs-3920	553	5	,	,	PUNCT
gs-3920	553	6	sinis	sinis	NOUN
gs-3920	553	7	,	,	PUNCT
gs-3920	553	8	s.	s.	PROPN
gs-3920	553	9	,	,	PUNCT
gs-3920	553	10	dimeas	dimeas	PROPN
gs-3920	553	11	,	,	PUNCT
gs-3920	553	12	g.	g.	PROPN
gs-3920	553	13	,	,	PUNCT
gs-3920	553	14	skrimizeas	skrimizeas	PROPN
gs-3920	553	15	,	,	PUNCT
gs-3920	553	16	s.	s.	PROPN
gs-3920	553	17	,	,	PUNCT
gs-3920	553	18	&	&	CCONJ
gs-3920	553	19	daniil	daniil	VERB
gs-3920	553	20	,	,	PUNCT
gs-3920	553	21	z.	z.	PROPN
gs-3920	553	22	(	(	PUNCT
gs-3920	553	23	2023	2023	NUM
gs-3920	553	24	)	)	PUNCT
gs-3920	553	25	.	.	PUNCT
gs-3920	554	1	a	a	DET
gs-3920	554	2	unique	unique	ADJ
gs-3920	554	3	case	case	NOUN
gs-3920	554	4	of	of	ADP
gs-3920	554	5	conservatively	conservatively	ADV
gs-3920	554	6	treated	treat	VERB
gs-3920	554	7	actinomyces	actinomyce	NOUN
gs-3920	554	8	empyema	empyema	NOUN
gs-3920	554	9	complicated	complicate	VERB
gs-3920	554	10	due	due	ADP
gs-3920	554	11	to	to	ADP
gs-3920	554	12	drug	drug	NOUN
gs-3920	554	13	reaction	reaction	NOUN
gs-3920	554	14	with	with	ADP
gs-3920	554	15	eosinophilia	eosinophilia	PROPN
gs-3920	554	16	and	and	CCONJ
gs-3920	554	17	systemic	systemic	ADJ
gs-3920	554	18	symptoms	symptom	NOUN
gs-3920	554	19	syndrome	syndrome	VERB
gs-3920	554	20	.	.	PUNCT
gs-3920	555	1	cureus	cureus	NOUN
gs-3920	555	2	.	.	PUNCT
gs-3920	556	1	23	23	NUM
gs-3920	556	2	.	.	PUNCT
gs-3920	557	1	dridi	dridi	PROPN
gs-3920	557	2	,	,	PUNCT
gs-3920	557	3	b.	b.	PROPN
gs-3920	557	4	,	,	PUNCT
gs-3920	557	5	agrebi	agrebi	NOUN
gs-3920	557	6	,	,	PUNCT
gs-3920	557	7	m.	m.	NOUN
gs-3920	557	8	,	,	PUNCT
gs-3920	557	9	sahnoun	sahnoun	PROPN
gs-3920	557	10	,	,	PUNCT
gs-3920	557	11	d.	d.	PROPN
gs-3920	557	12	,	,	PUNCT
gs-3920	557	13	&	&	CCONJ
gs-3920	557	14	salem	salem	PROPN
gs-3920	557	15	,	,	PUNCT
gs-3920	557	16	c.	c.	PROPN
gs-3920	557	17	b.	b.	PROPN
gs-3920	557	18	(	(	PUNCT
gs-3920	557	19	2024	2024	NUM
gs-3920	557	20	)	)	PUNCT
gs-3920	557	21	.	.	PUNCT
gs-3920	558	1	metronidazole	metronidazole	NOUN
gs-3920	558	2	-	-	PUNCT
gs-3920	558	3	induced	induce	VERB
gs-3920	558	4	drug	drug	NOUN
gs-3920	558	5	reaction	reaction	NOUN
gs-3920	558	6	with	with	ADP
gs-3920	558	7	eosinophilia	eosinophilia	PROPN
gs-3920	558	8	and	and	CCONJ
gs-3920	558	9	systemic	systemic	ADJ
gs-3920	558	10	symptoms	symptom	NOUN
gs-3920	558	11	(	(	PUNCT
gs-3920	558	12	dress	dress	NOUN
gs-3920	558	13	)	)	PUNCT
gs-3920	558	14	syndrome	syndrome	NOUN
gs-3920	558	15	with	with	ADP
gs-3920	558	16	parvovirus	parvovirus	NOUN
gs-3920	558	17	b19	b19	NOUN
gs-3920	558	18	reactivation	reactivation	NOUN
gs-3920	558	19	:	:	PUNCT
gs-3920	558	20	a	a	DET
gs-3920	558	21	pediatric	pediatric	ADJ
gs-3920	558	22	case	case	NOUN
gs-3920	558	23	.	.	PUNCT
gs-3920	559	1	cureus	cureus	NOUN
gs-3920	559	2	.	.	PUNCT
gs-3920	560	1	24	24	NUM
gs-3920	560	2	.	.	PUNCT
gs-3920	561	1	dutta	dutta	PROPN
gs-3920	561	2	,	,	PUNCT
gs-3920	561	3	p.	p.	PROPN
gs-3920	561	4	,	,	PUNCT
gs-3920	561	5	das	das	PROPN
gs-3920	561	6	,	,	PUNCT
gs-3920	561	7	s.	s.	PROPN
gs-3920	561	8	,	,	PUNCT
gs-3920	561	9	&	&	CCONJ
gs-3920	561	10	fershko	fershko	PROPN
gs-3920	561	11	,	,	PUNCT
gs-3920	561	12	a.	a.	NOUN
gs-3920	561	13	(	(	PUNCT
gs-3920	561	14	2021	2021	NUM
gs-3920	561	15	)	)	PUNCT
gs-3920	561	16	.	.	PUNCT
gs-3920	562	1	non	non	ADJ
gs-3920	562	2	-	-	ADJ
gs-3920	562	3	aromatic	aromatic	ADJ
gs-3920	562	4	anticonvulsant	anticonvulsant	NOUN
gs-3920	562	5	(	(	PUNCT
gs-3920	562	6	divalproex	divalproex	NOUN
gs-3920	562	7	sodium	sodium	NOUN
gs-3920	562	8	)	)	PUNCT
gs-3920	562	9	induced	induce	VERB
gs-3920	562	10	drug	drug	NOUN
gs-3920	562	11	reaction	reaction	NOUN
gs-3920	562	12	with	with	ADP
gs-3920	562	13	eosinophilia	eosinophilia	PROPN
gs-3920	562	14	and	and	CCONJ
gs-3920	562	15	systemic	systemic	ADJ
gs-3920	562	16	symptoms	symptom	NOUN
gs-3920	562	17	(	(	PUNCT
gs-3920	562	18	dress	dress	NOUN
gs-3920	562	19	)	)	PUNCT
gs-3920	562	20	syndrome	syndrome	NOUN
gs-3920	562	21	.	.	PUNCT
gs-3920	563	1	cureus	cureus	NOUN
gs-3920	563	2	.	.	PUNCT
gs-3920	564	1	25	25	NUM
gs-3920	564	2	.	.	PUNCT
gs-3920	565	1	gangireddy	gangireddy	PROPN
gs-3920	565	2	,	,	PUNCT
gs-3920	565	3	m.	m.	NOUN
gs-3920	565	4	,	,	PUNCT
gs-3920	565	5	sarao	sarao	PROPN
gs-3920	565	6	,	,	PUNCT
gs-3920	565	7	m.	m.	NOUN
gs-3920	565	8	s.	s.	PROPN
gs-3920	565	9	,	,	PUNCT
gs-3920	565	10	shrimanker	shrimanker	PROPN
gs-3920	565	11	,	,	PUNCT
gs-3920	565	12	i.	i.	PROPN
gs-3920	565	13	,	,	PUNCT
gs-3920	565	14	&	&	CCONJ
gs-3920	565	15	nookala	nookala	PROPN
gs-3920	565	16	,	,	PUNCT
gs-3920	565	17	v.	v.	PROPN
gs-3920	565	18	k.	k.	PROPN
gs-3920	565	19	(	(	PUNCT
gs-3920	565	20	2019	2019	NUM
gs-3920	565	21	)	)	PUNCT
gs-3920	565	22	.	.	PUNCT
gs-3920	566	1	a	a	DET
gs-3920	566	2	fatal	fatal	ADJ
gs-3920	566	3	case	case	NOUN
gs-3920	566	4	of	of	ADP
gs-3920	566	5	vancomycin	vancomycin	PROPN
gs-3920	566	6	associated	associate	VERB
gs-3920	566	7	drug	drug	NOUN
gs-3920	566	8	reaction	reaction	NOUN
gs-3920	566	9	with	with	ADP
gs-3920	566	10	eosinophilia	eosinophilia	PROPN
gs-3920	566	11	and	and	CCONJ
gs-3920	566	12	systemic	systemic	ADJ
gs-3920	566	13	symptoms	symptom	NOUN
gs-3920	566	14	syndrome	syndrome	VERB
gs-3920	566	15	in	in	ADP
gs-3920	566	16	a	a	DET
gs-3920	566	17	septuagenarian	septuagenarian	ADJ
gs-3920	566	18	.	.	PUNCT
gs-3920	567	1	cureus	cureus	NOUN
gs-3920	567	2	.	.	PUNCT
gs-3920	568	1	26	26	NUM
gs-3920	568	2	.	.	PUNCT
gs-3920	568	3	gayfield	gayfield	PROPN
gs-3920	568	4	,	,	PUNCT
gs-3920	568	5	s.	s.	PROPN
gs-3920	568	6	,	,	PUNCT
gs-3920	568	7	busken	busken	PROPN
gs-3920	568	8	,	,	PUNCT
gs-3920	568	9	j.	j.	PROPN
gs-3920	568	10	,	,	PUNCT
gs-3920	568	11	&	&	CCONJ
gs-3920	568	12	mansur	mansur	PROPN
gs-3920	568	13	,	,	PUNCT
gs-3920	568	14	s.	s.	PROPN
gs-3920	568	15	(	(	PUNCT
gs-3920	568	16	2022	2022	NUM
gs-3920	568	17	)	)	PUNCT
gs-3920	568	18	.	.	PUNCT
gs-3920	569	1	recurrent	recurrent	VERB
gs-3920	569	2	leflunomide	leflunomide	ADV
gs-3920	569	3	-	-	PUNCT
gs-3920	569	4	induced	induce	VERB
gs-3920	569	5	drug	drug	NOUN
gs-3920	569	6	reaction	reaction	NOUN
gs-3920	569	7	with	with	ADP
gs-3920	569	8	eosinophilia	eosinophilia	PROPN
gs-3920	569	9	and	and	CCONJ
gs-3920	569	10	systemic	systemic	ADJ
gs-3920	569	11	symptom	symptom	NOUN
gs-3920	569	12	(	(	PUNCT
gs-3920	569	13	dress	dress	NOUN
gs-3920	569	14	)	)	PUNCT
gs-3920	569	15	syndrome	syndrome	NOUN
gs-3920	569	16	despite	despite	SCONJ
gs-3920	569	17	prolonged	prolong	VERB
gs-3920	569	18	steroid	steroid	NOUN
gs-3920	569	19	taper	taper	NOUN
gs-3920	569	20	:	:	PUNCT
gs-3920	569	21	a	a	DET
gs-3920	569	22	case	case	NOUN
gs-3920	569	23	report	report	NOUN
gs-3920	569	24	.	.	PUNCT
gs-3920	570	1	cureus	cureus	NOUN
gs-3920	570	2	.	.	PUNCT
gs-3920	571	1	georgian	georgian	ADJ
gs-3920	571	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	571	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	571	4	ტ.	ტ.	VERB
gs-3920	571	5	7	7	NUM
gs-3920	571	6	n	n	DET
gs-3920	571	7	3	3	NUM
gs-3920	571	8	,	,	PUNCT
gs-3920	571	9	2025	2025	NUM
gs-3920	571	10	213	213	NUM
gs-3920	571	11	27	27	NUM
gs-3920	571	12	.	.	PUNCT
gs-3920	572	1	gómez	gómez	NOUN
gs-3920	572	2	,	,	PUNCT
gs-3920	572	3	d.	d.	PROPN
gs-3920	572	4	a.	a.	PROPN
gs-3920	572	5	g.	g.	PROPN
gs-3920	572	6	,	,	PUNCT
gs-3920	572	7	zorro	zorro	PROPN
gs-3920	572	8	,	,	PUNCT
gs-3920	572	9	s.	s.	PROPN
gs-3920	572	10	p.	p.	PROPN
gs-3920	572	11	,	,	PUNCT
gs-3920	572	12	barrios	barrio	NOUN
gs-3920	572	13	,	,	PUNCT
gs-3920	572	14	w.	w.	PROPN
gs-3920	572	15	a.	a.	PROPN
gs-3920	572	16	,	,	PUNCT
gs-3920	572	17	&	&	CCONJ
gs-3920	572	18	bayona	bayona	PROPN
gs-3920	572	19	,	,	PUNCT
gs-3920	572	20	j.	j.	PROPN
gs-3920	572	21	a.	a.	PROPN
gs-3920	572	22	c.	c.	PROPN
gs-3920	572	23	(	(	PUNCT
gs-3920	572	24	2020	2020	NUM
gs-3920	572	25	)	)	PUNCT
gs-3920	572	26	.	.	PUNCT
gs-3920	573	1	drug	drug	NOUN
gs-3920	573	2	reaction	reaction	NOUN
gs-3920	573	3	with	with	ADP
gs-3920	573	4	eosinophilia	eosinophilia	PROPN
gs-3920	573	5	and	and	CCONJ
gs-3920	573	6	systemic	systemic	ADJ
gs-3920	573	7	symptoms	symptom	NOUN
gs-3920	573	8	(	(	PUNCT
gs-3920	573	9	dress	dress	NOUN
gs-3920	573	10	)	)	PUNCT
gs-3920	573	11	with	with	ADP
gs-3920	573	12	severe	severe	ADJ
gs-3920	573	13	and	and	CCONJ
gs-3920	573	14	atypical	atypical	ADJ
gs-3920	573	15	lung	lung	NOUN
gs-3920	573	16	involvement	involvement	NOUN
gs-3920	573	17	.	.	PUNCT
gs-3920	574	1	radiology	radiology	NOUN
gs-3920	574	2	case	case	NOUN
gs-3920	574	3	reports	report	VERB
gs-3920	574	4	,	,	PUNCT
gs-3920	574	5	15(11	15(11	NUM
gs-3920	574	6	)	)	PUNCT
gs-3920	574	7	,	,	PUNCT
gs-3920	574	8	2178–2182	2178–2182	NOUN
gs-3920	574	9	.	.	PUNCT
gs-3920	575	1	28	28	NUM
gs-3920	575	2	.	.	X
gs-3920	575	3	gómez	gómez	NOUN
gs-3920	575	4	,	,	PUNCT
gs-3920	575	5	d.	d.	PROPN
gs-3920	575	6	a.	a.	PROPN
gs-3920	575	7	g.	g.	PROPN
gs-3920	575	8	,	,	PUNCT
gs-3920	575	9	zorro	zorro	PROPN
gs-3920	575	10	,	,	PUNCT
gs-3920	575	11	s.	s.	PROPN
gs-3920	575	12	p.	p.	PROPN
gs-3920	575	13	,	,	PUNCT
gs-3920	575	14	barrios	barrio	NOUN
gs-3920	575	15	,	,	PUNCT
gs-3920	575	16	w.	w.	PROPN
gs-3920	575	17	a.	a.	PROPN
gs-3920	575	18	,	,	PUNCT
gs-3920	575	19	&	&	CCONJ
gs-3920	575	20	bayona	bayona	PROPN
gs-3920	575	21	,	,	PUNCT
gs-3920	575	22	j.	j.	PROPN
gs-3920	575	23	a.	a.	PROPN
gs-3920	575	24	c.	c.	PROPN
gs-3920	575	25	(	(	PUNCT
gs-3920	575	26	2020	2020	NUM
gs-3920	575	27	)	)	PUNCT
gs-3920	575	28	.	.	PUNCT
gs-3920	576	1	drug	drug	NOUN
gs-3920	576	2	reaction	reaction	NOUN
gs-3920	576	3	with	with	ADP
gs-3920	576	4	eosinophilia	eosinophilia	PROPN
gs-3920	576	5	and	and	CCONJ
gs-3920	576	6	systemic	systemic	ADJ
gs-3920	576	7	symptoms	symptom	NOUN
gs-3920	576	8	(	(	PUNCT
gs-3920	576	9	dress	dress	NOUN
gs-3920	576	10	)	)	PUNCT
gs-3920	576	11	with	with	ADP
gs-3920	576	12	severe	severe	ADJ
gs-3920	576	13	and	and	CCONJ
gs-3920	576	14	atypical	atypical	ADJ
gs-3920	576	15	lung	lung	NOUN
gs-3920	576	16	involvement	involvement	NOUN
gs-3920	576	17	.	.	PUNCT
gs-3920	577	1	radiology	radiology	NOUN
gs-3920	577	2	case	case	NOUN
gs-3920	577	3	reports	report	VERB
gs-3920	577	4	,	,	PUNCT
gs-3920	577	5	15(11	15(11	NUM
gs-3920	577	6	)	)	PUNCT
gs-3920	577	7	,	,	PUNCT
gs-3920	577	8	2178–2182	2178–2182	NOUN
gs-3920	577	9	.	.	NOUN
gs-3920	577	10	29	29	NUM
gs-3920	577	11	.	.	PUNCT
gs-3920	578	1	hama	hama	PROPN
gs-3920	578	2	,	,	PUNCT
gs-3920	578	3	n.	n.	PROPN
gs-3920	578	4	,	,	PUNCT
gs-3920	578	5	abe	abe	PROPN
gs-3920	578	6	,	,	PUNCT
gs-3920	578	7	r.	r.	PROPN
gs-3920	578	8	,	,	PUNCT
gs-3920	578	9	gibson	gibson	PROPN
gs-3920	578	10	,	,	PUNCT
gs-3920	578	11	a.	a.	PROPN
gs-3920	578	12	,	,	PUNCT
gs-3920	578	13	&	&	CCONJ
gs-3920	578	14	phillips	phillips	PROPN
gs-3920	578	15	,	,	PUNCT
gs-3920	578	16	e.	e.	PROPN
gs-3920	578	17	j.	j.	PROPN
gs-3920	578	18	(	(	PUNCT
gs-3920	578	19	2022	2022	NUM
gs-3920	578	20	)	)	PUNCT
gs-3920	578	21	.	.	PUNCT
gs-3920	579	1	drug	drug	NOUN
gs-3920	579	2	-	-	PUNCT
gs-3920	579	3	induced	induce	VERB
gs-3920	579	4	hypersensitivity	hypersensitivity	NOUN
gs-3920	579	5	syndrome	syndrome	NOUN
gs-3920	579	6	(	(	PUNCT
gs-3920	579	7	dihs)/drug	dihs)/drug	ADJ
gs-3920	579	8	reaction	reaction	NOUN
gs-3920	579	9	with	with	ADP
gs-3920	579	10	eosinophilia	eosinophilia	PROPN
gs-3920	579	11	and	and	CCONJ
gs-3920	579	12	systemic	systemic	ADJ
gs-3920	579	13	symptoms	symptom	NOUN
gs-3920	579	14	(	(	PUNCT
gs-3920	579	15	dress	dress	NOUN
gs-3920	579	16	):	):	PUNCT
gs-3920	579	17	clinical	clinical	ADJ
gs-3920	579	18	features	feature	NOUN
gs-3920	579	19	and	and	CCONJ
gs-3920	579	20	pathogenesis	pathogenesis	NOUN
gs-3920	579	21	.	.	PUNCT
gs-3920	580	1	the	the	DET
gs-3920	580	2	journal	journal	PROPN
gs-3920	580	3	of	of	ADP
gs-3920	580	4	allergy	allergy	NOUN
gs-3920	580	5	and	and	CCONJ
gs-3920	580	6	clinical	clinical	ADJ
gs-3920	580	7	immunology	immunology	NOUN
gs-3920	580	8	in	in	ADP
gs-3920	580	9	practice	practice	NOUN
gs-3920	580	10	,	,	PUNCT
gs-3920	580	11	10(5	10(5	NUM
gs-3920	580	12	)	)	PUNCT
gs-3920	580	13	,	,	PUNCT
gs-3920	580	14	1155	1155	NUM
gs-3920	580	15	-	-	SYM
gs-3920	580	16	1167.e5	1167.e5	NUM
gs-3920	580	17	.	.	NOUN
gs-3920	580	18	30	30	NUM
gs-3920	580	19	.	.	PUNCT
gs-3920	581	1	hamid	hamid	PROPN
gs-3920	581	2	,	,	PUNCT
gs-3920	581	3	k.	k.	PROPN
gs-3920	581	4	,	,	PUNCT
gs-3920	581	5	jones	jones	PROPN
gs-3920	581	6	,	,	PUNCT
gs-3920	581	7	m.	m.	PROPN
gs-3920	581	8	e.	e.	PROPN
gs-3920	581	9	,	,	PUNCT
gs-3920	581	10	huang	huang	PROPN
gs-3920	581	11	,	,	PUNCT
gs-3920	581	12	j.	j.	PROPN
gs-3920	581	13	,	,	PUNCT
gs-3920	581	14	&	&	CCONJ
gs-3920	581	15	yu	yu	PROPN
gs-3920	581	16	,	,	PUNCT
gs-3920	581	17	j.	j.	PROPN
gs-3920	581	18	c.	c.	PROPN
gs-3920	581	19	(	(	PUNCT
gs-3920	581	20	2023	2023	NUM
gs-3920	581	21	)	)	PUNCT
gs-3920	581	22	.	.	PUNCT
gs-3920	582	1	guselkumab	guselkumab	NOUN
gs-3920	582	2	-	-	PUNCT
gs-3920	582	3	associated	associate	VERB
gs-3920	582	4	pulmonary	pulmonary	ADJ
gs-3920	582	5	disease	disease	NOUN
gs-3920	582	6	and	and	CCONJ
gs-3920	582	7	diffuse	diffuse	VERB
gs-3920	582	8	alveolar	alveolar	ADJ
gs-3920	582	9	hemorrhage	hemorrhage	NOUN
gs-3920	582	10	with	with	ADP
gs-3920	582	11	drug	drug	NOUN
gs-3920	582	12	rash	rash	NOUN
gs-3920	582	13	with	with	ADP
gs-3920	582	14	eosinophilia	eosinophilia	PROPN
gs-3920	582	15	and	and	CCONJ
gs-3920	582	16	systemic	systemic	ADJ
gs-3920	582	17	symptoms	symptom	NOUN
gs-3920	582	18	.	.	PUNCT
gs-3920	583	1	cureus	cureus	NOUN
gs-3920	583	2	.	.	PUNCT
gs-3920	584	1	31	31	NUM
gs-3920	584	2	.	.	PUNCT
gs-3920	585	1	hanna	hanna	PROPN
gs-3920	585	2	,	,	PUNCT
gs-3920	585	3	m.	m.	NOUN
gs-3920	585	4	,	,	PUNCT
gs-3920	585	5	&	&	CCONJ
gs-3920	585	6	yang	yang	PROPN
gs-3920	585	7	,	,	PUNCT
gs-3920	585	8	s.	s.	PROPN
gs-3920	585	9	(	(	PUNCT
gs-3920	585	10	2022	2022	NUM
gs-3920	585	11	)	)	PUNCT
gs-3920	585	12	.	.	PUNCT
gs-3920	586	1	covid-19	covid-19	PROPN
gs-3920	586	2	vaccine	vaccine	NOUN
gs-3920	586	3	:	:	PUNCT
gs-3920	586	4	a	a	DET
gs-3920	586	5	common	common	ADJ
gs-3920	586	6	suspect	suspect	NOUN
gs-3920	586	7	but	but	CCONJ
gs-3920	586	8	rare	rare	ADJ
gs-3920	586	9	culprit	culprit	NOUN
gs-3920	586	10	in	in	ADP
gs-3920	586	11	drug	drug	NOUN
gs-3920	586	12	rash	rash	NOUN
gs-3920	586	13	with	with	ADP
gs-3920	586	14	eosinophilia	eosinophilia	PROPN
gs-3920	586	15	and	and	CCONJ
gs-3920	586	16	systemic	systemic	ADJ
gs-3920	586	17	symptoms	symptom	NOUN
gs-3920	586	18	(	(	PUNCT
gs-3920	586	19	dress	dress	NOUN
gs-3920	586	20	)	)	PUNCT
gs-3920	586	21	syndrome	syndrome	NOUN
gs-3920	586	22	.	.	PUNCT
gs-3920	587	1	cureus	cureus	NOUN
gs-3920	587	2	.	.	PUNCT
gs-3920	588	1	32	32	NUM
gs-3920	588	2	.	.	PUNCT
gs-3920	589	1	hansen	hansen	PROPN
gs-3920	589	2	,	,	PUNCT
gs-3920	589	3	e.	e.	PROPN
gs-3920	589	4	,	,	PUNCT
gs-3920	589	5	gallardo	gallardo	PROPN
gs-3920	589	6	,	,	PUNCT
gs-3920	589	7	m.	m.	NOUN
gs-3920	589	8	,	,	PUNCT
gs-3920	589	9	yan	yan	PROPN
gs-3920	589	10	,	,	PUNCT
gs-3920	589	11	a.	a.	NOUN
gs-3920	589	12	,	,	PUNCT
gs-3920	589	13	mital	mital	NOUN
gs-3920	589	14	,	,	PUNCT
gs-3920	589	15	r.	r.	PROPN
gs-3920	589	16	,	,	PUNCT
gs-3920	589	17	jolley	jolley	PROPN
gs-3920	589	18	,	,	PUNCT
gs-3920	589	19	d.	d.	PROPN
gs-3920	589	20	,	,	PUNCT
gs-3920	589	21	mcfeeters	mcfeeter	NOUN
gs-3920	589	22	,	,	PUNCT
gs-3920	589	23	j.	j.	PROPN
gs-3920	589	24	,	,	PUNCT
gs-3920	589	25	gray	gray	ADJ
gs-3920	589	26	,	,	PUNCT
gs-3920	589	27	a.	a.	NOUN
gs-3920	589	28	,	,	PUNCT
gs-3920	589	29	sitton	sitton	PROPN
gs-3920	589	30	,	,	PUNCT
gs-3920	589	31	b.	b.	PROPN
gs-3920	589	32	,	,	PUNCT
gs-3920	589	33	kaffenberger	kaffenberger	PROPN
gs-3920	589	34	,	,	PUNCT
gs-3920	589	35	b.	b.	PROPN
gs-3920	589	36	h.	h.	PROPN
gs-3920	589	37	,	,	PUNCT
gs-3920	589	38	&	&	CCONJ
gs-3920	589	39	korman	korman	PROPN
gs-3920	589	40	,	,	PUNCT
gs-3920	589	41	a.	a.	NOUN
gs-3920	589	42	m.	m.	NOUN
gs-3920	589	43	(	(	PUNCT
gs-3920	589	44	2024	2024	NUM
gs-3920	589	45	)	)	PUNCT
gs-3920	589	46	.	.	PUNCT
gs-3920	590	1	risk	risk	NOUN
gs-3920	590	2	assessment	assessment	NOUN
gs-3920	590	3	of	of	ADP
gs-3920	590	4	drugs	drug	NOUN
gs-3920	590	5	associated	associate	VERB
gs-3920	590	6	with	with	ADP
gs-3920	590	7	dress	dress	NOUN
gs-3920	590	8	syndrome	syndrome	NOUN
gs-3920	590	9	based	base	VERB
gs-3920	590	10	on	on	ADP
gs-3920	590	11	publication	publication	NOUN
gs-3920	590	12	frequency	frequency	NOUN
gs-3920	590	13	:	:	PUNCT
gs-3920	590	14	a	a	DET
gs-3920	590	15	systematic	systematic	ADJ
gs-3920	590	16	review	review	NOUN
gs-3920	590	17	.	.	PUNCT
gs-3920	591	1	journal	journal	NOUN
gs-3920	591	2	of	of	ADP
gs-3920	591	3	the	the	DET
gs-3920	591	4	american	american	PROPN
gs-3920	591	5	academy	academy	PROPN
gs-3920	591	6	of	of	ADP
gs-3920	591	7	dermatology	dermatology	NOUN
gs-3920	591	8	,	,	PUNCT
gs-3920	591	9	91(5	91(5	NUM
gs-3920	591	10	)	)	PUNCT
gs-3920	591	11	,	,	PUNCT
gs-3920	591	12	962–966	962–966	NUM
gs-3920	591	13	.	.	PUNCT
gs-3920	592	1	33	33	NUM
gs-3920	592	2	.	.	PUNCT
gs-3920	592	3	henriques	henrique	NOUN
gs-3920	592	4	,	,	PUNCT
gs-3920	592	5	a.	a.	PROPN
gs-3920	592	6	,	,	PUNCT
gs-3920	592	7	guerra	guerra	NOUN
gs-3920	592	8	,	,	PUNCT
gs-3920	592	9	m.	m.	NOUN
gs-3920	592	10	,	,	PUNCT
gs-3920	592	11	correia	correia	PROPN
gs-3920	592	12	,	,	PUNCT
gs-3920	592	13	i.	i.	PROPN
gs-3920	592	14	,	,	PUNCT
gs-3920	592	15	nunes	nunes	PROPN
gs-3920	592	16	,	,	PUNCT
gs-3920	592	17	a.	a.	PROPN
gs-3920	592	18	l.	l.	PROPN
gs-3920	592	19	,	,	PUNCT
gs-3920	592	20	&	&	CCONJ
gs-3920	592	21	lima	lima	PROPN
gs-3920	592	22	,	,	PUNCT
gs-3920	592	23	j.	j.	PROPN
gs-3920	592	24	(	(	PUNCT
gs-3920	592	25	2025	2025	NUM
gs-3920	592	26	)	)	PUNCT
gs-3920	592	27	.	.	PUNCT
gs-3920	593	1	drug	drug	NOUN
gs-3920	593	2	reaction	reaction	NOUN
gs-3920	593	3	with	with	ADP
gs-3920	593	4	eosinophilia	eosinophilia	PROPN
gs-3920	593	5	and	and	CCONJ
gs-3920	593	6	systemic	systemic	ADJ
gs-3920	593	7	symptoms	symptom	NOUN
gs-3920	593	8	(	(	PUNCT
gs-3920	593	9	dress	dress	NOUN
gs-3920	593	10	)	)	PUNCT
gs-3920	593	11	syndrome	syndrome	NOUN
gs-3920	593	12	associated	associate	VERB
gs-3920	593	13	with	with	ADP
gs-3920	593	14	celecoxib	celecoxib	NOUN
gs-3920	593	15	:	:	PUNCT
gs-3920	593	16	a	a	DET
gs-3920	593	17	case	case	NOUN
gs-3920	593	18	report	report	NOUN
gs-3920	593	19	of	of	ADP
gs-3920	593	20	a	a	DET
gs-3920	593	21	rare	rare	ADJ
gs-3920	593	22	entity	entity	NOUN
gs-3920	593	23	.	.	PUNCT
gs-3920	594	1	cureus	cureus	NOUN
gs-3920	594	2	.	.	PUNCT
gs-3920	595	1	34	34	NUM
gs-3920	595	2	.	.	PUNCT
gs-3920	596	1	husain	husain	PROPN
gs-3920	596	2	,	,	PUNCT
gs-3920	596	3	z.	z.	PROPN
gs-3920	596	4	,	,	PUNCT
gs-3920	596	5	reddy	reddy	PROPN
gs-3920	596	6	,	,	PUNCT
gs-3920	596	7	b.	b.	PROPN
gs-3920	596	8	y.	y.	PROPN
gs-3920	596	9	,	,	PUNCT
gs-3920	596	10	&	&	CCONJ
gs-3920	596	11	schwartz	schwartz	PROPN
gs-3920	596	12	,	,	PUNCT
gs-3920	596	13	r.	r.	PROPN
gs-3920	596	14	a.	a.	PROPN
gs-3920	596	15	(	(	PUNCT
gs-3920	596	16	2013	2013	NUM
gs-3920	596	17	)	)	PUNCT
gs-3920	596	18	.	.	PUNCT
gs-3920	597	1	dress	dress	NOUN
gs-3920	597	2	syndrome	syndrome	NOUN
gs-3920	597	3	.	.	PUNCT
gs-3920	598	1	journal	journal	NOUN
gs-3920	598	2	of	of	ADP
gs-3920	598	3	the	the	DET
gs-3920	598	4	american	american	PROPN
gs-3920	598	5	academy	academy	PROPN
gs-3920	598	6	of	of	ADP
gs-3920	598	7	dermatology	dermatology	NOUN
gs-3920	598	8	,	,	PUNCT
gs-3920	598	9	68(5	68(5	NUM
gs-3920	598	10	)	)	PUNCT
gs-3920	598	11	,	,	PUNCT
gs-3920	598	12	693.e1	693.e1	NOUN
gs-3920	598	13	-	-	PUNCT
gs-3920	598	14	693.e14	693.e14	PROPN
gs-3920	598	15	.	.	PROPN
gs-3920	598	16	35	35	NUM
gs-3920	598	17	.	.	PUNCT
gs-3920	598	18	ilgin	ilgin	NOUN
gs-3920	598	19	,	,	PUNCT
gs-3920	598	20	s.	s.	PROPN
gs-3920	598	21	e.	e.	PROPN
gs-3920	598	22	,	,	PUNCT
gs-3920	598	23	yanartaş	yanartaş	NOUN
gs-3920	598	24	,	,	PUNCT
gs-3920	598	25	ö.	ö.	NOUN
gs-3920	598	26	,	,	PUNCT
gs-3920	598	27	&	&	CCONJ
gs-3920	598	28	akça	akça	PROPN
gs-3920	598	29	,	,	PUNCT
gs-3920	598	30	e.	e.	PROPN
gs-3920	598	31	(	(	PUNCT
gs-3920	598	32	2024	2024	NUM
gs-3920	598	33	)	)	PUNCT
gs-3920	598	34	.	.	PUNCT
gs-3920	599	1	risperidone	risperidone	NOUN
gs-3920	599	2	induced	induce	VERB
gs-3920	599	3	dress	dress	NOUN
gs-3920	599	4	syndrome	syndrome	NOUN
gs-3920	599	5	:	:	PUNCT
gs-3920	599	6	a	a	DET
gs-3920	599	7	case	case	NOUN
gs-3920	599	8	report	report	NOUN
gs-3920	599	9	.	.	PUNCT
gs-3920	600	1	european	european	ADJ
gs-3920	600	2	psychiatry	psychiatry	PROPN
gs-3920	600	3	,	,	PUNCT
gs-3920	600	4	67(s1	67(s1	NUM
gs-3920	600	5	)	)	PUNCT
gs-3920	600	6	,	,	PUNCT
gs-3920	600	7	s700	s700	PROPN
gs-3920	600	8	.	.	PUNCT
gs-3920	600	9	36	36	NUM
gs-3920	600	10	.	.	PUNCT
gs-3920	601	1	isaacs	isaacs	PROPN
gs-3920	601	2	,	,	PUNCT
gs-3920	601	3	m.	m.	NOUN
gs-3920	601	4	,	,	PUNCT
gs-3920	601	5	cardones	cardone	NOUN
gs-3920	601	6	,	,	PUNCT
gs-3920	601	7	a.	a.	PROPN
gs-3920	601	8	r.	r.	PROPN
gs-3920	601	9	,	,	PUNCT
gs-3920	601	10	&	&	CCONJ
gs-3920	601	11	rahnama	rahnama	PROPN
gs-3920	601	12	-	-	PUNCT
gs-3920	601	13	moghadam	moghadam	PROPN
gs-3920	601	14	,	,	PUNCT
gs-3920	601	15	s.	s.	PROPN
gs-3920	601	16	(	(	PUNCT
gs-3920	601	17	2018	2018	NUM
gs-3920	601	18	)	)	PUNCT
gs-3920	601	19	.	.	PUNCT
gs-3920	602	1	dress	dress	NOUN
gs-3920	602	2	syndrome	syndrome	NOUN
gs-3920	602	3	:	:	PUNCT
gs-3920	602	4	clinical	clinical	ADJ
gs-3920	602	5	myths	myth	NOUN
gs-3920	602	6	and	and	CCONJ
gs-3920	602	7	pearls	pearl	NOUN
gs-3920	602	8	.	.	PUNCT
gs-3920	603	1	pubmed	pubmed	PROPN
gs-3920	603	2	,	,	PUNCT
gs-3920	603	3	102(5	102(5	NUM
gs-3920	603	4	)	)	PUNCT
gs-3920	603	5	,	,	PUNCT
gs-3920	603	6	322–326	322–326	NUM
gs-3920	603	7	.	.	PUNCT
gs-3920	604	1	37	37	NUM
gs-3920	604	2	.	.	PUNCT
gs-3920	605	1	james	james	PROPN
gs-3920	605	2	,	,	PUNCT
gs-3920	605	3	f.	f.	PROPN
gs-3920	605	4	,	,	PUNCT
gs-3920	605	5	goh	goh	PROPN
gs-3920	605	6	,	,	PUNCT
gs-3920	605	7	m.	m.	PROPN
gs-3920	605	8	s.	s.	PROPN
gs-3920	605	9	,	,	PUNCT
gs-3920	605	10	vogrin	vogrin	ADV
gs-3920	605	11	,	,	PUNCT
gs-3920	605	12	s.	s.	PROPN
gs-3920	605	13	,	,	PUNCT
gs-3920	605	14	ng	ng	PROPN
gs-3920	605	15	,	,	PUNCT
gs-3920	605	16	i.	i.	PROPN
gs-3920	605	17	,	,	PUNCT
gs-3920	605	18	douglas	douglas	PROPN
gs-3920	605	19	,	,	PUNCT
gs-3920	605	20	a.	a.	PROPN
gs-3920	605	21	p.	p.	PROPN
gs-3920	605	22	,	,	PUNCT
gs-3920	605	23	holmes	holmes	PROPN
gs-3920	605	24	,	,	PUNCT
gs-3920	605	25	n.	n.	PROPN
gs-3920	605	26	e.	e.	PROPN
gs-3920	605	27	,	,	PUNCT
gs-3920	605	28	chua	chua	PROPN
gs-3920	605	29	,	,	PUNCT
gs-3920	605	30	k.	k.	PROPN
gs-3920	605	31	y.	y.	PROPN
gs-3920	605	32	,	,	PUNCT
gs-3920	605	33	de	de	X
gs-3920	605	34	luca	luca	PROPN
gs-3920	605	35	,	,	PUNCT
gs-3920	605	36	j.	j.	PROPN
gs-3920	605	37	,	,	PUNCT
gs-3920	605	38	sharma	sharma	PROPN
gs-3920	605	39	,	,	PUNCT
gs-3920	605	40	p.	p.	PROPN
gs-3920	605	41	,	,	PUNCT
gs-3920	605	42	zubrinich	zubrinich	PROPN
gs-3920	605	43	,	,	PUNCT
gs-3920	605	44	c.	c.	PROPN
gs-3920	605	45	,	,	PUNCT
gs-3920	605	46	aung	aung	PROPN
gs-3920	605	47	,	,	PUNCT
gs-3920	605	48	a.	a.	PROPN
gs-3920	605	49	k.	k.	PROPN
gs-3920	605	50	,	,	PUNCT
gs-3920	605	51	gin	gin	PROPN
gs-3920	605	52	,	,	PUNCT
gs-3920	605	53	d.	d.	PROPN
gs-3920	605	54	,	,	PUNCT
gs-3920	605	55	lambros	lambros	PROPN
gs-3920	605	56	,	,	PUNCT
gs-3920	605	57	b.	b.	PROPN
gs-3920	605	58	,	,	PUNCT
gs-3920	605	59	baker	baker	PROPN
gs-3920	605	60	,	,	PUNCT
gs-3920	605	61	c.	c.	PROPN
gs-3920	605	62	,	,	PUNCT
gs-3920	605	63	foley	foley	NOUN
gs-3920	605	64	,	,	PUNCT
gs-3920	605	65	p.	p.	PROPN
gs-3920	605	66	,	,	PUNCT
gs-3920	605	67	chong	chong	PROPN
gs-3920	605	68	,	,	PUNCT
gs-3920	605	69	a.	a.	PROPN
gs-3920	605	70	h.	h.	PROPN
gs-3920	605	71	,	,	PUNCT
gs-3920	605	72	thien	thien	PROPN
gs-3920	605	73	,	,	PUNCT
gs-3920	605	74	f.	f.	PROPN
gs-3920	605	75	,	,	PUNCT
gs-3920	605	76	fok	fok	PROPN
gs-3920	605	77	,	,	PUNCT
gs-3920	605	78	j.	j.	PROPN
gs-3920	605	79	s.	s.	PROPN
gs-3920	605	80	,	,	PUNCT
gs-3920	605	81	su	su	PROPN
gs-3920	605	82	,	,	PUNCT
gs-3920	605	83	j.	j.	PROPN
gs-3920	605	84	,	,	PUNCT
gs-3920	605	85	.	.	PUNCT
gs-3920	605	86	.	.	PUNCT
gs-3920	605	87	.	.	PUNCT
gs-3920	606	1	trubiano	trubiano	PROPN
gs-3920	606	2	,	,	PUNCT
gs-3920	606	3	j.	j.	PROPN
gs-3920	606	4	a.	a.	PROPN
gs-3920	606	5	(	(	PUNCT
gs-3920	606	6	2024	2024	NUM
gs-3920	606	7	)	)	PUNCT
gs-3920	606	8	.	.	PUNCT
gs-3920	607	1	the	the	DET
gs-3920	607	2	australasian	australasian	ADJ
gs-3920	607	3	registry	registry	NOUN
gs-3920	607	4	for	for	ADP
gs-3920	607	5	severe	severe	ADJ
gs-3920	607	6	cutaneous	cutaneous	ADJ
gs-3920	607	7	adverse	adverse	ADJ
gs-3920	607	8	reactions	reaction	NOUN
gs-3920	607	9	(	(	PUNCT
gs-3920	607	10	aus	aus	NOUN
gs-3920	607	11	-	-	PUNCT
gs-3920	607	12	scar	scar	NOUN
gs-3920	607	13	)	)	PUNCT
gs-3920	607	14	–	–	PUNCT
gs-3920	607	15	providing	provide	VERB
gs-3920	607	16	a	a	DET
gs-3920	607	17	roadmap	roadmap	NOUN
gs-3920	607	18	for	for	ADP
gs-3920	607	19	closing	close	VERB
gs-3920	607	20	the	the	DET
gs-3920	607	21	diagnostic	diagnostic	ADJ
gs-3920	607	22	,	,	PUNCT
gs-3920	607	23	patient	patient	ADJ
gs-3920	607	24	,	,	PUNCT
gs-3920	607	25	and	and	CCONJ
gs-3920	607	26	healthcare	healthcare	NOUN
gs-3920	607	27	gaps	gap	NOUN
gs-3920	607	28	for	for	ADP
gs-3920	607	29	a	a	DET
gs-3920	607	30	group	group	NOUN
gs-3920	607	31	of	of	ADP
gs-3920	607	32	rare	rare	ADJ
gs-3920	607	33	drug	drug	NOUN
gs-3920	607	34	eruptions	eruption	NOUN
gs-3920	607	35	.	.	PUNCT
gs-3920	608	1	world	world	NOUN
gs-3920	608	2	allergy	allergy	PROPN
gs-3920	608	3	organization	organization	PROPN
gs-3920	608	4	journal	journal	PROPN
gs-3920	608	5	,	,	PUNCT
gs-3920	608	6	17(8	17(8	NUM
gs-3920	608	7	)	)	PUNCT
gs-3920	608	8	,	,	PUNCT
gs-3920	608	9	100936	100936	NUM
gs-3920	608	10	.	.	PUNCT
gs-3920	609	1	38	38	NUM
gs-3920	609	2	.	.	PUNCT
gs-3920	610	1	jayakumar	jayakumar	NOUN
gs-3920	610	2	,	,	PUNCT
gs-3920	610	3	a.	a.	NOUN
gs-3920	610	4	,	,	PUNCT
gs-3920	610	5	s	s	PROPN
gs-3920	610	6	,	,	PUNCT
gs-3920	610	7	h.	h.	PROPN
gs-3920	610	8	,	,	PUNCT
gs-3920	610	9	philip	philip	PROPN
gs-3920	610	10	,	,	PUNCT
gs-3920	610	11	t.	t.	PROPN
gs-3920	610	12	,	,	PUNCT
gs-3920	610	13	&	&	CCONJ
gs-3920	610	14	jomey	jomey	PROPN
gs-3920	610	15	,	,	PUNCT
gs-3920	610	16	m.	m.	PROPN
gs-3920	610	17	r.	r.	PROPN
gs-3920	610	18	(	(	PUNCT
gs-3920	610	19	2024	2024	NUM
gs-3920	610	20	)	)	PUNCT
gs-3920	610	21	.	.	PUNCT
gs-3920	611	1	leflunomide	leflunomide	ADV
gs-3920	611	2	-	-	PUNCT
gs-3920	611	3	induced	induce	VERB
gs-3920	611	4	drug	drug	NOUN
gs-3920	611	5	reaction	reaction	NOUN
gs-3920	611	6	with	with	ADP
gs-3920	611	7	eosinophilia	eosinophilia	PROPN
gs-3920	611	8	and	and	CCONJ
gs-3920	611	9	systemic	systemic	ADJ
gs-3920	611	10	symptoms	symptom	NOUN
gs-3920	611	11	:	:	PUNCT
gs-3920	611	12	a	a	DET
gs-3920	611	13	diagnostic	diagnostic	ADJ
gs-3920	611	14	dilemma	dilemma	NOUN
gs-3920	611	15	.	.	PUNCT
gs-3920	612	1	cureus	cureus	NOUN
gs-3920	612	2	.	.	PUNCT
gs-3920	613	1	39	39	NUM
gs-3920	613	2	.	.	PUNCT
gs-3920	614	1	jiamsathit	jiamsathit	PROPN
gs-3920	614	2	,	,	PUNCT
gs-3920	614	3	w.	w.	PROPN
gs-3920	614	4	,	,	PUNCT
gs-3920	614	5	bunarong	bunarong	PROPN
gs-3920	614	6	,	,	PUNCT
gs-3920	614	7	k.	k.	PROPN
gs-3920	614	8	,	,	PUNCT
gs-3920	614	9	papenkort	papenkort	PROPN
gs-3920	614	10	,	,	PUNCT
gs-3920	614	11	s.	s.	PROPN
gs-3920	614	12	,	,	PUNCT
gs-3920	614	13	cox	cox	PROPN
gs-3920	614	14	,	,	PUNCT
gs-3920	614	15	a.	a.	PROPN
gs-3920	614	16	r.	r.	PROPN
gs-3920	614	17	,	,	PUNCT
gs-3920	614	18	&	&	CCONJ
gs-3920	614	19	jarernsiripornkul	jarernsiripornkul	PROPN
gs-3920	614	20	,	,	PUNCT
gs-3920	614	21	n.	n.	NOUN
gs-3920	614	22	(	(	PUNCT
gs-3920	614	23	2025	2025	NUM
gs-3920	614	24	)	)	PUNCT
gs-3920	614	25	.	.	PUNCT
gs-3920	615	1	drug	drug	NOUN
gs-3920	615	2	-	-	PUNCT
gs-3920	615	3	induced	induce	VERB
gs-3920	615	4	serious	serious	ADJ
gs-3920	615	5	cutaneous	cutaneous	ADJ
gs-3920	615	6	reactions	reaction	NOUN
gs-3920	615	7	in	in	ADP
gs-3920	615	8	hospitalized	hospitalize	VERB
gs-3920	615	9	patients	patient	NOUN
gs-3920	615	10	:	:	PUNCT
gs-3920	615	11	a	a	DET
gs-3920	615	12	cross	cross	ADJ
gs-3920	615	13	-	-	ADJ
gs-3920	615	14	sectional	sectional	ADJ
gs-3920	615	15	study	study	NOUN
gs-3920	615	16	.	.	PUNCT
gs-3920	616	1	journal	journal	NOUN
gs-3920	616	2	of	of	ADP
gs-3920	616	3	clinical	clinical	ADJ
gs-3920	616	4	medicine	medicine	NOUN
gs-3920	616	5	,	,	PUNCT
gs-3920	616	6	14(3	14(3	NUM
gs-3920	616	7	)	)	PUNCT
gs-3920	616	8	,	,	PUNCT
gs-3920	616	9	857	857	NUM
gs-3920	616	10	.	.	PUNCT
gs-3920	617	1	georgian	georgian	ADJ
gs-3920	617	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	617	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	617	4	ტ.	ტ.	VERB
gs-3920	617	5	7	7	NUM
gs-3920	617	6	n	n	DET
gs-3920	617	7	3	3	NUM
gs-3920	617	8	,	,	PUNCT
gs-3920	617	9	2025	2025	NUM
gs-3920	617	10	214	214	NUM
gs-3920	617	11	40	40	NUM
gs-3920	617	12	.	.	PUNCT
gs-3920	618	1	jörg	jörg	PROPN
gs-3920	618	2	,	,	PUNCT
gs-3920	618	3	l.	l.	PROPN
gs-3920	618	4	,	,	PUNCT
gs-3920	618	5	helbling	helbling	NOUN
gs-3920	618	6	,	,	PUNCT
gs-3920	618	7	a.	a.	NOUN
gs-3920	618	8	,	,	PUNCT
gs-3920	618	9	yerly	yerly	ADV
gs-3920	618	10	,	,	PUNCT
gs-3920	618	11	d.	d.	PROPN
gs-3920	618	12	,	,	PUNCT
gs-3920	618	13	&	&	CCONJ
gs-3920	618	14	pichler	pichler	NOUN
gs-3920	618	15	,	,	PUNCT
gs-3920	618	16	w.	w.	PROPN
gs-3920	618	17	j.	j.	PROPN
gs-3920	618	18	(	(	PUNCT
gs-3920	618	19	2020	2020	NUM
gs-3920	618	20	)	)	PUNCT
gs-3920	618	21	.	.	PUNCT
gs-3920	619	1	drug	drug	NOUN
gs-3920	619	2	-	-	PUNCT
gs-3920	619	3	related	relate	VERB
gs-3920	619	4	relapses	relapse	NOUN
gs-3920	619	5	in	in	ADP
gs-3920	619	6	drug	drug	NOUN
gs-3920	619	7	reaction	reaction	NOUN
gs-3920	619	8	with	with	ADP
gs-3920	619	9	eosinophilia	eosinophilia	PROPN
gs-3920	619	10	and	and	CCONJ
gs-3920	619	11	systemic	systemic	ADJ
gs-3920	619	12	symptoms	symptom	NOUN
gs-3920	619	13	(	(	PUNCT
gs-3920	619	14	dress	dress	NOUN
gs-3920	619	15	)	)	PUNCT
gs-3920	619	16	.	.	PUNCT
gs-3920	620	1	clinical	clinical	ADJ
gs-3920	620	2	and	and	CCONJ
gs-3920	620	3	translational	translational	ADJ
gs-3920	620	4	allergy	allergy	NOUN
gs-3920	620	5	,	,	PUNCT
gs-3920	620	6	10(1	10(1	NUM
gs-3920	620	7	)	)	PUNCT
gs-3920	620	8	.	.	PUNCT
gs-3920	621	1	41	41	NUM
gs-3920	621	2	.	.	PUNCT
gs-3920	621	3	kanabaj	kanabaj	PROPN
gs-3920	621	4	,	,	PUNCT
gs-3920	621	5	k.	k.	PROPN
gs-3920	621	6	,	,	PUNCT
gs-3920	621	7	jenerowicz	jenerowicz	PROPN
gs-3920	621	8	,	,	PUNCT
gs-3920	621	9	d.	d.	PROPN
gs-3920	621	10	,	,	PUNCT
gs-3920	621	11	jankowska	jankowska	PROPN
gs-3920	621	12	,	,	PUNCT
gs-3920	621	13	l.	l.	PROPN
gs-3920	621	14	,	,	PUNCT
gs-3920	621	15	&	&	CCONJ
gs-3920	621	16	żaba	żaba	PROPN
gs-3920	621	17	,	,	PUNCT
gs-3920	621	18	z.	z.	PROPN
gs-3920	621	19	(	(	PUNCT
gs-3920	621	20	2023	2023	NUM
gs-3920	621	21	)	)	PUNCT
gs-3920	621	22	.	.	PUNCT
gs-3920	622	1	dress	dress	NOUN
gs-3920	622	2	syndrome	syndrome	NOUN
gs-3920	622	3	–	–	PUNCT
gs-3920	622	4	a	a	DET
gs-3920	622	5	dermatological	dermatological	ADJ
gs-3920	622	6	emergency	emergency	NOUN
gs-3920	622	7	–	–	PUNCT
gs-3920	622	8	sulfasalazine	sulfasalazine	NOUN
gs-3920	622	9	-	-	PUNCT
gs-3920	622	10	related	relate	VERB
gs-3920	622	11	acute	acute	ADJ
gs-3920	622	12	drug	drug	NOUN
gs-3920	622	13	reaction	reaction	NOUN
gs-3920	622	14	case	case	NOUN
gs-3920	622	15	report	report	NOUN
gs-3920	622	16	.	.	PUNCT
gs-3920	623	1	heliyon	heliyon	NOUN
gs-3920	623	2	,	,	PUNCT
gs-3920	623	3	9(9	9(9	NUM
gs-3920	623	4	)	)	PUNCT
gs-3920	623	5	,	,	PUNCT
gs-3920	623	6	e20021	e20021	NOUN
gs-3920	623	7	.	.	PROPN
gs-3920	623	8	42	42	NUM
gs-3920	623	9	.	.	PUNCT
gs-3920	624	1	kardaun	kardaun	PROPN
gs-3920	624	2	,	,	PUNCT
gs-3920	624	3	s.	s.	PROPN
gs-3920	624	4	,	,	PUNCT
gs-3920	624	5	sekula	sekula	PROPN
gs-3920	624	6	,	,	PUNCT
gs-3920	624	7	p.	p.	NOUN
gs-3920	624	8	,	,	PUNCT
gs-3920	624	9	valeyrie	valeyrie	NOUN
gs-3920	624	10	-	-	PUNCT
gs-3920	624	11	allanore	allanore	NOUN
gs-3920	624	12	,	,	PUNCT
gs-3920	624	13	l.	l.	PROPN
gs-3920	624	14	,	,	PUNCT
gs-3920	624	15	liss	liss	PROPN
gs-3920	624	16	,	,	PUNCT
gs-3920	624	17	y.	y.	PROPN
gs-3920	624	18	,	,	PUNCT
gs-3920	624	19	chu	chu	PROPN
gs-3920	624	20	,	,	PUNCT
gs-3920	624	21	c.	c.	PROPN
gs-3920	624	22	,	,	PUNCT
gs-3920	624	23	creamer	creamer	NOUN
gs-3920	624	24	,	,	PUNCT
gs-3920	624	25	d.	d.	PROPN
gs-3920	624	26	,	,	PUNCT
gs-3920	624	27	sidoroff	sidoroff	PROPN
gs-3920	624	28	,	,	PUNCT
gs-3920	624	29	a.	a.	NOUN
gs-3920	624	30	,	,	PUNCT
gs-3920	624	31	naldi	naldi	PROPN
gs-3920	624	32	,	,	PUNCT
gs-3920	624	33	l.	l.	PROPN
gs-3920	624	34	,	,	PUNCT
gs-3920	624	35	mockenhaupt	mockenhaupt	PROPN
gs-3920	624	36	,	,	PUNCT
gs-3920	624	37	m.	m.	NOUN
gs-3920	624	38	,	,	PUNCT
gs-3920	624	39	&	&	CCONJ
gs-3920	624	40	roujeau	roujeau	PROPN
gs-3920	624	41	,	,	PUNCT
gs-3920	624	42	j.	j.	PROPN
gs-3920	624	43	(	(	PUNCT
gs-3920	624	44	2013	2013	NUM
gs-3920	624	45	)	)	PUNCT
gs-3920	624	46	.	.	PUNCT
gs-3920	625	1	drug	drug	NOUN
gs-3920	625	2	reaction	reaction	NOUN
gs-3920	625	3	with	with	ADP
gs-3920	625	4	eosinophilia	eosinophilia	PROPN
gs-3920	625	5	and	and	CCONJ
gs-3920	625	6	systemic	systemic	ADJ
gs-3920	625	7	symptoms	symptom	NOUN
gs-3920	625	8	(	(	PUNCT
gs-3920	625	9	dress	dress	NOUN
gs-3920	625	10	):	):	PUNCT
gs-3920	625	11	an	an	DET
gs-3920	625	12	original	original	ADJ
gs-3920	625	13	multisystem	multisystem	NOUN
gs-3920	625	14	adverse	adverse	ADJ
gs-3920	625	15	drug	drug	NOUN
gs-3920	625	16	reaction	reaction	NOUN
gs-3920	625	17	.	.	PUNCT
gs-3920	626	1	results	result	NOUN
gs-3920	626	2	from	from	ADP
gs-3920	626	3	the	the	DET
gs-3920	626	4	prospective	prospective	ADJ
gs-3920	626	5	regiscar	regiscar	NOUN
gs-3920	626	6	study	study	NOUN
gs-3920	626	7	.	.	PUNCT
gs-3920	627	1	british	british	ADJ
gs-3920	627	2	journal	journal	PROPN
gs-3920	627	3	of	of	ADP
gs-3920	627	4	dermatology	dermatology	NOUN
gs-3920	627	5	,	,	PUNCT
gs-3920	627	6	169(5	169(5	NUM
gs-3920	627	7	)	)	PUNCT
gs-3920	627	8	,	,	PUNCT
gs-3920	627	9	1071–1080	1071–1080	NUM
gs-3920	627	10	.	.	PUNCT
gs-3920	627	11	43	43	NUM
gs-3920	627	12	.	.	PUNCT
gs-3920	628	1	kawakami	kawakami	PROPN
gs-3920	628	2	,	,	PUNCT
gs-3920	628	3	t.	t.	PROPN
gs-3920	628	4	,	,	PUNCT
gs-3920	628	5	fujita	fujita	PROPN
gs-3920	628	6	,	,	PUNCT
gs-3920	628	7	a.	a.	PROPN
gs-3920	628	8	,	,	PUNCT
gs-3920	628	9	takeuchi	takeuchi	PROPN
gs-3920	628	10	,	,	PUNCT
gs-3920	628	11	s.	s.	PROPN
gs-3920	628	12	,	,	PUNCT
gs-3920	628	13	muto	muto	PROPN
gs-3920	628	14	,	,	PUNCT
gs-3920	628	15	s.	s.	PROPN
gs-3920	628	16	,	,	PUNCT
gs-3920	628	17	&	&	CCONJ
gs-3920	628	18	soma	soma	PROPN
gs-3920	628	19	,	,	PUNCT
gs-3920	628	20	y.	y.	PROPN
gs-3920	628	21	(	(	PUNCT
gs-3920	628	22	2008	2008	NUM
gs-3920	628	23	)	)	PUNCT
gs-3920	628	24	.	.	PUNCT
gs-3920	629	1	drug	drug	NOUN
gs-3920	629	2	-	-	PUNCT
gs-3920	629	3	induced	induce	VERB
gs-3920	629	4	hypersensitivity	hypersensitivity	NOUN
gs-3920	629	5	syndrome	syndrome	NOUN
gs-3920	629	6	:	:	PUNCT
gs-3920	629	7	drug	drug	NOUN
gs-3920	629	8	reaction	reaction	NOUN
gs-3920	629	9	with	with	ADP
gs-3920	629	10	eosinophilia	eosinophilia	PROPN
gs-3920	629	11	and	and	CCONJ
gs-3920	629	12	systemic	systemic	ADJ
gs-3920	629	13	symptoms	symptom	NOUN
gs-3920	629	14	(	(	PUNCT
gs-3920	629	15	dress	dress	NOUN
gs-3920	629	16	)	)	PUNCT
gs-3920	629	17	syndrome	syndrome	NOUN
gs-3920	629	18	induced	induce	VERB
gs-3920	629	19	by	by	ADP
gs-3920	629	20	aspirin	aspirin	NOUN
gs-3920	629	21	treatment	treatment	NOUN
gs-3920	629	22	of	of	ADP
gs-3920	629	23	kawasaki	kawasaki	PROPN
gs-3920	629	24	disease	disease	PROPN
gs-3920	629	25	.	.	PUNCT
gs-3920	630	1	journal	journal	PROPN
gs-3920	630	2	of	of	ADP
gs-3920	630	3	the	the	DET
gs-3920	630	4	american	american	PROPN
gs-3920	630	5	academy	academy	PROPN
gs-3920	630	6	of	of	ADP
gs-3920	630	7	dermatology	dermatology	NOUN
gs-3920	630	8	,	,	PUNCT
gs-3920	630	9	60(1	60(1	NUM
gs-3920	630	10	)	)	PUNCT
gs-3920	630	11	,	,	PUNCT
gs-3920	630	12	146–149	146–149	NUM
gs-3920	630	13	.	.	NOUN
gs-3920	630	14	44	44	NUM
gs-3920	630	15	.	.	PUNCT
gs-3920	631	1	kim	kim	PROPN
gs-3920	631	2	,	,	PUNCT
gs-3920	631	3	m.	m.	NOUN
gs-3920	631	4	,	,	PUNCT
gs-3920	631	5	kang	kang	PROPN
gs-3920	631	6	,	,	PUNCT
gs-3920	631	7	d.	d.	PROPN
gs-3920	631	8	y.	y.	PROPN
gs-3920	631	9	,	,	PUNCT
gs-3920	631	10	nam	nam	PROPN
gs-3920	631	11	,	,	PUNCT
gs-3920	631	12	y.	y.	PROPN
gs-3920	631	13	,	,	PUNCT
gs-3920	631	14	sim	sim	PROPN
gs-3920	631	15	,	,	PUNCT
gs-3920	631	16	d.	d.	PROPN
gs-3920	631	17	w.	w.	PROPN
gs-3920	631	18	,	,	PUNCT
gs-3920	631	19	kim	kim	PROPN
gs-3920	631	20	,	,	PUNCT
gs-3920	631	21	s.	s.	PROPN
gs-3920	631	22	,	,	PUNCT
gs-3920	631	23	lee	lee	PROPN
gs-3920	631	24	,	,	PUNCT
gs-3920	631	25	j.	j.	PROPN
gs-3920	631	26	k.	k.	PROPN
gs-3920	631	27	,	,	PUNCT
gs-3920	631	28	park	park	PROPN
gs-3920	631	29	,	,	PUNCT
gs-3920	631	30	j.	j.	PROPN
gs-3920	631	31	,	,	PUNCT
gs-3920	631	32	park	park	PROPN
gs-3920	631	33	,	,	PUNCT
gs-3920	631	34	h.	h.	PROPN
gs-3920	631	35	,	,	PUNCT
gs-3920	631	36	jung	jung	PROPN
gs-3920	631	37	,	,	PUNCT
gs-3920	631	38	j.	j.	PROPN
gs-3920	631	39	,	,	PUNCT
gs-3920	631	40	kim	kim	PROPN
gs-3920	631	41	,	,	PUNCT
gs-3920	631	42	c.	c.	PROPN
gs-3920	631	43	,	,	PUNCT
gs-3920	631	44	yang	yang	PROPN
gs-3920	631	45	,	,	PUNCT
gs-3920	631	46	m.	m.	NOUN
gs-3920	631	47	,	,	PUNCT
gs-3920	631	48	kim	kim	PROPN
gs-3920	631	49	,	,	PUNCT
gs-3920	631	50	j.	j.	PROPN
gs-3920	631	51	,	,	PUNCT
gs-3920	631	52	ye	ye	PROPN
gs-3920	631	53	,	,	PUNCT
gs-3920	631	54	y.	y.	PROPN
gs-3920	631	55	,	,	PUNCT
gs-3920	631	56	koh	koh	PROPN
gs-3920	631	57	,	,	PUNCT
gs-3920	631	58	y.	y.	PROPN
gs-3920	631	59	,	,	PUNCT
gs-3920	631	60	kang	kang	PROPN
gs-3920	631	61	,	,	PUNCT
gs-3920	631	62	h.	h.	PROPN
gs-3920	631	63	,	,	PUNCT
gs-3920	631	64	park	park	PROPN
gs-3920	631	65	,	,	PUNCT
gs-3920	631	66	s.	s.	PROPN
gs-3920	631	67	j.	j.	PROPN
gs-3920	631	68	,	,	PUNCT
gs-3920	631	69	&	&	CCONJ
gs-3920	631	70	kim	kim	PROPN
gs-3920	631	71	,	,	PUNCT
gs-3920	631	72	s.	s.	PROPN
gs-3920	631	73	(	(	PUNCT
gs-3920	631	74	2023	2023	NUM
gs-3920	631	75	)	)	PUNCT
gs-3920	631	76	.	.	PUNCT
gs-3920	632	1	clinical	clinical	ADJ
gs-3920	632	2	aspects	aspect	NOUN
gs-3920	632	3	of	of	ADP
gs-3920	632	4	severe	severe	ADJ
gs-3920	632	5	cutaneous	cutaneous	ADJ
gs-3920	632	6	adverse	adverse	ADJ
gs-3920	632	7	reactions	reaction	NOUN
gs-3920	632	8	caused	cause	VERB
gs-3920	632	9	by	by	ADP
gs-3920	632	10	beta	beta	NOUN
gs-3920	632	11	-	-	PUNCT
gs-3920	632	12	lactam	lactam	NOUN
gs-3920	632	13	antibiotics	antibiotic	NOUN
gs-3920	632	14	:	:	PUNCT
gs-3920	632	15	a	a	DET
gs-3920	632	16	study	study	NOUN
gs-3920	632	17	from	from	ADP
gs-3920	632	18	the	the	DET
gs-3920	632	19	korea	korea	PROPN
gs-3920	632	20	scar	scar	PROPN
gs-3920	632	21	registry	registry	PROPN
gs-3920	632	22	.	.	PUNCT
gs-3920	633	1	world	world	PROPN
gs-3920	633	2	allergy	allergy	PROPN
gs-3920	633	3	organization	organization	PROPN
gs-3920	633	4	journal	journal	PROPN
gs-3920	633	5	,	,	PUNCT
gs-3920	633	6	16(1	16(1	NUM
gs-3920	633	7	)	)	PUNCT
gs-3920	633	8	,	,	PUNCT
gs-3920	633	9	100738	100738	NUM
gs-3920	633	10	.	.	PUNCT
gs-3920	634	1	45	45	NUM
gs-3920	634	2	.	.	X
gs-3920	634	3	aphkhazava	aphkhazava	PROPN
gs-3920	634	4	,	,	PUNCT
gs-3920	634	5	d.	d.	PROPN
gs-3920	634	6	,	,	PUNCT
gs-3920	634	7	sulashvili	sulashvili	NOUN
gs-3920	634	8	,	,	PUNCT
gs-3920	634	9	n.	n.	NOUN
gs-3920	634	10	,	,	PUNCT
gs-3920	634	11	tupinashvili	tupinashvili	NOUN
gs-3920	634	12	,	,	PUNCT
gs-3920	634	13	t.	t.	PROPN
gs-3920	634	14	,	,	PUNCT
gs-3920	634	15	&	&	CCONJ
gs-3920	634	16	nozadze	nozadze	NOUN
gs-3920	634	17	,	,	PUNCT
gs-3920	634	18	m.	m.	NOUN
gs-3920	634	19	(	(	PUNCT
gs-3920	634	20	2024	2024	NUM
gs-3920	634	21	)	)	PUNCT
gs-3920	634	22	.	.	PUNCT
gs-3920	635	1	dynamic	dynamic	ADJ
gs-3920	635	2	cellular	cellular	ADJ
gs-3920	635	3	equilibrium	equilibrium	NOUN
gs-3920	635	4	theory	theory	NOUN
gs-3920	635	5	of	of	ADP
gs-3920	635	6	aging	aging	NOUN
gs-3920	635	7	:	:	PUNCT
gs-3920	635	8	integrating	integrate	VERB
gs-3920	635	9	maintenance	maintenance	NOUN
gs-3920	635	10	and	and	CCONJ
gs-3920	635	11	accumulation	accumulation	NOUN
gs-3920	635	12	in	in	ADP
gs-3920	635	13	the	the	DET
gs-3920	635	14	aging	age	VERB
gs-3920	635	15	process	process	NOUN
gs-3920	635	16	.	.	PUNCT
gs-3920	636	1	scientific	scientific	ADJ
gs-3920	636	2	journal	journal	NOUN
gs-3920	636	3	„	„	PUNCT
gs-3920	636	4	spectri	spectri	NOUN
gs-3920	636	5	“	"	PUNCT
gs-3920	636	6	,	,	PUNCT
gs-3920	636	7	8(2	8(2	NUM
gs-3920	636	8	)	)	PUNCT
gs-3920	636	9	.	.	PUNCT
gs-3920	637	1	https://doi.org/10.52340/spectri.2023.08.02.03	https://doi.org/10.52340/spectri.2023.08.02.03	ADJ
gs-3920	637	2	46	46	NUM
gs-3920	637	3	.	.	PUNCT
gs-3920	638	1	aphkhazava	aphkhazava	PROPN
gs-3920	638	2	,	,	PUNCT
gs-3920	638	3	d.	d.	PROPN
gs-3920	638	4	,	,	PUNCT
gs-3920	638	5	tuphinashvili	tuphinashvili	NOUN
gs-3920	638	6	,	,	PUNCT
gs-3920	638	7	t.	t.	NOUN
gs-3920	638	8	,	,	PUNCT
gs-3920	638	9	sulashvili	sulashvili	NOUN
gs-3920	638	10	,	,	PUNCT
gs-3920	638	11	n.	n.	NOUN
gs-3920	638	12	,	,	PUNCT
gs-3920	638	13	&	&	CCONJ
gs-3920	638	14	nozadze	nozadze	NOUN
gs-3920	638	15	,	,	PUNCT
gs-3920	638	16	m.	m.	NOUN
gs-3920	638	17	(	(	PUNCT
gs-3920	638	18	2023	2023	NUM
gs-3920	638	19	)	)	PUNCT
gs-3920	638	20	.	.	PUNCT
gs-3920	639	1	the	the	DET
gs-3920	639	2	features	feature	NOUN
gs-3920	639	3	and	and	CCONJ
gs-3920	639	4	role	role	NOUN
gs-3920	639	5	of	of	ADP
gs-3920	639	6	shp2	shp2	ADJ
gs-3920	639	7	protein	protein	NOUN
gs-3920	639	8	in	in	ADP
gs-3920	639	9	postnatal	postnatal	ADJ
gs-3920	639	10	muscle	muscle	NOUN
gs-3920	639	11	development	development	NOUN
gs-3920	639	12	.	.	PUNCT
gs-3920	640	1	scientific	scientific	ADJ
gs-3920	640	2	journal	journal	NOUN
gs-3920	640	3	„	„	PUNCT
gs-3920	640	4	spectri	spectri	NOUN
gs-3920	640	5	“	"	PUNCT
gs-3920	640	6	,	,	PUNCT
gs-3920	640	7	1	1	X
gs-3920	640	8	.	.	PUNCT
gs-3920	641	1	https://doi.org/10.52340/spectri.2023.01	https://doi.org/10.52340/spectri.2023.01	DET
gs-3920	641	2	47	47	NUM
gs-3920	641	3	.	.	PUNCT
gs-3920	642	1	sulashvili	sulashvili	NOUN
gs-3920	642	2	,	,	PUNCT
gs-3920	642	3	n.	n.	NOUN
gs-3920	642	4	,	,	PUNCT
gs-3920	642	5	beglaryan	beglaryan	ADJ
gs-3920	642	6	,	,	PUNCT
gs-3920	642	7	m.	m.	NOUN
gs-3920	642	8	,	,	PUNCT
gs-3920	642	9	gorgaslidze	gorgaslidze	PROPN
gs-3920	642	10	,	,	PUNCT
gs-3920	642	11	n.	n.	PROPN
gs-3920	642	12	,	,	PUNCT
gs-3920	642	13	kocharyan	kocharyan	PROPN
gs-3920	642	14	,	,	PUNCT
gs-3920	642	15	s.	s.	PROPN
gs-3920	642	16	,	,	PUNCT
gs-3920	642	17	chichoyan	chichoyan	PROPN
gs-3920	642	18	,	,	PUNCT
gs-3920	642	19	n.	n.	NOUN
gs-3920	642	20	,	,	PUNCT
gs-3920	642	21	gabunia	gabunia	NOUN
gs-3920	642	22	,	,	PUNCT
gs-3920	642	23	l.	l.	PROPN
gs-3920	642	24	,	,	PUNCT
gs-3920	642	25	zarnadze	zarnadze	PROPN
gs-3920	642	26	,	,	PUNCT
gs-3920	642	27	s.	s.	PROPN
gs-3920	642	28	(	(	PUNCT
gs-3920	642	29	davit	davit	PROPN
gs-3920	642	30	)	)	PUNCT
gs-3920	642	31	.	.	PUNCT
gs-3920	643	1	(	(	PUNCT
gs-3920	643	2	2023	2023	NUM
gs-3920	643	3	)	)	PUNCT
gs-3920	643	4	.	.	PUNCT
gs-3920	644	1	the	the	DET
gs-3920	644	2	disclosure	disclosure	NOUN
gs-3920	644	3	of	of	ADP
gs-3920	644	4	features	feature	NOUN
gs-3920	644	5	,	,	PUNCT
gs-3920	644	6	characteristics	characteristic	NOUN
gs-3920	644	7	,	,	PUNCT
gs-3920	644	8	possibilities	possibility	NOUN
gs-3920	644	9	and	and	CCONJ
gs-3920	644	10	specialties	specialty	NOUN
gs-3920	644	11	of	of	ADP
gs-3920	644	12	clinical	clinical	ADJ
gs-3920	644	13	pharmacists	pharmacist	NOUN
gs-3920	644	14	as	as	ADP
gs-3920	644	15	mediator	mediator	NOUN
gs-3920	644	16	among	among	ADP
gs-3920	644	17	doctors	doctor	NOUN
gs-3920	644	18	and	and	CCONJ
gs-3920	644	19	patients	patient	NOUN
gs-3920	644	20	for	for	ADP
gs-3920	644	21	enhancement	enhancement	NOUN
gs-3920	644	22	public	public	ADJ
gs-3920	644	23	health	health	NOUN
gs-3920	644	24	sector	sector	NOUN
gs-3920	644	25	in	in	ADP
gs-3920	644	26	a	a	DET
gs-3920	644	27	global	global	ADJ
gs-3920	644	28	world	world	NOUN
gs-3920	644	29	.	.	PUNCT
gs-3920	645	1	experimental	experimental	ADJ
gs-3920	645	2	and	and	CCONJ
gs-3920	645	3	clinical	clinical	ADJ
gs-3920	645	4	medicine	medicine	NOUN
gs-3920	645	5	georgia	georgia	PROPN
gs-3920	645	6	,	,	PUNCT
gs-3920	645	7	(	(	PUNCT
gs-3920	645	8	4	4	NUM
gs-3920	645	9	)	)	PUNCT
gs-3920	645	10	,	,	PUNCT
gs-3920	645	11	57–62	57–62	NUM
gs-3920	645	12	.	.	PUNCT
gs-3920	645	13	https://doi.org/10.52340/jecm.2023.04.15	https://doi.org/10.52340/jecm.2023.04.15	PROPN
gs-3920	645	14	48	48	NUM
gs-3920	645	15	.	.	PUNCT
gs-3920	646	1	sulashvili	sulashvili	NOUN
gs-3920	646	2	,	,	PUNCT
gs-3920	646	3	n.	n.	NOUN
gs-3920	646	4	,	,	PUNCT
gs-3920	646	5	gorgaslidze	gorgaslidze	PROPN
gs-3920	646	6	,	,	PUNCT
gs-3920	646	7	n.	n.	NOUN
gs-3920	646	8	,	,	PUNCT
gs-3920	646	9	gabunia	gabunia	NOUN
gs-3920	646	10	,	,	PUNCT
gs-3920	646	11	l.	l.	PROPN
gs-3920	646	12	,	,	PUNCT
gs-3920	646	13	giorgobiani	giorgobiani	PROPN
gs-3920	646	14	,	,	PUNCT
gs-3920	646	15	m.	m.	NOUN
gs-3920	646	16	,	,	PUNCT
gs-3920	646	17	&	&	CCONJ
gs-3920	646	18	ratiani	ratiani	PROPN
gs-3920	646	19	,	,	PUNCT
gs-3920	646	20	l.	l.	PROPN
gs-3920	646	21	(	(	PUNCT
gs-3920	646	22	2023	2023	NUM
gs-3920	646	23	)	)	PUNCT
gs-3920	646	24	.	.	PUNCT
gs-3920	647	1	manifestation	manifestation	NOUN
gs-3920	647	2	of	of	ADP
gs-3920	647	3	the	the	DET
gs-3920	647	4	particularities	particularity	NOUN
gs-3920	647	5	of	of	ADP
gs-3920	647	6	the	the	DET
gs-3920	647	7	usage	usage	NOUN
gs-3920	647	8	features	feature	NOUN
gs-3920	647	9	of	of	ADP
gs-3920	647	10	monoclonal	monoclonal	NOUN
gs-3920	647	11	antibodies	antibody	NOUN
gs-3920	647	12	in	in	ADP
gs-3920	647	13	various	various	ADJ
gs-3920	647	14	pharmacotherapeutic	pharmacotherapeutic	ADJ
gs-3920	647	15	applications	application	NOUN
gs-3920	647	16	.	.	PUNCT
gs-3920	648	1	experimental	experimental	ADJ
gs-3920	648	2	and	and	CCONJ
gs-3920	648	3	clinical	clinical	ADJ
gs-3920	648	4	medicine	medicine	NOUN
gs-3920	648	5	georgia	georgia	PROPN
gs-3920	648	6	,	,	PUNCT
gs-3920	648	7	(	(	PUNCT
gs-3920	648	8	4	4	NUM
gs-3920	648	9	)	)	PUNCT
gs-3920	648	10	,	,	PUNCT
gs-3920	648	11	52–57	52–57	NUM
gs-3920	648	12	.	.	PUNCT
gs-3920	649	1	georgian	georgian	ADJ
gs-3920	649	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	649	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	649	4	ტ.	ტ.	VERB
gs-3920	649	5	7	7	NUM
gs-3920	649	6	n	n	DET
gs-3920	649	7	3	3	NUM
gs-3920	649	8	,	,	PUNCT
gs-3920	649	9	2025	2025	NUM
gs-3920	649	10	215	215	NUM
gs-3920	649	11	49	49	NUM
gs-3920	649	12	.	.	PUNCT
gs-3920	650	1	sulashvili	sulashvili	NOUN
gs-3920	650	2	,	,	PUNCT
gs-3920	650	3	n.	n.	NOUN
gs-3920	650	4	,	,	PUNCT
gs-3920	650	5	davitashvili	davitashvili	ADJ
gs-3920	650	6	,	,	PUNCT
gs-3920	650	7	m.	m.	NOUN
gs-3920	650	8	,	,	PUNCT
gs-3920	650	9	gorgaslidze	gorgaslidze	PROPN
gs-3920	650	10	,	,	PUNCT
gs-3920	650	11	n.	n.	NOUN
gs-3920	650	12	,	,	PUNCT
gs-3920	650	13	gabunia	gabunia	NOUN
gs-3920	650	14	,	,	PUNCT
gs-3920	650	15	l.	l.	PROPN
gs-3920	650	16	,	,	PUNCT
gs-3920	650	17	beglaryan	beglaryan	ADJ
gs-3920	650	18	,	,	PUNCT
gs-3920	650	19	m.	m.	NOUN
gs-3920	650	20	,	,	PUNCT
gs-3920	650	21	alavidze	alavidze	NOUN
gs-3920	650	22	,	,	PUNCT
gs-3920	650	23	n.	n.	NOUN
gs-3920	650	24	,	,	PUNCT
gs-3920	650	25	…	…	PUNCT
gs-3920	650	26	sulashvili	sulashvili	NOUN
gs-3920	650	27	,	,	PUNCT
gs-3920	650	28	m.	m.	NOUN
gs-3920	650	29	(	(	PUNCT
gs-3920	650	30	2024	2024	NUM
gs-3920	650	31	)	)	PUNCT
gs-3920	650	32	.	.	PUNCT
gs-3920	651	1	the	the	DET
gs-3920	651	2	scientific	scientific	ADJ
gs-3920	651	3	discussion	discussion	NOUN
gs-3920	651	4	of	of	ADP
gs-3920	651	5	some	some	DET
gs-3920	651	6	issues	issue	NOUN
gs-3920	651	7	of	of	ADP
gs-3920	651	8	features	feature	NOUN
gs-3920	651	9	and	and	CCONJ
gs-3920	651	10	challenges	challenge	NOUN
gs-3920	651	11	of	of	ADP
gs-3920	651	12	using	use	VERB
gs-3920	651	13	of	of	ADP
gs-3920	651	14	car	car	NOUN
gs-3920	651	15	-	-	PUNCT
gs-3920	651	16	t	t	NOUN
gs-3920	651	17	cells	cell	NOUN
gs-3920	651	18	in	in	ADP
gs-3920	651	19	immunotherapy	immunotherapy	NOUN
gs-3920	651	20	.	.	PUNCT
gs-3920	652	1	georgian	georgian	ADJ
gs-3920	652	2	scientists	scientist	NOUN
gs-3920	652	3	,	,	PUNCT
gs-3920	652	4	6(4	6(4	NOUN
gs-3920	652	5	)	)	PUNCT
gs-3920	652	6	,	,	PUNCT
gs-3920	652	7	263–290	263–290	NUM
gs-3920	652	8	.	.	PUNCT
gs-3920	653	1	https://doi.org/10.52340/gs.2024.06.04.24	https://doi.org/10.52340/gs.2024.06.04.24	PROPN
gs-3920	653	2	50	50	NUM
gs-3920	653	3	.	.	PUNCT
gs-3920	654	1	sulashvili	sulashvili	NOUN
gs-3920	654	2	,	,	PUNCT
gs-3920	654	3	n.	n.	NOUN
gs-3920	654	4	,	,	PUNCT
gs-3920	654	5	gorgaslidze	gorgaslidze	PROPN
gs-3920	654	6	,	,	PUNCT
gs-3920	654	7	n.	n.	NOUN
gs-3920	654	8	,	,	PUNCT
gs-3920	654	9	gabunia	gabunia	NOUN
gs-3920	654	10	,	,	PUNCT
gs-3920	654	11	l.	l.	PROPN
gs-3920	654	12	,	,	PUNCT
gs-3920	654	13	giorgobiani	giorgobiani	PROPN
gs-3920	654	14	,	,	PUNCT
gs-3920	654	15	m.	m.	NOUN
gs-3920	654	16	,	,	PUNCT
gs-3920	654	17	&	&	CCONJ
gs-3920	654	18	ratiani	ratiani	PROPN
gs-3920	654	19	,	,	PUNCT
gs-3920	654	20	l.	l.	PROPN
gs-3920	654	21	(	(	PUNCT
gs-3920	654	22	2023	2023	NUM
gs-3920	654	23	)	)	PUNCT
gs-3920	654	24	.	.	PUNCT
gs-3920	655	1	manifestation	manifestation	NOUN
gs-3920	655	2	of	of	ADP
gs-3920	655	3	the	the	DET
gs-3920	655	4	particularities	particularity	NOUN
gs-3920	655	5	of	of	ADP
gs-3920	655	6	the	the	DET
gs-3920	655	7	usage	usage	NOUN
gs-3920	655	8	features	feature	NOUN
gs-3920	655	9	of	of	ADP
gs-3920	655	10	monoclonal	monoclonal	NOUN
gs-3920	655	11	antibodies	antibody	NOUN
gs-3920	655	12	in	in	ADP
gs-3920	655	13	various	various	ADJ
gs-3920	655	14	pharmacotherapeutic	pharmacotherapeutic	ADJ
gs-3920	655	15	applications	application	NOUN
gs-3920	655	16	.	.	PUNCT
gs-3920	656	1	experimental	experimental	ADJ
gs-3920	656	2	and	and	CCONJ
gs-3920	656	3	clinical	clinical	ADJ
gs-3920	656	4	medicine	medicine	NOUN
gs-3920	656	5	georgia	georgia	PROPN
gs-3920	656	6	,	,	PUNCT
gs-3920	656	7	(	(	PUNCT
gs-3920	656	8	4	4	NUM
gs-3920	656	9	)	)	PUNCT
gs-3920	656	10	,	,	PUNCT
gs-3920	656	11	52–57	52–57	NUM
gs-3920	656	12	.	.	PUNCT
gs-3920	656	13	https://doi.org/10.52340/jecm.2023.04.14	https://doi.org/10.52340/jecm.2023.04.14	X
gs-3920	657	1	51	51	NUM
gs-3920	657	2	.	.	PUNCT
gs-3920	657	3	sulashvili	sulashvili	NOUN
gs-3920	657	4	,	,	PUNCT
gs-3920	657	5	n.	n.	NOUN
gs-3920	657	6	,	,	PUNCT
gs-3920	657	7	gorgaslidze	gorgaslidze	PROPN
gs-3920	657	8	,	,	PUNCT
gs-3920	657	9	n.	n.	NOUN
gs-3920	657	10	,	,	PUNCT
gs-3920	657	11	gabunia	gabunia	NOUN
gs-3920	657	12	,	,	PUNCT
gs-3920	657	13	l.	l.	PROPN
gs-3920	657	14	,	,	PUNCT
gs-3920	657	15	ratiani	ratiani	PROPN
gs-3920	657	16	,	,	PUNCT
gs-3920	657	17	l.	l.	PROPN
gs-3920	657	18	,	,	PUNCT
gs-3920	657	19	khetsuriani	khetsuriani	PROPN
gs-3920	657	20	,	,	PUNCT
gs-3920	657	21	s.	s.	PROPN
gs-3920	657	22	,	,	PUNCT
gs-3920	657	23	kravchenko	kravchenko	PROPN
gs-3920	657	24	,	,	PUNCT
gs-3920	657	25	v.	v.	NOUN
gs-3920	657	26	,	,	PUNCT
gs-3920	657	27	sulashvili	sulashvili	NOUN
gs-3920	657	28	,	,	PUNCT
gs-3920	657	29	m.	m.	NOUN
gs-3920	657	30	(	(	PUNCT
gs-3920	657	31	2024	2024	NUM
gs-3920	657	32	)	)	PUNCT
gs-3920	657	33	.	.	PUNCT
gs-3920	658	1	manifestation	manifestation	NOUN
gs-3920	658	2	of	of	ADP
gs-3920	658	3	the	the	DET
gs-3920	658	4	particularities	particularity	NOUN
gs-3920	658	5	of	of	ADP
gs-3920	658	6	some	some	DET
gs-3920	658	7	key	key	ADJ
gs-3920	658	8	issue	issue	NOUN
gs-3920	658	9	aspects	aspect	NOUN
gs-3920	658	10	of	of	ADP
gs-3920	658	11	new	new	ADJ
gs-3920	658	12	immunotherapy	immunotherapy	NOUN
gs-3920	658	13	challenges	challenge	NOUN
gs-3920	658	14	and	and	CCONJ
gs-3920	658	15	perspectives	perspective	NOUN
gs-3920	658	16	by	by	ADP
gs-3920	658	17	car	car	NOUN
gs-3920	658	18	-	-	PUNCT
gs-3920	658	19	t	t	NOUN
gs-3920	658	20	cell	cell	NOUN
gs-3920	658	21	therapy	therapy	NOUN
gs-3920	658	22	.	.	PUNCT
gs-3920	659	1	experimental	experimental	ADJ
gs-3920	659	2	and	and	CCONJ
gs-3920	659	3	clinical	clinical	ADJ
gs-3920	659	4	medicine	medicine	NOUN
gs-3920	659	5	georgia	georgia	PROPN
gs-3920	659	6	,	,	PUNCT
gs-3920	659	7	(	(	PUNCT
gs-3920	659	8	4	4	NUM
gs-3920	659	9	)	)	PUNCT
gs-3920	659	10	,	,	PUNCT
gs-3920	659	11	119–121	119–121	NUM
gs-3920	659	12	.	.	PUNCT
gs-3920	659	13	https://doi.org/10.52340/jecm.2024.04.32	https://doi.org/10.52340/jecm.2024.04.32	NUM
gs-3920	659	14	.	.	NOUN
gs-3920	659	15	52	52	NUM
gs-3920	659	16	.	.	PUNCT
gs-3920	660	1	sulashvili	sulashvili	NOUN
gs-3920	660	2	,	,	PUNCT
gs-3920	660	3	n.	n.	NOUN
gs-3920	660	4	.	.	PUNCT
gs-3920	661	1	.	.	PUNCT
gs-3920	661	2	,	,	PUNCT
gs-3920	662	1	gorgaslidze	gorgaslidze	INTJ
gs-3920	662	2	,	,	PUNCT
gs-3920	662	3	n.	n.	PROPN
gs-3920	662	4	.	.	PUNCT
gs-3920	663	1	,	,	PUNCT
gs-3920	663	2	beglaryan	beglaryan	ADJ
gs-3920	663	3	,	,	PUNCT
gs-3920	663	4	m.	m.	NOUN
gs-3920	663	5	.	.	PUNCT
gs-3920	663	6	,	,	PUNCT
gs-3920	663	7	gabunia	gabunia	NOUN
gs-3920	663	8	,	,	PUNCT
gs-3920	663	9	l.	l.	PROPN
gs-3920	663	10	.	.	PROPN
gs-3920	663	11	,	,	PUNCT
gs-3920	663	12	chichoyan	chichoyan	PROPN
gs-3920	663	13	,	,	PUNCT
gs-3920	663	14	n.	n.	PROPN
gs-3920	663	15	.	.	PUNCT
gs-3920	663	16	,	,	PUNCT
gs-3920	663	17	giorgobiani	giorgobiani	PROPN
gs-3920	663	18	,	,	PUNCT
gs-3920	663	19	m.	m.	NOUN
gs-3920	663	20	.	.	PUNCT
gs-3920	664	1	,	,	PUNCT
gs-3920	664	2	…	…	PUNCT
gs-3920	664	3	zarnadze	zarnadze	INTJ
gs-3920	664	4	,	,	PUNCT
gs-3920	664	5	s.	s.	PROPN
gs-3920	664	6	(	(	PUNCT
gs-3920	664	7	davit	davit	PROPN
gs-3920	664	8	)	)	PUNCT
gs-3920	664	9	.	.	PUNCT
gs-3920	665	1	(	(	PUNCT
gs-3920	665	2	2022	2022	NUM
gs-3920	665	3	)	)	PUNCT
gs-3920	665	4	.	.	PUNCT
gs-3920	666	1	the	the	DET
gs-3920	666	2	scientific	scientific	ADJ
gs-3920	666	3	talks	talk	NOUN
gs-3920	666	4	of	of	ADP
gs-3920	666	5	essential	essential	ADJ
gs-3920	666	6	issue	issue	NOUN
gs-3920	666	7	,	,	PUNCT
gs-3920	666	8	invocation	invocation	NOUN
gs-3920	666	9	,	,	PUNCT
gs-3920	666	10	perspectives	perspective	NOUN
gs-3920	666	11	,	,	PUNCT
gs-3920	666	12	inclinations	inclination	NOUN
gs-3920	666	13	and	and	CCONJ
gs-3920	666	14	features	feature	NOUN
gs-3920	666	15	of	of	ADP
gs-3920	666	16	the	the	DET
gs-3920	666	17	clinical	clinical	ADJ
gs-3920	666	18	pharmacists	pharmacist	NOUN
gs-3920	666	19	globally	globally	ADV
gs-3920	666	20	.	.	PUNCT
gs-3920	667	1	experimental	experimental	ADJ
gs-3920	667	2	and	and	CCONJ
gs-3920	667	3	clinical	clinical	ADJ
gs-3920	667	4	medicine	medicine	NOUN
gs-3920	667	5	georgia	georgia	PROPN
gs-3920	667	6	,	,	PUNCT
gs-3920	667	7	(	(	PUNCT
gs-3920	667	8	7	7	NUM
gs-3920	667	9	)	)	PUNCT
gs-3920	667	10	.	.	PUNCT
gs-3920	668	1	53	53	NUM
gs-3920	668	2	.	.	PUNCT
gs-3920	669	1	sulashvili	sulashvili	PROPN
gs-3920	669	2	n	n	CCONJ
gs-3920	669	3	,	,	PUNCT
gs-3920	669	4	nimangre	nimangre	PROPN
gs-3920	669	5	rr	rr	PROPN
gs-3920	669	6	.	.	PUNCT
gs-3920	670	1	manifestation	manifestation	NOUN
gs-3920	670	2	of	of	ADP
gs-3920	670	3	some	some	DET
gs-3920	670	4	aspects	aspect	NOUN
gs-3920	670	5	of	of	ADP
gs-3920	670	6	cardiovascular	cardiovascular	ADJ
gs-3920	670	7	diseases	disease	NOUN
gs-3920	670	8	,	,	PUNCT
gs-3920	670	9	implications	implication	NOUN
gs-3920	670	10	,	,	PUNCT
gs-3920	670	11	pharmacotherapeutic	pharmacotherapeutic	ADJ
gs-3920	670	12	strategies	strategy	NOUN
gs-3920	670	13	,	,	PUNCT
gs-3920	670	14	effects	effect	NOUN
gs-3920	670	15	,	,	PUNCT
gs-3920	670	16	impacts	impact	NOUN
gs-3920	670	17	and	and	CCONJ
gs-3920	670	18	potential	potential	ADJ
gs-3920	670	19	hazards	hazard	NOUN
gs-3920	670	20	in	in	ADP
gs-3920	670	21	general	general	ADJ
gs-3920	670	22	.	.	PUNCT
gs-3920	671	1	jr	jr	PROPN
gs-3920	672	1	[	[	X
gs-3920	672	2	internet	internet	NOUN
gs-3920	672	3	]	]	PUNCT
gs-3920	672	4	.	.	PUNCT
gs-3920	673	1	2025	2025	NUM
gs-3920	673	2	feb	feb	X
gs-3920	673	3	.	.	PROPN
gs-3920	673	4	7	7	NUM
gs-3920	673	5	[	[	X
gs-3920	673	6	cited	cite	VERB
gs-3920	673	7	2025	2025	NUM
gs-3920	673	8	may	may	PROPN
gs-3920	673	9	22];3(1):1	22];3(1):1	NUM
gs-3920	673	10	-	-	SYM
gs-3920	673	11	27	27	NUM
gs-3920	673	12	.	.	PUNCT
gs-3920	674	1	available	available	ADJ
gs-3920	674	2	from	from	ADP
gs-3920	674	3	:	:	PUNCT
gs-3920	674	4	https://journals.4science.ge/index.php/jr/article/view/3393	https://journals.4science.ge/index.php/jr/article/view/3393	PROPN
gs-3920	674	5	.	.	PUNCT
gs-3920	675	1	54	54	NUM
gs-3920	675	2	.	.	PUNCT
gs-3920	676	1	sulashvili	sulashvili	PROPN
gs-3920	676	2	n	n	CCONJ
gs-3920	676	3	,	,	PUNCT
gs-3920	676	4	yaduvanshi	yaduvanshi	NOUN
gs-3920	676	5	u	u	NOUN
gs-3920	676	6	,	,	PUNCT
gs-3920	676	7	yadav	yadav	PROPN
gs-3920	676	8	m	m	PROPN
gs-3920	676	9	,	,	PUNCT
gs-3920	676	10	gabunia	gabunia	NOUN
gs-3920	676	11	l	l	NOUN
gs-3920	676	12	,	,	PUNCT
gs-3920	676	13	ghambashidze	ghambashidze	PROPN
gs-3920	676	14	k	k	PROPN
gs-3920	676	15	,	,	PUNCT
gs-3920	676	16	gorgaslidze	gorgaslidze	ADJ
gs-3920	676	17	n	n	CCONJ
gs-3920	676	18	,	,	PUNCT
gs-3920	676	19	et	et	PROPN
gs-3920	676	20	al	al	PROPN
gs-3920	676	21	.	.	PUNCT
gs-3920	677	1	the	the	DET
gs-3920	677	2	scientific	scientific	ADJ
gs-3920	677	3	discourse	discourse	NOUN
gs-3920	677	4	of	of	ADP
gs-3920	677	5	features	feature	NOUN
gs-3920	677	6	of	of	ADP
gs-3920	677	7	clinical	clinical	ADJ
gs-3920	677	8	use	use	NOUN
gs-3920	677	9	and	and	CCONJ
gs-3920	677	10	pharmacology	pharmacology	NOUN
gs-3920	677	11	of	of	ADP
gs-3920	677	12	vasoconstrictors	vasoconstrictor	NOUN
gs-3920	677	13	and	and	CCONJ
gs-3920	677	14	their	their	PRON
gs-3920	677	15	impact	impact	NOUN
gs-3920	677	16	on	on	ADP
gs-3920	677	17	cardiac	cardiac	ADJ
gs-3920	677	18	function	function	NOUN
gs-3920	677	19	.	.	PUNCT
gs-3920	678	1	jr	jr	PROPN
gs-3920	679	1	[	[	X
gs-3920	679	2	internet	internet	NOUN
gs-3920	679	3	]	]	PUNCT
gs-3920	679	4	.	.	PUNCT
gs-3920	680	1	2025	2025	NUM
gs-3920	680	2	feb	feb	X
gs-3920	680	3	.	.	PROPN
gs-3920	680	4	21	21	NUM
gs-3920	680	5	[	[	X
gs-3920	680	6	cited	cite	VERB
gs-3920	680	7	2025	2025	NUM
gs-3920	680	8	may	may	PROPN
gs-3920	680	9	22];3(1):28	22];3(1):28	NUM
gs-3920	680	10	-	-	SYM
gs-3920	680	11	6	6	NUM
gs-3920	680	12	.	.	PUNCT
gs-3920	681	1	available	available	ADJ
gs-3920	681	2	from	from	ADP
gs-3920	681	3	:	:	PUNCT
gs-3920	681	4	https://journals.4science.ge/index.php/jr/article/view/3414	https://journals.4science.ge/index.php/jr/article/view/3414	NOUN
gs-3920	681	5	.	.	PUNCT
gs-3920	682	1	55	55	NUM
gs-3920	682	2	.	.	PUNCT
gs-3920	683	1	nodar	nodar	PROPN
gs-3920	683	2	sulashvili	sulashvili	NOUN
gs-3920	683	3	,	,	PUNCT
gs-3920	683	4	nana	nana	PROPN
gs-3920	683	5	gorgaslidze	gorgaslidze	PROPN
gs-3920	683	6	,	,	PUNCT
gs-3920	683	7	margarita	margarita	PROPN
gs-3920	683	8	beglaryan	beglaryan	PROPN
gs-3920	683	9	,	,	PUNCT
gs-3920	683	10	luiza	luiza	PROPN
gs-3920	683	11	gabunia	gabunia	PROPN
gs-3920	683	12	,	,	PUNCT
gs-3920	683	13	nato	nato	PROPN
gs-3920	683	14	alavidze	alavidze	PROPN
gs-3920	683	15	,	,	PUNCT
gs-3920	683	16	nino	nino	PROPN
gs-3920	683	17	abuladze	abuladze	PROPN
gs-3920	683	18	,	,	PUNCT
gs-3920	683	19	marina	marina	PROPN
gs-3920	683	20	giorgobiani	giorgobiani	PROPN
gs-3920	683	21	,	,	PUNCT
gs-3920	683	22	marika	marika	PROPN
gs-3920	683	23	sulashvili	sulashvili	PROPN
gs-3920	683	24	,	,	PUNCT
gs-3920	683	25	tamar	tamar	PROPN
gs-3920	683	26	okropiridze	okropiridze	PROPN
gs-3920	683	27	,	,	PUNCT
gs-3920	683	28	and	and	CCONJ
gs-3920	683	29	lali	lali	PROPN
gs-3920	683	30	patsia	patsia	PROPN
gs-3920	683	31	.	.	PUNCT
gs-3920	684	1	2025	2025	NUM
gs-3920	684	2	.	.	PUNCT
gs-3920	685	1	“	"	PUNCT
gs-3920	685	2	the	the	DET
gs-3920	685	3	scientific	scientific	ADJ
gs-3920	685	4	discourse	discourse	NOUN
gs-3920	685	5	of	of	ADP
gs-3920	685	6	key	key	ADJ
gs-3920	685	7	issue	issue	NOUN
gs-3920	685	8	aspects	aspect	NOUN
gs-3920	685	9	of	of	ADP
gs-3920	685	10	features	feature	NOUN
gs-3920	685	11	of	of	ADP
gs-3920	685	12	candida	candida	PROPN
gs-3920	685	13	problems	problem	NOUN
gs-3920	685	14	,	,	PUNCT
gs-3920	685	15	antifungal	antifungal	ADJ
gs-3920	685	16	drugs	drug	NOUN
gs-3920	685	17	resistance	resistance	NOUN
gs-3920	685	18	concerns	concern	NOUN
gs-3920	685	19	,	,	PUNCT
gs-3920	685	20	mycotoxicology	mycotoxicology	NOUN
gs-3920	685	21	issues	issue	NOUN
gs-3920	685	22	,	,	PUNCT
gs-3920	685	23	mycoecology	mycoecology	NOUN
gs-3920	685	24	,	,	PUNCT
gs-3920	685	25	biosafety	biosafety	NOUN
gs-3920	685	26	risks	risk	NOUN
gs-3920	685	27	and	and	CCONJ
gs-3920	685	28	emerging	emerge	VERB
gs-3920	685	29	solutions	solution	NOUN
gs-3920	685	30	”	"	PUNCT
gs-3920	685	31	.	.	PUNCT
gs-3920	686	1	modern	modern	ADJ
gs-3920	686	2	scientific	scientific	ADJ
gs-3920	686	3	method	method	NOUN
gs-3920	686	4	,	,	PUNCT
gs-3920	686	5	no	no	INTJ
gs-3920	686	6	.	.	NOUN
gs-3920	686	7	9	9	NUM
gs-3920	686	8	(	(	PUNCT
gs-3920	686	9	march	march	PROPN
gs-3920	686	10	)	)	PUNCT
gs-3920	686	11	.	.	PUNCT
gs-3920	687	1	https://ojs.scipub.de/index.php/msm/article/view/5423	https://ojs.scipub.de/index.php/msm/article/view/5423	NOUN
gs-3920	687	2	.	.	NOUN
gs-3920	688	1	56	56	NUM
gs-3920	688	2	.	.	PUNCT
gs-3920	689	1	chen	chen	PROPN
gs-3920	689	2	,	,	PUNCT
gs-3920	689	3	che	che	PROPN
gs-3920	689	4	-	-	NOUN
gs-3920	689	5	hung	hung	ADJ
gs-3920	689	6	,	,	PUNCT
gs-3920	689	7	et	et	PROPN
gs-3920	689	8	al	al	PROPN
gs-3920	689	9	.	.	PUNCT
gs-3920	690	1	“	"	PUNCT
gs-3920	690	2	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	690	3	of	of	ADP
gs-3920	690	4	drug	drug	NOUN
gs-3920	690	5	hypersensitivity	hypersensitivity	NOUN
gs-3920	690	6	:	:	PUNCT
gs-3920	690	7	clinical	clinical	ADJ
gs-3920	690	8	implications	implication	NOUN
gs-3920	690	9	and	and	CCONJ
gs-3920	690	10	future	future	ADJ
gs-3920	690	11	directions	direction	NOUN
gs-3920	690	12	.	.	PUNCT
gs-3920	690	13	”	"	PUNCT
gs-3920	691	1	current	current	ADJ
gs-3920	691	2	drug	drug	NOUN
gs-3920	691	3	metabolism	metabolism	NOUN
gs-3920	691	4	15	15	NUM
gs-3920	691	5	,	,	PUNCT
gs-3920	691	6	no	no	INTJ
gs-3920	691	7	.	.	NOUN
gs-3920	691	8	3	3	NUM
gs-3920	691	9	(	(	PUNCT
gs-3920	691	10	2014	2014	NUM
gs-3920	691	11	):	):	PUNCT
gs-3920	691	12	265	265	NUM
gs-3920	691	13	–	–	PUNCT
gs-3920	691	14	76	76	NUM
gs-3920	691	15	.	.	PUNCT
gs-3920	692	1	georgian	georgian	ADJ
gs-3920	692	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-3920	692	3	მეცნიერები	მეცნიერები	NOUN
gs-3920	692	4	ტ.	ტ.	VERB
gs-3920	692	5	7	7	NUM
gs-3920	692	6	n	n	DET
gs-3920	692	7	3	3	NUM
gs-3920	692	8	,	,	PUNCT
gs-3920	692	9	2025	2025	NUM
gs-3920	692	10	216	216	NUM
gs-3920	692	11	57	57	NUM
gs-3920	692	12	.	.	PUNCT
gs-3920	693	1	kardaun	kardaun	PROPN
gs-3920	693	2	,	,	PUNCT
gs-3920	693	3	sylvia	sylvia	PROPN
gs-3920	693	4	h.	h.	PROPN
gs-3920	693	5	,	,	PUNCT
gs-3920	693	6	and	and	CCONJ
gs-3920	693	7	jean	jean	PROPN
gs-3920	693	8	-	-	PUNCT
gs-3920	693	9	claude	claude	PROPN
gs-3920	693	10	roujeau	roujeau	PROPN
gs-3920	693	11	.	.	PUNCT
gs-3920	694	1	“	"	PUNCT
gs-3920	694	2	dress	dress	NOUN
gs-3920	694	3	syndrome	syndrome	NOUN
gs-3920	694	4	or	or	CCONJ
gs-3920	694	5	drug	drug	NOUN
gs-3920	694	6	reaction	reaction	NOUN
gs-3920	694	7	with	with	ADP
gs-3920	694	8	eosinophilia	eosinophilia	PROPN
gs-3920	694	9	and	and	CCONJ
gs-3920	694	10	systemic	systemic	ADJ
gs-3920	694	11	symptoms	symptom	NOUN
gs-3920	694	12	:	:	PUNCT
gs-3920	694	13	why	why	SCONJ
gs-3920	694	14	the	the	DET
gs-3920	694	15	regiscar	regiscar	NOUN
gs-3920	694	16	scoring	scoring	NOUN
gs-3920	694	17	system	system	NOUN
gs-3920	694	18	should	should	AUX
gs-3920	694	19	be	be	AUX
gs-3920	694	20	used	use	VERB
gs-3920	694	21	.	.	PUNCT
gs-3920	694	22	”	"	PUNCT
gs-3920	695	1	british	british	ADJ
gs-3920	695	2	journal	journal	PROPN
gs-3920	695	3	of	of	ADP
gs-3920	695	4	dermatology	dermatology	NOUN
gs-3920	695	5	169	169	NUM
gs-3920	695	6	,	,	PUNCT
gs-3920	695	7	no	no	INTJ
gs-3920	695	8	.	.	NOUN
gs-3920	695	9	5	5	NUM
gs-3920	695	10	(	(	PUNCT
gs-3920	695	11	2013	2013	NUM
gs-3920	695	12	):	):	PUNCT
gs-3920	695	13	1001–2	1001–2	NUM
gs-3920	695	14	.	.	NOUN
gs-3920	695	15	58	58	NUM
gs-3920	695	16	.	.	PUNCT
gs-3920	696	1	cho	cho	PROPN
gs-3920	696	2	,	,	PUNCT
gs-3920	696	3	young	young	ADJ
gs-3920	696	4	-	-	PUNCT
gs-3920	696	5	min	min	NOUN
gs-3920	696	6	,	,	PUNCT
gs-3920	696	7	et	et	PROPN
gs-3920	696	8	al	al	PROPN
gs-3920	696	9	.	.	PUNCT
gs-3920	697	1	“	"	PUNCT
gs-3920	697	2	long	long	ADJ
gs-3920	697	3	-	-	PUNCT
gs-3920	697	4	term	term	NOUN
gs-3920	697	5	outcomes	outcome	NOUN
gs-3920	697	6	of	of	ADP
gs-3920	697	7	drug	drug	NOUN
gs-3920	697	8	reaction	reaction	NOUN
gs-3920	697	9	with	with	ADP
gs-3920	697	10	eosinophilia	eosinophilia	PROPN
gs-3920	697	11	and	and	CCONJ
gs-3920	697	12	systemic	systemic	ADJ
gs-3920	697	13	symptoms	symptom	NOUN
gs-3920	697	14	(	(	PUNCT
gs-3920	697	15	dress	dress	NOUN
gs-3920	697	16	)	)	PUNCT
gs-3920	697	17	syndrome	syndrome	NOUN
gs-3920	697	18	:	:	PUNCT
gs-3920	697	19	a	a	DET
gs-3920	697	20	retrospective	retrospective	ADJ
gs-3920	697	21	study	study	NOUN
gs-3920	697	22	of	of	ADP
gs-3920	697	23	33	33	NUM
gs-3920	697	24	patients	patient	NOUN
gs-3920	697	25	.	.	PUNCT
gs-3920	697	26	”	"	PUNCT
gs-3920	698	1	journal	journal	NOUN
gs-3920	698	2	of	of	ADP
gs-3920	698	3	the	the	DET
gs-3920	698	4	american	american	PROPN
gs-3920	698	5	academy	academy	PROPN
gs-3920	698	6	of	of	ADP
gs-3920	698	7	dermatology	dermatology	NOUN
gs-3920	698	8	68	68	NUM
gs-3920	698	9	,	,	PUNCT
gs-3920	698	10	no	no	INTJ
gs-3920	698	11	.	.	NOUN
gs-3920	698	12	4	4	NUM
gs-3920	698	13	(	(	PUNCT
gs-3920	698	14	2013	2013	NUM
gs-3920	698	15	):	):	PUNCT
gs-3920	698	16	558–66	558–66	NUM
gs-3920	698	17	.	.	NOUN
gs-3920	698	18	59	59	NUM
gs-3920	698	19	.	.	PUNCT
gs-3920	698	20	shiohara	shiohara	PROPN
gs-3920	698	21	,	,	PUNCT
gs-3920	698	22	tetsuo	tetsuo	PROPN
gs-3920	698	23	,	,	PUNCT
gs-3920	698	24	and	and	CCONJ
gs-3920	698	25	yumi	yumi	PROPN
gs-3920	698	26	kano	kano	PROPN
gs-3920	698	27	.	.	PUNCT
gs-3920	699	1	“	"	PUNCT
gs-3920	699	2	drug	drug	NOUN
gs-3920	699	3	reaction	reaction	NOUN
gs-3920	699	4	with	with	ADP
gs-3920	699	5	eosinophilia	eosinophilia	PROPN
gs-3920	699	6	and	and	CCONJ
gs-3920	699	7	systemic	systemic	ADJ
gs-3920	699	8	symptoms	symptom	NOUN
gs-3920	699	9	(	(	PUNCT
gs-3920	699	10	dress	dress	NOUN
gs-3920	699	11	):	):	PUNCT
gs-3920	699	12	incidence	incidence	NOUN
gs-3920	699	13	,	,	PUNCT
gs-3920	699	14	pathogenesis	pathogenesis	NOUN
gs-3920	699	15	and	and	CCONJ
gs-3920	699	16	management	management	NOUN
gs-3920	699	17	.	.	PUNCT
gs-3920	699	18	”	"	PUNCT
gs-3920	700	1	expert	expert	ADJ
gs-3920	700	2	opinion	opinion	NOUN
gs-3920	700	3	on	on	ADP
gs-3920	700	4	drug	drug	NOUN
gs-3920	700	5	safety	safety	NOUN
gs-3920	700	6	16	16	NUM
gs-3920	700	7	,	,	PUNCT
gs-3920	700	8	no	no	INTJ
gs-3920	700	9	.	.	NOUN
gs-3920	700	10	2	2	NUM
gs-3920	700	11	(	(	PUNCT
gs-3920	700	12	2017	2017	NUM
gs-3920	700	13	):	):	PUNCT
gs-3920	700	14	139–47	139–47	NUM
gs-3920	700	15	.	.	X
gs-3920	700	16	60	60	NUM
gs-3920	700	17	.	.	PUNCT
gs-3920	701	1	cacoub	cacoub	PROPN
gs-3920	701	2	,	,	PUNCT
gs-3920	701	3	patrice	patrice	PROPN
gs-3920	701	4	,	,	PUNCT
gs-3920	701	5	et	et	PROPN
gs-3920	701	6	al	al	PROPN
gs-3920	701	7	.	.	PUNCT
gs-3920	702	1	“	"	PUNCT
gs-3920	702	2	the	the	DET
gs-3920	702	3	dress	dress	NOUN
gs-3920	702	4	syndrome	syndrome	NOUN
gs-3920	702	5	:	:	PUNCT
gs-3920	702	6	a	a	DET
gs-3920	702	7	literature	literature	NOUN
gs-3920	702	8	review	review	NOUN
gs-3920	702	9	.	.	PUNCT
gs-3920	702	10	”	"	PUNCT
gs-3920	703	1	the	the	DET
gs-3920	703	2	american	american	PROPN
gs-3920	703	3	journal	journal	PROPN
gs-3920	703	4	of	of	ADP
gs-3920	703	5	medicine	medicine	PROPN
gs-3920	703	6	124	124	NUM
gs-3920	703	7	,	,	PUNCT
gs-3920	703	8	no	no	INTJ
gs-3920	703	9	.	.	NOUN
gs-3920	703	10	7	7	NUM
gs-3920	703	11	(	(	PUNCT
gs-3920	703	12	2011	2011	NUM
gs-3920	703	13	):	):	PUNCT
gs-3920	703	14	588–97	588–97	NUM
gs-3920	703	15	.	.	PUNCT
gs-3920	704	1	https://doi.org/10.1016/j.amjmed.2011.01.017	https://doi.org/10.1016/j.amjmed.2011.01.017	NOUN
gs-3920	704	2	.	.	PROPN
gs-3920	704	3	61	61	NUM
gs-3920	704	4	.	.	PUNCT
gs-3920	705	1	husain	husain	PROPN
gs-3920	705	2	,	,	PUNCT
gs-3920	705	3	zahir	zahir	PROPN
gs-3920	705	4	,	,	PUNCT
gs-3920	705	5	sherrie	sherrie	PROPN
gs-3920	705	6	reddy	reddy	PROPN
gs-3920	705	7	,	,	PUNCT
gs-3920	705	8	and	and	CCONJ
gs-3920	705	9	robert	robert	PROPN
gs-3920	705	10	k.	k.	PROPN
gs-3920	705	11	schwartz	schwartz	PROPN
gs-3920	705	12	.	.	PUNCT
gs-3920	706	1	“	"	PUNCT
gs-3920	706	2	dress	dress	NOUN
gs-3920	706	3	syndrome	syndrome	NOUN
gs-3920	706	4	:	:	PUNCT
gs-3920	706	5	part	part	NOUN
gs-3920	706	6	i.	i.	PROPN
gs-3920	706	7	clinical	clinical	ADJ
gs-3920	706	8	perspectives	perspective	NOUN
gs-3920	706	9	.	.	PUNCT
gs-3920	706	10	”	"	PUNCT
gs-3920	707	1	journal	journal	NOUN
gs-3920	707	2	of	of	ADP
gs-3920	707	3	the	the	DET
gs-3920	707	4	american	american	PROPN
gs-3920	707	5	academy	academy	PROPN
gs-3920	707	6	of	of	ADP
gs-3920	707	7	dermatology	dermatology	NOUN
gs-3920	707	8	68	68	NUM
gs-3920	707	9	,	,	PUNCT
gs-3920	707	10	no	no	INTJ
gs-3920	707	11	.	.	NOUN
gs-3920	707	12	5	5	NUM
gs-3920	707	13	(	(	PUNCT
gs-3920	707	14	2013	2013	NUM
gs-3920	707	15	):	):	PUNCT
gs-3920	707	16	693.e1–693.e14	693.e1–693.e14	NUM
gs-3920	707	17	.	.	NOUN
gs-3920	707	18	62	62	NUM
gs-3920	707	19	.	.	PUNCT
gs-3920	708	1	descamps	descamps	PROPN
gs-3920	708	2	,	,	PUNCT
gs-3920	708	3	vincent	vincent	PROPN
gs-3920	708	4	,	,	PUNCT
gs-3920	708	5	et	et	PROPN
gs-3920	708	6	al	al	PROPN
gs-3920	708	7	.	.	PUNCT
gs-3920	709	1	“	"	PUNCT
gs-3920	709	2	management	management	NOUN
gs-3920	709	3	of	of	ADP
gs-3920	709	4	drug	drug	NOUN
gs-3920	709	5	reaction	reaction	NOUN
gs-3920	709	6	with	with	ADP
gs-3920	709	7	eosinophilia	eosinophilia	PROPN
gs-3920	709	8	and	and	CCONJ
gs-3920	709	9	systemic	systemic	ADJ
gs-3920	709	10	symptoms	symptom	NOUN
gs-3920	709	11	(	(	PUNCT
gs-3920	709	12	dress	dress	NOUN
gs-3920	709	13	):	):	PUNCT
gs-3920	709	14	a	a	DET
gs-3920	709	15	retrospective	retrospective	ADJ
gs-3920	709	16	study	study	NOUN
gs-3920	709	17	of	of	ADP
gs-3920	709	18	38	38	NUM
gs-3920	709	19	cases	case	NOUN
gs-3920	709	20	.	.	PUNCT
gs-3920	709	21	”	"	PUNCT
gs-3920	710	1	archives	archive	NOUN
gs-3920	710	2	of	of	ADP
gs-3920	710	3	dermatology	dermatology	NOUN
gs-3920	710	4	145	145	NUM
gs-3920	710	5	,	,	PUNCT
gs-3920	710	6	no	no	INTJ
gs-3920	710	7	.	.	PROPN
gs-3920	710	8	12	12	NUM
gs-3920	710	9	(	(	PUNCT
gs-3920	710	10	2009	2009	NUM
gs-3920	710	11	):	):	PUNCT
gs-3920	710	12	1373–80	1373–80	NUM
gs-3920	710	13	.	.	PUNCT
gs-3920	711	1	63	63	NUM
gs-3920	711	2	.	.	X
gs-3920	711	3	yang	yang	PROPN
gs-3920	711	4	,	,	PUNCT
gs-3920	711	5	chia	chia	PROPN
gs-3920	711	6	-	-	PUNCT
gs-3920	711	7	yu	yu	PROPN
gs-3920	711	8	,	,	PUNCT
gs-3920	711	9	et	et	PROPN
gs-3920	711	10	al	al	PROPN
gs-3920	711	11	.	.	PUNCT
gs-3920	712	1	“	"	PUNCT
gs-3920	712	2	pharmacogenetics	pharmacogenetic	NOUN
gs-3920	712	3	and	and	CCONJ
gs-3920	712	4	genomic	genomic	ADJ
gs-3920	712	5	biomarkers	biomarker	NOUN
gs-3920	712	6	of	of	ADP
gs-3920	712	7	severe	severe	ADJ
gs-3920	712	8	cutaneous	cutaneous	ADJ
gs-3920	712	9	adverse	adverse	ADJ
gs-3920	712	10	reactions	reaction	NOUN
gs-3920	712	11	.	.	PUNCT
gs-3920	712	12	”	"	PUNCT
gs-3920	713	1	current	current	ADJ
gs-3920	713	2	pharmacogenomics	pharmacogenomic	NOUN
gs-3920	713	3	and	and	CCONJ
gs-3920	713	4	personalized	personalized	ADJ
gs-3920	713	5	medicine	medicine	NOUN
gs-3920	713	6	15	15	NUM
gs-3920	713	7	,	,	PUNCT
gs-3920	713	8	no	no	INTJ
gs-3920	713	9	.	.	NOUN
gs-3920	713	10	3	3	NUM
gs-3920	713	11	(	(	PUNCT
gs-3920	713	12	2017	2017	NUM
gs-3920	713	13	):	):	PUNCT
gs-3920	713	14	179–90	179–90	NUM
gs-3920	713	15	.	.	PUNCT
gs-3920	714	1	64	64	NUM
gs-3920	714	2	.	.	PUNCT
gs-3920	715	1	kang	kang	PROPN
gs-3920	715	2	,	,	PUNCT
gs-3920	715	3	hye	hye	PROPN
gs-3920	715	4	-	-	PUNCT
gs-3920	715	5	won	won	PROPN
gs-3920	715	6	,	,	PUNCT
gs-3920	715	7	et	et	PROPN
gs-3920	715	8	al	al	PROPN
gs-3920	715	9	.	.	PUNCT
gs-3920	716	1	“	"	PUNCT
gs-3920	716	2	clinical	clinical	ADJ
gs-3920	716	3	features	feature	NOUN
gs-3920	716	4	and	and	CCONJ
gs-3920	716	5	outcomes	outcome	NOUN
gs-3920	716	6	of	of	ADP
gs-3920	716	7	drug	drug	NOUN
gs-3920	716	8	reaction	reaction	NOUN
gs-3920	716	9	with	with	ADP
gs-3920	716	10	eosinophilia	eosinophilia	PROPN
gs-3920	716	11	and	and	CCONJ
gs-3920	716	12	systemic	systemic	ADJ
gs-3920	716	13	symptoms	symptom	NOUN
gs-3920	716	14	(	(	PUNCT
gs-3920	716	15	dress	dress	NOUN
gs-3920	716	16	)	)	PUNCT
gs-3920	716	17	in	in	ADP
gs-3920	716	18	korean	korean	ADJ
gs-3920	716	19	patients	patient	NOUN
gs-3920	716	20	.	.	PUNCT
gs-3920	716	21	”	"	PUNCT
gs-3920	717	1	allergy	allergy	NOUN
gs-3920	717	2	,	,	PUNCT
gs-3920	717	3	asthma	asthma	PROPN
gs-3920	717	4	&	&	CCONJ
gs-3920	717	5	immunology	immunology	PROPN
gs-3920	717	6	research	research	NOUN
gs-3920	717	7	11	11	NUM
gs-3920	717	8	,	,	PUNCT
gs-3920	717	9	no	no	INTJ
gs-3920	717	10	.	.	NOUN
gs-3920	717	11	4	4	NUM
gs-3920	717	12	(	(	PUNCT
gs-3920	717	13	2019	2019	NUM
gs-3920	717	14	):	):	PUNCT
gs-3920	717	15	507–15	507–15	NUM
gs-3920	717	16	.	.	PUNCT
gs-3920	718	1	65	65	NUM
gs-3920	718	2	.	.	PUNCT
gs-3920	718	3	pichler	pichler	NOUN
gs-3920	718	4	,	,	PUNCT
gs-3920	718	5	werner	werner	PROPN
gs-3920	718	6	j.	j.	PROPN
gs-3920	718	7	“	"	PUNCT
gs-3920	718	8	drug	drug	NOUN
gs-3920	718	9	hypersensitivity	hypersensitivity	NOUN
gs-3920	718	10	reactions	reaction	NOUN
gs-3920	718	11	:	:	PUNCT
gs-3920	718	12	classification	classification	NOUN
gs-3920	718	13	and	and	CCONJ
gs-3920	718	14	relationship	relationship	NOUN
gs-3920	718	15	to	to	ADP
gs-3920	718	16	t	t	NOUN
gs-3920	718	17	-	-	PUNCT
gs-3920	718	18	cell	cell	NOUN
gs-3920	718	19	activation	activation	NOUN
gs-3920	718	20	.	.	PUNCT
gs-3920	718	21	”	"	PUNCT
gs-3920	719	1	current	current	ADJ
gs-3920	719	2	opinion	opinion	NOUN
gs-3920	719	3	in	in	ADP
gs-3920	719	4	allergy	allergy	NOUN
gs-3920	719	5	and	and	CCONJ
gs-3920	719	6	clinical	clinical	ADJ
gs-3920	719	7	immunology	immunology	NOUN
gs-3920	719	8	8	8	NUM
gs-3920	719	9	,	,	PUNCT
gs-3920	719	10	no	no	INTJ
gs-3920	719	11	.	.	NOUN
gs-3920	719	12	4	4	NUM
gs-3920	719	13	(	(	PUNCT
gs-3920	719	14	2008	2008	NUM
gs-3920	719	15	):	):	PUNCT
gs-3920	719	16	291–96	291–96	NOUN
gs-3920	719	17	.	.	PUNCT
gs-3920	720	1	https://doi.org/10.1097/aci.0b013e3283060c8c	https://doi.org/10.1097/aci.0b013e3283060c8c	NOUN
gs-3920	720	2	.	.	PUNCT